,ID,tags,text
0,NCT02105766,"8:16:chronic_disease,20:32:treatment",portal fibrosis by liver biopsy
1,NCT03008070,22:34:treatment,Contra-indication to liver biopsy
2,NCT03008070,",32:44:treatment,,",Have a stable weight since the liver biopsy was performed defined by no more than a 5 % loss of initial body weight
3,NCT03008070,"26:38:treatment,",Subject agrees to have a liver biopsy performed after 24 weeks of treatment
4,NCT02515708,",43:55:treatment,",Liver steatosis (on visual estimate or on liver biopsy) > 30%
5,NCT02474199,"85:97:treatment,,","For subjects with elevated liver tests as defined above, local pathology reading of liver biopsy 6-10 days after darTregs infusion is without AR according to Banff criteria"
6,NCT02474199,11:23:treatment,"Screening liver biopsy with any of the following histological criteria, as determined by the reading of a central pathologist"
7,NCT02412540,",,42:54:treatment,","Weight reduction of >5% between baseline liver biopsy and enrollment, as weight loss >5% may change NASH severity"
8,NCT02094794,"1:22:treatment,26:61:treatment,,",Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50%
9,NCT02257138,"85:98:treatment,116:138:treatment",patients with newly diagnosed or previously treated disease are eligible as long as prior therapy does not include hypomethylating agents
10,NCT03126110,",54:67:treatment",Has not recovered to ? Grade 1 from toxic effects of prior therapy
11,NCT03104699,"32:45:treatment,,",Persisting toxicity related to prior therapy of NCI CTCAE grade >1 severity
12,NCT03007030,13:26:treatment,Any line of prior therapy
13,NCT02942095,"28:41:treatment,,",Patient who were receiving prior therapy will require wash out period of either more than 2 weeks or more than 5 half-lives whichever shorter
14,NCT02932280,"52:65:treatment,",have recovered from the acute toxic effects of all prior therapy to ? grade 1 before entering this study
15,NCT02912572,",,42:55:treatment",Persisting Grade >=2 toxicity related to prior therapy
16,NCT02584647,11:24:treatment,Allowable prior therapy
17,NCT02553460,9:22:treatment,Limited prior therapy
18,NCT02425904,49:62:treatment,There is no limitation of amount or the type of prior therapy or drugs
19,NCT02392572,"51:64:treatment,",Persistent clinically significant toxicities from prior therapy must not be greater than grade 1
20,NCT02383927,34:47:treatment,has relapsed or is refractory to prior therapy
21,NCT02370693,",,,,58:71:treatment",Fall in FVC > 10% over 6 months on at least 12 months of prior therapy
22,NCT02340156,61:74:treatment,Radiographic demonstration of disease progression following prior therapy
23,NCT02315612,67:80:treatment,"Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met"
24,NCT02302235,",,62:75:treatment",Failure to recover from <CTCAE grade 2 toxicities related to prior therapy
25,NCT02192359,42:55:treatment,Any clinically significant toxicity from prior therapy must have improved to grade 0 or grade 1
26,NCT02159495,"39:52:treatment,","Non hematological toxicity related to prior therapy must either have returned to =< grade 2, baseline, or deemed irreversible"
27,NCT02146924,"39:52:treatment,","Non-hematological toxicity related to prior therapy must either have returned to =< grade 3, baseline, or deemed irreversible"
28,NCT02101034,",49:62:treatment",Minimum of 14 days elapsed since the end of any prior therapy
29,NCT02013336,27:40:treatment,Disease progression after prior therapy in locally advanced or metastatic setting
30,NCT01954576,"36:49:treatment,,","Recovery from the toxic effects of prior therapy to not more than grade 1 or >3 weeks from prior therapy to registration, whichever is later"
31,NCT01906385,"30:43:treatment,,",Recovered from toxicities of prior therapy to grade 0 or 1
32,NCT01896999,"5:18:treatment,",All prior therapy must have been completed at least 21 days prior to enrollment
33,NCT01865162,",,62:75:treatment",Failure to recover from <CTCAE grade 2 toxicities related to prior therapy
34,NCT01849146,35:48:treatment,recovered from severe toxicity of prior therapy
35,NCT01553071,49:62:treatment,Patients must have recovered from toxicities of prior therapy
36,NCT01430390,67:80:treatment,"Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met"
37,NCT01371630,9:22:treatment,minimal prior therapy
38,NCT01037790,"74:87:treatment,","The subject has not recovered from clinically-meaningful toxicity due to prior therapy (i.e., back to baseline or Grade ? 1)"
39,NCT00412594,79:92:treatment,Patients with relapsed disease are eligible if they have had no more than one prior therapy
40,NCT00004317,",25:38:treatment",No more than 1 month of prior therapy
41,NCT02542202,"18:21:chronic_disease,69:128:treatment,,,","patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration"
42,NCT02346253,"1:4:chronic_disease,61:120:treatment,,,","HIV-positive patients are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter no more than 30 days prior to registration"
43,NCT03175159,1:4:chronic_disease,HIV-uninfected
44,NCT03175159,26:29:chronic_disease,Involvement in any other HIV Prevention study that may interfere with the ability to test major study outcomes
45,NCT03167606,1:4:chronic_disease,HIV+
46,NCT03167606,13:16:chronic_disease,Self-report HIV-negative or unknown status
47,NCT03157167,16:19:chronic_disease,The subject is HIV positive
48,NCT03135886,17:20:chronic_disease,are offered any HIV and/or HCV tests
49,NCT03132415,1:4:chronic_disease,HIV-positive
50,NCT03132415,16:19:chronic_disease,Self-report as HIV-negative or sero-status unaware
51,NCT03109431,23:26:chronic_disease,Acutely infected with HIV
52,NCT03109431,1:4:chronic_disease,HIV-negative (high-risk HIV-negative youth will be invited to participate in another study)
53,NCT03109431,1:4:chronic_disease,HIV-positive serostatus
54,NCT03088709,14:17:chronic_disease,Positive for HIV
55,NCT03086057,1:4:chronic_disease,HIV Positive at baseline
56,NCT03081559,38:41:chronic_disease,"Evidence of suboptimal engagement in HIV care, as indicated by one or more"
57,NCT03081559,1:4:chronic_disease,HIV+ confirmed via antibody testing
58,NCT03081559,"14:17:chronic_disease,",Reporting no HIV primary care appointments in the prior 6 months
59,NCT03078153,1:4:chronic_disease,HIV negative
60,NCT03078153,1:4:chronic_disease,HIV positive
61,NCT03078153,27:30:chronic_disease,Not enrolled in any other HIV prevention trial
62,NCT03060772,1:4:chronic_disease,HIV-positive
63,NCT03059355,23:26:chronic_disease,Be serum positive for HIV
64,NCT03056339,29:32:chronic_disease,Known positive serology for HIV
65,NCT03004170,"96:99:chronic_disease,",Report engaging in one or more occasions of condomless anal and/or vaginal intercourse with an HIV-negative or unknown HIV serostatus sex partner in the 3 months prior to study enrollment
66,NCT02979366,12:15:chronic_disease,arriers of HIV antibodies
67,NCT02953509,1:4:chronic_disease,HIV
68,NCT02944578,"1:4:chronic_disease,",HIV negative women
69,NCT02944578,"1:4:chronic_disease,",HIV positive women
70,NCT02929069,"1:4:chronic_disease,,","HIV sexual risk (?1 act of condomless anal with a male partner of unknown status or HIV+ status, unless with HIV+ partner with known undetectable viral load)"
71,NCT02929069,1:4:chronic_disease,HIV-negative status
72,NCT02929069,1:4:chronic_disease,HIV-positive status
73,NCT02915744,1:4:chronic_disease,HIV
74,NCT02907944,"27:30:chronic_disease,",Employed at participating HIV clinic for at least 6 months
75,NCT02907944,1:4:chronic_disease,HIV-infected
76,NCT02907944,11:14:chronic_disease,Receiving HIV care in the index clinic
77,NCT02895945,"1:4:chronic_disease,,",HIV+ with stable disease and CD4+ count ? 200 cells/mm^3 at screening
78,NCT02848417,1:4:chronic_disease,HIV
79,NCT02835729,7:10:chronic_disease,Known HIV-infected patients
80,NCT02833805,1:4:chronic_disease,HIV seropositivity
81,NCT02820350,1:4:chronic_disease,HIV
82,NCT02801747,"27:30:chronic_disease,,,","Sub-optimal engagement in HIV care (assessed from the medical record, defined as less than 1 visit in every 4-mo. period in the past year [two of them at least 90 days apart], pro-rated for those diagnosed less than a year ago) or > 2 missed visits (without prior cancellation) in the past year"
83,NCT02797262,1:4:chronic_disease,HIV-infected individuals in HIV care
84,NCT02796027,23:26:chronic_disease,positive confirmatory HIV test
85,NCT02772562,51:54:chronic_disease,"immunocompromised individuals, such as those with HIV"
86,NCT02770547,1:4:chronic_disease,HIV positive
87,NCT02770326,"1:4:chronic_disease,,",HIV infection with CD4 count <240
88,NCT02766998,1:4:chronic_disease,HIV positive mothers
89,NCT02764853,1:4:chronic_disease,HIV-positive
90,NCT02759575,1:4:chronic_disease,HIV
91,NCT02734771,24:27:chronic_disease,Patient is known to be HIV positive (test result not required for enrollment)
92,NCT02660528,1:4:chronic_disease,HIV
93,NCT02641093,1:4:chronic_disease,HIV
94,NCT02635360,18:21:chronic_disease,Known history of HIV
95,NCT02629120,1:4:chronic_disease,HIV positive
96,NCT02629120,9:12:chronic_disease,Must be HIV negative
97,NCT02610374,1:4:chronic_disease,HIV-infected cohort (Cohort A)
98,NCT02610374,1:4:chronic_disease,HIV-negative cohorts (Cohort B and C)
99,NCT02600273,10:13:chronic_disease,"Unstable HIV or associated comorbidities, as determined by a licensed medical professional"
100,NCT02593123,23:26:chronic_disease,Negative serology for HIV
101,NCT02578641,1:4:chronic_disease,HIV Positive
102,NCT02578641,"11:14:chronic_disease,",Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screening
103,NCT02567422,33:36:chronic_disease,patients with poorly controlled HIV
104,NCT02566395,1:4:chronic_disease,HIV positive
105,NCT02566304,1:4:chronic_disease,HIV positive
106,NCT02552953,13:16:chronic_disease,Known to be HIV-positive
107,NCT02543983,10:13:chronic_disease,Positive HIV test
108,NCT02542202,1:4:chronic_disease,HIV testing is not required for eligibility for this protocol
109,NCT02541903,7:10:chronic_disease,known HIV carrier
110,NCT02531932,20:23:chronic_disease,A known history of HIV seropositivity
111,NCT02531880,19:22:chronic_disease,Positive test for HIV
112,NCT02531295,",,37:40:chronic_disease",Pre-ART viral load <2000 copies/ml (HIV controllers)
113,NCT02529644,",143:146:chronic_disease",Minors 18 and under are intentionally excluded since the intervention study has been designed specifically for adults with information of how HIV affects the African American adult population
114,NCT02520427,24:27:chronic_disease,Known positiv test for HIV
115,NCT02515708,1:4:chronic_disease,HIV positive patient
116,NCT02508038,1:4:chronic_disease,HIV infection
117,NCT02472834,1:4:chronic_disease,HIV positive
118,NCT02457845,7:10:chronic_disease,Known HIV seropositivity
119,NCT02453113,12:15:chronic_disease,History of HIV
120,NCT02452268,1:4:chronic_disease,HIV positive patients
121,NCT02446093,13:16:chronic_disease,Known to be HIV+
122,NCT02442297,7:10:chronic_disease,Known HIV positivity
123,NCT02430077,7:10:chronic_disease,Known HIV-infected patient
124,NCT02408861,"1:4:chronic_disease,,","HIV viral load should be well suppressed, defined as below the limit of detection of the local assay or below 75 copies/mL by Food and Drug Administration (FDA)-approved assays, within 4 weeks prior to registration"
125,NCT02400463,7:10:chronic_disease,known HIV infection
126,NCT02393690,22:25:chronic_disease,"patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial"
127,NCT02384954,5:8:chronic_disease,Not HIV positive
128,NCT02379520,7:10:chronic_disease,Known HIV positivity
129,NCT02374333,1:4:chronic_disease,HIV infection
130,NCT02374021,1:4:chronic_disease,HIV
131,NCT02369406,",,39:42:chronic_disease,,,",57-365 days after birth if infant was HIV-negative based on testing performed within 96 hours after birth (or if unknown HIV status < 96 hours from birth) and then found to be HIV-positive based on testing performed between 96 hours and 42 days after birth
132,NCT02369406,"1:4:chronic_disease,",HIV-infection identified by testing conducted within 96 hours after birth
133,NCT02369406,"1:4:chronic_disease,",HIV-negative within 96 hours after birth
134,NCT02369406,"1:4:chronic_disease,,",HIV-positive between 96 hours and 42 days after birth
135,NCT02362997,1:4:chronic_disease,HIV-positive
136,NCT02358187,1:4:chronic_disease,HIV-positive patients
137,NCT02350764,23:26:chronic_disease,Any positive test for HIV
138,NCT02347891,30:33:chronic_disease,Have a historically positive HIV test or test positive at screening for HIV
139,NCT02344355,7:10:chronic_disease,Known HIV-positive individuals
140,NCT02340156,23:26:chronic_disease,"Positive results from HIV serology testing, if any available"
141,NCT02335138,48:51:chronic_disease,Either partner expresses unwillingness to have HIV test kits delivered to a home address
142,NCT02335138,52:55:chronic_disease,Either partner expresses unwillingness to test for HIV together with his male sexual partner
143,NCT02335138,"21:24:chronic_disease,,","Negative or unknown HIV status and not having tested in the last 6 months, with a partner meeting the same criteria OR in a sero-discordant with the negative/unknown partner reporting not having tested in the past 6 months"
144,NCT02335138,"30:33:chronic_disease,",Willingness to be tested for HIV with one's male sexual partner
145,NCT02335138,21:24:chronic_disease,Willingness to have HIV test kits delivered to a home address they provide
146,NCT02332850,7:10:chronic_disease,Known HIV seropositivity
147,NCT02329652,1:4:chronic_disease,HIV
148,NCT02321501,18:21:chronic_disease,Known history of HIV seropositivity
149,NCT02312596,1:4:chronic_disease,HIV
150,NCT02296684,18:21:chronic_disease,Known history of HIV (HIV 1/2 antibodies)
151,NCT02256631,"22:25:chronic_disease,",At increased risk of HIV acquisition defined as documentation of one or more of the following risk factors
152,NCT02256631,"47:50:chronic_disease,,",Mother with any detectable viral replication (HIV RNA above the limit of detection) at last measurement prior to delivery determined within 30 days of delivery
153,NCT02233868,17:20:chronic_disease,"Have a positive HIV test (clinical laboratory results, medical history)"
154,NCT02213913,7:10:chronic_disease,Known HIV positive status
155,NCT02204098,7:10:chronic_disease,Known HIV-positive status
156,NCT02203903,15:18:chronic_disease,Patients with HIV infection
157,NCT02203513,"1:4:chronic_disease,,,",HIV- positive patients who are not on HAART and have CD4 counts > 500 will be considered on an individual basis
158,NCT02186418,21:24:chronic_disease,Sero-positivity for HIV
159,NCT02179359,1:4:chronic_disease,HIV positive
160,NCT02164422,45:48:chronic_disease,other unstable medical conditions including HIV
161,NCT02159027,",,125:128:chronic_disease",score of < -0.5 OR a neurocognitive abnormality (< -0.5) in at least one cognitive domain known to be typically affected by HIV
162,NCT02140255,11:14:chronic_disease,Confirmed HIV infection defined as positive results from two samples collected at different time points
163,NCT02140255,"21:24:chronic_disease,",No confirmed plasma HIV RNA greater than or equal to 200 copies/mL at Step 2 Week 24 and up to but excluding Step 2 Week 48 (see the study protocol for procedural guidance related to this criterion)
164,NCT02140255,11:14:chronic_disease,No plasma HIV RNA detected at Step 2 Week 48 and thereafter
165,NCT02140255,11:14:chronic_disease,No plasma HIV RNA detected at the time of the second consecutive negative HIV DNA test (based on testing performed in the study's designated VQA-certified central laboratory)
166,NCT02140255,"11:14:chronic_disease,","No plasma HIV RNA detected by testing performed at the local CLIA-certified (US sites) or VQA-certified (non-US sites) laboratory, after criteria above have been confirmed, with specimen collection for the assay within 14 days prior to Step 3 Entry"
167,NCT02140255,8:11:chronic_disease,Plasma HIV RNA greater than or equal to LOD based on standard quantitative testing performed at the local CLIA-certified (US sites) or VQA-certified (non-US sites) laboratory after ART cessation (see the study protocol for procedural guidance related to this criterion)
168,NCT02140255,10:13:chronic_disease,Presumed HIV infection defined as greater than or equal to one positive rapid HIV antibody test obtained in the peripartum period
169,NCT02140255,"17:20:chronic_disease,,","Two consecutive HIV DNA tests with no DNA detected in at least 850,000 PBMCs assayed (performed in the study's designated central laboratory) at least 8 weeks apart"
170,NCT02140255,"26:29:chronic_disease,",Two consecutive negative HIV antibody tests by fourth generation enzyme-linked immunosorbent assay (ELISA) (performed in the study's designated central laboratory) at least 8 weeks apart
171,NCT02133196,18:21:chronic_disease,Seronegative for HIV antibody
172,NCT02128906,1:4:chronic_disease,HIV testing is not required for entry into this protocol
173,NCT02128100,1:4:chronic_disease,HIV testing is not manditory for this protocol
174,NCT02124902,7:10:chronic_disease,Known HIV-positivity
175,NCT02106988,13:16:chronic_disease,known to be HIV positive
176,NCT02105766,1:4:chronic_disease,HIV positive
177,NCT02101736,1:4:chronic_disease,"HIV testing will not be required as part of this trial, unless HIV is clinically suspected"
178,NCT02100891,1:4:chronic_disease,HIV seropositive patients
179,NCT02100891,1:4:chronic_disease,HIV-positive donors
180,NCT02081404,15:18:chronic_disease,Patients with HIV
181,NCT02078102,31:34:chronic_disease,Patients must be negative for HIV
182,NCT02075710,10:13:chronic_disease,positive HIV antibody test or hepatitis serologies
183,NCT02059239,26:29:chronic_disease,Known to be positive for HIV
184,NCT01976169,10:13:chronic_disease,Baseline HIV screening
185,NCT01962415,1:4:chronic_disease,HIV negative
186,NCT01956084,7:10:chronic_disease,Donor HIV negative
187,NCT01956084,16:19:chronic_disease,Donors who are HIV positive
188,NCT01953900,1:4:chronic_disease,HIV positivity
189,NCT01928576,1:4:chronic_disease,HIV-positive patients are excluded
190,NCT01925378,"31:34:chronic_disease,",Patients must have a negative HIV test within 14 days of starting the NFV
191,NCT01920737,7:10:chronic_disease,Known HIV positive status
192,NCT01913106,1:4:chronic_disease,HIV + patients
193,NCT01896999,1:4:chronic_disease,HIV viral loads undetectable by standard clinical HIV testing
194,NCT01807611,1:4:chronic_disease,HIV negative
195,NCT01804634,1:4:chronic_disease,HIV-positive
196,NCT01760655,1:4:chronic_disease,HIV positive
197,NCT01734512,20:23:chronic_disease,A known history of HIV seropositivity
198,NCT01730937,"1:4:chronic_disease,,",HIV positive with CD4 count < (350) cells/microliter
199,NCT01720836,7:10:chronic_disease,known HIV-positive patients
200,NCT01666080,1:4:chronic_disease,HIV positive
201,NCT01660607,1:4:chronic_disease,HIV ab
202,NCT01660607,1:4:chronic_disease,HIV positive
203,NCT01660607,18:21:chronic_disease,Seronegative for HIV 1 RNA (polymerase chair reaction (PCR)
204,NCT01631617,1:4:chronic_disease,HIV seropositiviy
205,NCT01599559,7:10:chronic_disease,Known HIV-positive serology
206,NCT01553942,7:10:chronic_disease,known HIV carrier
207,NCT01522768,7:10:chronic_disease,Known HIV carrier
208,NCT01481974,1:4:chronic_disease,HIV positive
209,NCT01473628,21:24:chronic_disease,Patients with known HIV infection
210,NCT01459107,1:4:chronic_disease,HIV (active or seropositive)
211,NCT01445821,1:4:chronic_disease,HIV positive
212,NCT01436968,1:4:chronic_disease,HIV+ patients
213,NCT01419561,5:8:chronic_disease,Any HIV status
214,NCT01419561,87:90:chronic_disease,"Any abnormality that would be scored as NCI CTC Grade 4 toxicity that is unrelated to HIV, its treatment"
215,NCT01364363,1:4:chronic_disease,HIV seronegativity
216,NCT01189786,7:10:chronic_disease,Known HIV Positivity
217,NCT01174121,18:21:chronic_disease,Seronegative for HIV antibody
218,NCT01140087,1:4:chronic_disease,HIV positive
219,NCT00967577,18:21:chronic_disease,Known history of HIV
220,NCT00959140,1:4:chronic_disease,HIV positive patients
221,NCT00896493,15:18:chronic_disease,Those who are HIV-positive
222,NCT00887146,22:25:chronic_disease,"patients known to be HIV positive, but without clinical evidence of an immunocompromised state"
223,NCT00799864,"11:14:chronic_disease,",Must have HIV-1 plasma viral load at screening greater than equal to 500 HIV-1 ribonucleic acid (RNA) copies/mL
224,NCT00788164,4:7:chronic_disease,No HIV seropositivity
225,NCT00720785,1:4:chronic_disease,HIV-positive patients
226,NCT00670358,10:13:chronic_disease,No known HIV positivity
227,NCT00472329,18:21:chronic_disease,Patients who are HIV positive
228,NCT00368355,26:29:chronic_disease,Patients with documented HIV positivity
229,NCT00001337,1:4:chronic_disease,HIV negative
230,NCT03136029,"1:7:chronic_disease,,,20:46:chronic_disease,,",Anemia (Hgb<9) and Severe Renal Insufficiency (individuals with creatinine clearance <30 by the Cockcroft-Gault formula)
231,NCT03095118,"1:7:chronic_disease,,",Anemia with Hgb < 8.5 g/dL
232,NCT02851472,"1:7:chronic_disease,,",Anemia with hematocrit (Hct) less than 28 %
233,NCT02844907,"1:7:chronic_disease,,",Anemia (hematocrit < 34%) as measured at screening visit
234,NCT02551679,1:7:chronic_disease,Anemia
235,NCT02457702,"1:7:chronic_disease,,",Anemia (hematocrit < 32%)
236,NCT02415387,1:7:chronic_disease,Anemia
237,NCT02234934,"1:7:chronic_disease,,",Anemia (hemoglobin < 8 g/dl)
238,NCT02157974,1:7:chronic_disease,Anemia
239,NCT02134392,"1:7:chronic_disease,",Anemia on complete blood count
240,NCT02101944,"1:7:chronic_disease,,,",Anemia > 2 g/dL below the lower limit of normal or a hemoglobin value < 10 g/dL
241,NCT01895777,"1:7:chronic_disease,,",Anemia (hemoglobin < 80g/L)
242,NCT01419561,"1:7:chronic_disease,,",Anemia (hemoglobin<12.0g/dL)
243,NCT01059786,"1:7:chronic_disease,,",Anemia (Hgb less than 10g/dL)
244,NCT00904046,1:7:chronic_disease,Anemia
245,NCT00862433,1:7:chronic_disease,Anemia
246,NCT02349867,"24:35:chronic_disease,43:57:chronic_disease",Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to confirm exclusion of patient due to QTc
247,NCT02236013,"13:24:chronic_disease,29:43:chronic_disease",Subject has hypokalemia and hypomagnesemia at Screening (defined as values below institutional lower limit of normal [LLN])
248,NCT02465060,23:34:chronic_disease,Patient must not have hypokalemia (value < institutional lower limit of normal)
249,NCT02465268,"7:23:chronic_disease,27:52:chronic_disease",Known active infection or immunosuppressive disease
250,NCT03149549,59:75:chronic_disease,"Serious concurrent illness, including clinically relevant active infection"
251,NCT03143153,49:65:chronic_disease,Any serious or uncontrolled medical disorder or active infection
252,NCT03060564,1:17:chronic_disease,active infection
253,NCT03035890,12:28:chronic_disease,ongoing or active infection
254,NCT03016871,72:88:chronic_disease,Patients should not have any uncontrolled illness including ongoing or active infection
255,NCT02991651,12:28:chronic_disease,ongoing or active infection
256,NCT02985554,"15:31:chronic_disease,","Patients with active infection, un-resolving more than grade 2 transplant-related toxicities"
257,NCT02950337,12:28:chronic_disease,ongoing or active infection
258,NCT02945800,12:28:chronic_disease,ongoing or active infection
259,NCT02890979,12:28:chronic_disease,ongoing or active infection
260,NCT02857218,12:28:chronic_disease,ongoing or active infection
261,NCT02843568,12:28:chronic_disease,ongoing or active infection
262,NCT02694029,12:28:chronic_disease,ongoing or active infection
263,NCT02656550,17:33:chronic_disease,Subject with an active infection
264,NCT02624804,7:23:chronic_disease,Known active infection
265,NCT02624258,14:30:chronic_disease,Uncontrolled active infection
266,NCT02581215,12:28:chronic_disease,Ongoing or active infection
267,NCT02464878,38:54:chronic_disease,Subjects with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection
268,NCT02419560,16:32:chronic_disease,Subject has an active infection
269,NCT02374333,14:30:chronic_disease,Uncontrolled active infection
270,NCT02320292,39:55:chronic_disease,Serious non-malignant disease such as active infection or other condition which in the opinion of the investigator would compromise other protocol objectives
271,NCT02291848,22:38:chronic_disease,Patients with severe active infection
272,NCT02272998,16:32:chronic_disease,Symptomatic or active infection
273,NCT02232516,12:28:chronic_disease,Ongoing or active infection
274,NCT02227199,1:17:chronic_disease,active infection
275,NCT02226159,1:17:chronic_disease,active infection
276,NCT02193191,12:28:chronic_disease,Ongoing or active infection
277,NCT02120222,14:30:chronic_disease,Uncontrolled active infection within one week prior to first dose
278,NCT02037048,37:53:chronic_disease,"Patients with a clinically apparent active infection will not be eligible (please note, an isolated elevation in the white blood cell count, by itself, does not constitute evidence of an infection)"
279,NCT02031250,15:31:chronic_disease,Patients with active infection
280,NCT01976585,15:31:chronic_disease,Patients with active infection
281,NCT01952730,14:30:chronic_disease,Uncontrolled active infection
282,NCT01919619,4:20:chronic_disease,No active infection
283,NCT01773707,9:25:chronic_disease,Have an active infection at time of randomization
284,NCT01037790,12:28:chronic_disease,ongoing or active infection
285,NCT00896493,14:30:chronic_disease,Uncontrolled active infection
286,NCT00412594,13:29:chronic_disease,Presence of active infection
287,NCT01802346,"1:16:cancer,65:92:treatment",Prostate cancer subjects may have received prior treatment with metronomic cyclophosphamide as this is considered anti-angiogenic/immunomodulatory and not cytotoxic
288,NCT01734512,"1:12:cancer,25:47:cancer","Astrocytoma, Low Grade (Fibrillary astrocytoma, WHO Grade 2) - 10065886"
289,NCT03003390,"11:42:treatment,54:64:treatment",required medical or surgical intervention to restore hemostasis
290,NCT02347111,"17:27:treatment,73:83:chronic_disease",Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital)
291,NCT02933034,12:22:chronic_disease,develop an arrhythmia prior to or during either of the exercise tests; SeeMore should not be administered
292,NCT02875301,14:24:chronic_disease,uncontrolled arrhythmia
293,NCT02793921,14:24:chronic_disease,uncontrolled arrhythmia
294,NCT02578641,14:24:chronic_disease,uncontrolled arrhythmia
295,NCT02421341,25:35:chronic_disease,No history of dangerous arrhythmia's
296,NCT02227199,14:24:chronic_disease,uncontrolled arrhythmia
297,NCT01850355,",69:79:chronic_disease","Clinically significant abnormalities on ECG (e.g., QT prolongation, arrhythmia)"
298,NCT01676259,10:20:chronic_disease,unstable arrhythmia
299,NCT01445821,28:38:chronic_disease,Untreated life-threatening arrhythmia
300,NCT00788164,13:23:chronic_disease,Symptomatic arrhythmia not controlled by medication
301,NCT00432094,1:11:chronic_disease,arrhythmia
302,NCT02085941,"36:51:cancer,60:70:cancer",must have histologically confirmed malignant tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
303,NCT02015390,35:50:cancer,Disseminated and/or nonresectable malignant tumor involving bone
304,NCT03121352,46:56:cancer,willing to undergo a preliminary biopsy of a metastatic focus for research purposes
305,NCT03109041,13:23:cancer,Patient has metastatic disease
306,NCT02496208,39:49:cancer,Histologically confirmed diagnosis of metastatic
307,NCT02166190,1:11:cancer,metastatic disease
308,NCT02143726,6:16:cancer,have metastatic disease or locally advanced unresectable disease
309,NCT02064673,26:36:cancer,no sign of lymph node or metastatic disease
310,NCT01954173,15:25:cancer,Patients with metastatic disease outside of the pelvis
311,NCT02754544,"14:29:treatment,108:141:cancer",undergoing a tumor resection at the University of Texas M. D. Anderson Cancer Center for a newly diagnosed primary or metastatic brain tumor located in or adjacent to motor brain areas
312,NCT02442297,19:34:treatment,Subjects having a tumor resection if medically feasible
313,NCT00924027,"1:21:cancer,64:76:treatment",gynecological cancer patients who may have received concurrent chemotherapy as a component of their treatment regimen
314,NCT03181126,",73:85:treatment",Refractory is defined as persistent disease after at least 2 courses of chemotherapy
315,NCT03153410,"33:45:treatment,",Must have received last dose of chemotherapy at least 14 days or longer prior to entry into the study
316,NCT03139227,",,47:59:treatment","Must be > 1 year from pregnancy, lactation or chemotherapy"
317,NCT03088709,",78:90:treatment",Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning
318,NCT03082612,42:54:treatment,Have completed surgery with no plans for chemotherapy
319,NCT03082612,46:58:treatment,Treatment plans to include weekly outpatient chemotherapy
320,NCT03051321,8:20:treatment,Active chemotherapy
321,NCT03011684,19:31:treatment,Has not yet begun chemotherapy
322,NCT02913430,29:41:treatment,More than one prior line of chemotherapy in the metastatic setting
323,NCT02912572,33:45:treatment,patients who have only received chemotherapy in the adjuvant setting
324,NCT02862938,19:31:treatment,Participant is on chemotherapy
325,NCT02793583,1:13:treatment,chemotherapy
326,NCT02774421,28:40:treatment,who have been treated with chemotherapy at time of recurrence
327,NCT02759146,12:24:treatment,Undergoing chemotherapy
328,NCT02758847,1:13:treatment,chemotherapy
329,NCT02658565,23:35:treatment,Patients who received chemotherapy directed at the present disease
330,NCT02639208,79:91:treatment,either in the context of standard treatment or a clinical trial and including chemotherapy
331,NCT02635360,1:13:treatment,chemotherapy
332,NCT02603757,29:41:treatment,Patients who do not undergo chemotherapy
333,NCT02589938,11:23:treatment,Receiving chemotherapy during study period
334,NCT02565498,9:21:treatment,Planned chemotherapy for (neo)adjuvant treatment
335,NCT02562716,",,,151:163:treatment",women/men of reproductive potential must have agreed to use an effective contraceptive method for up to 3 months after the final administered dose of chemotherapy
336,NCT02536794,23:35:treatment,Patients who have had chemotherapy
337,NCT02536794,",36:48:treatment",have received at least one line of chemotherapy in the metastatic setting
338,NCT02492867,37:49:treatment,Patients cannot tolerate concurrent chemotherapy
339,NCT02481765,66:78:treatment,"Intensive medical treatment means that the subject is undergoing chemotherapy for a hematologic/oncologic condition, is carrying a pacemaker or has been diagnosed with a cardiac anomaly which causes cardiac insufficiency not compensated with medications"
340,NCT02427841,",,,,156:168:treatment,,,","Women of child-bearing potential and men must be willing to use adequate contraception during the entire study and for 8 weeks following completion of all chemotherapy on study; this includes hormonal or barrier method, or abstinence"
341,NCT02416206,",43:55:treatment",Within 9 months of the start of induction chemotherapy and no evidence of relapse or progression
342,NCT02359825,12:24:treatment,undergoing chemotherapy
343,NCT02320292,19:31:treatment,No indication for chemotherapy
344,NCT02315196,",81:93:treatment",imaging must have been performed no greater than 30 days prior to initiation of chemotherapy
345,NCT02309892,10:22:treatment,Previous chemotherapy
346,NCT02308709,12:24:treatment,"Concurrent chemotherapy is allowed, but not required"
347,NCT02303977,",41:53:treatment","Pregnant or breast-feeding patients, as chemotherapy is thought to present substantial risk to the fetus/infant"
348,NCT02227199,54:66:treatment,Patients must be anticipated to complete 2 cycles of chemotherapy
349,NCT02203513,",147:159:treatment","Patients should have recurrent platinum-resistant, defined as disease recurrence by imaging within 6 months of the last receipt of platinum-based chemotherapy"
350,NCT02159703,"7:19:treatment,",Prior chemotherapy within the past 5 years
351,NCT02153229,",62:74:treatment",Subjects who have received more than 2 doses of neo-adjuvant chemotherapy
352,NCT02135588,",40:52:treatment",At least 2 days from administration of chemotherapy
353,NCT02128906,",,53:65:treatment",Pregnant women are excluded from this study because chemotherapy
354,NCT02128906,24:36:treatment,breast feeding because chemotherapy
355,NCT02115295,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program
356,NCT02101736,"21:33:treatment,",No myelosuppressive chemotherapy within 4 weeks of study entry
357,NCT02099591,49:61:treatment,Patients currently receiving the first cycle of chemotherapy
358,NCT02091999,1:13:treatment,chemotherapy
359,NCT02037048,",40:52:treatment",for 90 days following the last dose of chemotherapy
360,NCT02031250,43:55:treatment,Patients must be able to receive protocol chemotherapy in the judgment of the treating Medical Oncologist
361,NCT01953900,53:65:treatment,Recovered from the acute toxic effects of all prior chemotherapy
362,NCT01928589,73:85:treatment,Patient must have a Medical Oncology consult with the recommendation of chemotherapy
363,NCT01925573,58:70:treatment,6 weeks since the completion of a nitrosourea-containing chemotherapy regimen
364,NCT01919619,",,,,128:140:treatment,",diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
365,NCT01901562,"15:27:treatment,",Have received chemotherapy in the last 12 months
366,NCT01896999,46:58:treatment,Patients must have relapsed after first line chemotherapy
367,NCT01871766,",189:201:treatment",Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol
368,NCT01859819,13:25:treatment,No previous chemotherapy
369,NCT01807091,",,,87:99:treatment",Treatment-related mortality (TRM) score < 9.21 corresponding to a TRM rate of 3% when chemotherapy of similar intensity as proposed here is administered to inpatients
370,NCT01754298,1:13:treatment,chemotherapy treatment
371,NCT01730794,37:49:treatment,Immunosuppressed patients receiving chemotherapy
372,NCT01703949,",63:75:treatment",Patients must be anticipated to complete at least 2 cycles of chemotherapy on study
373,NCT01690468,31:43:treatment,"At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles"
374,NCT01676259,1:13:treatment,chemotherapy
375,NCT01620216,105:117:treatment,certain agents that prolong the corrected QT interval may be allowed but only after discussion with the chemotherapy pharmacist
376,NCT01614990,38:50:treatment,subjects may otherwise be undergoing chemotherapy
377,NCT01526603,"43:55:treatment,",Patients who are delayed in consolidation chemotherapy beyond 8 weeks
378,NCT01526603,40:52:treatment,Recovery from last induction course of chemotherapy
379,NCT01515527,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program
380,NCT01505569,48:60:treatment,Timing: Recovery from last induction course of chemotherapy
381,NCT01434316,7:19:treatment,Prior chemotherapy
382,NCT01238120,63:75:treatment,Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion
383,NCT01061515,41:53:treatment,All patients must be consented prior to chemotherapy
384,NCT01061515,"53:65:treatment,,,,",Patients must have adequate renal function prior to chemotherapy defined as serum creatinine ? 2.0 mg/dl or creatinine clearance ?60 ml.min/1.73 m² for patients with creatinine levels above 2.0 mg/dl
385,NCT01061515,21:33:treatment,have received prior chemotherapy
386,NCT01061515,105:117:treatment,must undergo a peritoneal scan documenting at least one working intraperitoneal port prior to receiving chemotherapy
387,NCT00911560,",,178:190:treatment","stage 4 with (any age) or without (>18 months old) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), MYCN-amplified stage 4S, or disease resistant to standard chemotherapy"
388,NCT00902720,1:13:treatment,chemotherapy
389,NCT00819208,63:75:treatment,"patients who are pre-planned to receive a shorter duration of chemotherapy, including as part of a research study"
390,NCT00719888,",,97:109:treatment",ligible with (M2 marrow) with =< 25% blasts in marrow after having failed one or more cycles of chemotherapy
391,NCT00719888,",81:93:treatment",patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval
392,NCT00632853,1:13:treatment,chemotherapy
393,NCT00632853,115:127:treatment,patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy
394,NCT00501826,36:48:treatment,failure to one induction course of chemotherapy are eligible
395,NCT00492778,23:35:treatment,Patients who received chemotherapy directed at the present recurrence
396,NCT00107289,52:64:treatment,Three weeks should have elapsed since last dose of chemotherapy
397,NCT02140554,"22:32:cancer,36:61:chronic_disease",Any prior or current malignancy or immunodeficiency disorder
398,NCT03171493,31:41:cancer,Patients with any other prior malignancy are not allowed
399,NCT03158974,"28:38:cancer,",Have evidence of an active malignancy or have been immunocompromised within the 60 days prior to Screening
400,NCT03158519,27:37:cancer,Diagnosis of other active malignancy
401,NCT03145298,"12:22:cancer,",History of malignancy within the last 5 years
402,NCT03141359,"16:26:cancer,",Prior invasive malignancy unless disease free for a minimum of 3 years from enrollment
403,NCT03123068,8:18:cancer,Active malignancy
404,NCT03113760,32:42:cancer,current or previous history of malignancy
405,NCT03113695,17:27:cancer,"Patients with a malignancy that has been treated, but not with curative intent"
406,NCT03113695,"1:11:cancer,",malignancy has been in remission without treatment for 2 years prior to enrollment
407,NCT03086369,"25:35:cancer,",Have a known additional malignancy that is progressing or required active treatment within the past 1 year
408,NCT03076333,"20:30:cancer,",History of a prior malignancy within past 5 years
409,NCT03075826,43:53:cancer,Individuals with a history of a different malignancy
410,NCT03059355,"28:38:cancer,",Have a clinical history of malignancy within 3 years
411,NCT03043742,61:71:cancer,Any condition that may adversely affect bone marrow such as malignancy or prior irradiation to the pelvic bone
412,NCT03008070,8:18:cancer,Active malignancy
413,NCT03006770,8:18:cancer,Active malignancy
414,NCT03006770,"12:22:cancer,",history of malignancy within 5 years prior to study entry
415,NCT03002519,"12:22:cancer,",History of malignancy (other than the disease that required the HCT) within 5 years prior to screening
416,NCT03001830,1:11:cancer,malignancy
417,NCT02961114,",,69:79:cancer",Prostate Specific Antigen (PSA) > 4 ng/mL with documentation of non-malignancy
418,NCT02950337,"34:44:cancer,",Patients with a known history of malignancy with a disease-free interval <3 years prior to enrollment
419,NCT02942095,"34:44:cancer,",Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease
420,NCT02924402,111:121:cancer,"History or evidence of a clinically unstable/uncontrollable disorder, condition or disease other than primary malignancy, that in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion"
421,NCT02920710,12:22:cancer,History of malignancy
422,NCT02912572,43:53:cancer,Individuals with a history of a different malignancy
423,NCT02876302,43:53:cancer,Individuals with a history of a different malignancy are ineligible
424,NCT02857218,"18:28:cancer,",History of other malignancy in the past 2 years
425,NCT02803164,21:31:cancer,Proven or suspected malignancy in the wound
426,NCT02719847,10:20:cancer,Patients malignancy is consistent with well differentiated neuroendocrine (carcinoid) histology
427,NCT02706353,7:17:cancer,Prior malignancy
428,NCT02693990,43:53:cancer,Individuals with a history of a different malignancy are ineligible except for the following circumstances
429,NCT02687464,23:33:cancer,current treatment for malignancy
430,NCT02682407,8:18:cancer,Have a malignancy
431,NCT02678910,29:39:cancer,have a medical condition or malignancy that requires removal of all or part of one or both ovaries
432,NCT02594111,8:18:cancer,Active malignancy
433,NCT02593123,24:34:cancer,Determination that the malignancy is high risk will be made by the investigator
434,NCT02592707,"20:30:cancer,,",Current history of malignancy; patients with a secondary tumor in remission of > 5 years can be included
435,NCT02588612,51:61:cancer,Subjects must be in complete remission from prior malignancy in order to be eligible to enter the study
436,NCT02588326,"12:22:cancer,",History of malignancy within the past five years
437,NCT02587962,32:42:cancer,Histologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative measures do not exist or are no longer effective (Dose Escalation phase only)
438,NCT02585973,41:51:cancer,Patients with a currently active second malignancy
439,NCT02584647,18:28:cancer,Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the Sponsor
440,NCT02584647,"42:52:cancer,",Subjects with a completely treated prior malignancy and no evidence of disease for ? 2 years are eligible
441,NCT02574910,20:30:cancer,Evidence of active malignancy
442,NCT02574728,57:67:cancer,Participants must have had a histologic verification of malignancy at original diagnosis or relapse
443,NCT02566304,55:65:cancer,Active involvement of the central nervous system with malignancy
444,NCT02565901,10:20:cancer,No prior malignancy
445,NCT02565901,"26:36:cancer,",Other adequately treated malignancy for which the patient is currently disease free for at least one year
446,NCT02565498,"7:17:cancer,",Prior malignancy within the previous five years
447,NCT02555189,"26:36:cancer,",Patient has a concurrent malignancy or malignancy within 3 years of enrollment
448,NCT02551679,14:24:cancer,Diagnosis of malignancy
449,NCT02541903,"21:31:cancer,",effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured
450,NCT02539160,12:22:cancer,Any active malignancy
451,NCT02538198,"34:44:cancer,",Diagnosed or treated for another malignancy within 3 years prior to study enrollment
452,NCT02532452,25:35:cancer,Uncontrolled relapse of malignancy
453,NCT02525029,13:23:cancer,Progressive malignancy
454,NCT02514083,7:17:cancer,Prior malignancy
455,NCT02510417,36:46:cancer,Active and uncontrolled relapse of malignancy
456,NCT02505165,57:67:cancer,The diagnosis is determined to be a relapse or a second malignancy
457,NCT02501954,"20:30:cancer,",evidence of active malignancy within the last five years
458,NCT02498951,18:28:cancer,History of other malignancy that could affect compliance with the protocol or interpretation of results
459,NCT02481310,"57:67:cancer,",Patients who have been diagnosed or treated for another malignancy within 2 years before study enrollment
460,NCT02481310,35:45:cancer,previously diagnosed with another malignancy and have any evidence of residual disease
461,NCT02474199,"12:22:cancer,",History of malignancy within 5 years of enrollment
462,NCT02473250,1:11:cancer,malignancy
463,NCT02471430,"12:22:cancer,",History of malignancy of any organ system within the past 5 years
464,NCT02466009,"25:35:cancer,",History of other active malignancy within past 2 years
465,NCT02464696,18:28:cancer,Have a diagnosed malignancy
466,NCT02458014,26:36:cancer,No active or co-existing malignancy
467,NCT02438995,"11:21:cancer,",Unrelated malignancy within 3 years
468,NCT02437851,49:59:cancer,Participants must not have any other concurrent malignancy
469,NCT02437812,"27:37:cancer,",Subjects with concomitant malignancy or a previous malignancy within the past three years
470,NCT02424968,67:77:cancer,Active central nervous system (CNS) involvement of the underlying malignancy
471,NCT02424968,7:17:cancer,Prior malignancy
472,NCT02424968,",,157:167:cancer","diagnosed > 5 years ago without evidence of disease, OR treated =< 5 years ago but have a greater than 50% chance of life expectancy of >= 5 years for that malignancy"
473,NCT02403193,"7:17:cancer,",Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol
474,NCT02401035,8:18:cancer,"Active malignancy of any type, or history of a malignancy"
475,NCT02393794,26:36:cancer,Subject has a concurrent malignancy
476,NCT02393794,"1:11:treatment,",malignancy within 3 years of study enrollment
477,NCT02392572,"51:61:cancer,",Subject has been diagnosed or treated for another malignancy within 3 years of enrolment
478,NCT02358850,24:34:cancer,Indications: Suspected malignancy
479,NCT02354547,51:61:cancer,Patients must have had histologic verification of malignancy at original diagnosis or relapse
480,NCT02353819,"16:26:cancer,",Prior invasive malignancy unless disease free for a minimum of 3 years
481,NCT02353728,"27:37:cancer,",History of another active malignancy within 5 years prior to study entry
482,NCT02352480,5:15:cancer,any malignancy in the wound area
483,NCT02350764,14:24:cancer,Other active malignancy requiring concurrent intervention
484,NCT02346526,"7:17:cancer,",Other malignancy treated within the last 3 years
485,NCT02344355,25:35:cancer,"Known active concurrent malignancy, as determined by treating physicians"
486,NCT02343549,11:21:cancer,Any other malignancy
487,NCT02342782,53:63:cancer,Research participants with presence of other active malignancy
488,NCT02332850,"34:44:cancer,",Diagnosed or treated for another malignancy within 3 years of enrollment
489,NCT02323880,51:61:cancer,patients must have had histologic verification of malignancy at original diagnosis or relapse
490,NCT02321501,"48:58:cancer,",Patients who have a history of another primary malignancy unless the patient has been disease free for >/= 3 years
491,NCT02319369,7:17:cancer,"Has a malignancy that is known to contain a non synonymous mutation, insertion, or deletion in the TP53 gene determined previously or at screening"
492,NCT02304458,51:61:cancer,Patients must have had histologic verification of malignancy at original diagnosis or relapse
493,NCT02296684,"20:30:cancer,",A history of other malignancy ? 3 years previous
494,NCT02276456,240:250:cancer,"Examples include transition of care goals to comfort care, transition of care to inpatient or outpatient hospice, or the development of complications during the hospitalization that require early follow up appointments (e.g., diagnosis of malignancy)"
495,NCT02266745,10:20:chronic_disease,Previous malignancy
496,NCT02257424,"12:22:cancer,",History of malignancy other than disease under study within 3 years of study enrollment
497,NCT02257424,12:22:cancer,History of malignancy with confirmed activating RAS mutation at any time
498,NCT02254863,19:29:cancer,Active concurrent malignancy
499,NCT02213289,28:38:cancer,No currently active second malignancy
500,NCT02210078,36:46:cancer,Active and uncontrolled relapse of malignancy
501,NCT02210078,28:38:cancer,Patients with or without a malignancy
502,NCT02203695,25:35:cancer,Currently active second malignancy
503,NCT02195232,49:59:cancer,Participants must have histologically confirmed malignancy that is metastatic or currently unresectable
504,NCT02192359,18:28:cancer,Any other active malignancy
505,NCT02159495,53:63:cancer,Research participants with presence of other active malignancy
506,NCT02159027,9:19:cancer,Current malignancy
507,NCT02152995,20:30:cancer,History of another malignancy
508,NCT02146924,53:63:cancer,Research participants with presence of other active malignancy
509,NCT02138214,19:29:cancer,Concurrent active malignancy of another type
510,NCT02134392,12:22:cancer,History of malignancy
511,NCT02131597,16:26:cancer,Any concurrent malignancy
512,NCT02128230,30:40:cancer,Patients must not have prior malignancy
513,NCT02128100,71:81:cancer,A reasonable attempt should be made to make a pathologic diagnosis of malignancy
514,NCT02128100,"7:17:cancer,",Prior malignancy within the last 3 years
515,NCT02124772,20:30:cancer,History of another malignancy including resected non-melanomatous skin cancer
516,NCT02122185,"28:38:cancer,,",concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years
517,NCT02100891,",57:67:cancer",Life expectancy severely limited by diseases other than malignancy
518,NCT02094625,48:58:cancer,(inclusive) at time of diagnosis of underlying malignancy
519,NCT02070549,20:30:cancer,History of another malignancy
520,NCT02068092,11:21:cancer,Any prior malignancy
521,NCT02050113,20:30:cancer,Patient has active malignancy
522,NCT02048332,25:35:cancer,Uncontrolled relapse of malignancy
523,NCT02047474,"10:20:cancer,",No other malignancy within past five years
524,NCT02047474,36:46:cancer,There is no evidence of the second malignancy at the time of study entry
525,NCT02020707,"14:24:cancer,",Other active malignancy =< 3 years prior to registration
526,NCT02008656,"36:46:cancer,",Patients with a history of a prior malignancy within the past 5 years
527,NCT01996449,12:22:cancer,History of malignancy
528,NCT01993810,"16:26:cancer,",Prior invasive malignancy unless disease free for a minimum of 3 years
529,NCT01976585,"7:17:cancer,",Prior malignancy (active within 5 years of screening)
530,NCT01947140,9:19:cancer,"Current malignancy or history of a prior malignancy, as outlined in the protocol"
531,NCT01945814,36:46:cancer,Active and uncontrolled relapse of malignancy
532,NCT01941316,86:96:cancer,have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy
533,NCT01905046,"14:24:cancer,",Other active malignancy =< 5 years prior to pre-registration
534,NCT01901562,20:30:cancer,Have suspicious of malignancy in ultrasound
535,NCT01865162,"3:13:cancer,,",A malignancy diagnosed ?2 years ago if the subject has had no evidence of disease for 2 years prior to screening
536,NCT01823198,",,85:95:cancer",Serum glutamate pyruvate transaminase (SGPT) =< 200 IU/ml unless related to patient malignancy
537,NCT01815359,73:83:cancer,"Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study, or places them at an unacceptable risk for participation in the study"
538,NCT01804465,21:31:cancer,Concurrent or prior malignancy
539,NCT01766297,14:24:cancer,negative for malignancy on pathology
540,NCT01760655,55:65:cancer,Active involvement of the central nervous system with malignancy
541,NCT01737502,14:24:cancer,Other active malignancy
542,NCT01716806,"20:30:cancer,",History of another malignancy within 1 year before first dose of study drug (Parts E and F only)
543,NCT01676259,7:17:cancer,Other malignancy that would interfere with the current intervention
544,NCT01600040,"24:34:cancer,",History of a different malignancy except if disease-free for at least 5 years and are deemed by the investigator ro be at low risk for recurrence of that malignancy
545,NCT01532687,7:17:cancer,Prior malignancy
546,NCT01532687,31:41:cancer,subjects who have had another malignancy and have been disease-free
547,NCT01505569,53:63:cancer,All patients must have histological verification of malignancy at original diagnosis
548,NCT01505062,"12:22:cancer,",History of malignancy within a five year period
549,NCT01494662,50:60:cancer,Individuals with a history of a different active malignancy
550,NCT01465100,20:30:cancer,Subject has active malignancy
551,NCT01459107,"14:24:cancer,",Negative for malignancy for past 5 years
552,NCT01445821,18:28:cancer,Prior history of malignancy
553,NCT01384513,55:65:cancer,Active involvement of the central nervous system with malignancy
554,NCT01366612,"34:44:cancer,",Diagnosed or treated for another malignancy within 3 years of enrollment
555,NCT01312857,18:28:cancer,History of other malignancy
556,NCT01293214,24:34:cancer,High risk of return of malignancy
557,NCT01087294,",,90:100:cancer","Platelet count less than 30,000/microL unless low platelet count is thought to be due to malignancy in the bone marrow and malignancy is documented in the bone marrow"
558,NCT00896493,"23:33:cancer,,,",Patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy
559,NCT00887146,"14:24:cancer,",Other active malignancy within 5 years of registration
560,NCT00788164,15:25:cancer,No concurrent malignancy
561,NCT00734877,10:20:cancer,No prior malignancy is allowed
562,NCT00734877,"7:17:cancer,",Prior malignancy is acceptable provided there has been no evidence of disease within the three-year interval
563,NCT03167359,"20:37:treatment,58:68:chronic_disease",Requiring regional nodal irradiation without evidence of N3 disease
564,NCT02232516,"62:84:treatment,71:84:treatment","All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program"
565,NCT02585973,"47:74:treatment,57:74:treatment",Unable or unwilling to discontinue use of any sensitive CYP3A4 substrates and CYP3A4 substrates with a narrow therapeutic window
566,NCT02518594,"32:45:cancer,110:120:treatment","Known, suspected or history of breast cancer because breast cancer is a contraindication to the active study medication"
567,NCT03186937,10:23:chronic_disease,Operable breast cancer
568,NCT03176979,17:30:cancer,Newly diagnosed breast cancer patients
569,NCT03143894,23:36:cancer,Evidence of recurrent breast cancer at the time of enrollment
570,NCT03120728,28:41:cancer,current or past history of breast cancer
571,NCT03096418,",40:53:cancer",Women with pathologically demonstrated breast cancer
572,NCT03096418,177:190:cancer,"studies (window studies, for example) that are deemed non-therapeutic, including those that utilize agents that are not FDA approved for the treatment of the patient's current breast cancer, are permitted"
573,NCT03025139,",,46:59:cancer,,,,","Women diagnosed with early stage, resectable breast cancer (Stage 0, I, II, or III) prior to age 50, and are within 5 years of diagnosis"
574,NCT03011684,5:18:cancer,New breast cancer diagnosis
575,NCT02982564,"18:31:cancer,,",Be classified in breast cancer stage grouping 0 to III according to the American Joint Committee on Cancer Classification of Malignant Tumors (TNM) Staging System (2013)
576,NCT02982564,16:29:cancer,Diagnosed with breast cancer
577,NCT02926729,46:59:cancer,Involvement in another therapeutic trial for breast cancer
578,NCT02924441,30:43:cancer,Must not have had history of breast cancer
579,NCT02876302,58:71:cancer,Participants must have histologically confirmed invasive breast cancer
580,NCT02860000,66:79:cancer,"Histologic proof of metastatic or locally advanced, unresectable breast cancer"
581,NCT02842658,49:62:cancer,Subjects will have been recently diagnosed with breast cancer
582,NCT02793921,28:41:cancer,Medical clearance by their breast cancer surgeon
583,NCT02791646,"14:27:cancer,",diagnosis of breast cancer (initial or recurrence) within the last two years
584,NCT02763228,26:39:cancer,Pathologically confirmed breast cancer
585,NCT02754752,",,39:52:cancer","Have a history of stage I, II, or III breast cancer"
586,NCT02690116,"16:29:cancer,,","Diagnosed with breast cancer, stage 0-III"
587,NCT02637349,24:37:cancer,Confirmed diagnosis of breast cancer (not metastatic)
588,NCT02608216,"54:67:cancer,,,,","History of histologically or cytologically confirmed breast cancer, any ER, PR or HER2 status is allowed as long as it expresses the Rb protein"
589,NCT02538484,28:41:cancer,Estrogen receptor positive breast cancer
590,NCT02536794,"97:110:cancer,,,","Patients must have a histologically documented (either primary or metastatic site) diagnosis of breast cancer that is HER2 non-overexpressing by immunohistochemistry, namely 0 or 1"
591,NCT02522468,7:20:cancer,Prior breast cancer on ipsilateral side
592,NCT02494869,"27:40:cancer,",Predicted 10-year risk of breast cancer of ? 2.31%
593,NCT02494869,"28:41:cancer,",Predicted lifetime risk of breast cancer >20% based on family history)
594,NCT02479230,26:39:cancer,Histologically confirmed breast cancer
595,NCT02427581,"25:38:cancer,",Evidence of progressive breast cancer within the last 30 days
596,NCT02393794,70:83:cancer,"Confirmed germline BRCA1 or BRCA2 mutation, regardless of subtype of breast cancer"
597,NCT02352025,21:34:cancer,"A prior, unrelated, breast cancer"
598,NCT02352025,15:28:cancer,All stages of breast cancer
599,NCT02352025,54:67:cancer,"Any prior treatment for the current, newly diagnosed breast cancer"
600,NCT02341235,"10:23:cancer,",Report a breast cancer diagnosis no more than 10 years prior to enrollmen
601,NCT02328313,",,45:58:cancer,","Histologically confirmed Stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)"
602,NCT02315196,",,58:71:cancer",Life expectancy >= 52 weeks excluding their diagnosis of breast cancer
603,NCT02204098,51:64:cancer,Newly diagnosed histologically confirmed invasive breast cancer
604,NCT02106598,1:14:cancer,breast cancer patients in whom SLN mapping is indicated
605,NCT02095184,"21:34:cancer,,,,",Unresected operable breast cancer stage I-III with primary tumor ? 2.0 cm
606,NCT02068092,183:196:cancer,"A known deleterious mutation in BRCA1, BRCA2, PTEN, or TP53. (Note: The participant must be a documented carrier to meet this criterion. If there is a known mutation in a hereditary breast cancer susceptibility gene in a participant's family member, the participant herself must have undergone genetic testing as per National Comprehensive Cancer Network guidelines to be eligible per this criterion.)"
607,NCT01953588,"10:23:cancer,,,,,,","Invasive breast cancer is estrogen receptor positive with an Allred score of 6, 7 or 8 by local institution standard protocol. If an Allred Score is not reported on the diagnostic pathology report, ER positivity in > 66% cells"
608,NCT01912612,",,26:39:cancer,",Diagnosis of stage 0-III breast cancer within 12 years prior to enrollment
609,NCT01912612,39:52:cancer,Pain that developed or worsened since breast cancer diagnosis and is not due to identifiable traumatic event or fracture
610,NCT01905046,31:44:cancer,Must be at increased risk for breast cancer
611,NCT01755208,"22:35:cancer,,,",Participants who are breast cancer free (mammogram negative within 1 month of testing) with the absence of clinical suspicion of breast cancer on physical exam or with clinical stage II or stage III breast cancer
612,NCT01622868,79:92:cancer,Pathologically (histologically or cytologically) proven diagnosis of invasive breast cancer
613,NCT01591356,1:14:cancer,breast cancer are not exclusionary
614,NCT01570998,30:43:cancer,Axillary lymph node positive breast cancer
615,NCT00948285,17:30:cancer,Newly diagnosed breast cancer patients
616,NCT00948285,"15:28:cancer,,,",Patients with breast cancer diagnosis during pregnancy (women who could bear children must have a negative pregnancy test before beginning this study)
617,NCT00924027,",20:33:cancer",male patients with breast cancer
618,NCT00909909,26:39:cancer,Histologically confirmed breast cancer
619,NCT02977468,",,,176:186:treatment",Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication
620,NCT02581982,",,,233:243:treatment,","Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year"
621,NCT02541565,",,,149:159:treatment",Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication
622,NCT02541565,",,,,,233:243:treatment","Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication"
623,NCT02535533,",,71:81:treatment",Pre-existing uncontrolled hypertension defined as > 150/90 mm Hg with medication
624,NCT02532543,25:35:treatment,Use of any substance or medication that will influence bone metabolism
625,NCT02527265,32:42:treatment,"Any disease or exposure to any medication which, in the judgment of the principal Investigator, may impact glucose metabolism"
626,NCT02502253,87:97:treatment,Deemed too unstable medically or neurologically to safely enroll in trial of research medication
627,NCT02446457,",,106:116:treatment",have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication
628,NCT02440815,42:52:treatment,Acute or uncontrolled medical illness or medication use impacting cognitive function
629,NCT02437773,16:26:treatment,"Not taking any medication, prescription or non-prescription, with psychotropic effects"
630,NCT02437370,",,,,149:159:treatment","Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required"
631,NCT02437370,",,,233:243:treatment,","Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year"
632,NCT02433977,138:148:treatment,"Any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study (e.g. due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures"
633,NCT02427997,1:11:treatment,medication regime is likely to change during the course of the study
634,NCT02407171,",,131:141:treatment",childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication
635,NCT02391402,71:81:treatment,Participants could be reconsidered for eligibility after stability on medication was achieved
636,NCT02378714,",,171:181:treatment,",women of childbearing potential must agree to use a medically acceptable method of birth control or abstain from sexual intercourse during the time they are taking study medication and for at least one month after the medication period ends
637,NCT02349867,19:29:treatment,Unable to swallow medication
638,NCT02346201,3:13:treatment,"A medication for apathy is appropriate, in the opinion of the study physician"
639,NCT02340156,",,73:83:treatment",Have diastolic blood pressure of > 90 mm Hg resting at baseline despite medication
640,NCT02338999,67:77:treatment,"History of poor compliance with medical care, study visits and/or medication use"
641,NCT02332850,24:34:treatment,inability to take oral medication
642,NCT02332668,",110:120:treatment",abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication
643,NCT02332668,",60:70:treatment",within 72 hours prior to receiving the first dose of study medication
644,NCT02321501,",,,143:153:treatment,,",Negative serum or urine pregnancy test beta-Human Chorionic Gonadotropin (beta hCG) within 2 weeks prior to receiving the first dose of study medication for women of childbearing age
645,NCT02302976,20:30:treatment,current use of any medication (prescription or over-the-counter) determined to cause potential drug interactions by the study physicians
646,NCT02266004,8:18:treatment,Stable medication regimen
647,NCT02234934,53:63:treatment,Contraindication for administration of conditioning medication
648,NCT02234934,54:64:treatment,patients with a correctable deficiency controlled on medication
649,NCT02231073,19:29:treatment,Recent changes in medication
650,NCT02193490,",,94:104:treatment",negative urine pregnancy test is required within 14 days of receiving her first dose of test medication (placebo/ study drug) along with definite evidence of contraceptive use during the duration of the study
651,NCT02178566,",,,125:135:treatment",Women of childbearing potential must use a reliable method of contraception from screening until 1 month after end of study medication
652,NCT02166905,40:50:treatment,The ability to swallow and retain oral medication
653,NCT02124772,98:108:treatment,Able to swallow and retain enterally (per oral [PO] or nasogastric or gastric tube) administered medication
654,NCT02070549,29:39:treatment,Current use of a prohibited medication
655,NCT02044120,",,,191:201:treatment",Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication
656,NCT02003222,64:74:treatment,"Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance"
657,NCT01954316,",,,194:204:treatment","Women and men of child producing potential must agree to use highly effective means of contraception during study participation, and for at least 30 days after the last administration of study medication"
658,NCT01943851,",,,102:112:treatment",Female subjects must agree to use contraception until at least 7 months after the last dose of study medication
659,NCT01943851,67:77:treatment,This method must be used from the time of the first dose of study medication until 16 weeks after the last dose of study medication
660,NCT01943851,",56:66:treatment",any subject who is expected to require a QT prolonging medication while on trial should not be enrolled
661,NCT01684397,36:46:treatment,Ability to swallow and retain oral medication
662,NCT01676753,",,,176:186:treatment",Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication
663,NCT01438073,17:27:treatment,no history of a medication reaction requiring emergency medical care
664,NCT00914823,17:27:treatment,no history of a medication reaction requiring emergency medical care
665,NCT00147056,",,23:33:treatment",diastolic BP > 100 on medication
666,NCT02169739,"1:33:treatment,,112:120:chronic_disease",Diffusion-weighted imaging (DWI) lesion < 2.0cm in size at largest dimension and corresponding to the clinical syndrome
667,NCT02110992,"1:8:treatment,12:24:treatment,",Surgery or chemotherapy within 4 weeks
668,NCT03038620,1:8:treatment,Surgery scheduled for the trial duration period
669,NCT02700178,1:8:treatment,Surgery
670,NCT02638454,"1:8:treatment,",Surgery in previous 6 months
671,NCT02606045,"1:8:treatment,",Surgery within the past 8 weeks
672,NCT02341235,"1:8:treatment,",Surgery in the past six months
673,NCT02204098,1:8:treatment,Surgery
674,NCT02053792,1:8:treatment,Surgery substudy
675,NCT01774019,"1:8:treatment,",Surgery intent within 4 weeks
676,NCT03181126,",73:85:treatment",Refractory is defined as persistent disease after at least 2 courses of chemotherapy
677,NCT03153410,"33:45:treatment,",Must have received last dose of chemotherapy at least 14 days or longer prior to entry into the study
678,NCT03139227,",,47:59:treatment","Must be > 1 year from pregnancy, lactation or chemotherapy"
679,NCT03088709,",78:90:treatment",Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning
680,NCT03082612,42:54:treatment,Have completed surgery with no plans for chemotherapy
681,NCT03082612,46:58:treatment,Treatment plans to include weekly outpatient chemotherapy
682,NCT03051321,8:20:treatment,Active chemotherapy
683,NCT03011684,19:31:treatment,Has not yet begun chemotherapy
684,NCT02913430,29:41:treatment,More than one prior line of chemotherapy in the metastatic setting
685,NCT02912572,33:45:treatment,patients who have only received chemotherapy in the adjuvant setting
686,NCT02862938,19:31:treatment,Participant is on chemotherapy
687,NCT02793583,1:13:treatment,chemotherapy
688,NCT02774421,28:40:treatment,who have been treated with chemotherapy at time of recurrence
689,NCT02759146,12:24:treatment,Undergoing chemotherapy
690,NCT02758847,1:13:treatment,chemotherapy
691,NCT02658565,23:35:treatment,Patients who received chemotherapy directed at the present disease
692,NCT02639208,79:91:treatment,either in the context of standard treatment or a clinical trial and including chemotherapy
693,NCT02635360,1:13:treatment,chemotherapy
694,NCT02603757,29:41:treatment,Patients who do not undergo chemotherapy
695,NCT02589938,11:23:treatment,Receiving chemotherapy during study period
696,NCT02565498,9:21:treatment,Planned chemotherapy for (neo)adjuvant treatment
697,NCT02562716,",,,151:163:treatment",women/men of reproductive potential must have agreed to use an effective contraceptive method for up to 3 months after the final administered dose of chemotherapy
698,NCT02536794,23:35:treatment,Patients who have had chemotherapy
699,NCT02536794,",36:48:treatment",have received at least one line of chemotherapy in the metastatic setting
700,NCT02492867,37:49:treatment,Patients cannot tolerate concurrent chemotherapy
701,NCT02481765,66:78:treatment,"Intensive medical treatment means that the subject is undergoing chemotherapy for a hematologic/oncologic condition, is carrying a pacemaker or has been diagnosed with a cardiac anomaly which causes cardiac insufficiency not compensated with medications"
702,NCT02427841,",,,,156:168:treatment,,,","Women of child-bearing potential and men must be willing to use adequate contraception during the entire study and for 8 weeks following completion of all chemotherapy on study; this includes hormonal or barrier method, or abstinence"
703,NCT02416206,",43:55:treatment",Within 9 months of the start of induction chemotherapy and no evidence of relapse or progression
704,NCT02359825,12:24:treatment,undergoing chemotherapy
705,NCT02320292,19:31:treatment,No indication for chemotherapy
706,NCT02315196,",81:93:treatment",imaging must have been performed no greater than 30 days prior to initiation of chemotherapy
707,NCT02309892,10:22:treatment,Previous chemotherapy
708,NCT02308709,12:24:treatment,"Concurrent chemotherapy is allowed, but not required"
709,NCT02303977,",41:53:treatment","Pregnant or breast-feeding patients, as chemotherapy is thought to present substantial risk to the fetus/infant"
710,NCT02227199,54:66:treatment,Patients must be anticipated to complete 2 cycles of chemotherapy
711,NCT02203513,",147:159:treatment","Patients should have recurrent platinum-resistant, defined as disease recurrence by imaging within 6 months of the last receipt of platinum-based chemotherapy"
712,NCT02159703,"7:19:treatment,",Prior chemotherapy within the past 5 years
713,NCT02153229,",62:74:treatment",Subjects who have received more than 2 doses of neo-adjuvant chemotherapy
714,NCT02135588,",40:52:treatment",At least 2 days from administration of chemotherapy
715,NCT02128906,",,53:65:treatment",Pregnant women are excluded from this study because chemotherapy
716,NCT02128906,24:36:treatment,breast feeding because chemotherapy
717,NCT02115295,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program
718,NCT02101736,"21:33:treatment,",No myelosuppressive chemotherapy within 4 weeks of study entry
719,NCT02099591,49:61:treatment,Patients currently receiving the first cycle of chemotherapy
720,NCT02091999,1:13:treatment,chemotherapy
721,NCT02037048,",40:52:treatment",for 90 days following the last dose of chemotherapy
722,NCT02031250,43:55:treatment,Patients must be able to receive protocol chemotherapy in the judgment of the treating Medical Oncologist
723,NCT01953900,53:65:treatment,Recovered from the acute toxic effects of all prior chemotherapy
724,NCT01928589,73:85:treatment,Patient must have a Medical Oncology consult with the recommendation of chemotherapy
725,NCT01925573,58:70:treatment,6 weeks since the completion of a nitrosourea-containing chemotherapy regimen
726,NCT01919619,",,,,128:140:treatment,",diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
727,NCT01901562,"15:27:treatment,",Have received chemotherapy in the last 12 months
728,NCT01896999,46:58:treatment,Patients must have relapsed after first line chemotherapy
729,NCT01871766,",189:201:treatment",Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol
730,NCT01859819,13:25:treatment,No previous chemotherapy
731,NCT01807091,",,,87:99:treatment",Treatment-related mortality (TRM) score < 9.21 corresponding to a TRM rate of 3% when chemotherapy of similar intensity as proposed here is administered to inpatients
732,NCT01754298,1:13:treatment,chemotherapy treatment
733,NCT01730794,37:49:treatment,Immunosuppressed patients receiving chemotherapy
734,NCT01703949,",63:75:treatment",Patients must be anticipated to complete at least 2 cycles of chemotherapy on study
735,NCT01690468,31:43:treatment,"At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles"
736,NCT01676259,1:13:treatment,chemotherapy
737,NCT01620216,105:117:treatment,certain agents that prolong the corrected QT interval may be allowed but only after discussion with the chemotherapy pharmacist
738,NCT01614990,38:50:treatment,subjects may otherwise be undergoing chemotherapy
739,NCT01526603,"43:55:treatment,",Patients who are delayed in consolidation chemotherapy beyond 8 weeks
740,NCT01526603,40:52:treatment,Recovery from last induction course of chemotherapy
741,NCT01515527,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program
742,NCT01505569,48:60:treatment,Timing: Recovery from last induction course of chemotherapy
743,NCT01434316,7:19:treatment,Prior chemotherapy
744,NCT01238120,63:75:treatment,Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion
745,NCT01061515,41:53:treatment,All patients must be consented prior to chemotherapy
746,NCT01061515,"53:65:treatment,,,,",Patients must have adequate renal function prior to chemotherapy defined as serum creatinine ? 2.0 mg/dl or creatinine clearance ?60 ml.min/1.73 m² for patients with creatinine levels above 2.0 mg/dl
747,NCT01061515,21:33:treatment,have received prior chemotherapy
748,NCT01061515,105:117:treatment,must undergo a peritoneal scan documenting at least one working intraperitoneal port prior to receiving chemotherapy
749,NCT00911560,",,178:190:treatment","stage 4 with (any age) or without (>18 months old) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), MYCN-amplified stage 4S, or disease resistant to standard chemotherapy"
750,NCT00902720,1:13:treatment,chemotherapy
751,NCT00819208,63:75:treatment,"patients who are pre-planned to receive a shorter duration of chemotherapy, including as part of a research study"
752,NCT00719888,",,97:109:treatment",ligible with (M2 marrow) with =< 25% blasts in marrow after having failed one or more cycles of chemotherapy
753,NCT00719888,",81:93:treatment",patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval
754,NCT00632853,1:13:treatment,chemotherapy
755,NCT00632853,115:127:treatment,patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy
756,NCT00501826,36:48:treatment,failure to one induction course of chemotherapy are eligible
757,NCT00492778,23:35:treatment,Patients who received chemotherapy directed at the present recurrence
758,NCT00107289,52:64:treatment,Three weeks should have elapsed since last dose of chemotherapy
759,NCT00896493,"14:38:chronic_disease,42:48:chronic_disease",Uncontrolled congestive heart failure or angina
760,NCT03075761,1:25:chronic_disease,congestive heart failure
761,NCT03060473,"8:32:chronic_disease,,",Active congestive heart failure (EF<45%)
762,NCT03035890,13:37:chronic_disease,symptomatic congestive heart failure
763,NCT03030859,1:25:chronic_disease,congestive heart failure
764,NCT03028012,14:38:chronic_disease,Pre-existing congestive heart failure
765,NCT03008408,"23:47:chronic_disease,,,",History of documented congestive heart failure (New York Heart Association functional classification III-IV)
766,NCT03007745,1:25:chronic_disease,congestive heart failure
767,NCT02991651,13:37:chronic_disease,symptomatic congestive heart failure
768,NCT02986815,23:47:chronic_disease,NYHA class III and IV congestive heart failure
769,NCT02931110,",,,41:65:chronic_disease",New York Heart Association Class 3 or 4 congestive heart failure
770,NCT02908906,"13:37:chronic_disease,,,",symptomatic congestive heart failure (New York Heart Association class III-IV)
771,NCT02807272,49:73:chronic_disease,New York Heart Association grade III or greater congestive heart failure
772,NCT02793921,1:25:chronic_disease,congestive heart failure
773,NCT02755116,54:78:chronic_disease,New York Heart Association (NYHA) Class II or higher congestive heart failure
774,NCT02694029,13:37:chronic_disease,symptomatic congestive heart failure
775,NCT02596776,1:25:chronic_disease,congestive heart failure
776,NCT02595866,"1:25:chronic_disease,,,",congestive heart failure (New York Heart Association class III or IV)
777,NCT02583893,13:37:chronic_disease,symptomatic congestive heart failure
778,NCT02576301,13:37:chronic_disease,Symptomatic congestive heart failure
779,NCT02567422,"13:37:chronic_disease,",Symptomatic congestive heart failure (requiring hospital stay within the last 6 months)
780,NCT02562755,"1:25:chronic_disease,",congestive heart failure within the preceding 12 months
781,NCT02541903,1:25:chronic_disease,congestive heart failure New York Heart Association (NYHA) classification of 3
782,NCT02531932,"13:37:chronic_disease,,,",Symptomatic congestive heart failure of New York heart Association Class III or IV
783,NCT02525861,"44:68:chronic_disease,,,",The participant has clinically significant congestive heart failure with New York Heart Association (NYHA) Class III/IV symptoms
784,NCT02489045,"28:52:chronic_disease,",Patients with uncontrolled congestive heart failure (NYHA Class IV)
785,NCT02465060,"13:37:chronic_disease,,,",Symptomatic congestive heart failure (New York Heart Association [NYHA] classification of III/IV)
786,NCT02446236,29:53:chronic_disease,Uncontrolled or symptomatic congestive heart failure
787,NCT02442635,",,53:77:chronic_disease",Have New York Heart Association class II or greater congestive heart failure
788,NCT02426476,1:25:chronic_disease,congestive heart failure
789,NCT02417701,13:37:chronic_disease,symptomatic congestive heart failure
790,NCT02411773,"22:46:chronic_disease,,",Clinical evidence of congestive heart failure or ejection fraction below 35%
791,NCT02405078,13:37:chronic_disease,Symptomatic congestive heart failure
792,NCT02392572,"14:38:chronic_disease,,,",uncontrolled congestive heart failure (New York Heart Association class III and IV)
793,NCT02383927,",,27:51:chronic_disease",NYHA Grade III or greater congestive heart failure
794,NCT02353728,1:25:chronic_disease,congestive heart failure
795,NCT02343549,",55:79:chronic_disease",New York Heart Association (NYHA) Grade II or greater congestive heart failure
796,NCT02321501,"23:47:chronic_disease,,,",history of documented congestive heart failure (New York Heart Association functional classification III-IV)
797,NCT02314377,",,71:95:chronic_disease",Patients must not have New York Heart Association Grade II or greater congestive heart failure
798,NCT02272998,26:50:chronic_disease,Patients with history of congestive heart failure are excluded
799,NCT02257424,",20:44:chronic_disease,",Current ? Class II congestive heart failure as defined by New York Heart Association
800,NCT02253316,",,,33:57:chronic_disease",uncompensated NYHA Class 3 or 4 congestive heart failure
801,NCT02232516,13:37:chronic_disease,Symptomatic congestive heart failure
802,NCT02227199,1:25:chronic_disease,congestive heart failure
803,NCT02209636,"12:36:chronic_disease,,",History of congestive heart failure (EF < 35%)
804,NCT02188745,1:25:chronic_disease,congestive heart failure
805,NCT02152995,"44:68:chronic_disease,",History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
806,NCT02143726,",,49:73:chronic_disease",New York Heart Association grade III or greater congestive heart failure
807,NCT02128906,16:40:chronic_disease,no symptomatic congestive heart failure
808,NCT02124772,"45:69:chronic_disease,",a history or evidence of current >=Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines
809,NCT02106650,"1:25:chronic_disease,,,",congestive heart failure Class III/IV according to the New York Heart Association (NYHA) Functional Classification
810,NCT02094118,11:35:chronic_disease,Prevalent congestive heart failure prior to randomization
811,NCT02081404,",,,22:46:chronic_disease",NYHA class III or IV congestive heart failure
812,NCT02070549,",44:68:chronic_disease,",History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
813,NCT02058095,34:58:chronic_disease,no clinical signs or symptoms of congestive heart failure
814,NCT01989585,",44:68:chronic_disease,",History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
815,NCT01954316,"27:51:chronic_disease,,,",Have clinical symptomatic congestive heart failure defined at >= Class II of the New York Heart Association functional classification system or LVEF < 50% at baseline
816,NCT01947673,22:46:chronic_disease,clinical evidence of congestive heart failure
817,NCT01943851,",43:67:chronic_disease",History or evidence of current >=Class II congestive heart failure as defined by New York Heart Association (NYHA)
818,NCT01919619,8:32:chronic_disease,Active congestive heart failure (New York Heart Association [NYHA] class III to IV)
819,NCT01842399,7:31:chronic_disease,Known congestive heart failure now or in the past
820,NCT01811368,14:38:chronic_disease,uncontrolled congestive heart failure
821,NCT01750567,"12:36:chronic_disease,,,",History of congestive heart failure defined as NYHA class III or IV
822,NCT01670877,",122:146:chronic_disease","Testing for LVEF is not required for pre-registration, but patient must not have a recent LVEF < LLN or have symptoms of congestive heart failure"
823,NCT01568177,14:38:chronic_disease,uncontrolled congestive heart failure
824,NCT01532687,",,17:41:chronic_disease,","Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)"
825,NCT01526603,",,,,67:91:chronic_disease","shortening fraction ? 27% or ejection fraction ? 50%, no clinical congestive heart failure"
826,NCT01515527,13:37:chronic_disease,symptomatic congestive heart failure
827,NCT01430390,",,,51:75:chronic_disease",New York Heart Association (NYHA) stage III or IV congestive heart failure
828,NCT01306045,38:62:chronic_disease,"Ongoing or uncontrolled, symptomatic congestive heart failure (Class III or IV as defined by the NYHA functional classification system"
829,NCT01239160,14:38:chronic_disease,Diagnosis of congestive heart failure (uncontrolled)
830,NCT00904046,12:36:chronic_disease,history of congestive heart failure NYHA class III or IV
831,NCT00715611,10:34:chronic_disease,No acute congestive heart failure
832,NCT00540761,1:25:chronic_disease,congestive heart failure
833,NCT00432094,15:39:chronic_disease,decompensated congestive heart failure
834,NCT00075387,",114:138:chronic_disease",Subjects with uncontrolled (over the last 30 days) clinically significant confounding medical conditions such as congestive heart failure
835,NCT00065676,1:25:chronic_disease,congestive heart failure
836,NCT00001379,12:36:chronic_disease,history of congestive heart failure will not be eligible to receive
837,NCT02891850,"1:19:chronic_disease,21:56:chronic_disease","orthopedic disease, peripheral artery occlusive disease, which affects the patient's ability to walk"
838,NCT02388685,"1:12:treatment,16:36:treatment,",angioplasty or lumbar sympathectomy within 3 months of enrollment
839,NCT02544880,"1:16:treatment,25:37:treatment",Prior radiation and any chemotherapy
840,NCT03181126,",73:85:treatment",Refractory is defined as persistent disease after at least 2 courses of chemotherapy
841,NCT03153410,"33:45:treatment,",Must have received last dose of chemotherapy at least 14 days or longer prior to entry into the study
842,NCT03139227,",,47:59:treatment","Must be > 1 year from pregnancy, lactation or chemotherapy"
843,NCT03088709,",78:90:treatment",Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning
844,NCT03082612,42:54:treatment,Have completed surgery with no plans for chemotherapy
845,NCT03082612,46:58:treatment,Treatment plans to include weekly outpatient chemotherapy
846,NCT03051321,8:20:treatment,Active chemotherapy
847,NCT03011684,19:31:treatment,Has not yet begun chemotherapy
848,NCT02913430,29:41:treatment,More than one prior line of chemotherapy in the metastatic setting
849,NCT02912572,33:45:treatment,patients who have only received chemotherapy in the adjuvant setting
850,NCT02862938,19:31:treatment,Participant is on chemotherapy
851,NCT02793583,1:13:treatment,chemotherapy
852,NCT02774421,28:40:treatment,who have been treated with chemotherapy at time of recurrence
853,NCT02759146,12:24:treatment,Undergoing chemotherapy
854,NCT02758847,1:13:treatment,chemotherapy
855,NCT02658565,23:35:treatment,Patients who received chemotherapy directed at the present disease
856,NCT02639208,79:91:treatment,either in the context of standard treatment or a clinical trial and including chemotherapy
857,NCT02635360,1:13:treatment,chemotherapy
858,NCT02603757,29:41:treatment,Patients who do not undergo chemotherapy
859,NCT02589938,11:23:treatment,Receiving chemotherapy during study period
860,NCT02565498,9:21:treatment,Planned chemotherapy for (neo)adjuvant treatment
861,NCT02562716,",,,151:163:treatment",women/men of reproductive potential must have agreed to use an effective contraceptive method for up to 3 months after the final administered dose of chemotherapy
862,NCT02536794,23:35:treatment,Patients who have had chemotherapy
863,NCT02536794,",36:48:treatment",have received at least one line of chemotherapy in the metastatic setting
864,NCT02492867,37:49:treatment,Patients cannot tolerate concurrent chemotherapy
865,NCT02481765,66:78:treatment,"Intensive medical treatment means that the subject is undergoing chemotherapy for a hematologic/oncologic condition, is carrying a pacemaker or has been diagnosed with a cardiac anomaly which causes cardiac insufficiency not compensated with medications"
866,NCT02427841,",,,,156:168:treatment,,,","Women of child-bearing potential and men must be willing to use adequate contraception during the entire study and for 8 weeks following completion of all chemotherapy on study; this includes hormonal or barrier method, or abstinence"
867,NCT02416206,",43:55:treatment",Within 9 months of the start of induction chemotherapy and no evidence of relapse or progression
868,NCT02359825,12:24:treatment,undergoing chemotherapy
869,NCT02320292,19:31:treatment,No indication for chemotherapy
870,NCT02315196,",81:93:treatment",imaging must have been performed no greater than 30 days prior to initiation of chemotherapy
871,NCT02309892,10:22:treatment,Previous chemotherapy
872,NCT02308709,12:24:treatment,"Concurrent chemotherapy is allowed, but not required"
873,NCT02303977,",41:53:treatment","Pregnant or breast-feeding patients, as chemotherapy is thought to present substantial risk to the fetus/infant"
874,NCT02227199,54:66:treatment,Patients must be anticipated to complete 2 cycles of chemotherapy
875,NCT02203513,",147:159:treatment","Patients should have recurrent platinum-resistant, defined as disease recurrence by imaging within 6 months of the last receipt of platinum-based chemotherapy"
876,NCT02159703,"7:19:treatment,",Prior chemotherapy within the past 5 years
877,NCT02153229,",62:74:treatment",Subjects who have received more than 2 doses of neo-adjuvant chemotherapy
878,NCT02135588,",40:52:treatment",At least 2 days from administration of chemotherapy
879,NCT02128906,",,53:65:treatment",Pregnant women are excluded from this study because chemotherapy
880,NCT02128906,24:36:treatment,breast feeding because chemotherapy
881,NCT02115295,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program
882,NCT02101736,"21:33:treatment,",No myelosuppressive chemotherapy within 4 weeks of study entry
883,NCT02099591,49:61:treatment,Patients currently receiving the first cycle of chemotherapy
884,NCT02091999,1:13:treatment,chemotherapy
885,NCT02037048,",40:52:treatment",for 90 days following the last dose of chemotherapy
886,NCT02031250,43:55:treatment,Patients must be able to receive protocol chemotherapy in the judgment of the treating Medical Oncologist
887,NCT01953900,53:65:treatment,Recovered from the acute toxic effects of all prior chemotherapy
888,NCT01928589,73:85:treatment,Patient must have a Medical Oncology consult with the recommendation of chemotherapy
889,NCT01925573,58:70:treatment,6 weeks since the completion of a nitrosourea-containing chemotherapy regimen
890,NCT01919619,",,,,128:140:treatment,",diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
891,NCT01901562,"15:27:treatment,",Have received chemotherapy in the last 12 months
892,NCT01896999,46:58:treatment,Patients must have relapsed after first line chemotherapy
893,NCT01871766,",189:201:treatment",Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol
894,NCT01859819,13:25:treatment,No previous chemotherapy
895,NCT01807091,",,,87:99:treatment",Treatment-related mortality (TRM) score < 9.21 corresponding to a TRM rate of 3% when chemotherapy of similar intensity as proposed here is administered to inpatients
896,NCT01754298,1:13:treatment,chemotherapy treatment
897,NCT01730794,37:49:treatment,Immunosuppressed patients receiving chemotherapy
898,NCT01703949,",63:75:treatment",Patients must be anticipated to complete at least 2 cycles of chemotherapy on study
899,NCT01690468,31:43:treatment,"At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles"
900,NCT01676259,1:13:treatment,chemotherapy
901,NCT01620216,105:117:treatment,certain agents that prolong the corrected QT interval may be allowed but only after discussion with the chemotherapy pharmacist
902,NCT01614990,38:50:treatment,subjects may otherwise be undergoing chemotherapy
903,NCT01526603,"43:55:treatment,",Patients who are delayed in consolidation chemotherapy beyond 8 weeks
904,NCT01526603,40:52:treatment,Recovery from last induction course of chemotherapy
905,NCT01515527,74:86:treatment,Patient with documented hypersensitivity to any of the components of the chemotherapy program
906,NCT01505569,48:60:treatment,Timing: Recovery from last induction course of chemotherapy
907,NCT01434316,7:19:treatment,Prior chemotherapy
908,NCT01238120,63:75:treatment,Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion
909,NCT01061515,41:53:treatment,All patients must be consented prior to chemotherapy
910,NCT01061515,"53:65:treatment,,,,",Patients must have adequate renal function prior to chemotherapy defined as serum creatinine ? 2.0 mg/dl or creatinine clearance ?60 ml.min/1.73 m² for patients with creatinine levels above 2.0 mg/dl
911,NCT01061515,21:33:treatment,have received prior chemotherapy
912,NCT01061515,105:117:treatment,must undergo a peritoneal scan documenting at least one working intraperitoneal port prior to receiving chemotherapy
913,NCT00911560,",,178:190:treatment","stage 4 with (any age) or without (>18 months old) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), MYCN-amplified stage 4S, or disease resistant to standard chemotherapy"
914,NCT00902720,1:13:treatment,chemotherapy
915,NCT00819208,63:75:treatment,"patients who are pre-planned to receive a shorter duration of chemotherapy, including as part of a research study"
916,NCT00719888,",,97:109:treatment",ligible with (M2 marrow) with =< 25% blasts in marrow after having failed one or more cycles of chemotherapy
917,NCT00719888,",81:93:treatment",patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval
918,NCT00632853,1:13:treatment,chemotherapy
919,NCT00632853,115:127:treatment,patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy
920,NCT00501826,36:48:treatment,failure to one induction course of chemotherapy are eligible
921,NCT00492778,23:35:treatment,Patients who received chemotherapy directed at the present recurrence
922,NCT00107289,52:64:treatment,Three weeks should have elapsed since last dose of chemotherapy
923,NCT03171493,",,98:107:treatment",Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment
924,NCT03158974,",,102:111:treatment,","If female of childbearing potential, must have a negative urine pregnancy test result prior to study treatment and must be willing to use a barrier method of birth control while enrolled in the study"
925,NCT03158974,"14:23:treatment,,",Received any treatment for their EGW within 60 days of planned study enrollment
926,NCT03154567,144:153:treatment,Candidates must meet DSM-5 criteria for Mild-to-Moderate Cannabis Use Disorder (CUD) and be willing to participate in research but not seeking treatment
927,NCT03153982,86:95:treatment,"Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness"
928,NCT03137771,",,133:142:treatment,",willing and able to use medically acceptable forms of contraception during the trial and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child
929,NCT03127826,19:28:treatment,Already receiving treatment (other than primary care) for this episode of LBP
930,NCT03115398,",65:74:treatment,",Agree to utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study therapy is completed
931,NCT03085784,",,,131:140:treatment,","Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception start of the first treatment, during the study, and for at least 3 months after the last dose"
932,NCT03077243,",61:70:treatment",Adequate renal and hepatic function within 4 weeks prior to treatment
933,NCT03077243,",,51:60:treatment","CBC/differential obtained within 8 weeks prior to treatment, with adequate bone marrow"
934,NCT03070899,",49:58:treatment",planning a pregnancy within the duration of the treatment period of the study
935,NCT03045341,35:44:treatment,Available for the duration of the treatment and follow-up (20 months)
936,NCT03042689,24:33:treatment,Previous assignment to treatment during this study
937,NCT03033212,",42:51:treatment",Failed at least 3 months of conservative treatment
938,NCT03025828,",26:35:treatment",More than three previous treatment regiments
939,NCT03013543,44:53:treatment,"Patient completes the initial ~3 months of treatment period without evidence of severe or clinically relevant adverse events, changes in vital signs, or changes in safety laboratories or ECGs"
940,NCT02932280,",,87:96:treatment,",Male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product
941,NCT02907944,108:117:treatment,"Meets criteria for lifetime or current tobacco, alcohol and/or opioid use disorder regardless of addiction treatment status"
942,NCT02863991,",,,82:91:treatment","Absolute neutrophil count ?1,000/mm3 without growth factor use ? 7 days prior to treatment (cycle 1 day 1, C1D1)"
943,NCT02863991,",,,187:196:treatment","Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment"
944,NCT02836574,"8:17:treatment,,",Stable treatment is defined as dose adjustment to no less than one half of the current dosage or to no more than 2 times the current dosage
945,NCT02799095,",,,101:110:treatment",Females of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and on Day 1 before the first dose is administered
946,NCT02780401,"59:68:treatment,",History of autoimmunity that has not been controlled with treatment in the last 12 months
947,NCT02762266,",,37:46:treatment",with score =< 9 ((within 4 weeks of treatment)
948,NCT02753283,62:71:treatment,Those with a history of hypocalcemia or contraindication for treatment
949,NCT02725177,",,,,,,,,,,,326:335:treatment","Women of childbearing potential must be using adequate birth control measures (abstinence, hormonal contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) and must agree to continue such precautions, and not become pregnant or plan a pregnancy for 6 months after receiving their last treatment with study agent"
950,NCT02656706,",,122:131:treatment",must agree to use adequate barrier birth control measures during the course of the study and up to 2 months after end of treatment
951,NCT02654236,",,93:102:treatment",Women of child bearing potential should be willing to practice contraception throughout the treatment period
952,NCT02639065,99:108:treatment,"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued"
953,NCT02639065,",,,,216:225:treatment",Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 12 weeks after treatment discontinuation
954,NCT02593526,30:39:treatment,History of poor adherence to treatment
955,NCT02592551,106:115:treatment,"Any condition that, in the opinion of the investigator, would interfere with the evaluation of the study treatment or interpretation of subject safety or study results"
956,NCT02589522,",,73:82:treatment",Life expectance of greater than two months to allow completion of study treatment and assessment of dose-limiting toxicity
957,NCT02587312,"30:39:treatment,",Participants who are seeking treatment for their smoking or who report that they intend to quit smoking within the next 30 days and have made a 24-hour quit attempt in the past year
958,NCT02585973,4:13:treatment,Co-treatment with weak inhibitors of CYP3A4
959,NCT02585973,",,,106:115:treatment",Women of childbearing potential (WOCBP) must have negative pregnancy test within 72 hours prior to D1 of treatment
960,NCT02584647,",,,,,,150:159:treatment",Creatinine ? 1.5 x ULN or calculated creatinine clearance (CrCl) > 60 mL/min using the Cockcroft-Gault formula less than eight days pior to start of treatment
961,NCT02582775,",,104:113:treatment","Available donor per section 5: targeted MFI < 1,000 (MFI exceeding 1000 must be approved by the PI and treatment team.)"
962,NCT02582775,112:121:treatment,"adult or parent (with information sheet for minors, if applicable) prior to any research related procedures or treatment"
963,NCT02581215,29:38:treatment,Known allergy to any of the treatment components
964,NCT02579044,",,169:178:treatment",Sexually active male and female subjects of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment
965,NCT02578901,50:59:treatment,"Able to provide informed consent and comply with treatment and monitoring, or having a Legally Authorized Representative (LAR)"
966,NCT02578901,71:80:treatment,Having been previously randomized in this study at any stage of their treatment
967,NCT02578732,",,,,,178:187:treatment",Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment
968,NCT02577406,",,,61:70:treatment",at least 5% leukemic blasts in bone marrow after at least 2 treatment cycles
969,NCT02576444,",67:76:treatment",Inadequate bone marrow reserve within past 28 days prior to study treatment
970,NCT02576444,108:117:treatment,Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
971,NCT02576444,103:112:treatment,"Patient must not have a co-morbid condition(s) that, in the opinion of the investigator, prevent safe treatment"
972,NCT02576431,",44:53:treatment",Subjects who received less than 28 days of treatment and discontinued because of intolerance or toxicity are eligible
973,NCT02575404,",,33:42:treatment","Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus"
974,NCT02575404,",,,132:141:treatment",Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment
975,NCT02573493,",,,,,,,237:246:treatment","Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 3 months after completing treatment"
976,NCT02560766,",,,,,,,,308:317:treatment,","Sexually active patients must agree to use 2 medically accepted methods of contraception, 1 of which is a highly effective method (e.g., hormonal or intrauterine device [IUD]) [the second may be a barrier method (e.g., male condom, female condom, diaphragm or cervical cap)], during the course of the study treatment and for 4 weeks after the last dose of study treatment"
977,NCT02555280,27:36:treatment,Appropriate candidate for treatment using posterior surgical approach
978,NCT02555280,123:132:treatment,"Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures"
979,NCT02555189,",,,120:129:treatment,",Sexually active males unless they use a condom during intercourse while taking the drug and for 30 days after stopping treatment and should not father a child in this period. A condom is required to be used by vasectomized men in order to prevent delivery of the drug via seminal fluid
980,NCT02554903,",,101:110:treatment",Agreement to undertake monthly serum pregnancy tests during the study and up to 30 days after study treatment discontinuation
981,NCT02553447,111:120:treatment,Patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment
982,NCT02542202,",,,158:167:treatment,",Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatment
983,NCT02535923,103:112:treatment,"Current problematic drug or alcohol use that impacts functioning and study engagement, as deemed by a treatment provider"
984,NCT02535923,61:70:treatment,Sufficient clinical stability to participate as deemed by a treatment provider
985,NCT02533674,56:65:treatment,Limitation of the patient's ability to comply with the treatment or follow-up protocol
986,NCT02532621,",59:68:treatment",The patient has had >2 previous arteriovenous accesses in treatment arm
987,NCT02532543,41:50:treatment,Previous enrollment or randomization of treatment in the present study
988,NCT02531932,",,63:72:treatment",Negative serum pregnancy test within 7 days prior to starting treatment
989,NCT02530034,",,,,,,,,,305:314:treatment","Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative urine pregnancy test within 2 weeks prior to beginning treatment on this trial"
990,NCT02527200,14:23:treatment,"No change in treatment plan with growth hormone (GH) from randomisation to the end of the open-label period patients on growth hormone to stay on, patients off GH to stay off during this period. Adjustments in doses of growth hormone will be permitted)"
991,NCT02524275,",,,,194:203:treatment",Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment
992,NCT02519322,",,,52:61:treatment",Albumin >= 2.5 g/dL (within 28 days of first study treatment)
993,NCT02519322,",,,52:61:treatment",Amylase < 1.5 X ULN (within 28 days of first study treatment)
994,NCT02519322,",,,55:64:treatment",Hemoglobin >= 8.5 g/dL (within 28 days of first study treatment)
995,NCT02519322,",,,51:60:treatment",Lipase < 1.5 X ULN (within 28 days of first study treatment)
996,NCT02519322,",,,,166:175:treatment",Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 X upper limit of normal (ULN) (within 28 days of first study treatment)
997,NCT02519322,",,,72:81:treatment",White blood cells (WBC) >= 2.0 X 10^9/L (within 28 days of first study treatment)
998,NCT02519322,",39:48:treatment",Within 2 weeks prior to time of study treatment
999,NCT02519322,",,,,,248:257:treatment","subjects with TnT or TnI levels between > 1 to 2 x ULN will be permitted if repeat levels within 24 hours are </= 1 x ULN; if TnT or TnI levels are > 1 to 2 x ULN within 24 hours, the subject may undergo a cardiac evaluation and be considered for treatment, following a discussion with the investigator or designee"
1000,NCT02515110,",,135:144:treatment",Women of child-bearing potential (WCBP) must agree to use a medically accepted form of pregnancy prevention for the duration of study treatment
1001,NCT02512926,",,,,196:205:treatment",Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 3 months after study treatment
1002,NCT02510417,7:16:treatment,"Early treatment for single or multiple infections with EBV, CMV and/or adenovirus"
1003,NCT02503358,21:30:treatment,Conception while on treatment must be avoided
1004,NCT02503358,",94:103:treatment,","Estimated life expectancy, in the judgment of the investigator, which will permit receipt of treatment of 12 weeks or more"
1005,NCT02503358,",,,86:95:treatment","Known actionable mutations (e.g., EGFR, ALK, ROS1), against which there is available treatment"
1006,NCT02503358,33:42:treatment,"Patients who progressed on such treatment, i.e., have developed acquired resistance and are no longer reasonably expected to derive therapeutic benefit are eligible for the trial"
1007,NCT02500602,30:39:treatment,Must consent to complete all treatment and follow-up visits
1008,NCT02498613,",74:83:treatment",A New York Heart Association (NYHA) classification of II controlled with treatment
1009,NCT02498535,37:46:treatment,Willing and able to comply with the treatment schedule and procedures
1010,NCT02496663,",,,112:121:treatment",Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment
1011,NCT02496663,23:32:treatment,patients must also be treatment naive to EGFR-monoclonal antibody
1012,NCT02496611,12:21:treatment,History of treatment with growth hormone
1013,NCT02496208,",91:100:treatment",Any of the following that have not resolved within 28 days before the first dose of study treatment
1014,NCT02496208,",,,100:109:treatment",Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment
1015,NCT02496208,",,,,,191:200:treatment",The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.5 x the laboratory ULN within 7 days before the first dose of study treatment
1016,NCT02496208,",68:77:treatment",To any other site(s) within 28 days before the first dose of study treatment
1017,NCT02495415,54:63:treatment,patient who tested positive subsequent to their last treatment regimen
1018,NCT02495168,21:30:treatment,on the first day of treatment (prior to randomization at Visit 2)
1019,NCT02494258,",100:109:treatment","She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact"
1020,NCT02483910,"69:78:treatment,",Stable educational plan with no planned changes in the intensity of treatment for 6 months
1021,NCT02482376,34:43:treatment,Subjects unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach at length
1022,NCT02481245,24:33:treatment,"History of significant treatment non-adherence or situations where the subjects is unlikely to adhere to treatment, in the opinion of the investigator"
1023,NCT02479906,34:43:treatment,Subject is able to adhere to the treatment schedule
1024,NCT02479230,9:18:treatment,Current treatment on another clinical trial
1025,NCT02471430,",,76:85:treatment",Willingness to continue to use contraceptives for 90 days after completing treatment
1026,NCT02466750,",,,88:97:treatment",Females must agree to not become pregnant for 3 months after receipt of the last study treatment (vaccination)
1027,NCT02466009,24:33:treatment,Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study
1028,NCT02465060,",,,,121:130:treatment","Absolute neutrophil count >= 1,500/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)"
1029,NCT02465060,",,,,107:116:treatment","Platelets >= 100,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)"
1030,NCT02465060,",85:94:treatment","patient must be off the drug for at least 5 half-lives prior to registration to the treatment step (Step 1, 3, 5, 7)"
1031,NCT02465060,",,81:90:treatment",within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration
1032,NCT02465060,",42:51:treatment",within 4 weeks following notification of treatment assignment
1033,NCT02459119,",,107:116:treatment",Fertile patients must use effective contraception during and for up to 3 months after completion of study treatment
1034,NCT02459119,24:33:treatment,Previous assignment to treatment during this study
1035,NCT02456857,",,,150:159:treatment","Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment"
1036,NCT02452268,",,,116:125:treatment,","Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during the treatment portion of the study and for 4 months after completion of hetIL-15 administration"
1037,NCT02446457,",,,78:87:treatment","Absolute neutrophil count (ANC) >= 1.0 x 10^9/L, performed within 28 days of treatment initiation"
1038,NCT02446457,",,,53:62:treatment","Hemoglobin >= 8.0 g/dL, performed within 28 days of treatment initiation"
1039,NCT02446457,",,,55:64:treatment","Platelets >= 75 x 10^9/L, performed within 28 days of treatment initiation"
1040,NCT02446457,",,,,,,,,,,,,,396:405:treatment","Serum creatinine OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) (creatinine clearance will be calculated per institutional standard) =< 1.5 x upper limit of normal (ULN) OR >= 60 mL/min GFR or CrCl for subjects with creatinine levels > 1.5 x institutional ULN, performed within 28 days of treatment initiation"
1041,NCT02446457,",,,,,,143:152:treatment","Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN, performed within 28 days of treatment initiation"
1042,NCT02446093,71:80:treatment,Patients with biliary obstruction must be stented prior to initiating treatment
1043,NCT02438995,",,124:133:treatment,,",Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study
1044,NCT02438995,",,214:223:treatment",will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period
1045,NCT02437851,",,,,,,,,,,395:404:treatment","all women of childbearing potential must agree to use a reliable birth control method (oral contraceptive pills, intrauterine device, Nexplanon, DepoProvera, or permanent sterilization, etc., or another acceptable method as determined by the investigator) during the entire period of the trial (3 years), and must not intend to become pregnant during study participation and for 3 months after treatment is discontinued"
1046,NCT02436408,",53:62:treatment,",Male patients must agree to not donate sperm during treatment and for 3 months after last dose
1047,NCT02436408,",,48:57:treatment,",Male patients must agree to use condoms during treatment and for 3 months after last dose
1048,NCT02429830,59:68:treatment,Subject has been informed of the study procedures and the treatment and has signed an informed consent form
1049,NCT02425904,",,,,,,,248:257:treatment",Female patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to enrollment. Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment
1050,NCT02423863,115:124:treatment,"Serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety"
1051,NCT02419495,",,,97:106:treatment,,",Negative serum pregnancy test in women of childbearing potential within 7 days of first dose of treatment and patients of child-bearing potential must agree to use effective contraception during/after 3 months post dose
1052,NCT02415660,"112:121:treatment,,,,","Able to make one initial appointment at the Army Medical Department Center and School at Fort Sam Houston, one treatment visit approximately 2-3 days after the initial visit, and then a final outcome visit approximately 5-7 days after 2nd visit"
1053,NCT02409888,63:72:treatment,agree not to seek additional alcohol or other substance abuse treatment during the study period
1054,NCT02409888,29:38:treatment,mandated to substance abuse treatment by a court order
1055,NCT02407171,",126:135:treatment","Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 28 days of protocol treatment"
1056,NCT02403193,108:117:treatment,Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
1057,NCT02403193,",,,,174:183:treatment,","Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use 2 highly effective methods of contraception while taking study treatment and for 90 days after the last dose of study treatment"
1058,NCT02400463,",,,99:108:treatment",all females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment
1059,NCT02393794,",,91:100:treatment","their partners must use contraception prior to study entry, continuing for 5 months after treatment"
1060,NCT02393794,56:65:treatment,who have not fully recovered from side effects of such treatment
1061,NCT02392572,",,85:94:treatment",must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial
1062,NCT02389023,",58:67:treatment",Any groin incision on index leg within 12 weeks prior to treatment initiation
1063,NCT02369653,",78:87:treatment",Subjects scheduled to have > 3 Lumbar Punctures over the course of the study treatment period
1064,NCT02369458,",,,,,,,236:245:treatment,,","Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 1 month after completing treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately"
1065,NCT02367040,",89:98:treatment",Adequate baseline laboratory values collected no more than 7 days before starting study treatment
1066,NCT02366819,",,,,,,,242:251:treatment","Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment"
1067,NCT02359825,"43:52:treatment,",willing to comply with all aspects of the treatment and evaluation schedule over a 12 months period
1068,NCT02354703,79:88:treatment,"Prior to Randomization, the subject is compelled to participate in an alcohol treatment program to maintain his/her liberty"
1069,NCT02349867,",,,100:109:treatment",Any other hemorrhage/bleeding event >= grade 3 (CTCAE v4.0) within 12 weeks prior to initiation of treatment
1070,NCT02349867,",,,145:154:treatment",Bronchopulmonary hemorrhage/bleeding event >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0) within 12 weeks prior to of treatment
1071,NCT02349867,",,,113:122:treatment",Women of childbearing potential and men must agree to use a medically accepted form of birth control during the treatment
1072,NCT02349867,",,,121:130:treatment",Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
1073,NCT02343549,",,,113:122:treatment",Participants of childbearing age must use effective contraception for at least 6 months following completion of treatment
1074,NCT02340156,",,,,217:226:treatment","Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment"
1075,NCT02335905,",,153:162:treatment,",Female subjects who have reached menarche and are sexually active must be willing to practice sexual abstinence or dual methods of birth control during treatment and for at least 28 days after the last dose of any study drug
1076,NCT02332928,",67:76:treatment,",willing to use an acceptable method of birth control during study treatment and for 3 months afterwards
1077,NCT02332850,",75:84:treatment",The following laboratory results must be met within 7 days of study drug (treatment) administration
1078,NCT02323191,",,60:69:treatment,,",Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women less than or equal to (<=) 12 months post-menopause
1079,NCT02321501,",,,,151:160:treatment,","Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment"
1080,NCT02321501,",,,,,131:140:treatment,,,,",Sexually active males unless they use a condom during intercourse while taking drug and for 3 months after the last dose of study treatment. Male patients for 3 months should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. Also male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception during the study and for 3 months after the end of enrollment
1081,NCT02320292,",,127:136:treatment",of childbearing potential who are unwilling to employ adequate contraception for at least three months after completing study treatment
1082,NCT02316574,30:39:treatment,Agree to not seek additional treatment
1083,NCT02316574,29:38:treatment,Legally mandated to receive treatment
1084,NCT02316574,9:18:treatment,Seeking treatment for Alcohol Use Disorder
1085,NCT02315196,",,,,,,205:214:treatment,","Patients with reproductive potential must use an adequate contraceptive method (e.g. abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment"
1086,NCT02314377,",,,109:118:treatment",Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of starting treatment
1087,NCT02312596,51:60:treatment,"Alcohol or drug abuse, defined as current medical treatment for substance abuse"
1088,NCT02312596,",,88:97:treatment",Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator
1089,NCT02312570,",88:97:treatment",Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator
1090,NCT02312518,",,88:97:treatment",Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator
1091,NCT02312518,81:90:treatment,Presence of another wound that is concurrently treated and might interfere with treatment of index wound
1092,NCT02311361,",,,,,,255:264:treatment","Enrolled patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, the duration of study participation and 180 days (female patients) or 90 days (male patients) after the end of the treatment"
1093,NCT02310464,",95:104:treatment",Subjects of child-bearing potential must agree to use acceptable contraceptive methods during treatment and until the end of the study
1094,NCT02308709,",22:31:treatment,",Life expectancy with treatment should be ?6 months in the estimation of the treating physicians
1095,NCT02305537,29:38:treatment,Patients ineligible for the treatment program
1096,NCT02305537,107:116:treatment,those who report that they are unwilling to refrain from self-injurious behaviors during the waitlist and treatment periods
1097,NCT02303977,110:119:treatment,"Patients must be capable of giving informed consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing"
1098,NCT02303977,",,109:118:treatment",Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
1099,NCT02302976,9:18:treatment,seeking treatment for drug abuse/dependence (for experimental cocaine component)
1100,NCT02293057,43:52:treatment,"Determined to be in need of substance use treatment by the court intake worker, probation officer, presiding judge or magistrate, and/or school counselor"
1101,NCT02293057,26:35:treatment,already in substance use treatment (residential or outpatient) and wish to remain with outside provider (as determined through referral partner)
1102,NCT02291978,"103:112:treatment,",Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 5 hrs of total table time)
1103,NCT02287337,26:35:treatment,Inability to comply with treatment and follow-up schedule
1104,NCT02273375,128:137:treatment,"Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up"
1105,NCT02273375,33:42:treatment,Patients must be accessible for treatment and follow-up
1106,NCT02273375,"10:19:treatment,",Protocol treatment is to begin within 2 working days of patient randomization
1107,NCT02272998,",35:44:treatment",through 4 months after the end of treatment
1108,NCT02271919,15:24:treatment,Interested in treatment that might change smoking behavior
1109,NCT02268253,85:94:treatment,has signed informed consent prior to initiation of any study-specific procedures or treatment
1110,NCT02266719,36:45:treatment,Patients that are not eligible for treatment with commercially available endografts
1111,NCT02261519,179:188:treatment,"The identified caregiver should be considered reliable by the Investigator and per the local regulations in providing support to the subject to help ensure compliance with study treatment, study visits and protocol procedures who preferably is also able to provide input helpful for completing study rating scales"
1112,NCT02259504,79:88:treatment,"Subject with social, medical, or psychological conditions that interfere with treatment and follow-up evaluation"
1113,NCT02236013,76:85:treatment,Subject agrees not to participate in another interventional study while on treatment
1114,NCT02234193,34:43:treatment,"Subject is unable to comply with treatment, home care or follow-up visits"
1115,NCT02208362,126:135:treatment,"Research participants with any non-malignant intercurrent illness which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the research participant on protocol"
1116,NCT02207439,116:125:treatment,Patients must sign an informed consent document that indicates they are aware of the investigational nature of the treatment in this protocol as well as the potential risks and benefits
1117,NCT02200445,",,,104:113:treatment,",Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment
1118,NCT02188121,"62:71:treatment,,,",defined as entering one of the two-year First Episode Clinic treatment programs as a de novo patient (new disease) or having been diagnosed >2 years ago and had at least six visits in the past 12 months (prevalent disease)
1119,NCT02184520,10:19:treatment,Requires treatment of more than two vertebral levels
1120,NCT02181478,6:15:treatment,such treatment may continue until the planned course is completed
1121,NCT02178709,",,,149:158:treatment","WOCBP and men must agree to use adequate contraception prior, to study entry, for the duration of study participation, and 8 weeks after the end of treatment"
1122,NCT02176967,58:67:treatment,"Patients must meet the specified criteria for one of the treatment groups defined below; genomic features include MYCN gene amplification, segmental chromosome aberrations (somatic copy number loss at 1p, 3p, 4p, or 11q or somatic copy number gain at 1q, 2p, or 17q) and deoxyribonucleic acid (DNA) index"
1123,NCT02171104,",,,97:106:treatment",menstruating females must have a negative serum or urine pregnancy test within 14 days of study treatment start
1124,NCT02166905,29:38:treatment,Have been informed of other treatment options
1125,NCT02166905,",,118:127:treatment","Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment"
1126,NCT02161211,11:20:treatment,inpatient treatment at Lodging Plus primarily for alcohol (vs. other drug) dependence
1127,NCT02159027,10:19:treatment,"Adequate treatment is defined as meeting the current recommendations of the Centers of Disease Control and Prevention (CDC), National Institutes of Health (NIH) and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA) guidelines33"
1128,NCT02159027,123:132:treatment,non-heterosexually active or have a an exclusive vasectomized partner from screening throughout the duration of the study treatment
1129,NCT02158793,64:73:treatment,willing and able to return to follow-up visits as described in treatment plan
1130,NCT02158234,",,,143:152:treatment",Women of childbearing potential or sexually active males must be willing to use effective contraception throughout their participation in the treatment phase of the study
1131,NCT02153229,101:110:treatment,"Patients must sign a document that indicates that they are aware of the investigative nature of the treatment of this protocol, and the potential benefits and risks"
1132,NCT02152995,"11:20:treatment,,",All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grade =< 1
1133,NCT02143050,",,70:79:treatment,","Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician"
1134,NCT02140255,159:168:treatment,"Otherwise assessed by the site investigator or designee, in consultation with the Clinical Management Committee (CMC), as having an indication to re-initiate treatment"
1135,NCT02135588,",,86:95:treatment",must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial
1136,NCT02133196,",,136:145:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
1137,NCT02132598,",69:78:treatment",Any of the following within 6 months before the first dose of study treatment
1138,NCT02132598,",99:108:treatment",Patients must have normal organ and marrow function as defined below: (within 4 days of beginning treatment unless noted otherwise)
1139,NCT02132598,",,,,191:200:treatment",The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial thromboplastin time (PTT) test ? 1.3 x the laboratory ULN within 7 days before the first dose of study treatment
1140,NCT02128230,107:116:treatment,Patients must have signed an IRB-approved informed consent indicating their understanding of the proposed treatment and understanding that the protocol has been approved by the IRB
1141,NCT02122081,",,,100:109:treatment",Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment
1142,NCT02122081,"116:125:treatment,,","If the patient has an intra-abdominal chloroma on presentation, and has a partial response or complete response to treatment (size reduction of chloroma and marrow blast < 10%), the patient is eligible"
1143,NCT02111850,",,142:151:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
1144,NCT02111850,",,122:131:treatment",Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
1145,NCT02111850,",,120:129:treatment",Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
1146,NCT02108860,",,95:104:treatment",Both women and men must be willing to use an effective means of birth control while receiving treatment through this study
1147,NCT02108860,33:42:treatment,Willing and able to comply with treatment and follow-up procedures
1148,NCT02106650,",,80:89:treatment,",Male patients are to agree to use a barrier method of contraception from study treatment initiation until at least 90 days after the last administration of Folotyn
1149,NCT02102113,21:30:treatment,Current or lifetime treatment
1150,NCT02101736,",,,98:107:treatment",Hemoptysis of ?0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment
1151,NCT02101034,",,,187:196:treatment","Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraceptive during the period of the trial and for at least 90 days after completion of treatment"
1152,NCT02100891,",,,110:119:treatment,","Fertile females who are unwilling to use contraceptive techniques during and for the twelve months following treatment, as well as females who are pregnant or actively breast feeding"
1153,NCT02100891,",,,108:117:treatment",Fertile males who are unwilling to use contraceptive techniques during and for the twelve months following treatment
1154,NCT02100891,86:95:treatment,"Patients, who in the opinion of the investigator, may not be able to comply with the treatment plan or safety monitoring requirements of the study Page 16 of 86 Children's Hospital of Wisconsin Medical College of Wisconsin"
1155,NCT02099058,",,,113:122:treatment",Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment
1156,NCT02098161,198:207:treatment,Any concurrent severe and/or uncontrolled medical conditions that could increase the patient's risk for toxicity while in the study or that could confound discrimination between disease- and study treatment-related toxicities
1157,NCT02098161,51:60:treatment,"Willing and able to comply with scheduled visits, treatment plan and laboratory tests"
1158,NCT02094794,",,149:158:treatment","The time from the end last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days from planned start of study treatment"
1159,NCT02080221,",,,,,178:187:treatment",Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment
1160,NCT02075671,",,,,,,257:266:treatment","They will also be required to be on at least one reliable form of effective birth control [examples: barrier method (condoms, diaphragm), oral, injectable, implant birth control or abstinence] during the course of this study and 30 days following the last treatment period"
1161,NCT02072356,",,117:126:treatment",Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs in a single treatment
1162,NCT02059239,",,,,128:137:treatment",Male and female subjects must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment
1163,NCT02056873,41:50:treatment,"(If the subject chooses not to have the treatment, they cannot participate in the study"
1164,NCT02055053,36:45:treatment,History of Chronic pain or ongoing treatment for chronic pain
1165,NCT02048371,76:85:treatment,Patients who progress on placebo are specifically allowed to enroll on the treatment arm of the study if they meet all other entry criteria
1166,NCT02048371,24:33:treatment,Previous assignment to treatment during this study
1167,NCT02043548,",,,104:113:treatment,",Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment
1168,NCT02020707,",,74:83:treatment",Willing to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuation
1169,NCT02016924,",,111:120:treatment",females of childbearing potential must agree to utilize highly effective contraception methods while on study treatment or agree to abstain from heterosexual intercourse throughout the study period
1170,NCT02013778,37:46:treatment,Participation in another concurrent treatment protocol
1171,NCT02004275,",65:74:treatment",Must agree to not become pregnant or breast feed a child during treatment on this protocol
1172,NCT02004275,65:74:treatment,Previous hypersensitivity to any of the components of the study treatment
1173,NCT01993719,",,142:151:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
1174,NCT01993719,",,122:131:treatment",Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
1175,NCT01993719,",,120:129:treatment",Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
1176,NCT01990209,",,,163:172:treatment,",Male patients (even those post vasectomy) who are willing to use adequate contraceptive measures or abstain from heterosexual intercourse during the entire study treatment period and for 4 months after the last dose of study drug
1177,NCT01989546,81:90:treatment,"for the duration of study participation, and for 30 days after completing study treatment"
1178,NCT01983462,84:93:treatment,"Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study"
1179,NCT01976585,25:34:treatment,Able to comply with the treatment schedule
1180,NCT01972919,35:44:treatment,Participation in another clinical treatment trial while on study
1181,NCT01967823,",,136:145:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
1182,NCT01967823,",,122:131:treatment",Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
1183,NCT01967823,",,120:129:treatment",Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
1184,NCT01966367,30:39:treatment,"Approval for the use of this treatment protocol by the individual institution's Human Rights Committee must be obtained, in accordance with the institutional assurance policies of the U. S. Department of Health and Human Services"
1185,NCT01959698,",,157:166:treatment","HBV DNA is negative, the subject may be included but must undergo at least every 2 months HBV DNA polymerase chain reaction (PCR) testing from the start of treatment throughout the duration the treatment course"
1186,NCT01959698,",,,,,125:134:treatment",Serum creatinine of =< 1.5 mg/dL; if creatinine > 1.5 mg/dL creatinine clearance must be > 60 mL/min within 7 days prior to treatment either measured or calculated using a standard Cockcroft and Gault formula
1187,NCT01943851,",73:82:treatment",at least 28 days (whichever is longer) following the last dose of study treatment
1188,NCT01920737,",,113:122:treatment,",Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and at least 4 months after treatment is finished
1189,NCT01896999,",,113:122:treatment","vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment"
1190,NCT01893554,75:84:treatment,Subjects with clinically insignificant cardiac abnormalities requiring no treatment may be enrolled
1191,NCT01884740,",,,144:153:treatment",Patients of reproductive age must agree to use a medically effective method of contraception during and for a period of three months after the treatment period
1192,NCT01877382,23:32:treatment,for which no standard treatment is available
1193,NCT01877382,"1:10:treatment,",treatment with small-molecule targeted agents within 2 weeks before study drug treatment
1194,NCT01873131,46:55:treatment,Willingness of parent/guardian to follow the treatment schedule and post treatment care requirements
1195,NCT01873131,56:65:treatment,Willingness of parent/guardian to receive EXPERIMENTAL treatment
1196,NCT01873131,48:57:treatment,"whose parent/guardian is unable to comply with treatment, home care or follow-up visits"
1197,NCT01871766,",,,,,,143:152:treatment",Female participants ? 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment
1198,NCT01869114,96:105:treatment,"Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing"
1199,NCT01861106,174:183:treatment,"Should a patient have progressive disease, or a donor becomes not available after enrollment, the patient will be referred back to their primary hematologist-oncologist for treatment"
1200,NCT01841333,",,,138:147:treatment",Serum/urine pregnancy test (for females of childbearing potential) that is negative within 72 hours prior to initiation of first dose of treatment
1201,NCT01829958,38:47:treatment,Must meet criteria for initiation of treatment
1202,NCT01827384,89:98:treatment,patients on other trials will be eligible as long as they are no longer receiving study treatment
1203,NCT01827384,",,99:108:treatment",radiofrequency ablation (RFA) of localized lesions should have been performed >= 2 weeks prior to treatment
1204,NCT01822522,",68:77:treatment",Any of the following within 28 days before the first dose of study treatment
1205,NCT01822522,",,,100:109:treatment",Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment
1206,NCT01822522,",,,,,195:204:treatment",The participant has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.3 x the laboratory ULN within 7 days before the first dose of study treatment
1207,NCT01817751,",,,117:126:treatment",Any other hemorrhage/bleeding event >= grade 3 (NCI CTCAE v4.0) within 4 weeks or less prior to first dose of study treatment
1208,NCT01817751,",,,121:130:treatment",Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
1209,NCT01811498,",,124:133:treatment",Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period
1210,NCT01804634,58:67:treatment,Patients must be willing to participate in all stages of treatment
1211,NCT01794793,",,,131:140:treatment",In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment
1212,NCT01794793,58:67:treatment,"Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures"
1213,NCT01787409,61:70:treatment,"During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up"
1214,NCT01776190,"49:58:treatment,",You are unable to come in three days a week for treatment for a 10-week period
1215,NCT01763970,",,79:88:treatment",refusal of women of child bearing potential to take a pregnancy test prior to treatment
1216,NCT01742299,58:67:treatment,"Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures"
1217,NCT01720836,",,59:68:treatment",Subjects must be within 4 to 12 weeks of standard of care treatment for their particular stage of disease
1218,NCT01720836,",63:72:treatment",Subjects must not be more than 12 weeks from standard of care treatment for their particular stage of disease
1219,NCT01670877,",,77:86:treatment,",Men must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product
1220,NCT01620216,",,175:184:treatment",Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatment
1221,NCT01620216,",100:109:treatment",Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment
1222,NCT01581749,58:67:treatment,implanted hardware or other material that would prohibit treatment planning or delivery
1223,NCT01562626,",,,82:91:treatment",women must have a negative serum or urine pregnancy test 1 week before beginning treatment on this trial
1224,NCT01532687,32:41:treatment,must be willing to comply with treatment and follow-up
1225,NCT01495637,20:29:treatment,Persistence (after treatment) of any of the following in the PICU before enrollment:
1226,NCT01367444,33:42:treatment,Enrolment in any other clinical treatment study throughout the duration of the SAR422459 study
1227,NCT01366612,",,,,90:99:treatment",unwilling to use acceptable birth control methods (men or women) for twelve months after treatment
1228,NCT01312857,",,54:63:treatment",Calcium ? lower limit of normal (? 48 hours prior to treatment start.)
1229,NCT01312857,",,31:40:treatment",Lab values ? 14 days prior to treatment start:
1230,NCT01312857,",,56:65:treatment",Magnesium ? lower limit of normal (? 48 hours prior to treatment start.)
1231,NCT01312857,",36:45:treatment",Renal function (? 14 days prior to treatment start)
1232,NCT01306045,",222:231:treatment",Individuals who meet the eligibility criteria for EGFR germline mutation testing but who do not have advanced cancer as defined in 3.1.1 may enroll for EGFR germline mutation testing only and will not be eligible for the treatment or NOS arms
1233,NCT01280669,18:27:treatment,are receiving no treatment
1234,NCT01269853,",,124:133:treatment",Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period
1235,NCT01261728,31:40:treatment,"Supportive care trials or non-treatment trials, e.g. QOL"
1236,NCT01220583,",,,123:132:treatment,",Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment
1237,NCT01174121,",,136:145:treatment",Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
1238,NCT01174121,18:27:treatment,The experimental treatment being evaluated in this protocol depends on an intact immune system
1239,NCT01174121,",,122:131:treatment",Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
1240,NCT01174121,",,120:129:treatment",Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
1241,NCT01059786,",59:68:treatment",agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment
1242,NCT00906984,",19:28:treatment",within 15 days of treatment demonstrating
1243,NCT00739362,31:40:treatment,Right-handedness (because the treatment will be given to the left dorsolateral prefrontal cortex and the evidence accumulated in this region was only in right-handed individuals)
1244,NCT00472329,",,,,99:108:treatment",Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
1245,NCT00338377,",,60:69:treatment",Pregnancy testing will be performed within 7 days prior to treatment. (Turnstile II)
1246,NCT00004317,"4:13:treatment,",No treatment within the first year of life
1247,NCT03179163,1:9:chronic_disease,diabetes
1248,NCT03099590,24:32:chronic_disease,laboratory evidence of diabetes
1249,NCT03060772,12:20:chronic_disease,History of diabetes
1250,NCT03058146,12:20:chronic_disease,History of diabetes
1251,NCT03041844,81:89:chronic_disease,DUs must be present on the ankle or foot and be secondary to complications from diabetes
1252,NCT03034213,"14:22:chronic_disease,,,",Uncontrolled diabetes (i.e. known HbA1C value > 7% within the prior 6 weeks of the Screening Visit)
1253,NCT03003689,1:9:chronic_disease,diabetes
1254,NCT02975986,1:9:chronic_disease,diabetes status
1255,NCT02967315,15:23:chronic_disease,Patients with diabetes
1256,NCT02964039,14:22:chronic_disease,"Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions"
1257,NCT02927639,"19:27:chronic_disease,",Have been seen in diabetes clinic in the last 6 months
1258,NCT02881515,12:20:chronic_disease,history of diabetes
1259,NCT02857283,1:9:chronic_disease,diabetes requiring medication
1260,NCT02838797,1:9:chronic_disease,diabetes
1261,NCT02836574,14:22:chronic_disease,uncontrolled diabetes (defined as metabolically unstable by the Investigator)
1262,NCT02823665,59:67:chronic_disease,Healthy non-surgical patients with no personal history of diabetes
1263,NCT02823665,56:64:chronic_disease,Healthy non-surgical patients with personal history of diabetes
1264,NCT02798458,"14:22:chronic_disease,,",Uncontrolled diabetes with a hemoglobin A1C greater than 10
1265,NCT02772562,14:22:chronic_disease,Uncontrolled diabetes
1266,NCT02751866,1:9:chronic_disease,diabetes
1267,NCT02723266,23:31:chronic_disease,signs and symptoms of diabetes
1268,NCT02690116,14:22:chronic_disease,Uncontrolled diabetes (fatigue-related factor)
1269,NCT02682147,1:9:chronic_disease,diabetes
1270,NCT02578732,14:22:chronic_disease,"Uncontrolled diabetes. If patient has diabetes, confirmation on status (controlled or uncontrolled) required at registration"
1271,NCT02555280,14:22:chronic_disease,Uncontrolled diabetes
1272,NCT02531932,"14:22:chronic_disease,,",uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
1273,NCT02522494,14:22:chronic_disease,Drug-induced diabetes
1274,NCT02462161,13:21:chronic_disease,Preexisting diabetes
1275,NCT02430077,"32:40:chronic_disease,,,,",Previous clinical diagnosis of diabetes mellitus or fasting blood glucose ? 126 mg/dL or hemoglobin A1c ? 6.5%
1276,NCT02425566,1:9:chronic_disease,diabetes
1277,NCT02417701,"26:34:chronic_disease,,",Patients with controlled diabetes are allowed on study; controlled diabetes is defined as fetal bovine serum (FBS) =< 130 mg/dL in the context of this study
1278,NCT02408120,36:44:chronic_disease,Hyperglycemia without a history of diabetes
1279,NCT02373644,1:9:chronic_disease,diabetes
1280,NCT02347995,"38:46:chronic_disease,,,,",untreated and / or poorly controlled diabetes with fasting blood glucose of greater than 170 and HbA1c greater than 10.0
1281,NCT02329652,1:9:chronic_disease,diabetes or any condition which requires frequent blood pressure monitoring or frequent venipuncture
1282,NCT02307565,1:9:chronic_disease,diabetes
1283,NCT02253368,1:9:chronic_disease,diabetes
1284,NCT02245841,28:36:chronic_disease,Patients with uncontrolled diabetes
1285,NCT02244814,23:31:chronic_disease,suspected preexisting diabetes
1286,NCT02226159,"1:9:chronic_disease,,",diabetes (type I or type II)
1287,NCT02219581,15:23:chronic_disease,Patients with diabetes
1288,NCT02169037,1:9:chronic_disease,diabetes (1 point)
1289,NCT02139436,1:9:chronic_disease,diabetes
1290,NCT02095808,19:27:chronic_disease,Poorly controlled diabetes
1291,NCT02087826,60:68:chronic_disease,Currently taking any medications used for the treatment of diabetes
1292,NCT01954966,1:9:chronic_disease,diabetes
1293,NCT01905046,",,74:82:chronic_disease",Patients with hemoglobin a1c > 6.3 or who are being actively treated for diabetes
1294,NCT01883258,12:20:chronic_disease,history of diabetes
1295,NCT01807897,"19:27:chronic_disease,,",Poorly controlled diabetes (HbA1c > 9.0)
1296,NCT01803451,25:33:chronic_disease,healthy control without diabetes
1297,NCT01653080,12:20:chronic_disease,History of diabetes
1298,NCT01627301,1:9:chronic_disease,diabetes
1299,NCT01573429,14:22:chronic_disease,Uncontrolled diabetes
1300,NCT01422746,"23:31:chronic_disease,,,,","Previous diagnosis of diabetes, fasting glucose ?126 mg/dL, or a hemoglobin A1c ?6.5%"
1301,NCT01421810,"23:31:chronic_disease,,,,","Previous diagnosis of diabetes, fasting glucose ?126 mg/dL, or a hemoglobin A1c >6.5%"
1302,NCT01269034,1:9:chronic_disease,diabetes
1303,NCT01028846,22:30:chronic_disease,No family history of diabetes
1304,NCT00930228,25:33:chronic_disease,A previous diagnosis of diabetes
1305,NCT00929006,"23:31:chronic_disease,,,,","Previous diagnosis of diabetes, fasting glucose > or = 126 mg/dl, or a hemoglobin A1c > or = 6.5%"
1306,NCT00862433,",,51:59:chronic_disease",Nonobese (BMI less than or equal to 29.9) without diabetes
1307,NCT00862433,",,54:62:chronic_disease",Overweight (BMI greater than or equal to 27) without diabetes
1308,NCT00678145,27:35:chronic_disease,1st degree relatives with diabetes
1309,NCT00678145,30:38:chronic_disease,No 1st degree relatives with diabetes
1310,NCT00594217,"25:33:chronic_disease,,,,","A previous diagnosis of diabetes, a fasting glucose ? 126 mg/dl, or a hemoglobin A1c > 6.5%"
1311,NCT00085982,13:21:chronic_disease,Presence of diabetes as defined by the 2006 ADA criteria
1312,NCT03177265,20:28:chronic_disease,ICD 9 diagnosis of dementia (excluded during data abstraction process)
1313,NCT03166371,9:17:chronic_disease,Current dementia
1314,NCT03134274,6:14:chronic_disease,Have dementia
1315,NCT03116464,"44:52:chronic_disease,",Be involved in the care of the person with dementia (at least 4 hours of care per day)
1316,NCT03116464,81:89:chronic_disease,Be the primary unpaid family or friend who helps or supports an individual with dementia
1317,NCT03070535,12:20:chronic_disease,"Be free of dementia, and able to cognitively and physically give informed consent"
1318,NCT03054519,",,52:60:chronic_disease",Mini-Mental Status Examination (MMSE) score <23 or dementia
1319,NCT03053908,",,74:82:chronic_disease",History of a first-degree family member with early onset (age <60 years) dementia
1320,NCT03046121,"21:29:chronic_disease,,,,","screen positive for dementia on well-validated scales (Montreal Cognitive Assessment {MoCA} ? 25 123-127 and AD8 >2 128,129)"
1321,NCT03037879,",,44:52:chronic_disease",Pre-screen MoCA score of < 22 (to rule out dementia)
1322,NCT02982759,63:71:chronic_disease,Exclusion criteria include children with clinically-diagnosed dementia
1323,NCT02955537,117:125:chronic_disease,Patients with other serious medical conditions that may affect their ability to self-monitor blood pressure (such a dementia)
1324,NCT02901041,1:9:chronic_disease,dementia
1325,NCT02872857,12:20:chronic_disease,History of dementia
1326,NCT02839759,13:21:chronic_disease,No signs of dementia
1327,NCT02833792,"33:41:chronic_disease,","Diagnosed with mild to moderate dementia for at least 3 months prior to enrollment, based on the National Institute of Neurological and Communicative"
1328,NCT02830074,64:72:chronic_disease,"unable to provide self-consent for participation (e.g., due to dementia)"
1329,NCT02778282,20:28:chronic_disease,DSM-V diagnosis of dementia
1330,NCT02762604,"13:21:chronic_disease,,,,",Presence of dementia (telephone-based memory impairment screen < 5 or Ascertain Dementia 8-item Informant Questionnaire score > 1)
1331,NCT02726906,12:20:chronic_disease,Absence of dementia
1332,NCT02726906,10:18:chronic_disease,Baseline dementia
1333,NCT02724930,1:9:chronic_disease,dementia
1334,NCT02698722,18:26:chronic_disease,Known history of dementia
1335,NCT02663934,13:21:chronic_disease,presence of dementia
1336,NCT02614365,",,35:43:chronic_disease",Scored below 24 on the MMSE (have dementia)
1337,NCT02600754,10:18:chronic_disease,probable dementia
1338,NCT02567227,13:21:chronic_disease,Presence of dementia
1339,NCT02567227,1:9:chronic_disease,dementia diagnosed by baseline cognitive assessment
1340,NCT02563574,13:21:chronic_disease,Evidence of dementia
1341,NCT02465034,"10:18:chronic_disease,",Signs of dementia (score < 24 on the Montreal Cognitive Assessment)
1342,NCT02461927,9:17:chronic_disease,Current dementia
1343,NCT02460900,"20:28:chronic_disease,,",Meets criteria for dementia by scoring below 10 on the Hopkins HIV Dementia Scale
1344,NCT02457832,12:20:chronic_disease,Absence of dementia
1345,NCT02427997,"11:19:chronic_disease,,",free from dementia as determined using the Mini Mental State Exam (MMSE>=24)
1346,NCT02414178,34:42:chronic_disease,"Cognitively normal, or with mild dementia, as assessed clinically"
1347,NCT02389465,21:29:chronic_disease,Absence of clinical dementia
1348,NCT02366611,13:21:chronic_disease,Substantial dementia
1349,NCT02347995,1:9:chronic_disease,dementia by clinical evaluation
1350,NCT02347202,71:79:chronic_disease,caregivers who participate must be spouses or partners of people with dementia living with them at home when they enter the study
1351,NCT02347202,86:94:chronic_disease,not having a family member with whom they are in communication about the person with dementia
1352,NCT02346929,1:9:chronic_disease,dementia
1353,NCT02332291,1:9:chronic_disease,dementia
1354,NCT02317523,41:49:chronic_disease,Providing in-home care to a spouse with dementia
1355,NCT02266004,1:9:chronic_disease,dementia
1356,NCT02260258,14:22:chronic_disease,Pre-existing dementia
1357,NCT02219555,81:89:chronic_disease,"someone who could be considered a vulnerable person, such as an individual with dementia"
1358,NCT02204956,22:30:chronic_disease,current diagnosis of dementia
1359,NCT02165449,14:22:chronic_disease,Diagnosis of dementia of any type
1360,NCT02137122,"13:21:chronic_disease,,",Evidence of dementia (MMSE < 20)
1361,NCT01973283,",,41:49:chronic_disease",Mini Mental Exam < 24 or a diagnosis of dementia
1362,NCT01811381,14:22:chronic_disease,diagnosis of dementia
1363,NCT01530958,11:19:chronic_disease,prevalent dementia
1364,NCT03178552,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positivity
1365,NCT03137771,"7:41:chronic_disease,,",Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter
1366,NCT03125902,10:44:chronic_disease,Negative human immunodeficiency virus (HIV) test at screening
1367,NCT03000257,37:71:chronic_disease,Confirmed positive test results for human immunodeficiency virus (HIV)
1368,NCT02845596,16:50:chronic_disease,Infection with human immunodeficiency virus (HIV)
1369,NCT02799095,41:75:chronic_disease,The subject is known to be positive for human immunodeficiency virus (HIV)
1370,NCT02682407,21:55:chronic_disease,Have a diagnosis of human immunodeficiency virus (HIV)
1371,NCT02663622,47:81:chronic_disease,Patients seropositive or PCR positive for the human immunodeficiency virus (HIV)
1372,NCT02547662,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positive
1373,NCT02536794,1:35:chronic_disease,human immunodeficiency virus (HIV)
1374,NCT02495415,47:81:chronic_disease,"Known history of, or positive test result for human immunodeficiency virus (HIV) infection"
1375,NCT02493530,18:52:chronic_disease,Known history of human immunodeficiency virus (HIV)
1376,NCT02456857,18:52:chronic_disease,Known history of human immunodeficiency virus (HIV) seropositivity
1377,NCT02417701,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positive patients who meet the following criteria
1378,NCT02411656,24:58:chronic_disease,Has a known history of human immunodeficiency virus (HIV)
1379,NCT02397083,38:72:chronic_disease,Patients who have a known history of human immunodeficiency virus (HIV) seropositivity
1380,NCT02394028,1:35:chronic_disease,human immunodeficiency virus (HIV)
1381,NCT02389309,21:55:chronic_disease,Patients with known human immunodeficiency virus (HIV)
1382,NCT02323191,12:46:chronic_disease,History of human immunodeficiency virus (HIV)
1383,NCT02273362,40:74:chronic_disease,Participants with a known diagnosis of human immunodeficiency virus (HIV)
1384,NCT02268253,11:45:chronic_disease,has known human immunodeficiency virus (HIV)
1385,NCT02227199,35:69:chronic_disease,Patients known to be positive for human immunodeficiency virus (HIV)
1386,NCT02215096,21:55:chronic_disease,A positive test for human immunodeficiency virus (HIV) antibody (testing at time of screening is not required)
1387,NCT02177838,15:49:chronic_disease,"Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria"
1388,NCT02165007,31:65:chronic_disease,Patients seropositive for the human immunodeficiency virus (HIV)
1389,NCT02163317,1:35:chronic_disease,human immunodeficiency virus (HIV) testing
1390,NCT02146924,"31:65:chronic_disease,",research participants who are human immunodeficiency virus (HIV) positive based on testing performed within 4 weeks of enrollment
1391,NCT02122081,31:65:chronic_disease,Patients seropositive for the human immunodeficiency virus (HIV)
1392,NCT02120222,13:47:chronic_disease,Known to be human immunodeficiency virus (HIV) seropositive
1393,NCT02106650,21:55:chronic_disease,"known, uncontrolled human immunodeficiency virus (HIV)-positive diagnosis"
1394,NCT02003222,21:55:chronic_disease,Patients with known human immunodeficiency virus (HIV) infection
1395,NCT01976585,18:52:chronic_disease,Known history of human immunodeficiency virus (HIV)
1396,NCT01976169,20:54:chronic_disease,Known positive for human immunodeficiency virus (HIV)
1397,NCT01951885,35:69:chronic_disease,Patients who are seropositive for human immunodeficiency virus (HIV)
1398,NCT01925131,"30:64:chronic_disease,",Patients who are known to be human immunodeficiency virus (HIV)+ are eligible providing they meet all of the following additional criteria within 28 days prior to registration
1399,NCT01919619,7:41:chronic_disease,Known human immunodeficiency virus (HIV) seropositive
1400,NCT01823198,30:64:chronic_disease,Patients who are known to be human immunodeficiency virus (HIV)-seropositive
1401,NCT01817751,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positivity
1402,NCT01620216,7:41:chronic_disease,Known human immunodeficiency virus (HIV)-positive patient
1403,NCT01415882,7:41:chronic_disease,Known human immunodeficiency virus (HIV) positive
1404,NCT01037790,45:79:chronic_disease,The subject is known to be positive for the human immunodeficiency virus (HIV)
1405,NCT00919503,31:65:chronic_disease,Patients who are positive for human immunodeficiency virus (HIV)
1406,NCT00716066,45:79:chronic_disease,Patients who are serologically positive for human immunodeficiency virus (HIV)
1407,NCT00358657,14:48:chronic_disease,Positive for human immunodeficiency virus (HIV)
1408,NCT03135171,"10:27:treatment,",The last radiation therapy must have occurred ?3 weeks prior to study registration
1409,NCT03113825,7:24:treatment,Prior radiation therapy to the chest [Period 2]
1410,NCT03077243,18:35:treatment,Prior history of radiation therapy to the head and neck
1411,NCT03076333,40:57:treatment,Previous radiation exposure precluding radiation therapy
1412,NCT02982226,12:29:treatment,History of radiation therapy of the affected foot
1413,NCT02774421,37:54:treatment,Patients who have already undergone radiation therapy for current recurrence
1414,NCT02501473,20:37:treatment,"For Parts 4 and 5, radiation therapy is omitted"
1415,NCT02496208,26:43:treatment,The subject has received radiation therapy
1416,NCT02442635,11:28:treatment,Receiving radiation therapy
1417,NCT02434809,32:49:treatment,Patient is planning to undergo radiation therapy for primary
1418,NCT02359825,1:18:treatment,radiation therapy
1419,NCT02315612,"1:18:treatment,",radiation therapy 3 weeks prior to apheresis
1420,NCT02291848,",,72:89:treatment",Pulse oximetry of >93% on room air in patients who previously received radiation therapy
1421,NCT02277548,33:50:treatment,Patients anticipated to receive radiation therapy with Protons
1422,NCT02236013,"13:30:treatment,",Subject has radiation therapy within 4 weeks prior to the first study dose
1423,NCT02217709,50:67:treatment,Patients should not be considered candidates for radiation therapy
1424,NCT02208362,",123:140:treatment",Radiographic evidence of progression/recurrence of the measurable disease more than 12 weeks after the end of the initial radiation therapy
1425,NCT02163317,",,139:156:treatment","willing and able to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire (baseline, 6, 12 and 24 months post end of radiation therapy)"
1426,NCT02160288,10:27:treatment,Previous radiation therapy to the anal canal and rectum
1427,NCT02132598,26:43:treatment,The subject has received radiation therapy
1428,NCT02125786,"32:49:treatment,",Interval from start of initial radiation therapy to enrollment > 9 months
1429,NCT02125786,",,67:84:treatment",Pregnant women are excluded from enrollment on this study because radiation therapy is an agent with the potential for teratogenic or abortifacient effects
1430,NCT02112617,83:100:treatment,Participants or their legal guardian must sign consent prior to the initiation of radiation therapy
1431,NCT02112617,"54:71:treatment,",Patients will be ineligible if any prior therapeutic radiation therapy > 500 cGy has been delivered
1432,NCT02112617,",,,99:116:treatment",Women of childbearing age/menstruating must have a negative pregnancy test prior to initiation of radiation therapy
1433,NCT02110992,31:48:treatment,Original pathology report and radiation therapy records not available
1434,NCT02078102,"33:50:treatment,",Patients must not have received radiation therapy within the past 4 weeks
1435,NCT01992861,24:41:treatment,Patients with no prior radiation therapy to the pelvis
1436,NCT01941316,"37:54:treatment,","Patients may have received previous radiation therapy, but it must have been completed at least 21 days prior to enrollment and the patient should have recovered from all associated toxicities"
1437,NCT01878617,29:46:treatment,Completed protocol-directed radiation therapy
1438,NCT01871766,30:47:treatment,Patients requiring emergency radiation therapy are eligible for enrollment on this study
1439,NCT01817751,",43:60:treatment,",At least 12 weeks since the completion of radiation therapy to a total of >=50Gy
1440,NCT01659203,27:44:allergy_name,History of sensitivity to radiation therapy
1441,NCT01333046,",,88:105:treatment",Pulse oximetry of more than 95 percent on room air in patients who previously received radiation therapy
1442,NCT03138512,35:53:chronic_disease,with an active known or suspected autoimmune disease
1443,NCT03123783,28:46:chronic_disease,"Active, known or suspected autoimmune disease"
1444,NCT03104699,26:44:chronic_disease,Active or history of any autoimmune disease
1445,NCT03001882,46:64:chronic_disease,"Participants with active, known or suspected autoimmune disease"
1446,NCT02988960,"57:75:chronic_disease,",Participant must not have an active or prior documented autoimmune disease in the last 2 years
1447,NCT02955251,"28:46:chronic_disease,",Active or prior documented autoimmune disease in the last 2 years
1448,NCT02947165,42:60:chronic_disease,"Patients with active, known or suspected autoimmune disease"
1449,NCT02912572,8:26:chronic_disease,Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
1450,NCT02910700,98:116:chronic_disease,inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease
1451,NCT02900794,1:19:chronic_disease,autoimmune disease
1452,NCT02869789,27:45:chronic_disease,"ctive, known or suspected autoimmune disease"
1453,NCT02832167,46:64:chronic_disease,"Subjects with an active, known, or suspected autoimmune disease"
1454,NCT02762006,"28:46:chronic_disease,",Active or prior documented autoimmune disease within the past 2 years
1455,NCT02759575,1:19:chronic_disease,autoimmune disease
1456,NCT02656706,42:60:chronic_disease,"Subjects with active, known or suspected autoimmune disease"
1457,NCT02635360,"23:41:chronic_disease,",Subject has an active autoimmune disease in the past 2 years
1458,NCT02592551,"28:46:chronic_disease,",Active or prior documented autoimmune disease within the past 2 years
1459,NCT02553642,22:40:chronic_disease,"Subjects with active autoimmune disease, symptoms or conditions"
1460,NCT02536794,38:56:chronic_disease,Patients with a history of or active autoimmune disease
1461,NCT02520791,43:61:chronic_disease,"Patients with active, known, or suspected autoimmune disease"
1462,NCT02519322,42:60:chronic_disease,"Subjects with active, known or suspected autoimmune disease"
1463,NCT02502708,8:26:chronic_disease,Active autoimmune disease
1464,NCT02477826,45:63:chronic_disease,"Subjects with an active, known or suspected autoimmune disease"
1465,NCT02454010,1:19:chronic_disease,autoimmune disease
1466,NCT02452268,12:30:chronic_disease,History of autoimmune disease
1467,NCT02439450,28:46:chronic_disease,"Active, known or suspected autoimmune disease"
1468,NCT02419495,45:63:chronic_disease,"subjects with an active, known or suspected autoimmune disease"
1469,NCT02401074,1:19:chronic_disease,autoimmune disease
1470,NCT02350764,45:63:chronic_disease,Patients with known or suspected history of autoimmune disease
1471,NCT02323126,53:71:chronic_disease,"any known or suspected, current or past history of, autoimmune disease"
1472,NCT02259621,66:84:chronic_disease,"Subjects are excluded if they have an active, known or suspected autoimmune disease"
1473,NCT01928576,31:49:chronic_disease,Any active history of a known autoimmune disease
1474,NCT01174121,24:42:chronic_disease,History of major organ autoimmune disease
1475,NCT03169543,9:19:chronic_disease,Current depression as assessed on the HDRS-17 (for depressed group only)
1476,NCT03107039,14:24:chronic_disease,Experiencing depression symptoms and generally healthy
1477,NCT03088592,"47:57:chronic_disease,,",Currently uncontrolled clinically significant depression (BDI>20)
1478,NCT03034564,19:29:chronic_disease,Poorly controlled depression
1479,NCT02979327,1:11:chronic_disease,depression
1480,NCT02964182,30:40:chronic_disease,Certain medications to treat depression
1481,NCT02880215,21:31:chronic_disease,moderate or greater depression symptoms
1482,NCT02809677,9:19:chronic_disease,current depression secondary to substances or general medical condition
1483,NCT02721537,12:22:chronic_disease,History of depression preceding a concussion
1484,NCT02674529,22:32:chronic_disease,history of resistant depression
1485,NCT02627495,"23:33:chronic_disease,,",Suffering from severe depression (as defined by a score of >30 in the Beck Depression Inventory)
1486,NCT02615353,11:21:chronic_disease,Diagnosed depression or other condition that may impact QoL
1487,NCT02570672,"11:21:chronic_disease,,",Untreated depression or Geriatric Depression Scale score on 15-item scale >7
1488,NCT02565199,"9:19:chronic_disease,,",Current depression (score more than 7 on the Hamilton Depression Rating Scale (HDRS))
1489,NCT02565199,"12:22:chronic_disease,,",No current depression (score less than 7 on the Hamilton Depression Rating Scale (HDRS))
1490,NCT02565199,"12:22:chronic_disease,,",No current depression (score less than a 7 on the Hamilton Depression Rating Scale (HDRS))
1491,NCT02466126,46:56:chronic_disease,must have clinically significant symptoms of depression
1492,NCT02440815,22:32:chronic_disease,Moderate severity of depression using the Hamilton Depression Rating Scale
1493,NCT02339233,27:37:chronic_disease,no clinically significant depression
1494,NCT02230605,"8:18:chronic_disease,,",Active depression as indicated by Geriatric Depression Scale screening test (score ? 10)
1495,NCT02131467,8:18:chronic_disease,Active depression
1496,NCT02104349,15:25:chronic_disease,Patients with depression (established during the screening questionnaire)
1497,NCT02013492,25:35:chronic_disease,Patients with worsening depression that has not been addressed clinically
1498,NCT01948739,11:21:chronic_disease,Untreated depression that may affect motivation to participate in the study
1499,NCT01770587,14:24:chronic_disease,Diagnosis of depression
1500,NCT01742182,"13:23:chronic_disease,,",Presence of depression defined as the Beck Depression Inventory (BDI) score >14
1501,NCT01614990,8:18:chronic_disease,Severe depression as determined by the investigator
1502,NCT01433315,21:31:chronic_disease,Those found to have depression on a depression screening tool (BDI-II)
1503,NCT00183482,53:63:chronic_disease,Families with at least one parent with a history of depression during the life of his or her child
1504,NCT03181893,61:76:treatment,"failed at least 1 standard of care systemic treatment, (eg, corticosteroids)"
1505,NCT03113760,36:51:treatment,Patients receiving stable doses of corticosteroids
1506,NCT03067571,"35:50:treatment,,","has received a cumulative dose of corticosteroids more than the equivalent of >= 140 mg of prednisone within the 2 week period before cycle 1, day 1"
1507,NCT02918981,1:16:treatment,corticosteroids
1508,NCT02819635,1:16:treatment,corticosteroids
1509,NCT02811679,"22:37:treatment,",Therapeutic doses of corticosteroids within 14 days prior to study entry
1510,NCT02776761,"5:20:treatment,,","For corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day"
1511,NCT02682407,"54:69:treatment,","For subjects in Cohort 2 and Cohort 3, have received corticosteroids within the 3 months prior to screening"
1512,NCT02527421,",75:90:treatment",Use within 30 days prior to the Screening Visit of any product containing corticosteroids
1513,NCT02508311,18:33:treatment,Currently taking corticosteroids
1514,NCT02488967,50:65:treatment,Conditions that would prohibit administration of corticosteroids
1515,NCT02469519,19:34:treatment,Already receiving corticosteroids for another condition
1516,NCT02469519,46:61:treatment,Any contraindications to the maternal use of corticosteroids
1517,NCT02340169,27:42:allergy_name,Allergy or sensitivity to corticosteroids or any drug hypersensitivity or intolerance that would compromise patient safety or study results
1518,NCT02336451,54:69:treatment,Patient is receiving unstable or increasing doses of corticosteroids
1519,NCT02321501,33:48:treatment,Unstable or increasing doses of corticosteroids
1520,NCT02304458,35:50:treatment,Patients requiring daily systemic corticosteroids
1521,NCT02272218,"40:55:treatment,",any clinical disorder requiring use of corticosteroids within one week of visit
1522,NCT02236000,63:78:treatment,Conditions that would prohibit intermittent administration of corticosteroids for T-DM1 premedication
1523,NCT02146924,15:30:treatment,Dependence on corticosteroids
1524,NCT02057133,48:63:treatment,Participants may be receiving a stable dose of corticosteroids
1525,NCT02043548,121:136:treatment,"there are complications or circumstances that, in the clinical site investigator's opinion, necessitate the tapering of corticosteroids"
1526,NCT01851694,"13:28:treatment,",intravenous corticosteroids within 6 weeks of study
1527,NCT01817751,"29:44:treatment,",Fixed or decreasing dose of corticosteroids (or no corticosteroids) for at least 1 week prior to cycle 1 day 1
1528,NCT01793519,"43:58:treatment,",Treated with intramuscular or intravenous corticosteroids in the last 6 months for RA activity
1529,NCT01631617,"16:31:treatment,","Use of topical corticosteroids on all intended sampling sites within 7 days, prior to baseline sampling"
1530,NCT00720785,19:34:treatment,Concurrent use of corticosteroids
1531,NCT03148795,24:46:chronic_disease,Clinically significant cardiovascular disease
1532,NCT03104699,39:61:chronic_disease,"Clinically significant (i.e., active) cardiovascular disease"
1533,NCT03071393,1:23:chronic_disease,cardiovascular disease
1534,NCT03037385,39:61:chronic_disease,"Clinically significant, uncontrolled, cardiovascular disease"
1535,NCT02937272,25:47:chronic_disease,Have moderate or severe cardiovascular disease
1536,NCT02913612,29:51:chronic_disease,"Hemodynamically significant cardiovascular disease, as determined by the investigator"
1537,NCT02881515,12:34:chronic_disease,history of cardiovascular disease
1538,NCT02881242,24:46:chronic_disease,Clinically significant cardiovascular disease
1539,NCT02857283,23:45:chronic_disease,including significant cardiovascular disease
1540,NCT02741180,18:40:chronic_disease,History of prior cardiovascular disease or significant risk factors
1541,NCT02728336,16:38:chronic_disease,No significant cardiovascular disease or risk factors
1542,NCT02663908,12:34:chronic_disease,Predefined cardiovascular disease
1543,NCT02607917,12:34:chronic_disease,History of cardiovascular disease
1544,NCT02562755,13:35:chronic_disease,Symptomatic cardiovascular disease
1545,NCT02519322,29:51:chronic_disease,Uncontrolled or significant cardiovascular disease
1546,NCT02514070,51:73:chronic_disease,"Subject must be healthy, with no known history of cardiovascular disease"
1547,NCT02488057,1:23:chronic_disease,cardiovascular disease
1548,NCT02452008,25:47:chronic_disease,Have moderate or severe cardiovascular disease
1549,NCT02425566,1:23:chronic_disease,cardiovascular disease
1550,NCT02278198,12:34:chronic_disease,History of cardiovascular disease that may adversely affect patient participation at the discretion of the primary investigator
1551,NCT02203695,24:46:chronic_disease,Clinically significant cardiovascular disease
1552,NCT02061761,29:51:chronic_disease,Uncontrolled or significant cardiovascular disease
1553,NCT02048852,12:34:chronic_disease,history of cardiovascular disease
1554,NCT01920061,29:51:chronic_disease,Uncontrolled or significant cardiovascular disease
1555,NCT01625234,24:46:chronic_disease,Clinically significant cardiovascular disease
1556,NCT03102320,1:6:cancer,Tumor type specific exclusion criteria
1557,NCT02885649,"1:6:cancer,,",Tumor with androgen receptor (AR) expressed >= 4580 copies/ug ribonucleic acid (RNA)
1558,NCT02724540,1:6:cancer,Tumor burden dominant in the liver
1559,NCT02639546,1:6:cancer,Tumor with known or expected RAS/RAF/MEK/ERK pathway involvement
1560,NCT02510456,"1:6:cancer,","Tumor size ? 2cm, measured on imaging or estimated by physical exam"
1561,NCT02507232,1:6:cancer,Tumor is supratentorially located and measureable
1562,NCT02468024,1:6:cancer,Tumor located peripherally within the lung
1563,NCT02465060,1:6:cancer,"Tumor tissue for the confirmation of rare variant by the MATCH assay is to be submitted, preferably from the same time of collection as that evaluated by the designated outside laboratory"
1564,NCT02438995,1:6:cancer,Tumor Recurrence which is surgically unresectable
1565,NCT02427841,1:6:cancer,Tumor-associated deformity of the SMV (superior mesenteric vein) or PV (portal vein)
1566,NCT02379377,1:6:cancer,Tumor confirmed by arteriography
1567,NCT02340156,1:6:cancer,Tumor foci detected below the tentorium or beyond the cranial vault
1568,NCT02207465,"1:6:cancer,",Tumor abutment to SMA but not to exceed greater than 180 degrees of circumferential vessel wall
1569,NCT02158234,"1:6:cancer,",Tumor within 1 cm of the spinal cord
1570,NCT02124772,1:6:cancer,Tumor tissue (archived or fresh) is required and must be available to be shipped to GSK or site specific laboratory
1571,NCT02085941,1:6:cancer,Tumor displacement from nerves may be required and will be performed as deemed appropriate to avoid nerve injury
1572,NCT02048722,1:6:cancer,Tumor deemed unresectable or metastatic
1573,NCT02041936,1:6:cancer,Tumor size not measurable
1574,NCT02013154,1:6:cancer,Tumor tissue for mandatory evaluation
1575,NCT01985087,"1:6:cancer,",Tumor o6-methylguanine-DNA-methyltransferase promoter methylation status must be determined
1576,NCT01891318,1:6:cancer,Tumor located in the brainstem
1577,NCT01799135,"1:6:cancer,,",Tumor between 1 cm and 6 cm
1578,NCT01505569,14:19:cancer,Arm A: Solid Tumor
1579,NCT01505569,1:6:cancer,Tumor may have originated in any primary site
1580,NCT02939183,"14:24:treatment,",received the transplant within 6 months prior to study day 1
1581,NCT02582775,",,93:103:treatment","Cardiac: left ventricular ejection fraction ? 45%, normal EKG or approved by Cardiology for transplant"
1582,NCT02474199,",27:37:treatment",Be 36 months or more post-transplant
1583,NCT02474199,",,55:65:treatment",?-fetoprotein (AFP) less than 100 ?g/L at the time of transplant
1584,NCT02440581,11:21:treatment,On active transplant list
1585,NCT02424968,72:82:treatment,Must be an HLA-matched or single allele mismatched sibling of enrolled transplant patient
1586,NCT02416674,"19:29:treatment,,",Elapsed injury-to-transplant time of more than 6 months and less than 15 years
1587,NCT02342782,67:77:treatment,Bone marrow (BM) harvest required to reach adequate cell dose for transplant
1588,NCT02158793,",,41:51:treatment,,,,",Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant
1589,NCT02143830,",,60:70:treatment,",Women must be willing to undergo a pregnancy test prior to transplant and avoid becoming pregnant while on study
1590,NCT02094794,32:42:treatment,"the patient, family member and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure"
1591,NCT02050347,85:95:treatment,An immune globulin rearrangement known to be a disease marker for this patient post transplant
1592,NCT02037048,57:67:treatment,Patients with any history of solid organ or bone marrow transplant will not be eligible
1593,NCT01943851,",48:58:treatment",At least 3 months has elapsed from the time of transplant
1594,NCT01908777,24:34:treatment,progressive disease at transplant work-up
1595,NCT01908777,29:39:treatment,who are deemed eligible for transplant by their treating physician Disease status: CR or PR required
1596,NCT01660607,79:89:treatment,Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow up care
1597,NCT01505569,",97:107:treatment",Minimum frozen PBSC of 4 x 106 CD34 cells/kg as 2 aliquots; i.e. 2 x 106 CD34 cells/kg for each transplant are mandatory
1598,NCT01459107,82:92:treatment,"USA citizen or equivalent, or foreigner with documentation of ability to pay for transplant and required follow-up care"
1599,NCT00711373,",,,124:134:treatment,",Women who are of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours of transplant and agree to use reliable contraception for one year following transplant
1600,NCT00630565,46:56:treatment,Patients can also be deemed not eligible for transplant because of specific organ toxicity
1601,NCT00432094,",165:175:treatment",Patients with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria by imaging techniques are not eligible to proceed to the second transplant
1602,NCT00432094,",,55:65:treatment",Total Collection of ? 4 x 10^6 CD34 cells/kg prior to transplant one
1603,NCT03186872,35:44:chronic_disease,evidence of active suicidality or psychosis (brief screen conducted by SWer in clinic using DSM-V cross cutting symptom inventory) to assess for psychosis
1604,NCT03157713,13:22:chronic_disease,have active psychosis
1605,NCT03108950,32:41:chronic_disease,Current use of medications for psychosis
1606,NCT03034863,27:36:chronic_disease,untreated or un-medicated psychosis
1607,NCT02841956,"13:22:chronic_disease,",Duration of psychosis > 2 years
1608,NCT02808468,17:26:chronic_disease,Exhibit current psychosis
1609,NCT02660528,12:21:chronic_disease,History of psychosis
1610,NCT02640950,"29:38:chronic_disease,",have no previous history of psychosis or substance dependence or abuse within the six months prior to Screening
1611,NCT02613936,12:21:chronic_disease,history of psychosis
1612,NCT02577666,24:33:chronic_disease,Evidence of unremitted psychosis or other condition which would impair mother's ability to understand or participate in the intervention or consent to the research
1613,NCT02533882,32:41:chronic_disease,Current use of medications for psychosis
1614,NCT02527564,9:18:chronic_disease,Current psychosis
1615,NCT02404194,",13:22:chronic_disease",One or more psychosis-risk syndromes as defined by the Structured Interview for Psychosis-Risk Syndromes (SIPS)
1616,NCT02394704,1:10:chronic_disease,psychosis
1617,NCT02357849,9:18:chronic_disease,"current psychosis (any positive symptom SOPS score of 6, i.e., extreme)"
1618,NCT02332291,17:26:chronic_disease,Current or past psychosis
1619,NCT02293057,56:65:treatment,"observable cognitive or developmental delays or active psychosis that would interfere with completing consent, assessment or intervention"
1620,NCT02131467,8:17:chronic_disease,Active psychosis
1621,NCT02102113,29:38:chronic_disease,Having a family member with psychosis
1622,NCT01989507,8:17:chronic_disease,active psychosis as evidenced by hallucinations or delusions
1623,NCT01964404,"22:31:chronic_disease,,",Positive symptoms of psychosis (> 4 [moderate]) on any item of the Positive and Negative Syndrome Scale psychosis subscale (once abstinent) except for the hallucination item
1624,NCT03041441,1:13:chronic_disease,coagulopathy
1625,NCT03008603,26:38:chronic_disease,Subject with significant coagulopathy
1626,NCT02973139,15:27:chronic_disease,Non corrected coagulopathy
1627,NCT02798458,27:39:chronic_disease,Untreated or unmanageable coagulopathy
1628,NCT02706249,"13:25:chronic_disease,,,",Presence of coagulopathy (PT or PTT> 1.2 x upper limit of normal)
1629,NCT02548104,1:13:chronic_disease,coagulopathy (as diagnosed by history or laboratory evaluation)
1630,NCT02464904,",,23:35:chronic_disease,,","Platelet count < 50K, coagulopathy defined as an International Normalized Ratio (INR) > 1.5"
1631,NCT02453373,"19:31:chronic_disease,,,,","Known preexisting coagulopathy, (INR > 1.3, PTT >1.5 x control)"
1632,NCT02407028,7:19:chronic_disease,Fixed coagulopathy
1633,NCT02394535,"30:42:chronic_disease,,","Known, existing uncontrolled coagulopathy, international normalized ratio (INR) > 1.5"
1634,NCT02329652,12:24:chronic_disease,History of coagulopathy
1635,NCT02323581,15:27:chronic_disease,Uncorrectable coagulopathy
1636,NCT02240498,15:27:chronic_disease,Uncorrectable coagulopathy
1637,NCT02166190,13:25:chronic_disease,Uncorrected coagulopathy
1638,NCT02073292,11:23:chronic_disease,Untreated coagulopathy
1639,NCT01975597,36:48:chronic_disease,"Patients with active, uncontrolled coagulopathy"
1640,NCT01940757,"26:38:chronic_disease,,,,",Laboratory evidence of a coagulopathy (PTT or PT INR greater than 1.1-times the upper reference limit)
1641,NCT01676259,35:47:chronic_disease,History of clinically significant coagulopathy
1642,NCT00862433,7:19:chronic_disease,Known coagulopathy
1643,NCT00483249,15:27:chronic_disease,Uncorrectable coagulopathy
1644,NCT00167219,1:13:chronic_disease,coagulopathy
1645,NCT02776891,12:20:cancer,Double hit lymphoma
1646,NCT02541565,",,88:96:cancer","Absolute neutrophil count (ANC) >= 1,500/mcL except in cases of marrow infiltration by lymphoma"
1647,NCT02541565,",,68:76:cancer","Platelets >= 100,000/mcL except in cases of marrow infiltration by lymphoma"
1648,NCT02541565,",,,80:88:cancer",emoglobin >= 9 g/dL or >= 5.6 mmol/L except in cases of marrow infiltration by lymphoma
1649,NCT02520713,1:9:cancer,lymphoma
1650,NCT02471911,59:67:cancer,Patients with known central nervous system involvement by lymphoma
1651,NCT02419560,11:19:cancer,Known CNS lymphoma
1652,NCT02408861,",,81:89:cancer,,","Platelets: >= 75,000/mm^3, unless decreased due to bone marrow involvement with lymphoma (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)"
1653,NCT02384954,32:40:cancer,No active CNS involvement with lymphoma
1654,NCT02374333,1:9:cancer,lymphoma
1655,NCT02341209,",,65:73:cancer","platelet count > 50,000 cells/mL unless felt to be secondary to lymphoma at which any count is permissible"
1656,NCT02232516,69:77:cancer,Patients who have known central nervous system (CNS) involvement of lymphoma
1657,NCT02106650,",,,,,,,,283:291:cancer","Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT), and gamma-glutamyltransferase (GGT) ?2.5 xupper limit of normal (ULN) (AST/ALT/GGT ?5 xULN if documented hepatic involvement with lymphoma)"
1658,NCT02078102,13:21:cancer,Transformed lymphoma
1659,NCT01996865,62:70:cancer,Presence or history of central nervous system involvement by lymphoma
1660,NCT01891318,1:9:cancer,lymphoma
1661,NCT01859819,50:58:cancer,Patients with newly diagnosed Group A (low risk) lymphoma
1662,NCT00670358,",,,,63:71:cancer",AST ? 3 times ULN (5 times ULN if direct liver involvement by lymphoma)
1663,NCT00670358,",,,,80:88:cancer",Alkaline phosphatase ? 3 times ULN (5 times ULN if direct liver involvement by lymphoma)
1664,NCT00001337,",,,105:113:cancer","greater than 1,000 and platelets greater than 100,000) unless impairment is due to organ involvement by lymphoma or immune-mediated mechanism caused by lymphoma"
1665,NCT03114891,7:25:chronic_disease,other psychotic disorder
1666,NCT03058952,9:27:chronic_disease,Current psychotic disorder
1667,NCT03011307,18:36:chronic_disease,Suffering from a psychotic disorder
1668,NCT02851914,12:30:chronic_disease,History of psychotic disorder
1669,NCT02826577,1:19:chronic_disease,psychotic disorder
1670,NCT02734602,45:63:chronic_disease,First degree relative with a diagnosis of a psychotic disorder
1671,NCT02709980,1:19:chronic_disease,psychotic disorder requiring admission
1672,NCT02709317,16:34:chronic_disease,have a current psychotic disorder severe enough to require inpatient treatment
1673,NCT02556606,25:43:chronic_disease,Documented history of a psychotic disorder in a first-degree relative
1674,NCT02536846,22:40:chronic_disease,"Without history of a psychotic disorder among parents, siblings, or children"
1675,NCT02481713,14:32:chronic_disease,diagnosis of psychotic disorder
1676,NCT02421315,30:48:chronic_disease,DSM-IV lifetime diagnosis of psychotic disorder
1677,NCT02418195,23:41:chronic_disease,A lifetime history of psychotic disorder
1678,NCT02402647,1:19:chronic_disease,psychotic disorder
1679,NCT02214667,7:25:chronic_disease,brief psychotic disorder
1680,NCT02214667,1:19:chronic_disease,psychotic disorder NOS
1681,NCT02155699,8:26:chronic_disease,have a psychotic disorder (at study entry) and/or have exhibited serious self-harm behaviors
1682,NCT02102113,38:56:chronic_disease,Having one relative with a confirmed psychotic disorder
1683,NCT01794559,16:34:chronic_disease,Diagnosis of a psychotic disorder
1684,NCT02828618,1:17:cancer,liver metastasis or bulky lymph-nodes in the mediastinum in CT chest and abdomen/pelvis
1685,NCT02730481,",,,106:122:cancer",Adequate liver function as demonstrated by:Total bilirubin of ?1.5 mg/dL or ?2.0 mg/dL for subjects with liver metastasis
1686,NCT02730481,",,,74:90:cancer",Alanine aminotransferase ?3 x upper limit of normal (ULN) or ?5 x ULN if liver metastasis is present
1687,NCT02592551,",,,,,,,,,,,,,,,,,,334:350:cancer","Hemoglobin ? 9.0 g/dL Absolute neutrophil count (ANC) ? 1.5 × 109/L (> 1500 per mm3) Platelet count ? 100 × 109/L (>100,000 per mm3) Serum bilirubin ? 1.5× institutional upper limit of normal (ULN)AST<3.0 Creatinine clearance >50mL/miN Aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5 × ULN (? 5 × ULN if documented liver metastasis are present)"
1688,NCT02536794,",27:43:cancer",#ERROR!
1689,NCT02536794,",27:43:cancer",#ERROR!
1690,NCT02422641,",,,67:83:cancer",Alkaline phosphatase <2.5x the ULN or <5x the ULN if secondary to liver metastasis
1691,NCT02321501,",,,,,,,,,,,,,,,371:387:cancer","Absolute Neutrophil Count (ANC) >/= 1,500/microliter; Platelets >/= 100,000/microliter; Hemoglobin (Hgb) >/= 9 g/dL; Creatinine </= 1.5 X upper limit of normal (ULN); Prothrombin Time (PT), Partial Thromboplastin Time(PTT) </= 1.5 X ULN; Total bilirubin </= 1.5X ULN; Alanine Transaminase (ALT) and Aspartate Aminotransferase (AST) < 1.5 X ULN (< 5 X ULN if patient has liver metastasis)"
1692,NCT02310464,",,,,76:92:cancer,,,,,,,,","AST/ALT ? 3X ULN (upper limit of normal) AST/ALT ? 5X ULN [with underlying liver metastasis] Total bilirubin ? 2.0 X ULN Serum creatinine ? 1.5X ULN ANC ? 1500 /µL Platelets > 100,000/µL"
1693,NCT02250157,",,,65:81:cancer",Total bilirubin of ? 1.5 mg/dL or ? 2.0 mg/dL for subjects with liver metastasis
1694,NCT02236000,",,,,157:173:cancer",aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab or less than or equal to 5 x ULN if liver metastasis
1695,NCT02188745,",,68:84:cancer,",ALT and AST ? 3.0 x upper limits of normal (ULN) For patients with liver metastasis: < 5 x upper limits of normal (ULN)
1696,NCT02112565,",,,,,,101:117:cancer",Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; AST/ALT =< 5 x ULN if liver metastasis is present
1697,NCT01952730,",41:57:cancer",Greater than 1 month since resection of liver metastasis for vaccine production
1698,NCT01676753,",,,,,,107:123:cancer","Aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase ALT (SGPT) ? 2.5 x ULN, ? 5 x ULN if liver metastasis"
1699,NCT01622868,",,,134:150:cancer,",Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times institutional upper limit of normal with or without liver metastasis (within 21 days prior to study entry)
1700,NCT01618357,",,,41:57:cancer",Bilirubin ? 1.5 mg/dL (? 3.0 mg/dL with liver metastasis)
1701,NCT01618357,",,,,78:94:cancer",Serum Glutamic-Oxaloacetic Transaminase (SGOT) ? 2.5 × ULN (? 5.0 × ULN with liver metastasis)
1702,NCT01618357,",,,74:90:cancer,",Serum Glutamic-Pyruvic Transaminase (SGPT) ? 2.5 × ULN (? 5.0 × ULN with liver metastasis) ULN = Upper normal limit of institution's normal range
1703,NCT03011684,1:13:treatment,Chemotherapy has already commenced or been completed
1704,NCT02860000,"1:13:treatment,",Chemotherapy =< 21 days
1705,NCT02843945,"1:13:treatment,,",Chemotherapy was administered for 2-6 cycles with any combination
1706,NCT02592707,"1:13:treatment,",Chemotherapy ? 3 months before enrolment
1707,NCT02442635,11:23:treatment,Receiving Chemotherapy
1708,NCT02418195,1:13:treatment,Chemotherapy
1709,NCT02360579,1:13:treatment,Chemotherapy
1710,NCT02204098,1:13:treatment,Chemotherapy
1711,NCT02176161,1:13:treatment,Chemotherapy
1712,NCT02167958,1:13:treatment,Chemotherapy-sensitive (complete or partial response
1713,NCT02130388,"1:13:treatment,,,",Chemotherapy within past 4 weeks or Absolute Neutrophil Count<500
1714,NCT02094794,"1:13:treatment,",Chemotherapy given within 14 days of planned study enrollment for the purpose of controlling counts is permitted
1715,NCT01893307,12:24:treatment,Concurrent Chemotherapy
1716,NCT01659203,"1:13:treatment,",Chemotherapy within 4 weeks prior to entering study
1717,NCT01625234,"1:13:treatment,",Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks
1718,NCT01625234,"1:13:treatment,",Chemotherapy regimens with delayed toxicity within the last 4 weeks
1719,NCT00909909,1:13:treatment,Chemotherapy allowed
1720,NCT00819208,"1:13:treatment,,",Chemotherapy must have been completed (i.e. last dose received) a minimum of 60 days and a maximum of 180 days prior to registration
1721,NCT03162731,8:19:chronic_disease,"active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive)"
1722,NCT02682407,1:12:chronic_disease,hepatitis B
1723,NCT02578641,10:21:chronic_disease,Positive hepatitis B surface antigen (HBsAg) results
1724,NCT02493530,"1:12:chronic_disease,",hepatitis B carriers with normal LFTs and undetectable viral loads
1725,NCT02424968,24:35:chronic_disease,donors with a positive hepatitis B PCR test
1726,NCT02412540,1:12:chronic_disease,hepatitis B
1727,NCT02320292,22:33:chronic_disease,"HBsAg negative, anti-hepatitis B surface antibody (HBs) positive and/or anti-hepatitis B core antibody (HBc) positive and detectable viral deoxyribonucleic acid (DNA"
1728,NCT02273375,34:45:chronic_disease,Patients with a past or resolved hepatitis B infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBSAg) are eligible
1729,NCT02109627,15:26:chronic_disease,patients with hepatitis B on antivirals and low viral load
1730,NCT02004275,7:18:chronic_disease,Known hepatitis B surface antigen positivity
1731,NCT01959698,",96:107:chronic_disease",Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on hepatitis B serological testing
1732,NCT01919619,41:52:chronic_disease,antiviral (except antiviral directed at hepatitis B)
1733,NCT01919619,1:12:chronic_disease,hepatitis B
1734,NCT01880567,22:33:chronic_disease,patients with active hepatitis B infection
1735,NCT01880567,16:27:chronic_disease,positive serum hepatitis B antibody
1736,NCT01660607,31:42:chronic_disease,PCR+ or sAg (surface antigen) hepatitis B
1737,NCT01660607,1:12:chronic_disease,hepatitis B sAg
1738,NCT03070535,",,108:120:treatment","Women must be post-menopausal for at least 1 year before enrolling in the study, or be one year out from a hysterectomy"
1739,NCT03042897,30:42:treatment,"Is a candidate for immediate hysterectomy, following evaluation by a physician"
1740,NCT03042897,34:46:treatment,"Is not a candidate for immediate hysterectomy, following evaluation by a physician, due to desire to preserve fertility, due to degree of obesity, due to comorbidities, or due to patient refusal of hysterectomy"
1741,NCT03033888,17:29:treatment,Had undergone a hysterectomy
1742,NCT03018704,20:32:treatment,who have not had a hysterectomy
1743,NCT03008408,"88:100:treatment,,","Patients in whom ovaries are present and were not previously menopausal at the time of hysterectomy, should have a serum estradiol <10 pm/mL to confirm ovarian senescence"
1744,NCT02969187,1:13:treatment,hysterectomy
1745,NCT02593123,",56:68:treatment,",Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines
1746,NCT02592551,12:24:treatment,history of hysterectomy
1747,NCT02536794,21:33:treatment,Has not undergone a hysterectomy
1748,NCT02515110,",56:68:treatment,,",Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative pregnancy test within 14 days prior to study registration
1749,NCT02514083,12:24:treatment,history of hysterectomy
1750,NCT02466750,"23:35:treatment,",Exception: documented hysterectomy or ? 3 years of menopause
1751,NCT02403193,21:33:treatment,history of complete hysterectomy
1752,NCT02400255,",,102:114:treatment,",Women of childbearing potential is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months
1753,NCT02236013,"46:58:treatment,",documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening)
1754,NCT01532687,3:15:treatment,A hysterectomy
1755,NCT03135522,12:24:chronic_disease,History of pancreatitis
1756,NCT03058029,"12:24:chronic_disease,",History of pancreatitis within the past 12 months
1757,NCT02527200,12:24:chronic_disease,History of pancreatitis (acute or chronic)
1758,NCT02521818,12:24:chronic_disease,history of pancreatitis
1759,NCT02496611,12:24:chronic_disease,History of pancreatitis
1760,NCT02496208,",,75:87:chronic_disease",Lipase and amylase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
1761,NCT02467478,12:24:chronic_disease,History of pancreatitis
1762,NCT02446093,36:48:chronic_disease,Evidence of clinically significant pancreatitis as determined by the investigator
1763,NCT02408861,56:68:chronic_disease,Participants with clinical or radiographic evidence of pancreatitis
1764,NCT02262806,25:37:chronic_disease,Decrease in episodes of pancreatitis
1765,NCT02251431,7:19:chronic_disease,Prior pancreatitis
1766,NCT02244814,12:24:chronic_disease,History of pancreatitis
1767,NCT02132598,",47:59:chronic_disease,",Lipase (no radiologic or clinical evidence of pancreatitis) < 2.0 x ULN
1768,NCT01906385,"33:45:chronic_disease,",History or clinical evidence of pancreatitis within 2 years
1769,NCT01822522,",,62:74:chronic_disease,",Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis (within 1 week of study entry)
1770,NCT01722240,12:24:chronic_disease,history of pancreatitis
1771,NCT03145298,8:30:chronic_disease,Active uncontrolled infection
1772,NCT02566395,8:30:chronic_disease,Active uncontrolled infection
1773,NCT02541903,15:37:chronic_disease,Any active or uncontrolled infection
1774,NCT02354547,22:44:chronic_disease,Patients who have an uncontrolled infection
1775,NCT02353728,1:23:chronic_disease,uncontrolled infection
1776,NCT02323880,22:44:chronic_disease,Patients who have an uncontrolled infection
1777,NCT02257138,31:53:chronic_disease,Active clinically serious and uncontrolled infection
1778,NCT02158793,16:38:chronic_disease,Subject has an uncontrolled infection
1779,NCT02143050,16:38:chronic_disease,Have any other uncontrolled infection
1780,NCT02114229,24:46:chronic_disease,"Presence of an active, uncontrolled infection"
1781,NCT02003222,33:55:chronic_disease,Patient must not have an active uncontrolled infection
1782,NCT01943851,23:45:chronic_disease,Evidence of severe of uncontrolled infection
1783,NCT01666080,9:31:chronic_disease,"Active, uncontrolled infection"
1784,NCT01532687,13:35:chronic_disease,Presence of uncontrolled infection
1785,NCT01515527,19:41:chronic_disease,ongoing or active uncontrolled infection
1786,NCT03042689,1:16:chronic_disease,Unstable angina (anginal symptoms at rest)
1787,NCT02986815,1:16:chronic_disease,Unstable angina
1788,NCT02842658,1:16:chronic_disease,Unstable angina
1789,NCT02780401,"1:16:chronic_disease,",Unstable angina within 4 months prior to enrollment
1790,NCT02516332,1:16:chronic_disease,Unstable angina
1791,NCT02494869,1:16:chronic_disease,Unstable angina
1792,NCT02484404,1:16:chronic_disease,Unstable angina
1793,NCT02418195,1:16:chronic_disease,Unstable angina
1794,NCT02095808,1:16:chronic_disease,Unstable angina
1795,NCT02074436,1:16:chronic_disease,Unstable angina
1796,NCT01959425,1:16:chronic_disease,Unstable angina
1797,NCT01684397,1:16:chronic_disease,Unstable angina
1798,NCT01668082,1:16:chronic_disease,Unstable angina
1799,NCT01532687,1:16:chronic_disease,Unstable angina
1800,NCT00788164,1:16:chronic_disease,Unstable angina
1801,NCT03179163,1:28:chronic_disease,peripheral vascular disease
1802,NCT03158519,13:40:chronic_disease,symptomatic peripheral vascular disease
1803,NCT03093272,"13:40:chronic_disease,",symptomatic peripheral vascular disease within 6 months prior to randomization
1804,NCT02833207,26:53:chronic_disease,Self-reported history of peripheral vascular disease
1805,NCT02555280,13:40:chronic_disease,"Significant peripheral vascular disease (e.g., with diminished dorsalis pedis or posterior tibial pulses)"
1806,NCT02473250,1:28:chronic_disease,peripheral vascular disease
1807,NCT02469857,21:48:chronic_disease,Patients with overt peripheral vascular disease in the involved area
1808,NCT02315196,13:40:chronic_disease,Symptomatic peripheral vascular disease
1809,NCT02314377,36:63:chronic_disease,Patients must not have symptomatic peripheral vascular disease
1810,NCT02020707,24:51:chronic_disease,Clinically significant peripheral vascular disease
1811,NCT02019641,128:155:chronic_disease,"Other medical conditions that may pose a risk to exercise testing or training as determined by the investigators (for example, peripheral vascular disease)"
1812,NCT01532687,13:40:chronic_disease,Symptomatic peripheral vascular disease
1813,NCT00540761,8:35:chronic_disease,severe peripheral vascular disease
1814,NCT00065676,1:28:chronic_disease,peripheral vascular disease
1815,NCT02834403,",25:35:chronic_disease",Patients with > Grade 2 neuropathy
1816,NCT02710396,",25:35:chronic_disease",Subjects with ? Grade 2 neuropathy are an exception to this criterion and may qualify for the study
1817,NCT02578732,13:23:chronic_disease,Preexisting neuropathy is not allowed from any cause
1818,NCT02574455,",,83:93:chronic_disease",all toxicity at study entry < Grade 1 by NCI CTCAE v4.00 (Patients with ? Grade 2 neuropathy are eligible)
1819,NCT02538198,"13:23:chronic_disease,",Significant neuropathy ?Grade 3 at baseline
1820,NCT02451423,",,16:26:chronic_disease",CTCAE Gr >/= 2 neuropathy
1821,NCT02383927,",,25:35:chronic_disease",Non-tolerable > Grade 2 neuropathy
1822,NCT02343042,",43:53:chronic_disease,,","In the SVd (Arm 2) only: Prior history of neuropathy Grade > 2, or Grade 2 neuropathy with pain at screening (within 21 days prior to C1D1)"
1823,NCT02187848,34:44:chronic_disease,Unresolved signs and symptoms of neuropathy
1824,NCT02091999,"21:31:chronic_disease,,",Preexisting sensory neuropathy Grade ? 2
1825,NCT02080221,13:23:chronic_disease,Preexisting neuropathy
1826,NCT01941316,"31:41:chronic_disease,,,","Must not have any significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to enrollment"
1827,NCT01919619,"13:23:chronic_disease,,",Significant neuropathy (grades 3 to 4 or grade 2 pain)
1828,NCT01220583,",24:34:chronic_disease",Pre-existing ? grade 2 neuropathy
1829,NCT03158116,12:24:chronic_disease,History of tuberculosis
1830,NCT03152058,12:24:chronic_disease,History of tuberculosis or untreated positive PPD
1831,NCT03059888,24:36:chronic_disease,Subject is at risk for tuberculosis
1832,NCT02915744,1:13:chronic_disease,tuberculosis
1833,NCT02639065,49:61:chronic_disease,Known history of previous clinical diagnosis of tuberculosis
1834,NCT02592551,49:61:chronic_disease,Known history of previous clinical diagnosis of tuberculosis
1835,NCT02570984,12:24:chronic_disease,history of tuberculosis
1836,NCT02536794,1:13:chronic_disease,tuberculosis
1837,NCT02484404,59:71:chronic_disease,Patients with a history of previous clinical diagnosis of tuberculosis are not eligible
1838,NCT02273375,29:41:chronic_disease,known clinical diagnosis of tuberculosis
1839,NCT02148796,1:13:chronic_disease,tuberculosis
1840,NCT02043548,"22:34:chronic_disease,",Patients treated for tuberculosis with no recurrence in 3 years are permitted
1841,NCT02007239,18:30:chronic_disease,Known history of tuberculosis
1842,NCT03116997,",,35:49:treatment",INR > 1.5 (except for patients on anticoagulants)
1843,NCT03040778,22:36:treatment,Patients taking oral anticoagulants
1844,NCT02786251,142:156:treatment,"Use of medications that are judged by the investigators to affect the study outcome measures or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study"
1845,NCT02719327,16:30:treatment,Current use of anticoagulants
1846,NCT02706288,46:60:treatment,"increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study"
1847,NCT02669173,23:37:treatment,Patients on full-dose anticoagulants
1848,NCT02656706,20:34:treatment,Therapeutic use of anticoagulants
1849,NCT02541565,69:83:treatment,"as long as PT or PTT is within therapeutic range of intended use of anticoagulants, or subject is shown to have an antiphospholipid antibody on workup"
1850,NCT02524275,",,,,161:175:treatment","Prothrombin time (PT) or international normalized ratio (INR), and partial thromboplastin time (PTT) =< 1.5 x upper limit of normal unless subject is receiving anticoagulants"
1851,NCT02233868,1:15:treatment,anticoagulants
1852,NCT02140554,35:49:treatment,patients on prophylactic doses of anticoagulants
1853,NCT02130687,16:30:treatment,Treatment with anticoagulants
1854,NCT02101736,18:32:treatment,Subject requires anticoagulants
1855,NCT03068442,"79:92:chronic_disease,,","MRI contraindications per ACR guidelines, including patients with pacemakers, renal failure with eGFR<30 ml/min/1.73m2, and contrast allergy"
1856,NCT03030859,1:14:chronic_disease,renal failure
1857,NCT02911831,"21:34:chronic_disease,,,",Patients with known renal failure and/or Cr > 5 within the last 6 months
1858,NCT02473250,1:14:chronic_disease,renal failure
1859,NCT02342444,13:26:chronic_disease,Presence of renal failure requiring non-standard dosing regimen
1860,NCT02312596,"7:20:chronic_disease,,",Known renal failure as determined by a Creatinine > 2.5 mg/dl
1861,NCT02219555,1:14:chronic_disease,renal failure
1862,NCT02095678,"12:25:chronic_disease,",Late stage renal failure with estimated glomerular filtration rate (eGFR)
1863,NCT01807897,"8:21:chronic_disease,,",Severe renal failure with estimated glomerular filtration rate <30 ml/min
1864,NCT01666665,35:48:chronic_disease,Previous diagnosis (pre -burn) of renal failure
1865,NCT01666665,1:14:chronic_disease,renal failure
1866,NCT01614990,"1:14:chronic_disease,,",renal failure (creatinine >1.5 mg/dL)
1867,NCT01572480,12:25:chronic_disease,Absence of renal failure
1868,NCT03186872,"4:17:treatment,",No psychotherapy within PCMH within past 6 months including with the psychologist
1869,NCT03114891,"17:30:treatment,",Newly initiated psychotherapy (less than 6 weeks)
1870,NCT03060096,"9:22:treatment,","Current psychotherapy [regular appointment(s) with a psychologist, counselor, or therapist within the last 30 days]"
1871,NCT03043573,77:90:treatment,Deemed too psychiatrically unstable to safely enroll in randomized trial of psychotherapy. Requiring psychiatric hospitalization at baseline for safety
1872,NCT02901041,32:45:treatment,Must be willing to discontinue psychotherapy for substance use disorder (except A.A.)
1873,NCT02567266,63:76:treatment,Adolescents will be excluded if they are receiving concurrent psychotherapy
1874,NCT02466126,30:43:treatment,Veterans currently receiving psychotherapy WILL be excluded
1875,NCT02397889,34:47:treatment,Use of evidence-based individual psychotherapy (such as prolonged exposure) during the study
1876,NCT02332291,20:33:treatment,Current or planned psychotherapy
1877,NCT02317523,64:77:treatment,Caregivers enrolled in another intervention study or receiving psychotherapy to improve well-being or reduce distress
1878,NCT02061553,52:65:treatment,Concurrent involvement in one-to-one counseling or psychotherapy for emotional issues
1879,NCT02046330,"33:46:treatment,",An adequate trial of individual psychotherapy (>20 sessions with an experienced psychotherapist)
1880,NCT03113695,",109:118:treatment",Males must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy
1881,NCT03067571,",,87:96:treatment,,","A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug"
1882,NCT02688647,",,146:155:treatment","Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) vasectomy"
1883,NCT02629120,",41:50:treatment",Male partner has previously undergone a vasectomy
1884,NCT02538198,",,,135:144:treatment",Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy
1885,NCT02382419,",,,,398:407:treatment",Using an adequate method of contraception for at least 3 months with no changes and will remain on the contraception for the duration of the trial; an adequate method of contraception is defined as either a hormonal based method (except vaginal rings); an intrauterine device (IUD) (inserted at least 30 days prior to enrollment); female sterilization; or sexual activity with a partner who had a vasectomy
1886,NCT02339922,",65:74:treatment","Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following"
1887,NCT01754857,",,,,158:167:treatment",FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy
1888,NCT01543490,40:49:treatment,provide documentation for having had a vasectomy (with documented infertility)
1889,NCT01415752,",,,137:146:treatment","Men must agree to use a latex condom during sexual contact with a female of child-bearing potential, even if they have had a successful vasectomy"
1890,NCT01054196,",,,107:116:treatment",Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy
1891,NCT00967785,",41:50:treatment",Male partner has previously undergone a vasectomy for which there is documentation of aspermatogenic sterility
1892,NCT02950337,1:38:chronic_disease,psychiatric illness/social situations that could limit compliance with study requirements
1893,NCT02945800,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements
1894,NCT02890979,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements
1895,NCT02857218,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements
1896,NCT02843568,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements
1897,NCT02811679,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements
1898,NCT02694029,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements
1899,NCT02639065,12:49:chronic_disease,History of psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
1900,NCT02337465,1:38:chronic_disease,psychiatric illness/social situations that would limit compliance with study requirements
1901,NCT02109627,38:75:chronic_disease,Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements
1902,NCT02012296,8:45:chronic_disease,Active psychiatric illness/social situations that would limit compliance with protocol requirements
1903,NCT01515527,1:38:chronic_disease,psychiatric illness/social situations
1904,NCT03188042,30:38:chronic_disease,Other optic comorbidity than glaucoma
1905,NCT03129542,1:9:chronic_disease,glaucoma
1906,NCT03018704,12:20:chronic_disease,history of glaucoma
1907,NCT02823665,12:20:chronic_disease,History of glaucoma
1908,NCT02785042,21:29:chronic_disease,Negative history of glaucoma (not including family history)
1909,NCT02561104,10:18:chronic_disease,advanced glaucoma
1910,NCT02503358,",,50:58:chronic_disease","Intra-ocular pressure > 21 mmHg, or uncontrolled glaucoma (irrespective of intra-ocular pressure)"
1911,NCT02402660,1:9:chronic_disease,glaucoma
1912,NCT02252432,49:57:chronic_disease,"Increased intraocular pressure (e.g., untreated glaucoma)"
1913,NCT02030990,"13:21:chronic_disease,,",Evidence of glaucoma or an intraocular pressure greater than 22 mm Hg at baseline
1914,NCT01547429,28:36:chronic_disease,Patients with uncontrolled glaucoma
1915,NCT03110107,43:54:cancer,"histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable)"
1916,NCT03007030,",,13:24:cancer",stage I-III solid tumor
1917,NCT02799095,59:70:cancer,the subject has histological or cytological evidence of a solid tumor
1918,NCT02730481,43:54:cancer,Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
1919,NCT02608125,58:69:cancer,Histological or cytological documentation of an advanced solid tumor
1920,NCT02520713,",,46:57:cancer",Age ? 30 years at time of initial qualifying solid tumor diagnosis
1921,NCT02451553,26:37:cancer,Histologically confirmed solid tumor malignancy
1922,NCT02112565,126:137:cancer,"Patients must have histologically or cytologically confirmed (at original diagnosis or subsequent recurrence or progression) solid tumor that is metastatic, unresectable, progressive, or recurrent, and for which standard curative or palliative measures do not exist or are no longer effective"
1923,NCT02076906,42:53:cancer,Radiographically evaluable or measurable solid tumor target lesion(s)
1924,NCT00720785,52:63:cancer,Diagnosed with histologically confirmed metastatic solid tumor
1925,NCT00720785,52:63:cancer,Disease not evaluable radiographically (applies to solid tumor patients only)
1926,NCT03058796,1:20:chronic_disease,Parkinson's disease
1927,NCT03053908,1:20:chronic_disease,Parkinson's disease
1928,NCT03036254,1:20:chronic_disease,Parkinson's disease
1929,NCT02744911,14:33:chronic_disease,Diagnosis of Parkinson's disease
1930,NCT02615873,36:55:chronic_disease,Continue to carry the diagnosis of Parkinson's disease consistent with UK brain bank criteria
1931,NCT02589340,1:20:chronic_disease,Parkinson's disease diagnosis
1932,NCT02479906,1:20:chronic_disease,Parkinson's disease
1933,NCT02424929,45:64:chronic_disease,All patients will have moderate to advanced Parkinson's disease
1934,NCT02332291,1:20:chronic_disease,Parkinson's disease
1935,NCT02266004,"1:20:chronic_disease,,,",Parkinson's disease stages 2-3 Hoehn and Yahr
1936,NCT01570816,1:20:chronic_disease,Parkinson's disease
1937,NCT02624258,"21:32:chronic_disease,",Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was >4 weeks before enrollment
1938,NCT02512497,21:32:chronic_disease,Patient with active CNS disease
1939,NCT02429934,22:33:chronic_disease,Subjects with active CNS disease
1940,NCT02315612,15:26:chronic_disease,Subjects with CNS disease
1941,NCT02191098,39:50:chronic_disease,History or evidence of uncontrollable CNS disease
1942,NCT02188745,"7:18:chronic_disease,","Known CNS disease, unless clinically stable for ? 3 months"
1943,NCT02122081,8:19:chronic_disease,Active CNS disease as identified by positive CSF cytospin at time of enrollment
1944,NCT01554371,51:62:chronic_disease,Patients with stable and clinically insignificant CNS disease
1945,NCT01494662,"44:55:chronic_disease,,,","In cohort 1, patients must have measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension with longest dimension ?10 mm by local radiology review"
1946,NCT01059786,13:24:chronic_disease,Presence of CNS disease
1947,NCT00914628,22:33:chronic_disease,Patients with active CNS disease
1948,NCT03181542,32:42:treatment,Emergency procedures requiring anesthesia
1949,NCT03151434,18:28:treatment,Desires Regional anesthesia for postoperative pain control
1950,NCT02770326,22:32:allergy_name,Contraindications to anesthesia for procedure
1951,NCT02148796,74:84:treatment,received mechanical ventilation with the exclusion of ventilation during anesthesia for a minor surgical procedure
1952,NCT02132130,34:44:treatment,Past serious adverse reaction to anesthesia
1953,NCT01554410,19:29:treatment,Examination under anesthesia (if indicated)
1954,NCT01505062,29:39:allergy_name,"Contraindications to use of anesthesia (local or general, as appropriate)"
1955,NCT01367444,29:39:treatment,"Contraindications to use of anesthesia (local or general, as appropriate)"
1956,NCT01011777,30:40:allergy_name,Previous adverse reaction to anesthesia
1957,NCT00618683,55:65:treatment,Electrophysiology study performed without sedation or anesthesia
1958,NCT03160547,"49:59:treatment,",Expected death or withdrawal of life-sustaining treatments within 7 days from screening
1959,NCT03143985,",169:179:treatment",Any > grade 1 (according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC AE) v.4.03) adverse reaction unresolved from previous treatments or not readily managed and controlled with supportive care
1960,NCT02636530,"15:25:treatment,","initiation of treatments that could impact bone metabolism (diuretics, hormones, bine anabolic agents) in the prior 6 months"
1961,NCT02382549,"61:71:treatment,",Participants who have received the following medications or treatments at any time within 4 weeks of registration
1962,NCT02359825,7:17:treatment,other treatments known to affect the growth of the neural and vascular system
1963,NCT02354703,56:66:treatment,Willingness to participate in behavioral and medicinal treatments for Alcohol Use Disorder
1964,NCT02343042,32:42:treatment,Hypersensitivity to any of the treatments for the Arm in which the patient is enrolled
1965,NCT02286154,68:78:treatment,Family unwillingness to sign informed consent or comply with study treatments
1966,NCT01967823,60:70:treatment,Recurrent disease/progression after receiving all standard treatments
1967,NCT00929006,39:49:treatment,Restrictions on use of other drugs or treatments
1968,NCT03114020,"39:63:treatment,",Exacerbation requiring treatment with systemic corticosteroids within the last 3 months
1969,NCT02574455,",35:59:treatment,,","At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted)"
1970,NCT02495168,23:47:treatment,Patients who required systemic corticosteroids (for any reason)
1971,NCT02460783,16:40:treatment,Current use of systemic corticosteroids
1972,NCT02446093,13:37:treatment,Patients on systemic corticosteroids
1973,NCT02393794,48:72:treatment,Subject is currently receiving or has received systemic corticosteroids
1974,NCT02311621,"4:28:treatment,",No systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollment
1975,NCT02304458,"33:57:treatment,",patients must not have received systemic corticosteroids within 7 days prior to enrollment
1976,NCT02075671,"8:32:treatment,",Use of systemic corticosteroids 3 months prior to Visit 1
1977,NCT01333046,20:44:treatment,Patients receiving systemic corticosteroids
1978,NCT03059888,"35:64:treatment,",Subject has undergone a change in immunosuppressive medications within the last three months prior to enrollment
1979,NCT02920710,17:46:treatment,Stable baseline immunosuppressive medications
1980,NCT02910700,"7:36:treatment,",other immunosuppressive medications within 14 days of study drug administration
1981,NCT02864147,8:37:treatment,taking immunosuppressive medications
1982,NCT02738749,17:46:treatment,Patients taking immunosuppressive medications
1983,NCT02725177,15:44:treatment,Escalation of immunosuppressive medications between screening and initiation of the study medication
1984,NCT02707692,11:40:treatment,Receiving immunosuppressive medications
1985,NCT02490631,1:30:treatment,immunosuppressive medications
1986,NCT02353819,17:46:treatment,Not actively on immunosuppressive medications
1987,NCT02259621,"7:36:treatment,",other immunosuppressive medications within 14 days of study drug administration
1988,NCT03029806,8:15:treatment,"Recent steroid use (injected, inhaled, oral)"
1989,NCT02914834,8:15:treatment,use of steroid medications
1990,NCT02536794,36:43:treatment,must have completed any prescribed steroid taper
1991,NCT02465060,10:17:treatment,Low dose steroid use for appetite
1992,NCT02451982,27:34:treatment,Using systemically active steroid use
1993,NCT02272556,"19:26:treatment,",Current or recent steroid use in last 3 months
1994,NCT02219581,17:24:treatment,Current chronic steroid use
1995,NCT01896999,53:60:treatment,a history of occasional (but not continuous) use of steroid inhalers is allowed
1996,NCT01876511,21:28:treatment,Systemically active steroid use
1997,NCT01524536,34:41:treatment,Willingness to perform the timed steroid challenge
1998,NCT02920788,36:39:chronic_disease,No history of any (mild to severe) TBI (as defined by DOD / VA; confirmed by medical records and in person Ohio State University TBI Instrument)
1999,NCT02719964,13:16:chronic_disease,Penetrating TBI
2000,NCT02709980,",61:64:chronic_disease",Report sleep problems for >1 month that developed after the TBI
2001,NCT02695043,76:79:chronic_disease,"medically documented (e.g., EMS report, hospital record, physician record) TBI as a result of a blow to the head requiring admission to an acute inpatient rehabilitation unit"
2002,NCT02504866,30:33:chronic_disease,Diagnosis of non-penetrating TBI
2003,NCT02407028,"21:24:chronic_disease,,,","Present with severe TBI, defined as GCS of 3 to 8"
2004,NCT02391402,"111:114:chronic_disease,,,,","Veterans with a history indicated by medical record review of a diagnosis of moderate, severe, or penetrating TBI, or self-reported history on the Structured Interview for Collecting Head Trauma Event Characteristics of TBI with Post-Traumatic Amnesia (PTA) greater than 24 hours or loss of consciousness (LOC) greater than 30 minutes"
2005,NCT02377089,"18:21:chronic_disease,,",report of severe TBI with coma duration (30 minutes or more) during the screening interview and/or duration of post
2006,NCT02310633,42:45:chronic_disease,who meet criteria for moderate or severe TBI during deployment
2007,NCT02266329,12:15:chronic_disease,History of TBI more severe than that classified as mild by DVBIC criteria
2008,NCT03182907,16:23:treatment,has received a vaccine directed against C
2009,NCT03153319,22:29:treatment,Requirement for live vaccine exposure that would be expected to occur during the time frame of the study
2010,NCT02865135,18:25:allergy_name,"Allergies to any vaccine, that after discussion with Immunovaccine"
2011,NCT02466750,",87:94:treatment","Agree to defer blood, bone marrow, and organ donation for 1 year after receipt of the vaccine"
2012,NCT01893554,90:97:treatment,whose parent/guardian understands and signs the study informed consent and who agrees to vaccine administration following a detailed explanation of the study
2013,NCT01893554,87:94:treatment,whose parents/guardians can understand and sign the informed consent and who agree to vaccine administration following detailed explanation of the study
2014,NCT01795313,48:55:treatment,willing to travel to Pittsburgh to receive the vaccine
2015,NCT01595529,1:8:treatment,vaccine
2016,NCT00186927,22:29:treatment,prior to evidence of vaccine clearance
2017,NCT03144245,52:63:treatment,patients with excessive blasts may be treated with hydroxyurea to bring counts down
2018,NCT03088709,13:24:treatment,(except for hydroxyurea)
2019,NCT02981329,"7:18:treatment,,","If on hydroxyurea, fetal hemoglobin less than 20% at maximum tolerated dose"
2020,NCT02728050,12:23:treatment,The use of hydroxyurea prior to study registration
2021,NCT02577406,1:12:treatment,hydroxyurea
2022,NCT02520011,",,55:66:treatment","Have a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #5 above)"
2023,NCT02186418,33:44:treatment,Patients who are unable to take hydroxyurea due to financial or safety monitoring constraints
2024,NCT02105766,28:39:treatment,Complication/ Eligible for hydroxyurea
2025,NCT01389024,33:44:allergy_name,Known allergy or intolerance of hydroxyurea
2026,NCT03129061,"12:24:treatment,",Received a live vaccine within 30 days of planned PD-1 start date
2027,NCT03113695,"20:32:treatment,",Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
2028,NCT03101566,"26:38:treatment,",Must not have received a live vaccine within 30 days of planned start of the study therapy
2029,NCT03059888,"26:38:treatment,",Subject has received any live vaccine within 3 months of screening
2030,NCT02977468,"16:28:treatment,",Has received a live vaccine within 30 days of planned start of study therapy
2031,NCT02567422,22:34:treatment,Patient who requires live vaccine administration
2032,NCT02324582,"12:24:treatment,",received a live vaccine within 30 days
2033,NCT02311361,"43:55:treatment,","Subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of both drugs"
2034,NCT01059786,"14:26:treatment,",Receipt of a live vaccine within 4 weeks prior to randomization
2035,NCT03120728,24:46:treatment,history of complicated solid organ transplant
2036,NCT02974686,36:58:treatment,Dual organ or kidney after another solid organ transplant
2037,NCT02927769,3:25:treatment,a solid organ transplant
2038,NCT02760498,28:50:treatment,Patients with a history of solid organ transplant
2039,NCT02751151,43:65:treatment,The patient has been the recipient of any solid organ transplant
2040,NCT02564198,12:34:treatment,History of solid organ transplant
2041,NCT02479698,12:34:treatment,history of solid organ transplant
2042,NCT02332668,15:37:treatment,Has undergone solid organ transplant at any time
2043,NCT02277613,10:32:treatment,Previous solid organ transplant
2044,NCT03084640,"35:48:treatment,",who have had SD must have been on pembrolizumab for at least 12 weeks
2045,NCT02977468,21:34:allergy_name,Hypersensitivity to pembrolizumab or any of its excipients
2046,NCT02799095,59:72:allergy_name,Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)
2047,NCT02635360,21:34:allergy_name,Hypersensitivity to pembrolizumab or similar drugs
2048,NCT02575404,117:130:treatment,Patients who have radiographic progression using Response Evaluation Criteria In Solid Tumors (RECIST) currently on pembrolizumab are also eligible
2049,NCT02509507,",,131:144:treatment",must be willing to use acceptable methods of effective contraception during treatment and through 4 months after the last dose of pembrolizumab
2050,NCT02501473,73:86:treatment,For patients enrolled in Part 2 or Part 4 with the potential to receive pembrolizumab
2051,NCT02437370,40:53:allergy_name,Has known hypersensitivity to MK-3475 (pembrolizumab) or any of its incipients
2052,NCT02362997,102:115:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab
2053,NCT03038620,27:42:chronic_disease,Any lifetime history of a suicide attempt
2054,NCT03034863,",,,170:185:chronic_disease,","plan or intent on the Columbia Suicide Severity Rating Scale (C-SSRS), but scoring less than or equal to 4 on the C-SSRS Behavior Scale, and without history of a lethal suicide attempt in the last 3 months"
2055,NCT02924194,26:41:chronic_disease,Subjects who have made a suicide attempt within the prior year
2056,NCT02685358,"1:16:chronic_disease,",suicide attempt in the last two months
2057,NCT02543983,60:75:chronic_disease,"For participants who still experience the effects of their suicide attempt, i.e. someone who overdosed is significantly drowsy or confused, the consenting process will occur after the patient has improved from the effects"
2058,NCT02513225,"32:47:chronic_disease,","Severe risk for suicide (i.e., suicide attempt within past 6 months)"
2059,NCT02496611,12:27:chronic_disease,History of suicide attempt
2060,NCT02460692,17:32:chronic_disease,Past history of suicide attempt
2061,NCT02377089,"1:16:chronic_disease,",suicide attempt within six months
2062,NCT02960555,7:51:chronic_disease,Known human immunodeficiency virus (HIV) infection
2063,NCT02819843,7:51:chronic_disease,Known human immunodeficiency virus (HIV) infection
2064,NCT02780401,18:62:chronic_disease,Known history of human immunodeficiency virus (HIV) infection
2065,NCT02533674,7:51:chronic_disease,Known human immunodeficiency virus (HIV) infection
2066,NCT02532231,12:56:chronic_disease,with known human immunodeficiency virus (HIV) infection
2067,NCT02367040,18:62:chronic_disease,Known history of human immunodeficiency virus (HIV) infection
2068,NCT01903330,1:45:chronic_disease,human immunodeficiency virus (HIV) infection
2069,NCT01389024,7:51:chronic_disease,Known human immunodeficiency virus (HIV) infection
2070,NCT00719888,12:56:chronic_disease,History of human immunodeficiency virus (HIV) infection
2071,NCT02905591,11:37:cancer,Recurrent non-small cell lung cancer
2072,NCT02588612,"79:105:cancer,,",Subject has a diagnosis of histologically or cytologically confirmed advanced non-small cell lung cancer (Stage IIIB or IV) or recurrent disease
2073,NCT02492867,",,70:96:cancer",Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer
2074,NCT02468024,"39:65:cancer,","Radiographic findings consistent with non-small cell lung cancer, including lesions with ground glass opacities with a solid component of 50% or greater"
2075,NCT02264678,34:60:cancer,advanced recurrent or metastatic non-small cell lung cancer
2076,NCT02194738,21:47:cancer,Completely resected non-small cell lung cancer with negative margins (R0)
2077,NCT02194738,35:61:cancer,Suspected diagnosis of resectable non-small cell lung cancer
2078,NCT01993810,53:79:cancer,Histologically or cytologically proven diagnosis of non-small cell lung cancer
2079,NCT01799135,26:52:cancer,Histologically confirmed non-small cell lung cancer
2080,NCT02759120,38:55:chronic_disease,"If the enrolling physician feels the renal dysfunction has resolved, documentation to that effect must be provided"
2081,NCT02620761,"16:33:chronic_disease,,,,,","No preexisting renal dysfunction, defined as serum creatinine > 1.0 mg/dl, or urine output <1.0 ml/kg/hour over the previous 24 hours"
2082,NCT02554253,"15:32:chronic_disease,,",pre-operative renal dysfunction including a baseline creatinine equal to or greater than 1.5 mg/dL or requiring dialysis
2083,NCT02243631,"13:30:chronic_disease,,",Significant renal dysfunction (CKD >stage 2)
2084,NCT02131467,13:30:chronic_disease,Significant renal dysfunction
2085,NCT02058095,",,,,206:223:chronic_disease,","a minimal distance on 6-minute walk of equal or >450 meters will be recruited and calculated creatinine clearance of equal or less than 90 ml/min and greater than 30 ml/min, using the (MDRD-measurement of renal dysfunction, formula) assessed within the past 36 months"
2086,NCT01757418,33:50:chronic_disease,known condition associated with renal dysfunction
2087,NCT01716806,",55:72:chronic_disease",have depressed ejection fraction or moderately severe renal dysfunction (Parts E and F only)
2088,NCT01625923,12:29:chronic_disease,History of renal dysfunction
2089,NCT02560766,"13:36:treatment,",Received an investigational product within 6 months prior to dosing
2090,NCT02551679,43:66:treatment,Participation at the same time in another investigational product or device study
2091,NCT02519322,",,,,184:207:treatment",WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of investigational product
2092,NCT02498613,104:127:treatment,"Any condition that, in the opinion of the treating investigator would interfere with evaluation of the investigational product or interpretation of subject safety or study results"
2093,NCT02441062,",,103:126:treatment","?60 years old,or of childbearing potential for whom a pregnancy test (with the results known prior to investigational product administration) is negative"
2094,NCT02401035,156:179:treatment,"Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study"
2095,NCT02311361,96:119:treatment,"Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results"
2096,NCT01532687,",32:55:treatment","for 14 days before exposure to investigational product, through the dosing period"
2097,NCT01532687,",45:68:treatment",for at least 21 days after the last dose of investigational product
2098,NCT03180398,26:49:cancer,Histologically confirmed prostate adenocarcinoma
2099,NCT03087903,26:49:cancer,Histologically confirmed prostate adenocarcinoma
2100,NCT03009981,26:49:cancer,Histologically confirmed prostate adenocarcinoma
2101,NCT02857218,10:33:cancer,low-risk prostate adenocarcinoma
2102,NCT02346253,39:62:cancer,Documented pathologic confirmation of prostate adenocarcinoma
2103,NCT02334579,23:46:cancer,Histologically proven prostate adenocarcinoma
2104,NCT01868386,14:37:cancer,diagnosis of prostate adenocarcinoma
2105,NCT01581749,"23:46:cancer,",histologically proven prostate adenocarcinoma within 1 year of enrollment
2106,NCT03152409,22:47:chronic_disease,Current diagnosis of major depressive disorder
2107,NCT03056287,1:26:chronic_disease,major depressive disorder
2108,NCT02943408,1:26:chronic_disease,"major depressive disorder (296.20-296.23, 296.30-296.33)"
2109,NCT02826577,47:72:chronic_disease,Meet MINI criteria for anything but untreated major depressive disorder
2110,NCT02769000,36:61:chronic_disease,"Evidence of clinically significant major depressive disorder identified in a psychological diagnostic interview according to the criteria of the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-V)"
2111,NCT02709980,1:26:chronic_disease,major depressive disorder
2112,NCT02332291,22:47:chronic_disease,"Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent or chronic, without psychotic features, as detected by MINI and clinical exam"
2113,NCT02214667,1:26:chronic_disease,major depressive disorder
2114,NCT03125226,",,72:91:treatment",Unable to have TraceIT hydrogel placement < 8 weeks prior to beginning radiation treatment
2115,NCT02843165,",,,82:101:treatment",Patient is a pregnant woman (pregnant women are excluded from this study because radiation treatment has known potential for teratogenic or abortifacient effects)
2116,NCT02496585,38:57:treatment,Reduction of any acute toxicity from radiation treatment to grade 1
2117,NCT02313428,18:37:treatment,Ulcer in area of radiation treatment
2118,NCT01894061,"38:57:treatment,",Minimum interval since completion of radiation treatment is 12 weeks
2119,NCT01766297,40:59:treatment,Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician
2120,NCT01737502,37:56:treatment,Recovered from the toxic effects of radiation treatment before study entry
2121,NCT00075387,",39:58:treatment",least 14 days must have elapsed since radiation treatment
2122,NCT03085485,"1:10:chronic_disease,,",Cirrhosis or elevated liver transaminases > 3X ULN
2123,NCT03014687,1:10:chronic_disease,Cirrhosis
2124,NCT02955537,1:10:chronic_disease,Cirrhosis
2125,NCT02595866,1:10:chronic_disease,Cirrhosis with Child-Pugh score of B or C
2126,NCT02323945,1:10:chronic_disease,Cirrhosis
2127,NCT02323698,1:10:chronic_disease,Cirrhosis
2128,NCT02128802,1:10:chronic_disease,Cirrhosis
2129,NCT01184547,1:10:chronic_disease,Cirrhosis
2130,NCT03067571,61:79:chronic_disease,"has any concurrent medical condition or disease (eg, active systemic infection, laboratory abnormalities) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study"
2131,NCT02549833,17:35:chronic_disease,Must be free of systemic infection
2132,NCT02515708,29:47:chronic_disease,Patient with current severe systemic infection
2133,NCT02391987,8:26:chronic_disease,Active systemic infection
2134,NCT02334865,17:35:chronic_disease,Must be free of systemic infection
2135,NCT02281409,"17:35:chronic_disease,",Any significant systemic infection within 4 weeks prior to dosing
2136,NCT02131389,104:122:chronic_disease,"Infection, or history of infection, acute or chronic, in the hip joint, or acute or chronic unresolved systemic infection"
2137,NCT01130077,26:44:chronic_disease,Patients must be free of systemic infection
2138,NCT02993406,1:22:chronic_disease,uncontrolled diabetes
2139,NCT02901041,35:56:chronic_disease,Significant medical problem (e.g. uncontrolled diabetes)
2140,NCT02504866,12:33:chronic_disease,History of uncontrolled diabetes
2141,NCT02382549,"19:40:chronic_disease,,","Participants with uncontrolled diabetes, defined as having a HgB-A1c greater than 7.5%"
2142,NCT02353728,1:22:chronic_disease,uncontrolled diabetes
2143,NCT01964859,16:37:chronic_disease,A diagnosis of uncontrolled diabetes
2144,NCT01925378,"15:36:chronic_disease,,",Patients with uncontrolled diabetes; as defined by hemoglobin A1C ? 7.1%
2145,NCT01570816,1:22:chronic_disease,uncontrolled diabetes
2146,NCT02920710,14:25:chronic_disease,Patient with sarcoidosis as defined by ATS/ERS/WASOG (American Thoracic Society/European Thoracic Society/World Association for Sarcoidosis and Other Granulomatous Disorders)
2147,NCT02725177,"53:64:chronic_disease,","Administration of an investigational medication for sarcoidosis within 3 months, or 5 half-lives, whichever is longer"
2148,NCT02725177,14:25:chronic_disease,Patient with sarcoidosis
2149,NCT02311361,12:23:chronic_disease,History of sarcoidosis syndrome
2150,NCT02298491,32:43:chronic_disease,"A highly probable diagnosis of sarcoidosis, as determined using the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Sarcoidosis Organ Assessment Instrument (Judson et al., 2014), with involvement not limited to the central nervous system"
2151,NCT02265874,"57:68:chronic_disease,","Eligible adult patients will have histologically proven sarcoidosis, diagnosed at least 6 months before screening"
2152,NCT02219555,1:12:chronic_disease,sarcoidosis
2153,NCT02210650,1:12:chronic_disease,sarcoidosis
2154,NCT02581215,83:95:cancer,Measurable disease determined using guidelines of Response Evaluation Criteria In Solid Tumors (RECIST 1.1)
2155,NCT02536794,74:86:cancer,Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
2156,NCT02503722,74:86:cancer,Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors
2157,NCT02498613,74:86:cancer,Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
2158,NCT02309892,",75:87:cancer",At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
2159,NCT02266745,44:56:cancer,"imaging by Response Evaluation Criteria in Solid Tumors (RECIST v1.1, Appendix 2)"
2160,NCT01990209,102:114:cancer,Patients must have MBC that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
2161,NCT01946074,74:86:cancer,Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
2162,NCT02433210,28:43:allergy_name,Problem with or allergy to anticoagulation
2163,NCT02423863,",,,,128:143:treatment","Transaminases ? 2 times above the upper limits of the institutional normal, - INR<2 (international normalized ratio) if off of anticoagulation"
2164,NCT02342444,26:41:treatment,Receiving other forms of anticoagulation
2165,NCT02195232,59:74:treatment,central line associated events whereby patients completed anticoagulation
2166,NCT02074436,19:34:treatment,Patient receiving anticoagulation
2167,NCT01999179,55:70:treatment,Participation in another clinical trial that requires anticoagulation
2168,NCT01890590,",35:50:treatment",Decreased platelet count and / or anticoagulation parameters that would preclude transcutaneous placement of fiducials
2169,NCT01781611,25:40:treatment,Current requirement for anticoagulation
2170,NCT03181516,"8:16:chronic_disease,",Active diarrhea (diarrhea is defined in this study as three or more loose stools per day for two consecutive days)
2171,NCT03114319,8:16:chronic_disease,Active diarrhea
2172,NCT02236000,",45:53:chronic_disease",Persistent greater than or equal to grade 2 diarrhea regardless of etiology
2173,NCT02134392,26:34:chronic_disease,Documentation of ongoing diarrhea at time of recruitment
2174,NCT01670877,",33:41:chronic_disease",Experiencing grade 2 or greater diarrhea
2175,NCT01494662,",76:84:chronic_disease",Any predisposing chronic condition resulting in baseline grade 2 or higher diarrhea
2176,NCT01072370,1:9:chronic_disease,diarrhea
2177,NCT03170375,1:16:chronic_disease,hepatic disease
2178,NCT02844907,13:28:chronic_disease,Significant hepatic disease
2179,NCT02836574,"24:39:chronic_disease,,,",clinically significant hepatic disease (ALT or AST greater than 3-times the upper limit of normal) as assessed at the Screening Visit
2180,NCT02834403,1:16:chronic_disease,hepatic disease
2181,NCT02833207,26:41:chronic_disease,Self-reported history of hepatic disease
2182,NCT02408120,21:36:chronic_disease,Clinically relevant hepatic disease
2183,NCT00368355,"22:37:chronic_disease,,,,",Patients with severe hepatic disease (direct bilirubin greater than 3 ug/dl or SGPT (serum glutamic-pyruvic transaminase) greater than 500 ug/dl)
2184,NCT03153410,"69:92:treatment,",Currently is participating or has participated in a study using any investigational therapy within the past 28 days or is currently using an investigational device
2185,NCT03125902,"16:39:treatment,",Treatment with investigational therapy within 30 days prior to initiation of study treatment
2186,NCT02680535,"10:33:treatment,",received investigational therapy within a period of 5 half-lives of the investigational therapy in question prior to the day of dosing with the PEGylated AuroShell particles
2187,NCT02496585,"7:30:treatment,",Other investigational therapy received within 8 weeks prior to screening visit
2188,NCT02291848,"37:60:treatment,",Patients should have been off other investigational therapy for one month prior to entry in this study
2189,NCT02004275,"4:27:treatment,",No investigational therapy within 14 days prior to registration
2190,NCT01333046,"37:60:treatment,",Patients should have been off other investigational therapy for one month prior to entry in this study
2191,NCT03138733,33:42:chronic_disease,Community- or hospital-acquired pneumonia
2192,NCT03121352,50:59:chronic_disease,"Patients with evidence of active, non-infectious pneumonia"
2193,NCT03060473,1:10:chronic_disease,pneumonia
2194,NCT03007745,1:10:chronic_disease,pneumonia
2195,NCT02696902,101:110:chronic_disease,"expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia"
2196,NCT02329652,1:10:chronic_disease,pneumonia
2197,NCT01568177,1:10:chronic_disease,pneumonia
2198,NCT03101566,30:53:chronic_disease,"Must have no ongoing active, uncontrolled infections"
2199,NCT02479698,21:44:chronic_disease,Patients with other uncontrolled infections
2200,NCT02203903,15:38:chronic_disease,Patients with uncontrolled infections
2201,NCT02135874,23:46:chronic_disease,"Patients with active, uncontrolled infections"
2202,NCT01945814,21:44:chronic_disease,Patients with other uncontrolled infections (see 2.3.2 for definitions)
2203,NCT01620216,4:27:chronic_disease,No uncontrolled infections as determined by the investigator
2204,NCT00432094,23:46:chronic_disease,Patients with serious uncontrolled infections
2205,NCT03092635,"1:19:treatment,","Prior chemotherapy is allowed, but last dose must have been at least 2 months prior to enrollment"
2206,NCT02555189,1:19:treatment,Prior chemotherapy
2207,NCT02207439,"1:19:treatment,",Prior chemotherapy within the past 5 years
2208,NCT02143726,"1:19:treatment,",Prior chemotherapy is allowed if ? 28 days prior to registration on this protocol
2209,NCT01570998,1:19:treatment,Prior chemotherapy
2210,NCT01312857,"1:19:treatment,",Prior chemotherapy is acceptable if last dose given ? 3 weeks prior to registration to this study
2211,NCT00412594,"1:19:treatment,",Prior chemotherapy (last 4 weeks)
2212,NCT03079297,21:40:chronic_disease,lifetime history of psychotic disorders
2213,NCT02669030,24:43:chronic_disease,history or presence of psychotic disorders
2214,NCT02607514,1:20:chronic_disease,psychotic disorders
2215,NCT02562430,1:20:chronic_disease,psychotic disorders
2216,NCT02481245,1:20:chronic_disease,psychotic disorders not elsewhere classified
2217,NCT02133898,7:26:chronic_disease,other psychotic disorders
2218,NCT01782599,1:20:chronic_disease,psychotic disorders not elsewhere classified (measured via the SCID 5)
2219,NCT03058029,5:13:chronic_disease,Non-diabetic subjects
2220,NCT03043963,"1:9:chronic_disease,,",diabetic patients who are insulin dependent (or have HbA1c>9.0%)
2221,NCT02572856,"1:9:chronic_disease,,,,",diabetic (both Type 1 & 2) patients who are self-monitoring glucose levels (via finger stick measurements) two to three times daily
2222,NCT02488057,1:9:chronic_disease,diabetic
2223,NCT02488057,5:13:chronic_disease,pre-diabetic
2224,NCT02213068,",,,40:48:chronic_disease",Proteinuria >1 g/day or > 0.5 g/day if diabetic
2225,NCT00678145,5:13:chronic_disease,Non-diabetic individuals
2226,NCT03023449,16:36:chronic_disease,History of any neurological disease
2227,NCT02982226,25:45:chronic_disease,Evidence of significant neurological disease of either foot
2228,NCT02875301,19:39:chronic_disease,No diagnosis of a neurological disease
2229,NCT02565199,4:24:chronic_disease,No neurological disease
2230,NCT02155946,12:32:chronic_disease,History of neurological disease or injury
2231,NCT02139436,7:27:chronic_disease,other neurological disease
2232,NCT01715571,",10:30:chronic_disease",Men with neurological disease
2233,NCT03014687,54:77:chronic_disease,"Concurrent antibiotics for another indication (i.e., urinary tract infection)"
2234,NCT02836574,15:38:chronic_disease,evidence of a urinary tract infection
2235,NCT02680535,7:30:chronic_disease,Acute urinary tract infection
2236,NCT02339233,1:24:chronic_disease,urinary tract infection that might interfere with stand or step training
2237,NCT02329652,1:24:chronic_disease,urinary tract infection
2238,NCT01754779,",,36:59:chronic_disease",high pH as >6.40 in the absence of urinary tract infection
2239,NCT01608438,30:53:chronic_disease,Concurrent pressure sores or urinary tract infection
2240,NCT02932956,1:23:chronic_disease,Uncontrolled infection
2241,NCT02776059,1:23:chronic_disease,Uncontrolled infection
2242,NCT02574728,1:23:chronic_disease,Uncontrolled infection
2243,NCT02400255,1:23:chronic_disease,Uncontrolled infection
2244,NCT02162420,1:23:chronic_disease,Uncontrolled infection
2245,NCT02109627,1:23:chronic_disease,Uncontrolled infection
2246,NCT00711373,1:23:chronic_disease,Uncontrolled infection
2247,NCT02796209,1:24:chronic_disease,Impaired renal function
2248,NCT02784535,"1:24:chronic_disease,,",Impaired renal function (serum creatinine equal or more than 1.6 mg/dl)
2249,NCT02540330,1:24:chronic_disease,Impaired renal function
2250,NCT02514083,1:24:chronic_disease,Impaired renal function
2251,NCT02169739,"1:24:chronic_disease,,",Impaired renal function: estimated GFR <40
2252,NCT02130687,"1:24:chronic_disease,,",Impaired renal function (eGFR< 50mL/min/1.73m2 as determined by the MDRD equation)
2253,NCT02053363,"1:24:chronic_disease,,",Impaired renal function or creatinine clearance <60 ml/min
2254,NCT02684201,20:30:treatment,have an upper-limb amputation
2255,NCT02383979,36:46:treatment,"Cooperative, patient scheduled for amputation, with time and availability to do fMRI prior to their operative date"
2256,NCT01714596,32:42:treatment,Patients who have high risk of amputation of the study limb (based on opinion of the initial managing physician)
2257,NCT01293214,10:20:treatment,"Level of amputation anywhere from the wrist (or ankle) joint to just below the shoulder (or hip) joint, which should be functional"
2258,NCT01293214,"20:30:treatment,,",Time elapsed since amputation more than 6 months but less than 15 years
2259,NCT00711373,29:39:treatment,Excessive proximal level of amputation: some presence of proximal muscles is required to motor a functioning hand
2260,NCT00711373,"12:22:chronic_disease,",History of amputation of less than six months
2261,NCT02635893,"1:4:chronic_disease,",SCI ( ?1 month of injury)
2262,NCT02524379,"17:20:chronic_disease,,,",Non-penetrating SCI at neurologic level from C2 to C8
2263,NCT02495545,18:21:chronic_disease,Prior history of SCI
2264,NCT02451683,39:42:chronic_disease,Any debilitating disease prior to the SCI that caused exercise intolerance
2265,NCT02446210,41:44:chronic_disease,Exclusion criteria for individuals with SCI and Healthy Controls
2266,NCT02446210,41:44:chronic_disease,Inclusion criteria for individuals with SCI
2267,NCT01983475,52:55:chronic_disease,Extensive life-threatening injuries in addition to SCI
2268,NCT02542657,"27:34:cancer,",Baseline marrow burden or myeloma of at least 30%
2269,NCT02542657,",121:128:cancer,",For patients without a measurable serum or urine M-component or serum free light chain level: % marrow involvement with myeloma (absolute increase must be >= 10%)
2270,NCT02516696,",,,85:92:cancer",Subject has a Karnofsky performance status ?60% (>50% if due to bony involvement of myeloma (see Appendix IV)
2271,NCT02101944,98:105:cancer,Evidence of any end organ damage criteria listed below (at any time) attributed to the patient's myeloma
2272,NCT02004275,"27:34:cancer,",Baseline marrow burden of myeloma of at least 30%
2273,NCT02004275,"18:25:cancer,",Marrow burden of myeloma of at least 30%
2274,NCT00734877,",,37:44:cancer","Platelet count < 30 x 109/L, unless myeloma-related"
2275,NCT03166371,1:17:chronic_disease,eating disorders
2276,NCT03097536,10:26:chronic_disease,comorbid eating disorders
2277,NCT03058029,"12:28:chronic_disease,,,,",History of eating disorders including binge eating (except for mild binge eating)or emesis ?2/week from any cause Weight change >3% within three(3) months prior to and during the Screening period
2278,NCT02962128,39:55:chronic_disease,Having a current or recent history of eating disorders
2279,NCT02607514,1:17:chronic_disease,eating disorders
2280,NCT02487251,21:37:chronic_disease,Significant feeding/eating disorders that would preclude participation in the interventions
2281,NCT03153410,45:75:cancer,Have histologically or cytologically proven adenocarcinoma of the pancreas
2282,NCT02873598,48:78:cancer,Histologically or cytopathologically confirmed adenocarcinoma of the pancreas
2283,NCT02442323,31:61:cancer,Have histologically confirmed adenocarcinoma of the pancreas
2284,NCT02427841,62:92:cancer,Subjects must have histologically or cytologically confirmed adenocarcinoma of the pancreas
2285,NCT02394535,34:64:cancer,Cytologic or histologic proof of adenocarcinoma of the pancreas
2286,NCT02207465,26:56:cancer,Pathologically confirmed adenocarcinoma of the pancreas
2287,NCT03143985,22:34:treatment,Prior treatment with pomalidomide
2288,NCT02343042,52:64:treatment,"In the expansion arm at RP2D, patients must not be pomalidomide refractory"
2289,NCT02287558,",,,,,,205:217:treatment,,,","Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide"
2290,NCT02004275,",,228:240:treatment","Must either commit to complete abstinence from heterosexual contact or begin TWO acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, AT THE SAME TIME, before starting pomalidomide"
2291,NCT02004275,",,,,199:211:treatment",Must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mlU/ml no more than 14 days prior to registration and must agree to repeat this test within 24 hours of starting pomalidomide
2292,NCT01464034,",52:64:treatment,",Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after completing the study
2293,NCT03135522,14:25:cancer,negative for lung cancer
2294,NCT02989974,30:41:cancer,Caregiver of a participating lung cancer survivor
2295,NCT02989974,42:53:cancer,Individuals who have been diagnosed with lung cancer (survivor)
2296,NCT02950337,36:47:cancer,Patients with any prior history of lung cancer
2297,NCT02950337,18:29:cancer,Prior history of lung cancer
2298,NCT02905591,22:33:cancer,At least part of the lung cancer must be viewable and measurable by CT or MRI
2299,NCT03104699,41:54:cancer,Histologic confirmation of the original primary tumor is required via pathology report
2300,NCT02542202,"27:40:cancer,,",this will be defined as a primary tumor < 10 cm in size or a primary lesion which can be treated to a dose of >= 8 Gy x 5 without excessive perceived risk of toxicity
2301,NCT02488967,27:40:cancer,"By pathologic evaluation, primary tumor must be pT1-3"
2302,NCT02176967,",,,51:64:cancer,",> 6 months and < 12 months of age with an adrenal primary tumor < 5 cm in greatest diameter
2303,NCT02095184,"40:53:cancer,,","Evidence of hormone sensitive, ER rich primary tumor defined by an Allred score of ?6"
2304,NCT00579514,68:81:cancer,All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites
2305,NCT03078907,8:30:chronic_disease,Severe coronary heart disease
2306,NCT03072238,11:33:chronic_disease,untreated coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing)
2307,NCT02471430,13:35:chronic_disease,Evidence of coronary heart disease
2308,NCT02471430,25:47:chronic_disease,No evidence of clinical coronary heart disease
2309,NCT02471430,16:38:chronic_disease,No evidence of coronary heart disease
2310,NCT01553214,12:34:chronic_disease,History of coronary heart disease
2311,NCT03069469,1:23:chronic_disease,Malabsorption syndrome or other illness that could affect oral absorption
2312,NCT02496208,1:23:chronic_disease,Malabsorption syndrome
2313,NCT02236000,1:23:chronic_disease,Malabsorption syndrome
2314,NCT02132598,1:23:chronic_disease,Malabsorption syndrome
2315,NCT01568255,1:23:chronic_disease,Malabsorption syndrome
2316,NCT01532687,1:23:chronic_disease,Malabsorption syndrome
2317,NCT03049033,14:33:chronic_disease,Diagnosis of Parkinson's Disease using the UK Brain Bank Criteria
2318,NCT03034564,14:33:chronic_disease,Diagnosis of Parkinson's Disease
2319,NCT03023059,1:20:chronic_disease,Parkinson's Disease
2320,NCT02781103,1:20:chronic_disease,Parkinson's Disease
2321,NCT02107638,26:45:chronic_disease,Medically diagnosed with Parkinson's Disease
2322,NCT02107638,26:45:chronic_disease,no clinical diagnosis of Parkinson's Disease
2323,NCT03016130,30:34:treatment,Underlying diagnosis for non-HSCT patients
2324,NCT02675959,41:45:treatment,Patients who have previously received a HSCT will not be eligible
2325,NCT02234934,27:31:treatment,Ineligible for autologous HSCT by the criteria at the clinical site
2326,NCT02105766,14:18:treatment,Eligible for HSCT
2327,NCT01461837,23:27:treatment,Previously received a HSCT
2328,NCT01174108,",,110:114:treatment",ECOG performance status of 3 or more (See Bone & Marrow Transplant Consortium Supportive Care Guidelines for HSCT Recipients)
2329,NCT03001830,"1:18:chronic_disease,,",liver dysfunction (persistently elevated ALT >1.5X upper limit of normal)
2330,NCT02816736,"8:25:chronic_disease,",Severe liver dysfunction (Childs-Pugh Class C)
2331,NCT02266745,8:25:chronic_disease,Severe liver dysfunction (Child-Pugh Class B or C)
2332,NCT02111824,"15:32:chronic_disease,,,,,","Patients with liver dysfunction: total bilirubin > 2.5 mg/dl; albumin < 2.5 mg/dl; alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 5 times upper limits of normal"
2333,NCT02092324,",,,,234:251:chronic_disease",Subjects with inadequate liver (alanine aminotransferase [ALT]/serum glutamate pyruvate transaminase [SGPT] above 4 X upper limit of normal [ULN] or direct bilirubin 4 X ULN AND the lab abnormalities are felt to be due to underlying liver dysfunction)
2334,NCT01648751,7:24:chronic_disease,Known liver dysfunction
2335,NCT02946892,"1:18:chronic_disease,,",Renal dysfunction defined as serum creatinine >2.0mg/dL
2336,NCT02739035,1:18:chronic_disease,Renal dysfunction
2337,NCT02700451,1:18:chronic_disease,Renal dysfunction
2338,NCT02536170,"1:18:chronic_disease,,",Renal dysfunction of creatinine greater than 1.0
2339,NCT01895777,1:18:chronic_disease,Renal dysfunction
2340,NCT01842399,"1:18:chronic_disease,,",Renal dysfunction (GFR less than 60 mL/min)
2341,NCT02914483,1:19:chronic_disease,pulmonary embolism
2342,NCT02664909,12:30:chronic_disease,history of pulmonary embolism
2343,NCT02473536,28:46:chronic_disease,Subjects with a history of pulmonary embolism is excluded
2344,NCT02370095,13:31:chronic_disease,Presence of pulmonary embolism
2345,NCT02188745,1:19:chronic_disease,pulmonary embolism
2346,NCT00969332,1:19:chronic_disease,pulmonary embolism
2347,NCT02842658,9:32:chronic_disease,Complex ventricular arrhythmias
2348,NCT02585973,21:44:chronic_disease,severe uncontrolled ventricular arrhythmias
2349,NCT02203695,35:58:chronic_disease,History of clinically significant ventricular arrhythmias
2350,NCT01925573,45:68:chronic_disease,History or presence of serious uncontrolled ventricular arrhythmias
2351,NCT01894061,45:68:chronic_disease,History or presence of serious uncontrolled ventricular arrhythmias
2352,NCT01366612,21:44:chronic_disease,severe uncontrolled ventricular arrhythmias
2353,NCT02776891,1:6:cancer,DLBCL without myc translocation or overexpression by the above methods
2354,NCT02564744,127:132:cancer,"For Part 2 and Part 3 of the study, participants must have histopathologically and clinically confirmed diagnosis of relapsed DLBCL"
2355,NCT02564744,42:47:cancer,The following participants with relapsed DLBCL will be enrolled
2356,NCT02061761,79:84:cancer,For dose escalation and dose expansion in combination with BMS-936558: HL and DLBCL
2357,NCT01959698,",,,31:36:cancer",Ann Arbor stage I to stage IV DLBCL at the time of relapsed/refractory disease to be eligible
2358,NCT01829958,26:31:cancer,Previously untreated for DLBCL
2359,NCT02669966,34:37:chronic_disease,"The donor candidate must be anti-HCV positive by ELISA and HCV RNA negative by PCR, with both tests repeated for confirmation, as per standard protocol"
2360,NCT02573376,"35:38:chronic_disease,",Considered an active drug user by HCV provider and self-reported drug use within the past month
2361,NCT02573376,"1:4:chronic_disease,,,","HCV genotype 1, 4, 5, 6"
2362,NCT02474199,1:4:chronic_disease,HCV RNA negative at time of study enrollment
2363,NCT02471430,10:13:chronic_disease,negative HCV PCR if anti-HCV antibodies are positive
2364,NCT02016924,27:30:chronic_disease,individuals with positive HCV antibody and without detectable HCV RNA are permitted to enroll
2365,NCT02543983,130:138:allergy_name,A medical finding or condition that in the clinical judgement of the investigator increases the risk of adverse effects from the ketamine administration (for example: findings suggesting difficulties with kidney or cardiac function that may be contradictions for an experimental intervention)
2366,NCT02543983,44:52:treatment,Intolerable or serious adverse reaction to ketamine during Phase II
2367,NCT02341963,12:20:allergy_name,Allergy to ketamine
2368,NCT02341963,46:54:treatment,the inability to avoid these products during ketamine administration
2369,NCT02165449,21:29:allergy_name,Contraindication to ketamine
2370,NCT02165449,29:37:treatment,Voluntary patient receiving ketamine
2371,NCT02513797,8:20:chronic_disease,Active endocarditis
2372,NCT02494869,8:20:chronic_disease,Active endocarditis
2373,NCT02453373,21:33:chronic_disease,Suspected/confirmed endocarditis
2374,NCT02216227,46:58:chronic_disease,Have an ICD-9 diagnosis code consistent with endocarditis
2375,NCT01568177,1:13:chronic_disease,endocarditis
2376,NCT00291525,22:34:chronic_disease,Patients with active endocarditis at the time of implant
2377,NCT02339922,"1:22:treatment,",platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
2378,NCT02304458,",,82:103:treatment,","Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)"
2379,NCT02124772,",,83:104:treatment,","platelets >=75,000/ microliter (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)"
2380,NCT02004275,"4:25:treatment,",No platelet transfusions within 7 days of registration to meet eligibility criteria
2381,NCT01880567,1:22:treatment,platelet transfusions
2382,NCT01464034,",51:72:treatment,",Screening platelet count should be independent of platelet transfusions for at least 2 weeks
2383,NCT03179605,"15:24:chronic_disease,,","Subjects with psoriasis involving ?10% Body Surface Area (BSA), not including the face, scalp, groin, axillae and other intertriginous areas at the Baseline Visit"
2384,NCT03168347,16:25:chronic_disease,Diagnosed with psoriasis (ICD-9: 696.1)
2385,NCT02595866,77:86:chronic_disease,"Mild autoimmunity not impacting the function of major organs (e.g., limited psoriasis)"
2386,NCT02527421,"15:24:chronic_disease,,",Subjects with psoriasis involving ? 10% BSA
2387,NCT01631617,1:10:chronic_disease,psoriasis
2388,NCT03166930,1:23:chronic_disease,neurological condition other than MS that is known to cause spasticity
2389,NCT02890485,15:37:chronic_disease,Presence of a neurological condition that would affect movement
2390,NCT02410954,13:35:chronic_disease,Any current neurological condition
2391,NCT02361554,15:37:chronic_disease,Subject has a neurological condition
2392,NCT02314221,7:29:chronic_disease,Other neurological condition that the study physician considers in his/her clinical judgment to be exclusionary
2393,NCT03159702,30:54:cancer,Patients with a diagnosis of hematological malignancy undergoing a related donor haploidentical HCT
2394,NCT02931110,65:89:cancer,"Rapidly progressive, clinically unstable central nervous system hematological malignancy"
2395,NCT02611063,23:47:cancer,Complete remission of hematological malignancy prior to transplantation
2396,NCT02323191,"31:55:cancer,",Participants has a history of hematological malignancy within the last 5 years prior to study entry
2397,NCT02074436,",,17:41:cancer",Age > 18 with a hematological malignancy
2398,NCT03135522,"26:70:chronic_disease,,,,,",Diagnosis or evidence of chronic obstructive pulmonary disease (COPD) as defined by forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 0.70 and FEV1% predicted < 80%
2399,NCT03067571,"11:55:chronic_disease,,",has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal
2400,NCT02578641,1:45:chronic_disease,chronic obstructive pulmonary disease (COPD)
2401,NCT02523443,"22:66:chronic_disease,,",Patients with severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 <50%
2402,NCT01983462,12:56:chronic_disease,History of chronic obstructive pulmonary disease (COPD)
2403,NCT03125902,38:51:chronic_disease,clinically significant (symptomatic) hypercalcemia
2404,NCT02332928,"1:14:chronic_disease,,",hypercalcemia (calcium >11 mg/dL) Ca = SerumCa + 0.8 * (NormalAlbumin - PatientAlbumin)
2405,NCT02172651,"14:27:chronic_disease,,,","Pre-existing hypercalcemia (defined as baseline serum calcium above the institutional ULN, corrected for albumin level if albumin is not within institutional limits of normal)"
2406,NCT02091141,29:42:chronic_disease,Uncontrolled or symptomatic hypercalcemia
2407,NCT01572480,12:25:chronic_disease,Absence of hypercalcemia
2408,NCT03105700,1:9:treatment,caffeine
2409,NCT02665338,1:9:treatment,caffeine
2410,NCT02067975,"31:39:treatment,","Excessive self-reported daily caffeine intake, defined as intake exceeding 1000 mg or the equivalent of 8 cups of coffee"
2411,NCT01940822,21:29:allergy_name,No prior history of caffeine sensitivity or allergy
2412,NCT01940822,18:26:allergy_name,Prior history of caffeine sensitivity or allergy
2413,NCT03096886,21:45:treatment,Willing to not take psychotropic medications for the duration of the study
2414,NCT02874898,"18:42:treatment,",Unstable dose of psychotropic medications in the prior 3 months
2415,NCT02768727,27:51:treatment,History or current use of psychotropic medications
2416,NCT02647723,8:32:treatment,Use of psychotropic medications
2417,NCT02316574,22:46:treatment,Currently taking any psychotropic medications
2418,NCT03072381,68:74:treatment,"self-reported failure of at least 2 of the most common treatments (NSAIDs, relative rest, ice, bracing) for CLE"
2419,NCT02844751,"19:25:treatment,",Consistent use of NSAIDs within 48 hours of procedure
2420,NCT02739035,16:22:allergy_name,Intolerance to NSAIDs
2421,NCT02700451,23:29:allergy_name,Documented allergy to NSAIDs
2422,NCT02650206,"1:7:treatment,",NSAIDs (must cease use 4 weeks prior to study enrollment)
2423,NCT03060096,"16:25:chronic_disease,",Self -reported psychotic symptoms in the last 30 days
2424,NCT02397889,29:38:chronic_disease,Past or current presence of psychotic symptoms
2425,NCT02305537,24:33:chronic_disease,those who are actively psychotic
2426,NCT02149823,23:32:chronic_disease,Currently meets for a psychotic episode
2427,NCT02056873,13:22:chronic_disease,Presence of psychotic features
2428,NCT03055767,14:31:chronic_disease,Diagnosis of Myasthenia gravis
2429,NCT02849639,1:18:chronic_disease,Myasthenia gravis
2430,NCT02823665,1:18:chronic_disease,Myasthenia gravis
2431,NCT02418195,1:18:chronic_disease,Myasthenia gravis
2432,NCT02097121,1:18:chronic_disease,Myasthenia gravis
2433,NCT03018704,"1:15:treatment,",tubal ligation or are less than two years postmenopausal
2434,NCT02950337,",,104:118:treatment","A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice)"
2435,NCT02536794,",76:90:treatment","A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice)"
2436,NCT02452697,3:17:treatment,A tubal ligation is adequate documentation that a patient is not of child bearing potential
2437,NCT01896999,",,114:128:treatment","a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation"
2438,NCT03005782,"21:54:cancer,",Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease
2439,NCT03001882,25:58:cancer,Patients with untreated central nervous system metastases
2440,NCT02303977,11:44:cancer,Untreated central nervous system metastases
2441,NCT02091999,14:47:cancer,Uncontrolled central nervous system metastases
2442,NCT01522768,15:48:cancer,"Asymptomatic, central nervous system metastases"
2443,NCT02981082,1:23:chronic_disease,Pulmonary hypertension
2444,NCT02950337,1:23:chronic_disease,Pulmonary hypertension
2445,NCT02562235,1:23:chronic_disease,Pulmonary hypertension related to conditions other than specified in the inclusion criteria
2446,NCT02503722,1:23:chronic_disease,Pulmonary hypertension
2447,NCT02436070,1:23:chronic_disease,Pulmonary hypertension
2448,NCT02914171,12:22:chronic_disease,history of thrombosis
2449,NCT02496585,"41:51:chronic_disease,,,,,","Inherited predisposition to bleeding or thrombosis, INR >2, PT and PTT >1.5x ULN"
2450,NCT02496585,35:45:chronic_disease,Known inherited predisposition to thrombosis
2451,NCT02489045,15:25:chronic_disease,"Patients with thrombosis within the hepatic, portal, or mesenteric veins"
2452,NCT00540761,82:92:treatment,"high-risk and complex lesions, including tortuous blood vessels and lesions with thrombosis"
2453,NCT02861417,1:24:chronic_disease,Uncontrolled infections
2454,NCT02663622,1:24:chronic_disease,Uncontrolled infections
2455,NCT02203903,1:24:chronic_disease,Uncontrolled infections
2456,NCT01904136,1:24:chronic_disease,Uncontrolled infections; principal investigator (PI) is the final arbiter of this criterion
2457,NCT00959140,1:24:chronic_disease,"Uncontrolled infections, defined as positive blood cultures"
2458,NCT02820350,1:5:chronic_disease,AIDS
2459,NCT02392286,1:5:chronic_disease,AIDS or AIDS-defining illness
2460,NCT02130388,"1:5:chronic_disease,,",AIDS defining illness or Cluster of Differentiation 4 < 200
2461,NCT02016924,"4:8:chronic_disease,",An AIDS defining condition with onset within 30 days prior to screening
2462,NCT01415752,15:19:chronic_disease,No history of AIDS-defining conditions
2463,NCT02762006,12:41:chronic_disease,History of leptomeningeal carcinomatosis
2464,NCT02592551,12:41:cancer,History of leptomeningeal carcinomatosis
2465,NCT02568267,42:71:cancer,"Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled"
2466,NCT02401347,15:44:cancer,Subjects with leptomeningeal carcinomatosis
2467,NCT02336451,33:62:cancer,Patients must be diagnosed with leptomeningeal carcinomatosis
2468,NCT02710396,24:58:chronic_disease,Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
2469,NCT02578641,1:35:chronic_disease,Human Immunodeficiency Virus (HIV) negative
2470,NCT02324582,"12:46:chronic_disease,",history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
2471,NCT01947140,21:55:chronic_disease,Patient known to be Human Immunodeficiency Virus (HIV)-positive
2472,NCT01676753,24:58:chronic_disease,Patient is known to be Human Immunodeficiency Virus (HIV)-positive
2473,NCT02667418,1:12:chronic_disease,hypotension
2474,NCT02620579,"1:12:chronic_disease,,",hypotension (resting systolic blood pressure below 90 mm Hg)
2475,NCT02263729,"6:17:chronic_disease,,,,,",Have hypotension (blood pressure less than or equal to 90 mmHg systolic pressure or less than or equal to 60 mmHg diastolic pressure)
2476,NCT02178566,"10:21:chronic_disease,,",Systemic hypotension with systolic blood pressure < 85 mmHg
2477,NCT02098876,",,,,,50:61:chronic_disease,",Systolic BP >160mmHg or diastolic BP>100 mmHg or hypotension (BP <90/60 mmHg)
2478,NCT02636530,8:23:treatment,use of glucocorticoids
2479,NCT02401035,24:39:treatment,Chronic (daily) use of glucocorticoids
2480,NCT02343042,23:38:treatment,Patients on long-term glucocorticoids during Screening do not require a washout period
2481,NCT02302235,26:41:treatment,Planned continued use of glucocorticoids
2482,NCT01865162,26:41:treatment,Planned continued use of glucocorticoids
2483,NCT02576431,23:33:cancer,Subjects with primary CNS tumors are eligible
2484,NCT02564198,43:53:cancer,participants with recurrent or refractory CNS tumors
2485,NCT02451215,18:28:cancer,Other high grade CNS tumors
2486,NCT02451215,17:27:cancer,Other low-grade CNS tumors
2487,NCT01505569,16:26:cancer,Arm B: Certain CNS tumors
2488,NCT02561988,"1:11:chronic_disease,,",Cytopenias: ANC < 1.0 × 10?/L
2489,NCT02315612,1:11:chronic_disease,Cytopenias deemed to be disease-related and not therapy-related
2490,NCT01829958,"1:11:chronic_disease,,,,","Cytopenias (leukocytes <1 × 109/L and/or platelets ,100 × 109/L)"
2491,NCT01430390,1:11:chronic_disease,Cytopenias deemed to be disease-related and not therapy-related
2492,NCT01389024,1:11:chronic_disease,Cytopenias
2493,NCT02542202,32:55:treatment,Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose
2494,NCT02192359,41:64:treatment,there is no time period requirement for prior radiation therapy
2495,NCT02143726,"15:38:treatment,,",have received prior radiation therapy to index lesions ? 28 days prior to registration on this protocol if there has been documented progression by RECIST criteria
2496,NCT01822522,"1:24:treatment,","prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration"
2497,NCT01618357,19:42:treatment,not have received prior radiation therapy to the involved breast at any time for any reason
2498,NCT02503358,"96:99:cancer,",Measurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment
2499,NCT01760655,1:4:cancer,ALL with any morphological evidence of disease will not be eligible
2500,NCT01614197,"36:39:cancer,",Bone marrow involvement defined as ALL ? 25% blasts (M2 or M3) with or without extramedullary involvement
2501,NCT01430390,76:79:cancer,Patients will be excluded if they have isolated extra-medullary relapse of ALL
2502,NCT01371630,36:39:cancer,"Patients with previously untreated ALL of pre-B, Philadelphia chromosome (Ph-) negative ALL"
2503,NCT02474927,1:12:chronic_disease,Neutropenia
2504,NCT02343549,"1:12:chronic_disease,,",Neutropenia (absolute neutrophil count < 1.5 x 103 )
2505,NCT02234934,"1:12:chronic_disease,,","Neutropenia (absolute granulocyte count <1,000/mm3)"
2506,NCT01597518,"1:12:chronic_disease,,",Neutropenia measured as absolute neutrophil count (ANC) measured in cells per microliter of blood of < 1500 at screening visit
2507,NCT01059786,"1:12:chronic_disease,,",Neutropenia (ANC less than 1000 cells/microl)
2508,NCT02452697,68:89:treatment,Patients likely to have a significantly better durable response to allogeneic transplant alone (better than 60% progression free longer than 2 years)
2509,NCT02165007,7:28:treatment,First allogeneic transplant
2510,NCT02162511,37:58:treatment,"Participant does not qualify for an allogeneic transplant due to medical screening, underlying disease, or lack of alternative donors"
2511,NCT02140554,21:42:treatment,Prior receipt of an allogeneic transplant
2512,NCT00630565,17:38:treatment,patient refuses allogeneic transplant
2513,NCT02390752,46:55:chronic_disease,Subjects who are wheelchair bound because of paralysis will be considered ambulatory when they are up in their wheelchair
2514,NCT02114229,44:53:chronic_disease,"Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered to be ambulatory for the purpose of assessing the performance score"
2515,NCT02076906,44:53:chronic_disease,"Patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score"
2516,NCT01570816,"29:38:chronic_disease,",problems walking because of paralysis for more than 6 months
2517,NCT01504373,37:46:chronic_disease,Patients who are receiving chemical paralysis
2518,NCT02346253,32:45:treatment,Prior allergic reaction to the study drug(s) involved in this protocol
2519,NCT02203513,",,196:209:treatment",All subjects of reproductive potential must also agree to use both a barrier method and a second method of birth control during the course of the study and for four months after the last dose of study drug(s)
2520,NCT02131597,",,,,,157:170:treatment",Women who are able to become pregnant and men who can father a child must use birth control while on study and for at least 8 weeks after your last dose of study drug(s)
2521,NCT01822522,",,,,,217:230:treatment,","sexually active participants (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 6 months after the last dose of study drug(s), even if oral contraceptives are also used"
2522,NCT01639508,",,,,,342:355:treatment,,,,","The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control. Women of childbearing potential must have a negative pregnancy test at screening"
2523,NCT03185208,1:26:chronic_disease,Major psychiatric illness
2524,NCT02706288,1:26:chronic_disease,Major psychiatric illness
2525,NCT02563574,1:26:chronic_disease,Major psychiatric illness
2526,NCT02137122,1:26:chronic_disease,Major psychiatric illness
2527,NCT03179449,27:38:allergy_name,Known hypersensitivity to ferumoxytol or any of its components
2528,NCT02857218,40:51:allergy_name,a known history of hypersensitivity to ferumoxytol
2529,NCT02857218,110:121:treatment,because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother
2530,NCT02359097,"27:38:treatment,",Subject who have received ferumoxytol within 3 weeks of study entry
2531,NCT03154476,61:93:treatment,All adult Fontan patients who have no contraindications for magnetic resonance imaging (MRI) will be eligible for the study
2532,NCT02217345,22:54:treatment,Contraindications to magnetic resonance imaging (MRI)
2533,NCT02133573,31:63:treatment,Maternal contraindication for magnetic resonance imaging (MRI)
2534,NCT02046330,56:88:treatment,Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI)
2535,NCT03148379,1:23:chronic_disease,inflammatory arthritis
2536,NCT02501733,15:37:chronic_disease,Patients with inflammatory arthritis
2537,NCT02219581,15:37:chronic_disease,Patients with inflammatory arthritis
2538,NCT01754298,1:23:chronic_disease,inflammatory arthritis
2539,NCT03144206,1:8:cancer,Sarcoma location other than lower extremity
2540,NCT03144206,1:8:cancer,Sarcoma of lower extremity location
2541,NCT02423863,1:8:cancer,Sarcoma
2542,NCT02423863,"1:8:cancer,,",Sarcoma Patients must be 14 years of age or older
2543,NCT03132636,19:46:treatment,Having received a solid organ transplantation
2544,NCT02774421,30:57:treatment,who have previously received solid organ transplantation
2545,NCT02509507,12:39:treatment,history of solid organ transplantation
2546,NCT02354547,30:57:treatment,Patients who have received a solid organ transplantation
2547,NCT03127722,15:37:cancer,Subjects with gynecologic malignancy
2548,NCT03037346,"23:45:cancer,,",Diagnosis of invasive gynecologic malignancy stages 1-4
2549,NCT02573883,35:57:cancer,Current or prior diagnosis of any gynecologic malignancy
2550,NCT02209545,12:34:cancer,history of gynecologic malignancy
2551,NCT03121352,15:39:cancer,Patients with carcinomatous meningitis
2552,NCT02576444,12:36:cancer,History of carcinomatous meningitis
2553,NCT02091141,12:36:cancer,History of carcinomatous meningitis
2554,NCT01928576,28:52:cancer,Patients with a history of carcinomatous meningitis are not eligible
2555,NCT03112759,16:36:chronic_disease,Diagnosed with chronic pancreatitis
2556,NCT03112759,62:82:chronic_disease,Participating in another clinical trial for the treatment of chronic pancreatitis at the time of screening
2557,NCT02992483,12:32:chronic_disease,History of chronic pancreatitis
2558,NCT02979366,11:31:chronic_disease,active or chronic pancreatitis
2559,NCT03090607,13:32:chronic_disease,Presence of Barrett's esophagus
2560,NCT02429830,21:40:chronic_disease,History of/or known Barrett's esophagus
2561,NCT02081404,12:31:chronic_disease,History of Barrett's esophagus
2562,NCT01942018,1:20:chronic_disease,Barrett's esophagus
2563,NCT03074474,"29:51:treatment,",Subject has participated in another clinical trial within the past 30 days or is currently involved in another clinical trial
2564,NCT02776761,26:48:treatment,Ongoing participation in another clinical trial (subjects continuing through Day 365 will not join other new studies until their final visit)
2565,NCT02495545,"18:40:treatment,",Participation in another clinical trial within the past 30 days
2566,NCT02169037,115:137:treatment,"willingness, ability and commitment to participate in baseline and follow-up evaluations without participation in another clinical trial (unless documented approval received from both sponsors)"
2567,NCT03070184,"1:14:chronic_disease,,",Renal disease (eGFR < 60ml/min/1.73m2)
2568,NCT02872857,"1:14:chronic_disease,,",Renal disease as defined by creatinine clearance less than 9 milliliters/min
2569,NCT00739362,"1:14:chronic_disease,,",Renal disease (serum creatinine concentrations greater than or equal to 1.5 mg/dl and/or overt proteinuria)
2570,NCT00716066,"1:14:chronic_disease,,,,",Renal disease with estimated glomerular filtration rate (GFR) by creatinine clearance or iothalamate clearance < 50 ml/min/1.73 m^2 body surface area
2571,NCT03058679,1:15:chronic_disease,Celiac disease
2572,NCT03035799,7:21:chronic_disease,Known Celiac disease
2573,NCT02778867,1:15:chronic_disease,Celiac disease
2574,NCT02202681,",50:64:chronic_disease",Subjects must be over 16 years for patients with Celiac disease
2575,NCT03041441,1:9:treatment,sedation
2576,NCT02410707,",,,106:114:treatment","American Society of Anesthesiologists (ASA) Physical Status Classification 1 or 2, who will be receiving sedation for an Emergency Department procedure"
2577,NCT01389024,",,34:42:treatment",Temperature >38? C on the day of sedation
2578,NCT01389024,51:59:treatment,The parents or guardians must provide consent for sedation
2579,NCT03036280,"48:73:chronic_disease,","Participants who have a history of moderate to severe hepatic impairment (eg, Child-Pugh Class B or C)"
2580,NCT02496585,15:40:chronic_disease,Patients with severe hepatic impairment
2581,NCT02340156,13:38:chronic_disease,Moderate to severe hepatic impairment
2582,NCT02048722,"15:40:chronic_disease,",Patients with severe hepatic impairment (Child-Pugh class C)
2583,NCT03016351,"1:12:chronic_disease,",Head injury within last 6 months
2584,NCT03004807,"1:12:chronic_disease,,",Head injury with loss of consciousness of > 5 minutes in the last 5 years
2585,NCT02418195,"1:12:chronic_disease,",Head injury of loss of consciousness in the past 6 months
2586,NCT01869322,1:12:chronic_disease,Head injury
2587,NCT03000998,63:74:treatment,the participant has already received any or all doses for the HPV vaccine
2588,NCT02994290,42:53:treatment,Have not already received 3 doses of the HPV vaccine at time of delivery
2589,NCT02864147,"48:59:treatment,,",Patients who have received their first dose of HPV vaccine < 4 weeks ago or their second dose < 12 weeks ago
2590,NCT02382419,17:28:treatment,Prior use of an HPV vaccine
2591,NCT02985554,15:31:chronic_disease,patients with Gilbert Syndrome
2592,NCT02259621,",,51:67:chronic_disease,,","Total Bilirubin ? 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)"
2593,NCT02124902,",,,,158:174:chronic_disease",Serum bilirubin within (or under ) normal limits (OR total bilirubin ? 3.0 x IULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)
2594,NCT01990209,"24:40:chronic_disease,,,,","in patients with known Gilbert Syndrome, a total bilirubin ?3.0 x ULN, with direct bilirubin ?1.5 x ULN"
2595,NCT02957149,32:56:cancer,Metastatic or locally advanced prostatic adenocarcinoma on preoperative evaluation
2596,NCT02957149,39:63:cancer,"Newly diagnosed, clinically localized prostatic adenocarcinoma"
2597,NCT02064036,"70:94:cancer,",Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate to high risk for recurrence
2598,NCT02040610,"51:75:cancer,",Pathological (histologically) proven diagnosis of prostatic adenocarcinoma within 365 days (1 year)
2599,NCT02932280,"1:9:cancer,",Leukemia patients must have >10% blasts (or blast equivalent) in the bone marrow
2600,NCT01920737,1:9:cancer,"Leukemia cell samples will be obtained from all patients enrolled before starting protocol treatment and submitted for Philadelphia chromosome testing by either karyotyping, or for bcr/abl1 translocation by FISH or by PCR for bcr/abl1"
2601,NCT01773395,1:9:cancer,Leukemia with active CNS involvement
2602,NCT01614197,1:9:cancer,Leukemia
2603,NCT02923921,27:55:chronic_disease,History of positivity for human immunodeficiency virus
2604,NCT02474667,21:49:chronic_disease,History of positive human immunodeficiency virus test
2605,NCT01865162,12:40:chronic_disease,History of human immunodeficiency virus
2606,NCT00293475,24:52:chronic_disease,Seropositivity for the human immunodeficiency virus
2607,NCT02918981,1:19:chronic_disease,Autoimmune disease
2608,NCT02061761,1:19:chronic_disease,Autoimmune disease
2609,NCT01968109,1:19:chronic_disease,Autoimmune disease
2610,NCT00788164,1:19:chronic_disease,Autoimmune disease
2611,NCT02908906,9:29:treatment,limited palliative radiation
2612,NCT02553642,33:53:treatment,The lesion being considered for palliative radiation is not a target lesion
2613,NCT02535533,21:41:treatment,3 days wash out for palliative radiation
2614,NCT02408861,33:53:treatment,The lesion being considered for palliative radiation is not a target lesion
2615,NCT02895945,29:51:treatment,scheduled to participate in another clinical study involving an investigational product (IP) or investigational device during the course of this study
2616,NCT02479906,"39:61:treatment,",Subject is currently participating in another clinical study or enrolled in another clinical study within 30 days prior to this study
2617,NCT02335242,18:40:treatment,Participating in another clinical study which may interfere
2618,NCT01726257,32:54:treatment,Participating in enrollment of another clinical study
2619,NCT02875301,1:32:treatment,coronary artery bypass grafting
2620,NCT02816736,1:32:treatment,coronary artery bypass grafting
2621,NCT02664909,11:42:treatment,undergone coronary artery bypass grafting
2622,NCT02276456,23:54:treatment,Patients treated with coronary artery bypass grafting will be excluded for the purposes of this trial to avoid conflicts with usual post-operative management
2623,NCT02864160,21:41:chronic_disease,Clinic diagnosis of diabetic retinopathy
2624,NCT02841540,1:21:chronic_disease,diabetic retinopathy
2625,NCT02402660,1:21:chronic_disease,diabetic retinopathy
2626,NCT01474889,25:45:chronic_disease,Untreated proliferative diabetic retinopathy
2627,NCT02856594,24:42:treatment,Scheduled for a second surgical procedure during hospital stay
2628,NCT02555280,",15:33:treatment",More than one surgical procedure at any combination of lumbar levels
2629,NCT02252081,"27:45:treatment,",Recent hospitalization or surgical procedure within 1 month prior to the study for any cause
2630,NCT01959204,"21:39:treatment,",an outpatient for a surgical procedure and is expected to remain hospitalized for at least 24 hours after dosing with study drug
2631,NCT02822378,"1:16:treatment,,,","bisphosphonates, parathyroid hormone or strontium within the past 12 months"
2632,NCT02128230,1:16:treatment,bisphosphonates
2633,NCT02107703,16:31:treatment,Have initiated bisphosphonates
2634,NCT01554371,20:35:treatment,Concomitant use of bisphosphonates
2635,NCT02793921,1:18:chronic_disease,pulmonary disease
2636,NCT02663934,1:18:chronic_disease,pulmonary disease that precludes ability to safely exercise
2637,NCT02154568,21:38:chronic_disease,Negative history of pulmonary disease
2638,NCT00065676,1:18:chronic_disease,pulmonary disease
2639,NCT02744430,",,,59:66:treatment",Single unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter
2640,NCT02584309,",147:154:treatment,","measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ? 10 mm with CT scan, as ? 20 mm by chest x-ray, or ? 10 mm with calipers by clinical exam"
2641,NCT02290951,",,,82:89:treatment",Must have at least one bi-dimensionally measurable lesion ?1.5 cm) documented by CT scan
2642,NCT02210650,"9:16:treatment,",Current CT scan within the 90-day pre-operative period
2643,NCT02675114,"16:43:chronic_disease,",Evidence of an acute myocardial infarction ? 1 month (30 days) before randomization
2644,NCT02637947,"20:47:chronic_disease,",subject has had an acute myocardial infarction within 30 days prior to enrollment
2645,NCT02277613,39:66:chronic_disease,Mechanical complications of the index acute myocardial infarction
2646,NCT02188745,1:28:chronic_disease,acute myocardial infarction
2647,NCT02650206,1:23:chronic_disease,Cardiovascular disease
2648,NCT02533882,"1:23:chronic_disease,",Cardiovascular disease event within the past six months
2649,NCT02519322,1:23:chronic_disease,Cardiovascular disease-related requirement for daily supplemental oxygen
2650,NCT02143726,1:23:chronic_disease,Cardiovascular disease
2651,NCT02589977,21:37:chronic_disease,moderate or greater valvular disease
2652,NCT02503722,13:29:chronic_disease,Significant valvular disease
2653,NCT02053246,9:25:chronic_disease,Primary valvular disease
2654,NCT02006069,9:25:chronic_disease,Primary valvular disease
2655,NCT02577406,39:76:cancer,Subject has or is suspected of having central nervous system (CNS) leukemia
2656,NCT02520011,13:50:cancer,Have active central nervous system (CNS) leukemia
2657,NCT02400255,25:62:cancer,Active and/or untreated central nervous system (CNS) leukemia
2658,NCT02152956,7:44:cancer,Known central nervous system (CNS) leukemia
2659,NCT02564744,122:130:cancer,Participants must have evaluable or measurable disease in accordance with the International Working Group Guidelines for Lymphoma
2660,NCT02512926,1:9:cancer,Lymphoma patients are permitted
2661,NCT02167958,1:9:cancer,Lymphoma
2662,NCT01614197,1:9:cancer,Lymphoma
2663,NCT02553161,"13:31:chronic_disease,,","evidence of mental retardation (IQ < 70) as determined by the Weschler Abbreviated Scale of Intelligence (WASI; Psychological Corporation, 1999)"
2664,NCT02361554,28:46:chronic_disease,Subject has a diagnosis of mental retardation
2665,NCT02346929,1:19:chronic_disease,mental retardation
2666,NCT02155699,1:19:chronic_disease,mental retardation
2667,NCT02522429,13:15:treatment,an abnormal CT
2668,NCT02469129,",,36:38:treatment",Non-measurable disease (< 1 cm) by CT (Kinetic Studies Arm only; disease-free participants can be enrolled in the Dosimetry Studies Arm)
2669,NCT02232516,",,69:71:treatment",Patients must have bi-dimensionally measurable disease (>= 1 cm) by CT imaging
2670,NCT00492778,"3:5:treatment,",a CT of the pelvis and abdomen with IV and oral (PO) contrast performed using multi-detector CT and equal or less than 5 mm slice thickness
2671,NCT02512926,",,53:72:treatment",Pulse Oximetry measurement ? 95% saturation without supplemental oxygen
2672,NCT02508038,4:23:treatment,No supplemental oxygen requirement
2673,NCT02208362,"31:50:treatment,,,",Research participant requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks
2674,NCT02129803,18:37:treatment,Subject requires supplemental oxygen
2675,NCT02496208,1:28:chronic_disease,Active peptic ulcer disease
2676,NCT02072148,1:28:chronic_disease,Active peptic ulcer disease defined as unhealed or clinically active
2677,NCT01822522,1:28:chronic_disease,Active peptic ulcer disease
2678,NCT01532687,1:28:chronic_disease,Active peptic ulcer disease
2679,NCT02479620,1:14:chronic_disease,osteomyelitis of the metatarsal or more proximal region
2680,NCT02335905,108:121:chronic_disease,Requirement for other reasons for another antibiotic potentially active against organisms commonly causing osteomyelitis in children
2681,NCT02099240,32:45:chronic_disease,Pathology report indicative of osteomyelitis
2682,NCT02015390,14:27:chronic_disease,Disseminated osteomyelitis throughout the bone
2683,NCT02465060,20:44:chronic_disease,"a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible"
2684,NCT02352025,70:94:chronic_disease,Patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug
2685,NCT01989546,5:29:chronic_disease,"Any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed"
2686,NCT01943851,13:37:chronic_disease,Presence of gastrointestinal disease that would significantly affect compound absorption
2687,NCT02385110,85:88:chronic_disease,It must be noted that no diagnostic criteria have been established for diagnosis of HLH in adult patients as this was a hitherto poorly identified and considered to be a very rare disease in adults
2688,NCT02385110,73:76:chronic_disease,The diagnostic criteria that have been traditionally used for children (HLH 1991 and HLH 2004) may not adequately diagnose HLH in adults
2689,NCT02385110,"47:50:chronic_disease,",We have seen an increasing number of cases of HLH at our institution over the last 2 years partly due to referrals and partly due to better understanding of the disease through discussions with our collaborators Dr Kenneth McClain and Dr Carl Allen at TCH (experts in pediatric HLH)
2690,NCT02007239,",46:49:chronic_disease","Fulfill the clinical diagnostic criteria for HLH, as defined by the Histiocyte Society (see Table 1). Only patients with de novo HLH are eligible"
2691,NCT02358187,"1:15:treatment,",corticosteroid for at least one week prior to study registration
2692,NCT02271711,9:23:treatment,Chronic corticosteroid dependence
2693,NCT01754298,22:36:treatment,History of prolonged corticosteroid
2694,NCT01524536,23:37:treatment,subjects on a current corticosteroid taper
2695,NCT02343549,1:22:cancer,Infra-tentorial tumor
2696,NCT01954576,1:22:cancer,Infra-tentorial tumor
2697,NCT01925573,1:22:cancer,Infra-tentorial tumor
2698,NCT01894061,1:22:cancer,Infra-tentorial tumor
2699,NCT02266719,1:27:chronic_disease,Uncorrectable coagulopathy
2700,NCT02089607,1:27:chronic_disease,Uncorrectable coagulopathy
2701,NCT02050113,1:27:chronic_disease,Uncorrectable coagulopathy
2702,NCT00488696,1:27:chronic_disease,Uncorrectable coagulopathy
2703,NCT02223520,39:56:treatment,Allergies to any agent used in either treatment regimen
2704,NCT01968109,",58:75:treatment","Progressed, or been intolerant to, at least one standard treatment regimen, except for subjects in 1st line cohorts"
2705,NCT01618357,",87:104:treatment",Patients must not be pregnant due to the potential for fetal harm as a result of this treatment regimen
2706,NCT01614197,",,122:139:treatment",Refractory bone marrow involvement defined as MRD ? 0.1% blasts done at a COG-approved MRD testing lab after most recent treatment regimen. in the bone marrow (M23) and any CNS status
2707,NCT02132598,32:43:chronic_disease,Any history of congenital long QT syndrome
2708,NCT01639508,32:43:chronic_disease,Any congenital history of long QT syndrome
2709,NCT01554371,",,68:79:chronic_disease",QTc prolongation >480 msec (Bazett's Formula) or congenitally long QT syndrome
2710,NCT00872950,14:25:chronic_disease,No prolonged QT syndrome as indicated by baseline EKG
2711,NCT01954173,1:18:chronic_disease,immunocompromised patients
2712,NCT01873131,9:26:chronic_disease,who are immunocompromised
2713,NCT01220583,49:66:chronic_disease,Protocol-specific requirements may also exclude immunocompromised patients
2714,NCT00670358,5:22:chronic_disease,Not immunocompromised
2715,NCT03185130,12:37:chronic_disease,History of intracranial hypertension
2716,NCT03179605,38:63:chronic_disease,Subject has a history or presence of intracranial hypertension
2717,NCT01525901,1:26:chronic_disease,intracranial hypertension
2718,NCT03181516,1:21:chronic_disease,Congenital anomalies
2719,NCT03019367,1:21:chronic_disease,Congenital anomalies
2720,NCT02847689,1:21:chronic_disease,Congenital anomalies
2721,NCT03179397,1:10:chronic_disease,Amblyopia
2722,NCT02365090,"1:10:chronic_disease,,,,,,","Amblyopia with amblyopic eye visual acuity 20/40-20/125, fellow eye visual acuity 20/16-20/25,"
2723,NCT02332369,1:10:chronic_disease,Amblyopia
2724,NCT03171480,46:58:chronic_disease,Induction of labor for clinical diagnosis of preeclampsia
2725,NCT02221830,"14:26:chronic_disease,,,,,,,,,,,,","diagnosis of preeclampsia (PE defined using standard definitions based on the ACOG bulletin and the NIH Working Group on High Blood Pressure in Pregnancy (i.e., a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of > 300mg per 24 hour period or > 1+ on dipstick)"
2726,NCT00881660,16:28:chronic_disease,"Preterm labor, preeclampsia"
2727,NCT03166371,19:37:chronic_disease,other significant movement disorders precluding protocol functional strength testing
2728,NCT03053908,7:25:chronic_disease,other movement disorders
2729,NCT02261519,"5:23:chronic_disease,,,,","Any movement disorders with a total score higher than 6 on SAS scale, or more than 2 on any items of the AIMS scale"
2730,NCT03153982,1:16:chronic_disease,Acute hepatitis
2731,NCT02409810,1:16:chronic_disease,Acute hepatitis
2732,NCT02162420,1:16:chronic_disease,Acute hepatitis
2733,NCT03149549,12:35:treatment,history of corneal transplantation
2734,NCT02138669,10:33:treatment,Who have corneal transplantation as the only remaining option to improve their functional vision
2735,NCT02091999,12:35:treatment,History of corneal transplantation
2736,NCT03138733,"1:12:chronic_disease,,",tachycardia (heart rate > 90 bpm)
2737,NCT02624765,11:22:chronic_disease,Untreated tachycardia at time of enrollment
2738,NCT02624765,1:12:chronic_disease,tachycardia
2739,NCT03131960,55:64:treatment,"Current requirement, or likely future requirement, of diathermy during the study duration"
2740,NCT02357784,5:14:treatment,has diathermy
2741,NCT02046330,35:44:treatment,Presence of a condition requiring diathermy
2742,NCT03118973,39:43:treatment,Patient has a clinical indication for ERCP
2743,NCT03098082,"8:12:treatment,",Recent ERCP (i.e. within 1 month)
2744,NCT03098082,23:27:treatment,Undergoing Outpatient ERCP
2745,NCT03112590,"26:53:cancer,,,",histologically confirmed HER2 positive breast cancer (by ImmunoHistoChemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) ratio ? 2.0)
2746,NCT02401347,1:28:cancer,HER2 positive breast cancer (Cohort B only)
2747,NCT02401347,34:61:cancer,Hormone receptor positive and/or HER2 positive breast cancer (Cohort A only)
2748,NCT03104699,"44:65:allergy_name,,",Known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE grade ?3)
2749,NCT01676259,1:22:treatment,monoclonal antibodies
2750,NCT01473628,37:58:allergy_name,No prior known allergic reaction to monoclonal antibodies
2751,NCT03096366,12:38:chronic_disease,History of deep vein thrombosis (DVT)
2752,NCT02053363,12:38:chronic_disease,History of deep vein thrombosis (DVT)
2753,NCT01684397,12:38:chronic_disease,History of deep vein thrombosis (DVT)
2754,NCT03088709,1:33:cancer,Acute myelogenous leukemia (AML)
2755,NCT02593123,1:33:cancer,Acute myelogenous leukemia (AML)
2756,NCT02181478,1:33:cancer,Acute myelogenous leukemia (AML)
2757,NCT03078530,24:39:chronic_disease,Clinically significant chronic disease
2758,NCT02425566,19:34:chronic_disease,Subjects with any chronic disease
2759,NCT01269034,5:20:chronic_disease,Any chronic disease
2760,NCT03065465,32:44:chronic_disease,Presence of a benign appearing peptic ulcer
2761,NCT02332850,8:20:chronic_disease,active peptic ulcer
2762,NCT01900093,35:47:chronic_disease,"History of, or the presence of, a peptic ulcer"
2763,NCT03058783,19:36:chronic_disease,Current or recent serious infection
2764,NCT02920710,21:38:chronic_disease,"Evidence of current serious infection, or a history of chronic or recurring infections"
2765,NCT02774421,26:43:chronic_disease,who have an uncontrolled serious infection
2766,NCT03053908,1:14:chronic_disease,hydrocephalus
2767,NCT02359864,12:25:chronic_disease,History of hydrocephalus
2768,NCT02122328,1:14:chronic_disease,hydrocephalus
2769,NCT03038620,1:26:treatment,minor surgical procedures
2770,NCT01993719,"29:54:treatment,,","Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less"
2771,NCT01967823,"29:54:treatment,,","Patients may have undergone minor surgical procedures within the past three weeks, as long as all toxicities have recovered to grade 1 or less"
2772,NCT03033212,1:10:chronic_disease,scoliosis
2773,NCT02513797,18:27:chronic_disease,Untreated severe scoliosis (documented and clinically defined by treating physician)
2774,NCT02271100,13:22:chronic_disease,Significant scoliosis
2775,NCT03019133,8:20:treatment,Use of vasopressors
2776,NCT02579265,28:40:treatment,History of shock requiring vasopressors
2777,NCT01459107,48:60:treatment,"Stable donor (i.e., does not require excessive vasopressors to maintain blood pressure)"
2778,NCT03016351,",15:43:treatment",more than one anti-hypertensive medication
2779,NCT02444689,18:46:treatment,New / changes in anti-hypertensive medication
2780,NCT01684397,",,120:148:treatment",the 3 values have to be below 150/90 mm Hg for eligibility and can only be obtained after 2 days of the last change in anti-hypertensive medication
2781,NCT03005782,"1:23:treatment,,",Corticosteroid therapy (>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drug
2782,NCT02408120,1:23:treatment,Corticosteroid therapy
2783,NCT02320292,1:23:treatment,Corticosteroid therapy at the time the patient enters the protocol
2784,NCT02988960,55:74:treatment,"In addition, participants must have received only one prior immunotherapy"
2785,NCT02358187,28:47:treatment,Patients who have received prior immunotherapy
2786,NCT01795313,28:47:treatment,Patients who have received prior immunotherapy
2787,NCT02959762,28:31:allergy_name,Subjects with a history of soy allergy
2788,NCT02366481,28:31:allergy_name,Subjects with a history of soy allergy
2789,NCT01972113,28:31:allergy_name,Subjects with a history of soy allergy
2790,NCT02946658,23:32:chronic_disease,Patients positive for Hepatitis
2791,NCT02347891,1:10:chronic_disease,Hepatitis status will be obtained from patients' medical records
2792,NCT00678145,1:10:chronic_disease,Hepatitis
2793,NCT02931110,34:61:chronic_disease,Ongoing risk for bleeding due to active peptic ulcer disease
2794,NCT02101736,1:28:chronic_disease,active peptic ulcer disease
2795,NCT01835626,1:28:chronic_disease,active peptic ulcer disease
2796,NCT02926248,35:45:allergy_name,Patients with reported allergy to colchicine
2797,NCT02594111,12:22:treatment,History of colchicine intolerance
2798,NCT02576301,16:26:treatment,Treatment with colchicine
2799,NCT02920086,",,,,,80:93:chronic_disease","Chronic obstructive lung disease - 2 of the 4 of: baseline PaCO2 of > 45 torr, cor pulmonale"
2800,NCT02525861,"68:81:chronic_disease,,",The participant is experiencing or has a history of chronic severe cor pulmonale (resting mean pulmonary artery pressure ?40 millimeter(s) of mercury (mm Hg))
2801,NCT02416102,22:35:chronic_disease,clinical evidence of cor pulmonale
2802,NCT02913430,77:96:treatment,Patients may be pre- or post-menopausal; pre-menopausal patients must be on ovarian suppression and must be adequately suppressed on LHRH agonists with estradiol levels in the post-menopausal range
2803,NCT02913430,",,99:118:treatment",Premenopausal patients cannot be pregnant and must agree to adequate birth control in addition to ovarian suppression
2804,NCT01990209,51:70:treatment,This group of patients may be pre-menopausal with ovarian suppression or post-menopausal
2805,NCT02907983,1:28:treatment,anticoagulation medications will be discontinued with the permission of the participant's prescribing physician
2806,NCT02520778,10:37:treatment,low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter
2807,NCT02250157,28:55:treatment,Require therapeutic use of anticoagulation medications
2808,NCT02901067,9:19:chronic_disease,Ongoing hemorrhage requiring blood product transfusion
2809,NCT02706249,"28:38:chronic_disease,",Any history of significant hemorrhage (requiring hospitalization or transfusion) within the last 6 months (excluding hemorrhage during operative procedure)
2810,NCT02048371,"5:15:chronic_disease,,,",Any hemorrhage or bleeding event ? NCI CTCAE Grade 3 within 4 weeks prior to study registration
2811,NCT02875301,1:13:chronic_disease,brain injury
2812,NCT02563678,18:30:chronic_disease,Co-enrollment in brain injury study
2813,NCT02445768,9:21:chronic_disease,another brain injury or illness related to the brain that has lasting effects or effects experienced at the moment of recruitment
2814,NCT02865135,1:10:chronic_disease,dysphagia
2815,NCT02429830,"13:22:chronic_disease,,",Symptoms of dysphagia more than once per week within the last 3 months
2816,NCT01341080,23:32:chronic_disease,Significant degree of dysphagia
2817,NCT02852057,1:12:chronic_disease,Bradycardia
2818,NCT02453373,"1:12:chronic_disease,,",Bradycardia (heart rate ? 50)
2819,NCT02192398,"1:12:chronic_disease,,",Bradycardia (resting heart rate < 60 bpm) will be reviewed by a study physician
2820,NCT02844465,"38:42:treatment,","Willing and able to remain on stable AEDs (and stable VNS setting, if applicable) for 12 months following the Visualase procedure"
2821,NCT02477839,",,80:84:treatment",Subject is on a stable (concurrently or sequentially) dosage regimen of 1 to 3 AEDs
2822,NCT02011971,",20:24:treatment",Taking more than 3 AEDs
2823,NCT02826382,12:31:chronic_disease,history of hyperparathyroidism
2824,NCT02088554,13:32:chronic_disease,Patient has hyperparathyroidism
2825,NCT01568255,"36:55:chronic_disease,",A co-existent diagnosis of primary hyperparathyroidism within the previous 6 months
2826,NCT02819635,1:19:treatment,immunosuppressants
2827,NCT02776761,",58:76:treatment",Administration of chronic (defined as more than 14 days) immunosuppressants
2828,NCT01293214,17:35:treatment,Willing to take immunosuppressants - drugs that help prevent rejection of the transplant - for life
2829,NCT02809677,13:30:chronic_disease,symptoms of persistent asthma in children not on a daily controller medication
2830,NCT02809677,25:42:chronic_disease,who have a diagnosis of persistent asthma
2831,NCT02588326,16:33:chronic_disease,ntermittent or persistent asthma
2832,NCT02796209,1:11:treatment,fluoxetine
2833,NCT02737930,72:82:treatment,Current use of a medication likely to have an adverse interaction with fluoxetine
2834,NCT02556606,23:33:treatment,Patients currently on fluoxetine
2835,NCT02776059,27:52:chronic_disease,uncontrolled recent upper gastrointestinal bleeding
2836,NCT02197351,38:63:chronic_disease,Patients who have evidence of active gastrointestinal bleeding will be excluded
2837,NCT01943851,"18:43:chronic_disease,",History of major gastrointestinal bleeding within the last 3 months or any evidence of active gastrointestinal bleeding excludes the subject
2838,NCT02753283,",12:21:treatment,","Those with vitamin D levels < 25ng/mL will be treated with vitamin D 50,000 IU/wk for 8 weeks"
2839,NCT02172651,102:111:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin D
2840,NCT02172651,"29:38:treatment,,","Regular use of supplemental vitamin D totaling ? 2,000 IU/day in the past year"
2841,NCT02740361,6:23:chronic_disease,very severe depression that would interfere with the ability to participate in the study (based on clinical judgment by the physician at the recruitment site)
2842,NCT02544503,13:30:chronic_disease,Moderate or severe depression
2843,NCT01128816,186:203:chronic_disease,"Any other medical, social, or geographical factor, which would make it unlikely that the patient will comply with the study procedures (e.g. alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or history of non-compliance)"
2844,NCT02721303,1:18:treatment,Bariatric surgery
2845,NCT02650206,7:24:treatment,Prior Bariatric surgery
2846,NCT02448498,1:18:treatment,Bariatric surgery
2847,NCT02686528,31:53:treatment,Patients undergoing a primary total hip arthroplasty via the posterior approach by participating attending surgeons at this institution
2848,NCT02507505,1:23:treatment,total hip arthroplasty
2849,NCT01917929,36:58:treatment,Patient is a candidate for primary total hip arthroplasty
2850,NCT02674529,55:67:treatment,Have a history of inadequate response/tolerability to escitalopram
2851,NCT01931202,44:56:allergy_name,history of allergic or adverse reaction to escitalopram
2852,NCT01931202,"35:47:treatment,",non-response to adequate trial of escitalopram (at least 4 weeks at dose of 20mg) during the current episode
2853,NCT02642939,13:29:chronic_disease,Significant cardiac diseases includes second/third degree heart block
2854,NCT02158858,53:69:chronic_disease,Impaired cardiac function or clinically significant cardiac diseases
2855,NCT01894061,67:83:chronic_disease,Patients with impaired cardiac function or clinically significant cardiac diseases
2856,NCT02608125,15:38:cancer,Patients with glioblastoma multiforme
2857,NCT02344355,",102:125:cancer","Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme"
2858,NCT01811498,50:73:chronic_disease,Patients with documented histologic diagnosis of glioblastoma multiforme (newly diagnosed)
2859,NCT02593123,1:35:cancer,Chronic myelogenous leukemia (CML)
2860,NCT02424968,1:35:chronic_disease,Chronic myelogenous leukemia (CML)
2861,NCT02181478,1:35:cancer,Chronic myelogenous leukemia (CML) in second chronic phase after accelerated or blast crisis; blast crisis defined as
2862,NCT02573883,8:11:chronic_disease,Active UTI
2863,NCT01994538,"15:18:chronic_disease,",Treatment for UTI in past 14 days
2864,NCT01595529,"27:30:chronic_disease,",A child with a history of UTI within the past 30 days
2865,NCT02554786,8:18:treatment,Repeat spirometry may be allowed once in an ad-hoc visit if the spirometry did not qualify due to ATS/ERS criteria
2866,NCT02554786,33:43:treatment,have not achieved an acceptable spirometry results at Visit 101 in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) criteria for acceptability and repeatability (rescreening allowed only once)
2867,NCT02240069,125:135:treatment,"Capable and willing to record symptom data and wood stove usage data, as well as complete pulmonary function testing (i.e., spirometry)"
2868,NCT02544880,29:34:cancer,Recurrent or second primary HNSCC arises within the previously irradiated field
2869,NCT02544880,52:57:cancer,"Surgically resectable, recurrent or second primary HNSCC"
2870,NCT02433626,9:14:cancer,"Part 2: HNSCC, with confirmed p53 mutations"
2871,NCT02541903,1:17:chronic_disease,chronic diarrhea
2872,NCT02047474,15:31:chronic_disease,No history of chronic diarrhea
2873,NCT00065676,1:17:chronic_disease,chronic diarrhea
2874,NCT02530463,",73:84:treatment",No response will be lack of clinical benefit after at least 6 cycles of HMA therapy
2875,NCT02530463,76:87:treatment,Patients need to have relapsed or progressed after any number of cycles of HMA therapy
2876,NCT02530463,33:44:treatment,Patients that do not respond to HMA therapy will also be allowed in the study
2877,NCT02525692,102:108:treatment,History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients
2878,NCT02525692,"16:22:treatment,,,,,,,,","The effects of ONC201 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately"
2879,NCT02392572,",67:73:treatment",Pregnant and nursing patients are excluded because the effects of ONC201on a fetus or nursing child are unknown
2880,NCT02515708,12:45:treatment,History of prior solid organ transplantation
2881,NCT02323880,30:63:treatment,Patients who have received a prior solid organ transplantation
2882,NCT02304458,28:61:treatment,Patients who have received prior solid organ transplantation
2883,NCT02513797,1:16:treatment,medical illness or comorbidity which would make the subject unsuitable to participate in this study as determined by the clinical site Primary Investigator
2884,NCT02069925,10:25:chronic_disease,Unstable medical illness
2885,NCT00715611,32:47:chronic_disease,Patients with serious unstable medical illness
2886,NCT02501473,",,50:67:chronic_disease,,",total serum bilirubin > 1.5 x ULN (patients with Gilbert's Disease may be included if their total bilirubin is ?3.0 mg/dL)
2887,NCT02178709,25:42:chronic_disease,History of or suspected Gilbert's Disease (testing not required if presence is not suspected)
2888,NCT02132598,",12:29:chronic_disease,",Bilirubin (Gilbert's Disease) < 3.0 mg/dL
2889,NCT02496208,1:29:chronic_disease,Gastrointestinal perforation
2890,NCT02132598,1:29:chronic_disease,Gastrointestinal perforation
2891,NCT01822522,1:29:chronic_disease,Gastrointestinal perforation
2892,NCT02478684,11:31:chronic_disease,Any major congenital anomalies
2893,NCT02148796,7:27:chronic_disease,major congenital anomalies
2894,NCT01595529,24:44:chronic_disease,A child diagnosed with congenital anomalies of the genitourinary tract
2895,NCT02474199,9:27:cancer,without cholangiocarcinoma morphology
2896,NCT02150967,48:66:cancer,with histologically or cytologically confirmed cholangiocarcinoma at the time of diagnosis
2897,NCT00737399,14:32:cancer,Diagnosis of cholangiocarcinoma
2898,NCT02464696,29:34:treatment,Inability to cooperate with NIPPV
2899,NCT02464696,20:25:treatment,Patient already on NIPPV at the time of screening
2900,NCT02464696,20:25:treatment,Refusal to receive NIPPV
2901,NCT02451982,45:59:treatment,Surgically resectable disease (R0 or R1) by spiral CT scan
2902,NCT02427841,",,,,,,295:309:treatment","Subjects must have measurable disease (by RECIST 1.1), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan"
2903,NCT01827384,",,,224:238:treatment","Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan"
2904,NCT02442102,",49:59:treatment",Patient is not expected to require ?48 hours of intubation
2905,NCT02109081,31:41:treatment,anticipation of postoperative intubation
2906,NCT01742338,23:33:treatment,Patients who requires intubation at time of recruitment
2907,NCT02413970,56:68:treatment,Documentation the subject not effectively treated with CPAP therapy
2908,NCT02261857,19:31:treatment,On-going need for CPAP therapy based on polysomnography
2909,NCT02261857,28:40:treatment,Subjects no longer needing CPAP therapy
2910,NCT02407028,8:15:chronic_disease,Severe hypoxia
2911,NCT02374333,",,50:57:chronic_disease",Adequate pulmonary function defined as < Grade 3 hypoxia
2912,NCT02159495,"41:48:chronic_disease,,,,",ONLY research participants experiencing hypoxia with oxygen saturation less than 92% are required to have diffusion capacity of carbon monoxide (DLCO) or forced expiratory volume in one second (FEV1) > 45% predicted
2913,NCT02395614,52:62:allergy_name,patients allergic to one or more components of the antibiotic solution
2914,NCT02134392,"4:14:treatment,",No antibiotic use within the last 90 days
2915,NCT01595529,95:105:treatment,A child whose urine culture reveals an organism that is resistant to the initially prescribed antibiotic
2916,NCT02383979,50:54:treatment,"Cooperative, with time and availability to do an fMRI"
2917,NCT02383979,22:26:treatment,Subjects who opt for fMRI portion of the study are willing and/or able to tolerate fMRI
2918,NCT02383979,30:34:treatment,Willing and able to tolerate fMRI
2919,NCT02369900,12:31:chronic_disease,Pronounced cardiac dysfunction
2920,NCT02092324,1:20:chronic_disease,cardiac dysfunction
2921,NCT01937884,16:35:chronic_disease,No evidence of cardiac dysfunction
2922,NCT02347891,",,,,,,78:86:chronic_disease,,,,,,,,,,","Presence of positive autoantibody (ANA >1:80 or RNP or SSA/SSB or any of the myositis specific autoantibody: antisynthetase autoantibodies (anti-Jo-1, PL-7, PL-12, EJ, OJ, KS), anti-SRP, anti-Mi-2, anti-p140)"
2923,NCT02245841,78:86:chronic_disease,"Although not mandatory, patients with evidence of current or previous active myositis"
2924,NCT02245841,44:52:chronic_disease,Patients with clear features of an overlap myositis
2925,NCT02329327,"1:15:chronic_disease,,,",Acute bleeding associated with a hemoglobin level of ?8 g/dL if no baseline hemoglobin is available
2926,NCT02329327,1:15:chronic_disease,"Acute bleeding in a critical area or organ such as intraspinal, pericardial, or intracranial"
2927,NCT02329327,1:15:chronic_disease,Acute bleeding that is potentially life-threatening
2928,NCT02315612,1:12:chronic_disease,Hematologic function
2929,NCT01505569,"1:12:chronic_disease,,,,","Hematologic: ANC ? 750/mm3, platelets ? 75,000/mm3"
2930,NCT01505569,"1:12:chronic_disease,,,,","Hematologic: hemoglobin of >9 gm/dl and platelet count > 20,000/?l"
2931,NCT02304458,47:63:cancer,Part B3: patients with relapsed or refractory rhabdomyosarcoma
2932,NCT02304458,47:63:cancer,Part D3: Patients with relapsed or refractory rhabdomyosarcoma
2933,NCT02304458,47:63:cancer,Part E3: Patients with relapsed or refractory rhabdomyosarcoma
2934,NCT02285114,"4:27:chronic_disease,",No opportunistic infection within 30 days of study entry (at baseline/Day 1)
2935,NCT02016924,"4:27:chronic_disease,",No opportunistic infection within 30 days of study entry (at Day -10)
2936,NCT01861106,32:55:chronic_disease,No history of life-threatening opportunistic infection
2937,NCT02270619,7:23:chronic_disease,other chronic diseases
2938,NCT01438073,4:20:chronic_disease,no chronic diseases
2939,NCT00914823,4:20:chronic_disease,no chronic diseases
2940,NCT02237183,131:139:allergy_name,Participants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition of iloprost
2941,NCT02237183,46:54:treatment,Participants must not have been treated with iloprost at any time
2942,NCT02237183,45:53:treatment,participants on the placebo arm of previous iloprost trials
2943,NCT02215096,"13:25:treatment,",Most recent enzalutamide dose received is 160 mg once daily with no change in dose for at least 2 weeks prior to Screening
2944,NCT02012296,",,38:50:treatment",PSA =<1.25 times the PSA at start of enzalutamide
2945,NCT02012296,"21:33:treatment,",Record of subject's enzalutamide start date and baseline PSA (within 28 days of starting) before starting enzalutamide available
2946,NCT02163317,",60:71:treatment",PSA should not be obtained prior to 90 days after stopping dutasteride
2947,NCT02163317,"8:19:treatment,",Use of dutasteride within 90 days prior to registration
2948,NCT02064036,",41:52:treatment",within 90 days after discontinuation of dutasteride
2949,NCT02140255,14:18:treatment,"Able to take ARVs by mouth, nasogastric tube, or gastrostomy tube"
2950,NCT02140255,"24:28:treatment,",Mother did not receive ARVs during the current pregnancy per criteria above
2951,NCT02140255,"15:19:treatment,",No receipt of ARVs during the current pregnancy
2952,NCT02097121,27:35:treatment,Current use of indwelling catheter or clean intermittent catheterization to empty the bladder
2953,NCT01959204,26:34:treatment,Has an indwelling access catheter for blood sampling
2954,NCT01595529,16:24:treatment,A child with a catheter-associated UTI
2955,NCT02033941,16:37:chronic_disease,No evidence of hepatic insufficiency
2956,NCT01950351,1:22:chronic_disease,hepatic insufficiency resulting in clinical jaundice
2957,NCT01525901,1:22:chronic_disease,hepatic insufficiency
2958,NCT01880567,1:24:cancer,Relapsed/refractory MCL: Any serious medical condition that places the patient at unacceptable risk and/or would prevent the subject from signing the informed consent form
2959,NCT01880567,"1:24:cancer,,",Relapsed/refractory MCL: Creatinine (Cr) clearance >= 30 mL/min
2960,NCT01880567,"1:24:cancer,,",Relapsed/refractory MCL: Serum bilirubin < 1.5 mg/dl
2961,NCT01823198,1:23:cancer,Acute myeloid leukemia in first remission with any of the following high risk features defined
2962,NCT01760655,1:23:cancer,Acute myeloid leukemia with high risk features
2963,NCT00357565,1:23:cancer,Acute myeloid leukemia
2964,NCT01572480,5:8:cancer,IgA SMM
2965,NCT01572480,",59:62:cancer,,,",Progressive increase in M protein level (evolving type of SMM; increase in serum M protein by greater than or equal to 25% on 2 successive evaluations within a 6-month period)
2966,NCT01572480,47:50:cancer,patients must also be classified as high-risk SMM per Mayo Clinic or Spanish PETHEMA criteria
2967,NCT00930228,",81:97:chronic_disease",Controls will be healthy women with regular menstrual cycles and no evidence of hyperandrogenism
2968,NCT00929006,",19:35:chronic_disease",For girls without hyperandrogenism: serum (calculated) free testosterone concentration within the Tanner stage-specific reference range and the absence of hirsutism
2969,NCT00594217,",56:72:chronic_disease",women with regular menstrual cycles and no evidence of hyperandrogenism
2970,NCT03186937,58:87:chronic_disease,Participants must have histologically confirmed operable triple negative breast cancer
2971,NCT02531932,"26:55:cancer,,,,,,,","Histologically confirmed triple negative breast cancer (ER< 10%, PR < 10%, Her2neu IHC 0 or 1 or FISH/ISH negative)"
2972,NCT03182907,66:86:treatment,is currently participating in or scheduled to participate in any other clinical study with an investigational agent during the 12-week study period
2973,NCT02508038,19:39:treatment,Enrollment in any other clinical study from screening up to Day 100
2974,NCT03181516,1:13:treatment,Tetracycline
2975,NCT02203552,1:13:allergy_name,Tetracycline allergy
2976,NCT03179163,1:16:chronic_disease,kidney problems
2977,NCT00737893,1:16:chronic_disease,kidney problems
2978,NCT03171480,1:10:chronic_disease,Eclampsia
2979,NCT03011567,1:10:chronic_disease,Eclampsia
2980,NCT03170401,1:24:chronic_disease,enterocutaneous fistula
2981,NCT03034213,23:46:chronic_disease,Suspected presence of enterocutaneous fistula
2982,NCT03170375,6:9:chronic_disease,with HTN
2983,NCT01836354,33:36:chronic_disease,Vascular risk factors including HTN history or elevated blood pressure
2984,NCT03158974,"1:24:treatment,",Topical corticosteroids if greater than 2 gm/day
2985,NCT01795313,1:24:treatment,Topical corticosteroids
2986,NCT03153410,32:43:treatment,Patient's acceptance to have a core biopsy
2987,NCT02259621,12:23:treatment,Diagnostic core biopsy specimens must be reviewed by a faculty pathologist at SKCCC or MSKCC
2988,NCT03151330,",50:68:chronic_disease",The subject has known elevated bilirubin levels (hyperbilirubinemia)
2989,NCT03143985,",,,85:103:treatment",Serum total bilirubin ? 2.0 mg/dL or >3.0 x ULN for subjects with hereditary benign hyperbilirubinemia
2990,NCT03145298,1:15:chronic_disease,LV dysfunction
2991,NCT00573027,1:15:chronic_disease,LV dysfunction
2992,NCT03143985,41:72:treatment,Patients who are primarily eligible for autologous stem cell transplant
2993,NCT02309580,"29:60:treatment,",Patients who have undergone autologous stem cell transplant > 6 months prior
2994,NCT03137082,26:54:chronic_disease,Having any other current Axis I psychiatric disorders or medical conditions requiring treatment or medication
2995,NCT02332291,36:64:chronic_disease,Current or past diagnoses of other Axis I psychiatric disorders
2996,NCT03135522,1:12:cancer,Lung cancer
2997,NCT00924027,1:12:cancer,Lung cancer
2998,NCT03133793,1:17:treatment,Heart transplant
2999,NCT02519946,"1:17:treatment,",Heart transplant >11 months before baseline visit
3000,NCT03131037,44:56:allergy_name,Known sensitivity or allergic reactions to valacyclovir
3001,NCT02446093,1:13:treatment,valacyclovir
3002,NCT03127358,14:27:treatment,Eligible for HCV treatment per 2016 AASLD/IDSA guidelines
3003,NCT03127358,20:33:treatment,Willing to receive HCV treatment on-site at DoSA clinics
3004,NCT03119363,"8:32:chronic_disease,","Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months)"
3005,NCT03090672,13:37:chronic_disease,Systemic or psychological impairment which would preclude patient tolerance and understanding of procedures and follow up
3006,NCT03116464,11:38:chronic_disease,Caregiver severe cognitive impairment
3007,NCT02707471,45:72:chronic_disease,"unable to provide meaningful consent (e.g., severe cognitive impairment)"
3008,NCT03112902,1:23:chronic_disease,restless legs syndrome
3009,NCT03109210,"1:23:chronic_disease,,",restless legs syndrome (score of >11 in the IRLS)
3010,NCT03112603,16:62:treatment,"Have undergone allogeneic stem cell transplantation (alloSCT) from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood"
3011,NCT02159495,139:185:treatment,In the case of a related donor: The identified donor must be the original donor whose stem cells were used for the research participant's allogeneic stem cell transplantation (alloSCT)
3012,NCT03106220,1:28:chronic_disease,"portopulmonary hypertension, inability to perform exercise"
3013,NCT01481974,41:68:chronic_disease,Those currently receiving treatment for portopulmonary hypertension
3014,NCT03102580,1:23:chronic_disease,Inflammatory arthritis
3015,NCT03059004,1:23:chronic_disease,Inflammatory arthritis
3016,NCT03097588,48:71:treatment,Subjects who have concurrent illness requiring systemic corticosteroid use
3017,NCT02995733,",,,147:170:treatment","Participant must also have an ACT score of 19 or less, or a history of one or more exacerbations in the past year that required patient report of systemic corticosteroid use"
3018,NCT03091790,28:49:treatment,Patient scheduled for open ventral hernia repair at LBJ General Hospital
3019,NCT02969187,1:22:treatment,ventral hernia repair with mesh
3020,NCT03088709,23:53:chronic_disease,Transfusion dependent myelodysplastic syndrome (MDS)
3021,NCT00357565,11:41:chronic_disease,Preceding myelodysplastic syndrome (MDS)
3022,NCT03088033,25:38:chronic_disease,Presence of significant valve disease defined by the site cardiologist
3023,NCT02145351,35:48:chronic_disease,"Significant left sided structural valve disease (>mild stenosis, >moderate regurgitation)"
3024,NCT03085485,20:35:chronic_disease,Known Diagnosis of Cystic Fibrosis
3025,NCT02498535,24:39:chronic_disease,Confirmed diagnosis of Cystic Fibrosis
3026,NCT03085043,"28:38:cancer,,",Patient is at low risk for metastasis with Gleason score at diagnosis < 8
3027,NCT01815359,46:56:cancer,Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces
3028,NCT03078504,1:5:treatment,CRRT duration of 48 hours or less using NxStage System One dialysis system
3029,NCT03078504,"24:28:treatment,",successfully tolerated CRRT for at least 4 hours without clotting or hemodynamic instability
3030,NCT03076333,1:22:chronic_disease,intracranial aneurysm clip
3031,NCT01801072,13:34:chronic_disease,Presence of intracranial aneurysm (with or without rupture)
3032,NCT03072238,20:58:cancer,adequately treated non-melanomatous carcinoma of the skin
3033,NCT02177838,1:39:cancer,non-melanomatous carcinoma of the skin
3034,NCT03069911,62:93:chronic_disease,meet Diagnostic and Statistical Manual (DSM)-IV criteria for major depressive disorder (MDD) as diagnosed by the M.I.N.I. at screening
3035,NCT02938559,14:45:chronic_disease,"Diagnosis of major depressive disorder (MDD), first episode, recurrent or chronic, according to DSM-5"
3036,NCT03061201,"12:33:chronic_disease,,",History of chronic renal disease or creatinine ? 1.5 mg/dL
3037,NCT02857283,1:22:chronic_disease,chronic renal disease
3038,NCT03059888,23:40:chronic_disease,Diagnosis of DEFINITE Myasthenia Gravis
3039,NCT00716066,1:18:chronic_disease,Myasthenia Gravis
3040,NCT03059030,50:80:cancer,worsens postoperative survival in the setting of hepatocellular carcinoma (HCC)
3041,NCT02762266,11:41:cancer,Confirmed hepatocellular carcinoma (HCC)
3042,NCT03058029,"1:25:treatment,",Systemic corticosteroids within one (1) month prior to Screening Visit
3043,NCT02309580,1:25:treatment,Systemic corticosteroids are permissible in the following circumstances
3044,NCT03054519,1:23:chronic_disease,Critical limb ischemia
3045,NCT02388685,1:23:chronic_disease,Critical limb ischemia
3046,NCT03052270,7:22:chronic_disease,Major fetal anomalies
3047,NCT02469519,13:28:chronic_disease,Known major fetal anomalies
3048,NCT03043794,1:26:cancer,Invasive ductal carcinoma
3049,NCT00909909,1:26:cancer,Invasive ductal carcinoma
3050,NCT03042767,"1:14:chronic_disease,,,",Acute illness within past 2 weeks prior to enrollment (defined as fever > 100.4ºF)
3051,NCT02519946,1:14:chronic_disease,Acute illness
3052,NCT03040778,17:37:chronic_disease,Patients with a vitamin K deficiency due to any cause
3053,NCT02053792,1:21:chronic_disease,vitamin K deficiency of the newborn
3054,NCT03036280,"19:55:treatment,",Have received any live vaccine/live attenuated vaccine in the 3 months before randomization
3055,NCT02956486,"19:55:treatment,",Have received any live vaccine/live attenuated vaccine in the 3 months before randomization
3056,NCT03034811,39:59:chronic_disease,Uncooperative patient or patient with neurologic disorders who is incapable of following directions
3057,NCT02607514,1:21:chronic_disease,neurologic disorders
3058,NCT03030118,"78:124:treatment,","Starting, stopping, or changing the dose of over the counter or prescription non-steroidal anti-inflammatory drugs (NSAIDs) in the three months prior to Visit 1"
3059,NCT02833207,1:47:treatment,non-steroidal anti-inflammatory drugs (NSAIDs)
3060,NCT03028012,1:13:chronic_disease,Fibromyalgia
3061,NCT02657993,1:13:chronic_disease,Fibromyalgia
3062,NCT03021486,1:9:chronic_disease,"Delirium as per DSM-V criteria (The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5))"
3063,NCT02159560,1:9:chronic_disease,Delirium
3064,NCT03014687,1:17:chronic_disease,Immunodeficiency
3065,NCT02554383,1:17:chronic_disease,Immunodeficiency
3066,NCT03009981,"8:35:treatment,",Use of 5-alpha reductase inhibitor within 42 days prior to cycle 1 day 1
3067,NCT02167009,"95:122:treatment,",Patient has experienced an irregular voiding pattern despite medical management with a stable 5-alpha reductase inhibitor dosage for 3 months or longer
3068,NCT03007745,1:30:chronic_disease,obstructive sleep apnea (OSA)
3069,NCT02962557,34:63:chronic_disease,Patients with known or suspected obstructive sleep apnea (OSA)
3070,NCT03006562,22:25:treatment,Active treatment for VTE
3071,NCT02464969,22:25:chronic_disease,Presence of an index VTE which is confirmed by imaging
3072,NCT02996227,"26:44:treatment,",Expected requirement for parenteral opioids for at least 72 hours for postoperative pain
3073,NCT02536170,213:231:treatment,"Pain requiring medical care in an acute care setting (such as the emergency department or ED, hospital ward, day hospital, clinic) not attributable to non-sickle cell causes, that is moderate-to-severe requiring parenteral opioids"
3074,NCT02993406,",33:40:treatment","inability to tolerate 2 or more statins, one at a low dose"
3075,NCT02433977,"9:16:treatment,","Current statins use (statins lower ADMA levels), patients may stop and re-enroll after 2 weeks of stopping statins"
3076,NCT02991248,"1:16:treatment,",Botox injection within 6 months of starting the study
3077,NCT02359253,"1:16:treatment,",Botox injection in upper extremity within 4 months
3078,NCT02986087,1:16:chronic_disease,placenta previa
3079,NCT02478684,15:30:chronic_disease,Bleeding from placenta previa
3080,NCT02981069,"30:64:chronic_disease,,,,,,,","Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine >1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg will be excluded"
3081,NCT02464878,23:57:chronic_disease,Untreated or unstable proliferative diabetic retinopathy
3082,NCT02977299,",46:70:treatment","not responded to more than five FDA-approved antidepressant treatment trials of adequate dose and duration during the current episode, or who did not respond to ECT in previous episodes"
3083,NCT02562430,"30:54:treatment,",Patients must have either no antidepressant treatment or stable (for at least 4 weeks prior to screening)
3084,NCT02960555,1:21:cancer,Plasma cell leukemia
3085,NCT02538198,1:21:cancer,Plasma cell leukemia
3086,NCT02950233,22:40:chronic_disease,Current diagnosis of Cushing's syndrome
3087,NCT00594217,13:31:chronic_disease,Evidence of Cushing's syndrome by history or physical exam
3088,NCT02946268,1:15:chronic_disease,skin infection involving the neck
3089,NCT01698658,11:25:chronic_disease,No active skin infection
3090,NCT02942095,49:57:treatment,"Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not"
3091,NCT02339922,18:26:allergy_name,"Known allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomib"
3092,NCT02932410,6:38:chronic_disease,with pulmonary veno-occlusive disease
3093,NCT02554903,12:44:chronic_disease,Documented pulmonary veno-occlusive disease
3094,NCT02931110,1:21:treatment,dabigatran etexilate
3095,NCT02815670,17:37:treatment,Patients taking dabigatran etexilate in the paediatric trials 1160.106 or 1160.108
3096,NCT02926378,1:18:chronic_disease,"Cerebral aneurysm clips - if magnetic, can move"
3097,NCT02479906,1:18:chronic_disease,Cerebral aneurysm
3098,NCT02924441,20:29:treatment,May not have taken ibuprofen or other pain medication within the Space last 12 hours (ASA 81 mg dose is allowed)
3099,NCT01238120,20:29:allergy_name,Have an allergy to ibuprofen
3100,NCT02923544,43:55:treatment,Participant must be scheduled for a total laparoscopic
3101,NCT02908841,",40:52:treatment",Women scheduled for standard multiport laparoscopic
3102,NCT02915744,19:44:chronic_disease,Significant known cardiovascular impairment
3103,NCT01554371,13:38:chronic_disease,Significant cardiovascular impairment
3104,NCT02912572,1:19:cancer,Endometrial cancer is very rare in the pediatric population
3105,NCT00924027,1:19:cancer,Endometrial cancer
3106,NCT02911116,1:15:chronic_disease,Active disease is defined
3107,NCT02514083,"1:15:chronic_disease,",Active disease as defined by at least one of the following (IWCLL consensus criteria)
3108,NCT02907918,91:103:cancer,Patients with histologically confirmed palpable lymph nodes may be enrolled regardless of breast tumor size
3109,NCT02515110,138:150:cancer,"Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) testing performed on the primary breast tumor"
3110,NCT02905370,1:17:chronic_disease,Terminal illness
3111,NCT02762604,"1:17:chronic_disease,,",Terminal illness with life expectancy <12 months
3112,NCT02901067,14:38:treatment,Inclusion in any other clinical trial
3113,NCT01853163,"21:45:treatment,",has participated in any other clinical trial within 30 days prior to enrolling in this study
3114,NCT02890979,1:34:chronic_disease,Uncontrolled intercurrent illness
3115,NCT01659203,1:34:chronic_disease,Uncontrolled intercurrent illness
3116,NCT02877394,16:33:treatment,Current use of opioid analgesics
3117,NCT02270619,1:18:treatment,opioid analgesics
3118,NCT02875405,18:30:chronic_disease,preoperative non-sinus rhythm
3119,NCT02750319,13:25:chronic_disease,Patients in sinus rhythm
3120,NCT02865135,1:18:cancer,carcinoma in situ of the cervix or bladder
3121,NCT01597518,"15:32:cancer,",Patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study
3122,NCT02862938,34:43:treatment,Participant has a requirement of acyclovir and/or related products during study duration
3123,NCT02446093,23:32:allergy_name,allergic reactions to acyclovir
3124,NCT02857218,20:39:chronic_disease,Patients must have regional adenopathy
3125,NCT01684904,19:38:chronic_disease,"Patients may have regional adenopathy including para-esophageal, gastric, gastroheptaic and celiac nodes"
3126,NCT02851407,",,,,206:217:treatment,",Female patients (and female partners of male patients) of childbearing potential who are sexually active must agree to use a highly effective method of contraception with their partners during exposure to defibrotide and for 1 week after the last dose of defibrotide
3127,NCT02675959,47:58:allergy_name,Patients with contraindications to the use of defibrotide
3128,NCT02844751,"1:25:treatment,",Corticosteroid injection at treatment site within 1 month
3129,NCT02844738,"1:25:treatment,",Corticosteroid injection at treatment site within 1 month
3130,NCT02835729,10:19:treatment,Previous allo-HSCT of any kind
3131,NCT02203903,37:46:treatment,Patients (Arm A) who have undergone allo-HSCT with high risk for relapse or residual/recurrent disease
3132,NCT02826681,"1:23:chronic_disease,,,,,,,","Iron-deficiency anemia defined as an Hgb <12 g/dl with a ferritin <20 ng/mL, or ferritin <100 when TSAT is <18%"
3133,NCT02531880,1:23:chronic_disease,Iron-deficiency anemia
3134,NCT02822599,53:71:treatment,Neonatal and infant cardiac patients presenting for open-heart surgery at Nicklaus Children's Hospital
3135,NCT02718001,15:33:treatment,High risk for open-heart surgery
3136,NCT02816736,1:26:chronic_disease,constrictive pericarditis
3137,NCT01445821,20:45:chronic_disease,Occult or clinical constrictive pericarditis
3138,NCT02811510,8:28:treatment,Taking estrogen supplements
3139,NCT02781519,"8:28:treatment,,",taking estrogen supplements or oral contraceptive pills (for women)
3140,NCT02796209,21:32:allergy_name,"Hypersensitivity to atomoxetine (severe allergic reaction, rash, urticaria, anaphylaxis)"
3141,NCT02784535,21:32:allergy_name,Hypersensitivity to atomoxetine
3142,NCT02793375,25:36:allergy_name,those with allergies to Montelukast and those currently using Montelukast
3143,NCT01597518,1:12:treatment,Montelukast
3144,NCT02781103,26:61:chronic_disease,"Any condition, including neurological or psychiatric illness, which per investigators' judgement may increase subject risk"
3145,NCT02452203,29:64:chronic_disease,"free of any current or past neurological or psychiatric illness, and capable of performing all tasks during each session of the experiment"
3146,NCT02770547,"1:22:chronic_disease,,,",Uncontrolled Diabetes (HbA1C > 8.5 measured within 3 months prior to date of consent)
3147,NCT02225548,"1:22:chronic_disease,,",Uncontrolled Diabetes (Hemoglobin A1C > 7.5)
3148,NCT02762266,107:111:treatment,"Radiographic evidence of persistent, progressive, or recurrent disease in an area previously treated with TACE"
3149,NCT02762266,",40:44:treatment",determined from 3 months after initial TACE
3150,NCT02759120,"10:31:treatment,",Received antimicrobial therapy in the past 30 days
3151,NCT01500551,"53:74:treatment,","Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 6 months prior to the first dose of study drug"
3152,NCT02746458,",173:192:treatment","Additional fracture, dislocations or soft tissue injuries to the study limb that would compromise the ability to weight bear as tolerated and initiate PT within 28 days of definitive fixation"
3153,NCT02746458,",156:175:treatment",Injuries to other body systems (or other medical conditions) that would preclude the ability to weight bear as tolerated and initiate PT within 28 days of definitive fixation
3154,NCT02743494,16:45:cancer,Diagnosed with cervical esophageal carcinoma
3155,NCT01684904,15:44:cancer,Patients with cervical esophageal carcinoma
3156,NCT02740543,"1:11:treatment,,,,,",Spirometry in the past 6 months or on day of evaluation with a bronchodilator* response of ? 12% and 200 ml improvement in FEV
3157,NCT02181257,42:52:treatment,For patients who are monitored with home Spirometry (subject to Institutional Review Board (IRB) approval)
3158,NCT02734602,12:27:treatment,History of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure
3159,NCT02122081,"18:33:treatment,",Patients who had prior radiation to more than 20% bone marrow containing areas or to any areas exceeding 2000 cGy
3160,NCT02724540,1:23:chronic_disease,hepatic encephalopathy
3161,NCT02562755,1:23:chronic_disease,hepatic encephalopathy
3162,NCT02721303,10:23:chronic_disease,Advanced organ failure
3163,NCT01816152,7:20:chronic_disease,major organ failure
3164,NCT02710396,1:36:cancer,squamous cell carcinoma of the skin
3165,NCT02343549,1:36:cancer,squamous cell carcinoma of the skin
3166,NCT02706249,21:42:chronic_disease,History of previous venous thromboembolic event (excluding superficial vein thrombosis)
3167,NCT02195232,"29:50:chronic_disease,",Prior history of documented venous thromboembolic event within the last 2 years
3168,NCT02703220,",12:24:chronic_disease",Males with hypogonadism
3169,NCT01983475,",16:28:chronic_disease",Men with known hypogonadism prior to SCI
3170,NCT02688647,",48:51:chronic_disease,",Chronic use of N-acetylcysteine prescribed for IPF (> 600 mg/day)
3171,NCT02478268,23:26:chronic_disease,Clinical diagnosis of IPF by established means
3172,NCT02682316,",27:33:allergy_name",Women with sensitivity to silver
3173,NCT02389023,27:33:allergy_name,Sensitivity or allergy to silver
3174,NCT02679560,"29:45:treatment,",Administration of any other local anesthetic in the 2 hours prior to the study enrollment
3175,NCT02148003,53:69:allergy_name,Subjects who have a history of adverse reactions to local anesthetic
3176,NCT02667418,",,,,74:92:treatment",Negative pregnancy test required for females <61 years of age or without prior hysterectomy
3177,NCT01037790,",,80:98:treatment,",Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months
3178,NCT02665338,1:14:treatment,brain surgery
3179,NCT01686373,12:25:treatment,History of brain surgery
3180,NCT02660528,1:6:chronic_disease,mania
3181,NCT02519543,1:6:chronic_disease,mania
3182,NCT02643381,",52:75:treatment",Adult patient (male or female) requiring emergency endotracheal intubation
3183,NCT02643381,13:36:treatment,who require endotracheal intubation without sedative medication
3184,NCT02639546,1:37:chronic_disease,Impaired gastrointestinal absorption
3185,NCT01433965,1:37:chronic_disease,Impaired gastrointestinal absorption
3186,NCT02632721,33:69:treatment,Patients who are candidates for allogeneic stem cell transplantation
3187,NCT02520791,29:65:treatment,Patients who have undergone allogeneic stem cell transplantation
3188,NCT02627495,12:24:treatment,"History of neurosurgery, as self-reported"
3189,NCT02192359,67:79:treatment,Neurosurgeon finds the prospective participant is able to undergo neurosurgery
3190,NCT02621944,45:55:chronic_disease,clinical signs and symptoms consistent with meningitis detected upon sepsis evaluation
3191,NCT02061761,1:11:chronic_disease,meningitis
3192,NCT02609685,64:91:cancer,Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma
3193,NCT02138214,"9:36:cancer,",Largest papillary thyroid carcinoma < 1 cm in size on ultrasound
3194,NCT02595372,"17:53:cancer,,,","Newly diagnosed triple negative breast cancer (TNBC) clinical stage Ic, II, or III"
3195,NCT02264678,22:58:cancer,Second or third line triple negative breast cancer (TNBC)
3196,NCT02593123,1:20:chronic_disease,bacterial infection
3197,NCT01364467,10:29:chronic_disease,signs of bacterial infection
3198,NCT02591147,18:24:chronic_disease,is adjacent to a lesion that is either filled or will receive a filling at the time of enrollment
3199,NCT02272998,25:31:chronic_disease,defined as at least one lesion that can be accurately measured in at least one dimension
3200,NCT02588326,1:10:chronic_disease,sinusitis
3201,NCT02554383,61:70:chronic_disease,Meets criteria for persistent or worsening presentations of sinusitis
3202,NCT02584933,55:64:treatment,Patient currently has unresolved toxicities for which ceritinib dosing has been interrupted in the parent study
3203,NCT02584933,64:73:treatment,Patient has been permanently and prematurely discontinued from ceritinib study treatment in the parent study due to any reason
3204,NCT02582827,19:30:cancer,"Centrally-located lung tumors originating in the lungs and situated in the carinal bifurcation, the lung hila, or the main bronchi"
3205,NCT02434809,16:27:cancer,Patients whose lung tumors are being monitored by MR imaging as part of standard clinical care
3206,NCT02579044,28:36:chronic_disease,Drugs to treat symptoms of progeria are permitted
3207,NCT02579044,23:31:chronic_disease,Genetically-confirmed progeria
3208,NCT02576444,43:51:allergy_name,Patients with a known hypersensitivity to olaparib or any of the excipients of the product
3209,NCT01858168,27:35:allergy_name,Known hypersensitivity to olaparib or any of the excipients of the product
3210,NCT02574728,"25:37:treatment,",Patients must be off of cannabis oil for 3 days prior to enrollment
3211,NCT02574728,12:24:treatment,The use of cannabis oil is prohibited during the first 2 cycles of this protocol
3212,NCT02573883,12:27:allergy_name,Allergy to topical steroid
3213,NCT02310464,21:36:treatment,Uses of inhaled and topical steroids are allowed
3214,NCT02573246,1:24:chronic_disease,Intellectual disability
3215,NCT02242110,1:24:chronic_disease,Intellectual disability
3216,NCT02570984,1:17:treatment,thoracic surgery
3217,NCT02416102,12:28:treatment,History of thoracic surgery
3218,NCT02566395,1:29:cancer,Acute lymphoblastic leukemia
3219,NCT01951885,1:29:cancer,Acute lymphoblastic leukemia
3220,NCT02565446,1:14:treatment,aneurysm clip
3221,NCT01508390,4:17:treatment,No aneurysm clip in the brain
3222,NCT02563678,"19:37:treatment,",Prior work in the hyperbaric chamber in the last 72 hours
3223,NCT02563678,30:48:treatment,"medically cleared to work as hyperbaric chamber inside attendants, reporting for a regular duty day"
3224,NCT02562755,1:28:chronic_disease,bleeding esophageal varices
3225,NCT01811368,14:41:chronic_disease,A history of bleeding esophageal varices
3226,NCT02562040,"19:43:chronic_disease,,",History of severe developmental disability or Adaptive Behavior Assessment System (ABAS-3) score ?60
3227,NCT02481713,13:37:chronic_disease,evidence of developmental disability
3228,NCT02556606,42:62:chronic_disease,"Patients with any clinically significant personality disorder that would, in the investigator's judgment, preclude safe study participation"
3229,NCT02418195,11:31:chronic_disease,Cluster A personality disorder
3230,NCT02553460,13:37:treatment,one dose of intrathecal chemotherapy
3231,NCT02512926,35:59:treatment,"This restriction does not include intrathecal chemotherapy, which is permitted"
3232,NCT02548546,"50:53:chronic_disease,,",Patients with either symptomatic or asymptomatic AAA as defined by aortic diameter ? 1.5x normal diameter
3233,NCT01726257,"6:9:chronic_disease,,",Have AAA with sac diameter ?5.0cm
3234,NCT02544503,8:24:treatment,Normal MRI of the brain
3235,NCT01389024,175:191:treatment,"Presence or planned permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth), which their physicians believe will interfere with the MRI of the brain"
3236,NCT02543983,"1:33:treatment,",Treatment with a reversible MAOI within 2 weeks prior to study Phase II
3237,NCT02543983,"1:33:treatment,",Treatment with a reversible MAOI within 2 weeks prior to study Phase III
3238,NCT02541903,8:29:chronic_disease,active hepatitis C infection (defined as presence of Hep C RNA)
3239,NCT02273375,14:35:chronic_disease,known active hepatitis C infection
3240,NCT02538198,32:66:treatment,"Patients requiring continuous, systemic immunosuppressive therapy"
3241,NCT02439450,36:70:treatment,Any condition requiring concurrent systemic immunosuppressive therapy
3242,NCT02535312,92:98:treatment,No studies have been performed to assess potential metabolic and transport interactions of TRC102
3243,NCT02535312,",,53:59:treatment",Pregnant women are excluded from this study because TRC102 is agent with the potential for teratogenic or abortifacient effects
3244,NCT02531932,43:54:allergy_name,Patients with a known hypersensitivity to carboplatin
3245,NCT02264678,37:48:allergy_name,Contra-indicated for treatment with carboplatin
3246,NCT02527200,1:32:chronic_disease,Type 2 diabetes mellitus (T2DM)
3247,NCT02412540,"19:50:chronic_disease,,",Poorly controlled Type 2 diabetes mellitus (T2DM) defined as hemoglobin A1C (HgbA1c) > 10%
3248,NCT02525029,",42:50:chronic_disease,","Active or recent (within prior 3 months) thrombus, irrespective of anticoagulation status"
3249,NCT02479620,7:15:chronic_disease,Acute thrombus in the target limb
3250,NCT02519322,",,87:111:cancer",Patients must have histologically or cytologically confirmed stage IIIB/C or stage IV oligometastatic melanoma
3251,NCT02519322,"1:25:cancer,",oligometastatic melanoma is defined as three or fewer areas of resectable disease excluding central nervous system and bone involvement
3252,NCT02516670,34:52:cancer,Have a pathological diagnosis of prostate carcinoma
3253,NCT00467987,5:23:cancer,h/o prostate carcinoma
3254,NCT02513485,61:69:treatment,"Substance dependence [or abuse within the past year (except nicotine)], unless otherwise approved by the PI or PI's designee"
3255,NCT02268448,"8:16:treatment,",Use of nicotine-containing products for the past 6 months prior to study start
3256,NCT02508311,21:30:allergy_name,Hypersensitivity to albuterol or any of its' constituents
3257,NCT02401074,"5:14:treatment,,",Pre-albuterol forced expiratory volume in the first second (FEV1) of >70% of the predicted value
3258,NCT02507011,",,24:32:chronic_disease",Second or third degree AV block without a permanent pacemaker
3259,NCT02453373,13:21:chronic_disease,High degree AV block
3260,NCT02503722,1:31:chronic_disease,Uncontrolled diabetes mellitus
3261,NCT02405078,1:31:chronic_disease,Uncontrolled diabetes mellitus
3262,NCT02501954,34:55:cancer,Patients with a history of other invasive malignancies
3263,NCT00492778,34:55:cancer,Patients with a history of other invasive malignancies
3264,NCT02501473,80:94:cancer,"During Patient Expansion, enrollment will be limited to relapsed or refractory follicular NHL"
3265,NCT02501473,60:74:cancer,"In Part 4, enrollment is limited to relapsed or refractory follicular NHL patients"
3266,NCT02498951,",53:65:treatment",Effective contraception is required while receiving obinutuzumab
3267,NCT02498951,",,,100:112:treatment","for women, effective contraception is required to continue for >= 12 months after the last dose of obinutuzumab"
3268,NCT02496611,1:22:chronic_disease,Neurological disorder
3269,NCT02386605,1:22:chronic_disease,Neurological disorder
3270,NCT02495415,"28:53:treatment,",Participation in any other investigational treatment within the 6 weeks prior to enrollment or concurrent with this study
3271,NCT02495168,"18:43:treatment,",plans to receive investigational treatment within 30 days after the study is completed
3272,NCT02494869,1:20:chronic_disease,Respiratory failure
3273,NCT02332187,1:20:chronic_disease,Respiratory failure present
3274,NCT02493257,73:90:chronic_disease,Confirmed negative skin prick test to common allergens (which rules out allergic rhinitis)
3275,NCT01976429,1:18:allergy_name,allergic rhinitis symptoms or cold on day of testing
3276,NCT02489045,15:39:chronic_disease,Patients with congenital heart defects
3277,NCT02460653,19:43:chronic_disease,Patients who have congenital heart defects
3278,NCT02487797,1:33:chronic_disease,spontaneous rupture of membranes
3279,NCT02121184,1:33:chronic_disease,spontaneous rupture of membranes
3280,NCT02485418,"16:31:treatment,",No long acting triptan therapy within 24 hours
3281,NCT02485418,"19:34:treatment,",No shorter acting triptan therapy within 6 hours
3282,NCT02481245,1:20:chronic_disease,delusional disorder
3283,NCT02214667,1:20:chronic_disease,delusional disorder
3284,NCT02476409,1:19:chronic_disease,Active myocarditis
3285,NCT01128816,1:19:chronic_disease,Active myocarditis
3286,NCT02474199,81:98:treatment,"Any other condition, in the investigator's judgment, that increases the risk of darTregs infusion or prevents safe trial participation"
3287,NCT02474199,",51:68:treatment",IS withdrawal resumes no later than 14 days after darTregs infusion
3288,NCT02471430,30:44:chronic_disease,History or other evidence of severe illness or other conditions
3289,NCT02075671,28:42:chronic_disease,"Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator, unsuitable for the study"
3290,NCT02468661,21:37:cancer,Locally advanced or metastatic NSCLC
3291,NCT02323126,62:78:cancer,"histologically documented locally advanced, recurrent and/or metastatic NSCLC"
3292,NCT02465060,24:43:chronic_disease,subjects with moderate valvular thickening should not be entered on study
3293,NCT02257424,24:43:chronic_disease,Subjects with moderate valvular thickening
3294,NCT02463305,25:46:chronic_disease,"Positive stool test for Clostridium difficile, ova and parasites, or routine stool culture"
3295,NCT02200445,25:46:chronic_disease,Positive stool test for Clostridium difficile
3296,NCT02457845,"1:22:treatment,",Monoclonal antibodies: At least 3 half-lives must have elapsed prior to study entry
3297,NCT01925131,"1:22:treatment,",Monoclonal antibodies must not have been received for 1 week prior to registration
3298,NCT02451553,"1:15:treatment,","Platelet count >= 100,000/uL"
3299,NCT01494324,"1:15:treatment,","Platelet count of <50,000 that cannot be corrected with transfusion"
3300,NCT02442635,19:38:treatment,Requiring chronic home oxygen therapy
3301,NCT02094118,8:27:treatment,Use of home oxygen therapy
3302,NCT02442297,",124:139:treatment",Sexually active subjects must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusion
3303,NCT02146924,70:85:treatment,Research participant has a released cryopreserved T cell product for T cell infusion on approximately day 0
3304,NCT02437110,29:40:treatment,History of having undergone gastrostomy at the time of screening
3305,NCT02127398,1:12:treatment,gastrostomy
3306,NCT02433626,1:16:chronic_disease,Angina pectoris
3307,NCT01737502,1:16:chronic_disease,Angina pectoris
3308,NCT02427841,32:60:treatment,Subjects who are receiving any other investigational agents
3309,NCT02013492,35:63:treatment,Patients may not be receiving any other investigational agents
3310,NCT02423863,69:84:chronic_disease,"While animal reproductive studies have been negative, the simulated viral infection and anti-proliferative activity of this experimental drug may theoretically affect the developing fetus or nursing infant"
3311,NCT02404155,1:16:chronic_disease,viral infection
3312,NCT02419495,26:45:treatment,must be recovered from a prior major surgery
3313,NCT02135588,",22:41:treatment",At least 7 days from prior major surgery
3314,NCT02416674,12:34:chronic_disease,Documented psychological disorder(s) or incomplete psychological clearance
3315,NCT02131389,44:66:chronic_disease,Is a known drug or alcohol abuser or has a psychological disorder that could affect the ability to complete patient reported questionnaires
3316,NCT02414139,29:32:cancer,Patients with characterized ALK-positive rearrangement
3317,NCT02201992,31:34:treatment,Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)
3318,NCT02408861,1:18:treatment,anabolic steroids
3319,NCT02408861,8:25:treatment,use of anabolic steroids
3320,NCT02401347,14:31:chronic_disease,Known active hepatitis B virus
3321,NCT01676259,1:18:chronic_disease,hepatitis B virus
3322,NCT02401074,1:27:chronic_disease,type I or type II diabetes
3323,NCT02322203,"28:54:chronic_disease,,",Patients with a history of type I or type II diabetes or HbA1c greater than 6.5%
3324,NCT02393885,"36:50:treatment,",Currently or has participated in a clinical study in the last 3 months prior to signing informed consent
3325,NCT02366481,"37:51:treatment,",Subjects who have participated in a clinical study more recently than one month before the current study
3326,NCT02389517,23:31:allergy_name,History of allergy to mannitol
3327,NCT01754857,63:71:allergy_name,Subjects must not have a known history of hypersensitivity to mannitol
3328,NCT02387905,21:43:treatment,Patients undergoing bisphosphonate therapy
3329,NCT01968590,"1:23:treatment,",bisphosphonate therapy for more than 3 months
3330,NCT02373644,1:16:treatment,Gaenslen's test (left)
3331,NCT02373644,1:16:treatment,Gaenslen's test (right)
3332,NCT02370056,12:23:treatment,completion proctectomy
3333,NCT02160288,7:18:treatment,Prior proctectomy
3334,NCT02366819,14:42:treatment,Eligible for surgery with curative intent
3335,NCT01730118,",46:74:treatment",Greater than or equal to 6 weeks s/p primary surgery with curative intent
3336,NCT02362308,24:51:chronic_disease,Clinically significant gastrointestinal impairment that could interfere with drug absorption
3337,NCT02130687,24:51:chronic_disease,Clinically significant gastrointestinal impairment that could interfere with drug absorption
3338,NCT02355002,1:22:treatment,deep brain stimulator
3339,NCT02343549,1:22:treatment,deep brain stimulator
3340,NCT02354547,72:102:treatment,Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy
3341,NCT01614197,72:102:treatment,Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy
3342,NCT02352480,"22:30:treatment,",Subject has received UCC care for ? 2 weeks at treating wound clinic
3343,NCT02352454,"22:30:treatment,",Subject has received UCC care for ? 2 weeks at treating wound clinic
3344,NCT02347891,"13:46:treatment,,",Patients on intravenous gamma globulin (IVIG) have to be on a stable dose and frequency regimen for ? 3 months
3345,NCT01306019,"30:63:treatment,,,",demonstrated requirement for intravenous gamma globulin (IVIG) (significant drop over 3 to 6 weeks between peak and trough IgG levels)
3346,NCT02343042,14:33:chronic_disease,"Known active hepatitis A, B or C"
3347,NCT01895777,24:43:chronic_disease,"including known active hepatitis A, B or C"
3348,NCT02341209,",,,152:163:treatment",Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication and monthly while on receiving doxycycline
3349,NCT01917721,45:56:treatment,Patients whose parents refuse to administer doxycycline
3350,NCT02339233,34:57:chronic_disease,stable medical condition without cardiopulmonary disease
3351,NCT02329652,8:31:chronic_disease,severe cardiopulmonary disease
3352,NCT02332369,14:30:chronic_disease,Preoperative ocular infection
3353,NCT02148263,8:24:chronic_disease,Active ocular infection
3354,NCT02327403,12:26:treatment,patient on mTOR inhibitor
3355,NCT01734512,51:65:treatment,Patients who have been previously treated with an mTOR inhibitor
3356,NCT02323191,1:23:cancer,Leptomeningeal disease
3357,NCT01622868,1:23:cancer,Leptomeningeal disease
3358,NCT02317991,10:21:chronic_disease,Adequate hematologic
3359,NCT01999179,9:20:chronic_disease,Current hematologic
3360,NCT02315612,43:73:treatment,There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects
3361,NCT01430390,43:73:treatment,There is no time restriction in regard to prior intrathecal chemotherapy provided tere is complete recovery from any acute toxic effects of such
3362,NCT02309580,56:75:cancer,Patients who have a standard curative option for their lymphoid malignancy at current state of disease
3363,NCT01994382,21:40:cancer,Prior treatment for lymphoid malignancy for progressive /refractory disease
3364,NCT02304458,47:63:treatment,"Parts C, D, and E: patients who have received prior ipilimumab"
3365,NCT01896999,32:48:treatment,patients may not have received prior ipilimumab
3366,NCT02290951,52:64:allergy_name,History of hypersensitivity to any compound in the tetracycline antibiotics group
3367,NCT02133885,7:19:treatment,other tetracycline
3368,NCT02272998,1:30:treatment,anti-hypertensive medications are permitted
3369,NCT02133885,6:35:treatment,more anti-hypertensive medications of different classes
3370,NCT02266784,38:53:chronic_disease,Has a primary diagnosis of any other Axis I Disorder (determined by the Structured Diagnostic Interview for DSM; SCID) that is significantly impairing and would contraindicate participation in the present study
3371,NCT02067975,20:35:chronic_disease,No DSM-IV-TR/DSM-5 Axis I Disorder (documented by SCID)
3372,NCT02262832,47:71:allergy_name,Subjects who have a known hypersensitivity to E. coli derived proteins (as leptin is derived from such proteins)
3373,NCT02262806,47:71:allergy_name,Subjects who have a known hypersensitivity to E. coli derived proteins
3374,NCT02255383,1:20:chronic_disease,Skeletal immaturity
3375,NCT02015390,"1:20:chronic_disease,,",Skeletal immaturity (open growth plate and/or age <18 years)
3376,NCT02250664,43:66:chronic_disease,Be without current (within the past year) serious mental disorder that would interfere with study results or completion as determined by the licensed medical professional or PI
3377,NCT02250534,40:63:chronic_disease,without current (within the past year) serious mental disorder
3378,NCT02243813,"33:51:treatment,","Agree to refrain from using any psychoactive drugs, including alcoholic beverages and nicotine, 24 hours before and after each drug administration"
3379,NCT02233868,20:38:treatment,Urine positive for psychoactive drugs (clinical laboratory results) on study days involving imaging (PET and MRI) and neuropsychological testing
3380,NCT02233868,12:32:chronic_disease,"History of coagulation disorder (clinical laboratory results, medical history)"
3381,NCT01912612,24:44:chronic_disease,Clinically significant coagulation disorder
3382,NCT02232516,1:35:cancer,Angioimmunoblastic T-cell lymphoma
3383,NCT01787409,1:35:cancer,Angioimmunoblastic T-cell lymphoma
3384,NCT02221830,21:29:allergy_name,contraindication to oxytocin
3385,NCT02121184,9:17:treatment,Receive oxytocin
3386,NCT02208362,44:57:treatment,Research participant must have appropriate venous access
3387,NCT02146924,30:43:treatment,he/she must have appropriate venous access
3388,NCT02197351,16:31:treatment,presenting for upper endoscopy for gastric indications
3389,NCT01953575,33:48:treatment,undergoing clinically indicated upper endoscopy
3390,NCT02192398,"7:17:treatment,",Takes vitamin B2 > 1.6mg/day during the study
3391,NCT01681264,"7:17:treatment,",Takes vitamin B2 > 1.6mg/day during the study
3392,NCT02181478,95:110:chronic_disease,subjects must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement
3393,NCT01896999,50:65:chronic_disease,Patient must have no current or prior history of CNS involvement
3394,NCT02177292,12:42:treatment,History of prior pelvic radiation therapy
3395,NCT02008656,4:34:treatment,No prior pelvic radiation therapy
3396,NCT02167958,1:19:cancer,Burkitt's lymphoma: second or subsequent CR
3397,NCT01994382,1:19:cancer,Burkitt's lymphoma
3398,NCT02159495,37:52:cancer,Research participants has undergone lymphodepletion
3399,NCT02146924,36:51:treatment,Research participant has undergone lymphodepletion
3400,NCT02152995,58:68:treatment,Animal reproductive studies have not been conducted with trametinib
3401,NCT02152995,",,,182:192:treatment","men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of trametinib administration"
3402,NCT02152956,20:37:chronic_disease,resolved childhood atopic dermatitis
3403,NCT02148796,21:38:chronic_disease,Physician-diagnosed atopic dermatitis in the participant
3404,NCT02145351,13:44:chronic_disease,Non-group 2 pulmonary arterial hypertension
3405,NCT01620216,7:38:chronic_disease,Known pulmonary arterial hypertension
3406,NCT02140255,1:12:treatment,ART regimen (described in criteria above) was taken daily from date of initiation until study entry
3407,NCT01896921,",,,57:68:treatment",HIV RNA ? 50 copies/ml for ? 12 months while taking any ART regimen
3408,NCT02131467,1:13:treatment,pioglitazone
3409,NCT00904046,21:33:treatment,Contraindication to pioglitazone use
3410,NCT02128906,",54:71:cancer",must be disease-free for at least 2 years except for carcinoma-in-situ of cervix
3411,NCT01737502,1:18:cancer,carcinoma-in-situ of the cervix
3412,NCT02124772,",,,,149:176:treatment","Adequate bone marrow function defined as absolute neutrophil count (ANC) >=1000/microliter, hemoglobin >=8.0 gram per deciliter (g/dL) (may receive red blood cell transfusions)"
3413,NCT02004275,1:28:treatment,red blood cell transfusions are allowed at any time
3414,NCT02111850,1:36:treatment,Concurrent systemic steroid therapy
3415,NCT01174121,1:36:treatment,Concurrent systemic steroid therapy
3416,NCT02107261,16:24:chronic_disease,Patients whose dystonia is not severe enough to interfere with musical performance in the opinion of a skilled examiner
3417,NCT02107261,35:43:chronic_disease,Patients with focal task-specific dystonia of one or both hands
3418,NCT02089607,40:54:treatment,"A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent-graft would be anticipated to seal off the dissection lumen"
3419,NCT02089607,17:31:treatment,Native aorta or surgical graft
3420,NCT02085941,32:44:treatment,may not be receiving any other study agents
3421,NCT01898793,46:58:allergy_name,Known hypersensitivity to one or more of the study agents
3422,NCT02074631,31:42:allergy_name,Known or suspected allergy to pamidronate or related products
3423,NCT02074631,",,,,189:200:treatment",Pregnancy or breastfeeding - menstruating females must have a negative pregnancy test prior to study enrollment and agree to repeat pregnancy testing and contraception use per protocol as pamidronate is Pregnancy Category D - positive evidence of human fetal risk based on adverse reaction data
3424,NCT02056470,1:16:chronic_disease,Paget's disease
3425,NCT01766297,1:16:chronic_disease,Paget's disease of the nipple
3426,NCT02040610,",,59:68:treatment",Patients with 2 or 3 risk factors will require a negative bone scan for eligibility
3427,NCT02012296,",26:35:treatment",2 or more new lesions on bone scan
3428,NCT02030028,1:24:chronic_disease,Abnormal renal function
3429,NCT01851694,1:24:chronic_disease,Abnormal renal function
3430,NCT02015390,49:72:treatment,Defect and/or soft tissue status ineligible for surgical reconstruction
3431,NCT02015390,",101:124:treatment","Presence of an extremity long bone (femur, tibia, humerus, ulna, radius) segmental defect requiring surgical reconstruction with at least one of the following etiologies"
3432,NCT02003222,68:80:treatment,Patients should meet the eligibility criteria for RANDOMIZATION TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3
3433,NCT02003222,18:30:treatment,RANDOMIZATION TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3
3434,NCT01976429,43:55:chronic_disease,no recent history of non-activity related otitis media
3435,NCT01976429,26:38:chronic_disease,syndrome predisposing to otitis media
3436,NCT01970345,21:30:chronic_disease,Active or suspected neoplasia
3437,NCT01525901,21:30:cancer,active or suspected neoplasia
3438,NCT01966367,10:17:chronic_disease,Adequate cardiac function per protocol
3439,NCT01653093,19:26:chronic_disease,Patients who have cardiac
3440,NCT01954966,1:17:chronic_disease,thrombophlebitis
3441,NCT01239160,"20:36:chronic_disease,",Diagnosis of acute thrombophlebitis (in last 2 months)
3442,NCT01943851,"1:22:treatment,",Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks
3443,NCT01943851,"1:22:treatment,",Chemotherapy regimens with delayed toxicity within the last 4 weeks
3444,NCT01898793,16:42:treatment,Relapsed after allogeneic transplantation
3445,NCT01512888,43:69:treatment,Availability of a HLA matched sibling for allogeneic transplantation
3446,NCT01884740,1:18:cancer,oligodendroglioma
3447,NCT01130077,19:36:cancer,Patients with any oligodendroglioma component
3448,NCT01865162,16:40:treatment,6 weeks from a nitrosourea chemotherapy
3449,NCT01849146,",16:40:treatment",6 weeks from a nitrosourea chemotherapy
3450,NCT01824836,102:113:treatment,"Patients must have adequate hepatic, hematologic and renal functioning to be able to be administered anastrozole at the discretion of the treating physician"
3451,NCT01824836,"20:31:treatment,",Plan to treat with anastrozole for at least 12 months
3452,NCT01810588,1:16:chronic_disease,Aplastic anemia
3453,NCT00258427,"1:16:chronic_disease,,,,,,,","Aplastic anemia is defined as having at least one of the following (with or without cytogenetic abnormalities): platelet count <20 * 10^9, - absolute neutrophil count (ANC) <5 * 10^8/L, - Hgb <8 g/dL /"
3454,NCT01801072,1:12:cancer,Brain tumor
3455,NCT01539109,1:12:cancer,Brain tumor
3456,NCT01774487,21:43:treatment,Infants receiving a Kasai portoenterostomy at another institution
3457,NCT01774487,13:35:treatment,No previous Kasai portoenterostomy performed at another institution
3458,NCT01703117,"31:62:allergy_name,","previously unable to tolerate acetylcholinesterase inhibitors and as a result, are no longer on the medication for at least 2 months"
3459,NCT01584076,52:83:allergy_name,Known allergies or contraindications to the use of acetylcholinesterase inhibitors
3460,NCT01666665,14:38:chronic_disease,Pre-existing type 1 diabetes mellitus
3461,NCT00678145,15:39:chronic_disease,Patients with type 1 diabetes mellitus
3462,NCT01631617,28:55:allergy_name,Known allergic reaction to sodium hypochlorite (NaOCl)
3463,NCT01631617,33:60:allergy_name,Known allergy or sensitivity to sodium hypochlorite (NaOCl)
3464,NCT01585402,33:37:chronic_disease,Subjects must be diagnosed with ACDC based on genetic tests confirming mutation(s) in NT5E and evidence of lower extremity arterial calcifications
3465,NCT01585402,29:33:chronic_disease,Subjects not diagnosed with ACDC
3466,NCT01532687,",94:103:treatment",within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
3467,NCT01532687,",43:52:treatment",within 14 days prior to the first dose of pazopanib
3468,NCT01494662,42:65:treatment,Cohort 3a will have participants with no prior lapatinib therapy
3469,NCT01494662,25:48:treatment,Cohort 3b will have had prior lapatinib therapy
3470,NCT01436968,1:26:cancer,Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients having only one NCCN high-risk feature
3471,NCT00737893,1:26:cancer,Localized prostate cancer
3472,NCT01419561,"33:37:chronic_disease,,","Immunohistochemical evidence of KSHV in tissues (for example by staining for LANA or vIL-6). Confirmed in the Laboratory of Pathology, CCR, NCI"
3473,NCT01419561,23:27:chronic_disease,"Molecular evidence of KSHV in whole blood, confirmed by testing at Focus Laboratories, CA (HHV-8 Quantitative PCR, Focus Unit Code 45700)"
3474,NCT01059786,"13:16:treatment,,,,","Evidence of HCL by flow cytometry of blood or a solid (lymph node) mass, confirmed by the Laboratory of Pathology, NCI, including positivity for CD19, CD22, CD20, and CD11c"
3475,NCT00412594,14:17:cancer,Diagnosis of HCL established by bone marrow examination
3476,NCT00719888,11:22:treatment,High-dose TBI regimen
3477,NCT00719888,18:29:treatment,Middle-intensity TBI regimen
3478,NCT00230607,38:47:treatment,be born to a mother who is receiving Fabrazyme during lactation
3479,NCT00230607,49:58:treatment,be enrolled in the Fabry Registry and receiving Fabrazyme while lactating
3480,NCT03188042,21:38:allergy_name,Photosensitivity to flickering lights
3481,NCT03187951,1:22:cancer,Neuroendocrine cancer
3482,NCT03187379,21:45:treatment,previous history of roux-en-y gastric bypass
3483,NCT03187028,1:26:chronic_disease,severe emotional distress
3484,NCT03185130,"1:16:treatment,",Lumbar puncture within the previous two weeks
3485,NCT03183102,"1:30:chronic_disease,,,,,","Chronic hepatobiliary disease, conservatively defined as liver function tests (AST, ALT, alkaline phosphatase, Total Bilirubin) >1.5 times the upper limit of normal"
3486,NCT03182907,21:46:chronic_disease,Has an uncontrolled chronic diarrheal illness
3487,NCT03182751,46:67:treatment,Surgically treated with sliding hip screw or cephalomedullary nail (short or long)
3488,NCT03181516,12:22:allergy_name,Allergy to strawberry
3489,NCT03181516,1:11:treatment,Cefadroxil
3490,NCT03181516,1:11:treatment,Cephradine
3491,NCT03181516,1:20:treatment,Mefoxin (Cefoxitin)
3492,NCT03181516,1:13:treatment,Trimethoprim
3493,NCT03181126,17:27:treatment,Participants on venetoclax at screening may enroll and remain on venetoclax
3494,NCT03180086,",36:45:treatment",women who have taken or are taking tamoxifen
3495,NCT03179397,1:21:chronic_disease,Diabetic retinopathy
3496,NCT03179397,10:25:treatment,Previous corneal surgery
3497,NCT03179163,12:27:allergy_name,allergy to test substances
3498,NCT03178552,69:79:cancer,Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb
3499,NCT03176784,56:75:treatment,desire to quit smoking but not be engaged currently in cessation treatment
3500,NCT03175978,15:44:chronic_disease,Patients with active extramedullary disease
3501,NCT03171493,14:54:cancer,"Diagnosis of Urothelial carcinoma (UC) of the bladder, with histologic confirmation of primary UC pathology"
3502,NCT03171168,10:38:chronic_disease,No major cardiovascular comorbidities (able to enroll in an active exercise program)
3503,NCT03170856,12:32:treatment,History of neurological surgery
3504,NCT03170453,1:23:chronic_disease,Organic brain syndrome
3505,NCT03170375,1:42:chronic_disease,moderate or severe valvular heart disease
3506,NCT03170349,19:22:treatment,Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
3507,NCT03169543,1:32:chronic_disease,debilitating medical conditions
3508,NCT03168776,29:69:treatment,an acceptable candidate for percutaneous coronary intervention (PCI) with drug-eluting stents
3509,NCT03168659,",25:45:treatment",failure of at least one anti-arrhythmic drug
3510,NCT03167216,16:57:chronic_disease,Diagnosed with Category III Chronic Pelvic Pain Syndrome
3511,NCT03165227,11:24:treatment,bilateral salpingectomy
3512,NCT03161028,53:66:treatment,Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to enrolment
3513,NCT03159936,"1:17:treatment,",Systemic therapy is allowed if on a stable dose and using for at least 3 months -background therapies outlined in Protocol
3514,NCT03159754,1:18:chronic_disease,Immunocompromized state
3515,NCT03158974,17:50:chronic_disease,"Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events"
3516,NCT03158974,",33:51:cancer","If female, have any evidence of cervical dysplasia"
3517,NCT03157713,1:34:chronic_disease,Chronic Kidney Disease stage IV/V
3518,NCT03156543,29:50:treatment,Limited to total or reverse shoulder arthroplasty
3519,NCT03154567,1:19:chronic_disease,Pulmonary diseases
3520,NCT03153982,1:15:cancer,"Primary tumors of any head and neck (oral cavity, oropharynx, hypopharynx, or larynx) site will be included"
3521,NCT03153969,38:56:treatment,Teeth that are non-vital or have had root canal therapy
3522,NCT03153319,14:25:chronic_disease,Diagnosis of MPS I or II
3523,NCT03153319,"4:22:treatment,",no treatment with ERT for ?1 year
3524,NCT03152058,58:70:allergy_name,Known contraindications or relative contraindications to certolizumab
3525,NCT03151330,7:30:chronic_disease,Known fetal genetic anomalies that are incompatible with life
3526,NCT03150004,1:29:cancer,Acute Promyelocytic Leukemia
3527,NCT03149783,39:50:allergy_name,Patients with a documented allergy to ropivacaine
3528,NCT03149549,11:35:chronic_disease,Active or chronic corneal disorder
3529,NCT03149549,1:24:chronic_disease,alcoholic liver disease
3530,NCT03148379,1:24:chronic_disease,knee avascular necrosis
3531,NCT03146663,",27:50:treatment",Received at least 3 prior chemotherapy-containing regimens
3532,NCT03145298,"1:31:chronic_disease,,",Non-pulmonary vascular disease with life expectancy of < 3 years
3533,NCT03145181,"1:29:treatment,",Proteasome inhibitor therapy within 14 days
3534,NCT03144206,1:28:chronic_disease,Active deep vein thrombosis in the treatment extremity
3535,NCT03143985,13:22:chronic_disease,Presence of aneurisms of the ascending aorta or aortic stress
3536,NCT03141164,1:19:chronic_disease,visual impairments due to partial vision loss
3537,NCT03140488,12:38:treatment,History of previous cesarean delivery
3538,NCT03138733,28:53:treatment,Requirement for continuous renal-replacement therapy
3539,NCT03137771,53:81:cancer,Clinical or radiologic evidence of untreated and/or progressive brain metastases
3540,NCT03137758,18:48:treatment,standard of care androgen deprivation treatment
3541,NCT03137173,1:48:chronic_disease,Uncomplicated skin and skin structure infection
3542,NCT03136029,1:21:cancer,End-stage Malignancy
3543,NCT03136029,1:33:chronic_disease,Sleep-related Breathing Disorder
3544,NCT03135171,1:38:chronic_disease,Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation
3545,NCT03133793,1:24:chronic_disease,Severe cardiac fibrosis
3546,NCT03132636,24:36:cancer,Confirmed diagnosis of invasive BCC
3547,NCT03131960,"1:27:chronic_disease,,",Severe or worse depression (Beck Depression Scale > 29)
3548,NCT03131037,1:33:chronic_disease,end-stage liver or renal disease
3549,NCT03129880,18:32:chronic_disease,Diagnosed with a Voice disorder
3550,NCT03129542,1:24:treatment,Fludrocortisone acetate is a current home medication
3551,NCT03128268,1:5:treatment,ICDs implanted
3552,NCT03128008,14:45:cancer,"Unresectable stage II, IIIA, or IIIB disease"
3553,NCT03125902,1:15:cancer,Leptomeningeal disease
3554,NCT03125226,4:20:treatment,No prior cystectomy
3555,NCT03123068,12:42:allergy_name,"Allergy to active ingredient of CocoaVia®, the study intervention"
3556,NCT03123055,",50:67:chronic_disease,",History of clinically significant coagulation or platelet disorder in the past 12 months
3557,NCT03122535,49:64:treatment,Subjects who are deemed suitable candidates for bilateral LASIK will be considered eligible for participation in this study
3558,NCT03121586,1:12:treatment,Cariprazine
3559,NCT03121352,10:31:treatment,A second post-treatment biopsy will be offered but will not be mandated
3560,NCT03121352,"23:38:treatment,",must not have been on steroid therapy for at least 4 weeks
3561,NCT03120728,1:23:cancer,hepatocellular adenoma
3562,NCT03120728,1:29:chronic_disease,systemic lupus erythematosus with positive antiphospholipid antibodies
3563,NCT03119363,1:74:treatment,Previous use of light therapy to alleviate fatigue or depressive symptoms
3564,NCT03118050,1:13:chronic_disease,Pre-diabetes per American Diabetes Association criteria
3565,NCT03116997,"27:63:chronic_disease,,",History of severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 < 50% of predicted
3566,NCT03116685,"20:30:treatment,",Patients receiving vitamin B6 must be receiving a stable dose for at least 3 months prior to screening and must not change the dose during the study
3567,NCT03115424,"14:41:treatment,",Prior use of glucose lowering medication in the 3 months prior to screening
3568,NCT03114891,19:37:chronic_disease,meet criteria for trauma-induced MDD
3569,NCT03114020,18:33:chronic_disease,Individuals with PiMZ deficiency are not allowed in the study
3570,NCT03113825,1:40:treatment,Radiation therapy to ipsilateral breast [Period 1]
3571,NCT03113760,25:76:chronic_disease,Patients suffering from familial hemophagocytic lymphohistiocytosis (f HLH)
3572,NCT03113760,1:48:treatment,disease modifying anti rheumatic drugs (DMARDs)
3573,NCT03113695,1:21:cancer,clonal large B-cells in peripheral blood or bone marrow
3574,NCT03112902,1:7:chronic_disease,eczema or sensitive skin
3575,NCT03112824,1:21:chronic_disease,Oral Corticosteroids
3576,NCT03112824,1:25:treatment,anti-insomnia medication on a regular basis
3577,NCT03112603,52:64:chronic_disease,Participants with clinically diagnosed moderate to severe cGvHD according to NIH Consensus Criteria prior to randomization
3578,NCT03112590,14:58:cancer,unresectable locally advanced or metastatic breast cancer
3579,NCT03110354,",,,141:177:treatment","Has prolonged corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is > 450 milliseconds (ms) based on triplicate electrocardiograms (ECGs)"
3580,NCT03108820,1:18:chronic_disease,Parkinson disease
3581,NCT03107897,25:77:chronic_disease,Subject has significant severe un-revascularized epicardial coronary disease
3582,NCT03107520,7:35:chronic_disease,Known heart or pulmonary condition
3583,NCT03105362,40:57:chronic_disease,Patients with a primary diagnosis of a motility disorder
3584,NCT03105362,1:25:chronic_disease,epithelial cell disorder
3585,NCT03104725,10:43:treatment,Taking a monoamine oxidase (MAO) inhibitor
3586,NCT03104699,1:45:cancer,basal or squamous cell carcinoma of the skin
3587,NCT03104699,1:19:chronic_disease,immunodeficiencies
3588,NCT03104517,",,,74:77:chronic_disease,","50 to 75 years of age who has primary and moderate-to-severe symptoms of SUI for at least 6 months, as confirmed by patient medical history and clinical symptoms, including a focused incontinence evaluation"
3589,NCT03104413,45:68:treatment,Subjects with unstable doses of concomitant Crohn's disease therapy
3590,NCT03102320,1:34:chronic_disease,Active hepatitis B or C infection
3591,NCT03101956,1:35:chronic_disease,Nervous system disease or disorder
3592,NCT03101085,17:70:treatment,Use any type of systemic estrogen or testosterone replacement therapy
3593,NCT03100461,1:22:chronic_disease,Acute medical illness
3594,NCT03100370,4:34:chronic_disease,No neuropsychiatric comorbidities
3595,NCT03098394,35:65:chronic_disease,Signs or symptoms consistent with sexually transmitted infection
3596,NCT03097536,1:17:chronic_disease,Chronic migraine
3597,NCT03096418,33:68:treatment,Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist
3598,NCT03096288,51:61:allergy_name,History of a serious hypersensitivity reaction to evolocumab
3599,NCT03096288,1:12:treatment,rivaroxaban
3600,NCT03093909,23:26:treatment,Subjects who received GCB systemically previously are eligible for participation
3601,NCT03092609,6:13:chronic_disease,High Anxiety
3602,NCT03091803,24:45:cancer,Patient with suspected intracranial neoplasm scheduled for routine MRI with GBCA (gadolinium naive patients)
3603,NCT03090607,",,41:52:treatment",GERD-HRQL score ?15 after discontinuing PPI therapy
3604,NCT03090607,7:30:treatment,Prior gastric or GERD surgery
3605,NCT03089853,10:44:treatment,Those on invasive or mechanical ventilation will not be enrolled
3606,NCT03089515,",,60:71:treatment,",Using ICS/LABA (Advair HFA equivalent > 115/21 mcg bid) or Fluticasone (110 mcg bid or equivalent) for at least 1 month before Study Visit 1
3607,NCT03089125,1:36:chronic_disease,Cognitive or psychiatric conditions prohibiting study consent or participation
3608,NCT03088072,1:37:treatment,LAA closure with the WATCHMAN device is planned
3609,NCT03088033,",,53:55:chronic_disease",Tricuspid valve regurgitation defined as grade > 2+ TR
3610,NCT03086369,12:59:cancer,Have known central nervous system malignancy or metastasis
3611,NCT03085485,1:7:chronic_disease,Angina symptoms
3612,NCT03085485,1:31:chronic_disease,stable coronary artery disease
3613,NCT03085095,12:31:treatment,History of surgical castration
3614,NCT03085004,52:56:chronic_disease,solid mass component within or associated with the cyst
3615,NCT03084640,40:72:treatment,currently receiving treatment with the anti-PD-1 antibody pembrolizumab either alone or in combination
3616,NCT03081390,40:63:allergy_name,Allergies or sensitivity to any of the ingredients of the meal
3617,NCT03080844,5:39:chronic_disease,Any neurologic or psychiatric disorder
3618,NCT03079401,15:39:chronic_disease,Patients with aortic or mitral atresia
3619,NCT03079297,1:25:chronic_disease,Psychiatric co-morbidity posing safety risk
3620,NCT03078530,",44:58:chronic_disease",Negative Tissue transglutaminase (TTG) for celiac disease
3621,NCT03078491,"1:30:chronic_disease,,",End stage renal insufficiency (eGFR<30)
3622,NCT03077243,1:20:chronic_disease,Psoriatic arthritis
3623,NCT03076658,1:22:chronic_disease,Severe osteoarthritis of the hips/knees/ankles
3624,NCT03075761,21:40:allergy_name,Contraindication to increasing activity
3625,NCT03074240,16:33:treatment,Chronic use of opioid medication
3626,NCT03073785,"48:54:treatment,",Patients may not be receiving or have received Zometa during/or within 3 weeks prior to treatment with Zometa
3627,NCT03073629,",87:101:chronic_disease",comprehensive echocardiogram within 3 months of index hospital visit showing isolated RV dysfunction
3628,NCT03073070,"16:34:treatment,",consumption of biotin supplements or raw eggs within 30 days
3629,NCT03072238,"22:55:treatment,","Administration of an investigational therapeutic agent within 28 days of Cycle 1, Day 1"
3630,NCT03072238,1:21:treatment,Radiopharmaceuticals for the purpose of imaging are permitted
3631,NCT03071393,",23:46:chronic_disease",Greater than 6 months post-spinal cord injury
3632,NCT03070899,12:26:treatment,History of uterus surgery that would interfere with the study
3633,NCT03070535,1:26:chronic_disease,cholesterol abnormalities as defined by the Adult Treatment Panel III classification
3634,NCT03069716,"1:39:treatment,",Stable PAH-specific medication regimen for three months prior to enrollment
3635,NCT03068780,1:20:chronic_disease,dystrophic EB (DEB)
3636,NCT03068442,6:18:allergy_name,"[18F]Flutemetamol contraindications per manufacturer guidelines, including patients with prior reactions"
3637,NCT03067051,7:32:chronic_disease,other severe concurrent disease
3638,NCT03065907,"22:66:chronic_disease,",Primary diagnosis of neovascular age-related macular degeneration in the index eye or in both eyes if habitual visual acuity (HVA) is equivalent in both eyes
3639,NCT03065465,",,54:84:chronic_disease",Life expectancy of at least 30 days based on lack of severe or terminal comorbidity as judged by the generalist or subspecialist caring for the patient
3640,NCT03063892,1:23:treatment,Active hormone therapy
3641,NCT03062462,1:43:chronic_disease,severe congestive heart failure NYHA II-IV
3642,NCT03061903,21:57:treatment,Patients undergoing primary total hip arthroplasty (THA) through a direct anterior approach by one of the investigating surgeons
3643,NCT03060772,14:36:treatment,Currently on pioglitazone treatment for another reason
3644,NCT03060473,",,37:58:treatment",Cervical dilation visually ? 5cm on sterile speculum exam
3645,NCT03060096,16:33:cancer,Diagnosis of a second malignancy
3646,NCT03059407,18:22:allergy_name,known allergy to dogs
3647,NCT03059355,1:23:chronic_disease,Elevated triglycerides
3648,NCT03059030,1:23:chronic_disease,Von Willebrand disease
3649,NCT03058952,14:45:chronic_disease,Diagnosis of borderline personality disorder
3650,NCT03058796,1:30:chronic_disease,uncontrolled seizure disorder
3651,NCT03058679,"32:37:treatment,",Start or change in dose of any 5-ASA medications within 2 weeks of screening
3652,NCT03057730,46:69:treatment,Areas that have previously been treated with root coverage surgeries
3653,NCT03056339,13:44:chronic_disease,Presence of active neurological disorder(s)
3654,NCT03055767,1:23:chronic_disease,Eaton Lambert Syndrome
3655,NCT03054519,",,,59:77:treatment",have an ABI > 0.90 with a 20% or higher drop in ABI after heel-rise exercise will be eligible
3656,NCT03053908,48:85:chronic_disease,Presence of any known or suspected obstructive disease of the gastrointestinal tract
3657,NCT03053908,1:10:chronic_disease,pulmonary
3658,NCT03053453,70:87:chronic_disease,Patients will be screened for eligibility based on whether they have chronic knee pain as a result of an arthritis-related condition
3659,NCT03053271,1:26:chronic_disease,cyclic Cushing's syndrome
3660,NCT03051516,"40:44:chronic_disease,","patients whose screening visit reveals HSIL on biopsy, may be re-screened >= 2 months after therapy"
3661,NCT03051282,28:37:allergy_name,Subjects hypersensitive to enalapril
3662,NCT03049189,16:39:treatment,Indication for surgical lesion removal with curative potential
3663,NCT03049189,1:30:chronic_disease,Serious non-malignant disease
3664,NCT03049033,45:65:treatment,Participants whose insurance does not cover Occupational Therapy costs or who have no insurance
3665,NCT03046030,28:79:chronic_disease,"Current or past history of major medical, neurological, or psychiatric illness"
3666,NCT03043794,1:15:treatment,Breast implant in the involved breast
3667,NCT03043742,"10:23:treatment,",Previous heart surgery within the last 6 months
3668,NCT03042689,14:55:cancer,Diagnosis of relapsed/refractory advanced malignancies
3669,NCT03042689,1:36:chronic_disease,noninvasive aerodigestive neoplasms
3670,NCT03041844,1:28:chronic_disease,"Active, untreated infection"
3671,NCT03040804,"14:38:chronic_disease,,,","Diagnosis of Hidradenitis Suppurativa made at the Montefiore Hidradenitis Suppurativa Treatment Center, with Hurley Stage 2-3 (defined as recurrent abscesses or boils with diffuse or broad involvement, multiple interconnected sinus tracts in the whole area)"
3672,NCT03040778,15:38:chronic_disease,Patients with ischemic heart diseases
3673,NCT03040778,1:14:treatment,ciprofloxacin
3674,NCT03038867,1:27:chronic_disease,current sexual dysfunction (classified as moderate or worse on IIEF)
3675,NCT03038620,"39:63:treatment,",Current participation in an organized weight reduction program or within the last 1 month prior to screening for this trial
3676,NCT03038308,1:25:chronic_disease,Untreated hypothyroidism
3677,NCT03038269,1:22:treatment,Dorsal root rhizotomy
3678,NCT03038269,8:31:treatment,use of anti-seizure medication
3679,NCT03037879,1:27:chronic_disease,Acute illness or infection
3680,NCT03037385,75:88:treatment,Patients in Groups 1-5 and 7 (Part 2) previously treated with a selective RET inhibitor
3681,NCT03036280,24:47:chronic_disease,Positive biomarker for brain amyloid pathology as indicated by either amyloid PET or CSF AD assessment or both
3682,NCT03036098,1:43:cancer,Metastatic or inoperable urothelial cancer
3683,NCT03035890,1:34:chronic_disease,primary immunodeficiency syndrome
3684,NCT03035474,22:30:chronic_disease,Hospitalizations for acute HF will be determined by local clinician-investigators
3685,NCT03034564,4:15:chronic_disease,No orthostatic symptoms
3686,NCT03034564,1:15:treatment,gastric bypass
3687,NCT03033498,105:113:treatment,Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive ABBV-951
3688,NCT03033212,12:28:chronic_disease,History of spinal infection
3689,NCT03033212,1:20:chronic_disease,facet joint disease
3690,NCT03032705,"5:26:treatment,",Any restorative treatment of the teeth involved in the study in the last 12 months
3691,NCT03030859,1:27:treatment,Post HNC primary treatment
3692,NCT03030118,1:60:chronic_disease,"Active bacterial, viral, fungal, or opportunistic infection"
3693,NCT03029884,1:28:chronic_disease,Stroke of ischemic etiology only
3694,NCT03028831,21:31:chronic_disease,any form of chronic GI disease resulting in disturbed gut function
3695,NCT03028298,"1:29:treatment,",Pre-ictal sildenafil therapy (last dose within 1 week of presentation)
3696,NCT03027388,",,67:82:treatment",Pregnant women are excluded from this study because the safety of PP2A inhibition on a developing fetus has not been established
3697,NCT03026816,9:34:chronic_disease,"Stable, motor-complete paraplegia"
3698,NCT03023449,1:22:chronic_disease,"Acute ischemic stroke in the territory of the anterior, middle, or posterior cerebral artery, on either side of the brain"
3699,NCT03022292,1:44:treatment,Prior or current systemic anti-VEGF therapy
3700,NCT03021902,1:54:chronic_disease,Pre-existing cognitive impairment or language barrier that prohibits outcomes assessment
3701,NCT03019510,",,,,,,154:178:chronic_disease,,,,,,",body mass index (BMI): 30-45 kg/m2 for the obese subjects <24.5 kg/m2 for the non-obese subjects weight stable during prior 6 months non-smokers OB with impaired fasting glucose: elevated elevated morning fasting glucose levels >110 mg/dL for 5 of 7 days non-obese and OB subjects: fasting glucose levels < 100 mg/dL - 2hr OGTT glucose value <140 mg/dL
3702,NCT03019133,1:44:treatment,Ventilator support via an endotracheal tube
3703,NCT03018704,9:27:treatment,current treatment with TOP or a medication approved for AUD
3704,NCT03017937,"18:29:chronic_disease,,",Able to tolerate hypercapnia for 1-2 minutes
3705,NCT03017118,1:30:chronic_disease,Post-traumatic osteoarthritis
3706,NCT03016351,12:59:chronic_disease,History of cardiovascular disease or cardiovascular events
3707,NCT03016130,"21:51:treatment,,","patients undergoing reduced intensity conditioning, only those regimens in which the expected neutropenia is ? 7 days are permitted and the patient must reside in the hospital"
3708,NCT03015272,",93:107:treatment",demonstrate minimal progress in speech acquisition despite having had at least 18 months of speech therapy
3709,NCT03014687,10:23:treatment,Previous sinus surgery
3710,NCT03013543,1:28:chronic_disease,Heterozygous POMC mutations
3711,NCT03013543,6:21:chronic_disease,Rare genetic disease patients genetically confirmed diagnoses (may be confirmed by test at Screening)
3712,NCT03011801,19:37:chronic_disease,An HPA axis or an endocrine disorder
3713,NCT03011567,1:25:chronic_disease,Gestational hypertension
3714,NCT03011567,"1:30:chronic_disease,,,",Significant liver dysfunction (AST or ALT >500)
3715,NCT03009110,1:16:chronic_disease,Irradiated skin
3716,NCT03008616,",34:53:chronic_disease",Meets modified ACOG criteria for severe preeclampsia
3717,NCT03008070,1:22:chronic_disease,Diabetic ketoacidosis
3718,NCT03008070,1:33:cancer,cutaneous basocellular carcinoma
3719,NCT03007030,27:57:allergy_name,Known hypersensitivity to brentuximab vedotin components
3720,NCT03006770,"1:27:chronic_disease,",CLI with major tissue loss (Rutherford Category 6) in either leg
3721,NCT03006770,1:53:chronic_disease,acquired immunodeficiency syndrome (AIDS) infections
3722,NCT03006562,1:19:treatment,Epidural analgesia
3723,NCT03005951,1:20:chronic_disease,Developmental delay
3724,NCT03004807,1:10:chronic_disease,Dysphagia or difficulty swallowing
3725,NCT03003780,1:24:chronic_disease,COPD or HF exacerbation in the previous month
3726,NCT03003689,"7:26:treatment,",taken systemic antibiotic medications within the previous 6 months
3727,NCT03002389,12:43:chronic_disease,History of alpha 1 anti-trypsin deficiency
3728,NCT03001830,"31:44:chronic_disease,,","confirmed diagnosis of severe Haemophilia A defined as baseline plasma FVIII levels of <1% of normal as assessed by a validated one-stage clotting assay or a chromogenic assay, resulting from intron 22 inversions, intron 1 inversions, splice-site mutations, small deletions/insertions and missense mutations"
3729,NCT03000439,10:40:treatment,Previous JIA treatment with tofacitinib
3730,NCT03000257,19:56:chronic_disease,"participants with chronic or active hepatitis A, B or C"
3731,NCT02996227,1:31:treatment,laparoscopic abdominal surgery
3732,NCT02993900,1:36:cancer,"Carcinoma of the uterus: Stage IIIB (vaginal involvement), inoperable, or vaginal recurrence"
3733,NCT02992275,1:21:chronic_disease,Cardiovascular Risks
3734,NCT02991677,",15:35:treatment",History of >1 chemotherapy regimen
3735,NCT02991651,25:55:treatment,Prior treatment with an EGFR tyrosine kinase inhibitor
3736,NCT02991144,"19:44:treatment,",On stable dose of ammonia scavenger therapy for ?4 weeks
3737,NCT02990481,60:90:cancer,Patients with histologically confirmed locally advanced or metastatic cholangiocarcinomas in Arm 3
3738,NCT02990377,",26:47:treatment",Past 3-month non-medical opioid analgesic (OA) use
3739,NCT02989597,1:24:chronic_disease,Obstructive sleep apnea
3740,NCT02988960,48:88:cancer,Participant must not have a known uncontrolled malignancy of the central nervous system
3741,NCT02988895,197:213:chronic_disease,other co-morbidities that in the investigator's opinion could require medical or surgical intervention to prevent or treat visual loss or media opacity that might result from that condition (i.e. severe cataracts)
3742,NCT02986087,1:25:chronic_disease,Maternal uterine anomaly
3743,NCT02983903,1:18:chronic_disease,Bullous emphysema in region of nodule
3744,NCT02983240,"1:32:chronic_disease,,",Severe fetal growth restriction (EFW < 5%)
3745,NCT02982772,1:32:treatment,Treatment for vascular problems
3746,NCT02982226,37:59:treatment,Express an unwillingness to receive human allograft tissue
3747,NCT02981173,10:26:chronic_disease,Episodic cluster headache with periods that are predictable
3748,NCT02981082,1:45:chronic_disease,Moderate to severe interstitial lung disease
3749,NCT02979366,1:40:chronic_disease,Uncontrolled hepatitis B or C infection
3750,NCT02978885,7:32:treatment,other major abdominal surgeries
3751,NCT02975986,"76:89:chronic_disease,,","In the Control group (N=10), we will include volunteers with no history of stone disease matched for age (within 5 years)"
3752,NCT02974686,",92:113:treatment",Experiencing GI toxicity from MPA as determined by the treating physician within 12 months post-renal transplant
3753,NCT02974257,",20:34:chronic_disease",Within 12 hours of cardiac arrest event
3754,NCT02971202,1:23:chronic_disease,diabetes comorbidities
3755,NCT02969187,22:67:treatment,Planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB)
3756,NCT02969187,1:19:treatment,laparoscopic bowel
3757,NCT02968602,9:50:treatment,Current treatment with tetracycline or derivative
3758,NCT02967315,15:85:chronic_disease,patients with anomalous coronary crossing the right ventricular outflow tract (RVOT)
3759,NCT02966223,51:63:treatment,Subjects who have contraindications for receiving Y-90 therapy and any routine procedures and imaging associated with Y-90 therapy
3760,NCT02964741,"15:35:treatment,,","No overuse of analgesic medication, defined as regular intake on ?15 days per month for more than 3 months"
3761,NCT02964182,1:10:treatment,Bupropion
3762,NCT02963831,1:15:cancer,"Archival tumor samples are requested, but are not required for eligibility"
3763,NCT02961114,1:16:chronic_disease,Severe nocturia
3764,NCT02960113,1:15:chronic_disease,Coagulopathies
3765,NCT02959671,24:39:allergy_name,Known allergies to any study materials
3766,NCT02958462,1:53:chronic_disease,Idiopathic cytopenias of unclear significance (ICUS)
3767,NCT02955537,1:13:chronic_disease,Hypertensive
3768,NCT02954185,1:20:treatment,Cortisone injection
3769,NCT02953860,1:24:cancer,ER+ Her2- breast cancer
3770,NCT02953509,1:26:treatment,Prior treatment with CD47
3771,NCT02953392,4:19:chronic_disease,No apical disorder/inflammation at the area of the implant site
3772,NCT02952534,29:64:chronic_disease,molecular evidence of other homologous recombination deficiency
3773,NCT02950649,7:39:chronic_disease,known severe peripheral artery disease
3774,NCT02950337,"1:30:treatment,",post-operative predicted FEV1<30% predicted
3775,NCT02947945,1:19:chronic_disease,"Glomerulonephritis (haematuria, red cell casts, proteinuria)"
3776,NCT02947945,1:25:chronic_disease,Wegener's Granulomatosis
3777,NCT02946892,41:95:chronic_disease,History or current clinical evidence of moderate-to-severe fixed obstructive pulmonary disease
3778,NCT02946892,1:26:chronic_disease,nondilated cardiomyopathy
3779,NCT02946658,1:12:chronic_disease,Hepatitis A history
3780,NCT02945969,1:24:treatment,Prior kidney transplant based on self-report
3781,NCT02945293,1:27:chronic_disease,cerebral vascular accident
3782,NCT02944825,1:28:treatment,shockwave lithotripsy [SWL]
3783,NCT02943915,1:33:chronic_disease,Severe muscular or skeletal pain
3784,NCT02943746,1:12:chronic_disease,Stage 2 NEC prior to tolerating fortified feeds
3785,NCT02943408,1:41:chronic_disease,"major depression with psychotic features (296.24, 296.34)"
3786,NCT02942095,1:27:cancer,Non-small cell lung cancer
3787,NCT02940288,19:30:treatment,Patients naïve to acupuncture
3788,NCT02939183,"1:32:treatment,",Autologous stem cell transplant < 90 days prior to study day 1
3789,NCT02937402,53:87:treatment,Enrollment into this study may occur in tandem with other clinical therapeutics trials occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does not violate protocol or inclusion criteria of that study
3790,NCT02933034,6:33:chronic_disease,have NYHA Grade IV heart failure
3791,NCT02932410,",41:64:treatment",Subjects receiving a combination of > 2 PAH-specific treatments at randomization
3792,NCT02932410,1:36:chronic_disease,pulmonary capillary hemangiomatosis
3793,NCT02932280,",,,134:151:treatment",Negative ?-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential ? 7 days before starting neratinib therapy
3794,NCT02931110,1:11:treatment,enoxaparin
3795,NCT02931110,1:29:treatment,low-molecular-weight heparin
3796,NCT02930018,"1:17:chronic_disease,,",Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS) > 5 at the time of randomization
3797,NCT02930018,15:47:chronic_disease,Patient has a severe or fatal comorbid illness that will prevent improvement or follow-up
3798,NCT02928991,1:29:chronic_disease,Congenital Dyserythropoietic
3799,NCT02928991,"62:76:chronic_disease,,","Patients with clinically diagnosed and/or genetically proven iBMF syndromes, resulting in chronic red blood cell or platelet-transfusion dependence and/or an absolute neutrophil count <500/µL"
3800,NCT02928991,11:49:chronic_disease,diagnosed inherited bone marrow failure syndrome
3801,NCT02927392,",26:44:treatment",Women who have undergone surgical menopause
3802,NCT02926924,10:25:chronic_disease,Previous spine infection
3803,NCT02926378,1:25:treatment,IV anticoagulant therapy
3804,NCT02926248,20:33:treatment,Patients requiring bilateral MUA
3805,NCT02925923,1:15:treatment,Clarithromycin
3806,NCT02925923,1:10:treatment,Lopinavir
3807,NCT02925923,1:12:treatment,Rivaroxaban
3808,NCT02925923,1:23:treatment,anti-retroviral agents
3809,NCT02924363,1:18:treatment,Cochlear implants
3810,NCT02924194,8:32:treatment,Use of cholinesterase inhibitor
3811,NCT02923167,"15:51:treatment,",Recent use of upper-limb robotic-assisted training within the last 3 months
3812,NCT02923011,10:20:cancer,"Targeted bone/tumor interface is accessible to the ExAblate device and located in a rib, extremity (excluding intra-articular location), pelvis, shoulders (including clavicles), or the sternum"
3813,NCT02921022,31:53:chronic_disease,"Known, clinically significant carotid artery disease"
3814,NCT02920710,14:34:allergy_name,Allergies to pig-derived proteins
3815,NCT02920086,1:13:treatment,Vasopressors
3816,NCT02918981,1:22:chronic_disease,Phenylketonuria (PKU)
3817,NCT02916524,",41:63:chronic_disease","At least 6 months post-onset of single, left-hemisphere stroke"
3818,NCT02914834,1:23:chronic_disease,autoimmune dysfunction
3819,NCT02914483,1:36:chronic_disease,acute exacerbation of heart failure
3820,NCT02914171,156:179:treatment,Individuals who have other clinical concerns as documented by a site investigator that could reasonably increase the risk of complications during or after surgical Ebstein repair
3821,NCT02914171,",67:89:treatment",Individuals with the following conditions within 60 days prior to Ebstein repair surgery
3822,NCT02913495,1:8:chronic_disease,accreta
3823,NCT02913430,"25:27:treatment,",The minimum duration of AI in the adjuvant setting is 2 years
3824,NCT02913430,1:29:cancer,skin squamous cell carcinoma
3825,NCT02912572,1:20:cancer,"Endometrial cancers that are MSS as determined by normal immunohistochemical nuclear expression of all the mismatch repair genes MSH2, MSH6, MLH1 and PMS2"
3826,NCT02911831,34:69:cancer,Patients with known or suspected endometrial/ovarian/cervical cancer
3827,NCT02911792,1:27:chronic_disease,major organ system disease
3828,NCT02911467,",30:70:chronic_disease","Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent"
3829,NCT02911467,",,29:38:chronic_disease,",bilirubin <1.5x ULN (unless Gilbert's is suspected in which case total bilirubin < 3 x ULN)
3830,NCT02911116,1:40:treatment,surgical sterilization (tubal ligation)
3831,NCT02910700,21:49:cancer,they have untreated leptomeningeal disease (LMD) as long as they fulfill all other eligibility requirements
3832,NCT02908906,45:57:cancer,Participants enrolled into Part 2 must have tumor tissue available for correlative studies
3833,NCT02908906,1:37:chronic_disease,psychiatric illness/social situation that would limited compliance with study requirements
3834,NCT02908841,6:28:treatment,open abdominal hysterectomy
3835,NCT02907983,",26:37:treatment",for women who refuse any oral therap
3836,NCT02907983,1:52:treatment,serotonin norepinephrine reuptake inhibitors (SNRI)
3837,NCT02905929,1:14:cancer,Active cancer
3838,NCT02905591,1:27:cancer,Exudative pleural effusion
3839,NCT02905578,97:131:treatment,"If all of the above are met, the potential participant will receive a 15 gram challenge dose of ascorbate via intravenous infusion. This is the final screening procedure"
3840,NCT02905370,1:25:chronic_disease,Congestive Heart Failure
3841,NCT02905370,1:23:chronic_disease,Gastrointestinal Bleed
3842,NCT02905370,1:28:chronic_disease,Peripheral Arterial Disease
3843,NCT02905188,11:47:treatment,Available autologous transduced T cell product
3844,NCT02903446,12:42:chronic_disease,History of osteonecrosis of the jaw (ONJ)
3845,NCT02903446,"1:21:chronic_disease,,,",Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)]
3846,NCT02901314,23:61:treatment,Currently enrolled in another experimental HF research study
3847,NCT02901067,27:56:allergy_name,Known contraindication to pharmacologic anticoagulation
3848,NCT02901041,18:30:allergy_name,Known allergy to sulfonamides
3849,NCT02900794,1:20:treatment,Prior sinus surgery
3850,NCT02898701,1:23:chronic_disease,acute medical problems
3851,NCT02895945,",69:92:chronic_disease",Participant has an ongoing or recent (within 3 months of screening) thrombo-embolic disease
3852,NCT02895945,"8:44:chronic_disease,,","Severe chronic liver dysfunction or disease (e.g., ? 5 × upper limit of normal [ULN] alanine aminotransferase [ALT], as confirmed by central laboratory at screening"
3853,NCT02891850,"26:43:chronic_disease,,",Patients with underlying medical disorders with an anticipated life expectancy below 2 years
3854,NCT02891447,1:29:cancer,Positive peritoneal cytology
3855,NCT02890485,19:42:treatment,Received previous dry needling treatments
3856,NCT02885649,1:15:cancer,Metastatic RCC
3857,NCT02881320,52:74:treatment,Individuals undergoing dose modifications to their antiretroviral regimen for growth or who are switching medication formulation(s) are considered to be on a stable antiretroviral regimen
3858,NCT02880215,8:47:treatment,stable psychiatric and neurological medication usage
3859,NCT02877381,73:76:allergy_name,"Patients scheduled for a head and liner/poly exchange, known allergy to TXA, acquired disturbances of color vision, refusal of blood products"
3860,NCT02876510,106:113:treatment,Patient is a candidate for a maximum of one further line of established therapy (prior to treatment with ACTolog)
3861,NCT02875405,1:16:chronic_disease,chest deformity
3862,NCT02875301,1:12:chronic_disease,Parkinson's
3863,NCT02875301,15:39:chronic_disease,not including general anxiety disorder
3864,NCT02873598,21:32:allergy_name,Contraindication to IV contrast
3865,NCT02871726,1:22:treatment,Prior prostate biopsy
3866,NCT02869789,26:73:cancer,Histologically confirmed Stage 4 or recurrent non-small cell lung cancer
3867,NCT02866279,1:28:chronic_disease,Polycystic Ovarian Syndrome
3868,NCT02864147,"50:76:cancer,","All Patients must have a histologic diagnosis of CIN 2,3 cervical lesion(s) confirmed by a study pathologist within past 10 weeks"
3869,NCT02864147,1:15:chronic_disease,cardiac issues as above
3870,NCT02863809,1:20:chronic_disease,Autoimmune diseases
3871,NCT02863809,41:58:chronic_disease,Inability to wear a contact lens due to lid abnormalities or shortened fornix
3872,NCT02863809,1:29:chronic_disease,systemic lupus erythematosis
3873,NCT02862938,17:36:chronic_disease,Participant has optic nerve atrophy beyond modest pallor
3874,NCT02862210,8:33:treatment,Use of antipsychotic medications
3875,NCT02860702,1:12:chronic_disease,Heterotaxia
3876,NCT02859142,33:50:allergy_name,History of adverse reactions to varenicline (VAR)
3877,NCT02857270,6:51:cancer,Have symptomatic central nervous system malignancy or metastasis
3878,NCT02857218,20:53:allergy_name,have an allergy to gadolinium (Gd) contrast material
3879,NCT02856412,1:20:chronic_disease,neurologic disorder
3880,NCT02852538,1:37:chronic_disease,Severe comorbid psychiatric disorder
3881,NCT02851914,1:29:chronic_disease,premorbid bipolar depression
3882,NCT02851407,"13:27:chronic_disease,",Patient has acute bleeding that is clinically significant within 24 hours before the start of study treatment
3883,NCT02849639,1:20:chronic_disease,Acid reflux disease
3884,NCT02848417,1:10:chronic_disease,Dementias of any type
3885,NCT02848417,1:24:chronic_disease,Primary sleep disorders
3886,NCT02847689,1:25:chronic_disease,Active seizure disorders
3887,NCT02847689,1:42:chronic_disease,Intraventricular Hemorrhage Grades III-IV
3888,NCT02846532,44:70:chronic_disease,History of or signs/symptoms suggestive of protein-losing enteropathy
3889,NCT02845596,24:38:chronic_disease,Confirmed diagnosis of idiopathic SAA
3890,NCT02845336,20:48:chronic_disease,Vision loss due to compressive optic neuropathy
3891,NCT02844465,",34:64:chronic_disease",MRI has evidence consistent with mesial temporal lobe sclerosis
3892,NCT02843568,51:67:chronic_disease,One biopsy site is adequate for multiple sites of thoracic disease
3893,NCT02842658,1:35:chronic_disease,Symptomatic severe aortic stenosis
3894,NCT02841540,24:54:chronic_disease,Known prior or current retinal or optic nerve disease
3895,NCT02840643,14:24:chronic_disease,Diagnosis of hemiplegia
3896,NCT02838797,"1:19:chronic_disease,,,,",active suicidality as measured by a most severe suicide ideation score of 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS)
3897,NCT02837510,1:20:treatment,Anti-anxiety agents
3898,NCT02837510,5:20:chronic_disease,any Axis 1 disorder
3899,NCT02836899,"1:35:treatment,,",Elective cardiac or aortic surgery with CPB>90 minutes
3900,NCT02836574,54:67:treatment,anatomic abnormalities that would interfere with the NKA injection procedure
3901,NCT02836574,44:70:treatment,"subject is not a good candidate to undergo percutaneous NKA injection, in the judgment of the surgeon or physician who will perform the procedure"
3902,NCT02834403,"23:32:treatment,",Patients who received docetaxel at any line of treatment within the past 12 months
3903,NCT02833792,12:29:cancer,History of cerebral neoplasm
3904,NCT02832167,16:49:cancer,Diagnosed with advanced or metastatic malignancy
3905,NCT02832115,8:23:chronic_disease,Severe Aortic Stenosis
3906,NCT02830074,",,102:110:chronic_disease",the investigators will offer to re-contact patients 90 days after a health event or after 90 days of sobriety
3907,NCT02829268,25:41:chronic_disease,definitive diagnosis of Wolfram syndrome
3908,NCT02828618,"17:51:cancer,,",newly diagnosed invasive epithelial ovarian cancer FIGO stage IIIB-IV
3909,NCT02826681,8:41:chronic_disease,Active acute or known chronic infections
3910,NCT02826577,30:33:treatment,Have a counter indication to EEG
3911,NCT02824276,"1:5:chronic_disease,",CLBP lasting for more than 6 months as the primary complaint
3912,NCT02823665,"1:18:chronic_disease,,",Hypoglycemic RYGB patients with documented blood glucose level <50 mg/dl
3913,NCT02822378,9:31:chronic_disease,current hypo- or hypercalcemia
3914,NCT02822378,"18:38:treatment,",systemic oral or transdermal estrogen within the past 3 months
3915,NCT02819843,",,76:102:treatment",History of high grade (CTCAE ? Grade 3) immune mediated adverse event from prior cancer immunotherapy
3916,NCT02819635,"10:37:treatment,",Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period
3917,NCT02819440,16:32:treatment,Current use of organic nitrates
3918,NCT02816736,1:24:chronic_disease,Symptomatic hypotension at randomization
3919,NCT02815917,20:63:treatment,Currently requires treatment with any psychoactive medications
3920,NCT02811263,1:21:chronic_disease,Perinatal depression based on at least one of the following
3921,NCT02808442,1:45:cancer,Active Central Nervous System (CNS) leukemia
3922,NCT02807883,17:33:chronic_disease,Medications for GVHD prophylaxis
3923,NCT02807272,19:76:treatment,Concurrent use of granulocyte macrophage colony-stimulating factor (GM-CSF)
3924,NCT02805504,12:23:allergy_name,Allergy to bupivacaine
3925,NCT02804230,1:39:chronic_disease,Lesions in the brainstem or cerebellum
3926,NCT02803359,12:25:allergy_name,Allergy to Oxymetazoline
3927,NCT02803359,12:30:chronic_disease,History of Neurologic Disease
3928,NCT02803164,8:31:chronic_disease,Patent bronchopleural fistulas
3929,NCT02802176,1:68:chronic_disease,"Vaginal inflammation or genital (vaginal, uterine, tubal) infection"
3930,NCT02801136,84:88:chronic_disease,Family member (parent if a minor) willing to participate and that the subject with PNES chooses
3931,NCT02799095,59:68:allergy_name,Subjects with known hypersensitivity to any components of ALKS 4230
3932,NCT02798458,1:29:treatment,Endoscopic mucosal resection
3933,NCT02796391,1:21:treatment,Clopidogrel (Plavix)
3934,NCT02796391,1:20:chronic_disease,Fluvoxamine (Luvox)
3935,NCT02796391,1:4:treatment,THC will be tested but will not be an exclusionary criterion
3936,NCT02796209,1:22:treatment,Effexor (venlafaxine)
3937,NCT02796209,1:23:treatment,Wellbutrin (Bupropion)
3938,NCT02793921,5:26:treatment,Any breast cancer surgery complications
3939,NCT02793921,52:78:chronic_disease,other symptoms that indicate increased risk for an acute cardiovascular event
3940,NCT02792257,16:23:treatment,Current use of lithium
3941,NCT02789228,15:25:chronic_disease,Patients with active HIV
3942,NCT02784535,1:10:chronic_disease,urticaria
3943,NCT02781103,12:27:chronic_disease,History of Hunner's lesion in the medical record
3944,NCT02780401,1:39:chronic_disease,Symptomatic restrictive cardiomyopathy
3945,NCT02779244,1:11:chronic_disease,Polytrauma patients
3946,NCT02778867,6:31:chronic_disease,Have pathological eosinophilia in segments of the GI tract other than the esophagus determined by local review
3947,NCT02778529,1:15:chronic_disease,Cerebral palsy participants
3948,NCT02778282,21:44:treatment,Seeking to initiate buprenorphine treatment or currently receiving buprenorphine treatment but had recent positive illicit opioid urine toxicology or missed scheduled urine toxicology
3949,NCT02776761,12:37:chronic_disease,history of severe allergic reactions
3950,NCT02775162,5:34:chronic_disease,has acute/fulminant liver failure
3951,NCT02774421,1:13:cancer,mixed glioma
3952,NCT02772562,1:42:treatment,Prior solid organ or stem cell transplant
3953,NCT02772302,1:16:chronic_disease,Locked-in state
3954,NCT02771626,1:58:chronic_disease,Active known or suspected exclusionary autoimmune disease
3955,NCT02770547,1:38:chronic_disease,Chronic Obstructive Pulmonary Disease
3956,NCT02770547,1:12:chronic_disease,paresthesia in the legs
3957,NCT02770326,9:38:chronic_disease,Serious cardiopulmonary comorbidities
3958,NCT02769611,15:49:chronic_disease,Patients with uncontrolled arterial hypertension
3959,NCT02768727,23:46:chronic_disease,Current or history of chronic sleep disorders
3960,NCT02767518,24:38:treatment,Medical clearance from cardiothoracic surgeon
3961,NCT02765633,"38:62:chronic_disease,,,,,,,,",Participants with evidence of severe hepatic or renal failure [aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three times normal for age or total bilirubin greater than 20 milligrams (mg)/deciliter (dL); creatinine greater than 2 times the normal upper limit]
3962,NCT02765425,24:63:chronic_disease,Significant history of cardiac or peripheral vascular problems that would preclude seated ankle exercises
3963,NCT02764801,1:36:chronic_disease,unstable cardiopulmonary conditions
3964,NCT02763917,1:18:chronic_disease,Persistent asthma (NAEPP criteria)
3965,NCT02763033,52:109:treatment,Subjects undergoing matched related full intensity allogeneic HSCT (hematopoietic stem cell transplantation)
3966,NCT02762773,40:61:treatment,Patients who are expected to receive a Pfannenstiel incision
3967,NCT02762266,"1:30:chronic_disease,",Active gastrointestinal bleed within 2 weeks of study enrollment
3968,NCT02762266,1:36:treatment,Prior radiofrequency ablation (RFA) to index lesion
3969,NCT02762032,1:19:treatment,Hydochlorothiazide
3970,NCT02762006,1:31:chronic_disease,controlled atrial fibrillation
3971,NCT02759575,18:42:chronic_disease,Known history of active tuberculosis (TB)
3972,NCT02759146,14:34:chronic_disease,Diagnosis of major mental illness on the medical record (verified by the recruiter)
3973,NCT02755896,",35:60:treatment",Post-menopausal women with status post segmental mastectomy
3974,NCT02755116,1:22:chronic_disease,Narrow angle glaucoma
3975,NCT02752191,38:56:treatment,other causes (for subjects receiving Feraheme injection only)
3976,NCT02750319,",38:63:treatment",Patients ?18 years old scheduled for elective thoracic surgery
3977,NCT02749786,"8:66:treatment,",Use of topical prescription medications or procedures to the face within one month of enrollment
3978,NCT02748070,1:44:chronic_disease,chronic rhinosinusitis with polyps (CRSwNP)
3979,NCT02747238,7:25:chronic_disease,Known spinal deformities
3980,NCT02746458,12:82:chronic_disease,History of Peripheral Artery Disease and/or Peripheral Vascular Disease (PAD/PVD)
3981,NCT02746458,1:12:treatment,Skin grafts in which all bleeding points must be readily distinguished
3982,NCT02744911,1:23:treatment,Bilateral hearing aids (since one free ear is required for use of the SpeechVive device)
3983,NCT02744430,4:29:treatment,On immunosuppressant therapy
3984,NCT02744391,",45:133:treatment","Current or recent (within the past 4 weeks) treatment with antidepressants, antipsychotics, dopaminergic agents, or mood stabilizers"
3985,NCT02743728,1:50:chronic_disease,Disorders of Cellular Migration and Proliferation
3986,NCT02743637,30:54:treatment,Patients that have undergone organ transplant surgery
3987,NCT02741791,51:76:treatment,History of inadequate response to 1 or 2 adequate antidepressant treatments
3988,NCT02740543,",,28:46:treatment",FEV1 <60% predicted normal pre-bronchodilator
3989,NCT02740361,"9:24:treatment,",started pharmacotherapy for depression within the last 2 months
3990,NCT02738749,9:46:chronic_disease,have an acute or chronic inflammatory illness that might alter white cell mRNA expression
3991,NCT02737202,10:30:treatment,Previous lung transplantation
3992,NCT02734134,1:18:chronic_disease,Fungal infections
3993,NCT02730481,",56:77:treatment",Have not recovered to ? Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs)
3994,NCT02728050,11:38:cancer,high-risk myeloproliferative neoplasm
3995,NCT02726347,",,,122:146:chronic_disease",individuals between the age of 19 and 80 who have a history of frequent bacterial infections and are being evaluated for humoral immunodeficiency
3996,NCT02725567,"57:81:treatment,",Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks before Day 1
3997,NCT02724540,22:49:treatment,Contraindications to hepatic artery embolization
3998,NCT02724540,1:34:cancer,morphologically progressive tumor by RECIST
3999,NCT02723994,1:14:cancer,CNS3 leukemia
4000,NCT02723994,1:30:treatment,Systemic steroid pretreatment without presteroid WBC documentation
4001,NCT02721303,63:79:treatment,Use of any medication known to significantly affect appetite (anti-depressants are allowable)
4002,NCT02719327,39:54:treatment,Use of medications that interact with icosapent ethyl
4003,NCT02715583,"1:30:treatment,",Systemic radioisotope therapy within 24 weeks prior to study enrollment
4004,NCT02710968,"1:20:chronic_disease,,",Maternal depression as assessed by a Beck Depression Inventory score equal to or greater than 17
4005,NCT02709980,1:31:chronic_disease,psychiatric comorbid condition
4006,NCT02707692,12:34:chronic_disease,History of Gullian Barre syndrome
4007,NCT02706288,1:26:chronic_disease,Polycystic ovary syndrome
4008,NCT02703220,"15:33:chronic_disease,,",Patients with severe sleep apnea (AHI>20/hr)
4009,NCT02700451,1:21:chronic_disease,Peptic Ulcer Disease
4010,NCT02700178,20:30:chronic_disease,disease leading to paraplegia
4011,NCT02695043,25:42:chronic_disease,Significant symptoms of receptive aphasia
4012,NCT02693990,30:59:chronic_disease,Patients may or may not have neurofibromatosis type 1 or 2
4013,NCT02690116,"14:21:chronic_disease,,",Experiencing fatigue (scoring < 75 on Vitality scale of Short Form (SF)-36)
4014,NCT02688647,"1:25:chronic_disease,,",Obstructive lung disease: FEV1/ FVC ratio < 0.70
4015,NCT02688569,22:66:treatment,"participation in any nonpharmacological treatment (including CBT) for pain, sleep, fatigue, or mood outside the current study"
4016,NCT02687906,43:65:allergy_name,Known significant hypersensitivity to any beta-lactam antibiotic
4017,NCT02687464,39:47:cancer,presentation with an appendix mass or phlegmon (on physical examination and/or imaging)
4018,NCT02685605,10:35:treatment,Previous cranial radiation therapy
4019,NCT02682407,"33:57:chronic_disease,",Have systemic manifestations of Henoch-Schonlein purpura within 2 years prior to Screening
4020,NCT02680574,1:21:chronic_disease,Severe heart failure at Screening (New York Heart Association Class IV)
4021,NCT02680535,",50:58:treatment",Prior MRI results dated within 120 days prior to ablation
4022,NCT02680535,1:25:cancer,seminal vesicle invasion
4023,NCT02678910,21:54:cancer,Participants with a large cancerous mass in the ovary that is being removed; cryopreservation will not be performed on portions of the ovary
4024,NCT02674984,"8:18:treatment,",Use of probiotics in the last 90 days
4025,NCT02674529,1:14:chronic_disease,schizophrenic
4026,NCT02671435,25:53:treatment,Subjects must be at the recurrent/metastatic setting
4027,NCT02670837,5:31:treatment,Off immune suppressive therapy
4028,NCT02669173,1:55:chronic_disease,Active infection with hepatitis B or hepatitis C virus
4029,NCT02667418,"36:65:treatment,",Anticipation of need for long term systemic antibiotic treatment (beyond 7 days)
4030,NCT02667418,8:13:chronic_disease,severe ileus
4031,NCT02666378,31:47:treatment,Scheduled to receive standard clinical therapy designed by their treating oncologist
4032,NCT02665338,28:44:chronic_disease,Life time history of major Axis I disorders
4033,NCT02664909,12:22:chronic_disease,History of hemophilia
4034,NCT02664909,6:23:chronic_disease,with coronary ischemia
4035,NCT02663934,1:21:chronic_disease,behavioral disorders that would prevent ability to follow the protocol
4036,NCT02663596,1:43:treatment,CVVH-continuous veno-venous hemofiltration
4037,NCT02660528,"1:37:chronic_disease,,,",Abnormal thyroid-stimulating hormone (TSH <0.4 or >5.0mlU/L)
4038,NCT02660528,21:59:treatment,having received the Bacillus Calmette-Guérin (BCG) vaccine
4039,NCT02658565,37:58:chronic_disease,"Preoperative evaluation to rule-out extra-uterine disease may include CT scan, MRI, or ultrasound"
4040,NCT02657993,"1:30:treatment,",Non-steroidal joint injection within the last 3 months
4041,NCT02655692,12:30:chronic_disease,history of severe head injury
4042,NCT02652247,",,,,,,160:188:chronic_disease,,,,","Conditions limiting the subject's ability to tolerate collection of lavage specimens, including: FIO2 > 80%; PEEP > 16 cmH2O; Intracranial pressure >20 cmH2O; Tracheal or mucosal bleeding; Platelet count < 20,000 cells/uL; INR > 2.0"
4043,NCT02650206,1:32:chronic_disease,Pancreatitis (acute or chronic)
4044,NCT02648347,"5:37:treatment,",Any erythropoietic stimulating agent within 8 weeks prior to randomization
4045,NCT02646930,10:37:treatment,previous uterine artery embolization
4046,NCT02645539,",25:34:treatment",Receiving more than two inotropes
4047,NCT02642640,12:26:chronic_disease,History of sleep disorder or regular use of sleep-promoting medication
4048,NCT02640950,"29:47:chronic_disease,,",The duration of the current depressive episode must be at least 4 weeks and no longer than 3 years in length
4049,NCT02640638,"1:15:chronic_disease,,",Morbid Obesity with BMI >49.99
4050,NCT02639390,"1:31:chronic_disease,",Ischemic or hemorrhagic stroke (with confirmatory neuroimaging) that occurred more than 6 months before entering the study
4051,NCT02639065,32:42:allergy_name,History of hypersensitivity to durvalumab or any excipient
4052,NCT02638935,",12:27:treatment",Women with breast implants on the same side as the lesion
4053,NCT02638454,1:30:treatment,Angiotensin receptor blockers
4054,NCT02637349,1:15:chronic_disease,"Severe illness that would preclude conversation or interface with a computer (e.g.,persistent nausea/vomiting, severe pain)"
4055,NCT02636283,26:51:chronic_disease,"Subject with symptoms of intermittent claudication, such as exercise-induced pain, cramps, fatigue, or other equivalent discomfort, involving large muscle groups of the leg(s) (calf, thigh, buttocks), relieved by rest"
4056,NCT02634957,1:10:cancer,Dysplasia
4057,NCT02634957,1:30:cancer,SCC (squamous cell carcinoma)
4058,NCT02633111,32:59:cancer,Histology-confirmed aggressive B-cell Non-Hodgkin lymphoma
4059,NCT02632422,29:42:chronic_disease,non-progressive etiology of spinal injury
4060,NCT02631850,"11:24:treatment,",Receiving Botox therapy currently or in the past 3 months
4061,NCT02628535,"1:15:chronic_disease,",GI perforation within 1 year
4062,NCT02624765,1:21:treatment,Antiarrhythmic drugs
4063,NCT02624765,31:57:chronic_disease,Relevant preexisting maternal obstructive airway disease
4064,NCT02624765,"1:38:chronic_disease,,",severe congenital fetal abnormalities (T 13 or 18; surgery or death expected < 1 month)
4065,NCT02624518,1:32:treatment,Post radical prostatectomy (RP)
4066,NCT02624258,"1:38:treatment,","Anti-CD20 monoclonal antibody therapy within the last 3 months, or absence of circulating B cells"
4067,NCT02624258,23:38:allergy_name,History of allergy to murine proteins
4068,NCT02622984,14:31:treatment,Currently in alcohol treatment
4069,NCT02622295,1:21:chronic_disease,Deep vein thrombosis
4070,NCT02620761,14:25:treatment,Infants with antenatally
4071,NCT02620579,1:25:chronic_disease,nonallergic bronchospasm
4072,NCT02617589,11:37:cancer,Any known tumor outside of the brain
4073,NCT02615249,"1:73:treatment,",Topical treatment with corticosteroids or other immunosuppressive agents on or near the test area during the 14 days prior to inclusion in this study
4074,NCT02613936,5:17:chronic_disease,any skull defect
4075,NCT02611427,47:62:chronic_disease,Patients will be excluded if they had any new cardiopulmonary symptoms since surgery
4076,NCT02610374,"8:49:treatment,",Use of systemic (oral or parenteral) antibiotics within two months prior to study entry
4077,NCT02607748,1:54:chronic_disease,Multiple premature ventricular or atrial contractions
4078,NCT02606396,20:40:chronic_disease,Prior diagnosis of esophageal achalasia
4079,NCT02606045,1:40:chronic_disease,Mild or moderate von Willebrand disease
4080,NCT02604277,12:38:chronic_disease,History of mood incongruent psychotic symptoms
4081,NCT02600897,",41:56:cancer",Histologically documented CD20-positive B-cell lymphoma as determined by the local laboratory
4082,NCT02600026,1:20:chronic_disease,language impairment that would interfere with the ability to participate in the educational intervention
4083,NCT02598713,1:18:chronic_disease,Status asthmatics
4084,NCT02595996,1:21:chronic_disease,Secondary lymphedema
4085,NCT02595372,1:27:treatment,Dexlansoprazole (Dexilant)
4086,NCT02595372,1:19:treatment,Prior hysterectomy
4087,NCT02594384,1:38:cancer,diffuse large B-cell lymphoma (DLBCL)
4088,NCT02594111,"1:11:treatment,",Colchicine use within 1 month
4089,NCT02594111,1:13:treatment,ketoconazole
4090,NCT02593526,",,52:68:treatment",Life expectancy <6 months or intention to withdraw dialysis therapy within 6 months
4091,NCT02593123,1:22:cancer,Hodgkin lymphoma (HL)
4092,NCT02593123,1:44:treatment,Previous therapeutic radiation therapy (RT) that exceeds critical structure tolerance doses as determined by a radiation oncologist
4093,NCT02593123,"1:35:treatment,",previous treatment with equine ATG is allowed if more than 3 months ago
4094,NCT02593110,12:16:allergy_name,Allergy to ARBs
4095,NCT02593110,1:23:chronic_disease,critical limb ischemia
4096,NCT02592707,14:24:chronic_disease,Diagnosis of thymic NET
4097,NCT02592551,32:40:allergy_name,History of hypersensitivity to MEDI4736 or any excipient
4098,NCT02592551,"12:21:treatment,",Receipt of sunitinib within 3 months of receiving tremelimumab
4099,NCT02592291,1:42:chronic_disease,severe and persistent psychiatric illness
4100,NCT02589977,1:31:chronic_disease,primary pulmonary hypertension
4101,NCT02589938,36:57:treatment,Over the counter products used for salivary substitution
4102,NCT02589522,102:108:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970
4103,NCT02589340,6:29:chronic_disease,Have proprioceptive deficits
4104,NCT02588664,1:47:chronic_disease,subdural or aneurysmal subarachnoid hemorrhage
4105,NCT02588391,1:30:chronic_disease,"Major neurosensory impairment (i.e., blind, deaf) or technology dependence (i.e., ventilator dependent) that interferes with testing"
4106,NCT02588326,1:12:chronic_disease,common cold
4107,NCT02588027,28:53:treatment,Patients with a history of prior rotator cuff repair
4108,NCT02587598,20:33:treatment,Prior receipt of a PIM inhibitor
4109,NCT02585973,1:16:chronic_disease,HPV (-) disease
4110,NCT02585973,1:28:cancer,non-invasive bladder cancer
4111,NCT02585232,34:42:chronic_disease,Dyads experiencing low levels of distress
4112,NCT02584647,33:82:cancer,"Phase 2: Advanced, unresectable malignant peripheral nerve sheath tumors (MPNSTs)"
4113,NCT02584309,1:20:cancer,Epithelioid sarcoma
4114,NCT02584309,1:31:cancer,Malignant fibrous histiocytoma
4115,NCT02584309,1:17:cancer,Synovial sarcoma
4116,NCT02584270,28:65:treatment,Patients with a history of prior head and neck radiation therapy
4117,NCT02584244,",,,,,192:222:treatment","Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) starting the day entering the study, and for 60 days after injection of the imaging agent"
4118,NCT02583893,15:47:chronic_disease,Subjects with uncontrolled high blood pressure
4119,NCT02582957,32:62:treatment,Lack of availability of Dräger Evita Infinity V500 ventilator as this is the only ventilator capable of delivering sigh breaths as described in the protocol
4120,NCT02582827,74:93:allergy_name,History of allergy or hypersensitivity to any of the constituents of the ABI-011 formulation
4121,NCT02582827,",,,,,241:267:treatment,",QTc prolongation defined as a QTc interval according to Bazett's formula of ? 450 msec for male patients or ?470 msec for female patients at Baseline. Interval determination will be based on a mean value obtained from 3 sequential baseline electrocardiographs (ECGs) obtained at least 5 minutes apart
4122,NCT02581982,18:27:chronic_disease,Known history of active TB
4123,NCT02581787,12:29:cancer,history of basal cell cancer is allowed
4124,NCT02581384,1:33:treatment,focal radiotherapy to the thorax
4125,NCT02580604,20:45:treatment,Currently taking a bisphosphonate medication
4126,NCT02580162,1:31:chronic_disease,Physical disability or illness in either the participating parent or the child that precludes moderate intensity physical activity
4127,NCT02579265,1:16:chronic_disease,Bell's stage 2B or higher
4128,NCT02579265,7:34:chronic_disease,Known inborn errors of metabolism
4129,NCT02579265,1:26:chronic_disease,necrotizing enterocolitis
4130,NCT02579174,60:71:treatment,Ligamentous instability that may necessitate a constrained TKR implant
4131,NCT02579096,34:77:treatment,Patients with a history of prior solid organ / hematopoietic transplantation
4132,NCT02579044,",,109:134:treatment",It is permissible for female subjects to take oral contraceptives or other hormonal methods while receiving treatment with everolimus
4133,NCT02578901,10:33:chronic_disease,Acquired storage pool deficiency
4134,NCT02578641,1:22:treatment,Adjuvant chemotherapy
4135,NCT02578641,1:40:treatment,Prior radiotherapy with curative intent
4136,NCT02578641,1:29:chronic_disease,ischemic heart disease (IHD)
4137,NCT02577731,15:38:chronic_disease,Patients with End Stage Renal Disease
4138,NCT02577549,33:52:chronic_disease,Knee Pain plus ACR Criteria for Knee Osteoarthritis
4139,NCT02577406,1:32:cancer,Carcinoma in situ of the cervix
4140,NCT02577406,65:78:treatment,"Subject is eligible for and willing to receive the pre-selected CCR treatment option, according to the investigator's assessment"
4141,NCT02576444,41:59:treatment,"Patients with concomitant use of drugs, herbal supplements and/or ingestion of foods known to strongly modulate CYP3A4 enzyme activity as specified in the drug specific appendix"
4142,NCT02576444,"1:24:treatment,",Whole blood transfusion in the last 120 days prior to entry to the study
4143,NCT02575404,41:60:treatment,Patients who have previously received a galectin antagonist
4144,NCT02574728,1:22:cancer,optic pathway gliomas
4145,NCT02574650,1:13:chronic_disease,NYHA II - IV
4146,NCT02574455,21:111:treatment,Prior exposure to a taxane (paclitaxel or docetaxel)-based regimen in localized or advanced/metastatic setting
4147,NCT02573883,1:34:treatment,Previous pelvic radiation therapy
4148,NCT02573597,1:11:chronic_disease,ASA I & II
4149,NCT02573493,15:24:cancer,Patients with T1 tumors
4150,NCT02572856,19:43:treatment,Scheduled to have elective general surgery at UW Medical Center
4151,NCT02570984,"13:42:treatment,",Enrolled in any clinical medication trial within the past 30 days
4152,NCT02570984,1:27:chronic_disease,chronic pulmonary diseases
4153,NCT02570854,23:29:treatment,Patients who received CSJ137 dose in the pas
4154,NCT02570321,1:14:chronic_disease,Corneal ulcer that is smear positive for either bacteria or filamentous fungus
4155,NCT02570256,1:7:chronic_disease,STROKE SURVIVORS
4156,NCT02568267,20:31:treatment,Ability to swallow entrectinib intact
4157,NCT02568267,25:62:cancer,Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene rearrangement of interest may be eligible
4158,NCT02567448,"1:27:treatment,",chest or abdominal surgery in the past three months
4159,NCT02567422,1:10:cancer,Carcinoma of the neck of unknown primary site origin (regardless of HPV/p16 status)
4160,NCT02567422,1:26:cancer,nasopharyngeal carcinomas
4161,NCT02566928,39:43:chronic_disease,presents with signs and symptoms of a SSTI
4162,NCT02565901,"22:49:treatment,","Administration of an investigational therapeutic within 30 days of cycle 1, day -2"
4163,NCT02565901,4:18:cancer,In situ carcinoma of any site
4164,NCT02565901,1:31:cancer,neuroendocrine differentiation
4165,NCT02565498,24:66:treatment,Deemed appropriate for preoperative or postoperative radiotherapy
4166,NCT02565446,1:32:treatment,ventriculoperitoneal (VP) shunt
4167,NCT02564978,",,,,,,377:405:treatment","Any female participant of childbearing potential (see Appendix 1 for definition) and any male participant able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent* from intercourse or must agree to practice two acceptable methods of contraception throughout the course of the study and for at least one week after investigational product (IP) discontinuation"
4168,NCT02564978,57:60:chronic_disease,Participant must have evidence of early or intermediate AMD as defined by characteristic presence of drusen and/or pigmentary changes
4169,NCT02564978,",98:105:chronic_disease",The study eye must have at least (Omega) disc area (approximately 1 mm(2)) of GA compatible with dry AMD
4170,NCT02564796,26:40:chronic_disease,Infants with significant co-morbidities
4171,NCT02564744,79:97:treatment,"For Part 2 and Part 3 of the study, participants that are eligible to undergo first time HD-ASCT"
4172,NCT02564744,25:40:treatment,"Prior treatment with an anti-CD20 agent, either alone or in combination, is allowed"
4173,NCT02563678,"1:18:treatment,",Hyperbaric oxygen exposure within the last 30 days
4174,NCT02563678,"63:94:treatment,",Time interval between removal from carbon monoxide source and first hyperbaric oxygen session >12 hours
4175,NCT02562755,1:14:cancer,Bulky disease patients
4176,NCT02562716,"20:36:treatment,",Patients must have surgical consult to verify patient is a surgical candidate within 21 days prior to registration
4177,NCT02562430,53:61:allergy_name,History of inadequate response/poor tolerability to bupropio
4178,NCT02562235,1:26:chronic_disease,Connective tissue disease
4179,NCT02562235,"1:13:treatment,,",Pretreatment with NO donors (e.g. nitrates) within the last 2-weeks before visit 1
4180,NCT02562040,24:26:chronic_disease,"Primary indication for AT is nocturnal obstructive symptoms (i.e., not recurrent infections or other indications)"
4181,NCT02561988,1:17:cancer,Brain malignancy
4182,NCT02561988,1:7:cancer,SM-AHN
4183,NCT02561104,40:54:chronic_disease,"Active, significant external ocular or eyelid disease"
4184,NCT02561104,13:27:treatment,presence of cornea implant
4185,NCT02560623,21:45:chronic_disease,Subjects with known Barrett's Esophagus (BE)
4186,NCT02559817,28:37:treatment,willing to discontinue any laxatives used before the Pretreatment Visit in favor of the protocol-permitted rescue medicine
4187,NCT02558010,1:21:chronic_disease,Idiopathic scoliosis
4188,NCT02557321,1:71:cancer,"Stage IV or Stage III (unresectable, in-transit or satellite) melanoma"
4189,NCT02556606,85:104:treatment,"Past intolerance or hypersensitivity to ketamine, or history of recreational use of phencyclidine (PCP) or ketamine"
4190,NCT02555280,"1:22:chronic_disease,,",Mild lumbar scoliosis (Cobb angle up to 25º)
4191,NCT02555280,17:35:cancer,Patients with a primary bony tumor
4192,NCT02555280,8:25:chronic_disease,Severe facet hypertrophy that requires extensive bone removal which would cause instability
4193,NCT02555280,1:11:chronic_disease,osteopenia
4194,NCT02555189,"1:64:treatment,","Prior isotope therapy with strontium-89, samarium or radium-223 within 12 weeks of enrollment"
4195,NCT02554903,",80:93:treatment",negative serum pregnancy test result during the Screening period (Visit 1) and Randomization (Visit 2)
4196,NCT02554383,12:35:allergy_name,Allergy to amoxicillin-clavulanate
4197,NCT02554253,1:26:chronic_disease,immunodeficiency syndrome
4198,NCT02553941,1:64:treatment,Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor
4199,NCT02553642,1:23:treatment,Prior therapy with BCG
4200,NCT02553265,24:26:chronic_disease,Confirmed diagnosis of FD (genetic testing)
4201,NCT02553265,43:69:allergy_name,Patients with a known hypersensitivity to any component of this drug
4202,NCT02553161,1:20:chronic_disease,Tourette's disorder
4203,NCT02551679,9:33:treatment,Chronic cytotoxic drug treatment
4204,NCT02551679,39:72:chronic_disease,Severe concurrent disease (other than Peripheral Vascular Disease (PAD)
4205,NCT02551679,13:42:chronic_disease,Uncorrected aorto-iliac occlusive disease
4206,NCT02549833,34:51:chronic_disease,History or clinical suspicion of neurofibromatosis
4207,NCT02548351,"24:28:chronic_disease,",Histologic evidence of NASH upon central read of a liver biopsy obtained no more than 6 months before Day 1 defined by presence of all 3 key histological features of NASH according to NASH CRN criteria
4208,NCT02548104,1:19:chronic_disease,Systemic infection
4209,NCT02547818,"1:23:treatment,",Investigational agents are prohibited one month prior to entry and for the duration of the trial
4210,NCT02547818,8:32:treatment,Taking inhaled protein products on a chronic basis
4211,NCT02547662,",,146:160:treatment","Diarrhea > grade 1, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading, in the absence of antidiarrheals"
4212,NCT02546583,",,46:56:treatment",Study Visit 1 loop diuretic dose ? 160 mg of furosemide equivalents
4213,NCT02544503,8:24:treatment,Use of CNS active drugs
4214,NCT02544373,27:38:treatment,Unwillingness to initiate PAP therapy if clinically indicated
4215,NCT02543944,1:23:chronic_disease,3rd degree heart block
4216,NCT02543944,21:74:chronic_disease,pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic)
4217,NCT02543866,32:56:chronic_disease,Lack of intestinal carriage of ESC-R Enterobacteriaceae (negative selective stool culture for ESC-R Enterobacteriaceae)
4218,NCT02542657,45:73:cancer,Definite development of new bone lesions or extramedullary plasmacytomas or definite increase in the size of existing bone lesions or extramedullary plasmacytomas
4219,NCT02541955,20:67:treatment,Stable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs)
4220,NCT02541903,15:63:cancer,Patients with metastatic or locally advanced unresectable PSCC
4221,NCT02541565,1:35:treatment,positron emission tomography (PET)
4222,NCT02540330,14:26:allergy_name,Allergies to imaging dyes
4223,NCT02540330,1:11:cancer,Non-Ductal Pathology: Lobular or Colloid type presence
4224,NCT02539160,8:29:chronic_disease,Active pathological bleeding
4225,NCT02538198,15:60:cancer,"Patients with progressive or refractory plasma cell myeloma, as defined by International Myeloma Workshop Consensus Panel criteria"
4226,NCT02536794,12:44:chronic_disease,History of primary immunodeficiency disease
4227,NCT02536794,",27:59:treatment",within 12 months of their last adjuvant systemic treatment
4228,NCT02535832,1:13:chronic_disease,Severe edema
4229,NCT02535325,16:37:treatment,The effects of methoxyamine (TRC102) on the developing human fetus are unknown
4230,NCT02535312,1:25:treatment,anti-seizure medications are eligible to participate
4231,NCT02535286,1:25:cancer,Richter's Transformation
4232,NCT02533674,1:32:chronic_disease,Concomitant diseases/conditions
4233,NCT02533674,1:35:cancer,Non-small cell lung cancer (NSCLC)
4234,NCT02533674,1:18:cancer,Urothelial cancer
4235,NCT02532621,53:88:chronic_disease,Subject has a documented and unsuccessfully treated ipsilateral central venous stenosis as determined by imaging
4236,NCT02532543,",,185:209:chronic_disease","Teeth adjacent (mesial and distal) to study site must consist of two stable natural teeth with minimal restorations, without signs of periodontal bone loss (> 3 mm) and/or significant soft tissue deficiencies"
4237,NCT02531932,71:95:treatment,Patient should also avoid close contact with others who have received live attenuated vaccines
4238,NCT02531711,1:22:chronic_disease,Cognitive dysfunction preventing informed consent
4239,NCT02530463,",,,155:188:treatment",Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and a period of 31 weeks after the last dose of investigational drug
4240,NCT02530073,8:17:treatment,Normal Karyotype
4241,NCT02530034,1:49:cancer,chronic myeloid leukemia in blast phase (CML-BP)
4242,NCT02527421,1:13:treatment,PUVA therapy
4243,NCT02527265,"23:53:treatment,",Currently receiving a regimen of basal/bolus insulin administered by MDI for at least 6 weeks prior to enrollment
4244,NCT02526511,38:45:allergy_name,Subjects with established allergy to IV GBCA
4245,NCT02525029,16:45:cancer,Diagnosis of a hormone responsive malignancy
4246,NCT02524379,"22:30:treatment,",Known treatment with Bosentan within past 7 days
4247,NCT02522871,1:44:treatment,Prior solid organ or bone marrow transplant
4248,NCT02522715,1:10:treatment,Flutamide; approximate half-life: 6 hours; washout period required: 36 hours
4249,NCT02522715,23:34:treatment,may not have received cabazitaxel in the past
4250,NCT02522429,1:14:treatment,deep sedation
4251,NCT02521103,22:49:treatment,Patient has a failed unicondylar knee prosthesis
4252,NCT02520791,"25:43:treatment,",Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment
4253,NCT02520791,1:9:chronic_disease,Vitiligo
4254,NCT02520778,23:46:treatment,be treatment naive to T790M-directed EGFR TKI
4255,NCT02520713,25:41:cancer,Histologic diagnosis of solid malignancy
4256,NCT02520713,25:44:treatment,Patient has already had molecular profiling
4257,NCT02520427,28:51:treatment,"Unresolved toxicities from prior antitumor therapy, defined as not having resolved to CTCAE, version 4.0 grade 1"
4258,NCT02520011,",36:48:treatment",Received >360 mg/m2 equivalents of daunorubicin
4259,NCT02519543,13:26:chronic_disease,presence of rapid cycling (by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5 criteria)
4260,NCT02519452,",70:90:treatment",Prior treatment with less than or equal to (>=) 2 treatment lines of anti-myeloma therapy
4261,NCT02519452,"26:69:treatment,",participant has received autologous stem cell transplantation (ASCT) within 12 weeks before Cycle 1 Day 1
4262,NCT02519322,5:33:treatment,the 28-8 clone for PD-L1 testing is required for assessment of PD-L1 status
4263,NCT02518594,"20:44:treatment,,",Cervical length on transvaginal examination of less than 30 mm within 10 days prior to randomization by a study certified sonographer
4264,NCT02518594,"18:46:treatment,",Participation in another interventional study that influences gestational age at delivery or neonatal morbidity or mortality
4265,NCT02516813,66:80:treatment,Measurable or evaluable disease by RECIST v1.1 (not required for ancillary cPoP part of the study)
4266,NCT02516462,",,,98:129:treatment",Infertile women of advanced maternal age (>35 years) who desire to conceive and come to CCRM for infertility treatment using IVF
4267,NCT02515708,92:128:treatment,Liver in which the investigator is unwilling or unable (for logistical reasons) to perform normothermic machine perfusion (NMP) preservation
4268,NCT02515110,1:23:treatment,Bilateral oophorectomy
4269,NCT02514915,23:50:cancer,Patients must have an extra-cranial primary tumor diagnosis
4270,NCT02514083,10:26:chronic_disease,Impaired hepatic function
4271,NCT02513797,"20:51:treatment,",Based on screening computed tomography angiography performed within 90 days prior to study intervention as confirmed by the core lab
4272,NCT02513797,",,35:58:treatment",LA diameter > 6 cm as measured by computerized tomography and confirmed by the imaging core laboratory
4273,NCT02512926,",,,64:83:treatment",ANC ? 750 - cannot be transfused (must be ? 72 hours from last neutrophil infusion)
4274,NCT02512926,1:25:treatment,Myelosuppressive therapy
4275,NCT02512718,12:59:treatment,History of parenteral nutrition use with SOLE prior to HCT
4276,NCT02512497,"50:66:chronic_disease,,,,","An EKG recorded at screening showing evidence of cardiac ischemia (ST depression depression of >/= 2 mm, measured from isoelectric line to the ST segment)"
4277,NCT02512497,17:30:treatment,stable doses of beta-blockers
4278,NCT02510456,26:46:treatment,No contraindications for primary chemotherapy
4279,NCT02509507,1:13:cancer,Liver tumors must not be estimated to invade approximately more than one-third of the liver
4280,NCT02509507,"15:37:treatment,",have received live-virus vaccination within 30 days of planned treatment start
4281,NCT02509260,1:21:treatment,intestinal resection
4282,NCT02508467,65:68:treatment,"For Part 3, the patient has not received prior treatment with a TKI"
4283,NCT02508311,",,,45:56:chronic_disease",Neurological level of injury between C3-C8 (Tetraplegia)
4284,NCT02508038,57:76:treatment,Is free from communicable disease risks associated with xenotransplantation
4285,NCT02508038,6:14:chronic_disease,RPR (Syphilis TP)
4286,NCT02508038,8:46:chronic_disease,active Central Nervous System (CNS) infection
4287,NCT02507505,31:48:allergy_name,Absolute contraindications to spinal anesthesia
4288,NCT02507011,46:66:treatment,Patient can be on either mono or combination PAH-specific therapy
4289,NCT02507011,5:47:chronic_disease,WHO category 1 pulmonary arterial hypertension (Nice 2013)
4290,NCT02506192,25:30:chronic_disease,Has been diagnosed with Lupus
4291,NCT02506192,1:11:chronic_disease,Vasculitis
4292,NCT02505035,"1:45:chronic_disease,",Chronic obstructive pulmonary disease (COPD) with home oxygen dependence or 2 or more hospitalizations in the past 12 months
4293,NCT02503722,23:51:treatment,No concomitant use of proton pump inhibitors (PPI)
4294,NCT02503722,",,,99:118:treatment",Women under 50 years must be postmenopausal for at least 12 months following the end of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution
4295,NCT02503358,1:28:chronic_disease,Ophthalmological conditions
4296,NCT02501954,23:60:treatment,Patients who have had pelvic or abdominal radiation therapy
4297,NCT02501954,15:43:cancer,Patients with recurrent endometrial cancer
4298,NCT02501733,22:52:treatment,Patients requiring a primary total knee replacement
4299,NCT02501473,1:62:treatment,Prior administration of other intratumoral immunotherapeutics
4300,NCT02500602,45:72:chronic_disease,"Subjects meeting DSM-5 criteria for current bipolar affective disorders, as the study protocol may be therapeutically insufficient"
4301,NCT02498951,"1:39:treatment,",Brain magnetic resonance imaging (MRI) documenting CR must be obtained within 30 days of study enrollment
4302,NCT02498613,"4:19:treatment,,",An ultrasound (US) within the last 6 months prior to registration will be required to document that it is =< 5 cm
4303,NCT02498535,"1:12:treatment,",Chest x-ray within the last six (6) months
4304,NCT02498301,15:34:chronic_disease,"Subject has a concomitant disease or condition that could interfere with, or for which treatment could interfere with, the conduct of the study, or could in the opinion of the investigator increase the risk of AEs during the subject's participation in the study"
4305,NCT02498301,1:20:treatment,warfarin (Coumadin)
4306,NCT02497300,1:30:chronic_disease,Diabetes mellitus (DM) type 1
4307,NCT02496611,1:16:chronic_disease,Bulimia nervosa
4308,NCT02496611,36:63:cancer,Personal- and/or family history of medullary thyroid carcinoma
4309,NCT02496585,16:46:chronic_disease,Active chronic Hepatitis C and/or B infection
4310,NCT02496208,16:52:cancer,Non-resectable squamous cell carcinoma of the penis
4311,NCT02495753,",19:49:chronic_disease",women with active herpes simplex virus infection
4312,NCT02495415,",48:76:treatment",Diseases refractory/relapsed after one or more systemic cytotoxic therapies
4313,NCT02495415,26:46:chronic_disease,Patients with any active hepatitis infections
4314,NCT02495415,48:81:cancer,with histologically or cytologically confirmed Peripheral T-cell lymphoma (PTCL)
4315,NCT02495168,1:25:treatment,Oral (not inhaled) SABAs for 24 hours
4316,NCT02495168,",42:70:treatment",at least 24 hours after the last dose of long-acting ? agonist (LABA) at the screening visit (Visit 1)
4317,NCT02494869,124:148:treatment,Any other condition or intercurrent illness that in the opinion of the investigator makes the subject a poor candidate for core biopsy or the trial
4318,NCT02494869,1:22:cancer,Metastatic malignancy of any kind
4319,NCT02494869,1:11:chronic_disease,Thrombosis of lower extremities
4320,NCT02494141,1:6:chronic_disease,ADPKD diagnosis
4321,NCT02493530,",60:85:treatment",Recovery to ? Grade 1 or baseline of any toxicities due to prior systemic treatments
4322,NCT02493426,25:44:treatment,Individuals that are on antipsychotic drugs will be excluded from participation. All subjects must lack a significant medical history
4323,NCT02493257,"1:19:treatment,",Intranasal steroid use >4 wks
4324,NCT02492867,29:70:cancer,Patients with evidence of a malignant pleural or pericardial effusion
4325,NCT02490631,12:28:chronic_disease,history of spine infections
4326,NCT02489591,1:20:chronic_disease,Periodontal disease and/or insufficient number of teeth
4327,NCT02489045,68:82:chronic_disease,"Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable"
4328,NCT02488967,23:53:chronic_disease,History of documented congestive heart failure (CHF)
4329,NCT02487797,",35:55:chronic_disease,",Diagnosed with at least 6 regular uterine contractions in an observation period of no more than 60 minutes
4330,NCT02487095,43:70:chronic_disease,Subjects with both platinum-sensitive and platinum-refractory disease
4331,NCT02485639,91:115:allergy_name,a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines
4332,NCT02484950,1:17:treatment,Revision surgery
4333,NCT02484404,29:81:treatment,Patients must have received prior treatment with enzalutamide and/or abiraterone
4334,NCT02484404,28:53:treatment,Patients who have received anti-angiogenesis therapy are eligible
4335,NCT02484404,",29:62:treatment",within 6 weeks prior to the first dose of the study treatment are not eligible
4336,NCT02484248,1:34:treatment,previous treatment with ketotifen
4337,NCT02483468,41:59:treatment,Unable or unwilling discontinue current behavioral therapy
4338,NCT02481765,1:11:treatment,Normal EEG
4339,NCT02481310,6:28:cancer,MYC+ plasmablastic lymphoma by histology
4340,NCT02481245,1:12:chronic_disease,Cyclothymia
4341,NCT02481245,",46:61:treatment",Subjects having failed two or more trials of somatic therapy
4342,NCT02480036,52:105:treatment,Patients with clinical or radiographic evidence of spinal cord or cauda equine compression or effacement
4343,NCT02479906,1:20:chronic_disease,Huntington's chorea
4344,NCT02479906,"1:26:chronic_disease,",Transient ischemic attack within two years
4345,NCT02479620,32:60:chronic_disease,"Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb from the popliteal artery to the ankle joint prior to the study procedure with Rutherford Category 4, 5 or 6"
4346,NCT02479230,"1:18:treatment,",Prior GEM therapy is acceptable as long as the last dose was ? 3 months from registration on this study
4347,NCT02478684,1:21:chronic_disease,Terminal bradycardia
4348,NCT02477839,16:42:chronic_disease,Subject has an arrhythmic heart condition requiring medical therapy
4349,NCT02476786,21:53:treatment,Currently receiving any other investigational agents
4350,NCT02476409,20:33:treatment,Daily oral dose of loop diuretic
4351,NCT02476409,15:39:chronic_disease,Patients with symptomatic hyponatremia will be excluded from the study
4352,NCT02475707,44:102:treatment,Only patients who receive infusions in the integrated Cell and Gene Therapy (CAGT) Transplant program at Texas Children's Hospital (TCH) or Houston Methodist Hospital (HMH)
4353,NCT02474667,",43:67:treatment",Must have a negative serum pregnancy test prior to transplantation
4354,NCT02474667,23:39:chronic_disease,Signs and symptoms of volume depletion
4355,NCT02474368,1:13:treatment,Cyclosporine
4356,NCT02474199,",,54:80:treatment",Clinical evidence of viral syndrome less than 7 days prior to darTregs infusion
4357,NCT02474199,1:26:chronic_disease,primary biliary cirrhosis
4358,NCT02473536,22:44:treatment,Patient eligible for IVC tumor thrombectomy as decided by the treating urologist
4359,NCT02473354,30:42:chronic_disease,has a clinically significant abnormal EKG [assessment by PI or delegate]
4360,NCT02473250,24:51:chronic_disease,Diagnosis of any other major psychiatric disorders
4361,NCT02473250,1:23:chronic_disease,autonomic neuropathies
4362,NCT02473250,1:17:chronic_disease,endocrinopathies
4363,NCT02472834,27:37:allergy_name,History of allergy to any amino acid compound
4364,NCT02472223,"1:12:treatment,",Eye surgery in the last 3 months
4365,NCT02471911,",52:118:treatment",Patients must have received at least two cycles of anthracycline based chemotherapy administered with curative intent
4366,NCT02471430,12:73:treatment,History of solid organ transplantation with an existing functional graft
4367,NCT02471430,29:61:chronic_disease,past or current evidence of immunologically mediated disease
4368,NCT02469857,"1:32:chronic_disease,,",Chronic neurological impairment that leads to a neuro mSOFA component ?2
4369,NCT02469662,97:111:chronic_disease,Instability or loss of motion when the degree of joint or soft tissue damage precludes reliable osteosynthesis
4370,NCT02469662,12:32:chronic_disease,Patient is mentally incompetent or unable to understand what participation in the study entails
4371,NCT02469129,"22:36:treatment,","Unable to lie in the PET/CT scanner for the time required for scanning, up to 1 hour and 15 min at a time and possibly with arms raised above the head for lung imaging"
4372,NCT02468778,18:77:treatment,Participation in another clinical study of an investigational drug or device that has not met its primary endpoint
4373,NCT02468024,10:42:treatment,No prior intra-thoracic radiation therapy
4374,NCT02467478,"1:29:chronic_disease,,",Chronic Kidney disease (CKD) Stages 1-3
4375,NCT02466971,29:80:chronic_disease,Patient does not have known glucose?6?phosphate dehydrogenase (G6PD) deficiency (G6PD testing optional)
4376,NCT02466750,41:62:treatment,Have any unresolved AE resulting from a previous immunization
4377,NCT02466685,18:36:chronic_disease,Individuals with tardive dyskinesia
4378,NCT02466009,27:40:chronic_disease,"Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study"
4379,NCT02465268,1:42:cancer,Recurrent or multifocal malignant gliomas
4380,NCT02465060,50:84:treatment,Registration to Step 0 must occur after stopping prior systemic anti-cancer therapy
4381,NCT02465060,1:29:treatment,low molecular weight heparin is permitted for prophylactic or therapeutic use
4382,NCT02464969,"1:24:treatment,",Anticoagulant treatment for the index VTE for greater than 7 days prior to randomization
4383,NCT02464878,"19:45:treatment,",Administration of live attenuated vaccine(s) within 2 months of enrollment
4384,NCT02464878,"1:35:chronic_disease,,,",Selective or severe IgA deficiency (levels < 5-7 mg/dL)
4385,NCT02464696,22:35:treatment,Contraindications to NIPPV therapy
4386,NCT02464696,1:6:chronic_disease,Shock
4387,NCT02464436,28:30:chronic_disease,Have clinical diagnosis of RP
4388,NCT02463305,14:23:chronic_disease,Diagnosis of severe UC
4389,NCT02462590,1:46:treatment,percutaneous gastric or jejunal feeding tubes already in situ as per Health Canada guidance
4390,NCT02461927,1:28:chronic_disease,Acute narrow-angle glaucoma
4391,NCT02460835,20:57:allergy_name,known allergies to intravenous iodinated contrast agents
4392,NCT02460783,",,56:67:treatment",weight less than or equal to 350 lbs (weight limit for MRI scanner)
4393,NCT02458482,38:64:treatment,Patients who have received nebulized bronchodilator medications at either a referring facility or at home will be included
4394,NCT02458014,"1:30:treatment,",Monoclonal antibodies therapy within 2 weeks before study entry
4395,NCT02457832,1:31:treatment,Deep brain stimulator implants
4396,NCT02457702,1:31:chronic_disease,Portal systemic encephalopathy
4397,NCT02456298,1:47:chronic_disease,Unstable or degenerative neurological disorder
4398,NCT02453373,8:25:chronic_disease,Active internal bleeding
4399,NCT02453373,1:25:chronic_disease,Ventricular fibrillation
4400,NCT02452697,34:54:chronic_disease,This may include patients with a mixed chimeric state or disease persistence or at high risk of relapse
4401,NCT02452268,"34:72:treatment,",autoimmune event associated with prior ipilimumab (anti-CTLA-4) therapy that has been completely resolved for more than 4 weeks prior to C1D1
4402,NCT02451982,1:22:chronic_disease,Stage I or II disease
4403,NCT02451553,",15:92:treatment",#ERROR!
4404,NCT02451488,15:41:treatment,Scheduled for sentinel lymph node biopsy as part of their standard surgical management
4405,NCT02451436,1:16:chronic_disease,Sleep disorders
4406,NCT02451423,39:63:treatment,Patients may be transfused or receive erythropoietic treatment to meet this criterion
4407,NCT02451423,16:25:treatment,The effects of MPDL3280A on the developing human fetus are unknown
4408,NCT02451215,1:40:cancer,Atypical teratoid rhabdoid tumor (ATRT)
4409,NCT02451215,1:11:cancer,Ependymoma
4410,NCT02451215,",,17:23:cancer",Grade III or IV glioma
4411,NCT02449980,",,,70:82:chronic_disease",Children ages 5 to 18 with clinical diagnosis of primary spontaneous pneumothorax (symptoms of chest pain and/or shortness of breath and pneumothorax demonstrated on chest radiograph) and no prior history of pneumothorax
4412,NCT02446886,39:43:allergy_name,Patients with known or new allergy to ACTH
4413,NCT02446236,39:95:treatment,Patients who have previously received high-dose chemotherapy with peripheral stem cell support
4414,NCT02446093,7:39:treatment,other systemic immunosuppressive drugs
4415,NCT02442622,12:38:treatment,History of cortical steroid injection to affected wrist and/or thumb
4416,NCT02442323,1:19:cancer,mucinous carcinoma
4417,NCT02442297,14:18:cancer,Diagnosis of DIPG
4418,NCT02442102,10:37:treatment,Expected tracheostomy tube placement while in hospital
4419,NCT02441140,27:43:chronic_disease,Known or suspected active pelvic infection
4420,NCT02440815,8:39:treatment,Use of cognitive enhancing medications
4421,NCT02440581,"24:36:treatment,",Planned or anticipated oral surgery within the next 12 months
4422,NCT02439450,1:35:chronic_disease,Significant cardiovascular disease
4423,NCT02438995,",25:48:treatment",Less than 6 months from prior Radiation Therapy (Arm 1)
4424,NCT02438371,"1:26:treatment,",prior tocolytic treatment during their pregnancy
4425,NCT02437773,"16:48:chronic_disease,",No evidence of suicidal intentions or behaviors in the past 6 months
4426,NCT02437110,7:18:allergy_name,Known sulfonamide allergy
4427,NCT02436070,7:27:chronic_disease,Other chronic lung disease
4428,NCT02435667,78:101:chronic_disease,individuals who are able to exercise (i.e. without orthopedic limitations or neuromuscular disorders)
4429,NCT02434809,45:66:treatment,Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines
4430,NCT02433977,31:49:allergy_name,Intolerance or allergy to the intervention drugs
4431,NCT02433210,8:34:chronic_disease,Stable arteriovenous (AV) fistula vascular access
4432,NCT02431897,12:31:treatment,History of vaginal irradiation
4433,NCT02430077,1:24:chronic_disease,Acute medical illnesses precluding participation in the studies
4434,NCT02430077,"45:62:treatment,",Use of drugs which can potentially decrease hepatic steatosis during previous 3 months
4435,NCT02429830,"32:36:chronic_disease,",Documented typical symptoms of GERD for longer than 6 months
4436,NCT02429830,1:16:chronic_disease,gastric varices
4437,NCT02427841,102:110:chronic_disease,History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABRAXANE or other agents used in the study
4438,NCT02427581,1:44:cancer,Invasive cancer in the contralateral breast
4439,NCT02426047,1:15:chronic_disease,Kidney disease
4440,NCT02424968,",171:210:treatment","Must be in a state of general good health and have completed a donor evaluation with history, medical examination and standard blood tests within 35 days of starting the hematopoietic cell collection procedure"
4441,NCT02423876,31:49:treatment,Patients must be eligible for epidural placement
4442,NCT02423863,26:40:treatment,Persistent toxicity from recent therapy that has not sufficiently resolved in the judgment of the study physician
4443,NCT02423525,177:186:treatment,Any history of or concomitant condition that would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
4444,NCT02422641,"1:27:treatment,,,","Partial brain radiotherapy (i.e., less than or equal to 40% of total brain volume) within the last two weeks"
4445,NCT02421380,10:34:chronic_disease,unstable cardiovascular condition
4446,NCT02421315,18:39:chronic_disease,Major medical or neurological problems
4447,NCT02421276,11:21:chronic_disease,Confirmed trisomy 21
4448,NCT02419560,22:46:treatment,Must be referred for treatment with ibrutinib
4449,NCT02419495,18:54:treatment,must have failed prior standard curative chemotherapy for their disease
4450,NCT02418195,12:24:chronic_disease,Autoimmune polymyositis
4451,NCT02418195,14:17:chronic_disease,Diagnosis of MDE as determined by the MINI (MDD participants)
4452,NCT02418195,1:21:chronic_disease,Polyarteritis nodosa
4453,NCT02418195,1:20:chronic_disease,Transverse myelitis
4454,NCT02417701,45:119:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
4455,NCT02416206,"66:70:treatment,",Availability of Cryopreserved peripheral blood stem cells with a CD34 dose of at least 2x106/kg
4456,NCT02415556,1:25:chronic_disease,Serious systemic disease that would interfere with conduction of clinical trial
4457,NCT02414607,33:52:allergy_name,Known history of sensitivity to elderberry products
4458,NCT02414178,"115:135:chronic_disease,","Other than DIAN study, currently participating in any research study and receiving an active study medication for Alzheimer's Disearse, an investigational drug, device, imaging, or placebo within the past 30 days before screening, and throughout this clinical trial up to 2-weeks past any study-related procedures"
4459,NCT02414139,20:69:treatment,Patients receiving treatment with any enzyme-inducing anticonvulsant
4460,NCT02413047,"30:52:chronic_disease,,",Evidence of or treatment for C. difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment
4461,NCT02412540,"16:25:treatment,",Stable dose of vitamin E that was started 12 months or more prior to biopsy is allowed
4462,NCT02411773,1:20:chronic_disease,Diabetic Neuropathy
4463,NCT02411656,45:78:treatment,Is currently participating in a study of an investigational anti-cancer agent
4464,NCT02409888,47:80:treatment,individuals reporting current enrollment in a substance abuse treatment program
4465,NCT02408861,"1:12:cancer,,,",Solid Tumor Expansion Cohort: CD4+ cell count greater than 200 cells/mm^3 obtained within 2 weeks prior to enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent
4466,NCT02408120,"18:42:chronic_disease,",Known history of Type 2 diabetes mellitus for >3 months
4467,NCT02408120,1:16:treatment,insulin therapy
4468,NCT02407028,39:46:chronic_disease,Coma suspected to de due to primarily non-TBI causes
4469,NCT02406885,13:27:treatment,Inducers of p-glycoprotein
4470,NCT02406599,1:30:treatment,Neo-adjuvant systemic therapy
4471,NCT02405078,"16:65:treatment,",Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only)
4472,NCT02404155,9:36:cancer,Current treated or untreated cancer
4473,NCT02404155,12:27:chronic_disease,History of paralytic ileus
4474,NCT02404012,"17:32:treatment,",Subject has had parenteral iron less than one month before screening visit
4475,NCT02403193,30:46:cancer,Symptomatic and/or untreated Brain Metastases
4476,NCT02402907,24:40:treatment,unplanned or emergency cesarean section
4477,NCT02401347,1:49:cancer,Brain or central nervous system (CNS) metastases
4478,NCT02401074,"1:16:chronic_disease,",Unstable asthma as indicated by self report of increased symptoms or increased beta-agonist use over the 2 weeks preceding the screening visit
4479,NCT02400554,",19:38:chronic_disease",Women who exhibit serious psychiatric symptoms determined by CNO trained staff
4480,NCT02400463,25:41:cancer,tissue demonstration of hemophagocytosis
4481,NCT02398773,44:70:treatment,"Patient is not now, and never has received adjuvant endocrine therapy OR patient is currently receiving or has received adjuvant endocrine therapy in the past"
4482,NCT02398240,",,36:39:treatment",Females who are pregnant (positive HCG)
4483,NCT02397889,",,100:120:treatment",Women of childbearing potential must have a negative pregnancy test at screening and prior to each intravenous infusion
4484,NCT02397083,9:22:chronic_disease,Genital actinomycosis
4485,NCT02395614,11:25:treatment,bilateral reconstruction using other techniques
4486,NCT02395393,35:58:treatment,to be unable to safely tolerate a bronchoscopic procedure
4487,NCT02394704,1:20:chronic_disease,Psychotic disorders
4488,NCT02394535,17:25:treatment,low dose (1 mg) Coumadin is allowed
4489,NCT02394028,"1:17:treatment,",anti-TNF therapy within 5 years from screening
4490,NCT02393885,1:24:chronic_disease,Refractory hypertension
4491,NCT02393794,"1:25:chronic_disease,,","ncontrolled hypertension, i.e., blood pressure (BP) of ? 160/95"
4492,NCT02393690,35:53:chronic_disease,"For patients with non-measurable, structural disease"
4493,NCT02393157,1:17:cancer,Burkitt Lymphoma
4494,NCT02393157,56:94:cancer,Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma
4495,NCT02393157,1:34:treatment,Prior solid organ transplantation
4496,NCT02392286,6:27:chronic_disease,NYHA Class 4 heart failure
4497,NCT02390752,30:33:chronic_disease,A first-degree relative with NF1
4498,NCT02390752,28:36:cancer,"Histologic confirmation of PN tumor is not necessary in the presence of consistent clinical and radiographic findings, but should be considered if malignant degeneration of a PN is clinically suspected"
4499,NCT02390752,1:21:cancer,Optic pathway glioma are located in the optic pathway and are typically hypo- or iso-intense on T1 and hyperintense on T2-weighted images
4500,NCT02390752,"25:42:chronic_disease,,","patients with confirmed Gilberts syndrome, the TBil should be less than or equal to 1.5 (SqrRoot) ULN"
4501,NCT02389517,",,38:53:treatment",Diarrhea > grade 1 in the absence of anti-diarrheals
4502,NCT02389023,1:21:treatment,Infrainguinal bypass without a groin incision including popliteal-tibial or pedal bypass
4503,NCT02387905,14:30:chronic_disease,Patents with cord compression
4504,NCT02387216,",13:52:treatment",Received >2 prior systemic anti-cancer drug regimen for locally advanced disease
4505,NCT02383979,15:34:treatment,scheduled for elective amputation
4506,NCT02382549,1:14:treatment,MEK inhibitor
4507,NCT02382549,29:48:chronic_disease,Participants with an active autoimmune disorder requiring these therapies are also excluded
4508,NCT02382419,8:22:chronic_disease,Active genital ulcers
4509,NCT02379156,20:43:allergy_name,Known allergies to midodrine hydrochloride
4510,NCT02378714,27:56:chronic_disease,medications indicated for bipolar or psychotic disorder if prescribed for bipolar or psychotic disorder
4511,NCT02378428,18:38:treatment,Have undergone a prior allogeneic BMT
4512,NCT02376205,",19:33:treatment",More than 2-level ACDF surgeries
4513,NCT02376153,1:39:treatment,vascular prosthetic graft implantation
4514,NCT02374333,114:128:treatment,beyond 1st CR with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT
4515,NCT02374021,"1:16:treatment,,,",MTX monotherapy for ? 8 weeks at ? 15mg weekly or ? 7.5 mg weekly with a documented intolerance to higher doses
4516,NCT02374021,1:22:chronic_disease,demyelinating disease
4517,NCT02373644,1:17:treatment,ASIS compression
4518,NCT02373644,21:43:chronic_disease,Patient must report sacroiliac dysfunction
4519,NCT02370732,19:51:treatment,In evaluation for Roux-en-Y gastric bypass surgery
4520,NCT02370095,15:26:treatment,Patient has a tracheotomy
4521,NCT02370056,1:27:treatment,Segmental colon resections
4522,NCT02369770,1:15:chronic_disease,Pressure ulcer
4523,NCT02369406,1:16:treatment,Hospitalization for severe medical illness
4524,NCT02367040,38:94:treatment,Documented evidence of resistance to prior treatment with idelalisib or other PI3K inhibitors
4525,NCT02367040,"1:32:cancer,,",Small lymphocytic lymphoma(SLL) with absolute lymphocyte count <5x10*9/L at study entry
4526,NCT02366871,1:28:chronic_disease,antithrombin III deficiency
4527,NCT02366871,11:27:chronic_disease,potential bleeding lesions
4528,NCT02366819,"1:9:chronic_disease,","Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)"
4529,NCT02365766,1:26:cancer,Clinical stage cT2-4aN0M0
4530,NCT02365467,51:68:allergy_name,Subject has a known allergy or intolerance to the device components
4531,NCT02365467,",,215:244:treatment",Subject has circumferential calcification in the external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 10mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned
4532,NCT02365467,44:72:treatment,Subject must be considered a candidate for revascularization of the LSA
4533,NCT02362308,13:31:chronic_disease,Biochemical hyperaldosteronism
4534,NCT02362308,"1:55:treatment,,",Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)
4535,NCT02361554,"29:84:treatment,",Subject has participated in another investigational drug trial or therapeutic trial within 30 days of Baseline Visit
4536,NCT02360579,1:44:treatment,Intrauterine hormone-releasing system (IUS)
4537,NCT02359864,36:58:treatment,Patient currently participating in another Clinical Trial
4538,NCT02359825,",47:61:treatment",repair within 48 hours of injury that require nerve grafting
4539,NCT02359097,66:84:cancer,Subjects must have a known or presumed radiological diagnosis of glioblastoma (GBM)
4540,NCT02358681,31:40:treatment,Contraindication to receiving ketorolac
4541,NCT02357784,16:44:chronic_disease,diagnosed with idiopathic dual incontinence
4542,NCT02357784,36:58:treatment,planning to undergo placement of a sacral nerve modulator
4543,NCT02356848,1:22:treatment,Prior foot amputation
4544,NCT02356653,9:18:cancer,Chronic leukemias
4545,NCT02355912,1:20:treatment,Lower Limb Amputees
4546,NCT02355535,1:8:cancer,Gliomas
4547,NCT02355002,"46:51:treatment,","Use of other psychotropic medications (e.g., SSRIs) will be allowed provided the dose has been stable for > 12 weeks"
4548,NCT02354703,",,,,,201:228:chronic_disease","Evidence of hepatic failure and/or ascites, prolonged prothrombin time (International Normalized Ratio [INR] > or = 1.7), bilirubin >10% above the upper limit of the central lab's normal range and/or esophageal variceal disease"
4549,NCT02354547,",43:68:treatment",At least 14 days after the last dose of a long-acting growth factor
4550,NCT02354547,15:50:cancer,Patients with relapsed or refractory solid tumors
4551,NCT02353728,"32:44:chronic_disease,",Clinically significant resting brachycardia (<50 beats per minute)
4552,NCT02353728,"1:44:treatment,",Treatment with other investigational agents within 30 days of Day 1
4553,NCT02352025,53:83:treatment,Patient may not be concurrently enrolled in another investigational drug treatment study
4554,NCT02351544,15:33:chronic_disease,Patients with episodic migraines
4555,NCT02350764,57:85:treatment,There is no restriction on the number of prior lines of systemic anti-cancer therapy
4556,NCT02349867,1:15:treatment,Anticoagulants at therapeutic doses
4557,NCT02349035,3:24:treatment,A upper limb amputation at the transradial level
4558,NCT02347891,",,,,,,124:148:treatment","Clinically significant elevation of GGT (>1.5xULN), bilirubin (>1.25xULN, direct 35%), or INR (>1.2, excluding patients on anti-coagulant therapies) or other clinically significant abnormal laboratory value in the opinion of the investigator"
4559,NCT02347891,"17:51:treatment,,",Have received a non-biologic investigational agent within 30 days or 5 half-lives of the agent (whichever is longer) prior to Screening
4560,NCT02347202,76:79:treatment,for counselors to be research participants in both the pilot study and the RCT
4561,NCT02347111,23:42:chronic_disease,History of typical or lone symptomatic AF
4562,NCT02346929,1:21:chronic_disease,High acuity/distress per the Attending ED physician
4563,NCT02346526,"10:31:treatment,",Received previous radiotherapy to approximately >25% of bone marrow
4564,NCT02346201,"24:30:chronic_disease,",Clinically significant apathy for at least four weeks for which either
4565,NCT02344355,",33:42:treatment",Tolerate one test dose (15g) of ascorbate
4566,NCT02343549,"19:38:treatment,",Inability to wear NovoTTF-100A System for an average of 18 hours per 24 hours
4567,NCT02343549,11:21:cancer,localized basal cell
4568,NCT02343042,1:14:cancer,Smoldering MM
4569,NCT02342808,"1:11:chronic_disease,,",Severe CKD (eGFR <40 ml/min/1.73m2)
4570,NCT02342782,",,,174:179:cancer",Serum glutamic oxaloacetic transaminase (SGOT) AND serum glutamate pyruvate transaminase (SGPT) < 2 x normal except in cases where abnormal LFTS are due to involvement with T-NHL
4571,NCT02341235,13:31:chronic_disease,Evidence of disease recurrence
4572,NCT02340156,39:57:allergy_name,Have a history of hypersensitivity to dacarbazine (DTIC)
4573,NCT02340156,11:25:treatment,Requiring renal dialysis
4574,NCT02339948,",32:36:treatment,",Prostate volume as assessed by TRUS > 60 cc
4575,NCT02339922,",,71:91:treatment","Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period"
4576,NCT02339233,1:13:chronic_disease,dysautonomia that would contraindicate standing
4577,NCT02339233,1:14:chronic_disease,pressure sore that might interfere with training
4578,NCT02338947,"24:52:treatment,","with the indication of myocardial revascularization with ?2 criteria of frailty by Fried Frailty Criteria, and suitable to undergo either Off-pump or On-pump CABG"
4579,NCT02338232,1:10:treatment,Melphalan 140 mg/m2
4580,NCT02336451,104:128:treatment,Patients must wait for the central laboratory result of the ALK rearrangement status before initiating treatment with ceritinib
4581,NCT02335905,1:22:chronic_disease,isseminated infection or is admitted to the pediatric intensive care unit
4582,NCT02335242,1:11:treatment,Amlodipine
4583,NCT02335242,37:40:chronic_disease,Has ulcerated or currently infected LMs
4584,NCT02334579,18:48:treatment,High risk group: three hormone therapy regimens
4585,NCT02333162,40:48:treatment,Since these patients already had first allo-SCT
4586,NCT02332863,1:4:treatment,EUS evidence of vessel interfering with path of fiducial marker
4587,NCT02332850,39:57:treatment,must be > than four half-lives of the experimental agent
4588,NCT02332668,1:9:cancer,Tumor(s) involving the brain stem
4589,NCT02332369,116:139:treatment,Capsular bag tearing beyond the point where the surgeon thinks it is in the best interest of the patient to have a capsular ring implanted
4590,NCT02332369,1:13:chronic_disease,Iris atrophy
4591,NCT02332369,1:21:chronic_disease,Retinal degeneration
4592,NCT02332291,5:40:chronic_disease,Any physical or intellectual disability adversely affecting ability to complete assessments
4593,NCT02332291,1:35:chronic_disease,generalized anxiety disorder (GAD) symptoms occurring during a depressive episode
4594,NCT02329652,36:50:treatment,Disorder or condition that require MRI monitoring
4595,NCT02329327,11:38:treatment,minimally invasive surgery/procedures
4596,NCT02327403,14:41:chronic_disease,active acute antibody-mediated rejection
4597,NCT02327312,1:20:chronic_disease,Open angle Glaucoma
4598,NCT02324582,"1:26:treatment,",Prior monoclonal antibody within 4 weeks prior to study
4599,NCT02324582,1:26:chronic_disease,substance abuse disorders
4600,NCT02324439,26:46:chronic_disease,Patients with concurrent uncontrolled illness
4601,NCT02324387,1:18:chronic_disease,nodal involvement (N0 - N3)
4602,NCT02323880,",,49:82:treatment",Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
4603,NCT02323698,12:39:treatment,Undergoing concurrent physical therapy
4604,NCT02323126,43:63:allergy_name,History of allergy or hypersensitivity to nivolumab components
4605,NCT02323100,"1:14:treatment,",Sinus surgery within 6 weeks of Screening Visit
4606,NCT02321501,1:49:treatment,Strong inhibitors or strong inducers of CYP3A4/5
4607,NCT02320292,28:31:treatment,Meet standard criteria for RIT
4608,NCT02319369,",,,,,,180:205:treatment","Has prolongation of corrected QT interval using Fridericia's method (QTcF) at rest, where the mean QTcF interval is > 450 ms for males or > 470 ms for females based on triplicate electrocardiograms (ECGs)"
4609,NCT02319369,1:39:treatment,Prior treatment with an MDM2 inhibitor
4610,NCT02317991,1:25:treatment,Major surgical procedure
4611,NCT02317523,"1:15:treatment,",Glucocorticoid use in the 2 weeks prior to enrollment
4612,NCT02316886,1:13:treatment,Bypass graft lesion
4613,NCT02316574,34:54:chronic_disease,Meets DSM-V criteria for current Alcohol Use Disorder
4614,NCT02315612,1:18:cancer,Hyperleukocytosis
4615,NCT02314377,"24:42:chronic_disease,",Clinically significant thrombotic episode within the last 24 weeks
4616,NCT02314221,14:33:chronic_disease,Diagnosis of neurological injury other than SCI
4617,NCT02313753,9:27:chronic_disease,Current psychotic symptoms severe enough to impair study participation
4618,NCT02313428,1:29:treatment,Debridement of infected bone if necessary
4619,NCT02312596,13:21:chronic_disease,Presence of Gangrene
4620,NCT02312245,83:110:treatment,Uncontrolled intercurrent illness judged by the treating investigator to preclude treatment with chemotherapy
4621,NCT02311621,19:41:cancer,Patients may have CNS intracranial tumor
4622,NCT02311621,1:20:cancer,Skull based disease with soft tissue extension
4623,NCT02311361,32:40:cancer,Each case will be discussed at GI tumor board with multidisciplinary team
4624,NCT02310867,79:107:chronic_disease,Inability or unwillingness to comply with protocol monitoring and therapy and immunodeficiency syndrome(s)
4625,NCT02310399,"90:111:treatment,",Clear surgical reason for poor CI performance that can be remediated with revision CI or contralateral surgery rather than ABI
4626,NCT02310399,18:40:treatment,Involvement in a rehabilitation program that emphasizes development of auditory skills with or without the use of supplementary visual communication
4627,NCT02310399,6:29:chronic_disease,Post-meningitis ossification
4628,NCT02310399,39:42:chronic_disease,normal cochlea and cochlear nerves or NF2
4629,NCT02309580,16:41:chronic_disease,without active graft-versus-host-disease
4630,NCT02307058,20:59:treatment,Distinct lesion on dynamic contrast-enhanced MRI (DCE-MRI) with early enhancement and later washout
4631,NCT02306954,15:67:chronic_disease,"Patients with active systemic, pulmonary, or pericardial infection"
4632,NCT02305537,26:64:chronic_disease,those who exhibit severe behavioral disinhibition or aggression
4633,NCT02304458,28:59:treatment,Patients who have received prior anti-PD1 directed therapy (monoclonal antibody [mAb] or small molecule)
4634,NCT02304458,42:62:chronic_disease,these patients will not be evaluable for hematologic toxicity
4635,NCT02301663,1:18:treatment,metallic implants
4636,NCT02299414,1:36:chronic_disease,Class C or higher diabetes mellitus
4637,NCT02298790,1:19:chronic_disease,Hearing impairment
4638,NCT02298504,1:14:chronic_disease,pulp necrosis
4639,NCT02293096,1:31:chronic_disease,active reactive airway disease
4640,NCT02291978,15:39:chronic_disease,Patients with gross spinal instability on imaging
4641,NCT02291523,"15:37:treatment,",Have received probiotic preparations ? 4 weeks prior to randomization
4642,NCT02290028,78:94:chronic_disease,"Presence of another life-threatening, underlying illness separate from their cardiac disorder"
4643,NCT02287558,",39:83:treatment",Recurrent bleeding after at least one previous interventional endoscopic procedure
4644,NCT02285101,1:46:treatment,Prior treatment with arginine depleting agent
4645,NCT02281409,17:38:treatment,Subjects on any immunomodulatory drug
4646,NCT02278367,47:72:chronic_disease,Have a history of additional risk factors for Torsades de Pointes (TdP)
4647,NCT02278315,",38:56:treatment","Grade 2 or greater toxicities due to previous therapies, subject to laboratory abnormalities listed below"
4648,NCT02278315,1:35:treatment,Serum free light chain (FLC) assay
4649,NCT02277782,1:31:chronic_disease,prolonged rupture of membranes
4650,NCT02276716,14:35:chronic_disease,Diagnosis of familial dysautonomia (with mutation testing)
4651,NCT02274116,1:30:chronic_disease,cardiopulmonary complications
4652,NCT02273375,15:51:cancer,Patients with large-cell neuroendocrine carcinomas are not eligible
4653,NCT02273362,"3:24:treatment,",A clinical liver biopsy (with research tissue specimens available for analysis) =< 3 months prior to pre-registration
4654,NCT02272998,28:55:treatment,Patients who have received prior FGFR targeted therapy
4655,NCT02272634,13:36:chronic_disease,Evidence of pulmonary heart disease
4656,NCT02272556,1:32:chronic_disease,Untreated Psychiatric Disorders
4657,NCT02272218,27:34:chronic_disease,clinically diagnosed with knee OA using American College of Rheumatology (ACR) criteria
4658,NCT02271711,135:151:treatment,"Extensive disease, disease location, and/or co-morbid condition that the PI or designee considers unsafe for surgical intervention of NK cell infusion"
4659,NCT02271100,1:24:treatment,Previous spinal surgery in the lumbar or sacral area (L1 through Sacrum)
4660,NCT02270970,"1:17:treatment,",oral antibiotics within two weeks of first dose
4661,NCT02269293,22:55:treatment,Patient who have had previous treatment with selinexor
4662,NCT02269124,32:55:chronic_disease,with mild to moderately severe unilateral hearing loss
4663,NCT02268448,"8:44:treatment,",Use of topical or oral anti-pruritic agents for 2 weeks prior to the study start
4664,NCT02267863,24:49:chronic_disease,Clinically significant intravascular coagulation
4665,NCT02266719,15:39:chronic_disease,Patients with ruptured aortic aneurysm requiring urgent or emergent repair
4666,NCT02266329,",398:413:treatment",Participation in a headache support group or other activity such as meditation or yoga intended to mitigate headache or other chronic pain must be stable for at least 4 weeks prior to beginning the preliminary screening period and should be intended to be continued for the duration of the trial. Participants will be encouraged to defer enrolling in such activities until they have completed the treatment trial
4667,NCT02265315,18:54:chronic_disease,Individuals with Idiopathic Parkinson's disease (IPD)
4668,NCT02264678,17:24:allergy_name,Bad reaction to AZD6738
4669,NCT02264678,19:41:cancer,The presence of a solid malignant tumour that is not considered appropriate for further standard treatment
4670,NCT02263274,7:23:allergy_name,Known adhesive allergy
4671,NCT02262806,1:22:chronic_disease,Partial lipodystrophy (either genetic or acquired)
4672,NCT02261519,37:42:treatment,The subject has previously received NaBen
4673,NCT02261519,1:28:treatment,systemic hormonal treatment
4674,NCT02259621,23:44:allergy_name,History of allergy to study drug components
4675,NCT02258438,1:21:chronic_disease,type 1 or 2 diabetes
4676,NCT02256631,28:47:treatment,Prior participation in any HIV-1 vaccine trial
4677,NCT02255383,18:29:treatment,"Stable, painless arthrodesis in a satisfactory functional position"
4678,NCT02254863,24:61:treatment,Prior participation in any gene or regenerative cell therapy study
4679,NCT02253316,22:39:chronic_disease,clinically important autonomic disease
4680,NCT02252432,10:21:treatment,Emergent laminectomy
4681,NCT02252081,29:49:chronic_disease,"Severe, unstable, or active inflammatory disease"
4682,NCT02251431,1:24:treatment,Prior bariatric surgery
4683,NCT02250157,",,,,187:189:treatment",Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of IP
4684,NCT02249039,38:50:treatment,Any infant or child who is receiving ECMO therapy
4685,NCT02245997,"15:19:cancer,,",Patients with INSS stage 2a or 2b
4686,NCT02245841,15:52:cancer,Patients with malignancy-associated dermatomyositis
4687,NCT02245841,1:30:chronic_disease,juvenile dermatomyositis (JD)
4688,NCT02244814,18:41:chronic_disease,Risk factors for placental insufficiency
4689,NCT02244814,1:15:chronic_disease,overt diabetes
4690,NCT02243631,1:17:chronic_disease,Blood dyscrasias
4691,NCT02242526,1:22:chronic_disease,"Paraesophageal hernia with clinically relevant symptoms such as heartburn, chest pain, regurgitation, dysphagia, postprandial abdominal pain, shortness of breath, or early satiety"
4692,NCT02242110,"11:29:treatment,",Stable on bipolar medication for at least 2 months
4693,NCT02240498,10:46:chronic_disease,Severely compromised cardiopulmonary function
4694,NCT02236377,1:28:chronic_disease,acute or apparent psychosis
4695,NCT02236013,"49:85:cancer,",Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to WHO classification (2008) documented within 28 days prior to enrollment
4696,NCT02236013,18:50:treatment,Subject requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject
4697,NCT02235623,1:25:chronic_disease,Bilateral cryptorchidism
4698,NCT02234934,"18:59:treatment,",Participation in another experimental therapeutic protocol within 6 months prior to baseline and during the study period
4699,NCT02234934,63:83:treatment,there is deemed to be an unacceptable risk associated with an allogeneic procedure
4700,NCT02234193,15:28:allergy_name,Subjects with tape adhesive allergies
4701,NCT02233868,1:25:treatment,anorexics (sibuteramine)
4702,NCT02233868,1:29:treatment,antifungal agents (systemic)
4703,NCT02233868,1:12:treatment,antiobesity
4704,NCT02232516,1:42:cancer,Hepatosplenic gamma-delta T-cell lymphoma
4705,NCT02232516,1:27:cancer,"Peripheral T-cell lymphoma, unspecified (not otherwise specified [NOS])"
4706,NCT02232516,"36:55:treatment,,",all patients must agree to undergo counseling sessions every 28 days about pregnancy precautions and risks of fetal exposure
4707,NCT02232165,38:52:allergy_name,Allergy or other contraindication to norepinephrine
4708,NCT02231073,78:90:chronic_disease,"Capable of following directions. iPD subjects: UK Brain Bank criteria, i.e., bradykinesia"
4709,NCT02230189,"8:27:treatment,",Use of Xolair (omalizumab) within the last 6 months
4710,NCT02227199,",35:79:treatment",Prior failed (< 5 x 10^6 CD34/kg) peripheral blood stem cell (PBSC) collection
4711,NCT02226341,"8:39:treatment,",Use of experimental therapeutic agents within the past 60 days
4712,NCT02225548,27:53:chronic_disease,Subject with a history of congenital QT prolongation
4713,NCT02225548,",11:20:treatment,",an IIEF-5 tadalafil-alone baseline score that is ? 18
4714,NCT02222545,6:14:chronic_disease,Have STEC-HUS
4715,NCT02219711,26:48:chronic_disease,History of a significant cardiovascular illness
4716,NCT02219581,38:45:treatment,Patients that have an intolerance to Toradol
4717,NCT02219555,1:12:chronic_disease,amyloidosis
4718,NCT02219555,1:25:chronic_disease,peripheral nerve disease
4719,NCT02217345,44:57:chronic_disease,use of any medications prescribed to treat hyperglycemia
4720,NCT02215096,",32:74:treatment",Completed at least 12 weeks of prior continuous therapy with enzalutamide
4721,NCT02214667,1:23:chronic_disease,"bipolar disorder I, II, or NOS"
4722,NCT02214550,"8:31:chronic_disease,",active genitourinary infection in the last four weeks
4723,NCT02213289,4:43:treatment,No prior treatment with any targeted agent
4724,NCT02213068,12:31:treatment,History of previous transplant
4725,NCT02210650,1:24:chronic_disease,medullary sponge kidney
4726,NCT02210078,15:26:chronic_disease,Patients with CMV disease
4727,NCT02209636,1:15:chronic_disease,CKD stage IIIb
4728,NCT02208362,",76:101:treatment",An interval of at least 12 weeks must have elapsed since the completion of initial radiation therapy
4729,NCT02207465,1:18:cancer,In-situ carcinoma is allowed
4730,NCT02207465,"1:52:treatment,",Treatment with an investigational anti-cancer agent within 4 weeks prior to enrollment into the study
4731,NCT02207439,",,,61:83:chronic_disease",Weight loss of > 10% over the past 6 months which is due to tumor wasting syndrome
4732,NCT02206945,1:10:treatment,anafranil
4733,NCT02204098,1:17:treatment,Hormonal therapy
4734,NCT02203903,8:41:chronic_disease,Active Bronchiolitis obliterans syndrome
4735,NCT02203695,1:41:treatment,Primary treatment with radiation therapy
4736,NCT02203513,",51:77:cancer",Patients with gBRCA1/2m with history of or active breast and ovarian cancers are considered for Cohort 1
4737,NCT02202681,28:54:chronic_disease,Subjects with a history of intestinal Crohn's disease
4738,NCT02200445,10:17:chronic_disease,Abnormal thyroid function tests
4739,NCT02200445,"18:48:treatment,",Received another investigational new drug (IND) within 5 half-lives of that agent before the planned commencement of SC IL-2
4740,NCT02199236,1:18:treatment,Prior pelvic EBRT
4741,NCT02195232,1:28:chronic_disease,Familial bleeding diathesis
4742,NCT02193932,54:86:treatment,Patients who meet the regular exclusion criteria for Magnetic Resonance Imaging (MRI) studies per the prescreening form reviewed with all patients prior to exams
4743,NCT02193841,15:20:chronic_disease,Patients with cysts crossing the growth plate (area where bone grows)
4744,NCT02193373,19:26:chronic_disease,Current or recent illness
4745,NCT02192359,44:52:cancer,Imaging studies show evidence of recurrent tumor(s)
4746,NCT02189889,1:24:chronic_disease,coagulation abnormality
4747,NCT02189798,4:54:treatment,No previous cochlear implant experience in either ear
4748,NCT02188745,40:53:treatment,Patient must have been treated with an anti-estrogen at any time in their disease history
4749,NCT02187848,1:27:chronic_disease,Cardiac conduction defects
4750,NCT02187848,1:32:treatment,Prior therapy targeting CEACAM5
4751,NCT02186418,10:38:treatment,Abnormal pulmonary function tests PFT
4752,NCT02185417,"15:34:treatment,,",Are receiving hydrochlorothiazide from the VA pharmacy at a daily dose of 25 or 50 mg
4753,NCT02184520,1:16:chronic_disease,pseudoarthrosis (failed previous fusion)
4754,NCT02181478,1:19:cancer,Myelofibrosis (MF)
4755,NCT02180412,",149:158:chronic_disease","Acute symptoms (7 days duration or less to time of enrollment) such as abdominal, back and/or limb pain, diagnosed by the investigator as caused by porphyria after initial evaluation has excluded other causes"
4756,NCT02180412,"52:96:treatment,","Most (~90 percent) will have deficient activity of erythrocyte porphobilinogen deaminase (PBGD), and almost all (>95 percent) will have a demonstrable disease-causing PBGD mutation"
4757,NCT02179853,12:44:chronic_disease,History of tuberculosis (TB) or TB exposure
4758,NCT02178566,"17:49:treatment,",Initiation of a pulmonary rehabilitation program within 3 months prior to screening or initiation or changes during the study
4759,NCT02177838,",,17:46:cancer","Stage III/IVa/b squamous cell carcinoma (SCC) by American Joint Committee on Cancer (AJCC) 7 criteria (advanced, but not metastatic)"
4760,NCT02177695,",37:60:treatment",disease measuring at least 10 mm on cross-sectional imaging
4761,NCT02176967,",,,51:64:cancer",< 12 months (< 365 days) of age at diagnosis with INRG stage L1
4762,NCT02176902,1:19:cancer,Clinical stage T2c or less
4763,NCT02176161,1:35:cancer,non-muscle invasive bladder cancer
4764,NCT02174549,1:41:cancer,Liver metastatic gastrointestinal cancer
4765,NCT02172950,",,47:77:chronic_disease,,",Males of any age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels < 1%)
4766,NCT02171429,25:46:treatment,Naive to treatment with TNF inhibitor therapy
4767,NCT02171104,1:23:chronic_disease,Aspartylglucosaminuria
4768,NCT02171104,1:28:chronic_disease,Globoid cell leukodystrophy
4769,NCT02171104,1:25:chronic_disease,MPS IH (Hurler syndrome)
4770,NCT02171104,1:60:chronic_disease,Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE)
4771,NCT02171104,1:25:chronic_disease,Niemann-Pick C subtype 2
4772,NCT02171104,1:19:chronic_disease,Zellweger syndrome
4773,NCT02169739,33:53:chronic_disease,Absence of signs or symptoms of cortical dysfunction
4774,NCT02169739,",,112:123:treatment",Well delinated hypointense lesion <1.5 cm in size at the largest dimension (including rostro-caudal extent) on FLAIR or T1 corresponding to the clinical syndrome
4775,NCT02169089,1:20:treatment,Oral contraceptives are disallowed
4776,NCT02169089,7:27:cancer,cured squamous cell cancer
4777,NCT02169037,9:12:treatment,in whom PVI has low success and 55 mm baskets are too small for the atria
4778,NCT02169037,1:17:chronic_disease,vascular disease (1 point)
4779,NCT02167022,1:41:treatment,Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study
4780,NCT02167009,12:19:allergy_name,History of gelatin allergy
4781,NCT02167009,"1:5:treatment,",TURP within the last two years
4782,NCT02165449,35:65:chronic_disease,Diagnosis: DSM-IV TR criteria for non-psychotic major depression
4783,NCT02165007,14:37:chronic_disease,Patient with active Hepatitis B or C determined by serology and/or NAAT
4784,NCT02164422,",59:96:chronic_disease",Meet DSM-IV criteria for current (past-6 month) attention deficit hyperactivity disorder (ADHD)
4785,NCT02162420,14:55:chronic_disease,Diagnosis of DC with a triad of mucocutaneous features
4786,NCT02162420,"1:21:cancer,,,,",Refractory cytopenia defined by bone marrow cellularity <50% (with < 30% residual hematopoietic cells)
4787,NCT02162420,1:15:chronic_disease,nail dystrophy
4788,NCT02162420,1:23:chronic_disease,severe portal fibrosis
4789,NCT02161380,1:21:treatment,Previous eye surgery in the eye selected for injection
4790,NCT02160288,13:31:chronic_disease,Presence of fecal incontinence
4791,NCT02160288,25:30:treatment,Previous treatment with Botox (possible antibodies)
4792,NCT02159560,1:13:chronic_disease,Chronic pain
4793,NCT02159495,1:13:cancer,Relapsed AML is defined as patients that had a first complete remission (CR) before developing recurrent disease (increased bone marrow blasts)
4794,NCT02159027,12:17:chronic_disease,History of HIV-2
4795,NCT02159027,15:32:chronic_disease,other serious medical illnesses (in the opinion of the site investigator)
4796,NCT02158858,4:29:treatment,No prior treatment with JAKi allowed
4797,NCT02158793,1:23:chronic_disease,Serious co-morbidities
4798,NCT02155946,14:26:chronic_disease,"Diagnosis of amnestic MCI based on criteria set forth by Petersen (2004). Additionally, other potential causes of cognitive deficit ruled out by the referring physician"
4799,NCT02154568,1:18:chronic_disease,Pulmonary Disease Subjects
4800,NCT02152995,1:4:treatment,RAI-refractory disease on structural imaging
4801,NCT02152995,24:46:cancer,patients with indolent secondary malignancies
4802,NCT02152956,1:20:treatment,ophthalmic solution
4803,NCT02151175,17:50:chronic_disease,Subjects with a cognitive or psychiatric disorder that limits the ability to give informed consent or are unable to cooperate with the testing
4804,NCT02150967,11:25:treatment,selective FGFR inhibitor (Cohorts 1 and 2 only)
4805,NCT02148796,1:14:treatment,chest surgery
4806,NCT02148796,1:38:chronic_disease,primary or secondary immunodeficiency
4807,NCT02148263,"1:18:treatment,",Topical eye drops within the last two hours of the study visit
4808,NCT02145351,27:43:allergy_name,Any contraindication to a pacemaker system
4809,NCT02145351,"8:31:treatment,",Stable cardiac medical therapy for ?30 days
4810,NCT02143830,1:27:cancer,"Acute Myelogenous Leukemia (untreated, in remission or with refractory or relapsed disease)"
4811,NCT02143726,1:58:treatment,Chronic concomitant treatment with strong CYP3A4 inducers
4812,NCT02143726,21:42:chronic_disease,No known history of prolonged QT syndrome
4813,NCT02143726,41:68:cancer,must have histopathologically confirmed Hürthle cell thyroid cancer by central review
4814,NCT02141919,15:29:cancer,Biopsy proven Renal neoplasm
4815,NCT02141074,"32:45:chronic_disease,,",Patients with the diagnosis of haemophilia B (FIX (coagulation factor IX) activity level below or equal to 2%) based on medical records or central laboratory results
4816,NCT02140554,51:75:chronic_disease,Immediate family member with a known or suspected Familial Cancer Syndrome
4817,NCT02140255,",,180:200:treatment,","Greater than or equal to 36 weeks gestational age at birth (assessment of gestational age will be based on the best clinical estimate determined by date of last menstrual period, antenatal ultrasound, fundal height, or Ballard Score)"
4818,NCT02139436,27:30:treatment,leg muscles responsive to FES
4819,NCT02138669,1:18:chronic_disease,corneal dystrophy
4820,NCT02138617,18:45:chronic_disease,Prior history of hypertensive encephalopathy
4821,NCT02138214,10:25:treatment,Previous thyroid surgery
4822,NCT02135874,29:66:cancer,Newly diagnosed or relapsed mixed phenotype acute leukemia (MPAL)
4823,NCT02135588,17:34:cancer,Presence of any intracranial mass
4824,NCT02134392,19:37:allergy_name,History of severe anaphylactic shock
4825,NCT02134392,24:48:chronic_disease,Symptoms indicative of irritable bowel syndrome
4826,NCT02133898,1:15:treatment,Concurrent ECT
4827,NCT02133898,1:52:treatment,repetitive transcranial magnetic stimulation (rTMS)
4828,NCT02133872,",49:65:treatment",More than one in-patient hospitalization for an antihypertensive crisis within the year
4829,NCT02133196,24:61:chronic_disease,Clinically significant atrial and/or ventricular arrhythmias
4830,NCT02132598,72:117:allergy_name,The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
4831,NCT02132130,104:107:treatment,"Immunocompromised patients, as judged by the investigators based on patient history, physical exam and CBC"
4832,NCT02132130,",93:136:treatment",Patients with intact vestibular function in at least one ear (non-study ear) as measured by vestibular evoked myogenic potential (VEMP)
4833,NCT02131467,",,,46:71:chronic_disease",18-65 year old male and female patients with primary cervical dystonia
4834,NCT02131467,1:10:treatment,efavirenz
4835,NCT02131389,7:31:treatment,Has a contralateral amputation
4836,NCT02130687,"1:44:treatment,",Treatment with antihypertensive medications for a minimum of 6 months
4837,NCT02129348,"1:27:chronic_disease,",glomerular filtration rate less than 44ml/min/ 1.73m2
4838,NCT02128906,37:61:cancer,with the exception of patients with bilateral tonsil cancers
4839,NCT02128802,7:26:treatment,Prior weight loss surgery
4840,NCT02127658,"12:20:treatment,",who had an incision and drainage of a culture-confirmed MRSA abscess in the Riley Emergency Department or Riley Operating Room within the two weeks prior to enrollment
4841,NCT02125786,"23:44:cancer,,",Any patient with both metastatic ependymoma and age < 3 years at the time of enrollment
4842,NCT02124902,1:27:treatment,Sentinel lymph node biopsy
4843,NCT02124772,12:44:chronic_disease,History of heparin-induced thrombocytopenia
4844,NCT02124772,1:31:treatment,prior treatment with sorafenib
4845,NCT02122328,11:15:chronic_disease,Confirmed TTTS patients
4846,NCT02122328,1:29:treatment,Prior intentional septostomy (purposely making a hole in the dividing membrane)
4847,NCT02122185,",,,,49:58:cancer",CEA ratio > 25 OR CA =< 250 with no evidence of GI cancer
4848,NCT02122081,1:17:chronic_disease,HIV seropositive
4849,NCT02121184,16:37:treatment,Use of chronic analgesic medications
4850,NCT02121158,21:44:treatment,Stable condition on Optimal Medical Therapy
4851,NCT02120222,22:61:cancer,Patients with active central nervous system (CNS) malignancy
4852,NCT02118610,8:41:treatment,Taking herbal or homeopathic medications where the metabolism of the drug is not known
4853,NCT02115685,1:18:chronic_disease,unhealed decubiti
4854,NCT02111850,58:94:allergy_name,History of severe immediate hypersensitivity reaction to any of the agents used in this study
4855,NCT02111824,",,92:129:treatment",subjects with peripheral lung lesions that are <1.5 cm in size who are planning to undergo percutaneous image guided lung biopsy as part of their routine medical care
4856,NCT02110069,1:33:cancer,Kaposiform Hemangioendotheliomas
4857,NCT02110069,1:15:cancer,Tufted angioma
4858,NCT02109627,16:28:treatment,The effects of ficlatuzumab on the developing human fetus are unknown
4859,NCT02108860,"16:19:treatment,",Treatment with CYC within 3 months prior to screening
4860,NCT02107703,",62:86:treatment",Have received recent (within 28 days prior to randomization) yellow fever vaccination
4861,NCT02106988,31:68:cancer,Patients with newly diagnosed stage I and II nasal NK cell lymphoma
4862,NCT02106598,40:57:treatment,Newly diagnosed patients with previous excisional biopsy
4863,NCT02106052,5:16:chronic_disease,All MS subtypes
4864,NCT02105766,76:91:treatment,Major anticipated illness or organ failure incompatible with survival from PBSC transplant
4865,NCT02105545,29:62:chronic_disease,"Patients may have existing, non-oncological genetic disorders"
4866,NCT02102113,27:49:chronic_disease,Current or lifetime major DSM-IV Axis I disorder
4867,NCT02101944,32:72:treatment,Patients who are receiving any other therapeutic investigational agents
4868,NCT02101853,18:23:cancer,"First relapse of B-ALL, allowable sites of disease include isolated bone marrow, combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular; extramedullary sites are limited to the CNS and testicles"
4869,NCT02101853,21:32:chronic_disease,Patients with known optic nerve and/or retinal involvement
4870,NCT02101736,77:92:chronic_disease,Dental braces or prosthesis that interferes with volumetric analysis of the neurofibroma(s)
4871,NCT02101034,1:31:treatment,Prior treatment with cetuximab for incurable disease is not permitted
4872,NCT02100891,1:41:cancer,Diffuse intrinsic pontine gliomas (DIPG) are excluded
4873,NCT02099591,17:31:chronic_disease,newly diagnosed constatipation
4874,NCT02099058,26:45:treatment,Subjects enrolled on the combination therapy phase must satisfy the above exclusion criteria
4875,NCT02098252,53:72:treatment,Hemorrhagic presentation with mass effect requiring surgical management
4876,NCT02097121,1:4:chronic_disease,OAB symptoms not adequately managed by 1 or more anticholinergic agents
4877,NCT02095678,39:75:allergy_name,Known history of allergic reaction to Magnetic Resonance contrast material
4878,NCT02094794,",58:84:chronic_disease,,,,,,","Agreement of men AND women-of-child-bearing-potential to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately"
4879,NCT02094118,1:34:chronic_disease,Immunoglobulin A (IgA) deficiency
4880,NCT02092324,32:61:allergy_name,Previous allergic reactions to janus kinase (JAK) inhibitors or excipients
4881,NCT02092324,28:48:chronic_disease,subjects with a history of Hepatitis B and/or C are allowed on trial if the virus is undetected at the time of enrollment
4882,NCT02091999,9:34:treatment,Routine antimicrobial prophylaxis is permitted
4883,NCT02091141,",,82:89:chronic_disease",History or presence of clinically significant ventricular or atrial dysrhythmia >Grade 2 per NCI CTCAE v4.0
4884,NCT02091141,19:42:chronic_disease,Participants with symptomatic bradycardia
4885,NCT02089607,51:72:chronic_disease,Absence of a non-aneurysmal aortic segment in the distal thoracic aorta above the diaphragmatic hiatus
4886,NCT02089607,1:18:chronic_disease,Innominate artery
4887,NCT02089607,24:40:chronic_disease,"Patients with ruptured aortic aneurysms requiring urgent or emergent repair, with the exception of patients with contained, stable ruptures with anatomy suitable for an off-the-shelf design"
4888,NCT02089607,39:55:treatment,The two vessels incorporated into the endograft repair would most commonly be the innominate artery and left common carotid artery
4889,NCT02088554,1:20:treatment,Hostile mediastinum
4890,NCT02088554,22:43:chronic_disease,Patient has Grade IV Diastolic Dysfunction
4891,NCT02088554,1:16:chronic_disease,Porcelain aorta
4892,NCT02086500,"1:12:chronic_disease,,",Tachycardia (heart rate >110 beats per minute)
4893,NCT02081404,12:25:treatment,A negative esophageal pH result and absence of erosions will be inclusion criteria for these patients
4894,NCT02081404,13:44:chronic_disease,Presence of macroscopic erosive esophagitis
4895,NCT02079857,1:15:chronic_disease,Alarm symptoms according to ROME III
4896,NCT02078102,"33:55:treatment,",Patients must not have received myeloid growth factors within 2 weeks before mobilization attempt on this study
4897,NCT02076906,50:54:treatment,Inability to tolerate stationary position during HIFU
4898,NCT02076906,1:26:treatment,Stem Cell Transplantation
4899,NCT02075710,1:30:chronic_disease,type 1 or 2 diabetes mellitus
4900,NCT02075671,"8:47:treatment,",Use of laser or light based rosacea treatments (on the face) within 1 month prior to Visit 1
4901,NCT02074631,"233:238:treatment,","Clinically significant fractures as defined by ISCD (a long bone fracture of the lower extremities, vertebral compression fracture, or two or more long bone fractures of the upper extremities) (88,89) indicated by a cast or a spine x-ray within the last 2 weeks"
4902,NCT02074436,1:26:chronic_disease,Grade 2 renal dysfunction
4903,NCT02074436,19:38:treatment,Patient receiving antiplatelet agents
4904,NCT02072148,"21:59:treatment,",Participation in an investigational therapeutic drug trial within 30 days of study entry
4905,NCT02069925,",25:40:chronic_disease",Within first 3 years of psychosis onset (per pre-defined SOS threshold criteria)
4906,NCT02068092,1:31:treatment,Prior breast reduction surgery
4907,NCT02064296,45:67:treatment,Able to travel to the study site to receive acupuncture treatments up to two times weekly
4908,NCT02064036,1:26:treatment,Previous hormonal therapy
4909,NCT02063438,21:36:chronic_disease,Previous history of thoracic trauma on the operative side
4910,NCT02061293,"12:24:treatment,,","History of hallucinogen use disorder, or any use in the past 1 year, or >25 lifetime uses"
4911,NCT02059239,",,,,95:98:treatment",Partial response of >50% reduction in bidirectional area of masses and SUV reduction to <8 in PET avid areas Subjects must have evaluable disease
4912,NCT02058095,1:10:treatment,Doxazosin
4913,NCT02058095,1:11:treatment,Tamsulosin
4914,NCT02057133,46:83:treatment,"For Parts A, B, C, D, E, F, H: Have received prior therapy with a CDK4/6 inhibitor"
4915,NCT02056873,31:74:treatment,History of noncompliance with previous medical and psychosocial treatment efforts
4916,NCT02056470,20:35:treatment,Patients requiring knee prosthesis
4917,NCT02056470,1:28:chronic_disease,systemic lupus erythmatosus
4918,NCT02053909,",,53:74:treatment",Serum creatinine >1.8 mg/dL (need for contrast with CT coronary angiogram)
4919,NCT02053792,"20:26:treatment,",Intravenous use of rIX-FP within 14 days of subcutaneous administration of rIX-FP
4920,NCT02053792,12:26:chronic_disease,congenital FIX deficiency
4921,NCT02053766,33:58:chronic_disease,Subject has been diagnosed with mitochondrial dysfunction based on modified Walker criteria
4922,NCT02053246,"32:62:chronic_disease,,,,",with World Health Organization Group 2 Pulmonary Hypertension (Mean pulmonary artery pressure ? 25 mmHg and pulmonary capillary wedge pressure ? 15 mmHg)
4923,NCT02050347,",,141:153:treatment",Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after ATL infusion
4924,NCT02050113,"12:23:treatment,,,",For use of Zenith Flex: diameter >32 mm or <18 mm
4925,NCT02050113,71:75:treatment,"Proximal neck, measured outer wall to outer wall on a sectional image (CT)"
4926,NCT02048371,52:63:cancer,"Patients with documentation of well differentiated liposarcoma only (of the well differentiated/dedifferentiated liposarcoma family) are specifically excluded, owing to its characteristically slow growth"
4927,NCT02046395,1:16:chronic_disease,Type 2 Diabetes
4928,NCT02046330,43:47:treatment,Presence of a condition requiring routine MRIs
4929,NCT02043392,46:68:treatment,Requires non-emergent operation to create an intestinal anastomosis for maintenance of intestinal continuity in which the Magnamosis device can be used instead of sutures or staples
4930,NCT02041936,"59:81:treatment,","Receive non-conventional fractionation schedules, such as stereotactic radiation (5 fractions or less)"
4931,NCT02041936,1:20:treatment,pancuronium bromide
4932,NCT02038257,12:26:chronic_disease,History of Acral Vitiligo
4933,NCT02037048,28:61:treatment,Patients who have received pelvic external beam radiotherapy are not eligible
4934,NCT02036853,23:63:chronic_disease,"History of or current suicidal ideation, behavior and attempts"
4935,NCT02035137,11:26:chronic_disease,They have active diarhhea
4936,NCT02033616,1:41:cancer,Active central nervous system metastases at the time of treatment
4937,NCT02031250,1:30:treatment,Prior head and neck radiation
4938,NCT02030015,33:77:chronic_disease,Subjects must have a documented infantile or juvenile gangliosidosis disease
4939,NCT02025543,21:47:treatment,contraindication to magnetic resonance imaging
4940,NCT02025023,20:28:chronic_disease,Single or multiple chalazia in a single eyelid
4941,NCT02021578,1:10:chronic_disease,Bipolar I (parent or child)
4942,NCT02020707,"1:28:treatment,,",Therapeutic anticoagulation requiring international normalized ratio (INR) > 2.0
4943,NCT02020018,1:8:treatment,Steroid-dependent patients
4944,NCT02019940,"1:23:chronic_disease,",Substance use disorder during the 3 months prior to screening; except for Cannabis and Alcohol use Disorders
4945,NCT02019641,1:27:chronic_disease,Severe psychiatric disease
4946,NCT02016781,1:45:chronic_disease,Human Immunodeficiency Virus (HIV) infection
4947,NCT02016781,"15:26:chronic_disease,","Patients with de novo MDS who have, or have previously had, Intermediate-2 or High risk disease as determined by the International Prognostic Scoring System (IPSS)"
4948,NCT02016781,"1:18:chronic_disease,",Refractory anemia with ringed sideroblasts (RARS)
4949,NCT02015390,1:71:chronic_disease,"Ipsilateral extremity defect (eg, tibia and femur ipsilateral defects)"
4950,NCT02013778,1:11:treatment,Prior TACE
4951,NCT02013154,7:35:cancer,Known osteoblastic bony metastasis
4952,NCT02013154,"1:33:treatment,",Treatment with radiation therapy within 14 days prior to study entry
4953,NCT02011971,"8:40:treatment,,",Stable antiepileptic drug (AED) therapy for last 2 months or more and willing not to change for 2 months
4954,NCT02008656,1:13:cancer,Rectal tumor at baseline which would be considered to require complete TME
4955,NCT02008136,1:19:chronic_disease,myotonic dystrophy
4956,NCT02007239,38:93:treatment,On-going or planned participation in another clinical trial involving HLH-directed treatment
4957,NCT02006069,1:14:chronic_disease,Persistent AF at the time of enrollment
4958,NCT02004275,55:69:treatment,Patients randomized to Arm 1 may opt to switch to the 3-drug regimen following disease progression; these patients must be re-registered to the study and meet the eligibility criteria
4959,NCT02004275,16:48:treatment,progression on lenalidomide maintenance therapy after initial induction +/- consolidation
4960,NCT02003690,22:47:treatment,willing to engage in pharmacotherapy treatment at the CABS specialty clinic
4961,NCT02003222,1:20:treatment,MAINTENANCE THERAPY
4962,NCT02003222,26:57:chronic_disease,Patient must not have an antecedent hematologic disorder
4963,NCT02000115,37:69:treatment,Subjects with pre-existing surgical bioprosthetic aortic heart valve should be considered for the Valve-in-Valve registry
4964,NCT01996449,21:34:allergy_name,Hypersensitivity to nitroprusside
4965,NCT01994538,29:50:treatment,Treatment initiated with an empiric antimicrobial to which the organism isolated in the urine culture is non-susceptible based on standard laboratory criteria
4966,NCT01994382,10:36:treatment,Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease afterwards
4967,NCT01993810,15:45:chronic_disease,Patients with non-malignant pleural effusion
4968,NCT01992861,15:59:cancer,Patients with small cell/neuroendocrine cervical carcinoma
4969,NCT01990209,",,97:121:treatment",Patient has recovered (to Grade ?1) from all clinically significant toxicities related to prior antineoplastic therapies
4970,NCT01990209,"1:16:cancer,,,",Triple negative (ER-/PR-/HER2-)
4971,NCT01989546,23:63:treatment,Patients who have had prior treatment with any PARP inhibitors are ineligible
4972,NCT01988246,"1:70:treatment,",Intravitreal anti-VEGF (vascular endothelial growth factor) treatment in the study eye within 6 months of the pre-operative baseline visit
4973,NCT01986075,1:26:chronic_disease,Coronary vascular disease
4974,NCT01983462,"1:29:treatment,,,,,,,,","Blood chemistries indicative of normal renal (creatinine <2.0 mg/dl), liver (<3 times upper limit for ALT, AST), and thyroid function (TSH between 0.4 - 5.0 mU/L)"
4975,NCT01978509,1:14:chronic_disease,Toxic colitis
4976,NCT01976429,10:28:chronic_disease,existing middle-ear disease
4977,NCT01974609,36:65:treatment,All patients undergoing elective a primary carpal tunnel release
4978,NCT01973283,"25:28:treatment,",Currently followed by a PCP (had an eval in last 6-months)
4979,NCT01972919,36:46:chronic_disease,Patients with and without regional adenopathy are eligible
4980,NCT01970345,105:125:treatment,Patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with IGF-1
4981,NCT01970306,47:64:allergy_name,Patients with known sensitivity or allergy to porcine materials
4982,NCT01969643,25:48:treatment,prior treatment with an MMAE-containing therapy
4983,NCT01968590,1:48:cancer,malignant peripheral nerve sheath tumor (MPNST)
4984,NCT01967823,25:35:cancer,PATIENTS WITH MALIGNANT MENINGIOMA
4985,NCT01967238,40:60:treatment,Willing to receive a single dose of an FDA-approved vaccine
4986,NCT01966367,1:23:chronic_disease,Seropositivity for HIV
4987,NCT01964261,1:22:chronic_disease,Autonomic dysreflexia
4988,NCT01964261,1:19:treatment,Prior cranioplasty
4989,NCT01962415,1:31:chronic_disease,Bare Lymphocyte Syndrome (BLS)
4990,NCT01962415,1:52:chronic_disease,Combined Variable Immune Deficiency (CVID) syndrome
4991,NCT01962415,1:28:chronic_disease,Dyskeratosis Congenita (DC)
4992,NCT01962415,1:25:chronic_disease,Hunter syndrome (MPS II)
4993,NCT01962415,1:30:chronic_disease,Leukocyte adhesion deficiency
4994,NCT01962415,1:22:chronic_disease,Mucopolysaccharidoses
4995,NCT01962415,1:25:chronic_disease,Primary Immunodeficiency syndromes
4996,NCT01962415,8:32:chronic_disease,Severe acquired aplastic anemia
4997,NCT01962415,1:36:chronic_disease,X-linked adrenoleukodystrophy (ALD)
4998,NCT01961778,22:42:allergy_name,contraindications to endoscopic treatment
4999,NCT01959698,"1:19:chronic_disease,",Myocardial infarct within 6 months before enrollment
5000,NCT01956084,"31:60:treatment,",Patients should have been off other investigational therapy for one month prior to entry in this study
5001,NCT01954173,1:43:chronic_disease,Acquired immune deficiency syndrome (AIDS)
5002,NCT01953900,7:32:chronic_disease,Known primary immune deficiency
5003,NCT01953588,1:18:treatment,Surgical axillary staging procedure prior to study entry
5004,NCT01953263,15:35:chronic_disease,Patients with urinary incontinence other than the categories being investigated
5005,NCT01952730,1:19:cancer,Hepatic metastases involving both branches of the portal vein or all three hepatic veins
5006,NCT01951885,1:18:cancer,Hodgkin's disease
5007,NCT01951885,",,47:56:treatment",Total body irradiation (TBI) (? 1200 cGy) and etoposide (60 mg/kg)
5008,NCT01947140,57:90:chronic_disease,Patients must have histologically confirmed relapsed or refractory Non-Hodgkin's lymphoma
5009,NCT01945814,11:54:treatment,Available multivirus-specific cytotoxic T lymphocytes
5010,NCT01943851,1:22:chronic_disease,Cardiac abnormalities as evidenced by
5011,NCT01942018,1:32:chronic_disease,Acute gastrointestinal bleeding
5012,NCT01942018,7:30:chronic_disease,Large esophageal diverticulum
5013,NCT01942018,"6:27:chronic_disease,,,",with symptomatic dysphagia (dysphagia score ?2) EGOO that is diagnosed by high resolution manometry
5014,NCT01941316,43:70:treatment,Patients must have disease outside of the previous surgical resection area or a new lesion must be present
5015,NCT01940757,12:34:chronic_disease,History of iron deficiency anemia
5016,NCT01937884,16:38:chronic_disease,A pre-existing bronchopleural fistula
5017,NCT01937884,4:46:treatment,On extracorporeal membrane oxygenation (ECMO)
5018,NCT01931202,1:20:chronic_disease,Adjustment Disorder
5019,NCT01925573,5:35:treatment,Any prior therapy with bevacizumab
5020,NCT01925131,"1:40:treatment,",Chimeric antigen receptor (CAR) T-cells must not have been received for 28 days prior to registration
5021,NCT01925131,75:106:allergy_name,Patients with a history of a serious allergic or anaphylactic reaction to humanized monoclonal antibodies are not eligible
5022,NCT01925131,"29:46:chronic_disease,",patients must have negative hepatitis B and C serologies performed within 28 days prior to registration
5023,NCT01923662,12:34:chronic_disease,"History of vestibular dysfunction, balance problems or spontaneous falls"
5024,NCT01920737,38:45:cancer,Patients who are later found to have Ph+ ALL should have treatment on this trial discontinued and will not be considered in the evaluation
5025,NCT01919619,7:26:chronic_disease,Prior auto-immune disease
5026,NCT01918683,"1:24:chronic_disease,",Active GI ulcer disease within 4 weeks of study enrollment
5027,NCT01918644,30:68:cancer,Patients with no evidence of regional or distant metastatic disease based on CT scan of the chest/ abdomen/pelvis
5028,NCT01917929,15:55:chronic_disease,"Patient has a neuromuscular or neurosensory deficiency that would create an unacceptable risk of instability, prosthesis fixation failure or complications in postoperative care, or which limits the ability to evaluate the safety and efficacy of the device"
5029,NCT01915095,71:81:treatment,Able to perform some small wrist flexion and extension (measured by a goniometer)
5030,NCT01913106,1:21:cancer,Second active cancer
5031,NCT01912612,14:35:chronic_disease,Uncontrolled narrow-angle glaucoma
5032,NCT01908777,11:32:chronic_disease,Any known cardiac abnormalities
5033,NCT01908777,1:42:cancer,Hepatosplenic Gamma Delta T cell lymphoma
5034,NCT01908777,1:42:treatment,prior autologous or allogeneic transplant
5035,NCT01905046,20:25:treatment,Willing to provide RPFNA and blood samples for correlative research purposes
5036,NCT01903330,13:45:cancer,presence of punctate hemorrhage in the tumor
5037,NCT01901562,6:26:cancer,Have BRCA 1 or 2 mutation
5038,NCT01900093,"12:43:treatment,",Received a live or live attenuated vaccine in the last 30 days before baseline
5039,NCT01896999,68:100:cancer,Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL)
5040,NCT01896921,"1:37:chronic_disease,",Chronic active hepatitis B infection as defined by presence of HBsAg
5041,NCT01895777,88:95:allergy_name,Patients who are allergic/sensitive to any component of the study medication including solvent
5042,NCT01895777,1:29:treatment,unfractionated heparin (UFH)
5043,NCT01894061,24:41:treatment,Minimum interval since last drug therapy
5044,NCT01893307,11:25:treatment,Bilateral Neck Radiation
5045,NCT01891812,36:39:treatment,any contraindications to receiving N2O
5046,NCT01890590,39:49:treatment,Inability to deliver target dose with CyberKnife due to normal tissue dose constraints
5047,NCT01884740,32:39:treatment,Because of known concerns with Avastin and wound healing
5048,NCT01884740,1:28:cancer,anaplastic astrocytoma (AA)
5049,NCT01884740,26:42:cancer,radiologically diagnosed brainstem glioma
5050,NCT01883076,20:53:treatment,undergoing planned Stage II palliative Glenn surgery
5051,NCT01877382,80:88:treatment,"Confirmation of TP53 nonmutant status is encouraged, but not required prior to DS-3032b dosing"
5052,NCT01877382,32:59:treatment,current participation in other therapeutic investigational procedures
5053,NCT01876511,28:72:treatment,Requires any other form of systemic or localized antineoplastic therapy while on study
5054,NCT01872975,"15:33:treatment,,",Patients with pathologic staging of ypN0(i+) or ypN0(mol+)
5055,NCT01871766,"1:17:chronic_disease,",Serum creatinine based on age and gender
5056,NCT01871727,1:34:treatment,Prior denileukin diftitox therapy
5057,NCT01871454,70:85:cancer,Pathologic or clinical diagnosis of a new or loco-regional recurrent lung malignancy
5058,NCT01865162,12:39:chronic_disease,History of uncontrolled hyperlipidemia
5059,NCT01864265,12:43:chronic_disease,History of severe congestive heart failure
5060,NCT01864265,41:85:cancer,with the exception of treated and cured squamous or basal cell carcinoma of the skin
5061,NCT01859819,1:53:cancer,B-Cell Anaplastic Large cell Ki 1 positive lymphomas
5062,NCT01859819,1:43:cancer,Primary Mediastinal B-Cell Lymphoma (PMBL)
5063,NCT01853163,35:49:treatment,0.025 mmol per kg body weight for Gadoxetic acid and 0.1 mmol per kg body weight for all other agents
5064,NCT01851694,1:25:chronic_disease,Pancreatic insufficiency
5065,NCT01851369,61:72:treatment,Patients must be able to swallow whole tablets or capsules; nasogastric or G-tube administration is not allowed
5066,NCT01850758,1:35:chronic_disease,Symptomatic lumbar spine pathology (e.g. radicular pain)
5067,NCT01849146,",18:90:treatment",4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents
5068,NCT01849146,21:43:treatment,unlimited number of prior therapy regimens
5069,NCT01842399,64:91:treatment,Unable to perform knee strength testing due to reasons such as bilateral knee replacements
5070,NCT01841333,",,24:44:treatment",Between days 28 and 50 post transplantation at the time of initiation of the study drug
5071,NCT01841333,1:18:treatment,azole antifungals
5072,NCT01835626,1:17:treatment,Prior vismodegib or other antagonists of the Hh pathway
5073,NCT01829958,1:26:chronic_disease,Systemic fungal infection
5074,NCT01824836,7:16:treatment,daily analgesic medication for active
5075,NCT01822522,1:42:treatment,Prior treatment with cabozantinib (XL184)
5076,NCT01822522,",,,182:194:treatment","men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of cabozantinib administration"
5077,NCT01821690,"4:13:treatment,",No surgeries planned during the 91-day participation
5078,NCT01817751,12:41:treatment,Current or prior valproic acid treatment is allowed
5079,NCT01815359,70:80:treatment,Any condition that would preclude the ability to deliver appropriate IP therapy
5080,NCT01812174,123:156:treatment,"Patients who are sufficiently ill to warrant replacement of their diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups"
5081,NCT01811368,1:20:chronic_disease,Alcoholic hepatitis
5082,NCT01811368,18:51:treatment,Patients fit for non-myeloablative transplantation or best treatment that have an available matched (9/10 or better) related or unrelated donor
5083,NCT01810588,1:35:chronic_disease,Chronic myeloproliferative disease
5084,NCT01809002,1:24:chronic_disease,Peripheral Nerve Injury
5085,NCT01807897,"21:40:treatment,",No change in active cardiac medications for 4 weeks prior to randomization
5086,NCT01807611,10:22:cancer,"If prior CNS leukemia, it must be treated and in CNS CR"
5087,NCT01804634,1:25:cancer,Metastatic Ewing Sarcoma
5088,NCT01804634,1:21:cancer,ganglioneuroblastoma
5089,NCT01804465,"1:27:treatment,,,","Prior radiopharmaceuticals (strontium, samarium) must be completed ? 8 weeks prior to enrollment"
5090,NCT01799538,1:21:chronic_disease,Cognitive Impairment
5091,NCT01799538,22:67:treatment,high serum levels of vascular endothelial growth factor D (VGEF-D)(1)
5092,NCT01795313,"28:42:treatment,",Patients may have received re-irradiation but not to the index lesion within 4 weeks
5093,NCT01794793,"1:19:treatment,,,",Male sterilization (at least 6 months prior to enrolling). For female patients on the study the vasectomized male partner should be the sole partner for that patient
5094,NCT01794559,25:41:chronic_disease,"History of, or current, open head trauma"
5095,NCT01793519,26:40:treatment,Unwilling to discontinue anti-TNF agent
5096,NCT01791543,"1:33:chronic_disease,",Thrombotic myocardial infarction within the preceding two (2) months
5097,NCT01789333,1:19:chronic_disease,Thinning of cornea
5098,NCT01787682,"13:18:chronic_disease,",Presence of fever within the last 3 days
5099,NCT01787409,30:55:treatment,Capable of swallowing intact study medication capsules
5100,NCT01787409,50:69:treatment,patient is permitted to participate in any other therapeutic therapy for their disease as long as it does not concern vitamin D
5101,NCT01782599,",27:37:treatment",Be pregnant (measured via urinalysis)
5102,NCT01777035,1:19:chronic_disease,Terminal condition
5103,NCT01774019,1:38:treatment,Previous biliary drainage by ERCP/PTC
5104,NCT01773707,18:38:chronic_disease,Have evidence of active EBV infection
5105,NCT01773694,",,66:80:treatment",will not be returning to the dermatology clinic in 7-14 days for suture removal
5106,NCT01766297,32:48:cancer,Histologic examination showing invasive lobular histology
5107,NCT01766297,28:53:cancer,Must have pathology proven invasive ductal carcinoma
5108,NCT01763970,1:19:cancer,tumor malignancies must meet certain criteria to be eligible
5109,NCT01760655,",,85:115:chronic_disease",Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder
5110,NCT01757418,"1:41:treatment,",Vaccination with a live attenuated virus in the preceding 6 weeks
5111,NCT01756040,1:32:chronic_disease,Lethal chromosome abnormalities
5112,NCT01754779,",,26:36:treatment",>300mg/d in men prior to indapamide use
5113,NCT01754298,23:43:treatment,Completed a course of conservative therapy
5114,NCT01754298,1:24:chronic_disease,osteogenesis imperfecta
5115,NCT01750567,7:29:chronic_disease,Known diabetes (type 1 or 2)
5116,NCT01743950,1:18:cancer,"Recurrent disease based on combination of clinical, imaging or histologic confirmation"
5117,NCT01742182,8:28:treatment,Use of hypno-sedative drugs for sleep or stimulants
5118,NCT01737502,1:20:chronic_disease,labile hypertension
5119,NCT01734512,"29:71:treatment,",Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
5120,NCT01730794,",34:48:chronic_disease",Equal to or greater than 3 total organ failures
5121,NCT01730118,",,,,,,,212:225:treatment","Willingness of female and male subjects to use effective contraception e.g. oral contraceptives, barrier device, intrauterine device, or condoms, during the study and for three months following the last dose of study vaccine"
5122,NCT01726257,1:36:chronic_disease,Proximal non-aneurysmal aortic neck
5123,NCT01720836,4:25:treatment,No prior vaccine therapy
5124,NCT01716806,44:70:cancer,"Histopathologically-confirmed diagnosis of classical Hodgkin lymphoma (Parts A, B, C, D, and E)"
5125,NCT01715571,"15:35:chronic_disease,,,",mild-moderate erectile dysfunction based on International Index of Erectile Function (IIEF) erectile function score 13-25
5126,NCT01714596,100:129:chronic_disease,"Patients likely to have severe problems maintaining follow-up, including patients diagnosed with a severe psychiatric conditions, patients who live too far outside the hospital's catchment area"
5127,NCT01712308,1:18:treatment,Prior sotatercept
5128,NCT01705119,8:30:chronic_disease,Active gastrointestinal blood loss
5129,NCT01703949,"1:19:treatment,",Radioimmunotherapy within 12 weeks
5130,NCT01703117,"27:36:treatment,",Subjects who have been on donepezil for longer than 5 years
5131,NCT01697930,",123:182:treatment","Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of [18F] 4-L-Fluoroglutamine (2S,4R) injection and blood draws.)"
5132,NCT01697865,1:24:chronic_disease,Teres minor dysfunction
5133,NCT01697371,34:46:treatment,Tense ascites requiring frequent paracentesis
5134,NCT01697293,"1:18:treatment,",tamoxifen therapy or other hormonal agents should be discontinued at least 1 week before the patient is enrolled on this study
5135,NCT01696734,1:20:chronic_disease,Torsades de pointes
5136,NCT01695967,1:39:chronic_disease,congenital head and neck malformations
5137,NCT01690468,102:108:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to TCN-PM
5138,NCT01690468,20:38:cancer,platinum-resistant epithelial ovarian
5139,NCT01685411,14:48:treatment,eligible for TBI containing preparative regimen
5140,NCT01684397,24:62:chronic_disease,History of symptomatic chronic congestive heart failure (CHF)
5141,NCT01681589,"1:13:chronic_disease,",Brain Injury at least 6 months prior
5142,NCT01676753,37:57:chronic_disease,"Patient has known history of active Hepatitis A, B, or C"
5143,NCT01676259,"5:20:treatment,",All radiology scans must be performed within 28 days prior to registration
5144,NCT01676259,1:15:cancer,in situ cancer
5145,NCT01675154,1:28:chronic_disease,Type I hyperlipoproteinemia
5146,NCT01668602,"9:19:chronic_disease,","Neglect/hemianopia, or unexplained dizziness in last 6 months"
5147,NCT01666769,23:64:treatment,Supported with either venoarterial (VA) or venovenous (VV) ECMO
5148,NCT01660607,",,22:54:chronic_disease",Complex karyotype(?3 clonal chromosomal abnormalities)
5149,NCT01660607,1:30:treatment,hematopoietic cell transplant
5150,NCT01659541,1:38:chronic_disease,Spinal cord injury C8 level or higher
5151,NCT01653093,34:50:cancer,Patients with known or suspected prostate disease based on clinical data
5152,NCT01652092,1:36:chronic_disease,Chronic Granulomatous Disease (CGD)
5153,NCT01652092,14:48:chronic_disease,Other severe Combined Immune Deficiencies (CID)
5154,NCT01648751,"10:41:treatment,",Previous bilateral salpingo-oophorectomy (women with 1 ovary will be eligible)
5155,NCT01648023,"15:37:chronic_disease,,",Patients with liver-dominant disease defined as ?80% tumor burden confined to the liver
5156,NCT01647321,19:60:chronic_disease,Subjects having a Stage 2 or greater sacral decubitus ulcer
5157,NCT01643473,18:41:chronic_disease,Have significant psychiatric comorbidity
5158,NCT01639508,1:34:treatment,Prior treatment with cabozantinib
5159,NCT01639508,1:24:chronic_disease,intra-abdominal abscess
5160,NCT01631617,33:56:treatment,Subjects must be co-enrolled in NIH protocol 08-HG-0059
5161,NCT01626079,70:91:chronic_disease,American College of Cardiology /American Heart Association (ACC/AHA) Stage D heart failure
5162,NCT01626079,",,65:99:treatment,",Mitral valve orifice area < 4.0 cm2 assessed by site based on a transthoracic echocardiogram (TTE) within 90 days prior to subject registration
5163,NCT01626079,18:56:treatment,Subjects in whom transesophageal echocardiography (TEE) is contraindicated or high risk
5164,NCT01626079,"1:46:treatment,",Transcatheter aortic valve replacement (TAVR) within 30 days prior to subject registration
5165,NCT01625923,24:35:chronic_disease,Subject has pronounced dehydration
5166,NCT01625234,23:40:chronic_disease,patients with a known ALK 1198 mutation
5167,NCT01624090,1:8:treatment,Dextran
5168,NCT01624090,61:81:treatment,"Normal ionized calcium, magnesium and phosphorus (can be on oral supplementation)"
5169,NCT01624090,1:20:treatment,Thrombolytic agents
5170,NCT01623167,"1:23:chronic_disease,,",Severe aplastic anemia characterized by Bone marrow cellularity less than 30 percent
5171,NCT01620216,11:43:treatment,No active graft versus host disease (GVHD)
5172,NCT01617161,1:38:chronic_disease,Chronic obstructive pulmonary disease exacerbation
5173,NCT01616108,1:21:chronic_disease,Paralytic strabismus
5174,NCT01614197,"12:26:treatment,",A positive fungal culture within 30 days
5175,NCT01614197,"29:50:treatment,,",Patients must have been off blinatumomab infusion for at least 4 days and all drug-related toxicity must have resolved to grade 2 or lower as outlined in the inclusion and exclusion criteria
5176,NCT01608438,110:130:treatment,"Administration of drugs that potentially lower seizure threshold [62], without concomitant administration of anticonvulsant drugs which potentially protect against seizures occurrence"
5177,NCT01600040,1:28:cancer,endometrial stromal sarcoma
5178,NCT01599559,200:245:cancer,"Patients must have histological confirmation of the diagnosis (it is recommended that the immunohistochemical panel includes: CD45, CD20, CD30, CD15, CD10, BCL6, BCL2, MUM-1), and in addition have a dominant mass within the anterior mediastinum"
5179,NCT01597518,21:29:allergy_name,Hypersensitivity to riluzole or any of its components
5180,NCT01597518,1:11:treatment,Mexiletine
5181,NCT01597518,1:14:treatment,Thiabendazole
5182,NCT01595529,56:64:allergy_name,A child with known anaphylactic allergies to the study products
5183,NCT01595529,11:40:chronic_disease,Confirmed UTI (Urinary Tract Infection) diagnosis
5184,NCT01595529,1:11:chronic_disease,flank pain
5185,NCT01595061,54:90:cancer,"Patients with locally advanced, previously untreated squamous cell carcinoma of the vulva"
5186,NCT01589263,"13:36:treatment,",Enrolled in another treatment trial for any disease within the past 30 days
5187,NCT01589263,",,67:76:treatment",Serum prostate specific antigen (PSA) level greater than 8 ng/ml (Hybritech)
5188,NCT01584076,59:75:treatment,Inability to swallow pills equivalent in size to the 5 mg donepezil tablet
5189,NCT01584076,"1:19:treatment,",Strabismus surgery planned within 22 weeks
5190,NCT01581580,18:20:chronic_disease,The diagnosis of ET will be confirmed on clinical examination in the NIH Movement Disorders Clinic (the diagnosis of ET will be based on bilateral
5191,NCT01573754,1:24:chronic_disease,Blistering skin lesions due to another condition
5192,NCT01572480,",84:94:treatment","Absence of lytic bone lesion on X-ray, CT, or PET/CT and not more than 1 lesion on spinal MRI"
5193,NCT01572480,1:31:treatment,Treatment with corticosteroids for other indications is permitted
5194,NCT01570998,1:20:cancer,Multicentric cancer in the same breast as diagnosed by clinical examination
5195,NCT01570998,1:25:treatment,prior in-field radiation
5196,NCT01570816,1:20:chronic_disease,severe osteoporosis
5197,NCT01568918,1:22:treatment,Cervical Foraminotomy
5198,NCT01568918,1:23:chronic_disease,Lumbar Anterior Fusion
5199,NCT01568918,1:19:treatment,Lumbar Laminectomy
5200,NCT01568255,24:38:treatment,An indication to be on statin therapy
5201,NCT01568177,21:31:treatment,Contraindication to Dobutamine
5202,NCT01568177,13:34:chronic_disease,significant aortic valve stenosis
5203,NCT01562626,13:24:chronic_disease,Presence of GI bleeding
5204,NCT01555905,16:41:chronic_disease,Diagnosis of a primary pulmonary disease
5205,NCT01555554,1:20:treatment,Sub-arachnoid block (spinal)
5206,NCT01554410,41:64:cancer,"Histologically-proven, invasive primary carcinoma of the cervix"
5207,NCT01554371,21:40:chronic_disease,"Patients with other significant disease or disorders that, in the Investigator's opinion"
5208,NCT01553942,7:23:treatment,Prior EGFR TKI therapy
5209,NCT01547429,1:29:chronic_disease,Chronic or recurrent uveitis or history of the same
5210,NCT01543490,"10:24:treatment,",Have had eyelid surgery in the study eye within twelve (12) months prior to Visit 1 or plan to have eyelid surgery during the study
5211,NCT01542879,58:72:allergy_name,patients with a positive history of allergic reaction to iron compounds or other severe allergic reactions
5212,NCT01538966,23:35:cancer,The patient harbors a macroadenoma with visual field defects due to chiasmatic compression
5213,NCT01534104,"1:33:cancer,","Primary or secondary brain tumor (enhancing mass lesion ± nonenhancing abnormality), known or suspected, located near (< 2 cm) any portion of the motor cortex"
5214,NCT01532687,13:27:treatment,Implants of levonorgestrel
5215,NCT01532687,24:81:treatment,Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
5216,NCT01530958,1:18:treatment,Kidney transplant recipients
5217,NCT01525901,8:17:chronic_disease,closed epiphyses
5218,NCT01522768,"59:79:treatment,,",HER2 overexpression and/or amplification as determined by immunohistochemistry (3+) or FISH (?2.0)
5219,NCT01522768,",,107:115:treatment","Patients aged 18 years or older, as no dosing or adverse event data are currently available on the use of afatinib in patients <18 years of age"
5220,NCT01508390,"21:30:cancer,,",Moderate high risk: Stage cT3 and Gleason 7 and any prostate-specific antigen
5221,NCT01505569,",67:88:treatment,,",Camera method is NOT allowed as measure of GFR prior to or during Consolidation therapy for patients with GFR or creatinine clearance of < 100 ml/min/1.73m2.)
5222,NCT01505569,33:48:treatment,"Organ Function, Arm C (to begin TI chemotherapy)"
5223,NCT01505569,1:56:cancer,Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)
5224,NCT01505062,20:47:treatment,Participation in a prior gene transfer therapy study
5225,NCT01504373,1:34:chronic_disease,Congenital cyanotic heart defects
5226,NCT01500551,1:19:chronic_disease,Chronic infections
5227,NCT01495637,16:33:treatment,Presence of an endotracheal tube at the time of enrollment
5228,NCT01494662,4:32:treatment,No prior therapy with neratinib
5229,NCT01494324,30:58:cancer,Patients with diagnosed with secondary hepatic malignancy
5230,NCT01474889,"1:63:treatment,",Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment
5231,NCT01473628,32:70:treatment,Patient with concurrent use of complementary or alternative medicines
5232,NCT01465100,22:36:chronic_disease,Subject has positive HIV serostatus
5233,NCT01464034,1:15:chronic_disease,POEMS syndrome
5234,NCT01464034,1:32:chronic_disease,Waldenström's macroglobulinemia
5235,NCT01459107,1:26:treatment,Below-shoulder amputation
5236,NCT01459107,1:22:chronic_disease,Paralysis of ischemic or traumatic origin
5237,NCT01459107,1:14:chronic_disease,Toxoplasmosis
5238,NCT01453088,"1:38:chronic_disease,",Sensory peripheral neuropathy grade 4 within 14 days of enrollment
5239,NCT01446094,24:44:treatment,Scheduled for invasive coronary angiography
5240,NCT01444209,45:80:cancer,Pathological or radiographic diagnosis of a pan-invasive pituitary macroadenoma
5241,NCT01436968,30:54:treatment,Patients planning to receive whole pelvic irradiation
5242,NCT01433315,54:86:chronic_disease,The investigators will exclude subjects who have any medical or psychiatric disorders
5243,NCT01430390,1:38:treatment,Previous infusion of CD19 CAR T cells at another institution
5244,NCT01422746,1:18:chronic_disease,Hyperandrogenemic
5245,NCT01422005,26:43:chronic_disease,Subjects must have had a unilateral stroke
5246,NCT01421797,"9:17:treatment,",Morning Cortisol <5 g/dL
5247,NCT01421095,1:33:treatment,pelvic or total body irradiation
5248,NCT01419561,1:21:chronic_disease,Altered mental state
5249,NCT01415882,"1:15:treatment,",Anthracyclines =< 14 days prior to registration
5250,NCT01407809,"8:28:chronic_disease,","Severe visual function loss, defined as grades 4 and 5 on the Humphrey Visual Field Analyzer SITA Standard 24-2 Test grading scale (Table 4) at initial presentation"
5251,NCT01399476,1:43:treatment,Previous mediastinal or esophageal surgery
5252,NCT01389024,19:43:chronic_disease,Other significant organ system dysfunction
5253,NCT01384513,"1:29:treatment,,,,,",ematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score > 4 points for patients ? 60 years old or > 5 points for patients < 60
5254,NCT01379573,15:38:chronic_disease,developmental tricuspid valve disease
5255,NCT01373112,21:43:treatment,Medically unfit for operative intervention
5256,NCT01371630,"15:38:cancer,",Patients with refractory-relapsed ALL of any age are eligible
5257,NCT01367444,"83:110:treatment,,",Enlargement in the area of central macular retinal thinning/photoreceptor loss by ocular coherence tomography at a rate of ?0.5 mm^2
5258,NCT01367444,",,65:79:treatment",Reduction in macular mean sensitivity of ?1.2 dB as assessed by microperimetry
5259,NCT01366612,7:25:chronic_disease,Known amyloid deposition in heart
5260,NCT01364363,",,19:45:treatment",Weight < 70kg for cord blood transplantation
5261,NCT01356290,1:20:chronic_disease,Active peptic ulcer
5262,NCT01351103,1:25:chronic_disease,Pathologic bone fracture
5263,NCT01341080,33:55:chronic_disease,Subjects will be diagnosed with Parkinson Disease (PD) by the UK Brain Bank criteria
5264,NCT01333046,31:40:treatment,multiply relapsed patients in remission who are at a high risk of relapse
5265,NCT01313533,",44:79:treatment",Any patient was has undergone more than 20 computerized tomography (CAT) scans
5266,NCT01312857,41:64:treatment,"However, patients who have responded to prior anti-EGFR therapy are eligible"
5267,NCT01293214,25:49:treatment,Single dominant hand or multiple limb amputation
5268,NCT01280669,12:30:chronic_disease,History of herpetic infection in the study eye or adnexa
5269,NCT01280669,1:19:chronic_disease,Pupillary dilation inadequate for quality fundus photography in the study eye
5270,NCT01269034,1:30:chronic_disease,juvenile rheumatoid arthritis
5271,NCT01261728,1:39:treatment,Prior radiation therapy to the bladder
5272,NCT01245712,1:36:treatment,Prior radiation to the index breast
5273,NCT01243931,6:23:chronic_disease,Deep corneal opacities and irregularities
5274,NCT01239160,21:111:cancer,have a diagnosis of primary or secondary late Stage 2 or 3 unilateral or bilateral lower extremity lymphoedema
5275,NCT01220583,",,71:95:cancer",High-grade acinic cell carcinoma or high-grade (>30% solid component) adenoid cystic carcinoma
5276,NCT01200940,1:34:chronic_disease,"Psychiatric or cognitive disorder that will, in the opinion of the investigators, limit the subject's ability to provide informed consent, or to comply with study procedures"
5277,NCT01189786,1:24:chronic_disease,Psychiatric disturbance
5278,NCT01187368,51:68:treatment,Patients with an unacceptable risk for successful LVAD implantation and maintenance
5279,NCT01185210,14:36:chronic_disease,Diagnosis of fructose malabsorption
5280,NCT01185132,"1:31:cancer,",Microscopic multifocal disease is only allowed when the entire span of identified disease measures 3.0 cm or less
5281,NCT01185132,"1:20:chronic_disease,",microscopic disease greater than 3.0 cm
5282,NCT01184547,1:22:chronic_disease,Malignant neuroleptic hyperthermia
5283,NCT01174121,42:72:treatment,Grade 3 or 4 major organ irAEs following treatment with anti-PD-1/PD-L1
5284,NCT01174108,1:24:treatment,Telomere Length Testing
5285,NCT01128816,30:54:chronic_disease,Exercise capacity limited by class IV angina pectoris
5286,NCT01099644,",,83:106:treatment,,",Pregnancy testing will be carried out within two weeks prior to administration of radioiodinated Burtomab in females of childbearing age
5287,NCT01072370,64:81:chronic_disease,Clinical evidence of a non-progressive motor disability due to brain dysfunction
5288,NCT01072370,1:39:chronic_disease,Severe intrauterine growth restriction
5289,NCT01059786,58:74:treatment,Efficacy and/or safety of immunization during periods of B-cell depletion have not been adequately studied
5290,NCT01050855,1:76:chronic_disease,Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome
5291,NCT01050855,8:32:cancer,severe Langerhans histiocytosis
5292,NCT01037790,1:37:cancer,ER positive metastatic breast tumors (data now shows all to be Rb positive.)
5293,NCT01028846,12:15:chronic_disease,History of CAD
5294,NCT01011777,1:24:chronic_disease,Grade IV hydronephrosis (Grade III dilation plus parenchymal thinning)
5295,NCT01011777,57:81:chronic_disease,"Renal ultrasound demonstrating Society of Fetal Urology Grade III hydronephrosis (widely split renal pelvis, renal calices uniformly dilated, no parenchymal thinning)"
5296,NCT00985205,"10:30:treatment,",Received glutamine supplement for > 24 hrs prior to randomization
5297,NCT00975520,10:31:treatment,Complete macroscopic resection of all known disease
5298,NCT00969332,1:22:treatment,Anticoagulant therapy
5299,NCT00967785,27:32:chronic_disease,Absence of a diagnosis of WHIMS
5300,NCT00967577,",,43:84:chronic_disease","Platelet count <150,000/mm3 or history of platelet count abnormality or dysfunction"
5301,NCT00959140,"1:5:treatment,,",DLCO (alveolar diffusion capacity for carbon monoxide) (corrected for hemoglobin) ? 50% of predicted
5302,NCT00946192,",62:76:chronic_disease,,,,","absence of menses for > three months (74) within a period of oligomenorrhea (cycle length > six weeks) for >six months, or absence of menarche at >16 years"
5303,NCT00929006,23:46:allergy_name,History of allergy to micronized progesterone
5304,NCT00926237,39:54:chronic_disease,Subjects must not have any history of Bipolar Disease
5305,NCT00924027,41:80:treatment,Patients currently receiving concurrent investigational chemotherapeutic agents
5306,NCT00920972,1:19:chronic_disease,Invasive infection
5307,NCT00919503,"19:36:treatment,",Receiving another experimental drug within 4 weeks of initiation of conditioning (day -6) unless approved by the PI
5308,NCT00914823,23:47:treatment,willing to complete a dopamine agonist washout
5309,NCT00911560,"1:23:chronic_disease,",bone marrow metastases plus high urine catecholamine levels
5310,NCT00909909,1:20:cancer,Medullary carcinoma
5311,NCT00909909,1:20:cancer,Papillary carcinoma
5312,NCT00904046,15:45:chronic_disease,Subjects with uric acid kidney stone disease
5313,NCT00902720,21:49:treatment,patients undergoing elective removal of an ovary for fertility preservation only
5314,NCT00887146,35:42:cancer,Patients with codeleted low grade gliomas must also be considered high risk by exhibiting one or more of the following characteristics
5315,NCT00881660,24:79:chronic_disease,"Confirmed diagnosis of severe or extremely severe left, right or bilateral CDH of the fetus"
5316,NCT00881660,1:11:chronic_disease,Severe CDH: -Fetal liver herniated into the hemithorax
5317,NCT00872950,22:41:allergy_name,"Known sensitivity to 3,4-DIAMINOPYRIDINE"
5318,NCT00862446,"13:26:treatment,",Anticipated TPN treatment for at least one month
5319,NCT00857207,"1:24:chronic_disease,",Frontal Lobe impairment will be determined by 1.5 standard deviations below the mean on either the D-KEFS Color Word Interference Testorthe EXAMINER composite score
5320,NCT00846742,12:20:cancer,defined as Stage IB
5321,NCT00819208,21:33:cancer,Synchronous primary colon cancer
5322,NCT00799864,31:78:chronic_disease,Has diagnosed with documented human immuno deficiency virus (HIV-1) infection
5323,NCT00788164,1:27:chronic_disease,Human papillomavirus (HPV) 16-positive disease by PCR
5324,NCT00788164,15:19:allergy_name,No allergy to eggs
5325,NCT00788164,"4:28:treatment,",No investigational agent(s) within the past 6 months
5326,NCT00788164,1:38:chronic_disease,Traumatic or pruritic skin conditions
5327,NCT00738101,"24:45:treatment,",Be expected to require intravenous nutrition for at least an additional 28 days
5328,NCT00737893,30:56:chronic_disease,The patient has a history of high or low blood pressure that is not controlled
5329,NCT00737893,42:50:treatment,The patient is taking medications called nitrates
5330,NCT00734877,",,46:69:cancer","Zubrod ? 2, unless solely due to symptoms of MM-related bone disease"
5331,NCT00720785,",30:53:treatment",At least 2 weeks since prior palliative radiotherapy
5332,NCT00720785,1:27:cancer,metastatic Ewing's sarcoma
5333,NCT00719888,"11:35:treatment,",Any prior myeloablative transplant within the last 6 months
5334,NCT00719888,49:75:treatment,UCB units will be selected according to current umbilical cord blood graft selection algorithm
5335,NCT00719888,",142:159:treatment",these patients must be discussed with the PI prior to enrollment; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval
5336,NCT00716066,16:50:chronic_disease,Concordant for autoimmune neurological disease(s) as determined by neurological evaluation
5337,NCT00716066,",47:60:treatment",Patients must have failed at least 2 lines of stand therapy as outlined for the specific diseases
5338,NCT00716066,1:25:chronic_disease,Rasmussen's encephalitis
5339,NCT00715611,1:18:treatment,Prior nephrectomy on the contralateral side of MPM
5340,NCT00713492,29:52:chronic_disease,Current or prior history of serious medical illness
5341,NCT00711373,1:10:chronic_disease,Blindness: blind amputees may be poor candidates because sensory return in the hand may not provide sufficient protective sensation
5342,NCT00703105,59:84:cancer,Patients must have a histologic or cytologic diagnosis of epithelial ovarian cancer
5343,NCT00703105,133:151:treatment,"there is an unknown but potential risk for adverse events in nursing infants, breastfeeding should be discontinued if the mother is treated with Ontak"
5344,NCT00673842,",22:42:treatment",> / = 3 months after coronary angioplasty
5345,NCT00673842,3:28:treatment,a cardiac resynchronization device
5346,NCT00670358,4:55:chronic_disease,No post-transplant lymphoproliferative disorder (PTLD)
5347,NCT00632853,44:73:cancer,Histologically or cytologically documented small cell lung cancer (SCLC)
5348,NCT00630253,"7:60:cancer,,","Early myelodysplastic syndrome, with multilineage dysplasia with < 5% blasts, with or without chromosomal anomalies"
5349,NCT00625417,1:28:treatment,excisional biopsy procedure
5350,NCT00606411,21:42:treatment,Previous history of Topiramate or Topamax use for any condition
5351,NCT00542373,52:63:cancer,Patients with either pre-malignant or a history of oral cancer based on patient history and clinical presentations
5352,NCT00540761,13:46:chronic_disease,unprotected left main coronary artery disease
5353,NCT00488696,26:43:allergy_name,Anaphylactic reaction to contrast material
5354,NCT00483249,58:89:treatment,Anticipated mortality comparable to published rates with conventional surgical treatment
5355,NCT00483249,"8:23:chronic_disease,",and/or iliac aneurysms larger than 4 cm in diameter
5356,NCT00467987,8:67:treatment,Use of over the counter health supplements which contain androgens
5357,NCT00409435,14:43:chronic_disease,Diagnosis of postural tachycardia syndrome
5358,NCT00392756,117:129:treatment,with a single serum sample demonstrating low estradiol (estrogen) in association with low or inappropriately normal gonadotropin levels
5359,NCT00383656,11:49:treatment,receiving physiologic glucocorticoid replacement if needed
5360,NCT00358657,"1:26:chronic_disease,",Cardiac ejection fraction < 30%
5361,NCT00357565,",84:100:treatment,,","All patients must be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a cellularity of ?15%"
5362,NCT00351611,",,25:44:treatment",Currently taking 1 to 3 antiepileptic drugs
5363,NCT00338377,",,,140:161:treatment",Patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery
5364,NCT00293475,1:18:cancer,Systemic lymphoma
5365,NCT00293475,1:20:treatment,spinal radiotherapy
5366,NCT00291525,1:35:chronic_disease,Left or right ventricular aneurysm
5367,NCT00291525,1:19:chronic_disease,Vascular pathology
5368,NCT00258427,1:26:cancer,Biallelic BRCA2 mutations
5369,NCT00209235,91:115:chronic_disease,"For the portion of the study in which growth hormone is used for participants who are not growth hormone deficient (ie., growth hormone sufficient)"
5370,NCT00186927,1:16:cancer,Immunodeficient household members
5371,NCT00167219,35:39:cancer,Patients must have a diagnosis of JMML and fulfill these minimal criteria (International diagnostic criteria for JMML)
5372,NCT00147056,22:37:allergy_name,Known sensitivity to gadolinium-DTPA
5373,NCT00107289,1:24:chronic_disease,grade 3 hearing deficit is acceptable
5374,NCT00085982,14:27:chronic_disease,"Syndromes of lipodystrophy are similar, but we already have approval to treat this group of patients"
5375,NCT00065676,1:39:chronic_disease,eye damage (proliferative retinopathy)
5376,NCT00004317,",,33:53:chronic_disease",Pregnant women with evidence of toxoplasma infection by clinical observation and amniotic fluid sampling
5377,NCT00001337,5:24:cancer,Non-Hodgkin's lymphomas
5378,NCT02535312,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5379,NCT02516670,"81:97:chronic_disease,111:135:chronic_disease,137:161:chronic_disease,163:181:chronic_disease,186:223:chronic_disease","Have uncontrolled intercurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5380,NCT02510456,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5381,NCT02498613,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5382,NCT02474368,"75:91:chronic_disease,105:129:chronic_disease,131:155:chronic_disease,157:175:chronic_disease,180:217:chronic_disease","Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5383,NCT02390752,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5384,NCT02237183,"12:28:chronic_disease,42:66:chronic_disease,68:92:chronic_disease,94:112:chronic_disease,117:154:chronic_disease","ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that in the opinion of investigators would jeopardize patient safety of data integrity"
5385,NCT02201992,"108:124:chronic_disease,138:162:chronic_disease,164:188:chronic_disease,203:221:chronic_disease,226:263:chronic_disease","Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5386,NCT02101034,"77:93:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,158:176:chronic_disease,181:218:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5387,NCT02059239,"57:73:chronic_disease,87:111:chronic_disease,113:137:chronic_disease,139:157:chronic_disease,162:199:chronic_disease","olled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5388,NCT02020707,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5389,NCT02013492,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5390,NCT01905046,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5391,NCT01670877,"77:93:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,158:176:chronic_disease,181:218:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5392,NCT00887146,"77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5393,NCT02547662,"13:20:chronic_disease,24:43:chronic_disease,132:141:treatment","Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol"
5394,NCT02542657,"13:20:chronic_disease,24:43:chronic_disease,132:141:treatment","Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol"
5395,NCT02481310,"27:34:chronic_disease,38:57:chronic_disease,146:155:treatment","Patients with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol"
5396,NCT02339948,"9:16:chronic_disease,20:39:chronic_disease,64:73:treatment",Current medical or psychiatric illness that may interfere with treatment completion and followup
5397,NCT02253316,"13:20:chronic_disease,24:43:chronic_disease,132:141:treatment","Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol"
5398,NCT01618357,"34:41:chronic_disease,45:64:chronic_disease,116:125:treatment",Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment
5399,NCT01045148,"7:14:chronic_disease,18:37:chronic_disease,104:113:treatment","Major medical or psychiatric illness, which in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up"
5400,NCT02562716,"90:106:chronic_disease,120:144:chronic_disease,146:161:chronic_disease,172:190:chronic_disease,195:214:chronic_disease","Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5401,NCT02427841,"77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5402,NCT02425904,"76:92:chronic_disease,106:130:chronic_disease,132:147:chronic_disease,158:176:chronic_disease,181:200:chronic_disease","Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5403,NCT02362997,"64:80:chronic_disease,94:118:chronic_disease,120:135:chronic_disease,146:164:chronic_disease,169:188:chronic_disease","Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or pose excess risk to the participant in the opinion of the treating clinician"
5404,NCT01720836,"77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5405,NCT02567422,",,,,,299:335:treatment,337:369:treatment,374:382:treatment","Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam"
5406,NCT02474173,",,,,,,,282:318:treatment,320:352:treatment,357:365:treatment","Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam"
5407,NCT02408861,",,,,,,283:319:treatment,321:353:treatment,358:366:treatment","Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam"
5408,NCT02272998,",,,,150:186:treatment,188:220:treatment,225:233:treatment","longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam"
5409,NCT02370693,"33:43:allergy_name,45:50:allergy_name,54:62:allergy_name","Patient has hypersensitivity to bortezomib, boron or mannitol"
5410,NCT01415752,"44:54:treatment,56:61:treatment,66:74:treatment","Patients must not have hypersensitivity to bortezomib, boron, or mannitol"
5411,NCT00734877,"21:31:allergy_name,33:38:allergy_name,43:51:allergy_name","Hypersensitivity to bortezomib, boron, or mannitol"
5412,NCT00720785,"32:42:allergy_name,44:49:allergy_name,53:61:allergy_name","Allergy or hypersensitivity to bortezomib, boron or mannitol by history"
5413,NCT03153410,"33:44:chronic_disease,59:67:treatment,92:117:chronic_disease","Has history of (non-infectious) pneumonitis that required steroids, history or evidence of interstitial lung disease or active, non-infectious pneumonitis"
5414,NCT02501473,"29:40:chronic_disease,55:63:treatment,94:119:chronic_disease",History of (non-infectious) pneumonitis that required steroids or has current pneumonitis or interstitial lung disease
5415,NCT02407171,"29:40:chronic_disease,55:63:treatment,100:125:chronic_disease","history of (non-infectious) pneumonitis that required steroids, current pneumonitis or evidence of interstitial lung disease"
5416,NCT02959762,"20:38:treatment,42:59:treatment,121:132:treatment,134:145:treatment","Subjects receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (salicylates, antibiotics)"
5417,NCT02366481,"20:38:treatment,42:59:treatment,121:132:treatment,134:145:treatment","Subjects receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (salicylates, antibiotics)"
5418,NCT01972113,"20:38:treatment,42:59:treatment,121:132:treatment,134:145:treatment","Subjects receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (salicylates, antibiotics)"
5419,NCT02639065,"20:38:chronic_disease,49:67:treatment,,187:204:treatment,208:232:treatment","Evidence of active autoimmune disease requiring systemic treatment within preceding 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents"
5420,NCT02407171,"8:26:chronic_disease,37:55:treatment,,174:191:treatment,195:219:treatment","active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents"
5421,NCT02365766,"15:33:chronic_disease,44:62:treatment,,181:198:treatment,202:226:treatment","Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents"
5422,NCT02515110,"8:33:chronic_disease,48:63:chronic_disease,,137:146:chronic_disease,148:176:chronic_disease,181:192:chronic_disease","Active collagen vascular disease, specifically dermatomyositis with a creatine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma"
5423,NCT01872975,"8:33:chronic_disease,48:63:chronic_disease,,139:148:chronic_disease,150:178:chronic_disease,183:194:chronic_disease","Active collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma"
5424,NCT01245712,"25:50:chronic_disease,65:80:chronic_disease,,156:165:chronic_disease,167:195:chronic_disease,200:211:chronic_disease","Documented diagnosis of collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma"
5425,NCT02487095,"33:45:treatment,60:73:treatment,,93:105:treatment,","Subjects must not have received chemotherapy, or undergone major surgery within 4 weeks and radiotherapy within 24 hours prior to enrollment"
5426,NCT02311361,"45:57:treatment,59:71:treatment,76:89:treatment,","Patients must not have had standard of care chemotherapy, radiotherapy, or major surgery within the last 2 weeks prior to entering the study"
5427,NCT01306045,"23:36:treatment,38:50:treatment,54:66:treatment,,","Patients who have had major surgery, chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier"
5428,NCT02314377,"37:54:chronic_disease,56:84:chronic_disease,89:112:chronic_disease,","Patients must not have a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment"
5429,NCT01903330,"12:29:chronic_disease,31:59:chronic_disease,64:87:chronic_disease,","History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1"
5430,NCT01532687,"12:29:chronic_disease,31:59:chronic_disease,64:87:chronic_disease","History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess"
5431,NCT02132598,"26:40:chronic_disease,44:63:chronic_disease,,109:118:treatment",Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
5432,NCT01822522,"26:40:chronic_disease,44:63:chronic_disease,,109:118:treatment",Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
5433,NCT01639508,"26:40:chronic_disease,44:63:chronic_disease,,109:118:treatment",concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
5434,NCT03150004,"15:18:cancer,34:37:cancer,85:98:treatment",Patients with MDS transformed to AML will be eligible even if they had not received prior therapy for AML
5435,NCT01515527,"26:29:cancer,45:48:cancer,82:95:treatment",Patients with history of MDS transformed to AML are eligible regardless of their prior therapy for MDS provided
5436,NCT03054519,"33:46:chronic_disease,57:65:treatment,67:79:chronic_disease,98:117:chronic_disease","Major medical illness including renal disease requiring dialysis, lung disease requiring oxygen, Parkinson's disease"
5437,NCT02593110,"33:46:chronic_disease,57:65:treatment,67:79:chronic_disease,98:117:chronic_disease","Major medical illness including renal disease requiring dialysis, lung disease requiring oxygen, Parkinson's disease"
5438,NCT03029442,"18:30:chronic_disease,32:59:chronic_disease,61:73:chronic_disease","History of prior bone disease (Paget's hyperparathyroidism, osteoporosis, etc.)"
5439,NCT01983475,"18:30:chronic_disease,32:59:chronic_disease,61:73:chronic_disease","History of prior bone disease (Paget's hyperparathyroidism, osteoporosis, etc.)"
5440,NCT02955394,"1:38:treatment,40:51:treatment,53:60:treatment,62:74:treatment,76:88:treatment,90:97:treatment,99:106:treatment,108:115:treatment,117:124:treatment,126:132:treatment","Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464)"
5441,NCT02953860,"1:38:treatment,40:51:treatment,53:60:treatment,62:74:treatment,76:88:treatment,90:97:treatment,99:106:treatment,108:115:treatment,117:124:treatment,126:132:treatment","Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464)"
5442,NCT02862210,"18:34:chronic_disease,38:51:chronic_disease,55:79:chronic_disease",The diagnosis of bipolar disorder or schizophrenia or schizoaffective disorder
5443,NCT02809677,"23:39:chronic_disease,43:56:chronic_disease,60:84:chronic_disease",depression as part of bipolar disorder or schizophrenia or schizoaffective disorder
5444,NCT02707471,"28:37:treatment,45:52:treatment,54:66:treatment,68:77:treatment","completed local definitive treatment (i.e., surgery, chemotherapy, radiation)"
5445,NCT02085941,"35:44:treatment,54:63:treatment,65:77:treatment,79:86:treatment","must have sustained all available treatment options (radiation, chemotherapy, surgery) as verified by the Dana Farber Cancer Institute's Head and Neck Tumor Board"
5446,NCT02656706,"1:17:cancer,58:80:cancer,90:105:cancer","Brain metastases, whether resected or not, and any known leptomeningeal disease or known bone metastases"
5447,NCT02519322,"1:17:cancer,19:41:cancer,45:60:cancer","Brain metastases, leptomeningeal disease or bone metastases"
5448,NCT02583893,"1:10:treatment,18:26:treatment,28:35:treatment,37:44:treatment","Verapamil (e.g., Calan SR, Isoptin, Verelan)"
5449,NCT01869114,"1:10:treatment,17:25:treatment,27:34:treatment,36:43:treatment","Verapamil (e.g. Calan SR, Isoptin, Verelan)"
5450,NCT02576444,"27:44:cancer,46:58:cancer,74:98:cancer","Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)"
5451,NCT02091141,"27:44:cancer,46:58:cancer,74:98:cancer","Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)"
5452,NCT02555189,",23:36:treatment,59:68:treatment,76:83:treatment",At least 4 weeks from prior therapy completion (including radiation and/or surgery) to enrollment
5453,NCT02419495,",16:29:treatment,52:61:treatment,69:76:treatment",> 4 weeks from prior therapy completion (including radiation and/or surgery)
5454,NCT02547818,"46:57:treatment,,114:145:treatment,153:162:treatment,","subjects must be on a stable dose of current medications for 4 weeks prior to study entry, with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on a stable dose for at least 12 weeks prior to study entry"
5455,NCT02547818,"20:51:treatment,59:68:treatment,103:114:treatment,",subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study
5456,NCT02542657,"1:10:treatment,21:24:chronic_disease,36:52:treatment,","Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3"
5457,NCT02004275,"1:10:treatment,21:24:chronic_disease,36:52:treatment,,,","Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 within 28 days prior to registration"
5458,NCT02534922,"5:21:treatment,38:53:cancer,,132:159:treatment",Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted
5459,NCT01042522,"5:21:treatment,38:53:cancer,,132:159:treatment",Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted
5460,NCT02521103,"29:45:chronic_disease,52:71:chronic_disease,78:96:chronic_disease,103:118:chronic_disease",Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration
5461,NCT01917929,"109:125:chronic_disease,132:151:chronic_disease,158:176:chronic_disease,183:198:chronic_disease","Patient has bone stock that is inadequate for support or fixation of the prosthesis, or is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration"
5462,NCT02516670,"1:12:treatment,14:28:treatment,30:42:treatment,44:57:treatment,59:73:treatment","Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin"
5463,NCT01822522,"1:12:treatment,14:28:treatment,30:42:treatment,44:57:treatment,59:73:treatment","Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin"
5464,NCT02512718,"12:15:allergy_name,17:21:allergy_name,26:29:allergy_name,30:45:allergy_name","Allergy to egg, fish, or soy/legume products"
5465,NCT02512718,"12:15:allergy_name,17:21:allergy_name,26:29:allergy_name,30:45:allergy_name","allergy to egg, fish, or soy/legume products"
5466,NCT02496663,"55:66:treatment,68:86:treatment,143:149:treatment","all patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects of CYP3A4"
5467,NCT01620216,"12:23:treatment,27:45:treatment,88:94:treatment",Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4
5468,NCT02488967,"12:35:cancer,48:63:cancer,80:94:treatment,99:109:cancer,114:150:cancer,",History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization
5469,NCT01872975,"12:35:cancer,48:63:cancer,80:94:treatment,99:109:cancer,114:150:cancer,",History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization
5470,NCT02468024,"10:29:cancer,,100:124:cancer,126:141:cancer","No prior invasive malignancy, unless disease-free for ? 3 years prior to registration (exceptions: non-melanoma skin cancer, in-situ cancers)"
5471,NCT02468024,"7:26:cancer,,97:121:cancer,123:138:cancer","prior invasive malignancy, unless disease-free for ? 3 years prior to registration (exceptions: non-melanoma skin cancer, in-situ cancers)"
5472,NCT02451423,"82:90:allergy_name,94:114:allergy_name,118:133:allergy_name","History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins"
5473,NCT02091141,"82:90:allergy_name,94:114:allergy_name,118:133:allergy_name","History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins"
5474,NCT02414269,"1:45:treatment,52:65:treatment,67:81:treatment,85:100:treatment,,175:190:treatment","Prior immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor or CTL4-antagonist or similar agent) must have been completed more than 1 month prior to the T cell infusion"
5475,NCT02414269,"1:45:treatment,52:65:treatment,67:81:treatment,85:100:treatment,,175:190:treatment","Prior immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor or CTL4-antagonist or similar agent) must have been completed more than 1 month1prior to the T cell infusion"
5476,NCT02394535,"31:38:chronic_disease,56:61:chronic_disease,63:74:chronic_disease,76:85:chronic_disease,87:116:chronic_disease,130:158:chronic_disease","history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis or pulmonary hypersensitivity pneumonitis"
5477,NCT02080221,"31:38:chronic_disease,56:61:chronic_disease,63:74:chronic_disease,76:85:chronic_disease,87:116:chronic_disease,128:156:chronic_disease","history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis"
5478,NCT02390752,"1:30:treatment,,72:101:treatment,120:131:treatment",Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
5479,NCT02323880,"1:30:treatment,,72:101:treatment,,120:131:treatment",Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
5480,NCT02358187,"58:78:chronic_disease,89:98:treatment,102:127:treatment","Patients must not have a history of, or currently active autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement"
5481,NCT02334865,"11:31:chronic_disease,42:51:treatment,55:80:treatment",Any prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement
5482,NCT02334865,"34:49:chronic_disease,55:89:chronic_disease,91:114:chronic_disease,118:141:chronic_disease","Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)"
5483,NCT02293109,"32:47:chronic_disease,53:87:chronic_disease,89:112:chronic_disease,116:139:chronic_disease","Known sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)"
5484,NCT02319369,"130:145:treatment,169:185:chronic_disease,227:234:treatment","Is able to provide written informed consent (or authorized representative), comply with protocol visits and procedures, and take oral medication, and does not have any active infection or comorbidity that would interfere with therapy"
5485,NCT01877382,"121:136:treatment,155:171:chronic_disease,213:220:treatment","Subject should be able to provide written informed consent, comply with protocol visits and procedures, be able to take oral medication, and not have any active infection or comorbidity that would interfere with therapy"
5486,NCT02304458,"21:55:chronic_disease,59:70:chronic_disease,74:75:chronic_disease",Patients with known human immunodeficiency virus (HIV) or hepatitis B or C
5487,NCT02101944,"30:64:chronic_disease,85:96:chronic_disease,100:101:chronic_disease",Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections
5488,NCT02217709,"77:93:chronic_disease,95:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5489,NCT01989546,"77:93:chronic_disease,95:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5490,NCT02165007,"28:37:chronic_disease,39:44:chronic_disease,48:65:chronic_disease,90:99:treatment,","Patients with uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning"
5491,NCT02122081,"35:44:chronic_disease,46:51:chronic_disease,55:72:chronic_disease,97:106:treatment","Patients with active uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms)"
5492,NCT02133196,"1:27:chronic_disease,45:69:treatment,72:93:chronic_disease,137:154:chronic_disease","Active systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active or uncompensated major medical illnesses"
5493,NCT01967823,"1:27:chronic_disease,38:62:treatment,64:85:chronic_disease,130:147:chronic_disease","Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses"
5494,NCT02101736,"25:37:chronic_disease,,,,,,116:150:treatment,141:150:treatment,","Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days before the first dose of study treatment"
5495,NCT01822522,"25:37:chronic_disease,,,,,131:165:treatment,156:165:treatment,","Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment"
5496,NCT02058095,"17:34:treatment,38:68:treatment,70:82:treatment,84:96:treatment,98:110:treatment,112:122:treatment,124:134:treatment,138:164:treatment,169:172:chronic_disease,204:215:treatment","Patients taking alpha antagonists or cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine or serum proteases inhibitors for HIV) who cannot be taken off these medications for the duration of the study"
5497,NCT01970176,"17:34:treatment,38:68:treatment,70:82:treatment,84:96:treatment,98:110:treatment,112:122:treatment,124:134:treatment,138:164:treatment,169:172:chronic_disease,204:215:treatment","Patients taking alpha antagonists or cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine or serum proteases inhibitors for HIV) who cannot be taken off these medications for the duration of the study"
5498,NCT01925573,",56:66:treatment,68:94:chronic_disease,103:118:chronic_disease,120:155:treatment,157:187:chronic_disease,189:219:chronic_disease,221:252:chronic_disease,254:277:chronic_disease","Any of the following within 6 months prior to starting study drug: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)"
5499,NCT01894061,",56:66:treatment,68:94:chronic_disease,103:118:chronic_disease,120:155:treatment,157:187:chronic_disease,189:219:chronic_disease,221:252:chronic_disease,254:277:chronic_disease","Any of the following within 6 months prior to starting study drug: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)"
5500,NCT01804634,"14:19:chronic_disease,21:30:chronic_disease,35:52:chronic_disease","Uncontrolled viral, bacterial, or fungal infections"
5501,NCT01701986,"21:30:chronic_disease,32:37:chronic_disease,41:58:chronic_disease","Active uncontrolled bacterial, viral or fungal infections"
5502,NCT01438073,"52:63:treatment,80:97:treatment,99:108:treatment,116:147:treatment,152:174:treatment","all medical conditions stable and well controlled, medications allowed include asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication"
5503,NCT01438073,"17:28:treatment,,73:90:treatment,92:101:treatment,109:140:treatment,145:167:treatment","no prescription medications for at least 2 months with the exception of asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication"
5504,NCT03188185,"50:62:chronic_disease,64:75:chronic_disease,80:89:chronic_disease","Has any other significant medical condition (eg, neurological, psychiatric, or metabolic) or clinical symptom that could unduly risk the subject or affect the interpretation of study data"
5505,NCT03188042,"1:24:chronic_disease,81:89:chronic_disease,91:97:chronic_disease","End-stage organ disease or medical condition with subsequent vision loss (e.g., diabetes, stroke)"
5506,NCT03183388,"12:34:chronic_disease,58:69:chronic_disease,,129:145:chronic_disease,147:162:chronic_disease,166:183:cancer,188:214:chronic_disease","history of neurologic abnormality, including significant head trauma (defined by loss of consciousness of ?5-minutes duration), seizure disorder, cerebrovascular or neoplastic lesion, or neurodegenerative disorder"
5507,NCT03182751,"12:15:chronic_disease,17:19:chronic_disease,24:27:chronic_disease,","History of CVA, MI, or VTE within the previous 30 days"
5508,NCT03181893,"19:41:chronic_disease,50:68:chronic_disease,86:107:chronic_disease","Have pre existing demyelinating disorder such as multiple sclerosis, or other severe neurological deficits"
5509,NCT03180905,"10:18:chronic_disease,20:32:chronic_disease,34:44:chronic_disease,48:72:chronic_disease","No known physical, neurological, behavioral or psychological impairment that would affect their ability to perform the test"
5510,NCT03179397,"17:34:chronic_disease,42:52:chronic_disease,66:87:chronic_disease","Clinical severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy)"
5511,NCT03179163,"28:41:treatment,76:85:treatment,87:97:treatment","history of having taken an ACE inhibitor with antioxidant properties (e.g. Captopril, Zofenopril)"
5512,NCT03176979,",23:31:treatment,33:40:treatment,45:62:treatment,67:80:cancer","Women with history of surgical, medical, or radiation therapy for breast cancer"
5513,NCT03175978,"16:24:chronic_disease,30:46:chronic_disease,66:74:chronic_disease",Any history of epilepsy or a seizure disorder or any known prior seizures
5514,NCT03171493,"20:30:cancer,34:59:cancer,53:59:cancer,61:84:cancer,105:125:cancer",Adequately treated basal cell or squamous cell skin cancer; In situ cervical cancer; Adequately treated Stage I or II cancer from which the patient is currently incomplete remission or other cancer from which the patient has been disease-free for 2 years
5515,NCT03171480,"1:4:chronic_disease,8:25:chronic_disease,33:46:treatment",DIC or active hemorrhage before randomization
5516,NCT03170453,"14:20:chronic_disease,22:41:chronic_disease,46:78:chronic_disease","Diagnosis of autism, Asperger's syndrome, or pervasive developmental disorder not otherwise specified (NOS) verified by the autism diagnostic observation schedule (ADOS) or autism diagnostic interview-revised (ADI-R)"
5517,NCT03169543,"12:28:chronic_disease,30:38:chronic_disease,40:48:chronic_disease,50:67:chronic_disease,69:82:chronic_disease,93:112:chronic_disease","History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders"
5518,NCT03167125,"16:34:chronic_disease,42:60:chronic_disease,64:73:treatment","Persons having colorectal disease (e.g., ulcerative colitis or colectomy)"
5519,NCT03165227,",,,102:109:treatment,111:149:treatment,157:185:treatment","Patients with type 1 or type 2 diabetes mellitus, diagnosed before informed consent and treated with insulin, glucagon-like peptide (GLP) 1 agonists and/or oral antidiabetic medication"
5520,NCT03162731,"18:34:chronic_disease,38:71:treatment,,95:105:treatment,",Any diagnosis of immunodeficiency or current immunosuppressive therapy including >10mg/day of prednisone within 14 days of enrollment is not permitted
5521,NCT03162731,"15:23:chronic_disease,25:49:chronic_disease,73:79:chronic_disease,80:85:chronic_disease","subjects with vitiligo, type I diabetes mellitus, or resolved childhood asthma/atopy would be an exception to this rule"
5522,NCT03161028,"9:34:chronic_disease,46:48:chronic_disease,56:62:cancer,64:77:chronic_disease,89:112:chronic_disease,114:144:chronic_disease","Current major disease or disorder other than MS (e.g., cancer, renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may interfere with study procedures"
5523,NCT03158519,"19:34:treatment,66:75:treatment,79:98:treatment,111:118:treatment,120:129:treatment,138:150:treatment,","Completion of all primary therapy (with the exception of ongoing endocrine or trastuzumab therapy), including surgery, radiation, and/or chemotherapy greater than 4 weeks prior to study enrollment"
5524,NCT03154580,"1:22:chronic_disease,29:35:chronic_disease,37:45:chronic_disease","Neurological diseases (e.g. stroke, seizures)"
5525,NCT03154151,"29:44:chronic_disease,46:67:chronic_disease,120:131:chronic_disease","have a current uncontrolled medical illness, neurological disorder affecting the central nervous system, or history of head injury"
5526,NCT03153982,"1:14:treatment,19:39:cancer,110:126:treatment,,202:211:treatment,304:324:treatment","Prior therapy for head and neck cancer is allowed, and the number of treatments is not limited. However, any systemic therapy should have been completed at least 30 days prior to study enrollment. Any radiation to the head and neck should have been completed at least 30 days prior to study enrollment. Palliative radiation outside of the head and neck does not require a washout"
5527,NCT03153410,"16:34:chronic_disease,36:62:chronic_disease,75:93:chronic_disease,98:113:chronic_disease,116:136:chronic_disease,138:168:chronic_disease,170:181:chronic_disease,184:218:chronic_disease,219:240:chronic_disease,248:272:chronic_disease,275:278:chronic_disease,282:298:chronic_disease,344:367:chronic_disease,369:386:chronic_disease,388:406:chronic_disease","History of any autoimmune disease: inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), CNS or motor neuropathy considered to be of autoimmune origin (e.g., Guillian-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis"
5528,NCT03153319,"1:24:chronic_disease,32:70:chronic_disease,81:99:chronic_disease,104:118:chronic_disease,123:158:chronic_disease,169:192:chronic_disease","Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome)"
5529,NCT03152058,"12:31:chronic_disease,39:59:chronic_disease,64:87:chronic_disease","History of recurrent infection, e.g., recurrent cellulitis, or opportunistic infection"
5530,NCT03150004,",,,,,165:168:cancer,172:188:chronic_disease,192:201:chronic_disease","Direct bilirubin ? 1.5 X the upper limit of the normal range (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 X ULN unless related to AML or Gilbert syndrome or hemolysis"
5531,NCT03148795,",146:156:treatment,158:168:treatment,170:184:treatment,186:196:treatment,198:207:treatment,209:220:treatment,222:234:treatment,236:245:treatment,247:259:treatment,261:273:treatment,275:284:treatment,286:295:treatment,297:308:treatment,310:319:treatment,321:331:treatment,333:342:treatment,344:354:treatment,356:366:treatment,368:378:treatment,380:389:treatment,395:404:treatment","Current or anticipated use within 7 days prior to first dose of study drug or anticipated use during the study of the following P gp inhibitors (amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar)"
5532,NCT03146663,"16:31:chronic_disease,58:74:chronic_disease,85:99:treatment","Presence of an serious illness, uncontrolled illness, or active infection requiring IV antibiotics"
5533,NCT03145298,"33:37:chronic_disease,39:43:chronic_disease,45:52:chronic_disease,54:61:chronic_disease","Confirmed clinical diagnosis of IPAH, HPAH, PAH-CTD, PAH-HIV"
5534,NCT03145298,"15:25:cancer,29:52:cancer,62:80:chronic_disease,100:123:cancer","resected skin basal cell or squamous cell carcinoma, treated cervical dysplasia or treated in-situ cervical cancer grade 1"
5535,NCT03144245,",22:31:treatment,32:48:treatment,58:72:chronic_disease,,99:119:treatment","No more than 3 prior induction/salvage regimens to treat active disease, and no more than 1 prior stem cell transplant"
5536,NCT03144206,"1:17:chronic_disease,83:92:treatment,109:136:chronic_disease,161:181:chronic_disease","Vascular disease resulting in clinically apparent compromise in blood flow to the treatment extremity (i.e. peripheral vascular disease with diminished pulses, venous insufficiency with clinical evidence of vascular congestion)"
5537,NCT03143985,"42:59:treatment,66:79:treatment,84:95:treatment,",Patients should have discontinued strong CYP1A2 inhibitors (e.g. ciprofloxacin and fluvoxamine) at least five half-lives before beginning study treatment
5538,NCT03143894,"1:11:chronic_disease,15:22:chronic_disease,52:77:treatment,82:92:chronic_disease,",Depression or anxiety as defined either by ongoing pharmacological treatment for depression or anxiety or a HADS score on initial screening
5539,NCT03141359,"10:34:cancer,45:60:cancer,82:97:cancer,99:131:cancer,176:182:cancer,","However, non-melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the breast, oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the subject according to the treating investigator is permissible"
5540,NCT03140527,"27:61:chronic_disease,63:98:chronic_disease,103:137:chronic_disease","Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb)"
5541,NCT03139318,"25:45:treatment,50:65:treatment,74:83:treatment,87:124:cancer",Subject is eligible for routine chemotherapy and routine surgery for the treatment of non-metastatic extremity osteosarcoma
5542,NCT03138733,"1:54:chronic_disease,130:142:treatment,146:155:treatment",Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam
5543,NCT03137771,"20:36:treatment,38:68:treatment,74:79:cancer",Patients receiving targeted therapy (non-cytotoxic systemic therapy) for NSCLC in the first-line setting
5544,NCT03137771,"31:49:cancer,,,107:112:cancer,136:146:cancer",patients newly diagnosed with metastatic disease or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop metastases
5545,NCT03137498,"26:43:chronic_disease,49:58:chronic_disease,84:106:chronic_disease,,162:190:chronic_disease,192:200:chronic_disease,234:243:treatment,259:285:chronic_disease,362:371:chronic_disease","Past medical history of: liver dysfunction (ie: cirrhosis), chronic alcohol abuse, gastrointestinal bleed or recent gastrointestinal bleed (within past 5 days), renal dysfunction or disease, seizures (or currently actively receiving treatment for seizures), inflammatory bowel disease (or currently actively receiving treatment for inflammatory bowel disease), hepatitis (or currently actively receiving treatment for hepatitis)"
5546,NCT03137121,"19:31:treatment,35:44:treatment,,94:110:treatment,114:130:treatment,176:208:treatment",Have not received chemotherapy or radiation for >14 days (advanced cancer patients receiving hormonal therapy or targeted therapy that does not come with a recommendation for prophylactic anti-emetic therapy are eligible)
5547,NCT03136029,"35:49:chronic_disease,51:59:chronic_disease,64:76:chronic_disease,,,,,,146:163:treatment","subjects with a history of stable cardiomyopathy (ischemic and non-ischemic, >3 months duration, ages 45-75 yrs) despite a minimum of 6 weeks of optimal treatment"
5548,NCT03135522,"14:39:chronic_disease,49:74:chronic_disease,76:105:chronic_disease,107:116:chronic_disease,121:123:chronic_disease","negative for parenchymal lung diseases (such as interstitial lung disease, idiopathic pulmonary fibrosis, pneumonia, or TB)"
5549,NCT03135171,",,127:138:treatment,140:151:treatment,156:166:treatment","must use two forms of effective contraception during the duration of the trial and for minimum of 7 months after last dose of tocilizumab, trastuzumab, or pertuzumab"
5550,NCT03131960,"1:17:treatment,25:62:treatment,,110:117:treatment",Botox injections or any other non-study active rehabilitation of the upper extremity within 4 weeks prior to therapy through the post-30 day visit (Visit 6)
5551,NCT03131037,"23:47:chronic_disease,57:72:chronic_disease,74:98:chronic_disease,112:156:chronic_disease","Presence of any other life-threatening illness, such as unstable angina, severe oxygen dependence, significant chronic obstructive pulmonary disease (COPD)"
5552,NCT03130543,"63:87:chronic_disease,95:116:chronic_disease,133:149:chronic_disease,157:177:chronic_disease","Patients with any pre-existing significant medical diagnosis (congenital heart disease, known neurologic impairment with or without seizure disorder, other congenital anomalies)"
5553,NCT03127358,"37:45:allergy_name,47:58:allergy_name,63:72:allergy_name","Known hypersensitivity (allergy) to elbasvir, grazoprevir, or ribavirin"
5554,NCT03125902,",,,135:144:treatment,,201:213:treatment,214:221:treatment,,271:281:treatment","For men and women of child bearing potential: agreement to remain abstinent or use protocol defined contraceptive measures during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo, or for at least 6 months after the last dose of paclitaxel"
5555,NCT03125226,"1:10:treatment,,67:86:treatment,67:76:treatment,115:127:treatment","Treatment plan for bladder must include at least 4 weeks of daily radiation treatment (most patients will receive chemotherapy concurrent with radiation, but this is not required for trial enrollment)"
5556,NCT03123783,"44:63:treatment,67:77:treatment,91:101:cancer,122:148:cancer,174:183:treatment","Histologically or cytologically confirmed, immunotherapy naïve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment"
5557,NCT03123783,"15:39:cancer,67:81:treatment,89:110:treatment,120:143:treatment",Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy
5558,NCT03123055,"38:70:treatment,,94:105:treatment,109:127:treatment",Have progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
5559,NCT03122912,"13:20:allergy_name,22:33:allergy_name,35:42:allergy_name,46:53:allergy_name","Allergic to soybean, soybean oil, peanuts or seafood"
5560,NCT03122691,"35:54:chronic_disease,58:77:chronic_disease,85:104:chronic_disease","History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)"
5561,NCT03121586,"59:70:chronic_disease,72:82:chronic_disease,84:98:chronic_disease,100:111:chronic_disease,113:129:chronic_disease,131:136:chronic_disease,138:145:chronic_disease,147:158:chronic_disease,169:185:chronic_disease,197:203:cancer,207:219:cancer","Patient has current evidence of a serious and/or unstable psychiatric, neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program"
5562,NCT03121352,"15:28:treatment,34:74:treatment,82:91:treatment,93:103:treatment","Patients with prior therapy with antibodies that modulate T-cell function (e.g., anti-PD-1, anti-PD-L1)"
5563,NCT03120585,"1:27:chronic_disease,31:63:chronic_disease,67:83:chronic_disease",Neonates with hypoglycemia or clinical evidence of dehydration or volume depletion requiring fluid bolus
5564,NCT03118973,"1:30:treatment,36:60:treatment,62:89:treatment","Complex post-surgical anatomy e.g. Billroth type II anatomy, Roux-en-Y-gastrojejunostomy"
5565,NCT03116685,"54:77:treatment,79:87:treatment,,154:157:treatment,198:223:treatment","Participation in any interventional study of another investigational product, biologic, device, or other agent within 60 days prior to the first dose of OC5 or not willing to forego other forms of investigational treatment during this study"
5566,NCT03115424,"18:30:chronic_disease,32:46:chronic_disease,50:63:chronic_disease","Prior history of pancreatitis, cholelithiasis or cholecystitis"
5567,NCT03114891,"64:67:treatment,69:79:treatment,81:95:treatment,97:104:treatment","Medication use that substantially reduces seizure threshold to TMS (olanzapine, chlorpromazine, lithium)"
5568,NCT03113825,"1:27:treatment,31:41:treatment,44:48:treatment,52:56:treatment,64:74:treatment",Primary surgical treatment is lumpectomy + SLNB or ALND --or-- mastectomy + ALND
5569,NCT03113136,"51:62:chronic_disease,64:70:chronic_disease,75:88:chronic_disease","unstable or significant medical condition such as respiratory, kidney, or liver disease that could potentially affect biomarker data"
5570,NCT03112603,"1:8:treatment,20:25:chronic_disease,58:89:treatment,107:127:treatment,131:141:cancer",Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence
5571,NCT03112590,"16:38:treatment,,53:63:treatment,93:108:treatment,110:158:treatment,227:248:chronic_disease","Current use of corticosteroid therapy > 5 mg/day of prednisone or equivalent doses of other corticosteroids (topical, intranasal, and inhaled corticosteroids in standard doses and physiologic replacement for participants with adrenal insufficiency are allowed)"
5572,NCT03112174,"71:84:treatment,90:99:treatment,109:123:treatment",Concurrent enrollment in another therapeutic investigational study or prior therapy with ibrutinib or other BTK inhibitors
5573,NCT03110354,"5:8:cancer,12:15:cancer,31:54:treatment,86:99:treatment",Has AML or ALL and failed any prior induction therapy regimen or have relapsed after prior therapy
5574,NCT03110107,"1:17:treatment,,74:99:treatment,118:131:treatment","Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy"
5575,NCT03109210,"1:17:chronic_disease,25:31:cancer,37:70:chronic_disease,78:86:chronic_disease","terminal illness (e.g., cancer), or neurological degenerative disease (e.g., dementia)"
5576,NCT03104725,"19:50:treatment,58:76:treatment,78:83:treatment","Already taking an anti-oxidant dietary supplement (e.g., Olive Leaf Extract, MitoQ)"
5577,NCT03104699,"40:50:cancer,71:83:cancer,97:113:treatment",Histologically or cytologically proven metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed
5578,NCT03104699,"20:34:treatment,38:47:treatment,75:84:treatment,,129:137:treatment",Subjects receiving bisphosphonate or denosumab are eligible provided that treatment was initiated ?14 days before first dose of AGEN2034
5579,NCT03104413,"12:27:chronic_disease,37:52:treatment,54:64:treatment,66:76:treatment,78:90:treatment,92:103:treatment,105:116:treatment,,153:164:treatment,","Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline)"
5580,NCT03101566,"19:43:chronic_disease,45:59:chronic_disease,75:94:treatment,96:110:chronic_disease,120:128:chronic_disease,130:139:chronic_disease,144:152:chronic_disease,168:186:treatment","Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll"
5581,NCT03101085,"16:22:cancer,39:51:treatment,55:72:treatment,",any history of cancer that required a chemotherapy or radiation therapy intervention within the past 5 years
5582,NCT03099590,"13:25:chronic_disease,27:37:chronic_disease,42:60:chronic_disease","Presence of neurological, infectious, or neoplastic disease"
5583,NCT03096288,"4:13:treatment,23:41:treatment,53:60:treatment,65:76:treatment,",On treatment with any antiplatelet agent other than aspirin and clopidogrel in the past 14 days
5584,NCT03093909,"37:51:treatment,62:74:treatment,76:89:treatment,94:110:treatment","Patients receiving other concurrent cancer therapy including chemotherapy, immunotherapy, or biologic therapy"
5585,NCT03093272,"1:8:chronic_disease,52:59:chronic_disease,96:102:chronic_disease,104:129:chronic_disease,,168:200:chronic_disease,205:224:cancer,233:244:cancer,249:260:cancer,278:283:chronic_disease","Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)"
5586,NCT03092635,",21:38:treatment,69:82:cancer,84:97:cancer",More than two prior endocrine therapy regimens for the treatment of metastatic ER+ breast cancer
5587,NCT03090607,"48:75:chronic_disease,87:104:chronic_disease,106:119:treatment,138:146:chronic_disease,150:169:chronic_disease","Has a condition that could lead to significant postoperative complications, including current infection, anticoagulant use, uncontrolled diabetes or autoimmune disorder"
5588,NCT03089853,"24:48:chronic_disease,59:81:chronic_disease,124:133:chronic_disease,135:149:chronic_disease,154:165:cancer","Secondary diagnosis of congestive heart failure and other respiratory conditions that could confound the diagnosis such as pneumonia, bronchiectasis and lung cancer will be excluded"
5589,NCT03088072,"36:61:treatment,67:74:treatment,79:90:treatment",A need for on-going treatment with dual antiplatelet therapy with aspirin and clopidogrel
5590,NCT03088033,",,,107:135:chronic_disease,128:135:chronic_disease,137:146:chronic_disease,","NYHA class II with a history of > NYHA class II; OR NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening; or signs (any rales post cough, chest x-ray demonstrating pulmonary congestion,) within past 12 months"
5591,NCT03087903,"1:14:treatment,16:25:treatment,30:75:treatment,,94:109:treatment","Major surgery, radiation, or treatment with any other investigational drug within 2 weeks of study treatment"
5592,NCT03085784,"18:45:treatment,62:86:cancer,122:143:chronic_disease",Undergone either ocular or orbital radiation for any primary ocular or orbital cancer within clinical evidence of having radiation retinopathy
5593,NCT03085485,"28:50:treatment,65:72:treatment,77:94:chronic_disease,",Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary disease within 28 days before receiving the first dose of study drug
5594,NCT03084640,"75:90:treatment,92:99:treatment,103:128:treatment,146:161:cancer","Requires prohibited treatment that is, non-protocol specified anticancer. pharmacotherapy, surgery or conventional radiotherapy for treatment of malignant tumor)"
5595,NCT03084146,"8:44:treatment,49:58:chronic_disease,,97:114:treatment,","use of systemic immunosuppressive treatment for psoriasis within 4 weeks of baseline, or use of topical treatment for psoriasis within 2 weeks"
5596,NCT03078530,"1:4:chronic_disease,6:13:chronic_disease,15:24:chronic_disease,26:33:chronic_disease,37:54:chronic_disease","HIV, cardiac, pulmonary, hepatic or renal dysfunction"
5597,NCT03078491,"8:21:chronic_disease,80:88:chronic_disease,97:114:chronic_disease,123:146:chronic_disease","Severe comorbidities that prevent completing outcome measurements (e.g. severe dementia, severe vision impairment, severe functional disabilities, inability to perform basic activities of daily living)"
5598,NCT03078023,"16:25:chronic_disease,40:49:treatment,56:74:chronic_disease,76:85:chronic_disease,87:90:chronic_disease,92:96:chronic_disease,98:107:chronic_disease,109:128:cancer","Other cause of dysphagia identified at endoscopy (e.g. reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm)"
5599,NCT03077243,"1:7:treatment,15:38:cancer,47:50:chronic_disease",Biopsy proven squamous cell carcinoma that is HPV and/or p16 positive
5600,NCT03076658,"10:16:chronic_disease,20:29:chronic_disease,65:72:treatment",Previous trauma or fractures of the lower extremities requiring surgery
5601,NCT03075826,"1:34:chronic_disease,66:75:chronic_disease,77:113:chronic_disease,115:139:chronic_disease,141:159:chronic_disease,164:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5602,NCT03073785,"21:31:cancer,79:118:cancer,139:161:cancer,172:179:cancer,","Patients with prior malignancy will be excluded except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancers from which the patient has been disease-free for at least 5 years"
5603,NCT03073629,"12:37:chronic_disease,41:55:chronic_disease,73:89:treatment",those with indeterminate RV function OR LV dysfunction on comprehensive echocardiography
5604,NCT03072238,"13:32:chronic_disease,44:63:chronic_disease,78:93:treatment",Any ongoing cardiac arrhythmias (including atrial fibrillation) that require medical therapy
5605,NCT03072238,"51:67:chronic_disease,73:76:chronic_disease,102:129:treatment",Immunocompromised status because of current known active infection with HIV or because of the use of immunosuppressive therapies for other conditions
5606,NCT03072238,"10:19:treatment,25:34:treatment,36:60:treatment,51:60:treatment,73:82:treatment,84:96:treatment,98:108:treatment,113:136:treatment","Previous treatment with flutamide, steroidal anti-androgens, androgens, estrogens, bicalutamide, nilutamide, or 5-? reductase inhibitor is permitted"
5607,NCT03072238,"57:68:chronic_disease,70:84:chronic_disease,86:98:chronic_disease","clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia)"
5608,NCT03071692,"13:32:chronic_disease,38:63:chronic_disease,65:74:chronic_disease,76:111:chronic_disease,116:132:treatment,,","Symptomatic lower extremity PAD (ie, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major amputation with either ankle-brachial index ? 0.9 or other diagnostic testing [eg, toe-brachial index, angiogram, or other imaging study])"
5609,NCT03071328,",39:43:cancer,45:55:cancer,60:76:cancer","Radiographic evidence of at least one bone, lymph node, or liver metastasis, that is amenable to iodinated contrast injection, as judged by the study radiologist"
5610,NCT03070535,"1:6:chronic_disease,11:25:chronic_disease,27:47:chronic_disease",Liver and kidney disease: Active liver disease will be excluded
5611,NCT03070535,"47:62:treatment,74:92:cancer,127:142:treatment","Those with medical conditions that preclude a lumbar puncture such as an intracranial tumor, lower spinal hardware, or use of anticoagulation"
5612,NCT03070340,",57:76:treatment,81:94:cancer,118:137:treatment,142:151:treatment",Any woman who has completed or is nearing completion of neoadjuvant therapy for breast cancer and is scheduled for a post-NAT breast MRI and mammogram
5613,NCT03070145,"1:15:chronic_disease,17:28:chronic_disease,32:55:chronic_disease,59:64:chronic_disease","Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity"
5614,NCT03069716,"16:26:chronic_disease,28:37:chronic_disease,54:79:chronic_disease,99:136:chronic_disease","Diagnosed with idiopathic, heritable, or associated (connective tissue disease, drugs, or toxins) pulmonary arterial hypertension (PAH) according to World Health Organization consensus recommendations"
5615,NCT03068442,"7:20:cancer,31:49:chronic_disease,53:64:cancer",Known stroke mimics including multiple sclerosis or brain tumor
5616,NCT03067129,"1:24:chronic_disease,49:56:chronic_disease,69:86:chronic_disease,115:145:chronic_disease","Decompensated cirrhosis defined as: presence of ascites, history of variceal bleeding, lab values consistent with Child's class B or C cirrhosis"
5617,NCT03065465,"1:21:treatment,30:35:chronic_disease,53:62:treatment",UGI post-polypectomy induced ulcer with some SRH on endoscopy
5618,NCT03060096,"23:29:cancer,31:41:cancer,43:62:cancer,67:89:cancer","previous diagnosis of breast, colorectal, gynecologic cancers and non-Hodgkin's lymphoma"
5619,NCT03059030,"100:116:chronic_disease,118:137:chronic_disease,156:180:chronic_disease,184:203:chronic_disease","Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, cardiac arrhythmias, and uncontrolled congestive heart failure or respiratory disease"
5620,NCT03058679,"28:50:treatment,70:73:chronic_disease,79:94:treatment",Currently participating in another clinical trial of a drug to treat IBD or a dietary therapy for any indication
5621,NCT03058146,"15:36:chronic_disease,38:51:chronic_disease,69:87:chronic_disease","Chronic major psychiatric disorders (schizophrenia, major recurrent affective disorder)"
5622,NCT03058029,"19:37:treatment,39:57:treatment,59:69:treatment,73:83:treatment","Administration of Prototype 2 (GSP2), Prototype 3 (GSP3), Gelesis100,or Gelesis200 in a previous study"
5623,NCT03056339,",,60:80:chronic_disease,101:105:treatment,109:113:treatment","Cardiac: Cardiac ejection fraction >/= 50%, no evidence of pericardial effusion as determined by an ECHO or MUGA, and no clinically significant ECG findings"
5624,NCT03056339,"13:19:chronic_disease,21:30:chronic_disease,32:37:chronic_disease,48:57:chronic_disease,68:85:treatment","Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management"
5625,NCT03053518,"19:32:chronic_disease,34:48:chronic_disease,53:64:chronic_disease","have a history of heart disease, kidney disease, or retinopathy (to rule-out those with long-standing, undiagnosed T2D)"
5626,NCT03050801,"13:55:chronic_disease,85:91:chronic_disease,93:110:chronic_disease,112:129:chronic_disease,131:144:chronic_disease,148:164:chronic_disease","Any current major neurological or psychiatric disorder such as (but not limited to) stroke, Parkinson disease, Alzheimer disease, schizophrenia or major depression"
5627,NCT03049189,"27:31:allergy_name,33:45:allergy_name,54:78:allergy_name,82:92:allergy_name,96:126:allergy_name","Known hypersensitivity to DOTA, lutetium-177, or any excipient of edotreotide or everolimus or any other Rapamycin derivative"
5628,NCT03048448,"8:22:treatment,63:89:treatment,114:118:treatment,120:127:treatment,133:137:treatment,168:178:treatment,180:189:treatment,191:204:treatment,210:218:treatment","Use of co-medications that may impact QAW039 exposure such as broad range UGT inhibitors or strong inhibitors of OAT3, OATP1B3, and P-gp, including but not limited to probenecid, ritonavir, valproic acid, and rifampin"
5629,NCT03043807,"1:23:chronic_disease,35:48:chronic_disease,50:86:chronic_disease,91:112:chronic_disease,","Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within previous six months"
5630,NCT03043807,"1:33:treatment,43:58:cancer,65:82:treatment,84:97:treatment","Prior local non-surgical therapy to treat prostate cancer (e.g. radiation therapy, brachytherapy)"
5631,NCT03042767,"19:40:chronic_disease,52:57:chronic_disease,59:76:chronic_disease,78:97:chronic_disease,99:115:chronic_disease","Evidence of other chronic liver disease other than NAFLD (Hepatitis B and C, Alpha-1 antitrypsin, Wilson's disease)"
5632,NCT03042689,"14:35:chronic_disease,78:94:chronic_disease,108:132:chronic_disease,134:159:chronic_disease,161:185:chronic_disease,200:218:chronic_disease,223:260:chronic_disease","Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5633,NCT03040778,"46:60:allergy_name,62:71:allergy_name,76:86:allergy_name","Patients with allergy or hypersensitivity to pentoxifylline, xanthines, or tocopherol"
5634,NCT03040726,"14:50:treatment,52:62:treatment,64:78:treatment,80:90:treatment,92:101:treatment,103:115:treatment,117:129:treatment,131:140:treatment,141:150:treatment,152:162:treatment,164:174:treatment,176:186:treatment,188:200:treatment,213:223:treatment,225:235:treatment,237:250:treatment,252:264:treatment,266:276:treatment,278:288:treatment,290:300:treatment,302:315:treatment,317:326:treatment,338:347:treatment,349:361:treatment,363:374:treatment,376:389:treatment,391:407:treatment,409:417:treatment,419:428:treatment,","On scheduled strong or moderate CYP3A4 inhibitors (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole; amprenavir, aprepitant, atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil) within one week of study enrollment"
5635,NCT03038620,"12:31:chronic_disease,33:47:chronic_disease,51:64:chronic_disease",History of gallbladder disease (cholelithiasis or cholecystitis)
5636,NCT03037983,"8:19:chronic_disease,21:37:chronic_disease,47:84:chronic_disease,100:122:chronic_disease","Have a mass lesion, cerebral infarct or other active central nervous system disease, or history of traumatic brain injury"
5637,NCT03037931,"8:21:chronic_disease,,,,38:76:treatment,,158:171:treatment",Stable heart failure (NYHA II-IV) on maximally-tolerated background therapy (as determined by the site Principle Investigator) for at least 2 weeks prior to randomization
5638,NCT03037554,"95:122:treatment,124:133:treatment,135:145:treatment,150:161:treatment,206:215:chronic_disease","Unable to taper off, with health care provider's agreement, hypnotic or sedative medications, hormone replacement therapy, clonidine, gabapentin, or isoflavones and other botanical compounds used to treat vasomotor symptoms of menopause"
5639,NCT03036280,"1:22:chronic_disease,42:56:chronic_disease,58:74:chronic_disease,76:85:chronic_disease","Psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, delusions, etc.)"
5640,NCT03035773,"1:9:cancer,13:30:cancer,37:50:cancer",prostate or colorectal cancer (i.e. Stage 0 or IV)
5641,NCT03034811,"1:10:chronic_disease,12:18:chronic_disease,24:37:chronic_disease","Infection, sepsis, and osteomyelitis"
5642,NCT03034213,"19:33:chronic_disease,43:52:chronic_disease,54:64:chronic_disease,68:84:chronic_disease","Any other type of ventral hernia, such as umbilical, epigastric or Spigelian hernia"
5643,NCT03033498,"24:52:chronic_disease,60:69:chronic_disease,71:88:chronic_disease","History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis, etc.)"
5644,NCT03030118,"26:57:treatment,35:49:treatment,,80:90:treatment,","Co-morbidities requiring systemic corticosteroid therapy greater than 10 mg of prednisone per day, or equivalent, or a change in corticosteroid dose within the 3 months prior to Visit 1"
5645,NCT03030118,"51:68:treatment,70:86:treatment,91:112:treatment","The subject is currently or has been treated with immunosuppressive, immune modifying, or cytotoxic medications as listed in Section 7.2"
5646,NCT03029884,"19:27:treatment,31:64:treatment,69:76:treatment",Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery
5647,NCT03029884,"1:22:chronic_disease,29:58:chronic_disease,60:91:chronic_disease,108:135:chronic_disease","personality disorders (e.g. multiple personality disorder, borderline personality disorder, etc.) or other neuropsychiatric conditions that evaluating psychiatrist would recommend exclusion of patient after neuropsychiatric evaluation"
5648,NCT03028350,"5:32:treatment,62:74:treatment,76:88:treatment,90:103:treatment,105:115:treatment,117:121:treatment,123:136:treatment,138:151:treatment,153:171:treatment,173:185:treatment,191:207:treatment,","Any immunosuppressive treatment including but not limited to methotrexate, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine, hydroxychloroquine, azathioprine, and cyclophosphamide in the last two weeks before starting treatment"
5649,NCT03028012,"36:41:allergy_name,43:45:allergy_name,50:66:allergy_name","Allergy or contraindication to any NSAID, CS, or local anesthetic"
5650,NCT03025828,"12:18:cancer,27:44:cancer,49:62:cancer,67:91:cancer","History of cancer, except carcinoma in situ and treated basal and squamous cell carcinomas"
5651,NCT03023631,",54:76:cancer,,,104:145:treatment,169:207:treatment",All English-speaking adult MD Anderson patients with hematologic malignancy at 6-12 months +/- 8 weeks post allogeneic stem cell transplantation who will receive usual post-stem cell transplant vaccinations
5652,NCT03023059,"5:18:chronic_disease,43:63:chronic_disease,109:125:treatment","Any eye condition, disease, or history of trauma in either eye, which can impair vision, except cataract or cataract surgery"
5653,NCT03022292,"1:37:treatment,,143:174:treatment,176:220:treatment","Prior focal corticosteroid treatment is allowed, as long as the study eye is not involved. However prior (within 90 days of Day 0) or current systemic corticosteroid therapy (oral or intravenous corticosteroid treatment) is not permitted"
5654,NCT03019133,"21:29:chronic_disease,31:50:chronic_disease,61:87:chronic_disease","Subjects with known Dementia, Parkinson's disease, or other neurodegenerative disorder"
5655,NCT03017118,"13:21:treatment,22:30:treatment,31:37:treatment,38:45:treatment",Patients on Coumadin/Steroids/NSAIDs/Tylenol
5656,NCT03016871,"29:31:treatment,38:55:treatment,71:89:chronic_disease",patients who do not achieve CR after induction therapy are considered primary refractory and are allowed to enter study
5657,NCT03013543,"33:42:chronic_disease,44:51:chronic_disease,56:73:chronic_disease","Current, clinically significant pulmonary, cardiac, or oncologic disease, if these were severe enough to interfere with the study and/or would confound the results"
5658,NCT03011684,"20:39:treatment,44:60:treatment,70:86:treatment",Desires to undergo ovarian stimulation and oocyte retrieval prior to cancer treatment
5659,NCT03010137,"73:82:allergy_name,99:113:treatment,133:154:treatment","All patients who previously demonstrated a hypersensitivity reaction to adhesives and qualify for panniculectomy in preparation for renal transplantation, or all patients who are undergoing panniculectomy for reasons other than in preparation for renal transplantation (i.e. after massive weight loss or for cosmetic reasons)"
5660,NCT03009981,"1:10:treatment,7:10:treatment,18:92:treatment,126:135:treatment,139:146:treatment,201:231:treatment,,,","Prior ADT and/or first generation anti-androgen in the (neo)adjuvant and/or salvage setting before, during, and/or following radiation or surgery is allowed provided last effective dose of ADT and/or first-generation anti-androgen is > 9 months prior to date of randomization and total duration of prior therapy is ? 36 months"
5661,NCT03008408,"19:28:cancer,104:118:treatment,135:151:cancer",Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
5662,NCT03008408,"29:47:treatment,53:68:treatment,80:103:treatment","Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent"
5663,NCT03008070,"12:60:treatment,,153:168:treatment,170:189:treatment,191:203:treatment,205:217:treatment,221:231:treatment,","History of gastrointestinal malabsorptive bariatric surgery within less than 5 years or ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months"
5664,NCT03008070,",,47:55:chronic_disease,,,118:130:chronic_disease,140:157:treatment,158:171:chronic_disease,175:196:treatment,211:218:treatment,","Weight change > 5kg in the last three months, diabetes with poor glycemic control (HbA1c > 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening"
5665,NCT03006770,"8:33:treatment,35:46:treatment,48:71:treatment,73:93:treatment,95:109:treatment,149:187:treatment","Use of hyperbaric oxygen therapy, prostanoids, spinal cord stimulation, lumbar sympathectomy, wound dressing containing cells or growth factors, or topical platelet derived growth factor"
5666,NCT03006302,"5:23:chronic_disease,35:62:chronic_disease,67:89:chronic_disease,","New pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within 2 months of study enrollment"
5667,NCT03005418,"1:22:treatment,157:184:chronic_disease,232:249:treatment","Autologous vein graft is either not feasible in the judgment of the treating surgeon (e.g. because of lack of availability of suitable conduit, presence of severe venous insufficiency) or is not desirable because of the urgency of revascularization"
5668,NCT03004807,"14:20:cancer,26:38:treatment,42:61:treatment,",diagnosis of cancer with chemotherapy or radiation treatment during the previous 5 years
5669,NCT03004287,"19:31:chronic_disease,33:50:chronic_disease,75:84:chronic_disease","Poorly controlled hypertension, diabetes mellitus, active or uncontrolled hepatitis"
5670,NCT03002519,"1:7:chronic_disease,17:27:chronic_disease,29:44:chronic_disease","anemia (such as blood loss, iron deficiency, etc.)"
5671,NCT03001830,"1:24:chronic_disease,8:24:chronic_disease,30:35:chronic_disease,39:42:chronic_disease,99:116:treatment","active hepatitis B or C, and HBsAg or HCV RNA viral load positivity, respectively or currently on antiviral therapy for hepatitis B or C"
5672,NCT03000257,"20:36:chronic_disease,38:65:treatment,67:95:cancer,97:124:treatment,160:172:chronic_disease","History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis"
5673,NCT02998918,"21:44:treatment,48:65:treatment,82:94:chronic_disease",Taking prescription anti-inflammatory drugs or supplements/drugs that may affect inflammation
5674,NCT02995590,"1:15:chronic_disease,17:35:treatment,37:45:chronic_disease,100:109:treatment,139:150:treatment","Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning"
5675,NCT02995330,"1:19:treatment,21:30:treatment,32:43:treatment,49:83:cancer","Prior chemotherapy (docetaxel, cabazitaxel) for castrate resistant prostate cancer"
5676,NCT02994940,"15:28:treatment,33:46:treatment,51:74:chronic_disease,127:142:treatment,144:179:treatment,181:212:treatment,220:228:treatment","scheduled for tonsillectomy and adenoidectomy for obstructive sleep apnea with or without additional minor procedures such as sleep endoscopy, unilateral or bilateral myringotomy, insertion of tympanostomy tubes and/or ear exam. ( Minor additional procedures that are frequently combined with tonsillectomy and adenoidectomy but are not commonly considered to have pain that is significantly greater than the tonsillectomy and adenoidectomy)"
5677,NCT02992899,"32:45:chronic_disease,47:71:chronic_disease,76:84:chronic_disease,98:102:chronic_disease","Current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia, based on the SCID"
5678,NCT02991651,"45:52:allergy_name,56:65:allergy_name,93:101:allergy_name,105:125:allergy_name",History of allergic reactions attributed to IRX4204 or erlotinib or to compounds of similar chemical or biologic composition
5679,NCT02990481,"16:33:treatment,35:42:treatment,44:56:treatment,61:84:treatment,","Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry"
5680,NCT02988960,"40:64:chronic_disease,66:93:treatment,95:123:cancer,125:152:treatment,185:197:chronic_disease,199:225:chronic_disease,227:252:chronic_disease,273:284:chronic_disease","Participant must not have a history of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, previous clinical diagnosis of tuberculosis, inflammatory bowel disease, interstitial lung disease, or immune-mediated pneumonitis"
5681,NCT02988895,",,76:79:chronic_disease,81:113:chronic_disease,126:144:chronic_disease","Fellow eye with a BCVA of 20/63 Snellen Equivalent or worse, with advanced AMD (neovascular or non-exudative AMD with foveal geographic atrophy)"
5682,NCT02986087,"1:13:chronic_disease,15:25:chronic_disease,27:38:chronic_disease","Maternal HIV, Hepatits B, Hepatitis C"
5683,NCT02985554,"15:40:chronic_disease,22:40:chronic_disease,141:169:treatment,180:204:treatment","Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids"
5684,NCT02985554,"15:23:chronic_disease,25:47:chronic_disease,58:69:chronic_disease,126:141:treatment","Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids"
5685,NCT02985411,"7:24:chronic_disease,80:101:chronic_disease,103:131:treatment,,,148:157:chronic_disease,159:167:chronic_disease,169:178:chronic_disease,190:210:chronic_disease,215:236:chronic_disease,238:262:chronic_disease,292:298:treatment,302:317:treatment","Has a medical condition that precludes safe pursuit of gardening, i.e., severe orthopedic conditions, pending hip/knee replacement (within 6 mo.), paralysis, dementia, blindness, untreated stage 3 hypertension, or myocardial infarction, congestive heart failure, or conditions that required oxygen or hospitalization within 6 mo"
5686,NCT02982226,",38:85:treatment,93:114:treatment,116:121:treatment,123:129:treatment,131:140:treatment,142:158:treatment","Completed a minimum of two months of conservative, non-injection treatment/therapies (i.e., activity modification, icing, NSAIDs, orthotics, physical therapy, etc.)"
5687,NCT02979574,"10:26:treatment,28:35:treatment,37:49:treatment,58:70:treatment,,140:157:treatment","Complete active treatment (surgery, chemotherapy, and/or radiotherapy) at least one month prior to study initiation (patients on continued hormone treatment will not be excluded)"
5688,NCT02978443,"84:89:cancer,101:131:treatment,136:158:treatment",Patients must have a tissue block (or 20 unstained slides) available with adequate tumor to perform multiplex immunohistochemistry and nucleic acids analyses ( i.e. whole exome sequencing)
5689,NCT02977468,"23:48:cancer,87:104:treatment,106:127:treatment,132:145:treatment,149:152:treatment,157:161:treatment","Histologically proven invasive breast carcinoma with triple negative receptor status (Estrogen receptor, Progesterone receptor and HER2 negative by IHC and FISH)"
5690,NCT02975986,"22:27:treatment,25:27:treatment,,58:79:chronic_disease,,,107:118:treatment,120:150:treatment,170:186:chronic_disease,203:216:chronic_disease,,,,,368:374:chronic_disease,380:447:treatment,456:480:treatment","Contraindications to SPECT/CT, pregnancy, breastfeeding, chronic renal disease (eGFR < 60 ml/min/1.73m2), proteinuria, genetic diseases of the kidney, inborn defects of lipid metabolism, alcohol abuse, liver disease (patients with highly elevated total bilirubin, elevated liver enzymes AST, ALT and alkaline phosphatase and those with an established liver disease), anemia, and pharmacological treatment with insulin or insulin-sensitizing drugs such as thiazolidinediones (TZD)"
5691,NCT02973139,"10:26:treatment,30:50:treatment,63:72:chronic_disease",Previous thoracic surgery or thrombolytic therapy for pleural infection
5692,NCT02968446,"18:30:treatment,32:42:treatment,44:58:treatment,60:73:treatment,75:84:treatment,89:100:treatment","Currently taking ketoconazole, colestipol, cholestyramine, phenobarbitol, phenytoin, or mineral oil"
5693,NCT02966665,"43:47:chronic_disease,49:52:chronic_disease,54:56:chronic_disease,61:73:chronic_disease","Subject has physical ailments (other than COPD, PAH, HF, or hypertension) that would prevent them from study participation in the judgment of the investigator"
5694,NCT02964741,"34:52:chronic_disease,59:72:chronic_disease,94:101:chronic_disease,105:128:chronic_disease,,","History or current evidence of a psychotic disorder (e.g. schizophrenia) or substance abuse; bipolar or severe major depression, as evidenced by Beck Depression score of ? 30"
5695,NCT02963831,"15:33:cancer,50:77:treatment,114:139:cancer,143:177:cancer",Subjects with peritoneal disease who have failed prior standard chemotherapy and have histologic confirmation of epithelial ovarian cancer or metastatic colorectal cancer (CRC) including cancer originating from the appendix
5696,NCT02962557,"27:50:treatment,52:65:treatment,67:84:treatment,90:103:treatment","Sample procedures include major extremity surgery, spine surgery, abdominal surgery, and chest surgery that require a post operative in patient hospital stay"
5697,NCT02960763,"23:47:chronic_disease,49:62:chronic_disease,64:88:chronic_disease,90:115:chronic_disease,117:136:chronic_disease","Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms"
5698,NCT02960555,"41:58:chronic_disease,,188:194:chronic_disease,196:233:chronic_disease,,323:334:chronic_disease","Patients with pre-existing uncontrolled pulmonary disease will be excluded; uncontrolled refers to patients having had at least one hospitalization due to pulmonary disease (for example, asthma, chronic obstructive pulmonary disease) within the 6 months prior to enrollment in the study; patients with previous history of pneumonitis will be excluded"
5699,NCT02960113,"12:31:chronic_disease,33:41:chronic_disease,45:54:chronic_disease","History of open angle glaucoma, seizures or psychosis"
5700,NCT02957149,"8:15:treatment,19:26:treatment,42:63:treatment",Use of aspirin or heparin 2 weeks before radical prostatectomy
5701,NCT02955537,"23:50:chronic_disease,52:79:chronic_disease,90:113:chronic_disease","Previous diagnosis of acute myocardial infarction, angina (stable or unstable), or known coronary artery disease"
5702,NCT02955251,"51:62:cancer,80:89:treatment,93:109:treatment",combination therapy cohorts must have an advanced solid tumor where the use of nivolumab is standard therapy
5703,NCT02952534,"1:16:treatment,26:40:treatment,42:54:treatment,56:72:treatment,80:107:treatment","Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy"
5704,NCT02950337,"1:20:treatment,22:29:treatment,33:45:treatment,85:90:cancer","Prior local therapy (surgery or radiotherapy) for the current, clinically-diagnosed NSCLC"
5705,NCT02947945,"30:70:treatment,48:51:treatment,,188:194:treatment,,","Subjects who have received a cyclophosphamide (CYC) induction regimen may be included a minimum of 2 weeks after the last dose of daily oral CYC, or 3 weeks after the last dose of pulsed IV CYC prior to visit 1, if their total WBC is ?4x109/L prior to visit 1"
5706,NCT02947165,"15:23:chronic_disease,25:49:chronic_disease,51:74:chronic_disease,90:109:treatment,111:120:chronic_disease,135:153:treatment","Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger"
5707,NCT02946892,"1:50:chronic_disease,67:79:treatment,97:122:treatment",Sustained or symptomatic ventricular dysrhythmias uncontrolled by drug therapy or the use of an implantable defibrillator
5708,NCT02946697,"18:35:treatment,37:44:treatment,46:58:treatment,63:75:treatment,","having completed primary treatment (surgery, chemotherapy, or radiotherapy) within the last 36 months"
5709,NCT02945800,"24:37:treatment,50:61:treatment,65:79:treatment",Must not have received prior therapy with either gemcitabine or nab-paclitaxel
5710,NCT02945800,"36:48:cancer,50:63:cancer,68:84:cancer,92:128:cancer","have had a histologic diagnosis of osteosarcoma, Ewing sarcoma, or rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma either at diagnosis or relapse"
5711,NCT02942095,"34:59:chronic_disease,71:96:chronic_disease,111:130:chronic_disease,144:168:chronic_disease,170:185:chronic_disease,190:211:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months"
5712,NCT02942095,"28:54:cancer,59:91:cancer,123:171:treatment",first 5 patients from both non-small cell lung cancer and pancreatic ductal adenocarcinoma patients will need to agree to mandatory pre- and post-treatment tumor biopsies
5713,NCT02939183,"72:97:cancer,72:88:cancer,102:132:chronic_disease,,159:166:treatment","Subject must have a pathologically documented, definitively diagnosed, multiple myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy for multiple myeloma"
5714,NCT02937402,"1:29:treatment,31:41:treatment,43:53:treatment,55:65:treatment,70:90:treatment,102:112:treatment,166:172:cancer","Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)"
5715,NCT02932280,"25:57:chronic_disease,52:56:chronic_disease,71:96:treatment",Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD
5716,NCT02931110,"19:22:cancer,26:29:cancer,,85:112:treatment,,","For subjects with ALL or AML, presence of >5% blasts in the bone marrow (based on a bone marrow aspirate/biopsy sample with ?200 nucleated cells and the presence of bone marrow spicules)"
5717,NCT02931110,"41:46:cancer,48:50:cancer,52:55:cancer,57:59:cancer,61:64:cancer,65:68:cancer,70:73:cancer,75:77:cancer,82:85:cancer","Part 2 (Cohort Expansion): Diagnosis of DLBCL, FL, MCL, HL, CLL/SLL, ALL, MM, or AML as documented in medical records"
5718,NCT02929589,"36:49:treatment,56:107:treatment,179:188:treatment,189:202:treatment,219:228:treatment,333:339:treatment,341:348:treatment,350:361:treatment,363:376:treatment,378:386:treatment,388:397:treatment,399:410:treatment,412:432:treatment","Elective, open unilateral inguinal herniorrhaphy using Lichtenstein (tension free with mesh) hernia repair technique Agree to take only the prescribed oral analgesic medication (oxycodone/acetaminophen), plus or minus ibuprofen, for the initial fourteen-day post-operative period, with allowed exception of any currently prescribed opioid (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, transdermal fentanyl), which can be continued.Agree to honestly complete a depression screening questionnaire, illicit drug use personal history and questionnaire, and physical activity assessment questionnaire, with the knowledge that if the patient is an active duty member, this information could result in a referral to medical or command authorities for potential Uniform Code of Military Justice (UCMJ) violations or concerns for subject health and fitness for duty"
5719,NCT02926729,"14:39:treatment,41:51:treatment,56:65:treatment","Eligible for breast conserving surgery, lumpectomy and radiation"
5720,NCT02926248,"15:30:chronic_disease,38:51:chronic_disease,53:62:chronic_disease,,","Patients with hepatic disease (known liver disease, cirrhosis, and/or AST/ALT>60)"
5721,NCT02924402,"21:46:cancer,25:28:cancer,54:57:cancer",Diagnosis of either Non-CLL B cell malignancy or CLL/SLL
5722,NCT02924194,"49:66:treatment,68:81:treatment,83:98:treatment,103:119:treatment","Subjects with an implanted stimulator such as a cardiac pacemaker, defibrillator, neurostimulator and cochlear implant"
5723,NCT02923921,"32:70:chronic_disease,79:97:chronic_disease,99:113:chronic_disease,117:147:chronic_disease","Participants with a history of immune-mediated neurological disorders such as multiple sclerosis, Guillain-Barré or inflammatory CNS/PNS disorders"
5724,NCT02923011,"18:34:chronic_disease,45:58:chronic_disease,60:72:chronic_disease,83:103:chronic_disease","Patients with an active infection or severe hematological, neurological, or other uncontrolled disease"
5725,NCT02921022,"13:25:treatment,27:34:treatment,36:48:treatment,53:76:treatment","no previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of PDAC"
5726,NCT02920086,"1:19:chronic_disease,11:19:chronic_disease,132:145:chronic_disease","End-stage dementia (inability to perform all ADLs, mutism or minimal verbal output secondary to dementia, bed-bound state prior to acute illness)"
5727,NCT02918175,"1:22:chronic_disease,9:22:chronic_disease,,,,84:93:treatment,99:110:treatment,","Chronic heart failure, New York Heart Association (NYHA) class II-IV, with ongoing treatment with medications for heart failure for at least 1 month prior to enrollment"
5728,NCT02915744,"7:17:cancer,30:43:cancer,,114:127:treatment",Prior malignancy (other than breast cancer) unless diagnosed and definitively treated more than 5 years prior to randomization
5729,NCT02914561,",162:171:treatment,201:216:treatment,218:234:treatment,236:282:treatment,287:298:treatment","Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines): corticosteroids, immunomodulators, tumor necrosis factor alpha (TNFa) antagonists, or vedolizumab"
5730,NCT02913495,"7:20:chronic_disease,34:44:treatment,54:74:chronic_disease",Major fetal anomaly diagnosed on ultrasound or known chromosomal disorder
5731,NCT02912572,",94:118:treatment,120:142:treatment,147:168:treatment,","Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or post-menopausal (defined as ? 12 months with no menses without an alternative medical cause)"
5732,NCT02912572,"15:30:chronic_disease,32:40:chronic_disease,42:51:chronic_disease,53:82:chronic_disease,97:124:treatment","Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment"
5733,NCT02912572,"14:34:chronic_disease,77:101:chronic_disease,103:127:chronic_disease,129:147:chronic_disease,152:171:chronic_disease,172:189:chronic_disease","Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5734,NCT02911831,"21:48:chronic_disease,65:80:chronic_disease,92:114:chronic_disease,118:136:chronic_disease",Patients with known bleeding/clotting disorders or a history of thromboembolism (including deep venous thrombosis or pulmonary embolism)
5735,NCT02911467,"26:51:allergy_name,75:121:treatment,125:130:allergy_name","No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy)"
5736,NCT02910700,"26:56:cancer,60:82:cancer,107:134:treatment",Histologically confirmed metastatic melanoma (stage IV) or unresectable stage III that have progressed on prior PD-1 directed therapy
5737,NCT02910700,"1:11:cancer,,121:130:treatment,,183:192:treatment",metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for 2 weeks after treatment is complete and within 14 days of the first dose of nivolumab administration
5738,NCT02907983,",75:90:treatment,98:113:treatment,117:127:treatment","post-menopausal women whose vasomotor symptoms are refractory to approved oral treatments (i.e., hormone therapy or paroxetine)"
5739,NCT02905591,"42:48:treatment,50:61:treatment,63:75:treatment,82:108:cancer","Pathologic diagnosis (i.e., cell sample, biopsy, tissue swap, bronchoscopy) with non-small cell lung cancer"
5740,NCT02901314,"27:29:chronic_disease,31:43:chronic_disease,47:82:chronic_disease,84:108:chronic_disease,112:136:chronic_disease","A non-traditional form of HF (hypertrophic or restrictive forms of cardiomyopathy, congenital heart disease or Takotsubo cardiomyopathy)"
5741,NCT02901041,"31:43:treatment,45:58:treatment,60:89:treatment,91:100:treatment,106:120:treatment","drugs with sulfa moiety (e.g. sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics)"
5742,NCT02898597,"12:36:chronic_disease,44:57:chronic_disease,62:78:chronic_disease","History of serious mental illnesses (e.g., schizophrenia and bipolar disorder)"
5743,NCT02891681,"22:46:treatment,93:115:cancer,140:169:treatment,152:169:treatment,196:203:treatment,232:268:cancer","Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed, locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy with the eventual goal of surgery of newly diagnosed clinical stage II-III ER+ HER2- breast cancer (for the endocrine therapy cohort)"
5744,NCT02890979,"21:38:cancer,40:54:cancer,58:81:cancer",Subjects with known esophageal cancer (adenocarcinoma or squamous cell carcinoma)
5745,NCT02886572,"53:73:cancer,75:91:cancer,93:101:cancer,103:111:cancer,117:133:cancer","Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell tumors, lymphoma, leukemia, and multiple myeloma)"
5746,NCT02881320,"42:61:treatment,63:78:treatment,83:128:treatment","No documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), or integrase strand transfer inhibitors (INSTIs) including, but not limited to, the reverse transcriptase resistance mutations K65R and M184V/I"
5747,NCT02879136,"118:132:chronic_disease,134:144:chronic_disease,148:157:chronic_disease,159:167:chronic_disease,169:184:chronic_disease,186:194:chronic_disease,196:214:chronic_disease,227:244:chronic_disease,246:261:chronic_disease","Comorbidities that contraindicate the use of the methylphenidate or atomoxetine: history of substance abuse, current severe anxiety, depression or psychosis, epilepsy, hyperthyroidism, glaucoma, cardiac arrhythmia, history of Tourette syndrome, hepatic disease, allergy to methylphenidate or atomoxetine"
5748,NCT02877394,"16:32:treatment,39:52:treatment,54:67:treatment,69:80:treatment","Current use of anticholinergics (e.g. nortriptyline, amitriptyline, hyoscyamine)"
5749,NCT02877134,",,,,177:188:treatment,219:228:chronic_disease,,337:347:cancer","A participant who has had extensive colitis for greater than or equal to (>=) 8 years, or disease limited to the left side of the colon for >= 12 years, must either have had a colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study agent or a colonoscopy to assess for the presence of malignancy at the screening visit, with no evidence of malignancy"
5750,NCT02877134,"6:21:chronic_disease,25:52:chronic_disease,,90:97:chronic_disease,99:106:chronic_disease,111:122:chronic_disease,161:172:treatment,192:201:treatment","Have Crohn's disease or fistulizing Crohn's disease of at least 3 months' duration, with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy"
5751,NCT02876510,"9:27:chronic_disease,71:97:chronic_disease,109:124:chronic_disease,129:147:chronic_disease,152:172:chronic_disease,181:201:chronic_disease,203:247:chronic_disease,249:277:chronic_disease,281:302:chronic_disease,309:333:chronic_disease","Serious autoimmune disease: Patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) or autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic Lupus Erythematosus or autoimmune vasculitis [e.g. Wegener's Granulomatosis] are excluded from this study"
5752,NCT02876302,"26:28:cancer,30:32:cancer,38:42:cancer,61:97:cancer","Patients must have known ER, PR, and HER2 status defined as triple-negative breast cancer (TNBC)"
5753,NCT02873715,",146:171:chronic_disease,211:225:chronic_disease,490:508:treatment,,546:563:chronic_disease,662:681:treatment,729:751:treatment,842:863:treatment,874:902:treatment,924:935:chronic_disease","The participating parent or child will not have had a concussion in the past three months; will not have any significant developmental delays or intellectual disabilities; will not be receiving treatment for a DSM-5 disorder that interferes with treatment delivered as part of the intervention; will not have a physical disability or diagnosis that prevents performance of physical activity at a level equivalent to a brisk walk or that places severe restriction on diet; will not be on a medication regimen that affects weight; will not have a medical condition that alters nutritional status, intestinal absorption, or affects weight; will not have undergone weight loss surgery; and will not be participating in an alternate weight control program. Families in which either the participating child or parent is actively involved in other weight-loss treatment, is using weight-affecting medications, or has an impairing psychiatric or medical condition that would hinder participation in the study will be excluded as identified by the screening assessments"
5754,NCT02867696,"85:102:chronic_disease,104:110:cancer,112:139:chronic_disease,141:156:chronic_disease,158:172:chronic_disease,174:195:chronic_disease","Reports being treated for a current medical condition that could affect body weigh (diabetes mellitus, cancer, chronic renal insufficiency, hyperthyroidism, hypothyroidism, chronic liver disease)"
5755,NCT02867124,"26:42:treatment,102:111:treatment,113:126:treatment","Willingness to enroll in XR-NTX treatment in prison [not currently in or planning to pursue agonist (methadone, buprenorphine) treatment at release]"
5756,NCT02865135,"111:132:treatment,176:183:treatment,187:204:treatment",Relapsed or progressive disease at the primary site and/or regional lymph nodes after initial treatment (e.g. systemic chemotherapy) with no potentially curative option (i.e. surgery or chemoradiotherapy)
5757,NCT02864862,"41:44:allergy_name,46:56:allergy_name,58:67:allergy_name,69:78:allergy_name,80:91:allergy_name,96:106:allergy_name","allergy to antibiotics contained in the ADM (Gentimicin, Cefoxitin, Lincomcin, polymixin B and Vancomycin) will not be included in the immediate implant combined with ADM group"
5758,NCT02864147,"1:17:chronic_disease,18:24:chronic_disease,35:49:treatment",active infection/sepsis requiring IV antibiotics
5759,NCT02863991,",48:69:chronic_disease,78:93:chronic_disease,95:134:treatment,148:172:chronic_disease,174:198:chronic_disease,200:225:chronic_disease,241:259:chronic_disease","Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism"
5760,NCT02862210,"28:55:chronic_disease,63:87:chronic_disease,89:95:chronic_disease,129:147:chronic_disease,149:168:chronic_disease","Current diagnosis of other major neurological disorder, e.g., Alzheimer's Disease (AD), stroke with residual clinical deficits, multiple sclerosis, Parkinson's disease"
5761,NCT02860702,"1:20:chronic_disease,39:53:chronic_disease,55:78:chronic_disease,80:99:chronic_disease","Metabolic disorders affecting growth: homocystinuria, methylmalonic acidemias, propionic acidemias, urea cycle defects"
5762,NCT02860000,"22:47:treatment,51:72:treatment,77:93:cancer,153:156:treatment,","Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration"
5763,NCT02857218,"1:35:chronic_disease,57:91:treatment,136:164:treatment,170:181:treatment",Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
5764,NCT02851914,"20:35:treatment,44:80:treatment,82:135:treatment","Currently on other antidepressants such as monoamine oxidase inhibitors (MAOIs), selective norepinephrine re-uptake inhibitors (SNRIs) etc"
5765,NCT02849457,"17:36:treatment,45:55:treatment,59:68:treatment",Has received an oral mTOR inhibitor such as everolimus or sirolimus
5766,NCT02848417,"1:17:chronic_disease,23:32:chronic_disease,36:47:chronic_disease",Major depression with psychotic or melancholic features
5767,NCT02844738,"1:11:treatment,17:36:treatment,,88:111:chronic_disease",Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than shoulder osteoarthritis
5768,NCT02843945,"17:28:treatment,30:42:treatment,47:72:treatment","with concurrent gemcitabine, capecitabine, or infusional 5-fluorouracil"
5769,NCT02841540,"19:52:chronic_disease,54:86:chronic_disease,88:119:chronic_disease,121:142:chronic_disease,163:184:chronic_disease","Family history of Leber Hereditary Optic Neuropathy, Autosomal Dominant Optic Atrophy, Late-Onset Retinal Degeneration, Familial Dysautonomia or other hereditary mitochondrial disease, unless the causative mutation(s) in the family have been determined and the participant has tested negative for the mutation(s)"
5770,NCT02838797,"16:40:treatment,81:92:treatment,102:113:treatment,115:131:treatment,136:169:treatment,174:193:chronic_disease","history of any gastrointestinal surgery that might impact drug absorption (e.g. gastrectomy), use of apomorphine, anticholinergics, or carbidopa/levodopa intestinal gel for Parkinson's Disease"
5771,NCT02837510,"1:17:treatment,19:29:treatment,31:37:treatment,66:71:treatment,73:83:treatment,84:89:treatment","Anti-depressants (tricyclics, SSRI's, selective and nonselective MAOIs, Wellbutrin/Zyban)"
5772,NCT02836574,"35:59:treatment,95:121:chronic_disease,,141:154:treatment","immunocompromised or is receiving immunosuppressive agents, including individuals treated for chronic glomerulonephritis within 3 months of NKA injection"
5773,NCT02835729,"59:62:cancer,107:129:cancer,141:171:chronic_disease",A histologically or pathologically confirmed diagnosis of AML based on WHO classification with or without extramedullary disease except for central nervous system disease
5774,NCT02834780,"26:43:chronic_disease,52:69:chronic_disease,73:90:chronic_disease","Uncontrolled significant active infections, except Hepatitis B (HBV) or Hepatitis C (HCV)"
5775,NCT02833805,"7:19:cancer,37:52:cancer,64:90:cancer,92:98:cancer,,162:169:cancer",Prior malignancies except: resected basal carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent > 5 years previously. Other prior cancers will not be allowed unless approved by the PI
5776,NCT02832687,"1:16:treatment,20:26:treatment,53:77:chronic_disease",Chronic steroid or opioid user (as prescribed for a chronic systemic illness)
5777,NCT02832115,"8:18:treatment,20:31:treatment,36:62:treatment,","Use of sublingual, transdermal, or intravenous nitroglycerine within 6 hours prior to IP administration"
5778,NCT02826681,"240:250:cancer,252:277:chronic_disease,279:310:chronic_disease,315:345:chronic_disease","Any other pre-existing laboratory abnormality, medical condition, or disease that, in the opinion of Investigator, may cause the subject to be unsuitable for the study or place the subject at potential risk from being in the study, e.g. a malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus"
5779,NCT02826681,"1:16:treatment,18:50:treatment,58:75:treatment,","Parenteral iron, erythropoiesis stimulating agent use or blood transfusion within six weeks prior to the screening visit"
5780,NCT02826343,"12:38:chronic_disease,41:47:chronic_disease,73:85:chronic_disease","History of myocardial infarction (MI) , stroke and/or poorly controlled hypertension"
5781,NCT02822378,"14:17:chronic_disease,19:24:chronic_disease,28:49:chronic_disease,54:64:cancer","positive for HIV, Hep-C or Hep-B surface antigen and malignancy"
5782,NCT02820350,"17:39:treatment,56:67:treatment,71:91:treatment,",Patients with a solid organ transplant or those with a bone marrow or stem cell transplant in the previous 100 days or who have not engrafted
5783,NCT02819843,"12:42:chronic_disease,52:57:chronic_disease,59:70:chronic_disease,72:87:chronic_disease,89:107:chronic_disease,119:137:treatment,151:166:treatment,170:188:treatment","History of symptomatic autoimmune disease (such as lupus, scleroderma, Crohn's disease, ulcerative colitis) requiring systemic treatment (for example corticosteroids or immunosuppressants)"
5784,NCT02819635,"10:22:treatment,24:34:treatment,36:57:treatment,62:73:treatment,","Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline"
5785,NCT02819141,"8:43:chronic_disease,53:57:chronic_disease,59:67:chronic_disease","Severe cognition or communication problems (such as coma, deafness without signing literacy, physician-documented dementia)"
5786,NCT02818972,"102:119:chronic_disease,121:140:chronic_disease,142:173:chronic_disease,175:196:chronic_disease,199:215:chronic_disease","Subject has specified disease of the thoracic aorta which is not included in the trial, for example: aortic dissection, intramural hematoma, traumatic injury or transection, aortic false aneurysm, ruptured aneurysm"
5787,NCT02816736,"62:70:allergy_name,76:80:allergy_name,84:87:allergy_name,147:168:chronic_disease","History of hypersensitivity or intolerance (unmodifiable) to Entresto, an ACEI or ARB as well as known or suspected contraindications (including hereditary angioedema) to the study drugs"
5788,NCT02815670,"36:43:treatment,47:65:treatment,81:92:treatment",A condition requiring an emergency surgery or invasive procedure where adequate haemostasis
5789,NCT02811679,"26:36:cancer,49:73:cancer,75:108:cancer,123:138:cancer,","Prior history of another malignancy (except for non-melanoma skin cancer, in situ cervical or breast cancer, or localized prostate cancer) unless disease free for at least one year and felt at low risk of relapse by treating physician"
5790,NCT02811263,"45:63:treatment,77:105:treatment,116:128:treatment,130:146:treatment,151:155:treatment","Need for resuscitation at 10 minutes (i.e., chest compressions, or positive pressure respiratory support including endotracheal, mask ventilation, or CPAP)"
5791,NCT02809677,"11:43:chronic_disease,67:93:chronic_disease,100:124:chronic_disease,126:141:chronic_disease,143:170:chronic_disease,175:181:cancer,222:228:chronic_disease,230:237:chronic_disease,239:249:chronic_disease","severe or life-threatening medical illness, such as other serious cardiopulmonary conditions (e.g. congenital heart disease, cystic fibrosis, alpha-1-antitrypsin disease) or cancer, which would confound the assessment of asthma, anxiety, depression or quality of life"
5792,NCT02807272,"1:19:chronic_disease,20:44:chronic_disease,56:60:cancer",Myeloproliferative/myelodysplastic syndrome other than CMML
5793,NCT02806570,"54:93:treatment,97:145:treatment,150:188:treatment",Implant or revision of any rhythm management device (cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy device (CRT-D)) or implantable cardioverter defibrillator within the prior month
5794,NCT02805504,"8:22:chronic_disease,24:31:chronic_disease,33:46:chronic_disease,50:73:chronic_disease","Severe cardiovascular, hepatic, renal disease or neurological impairment"
5795,NCT02800629,"98:107:chronic_disease,,,,,,,209:232:chronic_disease,,,278:300:chronic_disease","While this supplement is considered very safe and low risk, patients with underlying significant cytopenia (white blood cell count less than 4.0, hemoglobin less than 10, or platelets less than 100), or with impaired renal function (glomerular filtration rate less than 60) or elevated liver enzymes will be excluded as well"
5796,NCT02798458,"38:51:treatment,60:92:treatment,,124:133:treatment",Symptomatic subjects necessitating a sigmoidoscopy who are enzyme replacement therapy (ERT) naive OR less than 6 months of treatment
5797,NCT02793583,"14:36:cancer,47:76:cancer,78:88:cancer,90:110:cancer,115:137:cancer","Diagnosis of Non-Hodgkin's Lymphoma including Diffuse Large B-cell Lymphoma, Follicular, Mantle Cell Lymphoma and Marginal Zone Lymphoma"
5798,NCT02789228,"1:19:chronic_disease,21:48:chronic_disease,59:79:treatment,83:99:chronic_disease","Refractory disease, residual detectable disease following conventional therapy or relapsed disease"
5799,NCT02784535,"60:82:treatment,84:105:treatment,107:128:treatment,130:154:treatment,156:177:treatment","Use of other norepinephrine transporter inhibitors such as Wellbutrin (Bupropion), Cymbalta (Duloxetine), Effexor (venlafaxine), Pristiq (desvenlafaxine), Savella (milnacipran)"
5800,NCT02780401,",35:62:treatment,64:76:treatment,78:97:treatment,111:127:treatment","Patients must be at least 28 days post cytotoxic chemotherapy, radiotherapy, monoclonal antibody and/or other biologic therapy, prior to enrollment"
5801,NCT02780271,",18:35:treatment,37:53:treatment,58:75:treatment,76:85:treatment,93:107:treatment,124:140:treatment,161:170:treatment,175:195:treatment","At least 90 days post chemotherapy, biologic therapy, or radiation therapy treatment and/or breast surgery. Current use of hormonal therapy is permitted (e.g., tamoxifen and aromatase inhibitors)"
5802,NCT02776761,"5:42:chronic_disease,54:62:chronic_disease,67:75:chronic_disease","Any chronic or active neurologic disorder, including seizures and epilepsy"
5803,NCT02776761,"15:23:treatment,28:37:treatment,41:47:chronic_disease",daily inhaled steroids for treatment of asthma
5804,NCT02772562,"1:13:chronic_disease,17:42:chronic_disease,51:57:chronic_disease,59:68:chronic_disease","Inflammatory or exfoliative skin diseases such as eczema, psoriasis that disrupt epidermis"
5805,NCT02771626,"1:17:chronic_disease,39:50:treatment,52:62:treatment,67:78:treatment,,117:127:treatment","Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks prior to first dose of study drug"
5806,NCT02771626,"1:14:treatment,18:36:treatment,41:62:treatment,","Immunotherapy or biological therapy, or investigational agent within 3 weeks"
5807,NCT02770326,"63:71:chronic_disease,,110:128:treatment,132:142:cancer",Clinical and microbiologic relapse of C. difficile associated diarrhea after at least one course of adequate antibiotic therapy or refractory disease that does not respond to treatment
5808,NCT02763228,",90:105:treatment,107:119:treatment,123:140:treatment,172:188:treatment,193:209:treatment","Patients who have completed treatment but are within five years of treatment completion (primary surgery, chemotherapy or radiation therapy), whichever was received last. Hormonal therapy and targeted therapy are allowed"
5809,NCT02762006,"25:53:treatment,,94:104:treatment,144:167:treatment,152:166:treatment,171:195:treatment,,257:267:treatment","Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid"
5810,NCT02762006,"8:26:chronic_disease,84:103:chronic_disease,105:116:chronic_disease,137:171:chronic_disease","active bleeding diathesis including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C (detectable RNA) or human immunodeficiency virus (HIV)"
5811,NCT02759211,"42:57:chronic_disease,59:92:chronic_disease,111:145:chronic_disease,147:185:chronic_disease,187:210:chronic_disease,214:234:chronic_disease,247:250:chronic_disease,252:269:chronic_disease,273:285:chronic_disease,287:311:chronic_disease,313:338:chronic_disease,344:365:chronic_disease","Current self-reported medical history of unstable angina, uncontrolled cardiac dysrhythmias causing symptoms, symptomatic severe aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus or pulmonary infarction, history of DVT, acute myocarditis or pericarditis, acute systemic infection, uncontrolled hypertension, and uncontrolled diabetes [11]"
5812,NCT02758847,"39:67:chronic_disease,98:123:treatment,128:155:treatment,159:177:chronic_disease",Patient population: all patients with CLI (critical limb ischemia) and tissue loss scheduled for endovascular intervention for femoral popliteal occlusive or multilevel disease
5813,NCT02753283,"20:27:treatment,39:53:treatment,55:64:treatment,69:81:treatment,,,173:188:treatment","Those currently on therapy (including bisphosphonate, denosumab, or teriparatide) or who have been on a bisphosphonate for > 1year during the previous 2 years because some bisphosphonates are long acting"
5814,NCT02748109,"1:21:chronic_disease,77:107:chronic_disease,109:115:chronic_disease,117:129:chronic_disease,131:157:treatment","neurological illness that could potentially explain balance deficits (e.g., Central Nervous System disease, stroke, moderate TBI, lower extremity amputation)"
5815,NCT02744391,"21:46:chronic_disease,48:57:chronic_disease,62:72:chronic_disease","DSM 5 non-psychotic Major Depressive Disorder, Dysthymia, or Depression Not Otherwise Specified"
5816,NCT02744391,"56:59:chronic_disease,61:70:chronic_disease,75:89:chronic_disease,97:122:treatment,126:139:treatment","Prefer not to be treated with a standard treatment for MDD, Dysthymia, or Depression NOS (e.g., antidepressant medication or psychotherapy)"
5817,NCT02743637,"1:40:chronic_disease,,,,,78:89:chronic_disease,,,129:146:treatment","Uncontrolled or refractory hypertension: systolic >180 or diastolic >110, or hypotension: systolic <90 or diastolic <50 despite medical treatment"
5818,NCT02740543,"1:19:chronic_disease,28:60:chronic_disease,64:89:chronic_disease",Pulmonary diseases such as Chronic Pulmonary Disease (COPD) or Interstitial Lung Disease
5819,NCT02739620,"1:19:cancer,40:46:cancer,58:82:cancer,104:116:treatment","metastatic disease, a prior history of cancer, excluding non-melanoma skin cancer, or prior receipt of chemotherapy"
5820,NCT02737475,"34:46:allergy_name,48:56:allergy_name,61:75:allergy_name","Patients with known allergies to egg products, neomycin, or tetanus toxoid"
5821,NCT02734771,"17:30:treatment,35:40:cancer,44:46:chronic_disease,81:91:treatment,,134:142:cancer,179:198:cancer,219:257:treatment","Has received no prior therapy for DLBCL or HT with the exception of a course of prednisone of less than or equal to 7 days given for lymphoma related symptoms; prior therapy for follicular lymphoma is accepted, but no prior anthracycline-containing therapy"
5822,NCT02734602,"42:51:chronic_disease,53:57:chronic_disease,62:78:chronic_disease","No first-degree relative with history of psychotic, mood, or anxiety disorder"
5823,NCT02728284,"70:78:chronic_disease,82:106:chronic_disease,150:164:chronic_disease","pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest"
5824,NCT02728050,"16:19:chronic_disease,23:26:chronic_disease,63:66:cancer,129:145:treatment",such high-risk MDS or MPN have natural history much closer to AML than to lower risk MDS or MPN and have responded similarly to AML-type therapy
5825,NCT02725177,"1:17:chronic_disease,,60:83:treatment,142:157:treatment","Anterior uveitis requiring 4 or more daily applications of topical corticosteroids to maintain control of inflammation, or uncontrolled with topical therapy"
5826,NCT02724540,"1:17:chronic_disease,31:40:chronic_disease,45:61:chronic_disease",Active infection (Symptomatic bacterial and fungal infection - newly diagnosed and/or requiring treatment)
5827,NCT02723266,"13:16:chronic_disease,33:51:chronic_disease,53:65:chronic_disease,,,,","at risk for GDM (such as having metabolic syndrome, pre-diabetes, or BMI > 85%; and an A1C < 6.5%)"
5828,NCT02715583,"12:18:treatment,51:85:cancer,95:113:cancer",History of biopsy proven or clinically documented castrate resistant prostate cancer which is metastatic to bone as assessed by medical record review
5829,NCT02706353,",106:121:treatment,123:125:treatment,129:132:treatment,160:169:chronic_disease,171:183:treatment,185:190:chronic_disease,,","At least two injectable lesions (amenable for direct injection or through the use of image guidance such ultrasound [US], CT or MRI) defined as any injectable cutaneous, subcutaneous, nodal, or visceral melanoma lesion >/= 10 mm in longest diameter"
5830,NCT02706249,"13:37:chronic_disease,44:59:chronic_disease,61:88:chronic_disease,90:115:chronic_disease,117:140:chronic_disease","Established hereditary thrombophilia (e.g. Factor V Leiden, G20210 prothrombin mutation, protein C or S deficiency, antithrombin deficiency)"
5831,NCT02703272,"25:34:allergy_name,36:52:allergy_name,72:81:allergy_name","Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)"
5832,NCT02702492,"21:34:treatment,39:48:treatment,61:79:cancer,83:86:cancer",Time since the last prior therapy for treatment of advanced solid malignancies or NHL
5833,NCT02699697,"12:33:treatment,35:51:treatment,66:81:treatment,127:139:treatment","Changes in systemic chemotherapy, hormonal therapy or the use of bisphosphonates for 4 weeks before and after the delivery of radiotherapy are allowed, but recording and accounting for this in the statistical analysis is required"
5834,NCT02695043,",,60:70:treatment,72:80:treatment,84:96:treatment","GCS in emergency department of less than 13 (unless due to intubation, sedation or intoxication)"
5835,NCT02692651,"64:76:treatment,78:90:chronic_disease,101:127:chronic_disease,129:138:chronic_disease","Patients with severe-complicated disease that would compromise oral therapy (hypotenstion or shock, ileus or bowel obstruction, megacolon)"
5836,NCT02688647,"1:18:treatment,22:37:treatment,48:64:treatment,69:81:treatment",Immunosuppressive or cytotoxic drugs including cyclophosphamide and azathioprine
5837,NCT02688309,"35:65:chronic_disease,145:180:chronic_disease,182:201:chronic_disease,204:212:chronic_disease,214:223:chronic_disease,225:249:chronic_disease,255:270:chronic_disease","Patients with active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases"
5838,NCT02682836,"33:36:chronic_disease,,66:78:treatment,82:99:treatment","Receiving treatment regimen for MBC, but no more than 3 previous chemotherapy or biologic regimens"
5839,NCT02682147,"1:18:treatment,24:35:treatment,40:52:chronic_disease,57:82:chronic_disease","antihypertensives, and medications for osteoporosis and gastrointestinal diseases"
5840,NCT02679560,"12:19:chronic_disease,12:28:chronic_disease,59:83:chronic_disease","History of seizure disorder, recent seizure or a document intra-cranial hemorrhage"
5841,NCT02674984,"1:26:chronic_disease,35:49:chronic_disease,51:77:chronic_disease","Gastrointestinal diseases such as celiac disease, inflammatory bowel disease"
5842,NCT02670044,"109:140:chronic_disease,141:180:chronic_disease,182:210:chronic_disease,215:247:chronic_disease","History or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration"
5843,NCT02669966,"22:34:chronic_disease,22:25:chronic_disease,82:94:chronic_disease,98:101:treatment",The recipient may be HCV antibody negative or anti-HCV antibody positive but HCV RNA negative by PCR
5844,NCT02669173,"21:46:chronic_disease,87:102:chronic_disease,104:117:chronic_disease,","Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ?2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at screening)"
5845,NCT02666638,"15:30:chronic_disease,32:42:chronic_disease,44:56:cancer","no history of chronic illness, concussion, malignancies, etc"
5846,NCT02665338,"28:49:chronic_disease,86:99:chronic_disease,115:134:chronic_disease",History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment
5847,NCT02663622,"8:24:treatment,57:60:treatment,62:73:treatment","Use of T cell depletion either ex vivo or in vivo (i.e. ATG, alemtuzumab) is prohibited"
5848,NCT02660528,"23:41:chronic_disease,53:71:chronic_disease,76:102:chronic_disease","History of or current autoimmune disease, including multiple sclerosis and inflammatory bowel disease"
5849,NCT02658565,"42:54:treatment,59:90:treatment,95:128:treatment",must be surgical candidates for complete hysterectomy and bilateral salpingo-oophorectomy and pelvic and aortic lymphadenectomy
5850,NCT02656706,"15:30:chronic_disease,61:77:chronic_disease,,114:135:chronic_disease,",Patients with unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
5851,NCT02654236,"42:56:chronic_disease,65:81:chronic_disease,83:90:chronic_disease,106:124:chronic_disease,128:150:chronic_disease","Previous history of jaundice or signs of liver diseases such as spider angiomata, ascites, or history of esophageal varices or hepatic encephalopathy"
5852,NCT02648282,"28:48:chronic_disease,90:106:chronic_disease,119:143:chronic_disease,145:169:chronic_disease,171:189:chronic_disease,193:214:chronic_disease","Patients with uncontrolled intercurrent illness, including but not limited to ongoing or active infection, systematic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements"
5853,NCT02646930,"63:74:treatment,83:94:treatment,99:135:treatment,139:154:treatment,200:218:treatment,","Post-enrollment exclusion will include patients receiving any antibiotics, except prophylaxis for transvaginal oocyte retrieval (TVOR) or glucocorticoids, except nasal preparations, from the time of endometrial biopsy until initial transvaginal ultrasound (TVUS) for pregnancy"
5854,NCT02642939,"5:20:treatment,48:57:treatment,98:133:treatment,135:144:treatment,146:159:treatment,161:174:treatment,176:184:treatment,186:195:treatment,197:212:treatment,217:233:treatment,235:247:treatment,249:261:treatment,263:273:treatment,275:284:treatment,,298:307:treatment,309:330:treatment,332:345:treatment,347:357:treatment,359:373:treatment,375:385:treatment,387:396:treatment,,,424:434:treatment,436:449:treatment,454:466:treatment","For two weeks prior to first day of study drug treatment, administration of any of the following cytochrome P450 3A (CYP3A) inducers: phenytoin, phenobarbital, carbamazepine, rifampin, rifabutin, St. John's Wort; or CYP3A inhibitors: ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir amprenavir, fosamprenavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, telithromycin, or voriconazole"
5855,NCT02642939,"19:31:chronic_disease,33:57:chronic_disease,242:249:chronic_disease","poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)"
5856,NCT02639546,"116:143:treatment,145:164:treatment,166:179:treatment","Measurable disease as defined by mINRC, RANO criteria for HGG, RANO criteria for LGG, RECIST v1.1, or evaluable by nuclear medicine techniques, immunocytochemistry, tumor markers, or other reliable measures"
5857,NCT02639208,"42:54:treatment,91:118:treatment,122:131:treatment,",Patients who did not enroll during their chemotherapy are still eligible to enroll during subsequent hormonal therapy or radiation as long as it is within 6 months of diagnosis
5858,NCT02639065,"1:39:treatment,24:38:treatment,43:67:treatment,,129:139:treatment","intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid"
5859,NCT02637349,"30:39:chronic_disease,41:49:chronic_disease,51:65:chronic_disease","Altered mental status (e.g., psychosis, delirium, disorientation)"
5860,NCT02633163,"17:26:treatment,,75:84:treatment,94:127:treatment,","Having received belimumab within 2 months of Baseline, or having received rituximab or other B cell depleting biologic therapy within 6 months of Baseline"
5861,NCT02633163,",43:56:treatment,,81:97:treatment,127:139:treatment",Therapy must include at least 6 months of mycophenolate or at least 3 months of cyclophosphamide followed by mycophenolate or azathioprine
5862,NCT02632422,"1:10:chronic_disease,17:24:chronic_disease,27:39:chronic_disease,41:63:chronic_disease,65:82:chronic_disease,84:103:chronic_disease,135:159:chronic_disease,200:216:chronic_disease","infection (e.g. bladder), hypertension, cardiovascular disease, pulmonary disease, severe osteoporosis (history of fractures), active heterotopic ossification in the lower extremities, or history of peripheral nerve injury in the legs"
5863,NCT02628535,"8:13:chronic_disease,15:24:chronic_disease,29:54:chronic_disease,65:85:treatment,","Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration"
5864,NCT02628535,"1:21:cancer,23:40:cancer,,,46:62:treatment","pleural mesothelioma, pancreatic cancer: 1-3 prior treatments"
5865,NCT02624258,"69:88:allergy_name,90:94:allergy_name,100:110:allergy_name","History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)"
5866,NCT02617589,"17:29:cancer,33:38:cancer,46:58:cancer,62:65:cancer",Newly-diagnosed brain cancer or tumor called glioblastoma or GBM
5867,NCT02616185,"22:42:chronic_disease,74:91:chronic_disease,93:104:chronic_disease,106:117:chronic_disease,119:139:chronic_disease,141:159:chronic_disease,161:189:chronic_disease,191:202:chronic_disease","History of or active autoimmune disorders (including but not limited to: myasthenia gravis, thyroiditis, pneumonitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma) and other conditions that disorganize or alter the immune system"
5868,NCT02615249,",,,155:167:treatment,169:190:treatment,192:208:treatment,212:236:treatment","Inability to become pregnant includes all male subjects and female subjects who are postmenopausal for at least 1 year, or surgically sterile- have had a hysterectomy, bilateral ovariectomy, uterine ablation or bilateral tubal ligation"
5869,NCT02614365,"14:26:chronic_disease,28:38:chronic_disease,84:92:chronic_disease","persons with neurological, psychiatry or other clinical conditions likely to cause dementia"
5870,NCT02611063,"20:34:treatment,80:92:chronic_disease,142:149:treatment,153:163:chronic_disease",Participation in a clinical trial evaluating another preventative strategy for chronic GVHD or ongoing participation in a clinical trial for therapy of acute GVHD
5871,NCT02608125,"28:61:treatment,,106:117:treatment,119:129:treatment,134:145:treatment","Patients who have received prior systemic anticancer therapy ? 3 weeks prior to study start (6 weeks for nitrosourea, antibodies, or mitomycin-C)"
5872,NCT02607748,"1:24:chronic_disease,49:77:chronic_disease,,124:153:treatment,",Acute Coronary Syndrome group: 40 patients with type 1 myocardial infarction within 21 days prior to the imaging visit and invasive coronary angiography with angiographic evidence of at least a 50% stenosis in one or more coronary arteries
5873,NCT02607514,"1:19:chronic_disease,62:79:chronic_disease,81:103:chronic_disease,105:117:chronic_disease,,,,156:167:chronic_disease,,223:246:chronic_disease,328:348:chronic_disease,350:360:cancer,365:386:chronic_disease","Medical conditions that may make participation unsafe (e.g., diabetes [I & II], cardiovascular disease, hypertension [>140 systolic and/or >90 diastolic], hypotension [<90 systolic and/or <60 diastolic, during screening], orthostatic hypotension [systolic drop of 20 points or 10 point diastolic or heart rate increase by 10], autoimmune disorders, malignancy, or autonomic dysfunction)"
5874,NCT02606045,"20:38:treatment,40:54:treatment,56:63:treatment,65:72:treatment,76:82:treatment","Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs"
5875,NCT02601027,"10:30:chronic_disease,39:52:chronic_disease,56:72:chronic_disease",Specific mental health issues such as schizophrenia or bipolar disorder
5876,NCT02600897,"1:25:treatment,31:39:cancer,47:81:treatment","fluorodeoxyglucose (FDG)-avid lymphoma (i.e., positron emission tomography (PET)-positive lymphoma)"
5877,NCT02595866,"28:35:treatment,,56:71:treatment,92:99:chronic_disease,110:132:treatment,153:162:treatment,167:186:chronic_disease","patients who are receiving therapy beyond month one of initial therapy with no evidence of TB IRIS requiring corticosteroid therapy, or those receiving treatment for latent tuberculosis (INH or alternative) may be eligible after discussion with the protocol P.I"
5878,NCT02594501,"56:59:allergy_name,61:72:allergy_name,74:82:allergy_name","Known allergy or intolerance to the study medications: ASA, clopidogrel, coumadin and its derivatives"
5879,NCT02594384,"17:34:chronic_disease,38:62:chronic_disease,64:98:chronic_disease,100:111:chronic_disease,115:126:chronic_disease","Past history of tuberculosis (TB) or active infection with TB, human immunodeficiency virus (HIV), hepatitis B or hepatitis C"
5880,NCT02593123,"1:8:chronic_disease,10:23:chronic_disease,28:44:chronic_disease","Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements"
5881,NCT02592707,"20:29:treatment,33:43:treatment,72:79:cancer,84:92:cancer,124:150:treatment","In countries where sunitinib or everolimus are marketed, patients with GEP NET and lung NET will be progressive under this prior anti-tumor treatment for the respective indication"
5882,NCT02592707,"22:36:cancer,102:147:cancer,152:175:cancer",unresectable typical lung carcinoid or atypical lung carcinoid are acceptable (with the exception of Large Cell Bronchial Neuroendocrine Neoplasms and Small Cell Lung Cancers) (Caplin 2015)
5883,NCT02592551,"9:28:treatment,33:36:cancer,38:70:treatment,74:109:treatment",Planned resectional surgery for MPM [extrapleural pneumonectomy (EPP) or pleurectomy and decortication (P/D)]
5884,NCT02592551,"29:45:cancer,56:76:treatment,110:117:treatment,119:128:treatment,137:152:treatment","Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids"
5885,NCT02592473,"23:41:treatment,43:59:treatment,64:118:treatment,","Patients on long-term narcotic analgesia, androgen therapy, or GNRH (gonadotropin-releasing hormone) analogue therapy within 2 months of study"
5886,NCT02589977,"7:29:chronic_disease,31:51:chronic_disease,62:81:treatment","known cardiovascular disease, cardiac risk factors or use of cardiac medications"
5887,NCT02589522,"28:59:treatment,61:74:treatment,,116:120:treatment,,,298:318:treatment,332:354:treatment,,,404:416:treatment,420:431:treatment,477:486:treatment","Patients who have received systemic cytotoxic chemotherapy, immunotherapy for 3 weeks before initiation of planned WBRT or patients who have not recovered from serious (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or more) adverse events from the previously received agents; for oral targeted agents or any other investigational agents, at least 4 half-lives of the agent (6 weeks for nitrosoureas or mitomycin C) should have elapsed prior to starting study treatment"
5888,NCT02589522,"166:196:chronic_disease,207:223:treatment,265:289:chronic_disease,291:315:chronic_disease,342:360:chronic_disease,365:402:chronic_disease","Uncontrolled intercurrent illness that would increase the risk of toxicity or limit compliance with study requirements; this includes but is not limited to, ongoing uncontrolled serious infection requiring i.v. antibiotics at the time of registration, symptomatic congestive heart failure, unstable angina pectoris, symptomatic/uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5889,NCT02588612,"1:17:chronic_disease,23:57:chronic_disease,53:56:chronic_disease,59:82:chronic_disease,84:107:chronic_disease,111:149:chronic_disease,211:239:chronic_disease,289:317:chronic_disease,369:381:treatment,646:657:chronic_disease","Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or human T-cell lymphotropic virus (HTLV) as minimally defined below: a) Positive serology for HIV. b) Active hepatitis B infection as determined by hepatitis B surface antigen. c) Active hepatitis C infection as determined by hepatitis C RNA; A subject who is HCV antibody positive will be screened for HCV ribonucleic acid (RNA) by any reverse transcriptase (RT) polymerase chain reaction (PCR) or bDNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value. d) Positive serology for HTLV 1 or 2"
5890,NCT02588612,"1:15:treatment,27:54:treatment,82:100:treatment","Immune therapy (including monoclonal antibody therapy, checkpoint inhibitors) or biological therapy with no wash-out times required"
5891,NCT02588612,",,,,,,,309:322:treatment,,,442:469:treatment,,,,,,751:769:chronic_disease,,",Subject must have adequate organ function as indicated by the following laboratory values: a) Absolute Neutrophil count (ANC) >=1.0 x10^9 per liter (/L) (without G-CSF support); b) Platelets >= 75 x10^9/L; c) Hemoglobin >80 grams per deciliter (g/dL) (without transfusion support within 7 days from start of leukapheresis); d) Prothrombin Time or International Normalized Ratio (INR) <=1.5 times upper limit of normal (ULN) unless receiving therapeutic anticoagulation. e) Partial Thromboplastin Time (PTT) <=1.5 times upper limit of normal (ULN) unless receiving therapeutic anticoagulation. f) Calculated or measured creatinine clearance >=40 milliliters per minute (mL/min); g) Serum total bilirubin <=1.5 times ULN (unless subject had documented Gilbert's Syndrome); h) Alanine aminotransferase (ALT)/Serum Glutamic Pyruvic Transaminase (SGPT) <=2.5 times ULN
5892,NCT02588612,"1:16:treatment,30:55:treatment,,80:93:treatment",corticosteroids or any other immunosuppressive therapy within 2 weeks prior to leukapheresis
5893,NCT02588326,"21:40:chronic_disease,50:65:chronic_disease,69:73:chronic_disease",No history of major respiratory disease (such as cystic fibrosis or COPD)
5894,NCT02588326,"12:20:treatment,22:29:treatment,31:38:treatment,43:63:treatment,","Use of any systemic, topical, inhaled, or nasal corticosteroid within 30 days prior to enrollment"
5895,NCT02587962,"47:72:cancer,58:72:cancer,74:99:cancer,103:136:cancer,194:201:treatment","Patients must have a histologically confirmed epithelial ovarian cancer, primary peritoneal cancer or fallopian tube solid tumor cancer that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (ovarian cancer cohort only)"
5896,NCT02587962,"62:99:cancer,157:164:treatment,261:273:cancer",Patients must have histologically or cytologically confirmed head and neck squamous cell carcinoma that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (various solid tumors cohort: head and neck squamous cell carcinoma groups only)
5897,NCT02587962,"1:19:treatment,21:52:treatment,56:68:treatment,,107:117:treatment","Prior chemotherapy, targeted small molecule therapy or radiotherapy within 2 weeks prior to first dose of study drug"
5898,NCT02587598,",52:55:cancer,64:73:treatment,94:116:treatment",Elderly subjects (? 65 years) with newly diagnosed AML must be treatment naive and unfit for intensive chemotherapy
5899,NCT02587403,"21:31:cancer,51:63:treatment,,,164:167:cancer,171:174:cancer",Have a known active malignancy present and/or had chemotherapy 12 weeks prior to screening or planned chemotherapy within 12 weeks of enrollment with exception of BCC or SCC
5900,NCT02585973,"39:42:treatment,72:94:chronic_disease,106:109:chronic_disease,128:145:chronic_disease","Not deemed a candidate for concurrent CRT for medical reasons, such as uncontrolled infection (including HIV), or uncontrolled diabetes mellitus which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient"
5901,NCT02585791,"34:38:chronic_disease,40:46:chronic_disease,48:62:chronic_disease","Presence of airflow obstruction (COPD, asthma, bronchiectasis)"
5902,NCT02584647,"32:37:cancer,41:76:cancer,78:109:cancer,","Examples of the latter include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, and isolated elevation of prostate-specific antigen"
5903,NCT02584647,"10:15:cancer,,,25:50:treatment,55:73:treatment",Phase 2: MPNST with 0-3 prior systemic treatments (no prior radiotherapy is necessary)
5904,NCT02584647,"8:24:treatment,33:45:treatment,49:65:treatment",Strong CYP3A inhibitors such as ketoconazole or grapefruit juice are not permitted
5905,NCT02584647,"10:33:chronic_disease,35:61:chronic_disease,,128:146:chronic_disease",unstable coronary artery disease (myocardial infarction (MI) more than 6 months prior to study entry is permitted); or serious cardiac arrhythmia
5906,NCT02584309,"10:37:cancer,,72:103:cancer,120:135:cancer,140:150:cancer,154:189:cancer,214:229:treatment","Prior or second primary malignancies within the last two years (except carcinoma in situ of the cervix, non-metastatic prostate cancer, or basal cell or squamous cell carcinoma of the skin which were treated with local resection only"
5907,NCT02584244,"62:72:cancer,74:84:cancer,88:113:cancer,155:161:treatment,171:178:treatment,205:223:treatment","Subjects must have histologically or cytologically confirmed esophageal, colorectal or pancreatic adenocarcinoma (inclusive of high grade dysplasia) on a biopsy prior to surgery and must be scheduled for surgical resection"
5908,NCT02583893,"13:21:cancer,41:65:treatment,94:111:cancer",Evidence of leukemia recurrence after a nadir bone marrow biopsy demonstrates no evidence of residual leukemia
5909,NCT02583893,"1:11:treatment,18:25:treatment,43:54:treatment,56:68:treatment,70:82:treatment,84:96:treatment,102:114:treatment,","Tacrolimus (e.g. Prograf) Subjects taking fluconozole, voriconizole, itraconazole, posaconazole, and ketokonazole within 72 hours of study drug starting"
5910,NCT02583789,"1:26:chronic_disease,28:45:chronic_disease,58:81:chronic_disease,83:97:chronic_disease,101:122:chronic_disease,,152:162:cancer,175:188:treatment","Uncontrolled hypertension, diabetes mellitus, history of orthostatic hypotension, acute coronary or cerebrovascular event within 3 months, evidence of malignancy, history of sympathectomy"
5911,NCT02583360,"1:22:chronic_disease,,,44:77:chronic_disease,81:110:chronic_disease,112:130:chronic_disease,134:140:chronic_disease","Neurological diseases such as Grade 3 or 4 intraventricular hemorrhage (IVH) or intracranial hemorrhage (ICH), perinatal asphyxia or stroke"
5912,NCT02582905,"1:15:chronic_disease,27:34:chronic_disease,,,56:80:chronic_disease,100:111:chronic_disease,113:134:chronic_disease,136:149:chronic_disease,196:215:chronic_disease,258:265:chronic_disease","Mood disorders other than bipolar I or II disorders or schizoaffective disorder bipolar type (e.g. bipolar NOS, cyclothymic disorders, schizophrenia, schizoaffective disorder depressive type, or unipolar depression based on the SCID); other disorders (e.g. anxiety, will be allowed)"
5913,NCT02582827,"34:42:chronic_disease,51:69:treatment,71:78:treatment,83:95:treatment,","All adverse events (AEs) (except alopecia) of any prior chemotherapy, surgery, or radiotherapy must have resolved to Grade ? 1"
5914,NCT02582827,"1:18:treatment,74:96:chronic_disease,101:125:chronic_disease","Electrocardiogram findings suggestive of significant current or previous ischemic heart disease, or left bundle branch block"
5915,NCT02582827,"12:23:chronic_disease,35:55:chronic_disease,125:134:treatment","History of retinopathy, including diabetic retinopathy. All patients must be evaluated by an ophthalmologist prior to study treatment"
5916,NCT02582827,"1:14:treatment,,65:75:treatment,97:115:treatment,160:173:treatment","Major surgery within 6 weeks before the first administration of study drug; needle aspirations, bone marrow biopsy and other similar procedures are allowable; minor surgery may be allowable following discussion and approval by Medical Monitor"
5917,NCT02582775,"27:36:chronic_disease,48:63:treatment,75:91:chronic_disease,",Active untreated systemic infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days)
5918,NCT02581982,"14:30:chronic_disease,47:71:treatment,93:118:treatment,,160:175:treatment",Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
5919,NCT02581982,"1:58:treatment,60:103:treatment,108:157:treatment","Prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death-ligand 1 (PD-L1), or anti-programmed cell death-ligand 2 (PD-L2) agent"
5920,NCT02581215,"10:15:cancer,53:99:treatment,103:135:treatment",Baseline tumor assessment should be performed using high resolution computed tomography (CT) scans or magnetic resonance imaging (MRI)
5921,NCT02581215,"1:14:treatment,,43:73:treatment,78:91:treatment,92:135:treatment,","Major surgery within 28 days prior to the first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 2 days prior to first dose of protocol therapy"
5922,NCT02581215,"57:83:treatment,87:102:treatment,110:118:treatment,122:133:treatment",Subjects whose disease has progressed after 6 months of last systemic chemotherapy or chemo-radiation in the adjuvant or neoadjuvant setting
5923,NCT02580604,"32:47:treatment,,109:127:treatment,129:149:treatment","Use of medications (other than bisphosphonates) in the past 6 months known to affect bone metabolism (e.g., thiazide diuretics, oral glucocorticoids)"
5924,NCT02579967,",124:136:chronic_disease,138:141:chronic_disease,143:146:chronic_disease,148:152:chronic_disease,154:158:chronic_disease","Chronic elevation in the blood (greater than or equal to 2 documented elevations over a period of 6 months or longer) of a latent virus (EBV, CMV, HHV6, HHV8, etc.)"
5925,NCT02579967,",,,75:99:treatment,94:98:treatment,103:107:treatment,,,209:212:treatment,214:217:treatment,222:229:treatment,,413:416:treatment","Left ventricular ejection fraction (LVEF) greater than or equal to 40% by 2D echocardiogram (ECHO) or MUGA, or left ventricular shortening fraction greater than or equal to 20% by ECHO for patients receiving MAC, RIC, or RIC-MMF, or LVEF greater than or equal to 30% if the patient has radiologic evidence of aortic, renal, or coronary artery vasculitis. LVEF greater than or equal to 30% for patients receiving IOC"
5926,NCT02579967,"15:49:chronic_disease,53:83:chronic_disease,109:117:cancer,165:189:chronic_disease",Patients with hemophagocytic lymphohistiocytosis or macrophage activation syndrome related to an underlying lymphoma with no other clinical history suggestive of a primary immunodeficiency
5927,NCT02579096,"16:28:treatment,30:44:treatment,46:56:treatment,58:74:treatment,79:89:treatment","Current use of azathioprine, mercaptopurine, didanosine, cyclophosphamide, or probenecid"
5928,NCT02579044,"130:138:chronic_disease,153:165:chronic_disease,167:183:chronic_disease,185:204:chronic_disease,206:219:chronic_disease,223:236:chronic_disease,245:270:chronic_disease","Other concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration)"
5929,NCT02578901,"12:15:chronic_disease,17:20:chronic_disease,24:27:chronic_disease","History of ITP, TTP or HUS"
5930,NCT02578901,"54:62:chronic_disease,66:87:chronic_disease,106:129:chronic_disease,131:158:chronic_disease,163:179:chronic_disease,183:200:chronic_disease","Subjects with a past history or current diagnosis of arterial or venous thromboembolic disease including acute coronary syndrome, peripheral vascular disease and retinal arterial or venous thrombosis"
5931,NCT02578732,"28:53:chronic_disease,85:92:chronic_disease,117:128:chronic_disease,130:139:chronic_disease,141:170:chronic_disease,172:210:chronic_disease","Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies that in the investigator's opinion would put the patient at an increased risk"
5932,NCT02578641,"18:21:cancer,64:79:treatment,83:90:treatment",undifferentiated NPC* who do not have curative options such as chemo-radiation or surgery
5933,NCT02577406,",,,,,389:398:treatment,436:446:treatment,484:495:treatment","Male subjects must agree to practice true abstinence from sexual intercourse or to the use of highly effective contraceptive methods (as described above) with non-pregnant female partners of childbearing potential at screening and throughout the course of the study, and should avoid conception with their partners during the course of the study and for 4 months following the last study treatment (6 months following the last dose of cytarabine; 6 months following the last dose of azacitidine in Canada)"
5934,NCT02577406,"42:48:chronic_disease,50:59:chronic_disease,64:79:chronic_disease,70:79:chronic_disease,180:191:treatment,193:210:treatment,225:234:treatment","Subject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)"
5935,NCT02577406,"22:49:treatment,53:65:treatment,,104:113:treatment",Subject has received systemic anticancer therapy or radiotherapy < 14 days prior to the start of study treatment
5936,NCT02577406,"40:68:cancer,78:88:treatment,90:105:treatment,107:122:treatment,127:136:treatment","Subject is suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype"
5937,NCT02577406,",,52:73:treatment,77:112:treatment,,165:174:treatment",left ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment
5938,NCT02576444,",,,,,189:213:treatment,210:212:treatment,217:249:treatment,245:248:treatment,266:274:treatment,278:291:treatment,392:403:treatment","At least one lesion, not previously irradiated, that can be accurately measured at baseline as ? 10 mm in the longest diameter (except lymph nodes which must have short axis ? 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) or ? 10 mm with calipers by clinical exam OR At least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/plain x-ray/clinical exam at baseline and follow up visits"
5939,NCT02576444,"72:88:chronic_disease,90:120:chronic_disease,124:130:chronic_disease,132:154:chronic_disease,211:233:chronic_disease,235:262:chronic_disease,274:296:chronic_disease,300:309:treatment,317:337:chronic_disease","Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent"
5940,NCT02576444,"66:81:chronic_disease,89:105:chronic_disease,145:163:treatment","Patients with known (testing is not part of the protocol) active hepatic disease (i.e., Hepatitis B or C) due to risk of drug interactions with anti-viral therapy"
5941,NCT02576444,"41:66:chronic_disease,73:99:chronic_disease,116:131:treatment","Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease) or significant bowel resection that would preclude adequate absorption"
5942,NCT02575404,"22:40:chronic_disease,52:74:chronic_disease,78:86:chronic_disease",Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo
5943,NCT02574910,"1:40:chronic_disease,52:77:chronic_disease,133:152:treatment",Concurrent medical condition or disease other than 21-hydroxylase deficiency that may interfere with linear growth or that requires concomitant therapy that is likely to interfere with study procedures or results
5944,NCT02574910,"1:61:treatment,63:90:treatment,92:104:treatment,106:118:treatment,120:134:treatment,136:146:treatment,148:158:treatment,160:170:treatment,172:185:treatment,187:196:treatment,198:207:treatment,209:219:treatment,221:233:treatment,239:254:treatment,262:271:treatment,273:286:treatment,288:296:treatment,298:307:treatment,309:320:treatment,322:335:treatment","Treatment with potentially hepatotoxic medications (statins); strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole), or CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital)"
5945,NCT02573883,"1:31:treatment,33:43:treatment,45:57:treatment","topical calcineurin inhibitors (tacrolimus, pimecrolimus)"
5946,NCT02573493,"1:19:treatment,21:48:treatment,53:76:treatment,81:86:cancer","Prior chemotherapy, prior EGFR targeted therapy, or prior radiation therapy for HNSCC"
5947,NCT02573376,"76:86:treatment,97:110:treatment,112:157:treatment,159:171:treatment,173:183:treatment","Medications not recommended per the SOF/LDV prescribing information (e.g., tipranavir and other P-gp inducers, tenofovir disoproxil fumarate plus cobicistat, rosuvastatin, amiodarone)"
5948,NCT02573246,"26:35:treatment,47:60:treatment,104:124:treatment,",Has any of the following treatment histories: TMS treatment at any point in their lifetime; use of any investigational drug or device within 4 weeks of the screening
5949,NCT02573246,"47:57:chronic_disease,59:66:chronic_disease,68:88:chronic_disease,90:97:chronic_disease,99:110:chronic_disease,112:118:chronic_disease,123:129:chronic_disease,134:158:chronic_disease","Meets diagnostic criteria for a current DSM-5 depressive, anxiety, obsessive-compulsive, somatic, personality, eating, or trauma and stress-related disorders (including in partial remission)"
5950,NCT02572791,",59:75:chronic_disease,100:127:treatment,140:148:treatment,168:191:treatment","Patients with traditional risk factors for HA-MRSA (e.g., immunodeficiency, indwelling catheter or percutaneous medical device, undergoing dialysis, presenting with a surgical site infection, or residing in a long-term care facility within the past year)"
5951,NCT02572323,"37:62:treatment,71:77:treatment,124:148:treatment,153:167:treatment,237:246:treatment","Anticipated need to start new daily anti-inflammatory therapy such as NSAIDs (excluding aspirin for vascular prophylaxis), systemic corticosteroids, or anti-malarials, or plan to discontinue regular dosing with these drugs during study treatment"
5952,NCT02572323,"12:49:chronic_disease,111:117:chronic_disease,132:150:chronic_disease,152:181:chronic_disease,193:220:chronic_disease","History of neurocognitive confounding conditions that explain current impairment including but not limited to stroke, head injury, psychotic disorder, active substance use disorder by DSM, or opportunistic CNS infection"
5953,NCT02570984,",36:44:chronic_disease,49:71:chronic_disease,75:80:chronic_disease,","More than four days of symptoms of wheezing, or tightness in the chest or cough in the past two weeks causing at least minimal limitation of activity"
5954,NCT02570854,"20:35:chronic_disease,37:59:cancer,61:81:cancer,85:109:cancer","Known diagnosis of hemochromatosis, bone marrow malignancy, lymphatic malignancy or myelodysplastic syndrome"
5955,NCT02570672,"28:41:chronic_disease,,,99:116:chronic_disease,118:125:chronic_disease,208:220:treatment",History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation)
5956,NCT02568267,"7:32:chronic_disease,47:55:chronic_disease,105:116:chronic_disease","Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis"
5957,NCT02567448,"21:26:allergy_name,28:37:allergy_name,41:50:allergy_name","hypersensitivity to Afrin, Lidocaine or albuterol"
5958,NCT02567422,"12:28:chronic_disease,39:62:treatment,78:87:treatment",Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation
5959,NCT02567266,"40:63:chronic_disease,113:140:chronic_disease,276:283:treatment","Adolescents with a reported history of intellectual disability or for whom there is substantial evidence (e.g., multiple learning disorders, extensive school-based accommodations for learning) that the cognitive level of the UP-A would make it inappropriate as an individual therapy modality, as determined via Family Background Questionnaire and/or based on PI judgement"
5960,NCT02567227,"5:22:chronic_disease,26:44:treatment,56:68:treatment,133:149:chronic_disease,,","Any medical condition or chronic medication use (e.g., neuroleptics) that will compromise safety or affect cognitive functioning or terminal illness with life expectancy less than 12 months"
5961,NCT02566304,"28:39:treatment,43:65:treatment,,88:98:treatment,131:140:treatment",Patients who have received alemtuzumab or antithymocyte globulin within 8 weeks of the transplant admission. The absence of these therapies in the medical record will serve as documentation that they were not given
5962,NCT02565901,"1:20:chronic_disease,31:49:chronic_disease,68:75:treatment","Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy"
5963,NCT02565901,"17:35:cancer,48:72:treatment,76:100:treatment,94:100:treatment,119:149:cancer,151:157:cancer,159:164:cancer,168:175:cancer,179:190:cancer,194:210:cancer","The presence of metastatic disease amenable to computed tomography (CT) or ultrasound guided biopsy; this may include thoracolumbar vertebral bodies, pelvis, femur or humerus or soft tissue or nodal metastasis amenable to biopsy"
5964,NCT02565498,"12:22:cancer,64:84:cancer,100:117:cancer",concurrent malignancy with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in-situ of the cervix
5965,NCT02565407,"25:49:treatment,56:75:treatment,84:109:treatment",Is currently taking any pro-epileptic medication (e.g. epileptogenic drugs such as tricyclic antidepressants)
5966,NCT02564978,"27:37:treatment,73:84:treatment,93:107:treatment",Participant is taking any medication that could adversely interact with minocycline such as methoxyflurane
5967,NCT02564744,"29:51:cancer,53:62:cancer,67:83:cancer,94:110:cancer","Participants who have known central nervous system, meningeal, or epidural disease including brain metastases"
5968,NCT02563678,"51:73:chronic_disease,75:102:chronic_disease,104:111:chronic_disease,115:161:chronic_disease,163:181:chronic_disease,183:206:chronic_disease,208:235:chronic_disease,237:243:chronic_disease,245:251:chronic_disease,253:269:chronic_disease,273:286:chronic_disease,288:307:chronic_disease,309:326:chronic_disease,331:345:chronic_disease,346:361:chronic_disease","History of significant health problems, including metabolic bone disease, skeletal muscle pathologies, cardiac or peripheral cardiovascular system abnormalities, clotting disorders, coronary artery disease, peripheral vascular disease, stroke, cancer, high cholesterol or triglycerides, high blood pressure, diabetes mellitus, or impaired liver/kidney function"
5969,NCT02563678,",12:29:treatment,102:133:chronic_disease,137:161:chronic_disease",at least 4 hyperbaric oxygen sessions for chronic clinical indications (possible indications include diabetic lower extremity wounds or refractory osteomyelitis)
5970,NCT02562755,"19:35:chronic_disease,69:72:chronic_disease,73:77:chronic_disease","Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS)"
5971,NCT02562716,"1:3:treatment,7:10:treatment,39:67:treatment,68:87:treatment",CT or MRI without contrast as part of positron emission tomography [PET]/CT or PET/MRI
5972,NCT02562430,"53:56:treatment,58:61:treatment,65:69:treatment","Receiving or have received during the index episode VNS, ECT or rTMS"
5973,NCT02562430,"30:44:chronic_disease,46:59:chronic_disease,61:65:chronic_disease,67:70:chronic_disease,75:78:chronic_disease","current primary diagnoses of panic disorder, social phobia, PTSD, GAD, or OCD"
5974,NCT02562235,"34:45:treatment,47:83:treatment,93:103:treatment,105:114:treatment,116:126:treatment,145:179:treatment,181:193:treatment,195:207:treatment,210:218:treatment,241:253:treatment","Concomitant use of the following medications: phosphodiesterase (PDE) 5 inhibitors (such as sildenafil, tadalafil, vardenafil) and non-specific phosphodiesterase (PDE) inhibitors (theophylline, dipyridamole), nitrates or NO donors (such as amyl nitrite) in any form"
5975,NCT02562235,"38:53:treatment,64:101:treatment,109:137:treatment,","Patients must be on standard of care PAH medications, allowing Endothelin Receptor Antagonists (ERA) and/or Prostacyclin Analogues (PCA), for at least 12 weeks prior to baseline visit"
5976,NCT02562066,"23:26:chronic_disease,37:66:chronic_disease,68:85:chronic_disease,87:102:chronic_disease,104:120:chronic_disease,122:137:chronic_disease,138:156:chronic_disease,162:183:chronic_disease","Genetically-confirmed CMS involving acetylcholine receptor defect, Rapsyn deficiency, MuSK deficiency, Dok-7 deficiency, SYT2 deficiency,SNAP25B deficiency, and fast channel syndrome"
5977,NCT02562040,"46:54:chronic_disease,56:66:chronic_disease,72:96:chronic_disease","Other severe chronic health problems such as diabetes, narcolepsy, and poorly controlled asthma"
5978,NCT02561988,"1:22:treatment,23:39:chronic_disease,,,,,,,186:202:treatment","Transfusion-dependent thrombocytopenia, defined as: transfusion of ? 6 units of apheresed platelets (or ? 6 pools of random donor or buffy coat platelets) during the 12 weeks preceding treatment (C1D1)"
5979,NCT02561104,"41:65:chronic_disease,70:86:chronic_disease,98:135:treatment",History of lens abnormalities including posterior polar cataract and zonular weakness precluding standard non?complex cataract surgery
5980,NCT02560766,"28:36:chronic_disease,57:78:treatment,123:130:chronic_disease,","Patients with a history of epilepsy, subjects currently prescribed treatments for epilepsy, or subjects with a history of seizure in the last 5 years"
5981,NCT02560623,"34:58:chronic_disease,60:69:chronic_disease,73:97:chronic_disease","Patients with current history of eosinophilic esophagitis, achalasia or uninvestigated dysphagia"
5982,NCT02558010,"1:9:allergy_name,11:24:allergy_name,28:37:allergy_name","Morphine, hydromorphone or methadone allergies"
5983,NCT02557321,"32:47:treatment,49:54:cancer,58:81:cancer,83:114:cancer,116:159:cancer,161:184:cancer,203:217:cancer","adequately treated (i.e., with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer"
5984,NCT02556619,",,37:55:treatment,57:65:treatment,69:89:treatment","Child-Pugh A, not eligible for TXP, surgical resection, ablation or locoregional therapy"
5985,NCT02556606,"22:57:chronic_disease,61:76:chronic_disease,78:93:chronic_disease,97:113:chronic_disease",Current diagnosis of obsessive-compulsive disorder (OCD) or eating disorder [bulimia nervosa or anorexia nervosa]
5986,NCT02556606,"56:92:treatment,96:119:treatment,127:135:treatment,137:147:treatment,149:160:treatment,162:171:treatment,173:183:treatment,185:201:treatment,203:216:treatment,226:243:treatment","Patients taking medications with known activity at the N-methyl-D-aspartate receptor (NMDA) or AMPA glutamate receptor [e.g., riluzole, amantadine, lamotrigine, memantine, topiramate, dextromethorphan, D-cycloserine], or the muopioid receptor"
5987,NCT02555280,"1:22:chronic_disease,35:53:chronic_disease,62:78:chronic_disease,104:159:chronic_disease","Cauda equina syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction"
5988,NCT02555280,"64:68:chronic_disease,70:73:chronic_disease,82:91:chronic_disease","Known or documented history of communicable disease, including AIDS, HIV, active Hepatitis"
5989,NCT02555189,"19:36:treatment,38:50:treatment,52:63:treatment","Administration of antifungal agents (itraconazole, fluconazole, etc) within 4 weeks of enrollment or unrecovered AEs due to agents administered more than 4 weeks of enrollment"
5990,NCT02555189,"12:21:chronic_disease,25:44:chronic_disease,74:83:chronic_disease,87:108:chronic_disease","History of pituitary or adrenal dysfunction, active or symptomatic viral hepatitis or chronic liver disease"
5991,NCT02555189,"13:57:chronic_disease,61:71:chronic_disease,123:134:treatment,142:161:chronic_disease,194:202:chronic_disease,204:226:chronic_disease,231:252:chronic_disease","Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)"
5992,NCT02555189,"35:56:treatment,35:48:treatment,64:73:treatment,75:87:treatment,89:99:treatment,","Patients on long term (>6 months) anti-androgen therapy (e.g., flutamide, bicalutamide, nilutamide) will need to be off anti-androgen for 4 weeks (wash out period) and show evidence of disease progression off the anti-androgen. Patients that have been on an anti-androgen 6 months or less will need to discontinue anti-androgen therapy prior to enrollment (no wash out period required)"
5993,NCT02555189,"1:8:treatment,14:21:treatment,23:58:treatment,62:74:treatment","Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux"
5994,NCT02554903,"1:54:treatment,56:93:treatment,101:113:treatment,125:141:treatment,146:175:treatment,183:195:treatment,221:230:treatment","Treatment with endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE5) inhibitors, i.v., subcutaneous (s.c.), or oral prostanoids, or guanylate cyclase stimulators within 7 days prior to Baseline RHC or study treatment initiation"
5995,NCT02554812,"40:45:cancer,41:45:cancer,70:86:treatment,79:86:treatment,168:176:cancer,178:183:cancer,185:189:cancer","Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC"
5996,NCT02554786,"13:19:chronic_disease,50:67:treatment,71:86:treatment,",have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening)
5997,NCT02554383,"7:27:chronic_disease,35:44:chronic_disease,46:64:chronic_disease,66:91:chronic_disease","Other concurrent infection (e.g., pneumonia, acute otitis media, streptococcal pharyngitis)"
5998,NCT02553941,"1:11:cancer,25:40:treatment,,122:132:treatment",Malignancy treated with curative intent and with no known active disease present for >= 1 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician
5999,NCT02553642,"29:45:chronic_disease,149:159:treatment,230:237:treatment","Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy or interfere with the interpretation of study results"
6000,NCT02553642,",32:42:treatment,47:56:treatment,58:83:treatment,88:112:treatment","Must be at least 28 days since craniotomy and resection, stereotactic radiosurgery, or whole brain radiotherapy"
6001,NCT02553642,"19:42:chronic_disease,38:41:chronic_disease,105:128:chronic_disease,124:127:chronic_disease,194:220:chronic_disease",Positive test for hepatitis B virus (HBV) using HBV surface antigen (HBV sAg) test or positive test for hepatitis C virus (HCV) using HCV ribonucleic acid (RNA) or HCV antibody test indicating acute or chronic infection
6002,NCT02553642,",68:79:treatment,83:99:treatment,104:118:cancer",Subjects with disease recurrence within 1 year of a platinum based neoadjuvant or adjuvant therapy for bladder cancer
6003,NCT02553642,"5:11:treatment,89:94:cancer,106:119:treatment","The biopsy site must, in the opinion of the investigator, be likely to yield acceptable tumor sample for core biopsies as described in Appendix 4"
6004,NCT02553265,"17:34:treatment,36:47:treatment,52:66:treatment",Patients taking neuroleptic drugs (haloperidol and chlorpromazine)
6005,NCT02553161,"26:50:chronic_disease,69:74:chronic_disease,76:89:chronic_disease,94:110:chronic_disease,116:125:chronic_disease","any history of syndromal bipolar I or II disorder (i.e., history of mania, mixed episode, or major depression with hypomania)"
6006,NCT02551679,"1:22:chronic_disease,26:58:chronic_disease,80:93:chronic_disease",Myocardial infarction or uncontrolled myocardial ischemia or persistent severe heart failure
6007,NCT02549937,"24:48:chronic_disease,67:74:chronic_disease,75:89:chronic_disease,93:111:chronic_disease,116:133:chronic_disease,151:173:cancer,269:302:chronic_disease,306:317:chronic_disease","History or presence of digestive tract diseases, including active gastric/duodenal ulcer or ulcerative colitis, or active hemorrhage of an unresected gastrointestinal tumor, or an evaluation by investigators of having any other condition that could possibly result in gastrointestinal tract hemorrhage or perforation"
6008,NCT02549937,"10:35:treatment,39:61:treatment,,90:128:treatment",Received investigational treatment in another clinical study within 4 weeks prior to the initiation of investigational treatmen
6009,NCT02549937,"21:36:cancer,60:70:treatment,72:81:treatment","locally advanced or metastatic pNET that has progressed on everolimus, sunitinib or both, during the expansion phase"
6010,NCT02549833,"13:27:treatment,,70:89:treatment,73:89:treatment,",must be off corticosteroid for at least for 2 weeks before the first neoadjuvant vaccine and for at least 2 weeks prior to the first adjuvant vaccine
6011,NCT02548351,"40:61:chronic_disease,70:93:chronic_disease,95:106:chronic_disease,108:119:chronic_disease,121:124:chronic_disease,126:129:chronic_disease,131:151:chronic_disease,153:167:chronic_disease,169:182:chronic_disease,184:214:chronic_disease,216:241:chronic_disease,262:292:cancer","Evidence of other known forms of known chronic liver disease such as alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)"
6012,NCT02547818,"17:37:chronic_disease,69:71:chronic_disease,81:100:chronic_disease,102:124:chronic_disease,126:146:chronic_disease,148:177:chronic_disease,179:190:cancer,192:222:chronic_disease,224:240:chronic_disease,242:259:chronic_disease,261:279:chronic_disease,371:401:chronic_disease","Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities"
6013,NCT02547662,"13:37:cancer,39:77:cancer,53:62:cancer","EXCEPTIONS: Non-melanoma skin cancer, ductal breast carcinoma in situ (DCIS) or carcinoma-in-situ of the cervix"
6014,NCT02547662,"1:47:treatment,54:62:treatment,64:75:treatment,77:86:treatment,88:101:treatment,103:112:treatment,114:127:treatment,129:142:treatment,144:159:treatment,","Systemic treatment with strong CYP3A4 inducers (e.g. rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, gingko biloba, St. John's wort) within 7 days before registration"
6015,NCT02546583,"18:63:treatment,,74:88:treatment,,102:112:treatment,117:126:treatment",Use of high dose mineralocorticoid receptor antagonist therapy (>50mg of spironolactone or >100mg of eplerenone) or amiloride
6016,NCT02544880,"7:16:treatment,39:46:treatment,54:66:treatment,117:122:cancer","Prior radiation with or without prior surgery and/or chemotherapy, to the head and neck for definitive treatment of HNSCC of the oral cavity, oropharynx, hypopharynx or larynx with previously documented complete clinical or radiographic response to initial treatment"
6017,NCT02544880,"1:20:chronic_disease,25:44:chronic_disease,60:74:treatment","Unilateral deafness, or severe hearing loss dependent upon hearing aid(s) for serviceable communication"
6018,NCT02544373,"13:40:chronic_disease,102:111:chronic_disease,115:131:chronic_disease",Concomitant systemic autoimmune disease with secondary central nervous system involvement (including CNS lupus or neurosarcoidosis)
6019,NCT02544373,"13:43:chronic_disease,84:113:chronic_disease,115:134:chronic_disease,136:155:chronic_disease,160:178:chronic_disease","concomitant central nervous system disease that could influence cognition, such as large vessel territory stroke, Alzheimer's disease, Parkinson's disease, or Lewy body dementia"
6020,NCT02543983,"21:30:chronic_disease,58:71:chronic_disease,85:103:chronic_disease",Presence of current psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV
6021,NCT02543944,"14:34:chronic_disease,36:45:chronic_disease,47:60:chronic_disease,62:69:chronic_disease","have a major psychiatric disorder (psychosis, schizophrenia, bipolar)"
6022,NCT02543866,"30:64:chronic_disease,92:112:treatment,103:112:treatment",Patients with current active ESC-R Enterobacteriaceae infection who have not yet completed antibiotic treatment will be excluded until their treatment is completed
6023,NCT02542657,"34:59:chronic_disease,71:96:chronic_disease,119:130:chronic_disease,155:168:chronic_disease,170:185:chronic_disease,190:211:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months"
6024,NCT02542202,"1:3:treatment,7:39:treatment,89:107:chronic_disease",CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms
6025,NCT02542202,"27:39:treatment,32:39:treatment,41:54:treatment,56:68:treatment,","Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month"
6026,NCT02541955,"36:60:treatment,,103:113:treatment,122:136:treatment",Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)
6027,NCT02541565,"35:40:cancer,71:79:cancer,88:107:cancer","Discordant presentations, such as DLBCL in a lymph node and low-grade lymphoma such as follicular lymphoma in the bone marrow"
6028,NCT02541565,"13:21:cancer,27:32:cancer,84:97:treatment","Transformed lymphoma with DLBCL histology, as long as the patient has not received prior therapy for lymphoma"
6029,NCT02540616,"57:79:treatment,81:95:treatment,97:117:treatment,119:136:treatment","Implanted metal in the head or neck (metal or shrapnel, deep brain stimulators, aneurysm clips, cochlear stimulators, retinal implants, etc)"
6030,NCT02540330,"1:19:chronic_disease,21:37:chronic_disease,49:62:treatment","bleeding diatheses, thrombocytopenia or current anticoagulant use"
6031,NCT02539160,"12:32:treatment,41:48:treatment,53:64:treatment",Use of any antiplatelet therapy (except aspirin and clopidogrel)
6032,NCT02538198,"15:27:treatment,55:62:treatment,,255:275:treatment","Refractory to lenalidomide in the most recent line of therapy, as defined by the International Myeloma Consensus Panel criteria [47]- as failure to achieve minimal response or development of progressive disease while on lenalidomide or within 30 days of lenalidomide therapy"
6033,NCT02536846,"30:44:chronic_disease,46:64:chronic_disease,82:88:treatment,107:130:treatment,132:160:treatment,168:192:treatment,194:214:treatment,216:228:treatment,230:242:treatment,252:275:treatment,400:427:treatment,429:450:treatment","Contraindication to MR scan (claustrophobia, cardiac pacemakers, metal clips and stents on blood vessels, artificial heart valves, artificial arms, hands, legs, etc., brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings, other metallic surgical hardware in vital areas, certain tattoos with metallic ink, certain transdermal patches, metal-containing IUDs)"
6034,NCT02536794,"57:64:treatment,66:70:treatment,72:95:treatment,97:102:treatment,106:157:treatment","including but not limited to cluster of differentiation [CD]137, OX40, programmed death [PD]-1, PD-L1 or cytotoxic T-lymphocyte antigen 4 [CTLA4] inhibitors"
6035,NCT02535923,"82:105:chronic_disease,,,121:140:chronic_disease,,,,,172:188:chronic_disease","Diagnostic and Statistical Manual of Disorders, 5th edition (DSM 5) diagnosis of schizophrenic disorders (295.0-295.9), affective psychoses (296.0-296.1, 296.4-296.8), or major depression with psychotic features (296.24, 296.34)"
6036,NCT02535533,"37:73:treatment,75:96:treatment,104:116:treatment,118:130:treatment,132:146:treatment,148:158:treatment,160:169:treatment,171:181:treatment,183:193:treatment,195:204:treatment,206:216:treatment,218:231:treatment,237:249:treatment,251:259:treatment,261:270:treatment,272:285:treatment,287:296:treatment,298:308:treatment,310:323:treatment,329:344:treatment,346:354:treatment,356:365:treatment,367:377:treatment,379:388:treatment,394:403:treatment","Present use or anticipated need for cytochrome P450 (CYP) 3A4-inhibiting, CYP3A4-inducing drugs (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole, rifampin, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and St. John's wort, bosentan, efavirenz, etravirine, modafinil, and nafcillin)"
6037,NCT02535312,"16:22:treatment,118:136:treatment,,,,,,,425:436:treatment","The effects of TRC102 on the developing human fetus are unknown; for this reason and because TRC102 as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of the study drugs"
6038,NCT02535286,"1:27:chronic_disease,51:78:chronic_disease,82:85:chronic_disease",Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)
6039,NCT02534922,"5:18:treatment,35:50:cancer,62:80:treatment,85:97:treatment,,,175:187:treatment,191:202:treatment","Any prior therapy directed at the malignant tumor, including immunologic agents and chemotherapy, must be discontinued at least four weeks prior to registration (6 weeks for nitrosoureas or mitomycin C)"
6040,NCT02534922,",97:113:treatment,133:158:treatment,207:224:treatment,312:328:treatment",Subjects must either: (i) have relapsed within 6 months after (or progressed during) their last platinum regimen (this may be their primary/ adjuvant regimen); or (ii) have progressed after 2 or more prior platinum regimens (regardless of duration since most recent platinum regimen); or (iii) can not tolerate platinum therapy due to hypersensitivity or other allergic reactions
6041,NCT02533674,"24:39:chronic_disease,41:62:chronic_disease,64:88:chronic_disease,93:138:chronic_disease,","History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year"
6042,NCT02532621,"25:61:treatment,93:115:treatment,119:138:treatment","patients who are taking oral anticoagulants (blood thinners) including, but not limited to, Xarelto® (rivaroxaban) or Eliquis® (apixaban)"
6043,NCT02532231,"15:34:chronic_disease,42:62:chronic_disease,64:108:chronic_disease,110:138:chronic_disease,140:161:chronic_disease,169:193:chronic_disease","Patients with autoimmune diseases (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's granulomatosis])"
6044,NCT02531932,"24:51:treatment,59:71:treatment,73:85:treatment,87:96:treatment,101:121:treatment","Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) or P-glycoprotein (PgP)"
6045,NCT02531932,"28:66:treatment,68:77:treatment,79:91:treatment,93:103:treatment","Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus)"
6046,NCT02531932,"1:7:chronic_disease,9:14:chronic_disease,18:25:chronic_disease,30:60:chronic_disease",active (acute or chronic) or uncontrolled severe infections
6047,NCT02531880,"58:75:treatment,79:92:treatment,102:119:treatment","(e.g., any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects or body piercings that cannot be removed, or history of being a welder or metal worker due to small metal fragments in the eye)"
6048,NCT02531711,"8:17:treatment,55:65:cancer,67:77:chronic_disease,79:105:chronic_disease","Active treatment for a major medical illness, such as malignancy, autoimmune, immune deficiency disorder"
6049,NCT02531295,"22:47:chronic_disease,89:106:chronic_disease,128:148:treatment,159:185:chronic_disease,187:203:chronic_disease,240:265:chronic_disease,,,310:317:chronic_disease,321:336:chronic_disease,338:375:chronic_disease,384:399:chronic_disease,403:421:chronic_disease","Any known history of gastrointestinal diseases including but not limited to: history of diarrheal illness requiring the use of anti-motility agents including inflammatory bowel disease, chronic diarrhea not otherwise specified; history of gastrointestinal bleeding with hemoglobin below 12.5 g/dL; history of gastric or duodenal ulcers; inflammatory gastrointestinal disease such as Crohn's disease or ulcerative colitis"
6050,NCT02530463,"5:18:treatment,20:32:treatment,34:46:treatment,48:64:treatment,66:79:treatment,81:101:treatment,,130:159:treatment","Any major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 2 weeks prior to the first dose of the study drugs"
6051,NCT02530463,"35:46:chronic_disease,89:110:chronic_disease,89:100:chronic_disease,156:173:treatment,",Patients known to be positive for hepatitis B surface antigen expression or with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)
6052,NCT02530034,"66:81:treatment,93:103:treatment,,150:166:treatment,,197:216:treatment","In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents, or at least 5 half-lives for noncytotoxic agents"
6053,NCT02530034,"65:87:chronic_disease,78:87:chronic_disease,,,,225:244:chronic_disease,308:321:chronic_disease,342:363:chronic_disease,,402:425:chronic_disease,450:461:chronic_disease,480:490:treatment,508:532:chronic_disease,,,","Uncontrolled intercurrent illness including, but not limited to uncontrolled infection (patients must have no temperature >= 38.3 degree Celsius [C] due to infection for at least 48 hrs to consider an infection controlled), psychiatric illness that would limit compliance with study requirements, or active heart disease including confirmed myocardial infarction within previous 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication, or uncontrolled congestive heart failure New York (NY) Heart Association class III or IV"
6054,NCT02527564,"137:164:chronic_disease,166:194:chronic_disease,199:215:chronic_disease,266:274:chronic_disease,286:311:chronic_disease","Adult outpatients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder (296.70), bipolar II disorder (296.89), or bipolar disorder not otherwise specified (296.80), with concurrent insomnia related to bipolar disorder (307.42)"
6055,NCT02527421,"12:28:treatment,39:56:treatment,58:61:chronic_disease","History of organ transplant requiring immunosuppression, HIV, or other immunocompromised state"
6056,NCT02527421,"1:34:treatment,42:63:treatment,65:78:treatment,80:93:treatment","systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine)"
6057,NCT02527265,"35:41:chronic_disease,76:93:chronic_disease,109:120:treatment","History of physician diagnosis of asthma or any other clinically important pulmonary disease, or use of any medications to treat such conditions within the last year"
6058,NCT02526511,"19:42:cancer,19:29:cancer,85:105:cancer,,154:156:treatment,160:163:treatment","For patients with metastatic renal tumors to be enrolled, a histologic diagnosis of renal cell carcinoma must exist and any burden of disease >= 1 cm by CT or MRI is acceptable; the metastatic sites may be kidney, intra-abdominal (such as liver), brain, bone, or lymph nodes; lung lesions are NOT eligible because of the motion artifact caused by respiration"
6059,NCT02525861,"31:44:treatment,48:69:treatment,79:87:treatment,92:103:treatment,,,266:280:treatment,298:314:treatment","If a participant is receiving anticoagulant or anti-platelet therapy (such as warfarin and clopidogrel), the participant is unwilling to or unable to safely discontinue anticoagulant or anti-platelet therapy within 7 days prior to until at least 24 hours after the BAL procedures. An exception is low-dose aspirin alone which is allowed"
6060,NCT02525861,"34:38:treatment,48:64:treatment,54:64:treatment,118:136:treatment","The participant has a history of lung or other organ transplant, is currently on a transplant list, or has undergone major lung surgery"
6061,NCT02525861,"37:59:treatment,73:96:treatment,100:122:treatment,116:122:treatment,",The participant has participated in another clinical study involving an investigational product or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study
6062,NCT02525861,",63:88:treatment,98:122:treatment,,158:168:treatment,190:211:treatment,213:225:treatment,227:243:treatment,249:258:treatment","The participant is receiving or requires long-term (>4 weeks) immunosuppressive therapy, such as systemic corticosteroids at doses greater than 10 mg/day of prednisone (or its equivalent), mycophenolate mofetil, azathioprine, cyclophosphamide, and rituximab"
6063,NCT02525692,"20:39:treatment,51:60:treatment,,118:128:treatment",Concomitant use of CYP3A4/5 inhibitors during the treatment phase of the study and within 72 hours prior to starting study drug administration
6064,NCT02525692,"18:28:cancer,68:77:treatment,,105:115:treatment,136:168:cancer,170:205:cancer,210:233:cancer,265:281:treatment","Known additional malignancy that is progressing or requires active treatment within 3 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy"
6065,NCT02525692,"1:32:treatment,34:68:treatment,72:85:treatment,102:108:treatment,176:181:cancer,260:299:treatment,320:329:treatment","Prior stereotactic radiotherapy, convection enhanced delivery (CED) or brachytherapy must have had a biopsy to confirm radiographic progression is consistent with progressive tumor and not treatment-related necrosis. If the recurrent lesion is outside of any prior high-dose radiation target volume or distant from the prior CED or brachytherapy site, subjects will be considered eligible"
6066,NCT02525510,"1:13:chronic_disease,15:38:chronic_disease,40:64:chronic_disease,79:93:chronic_disease","Coagulopathy, Hemodynamic instability, Electrolyte deficiencies, Pre-existing kidney disease (per study protocol)"
6067,NCT02525029,",,,39:42:treatment,,,70:88:chronic_disease,92:120:chronic_disease","Pediatric or adult (ages 12-76 years) HCT recipient with grade II-IV steroid refractory or steroid-dependent acute GVHD, defined as any one of the following"
6068,NCT02524275,"23:67:cancer,143:150:treatment,158:175:treatment,208:226:cancer",Histologically proven squamous cell carcinoma of the head and neck with measurable disease that is either recurrent after attempted cure with surgery and/or radiation therapy or newly diagnosed disease with distant metastases or incurable at diagnosis
6069,NCT02523443,"21:38:allergy_name,59:77:chronic_disease,79:104:chronic_disease,106:141:chronic_disease,143:165:chronic_disease,171:188:chronic_disease,191:215:chronic_disease,217:235:chronic_disease,237:268:chronic_disease,272:315:chronic_disease,318:348:treatment,352:374:chronic_disease,397:411:treatment,499:525:chronic_disease,,,,,,,","Contraindication to epidural catheter placement including bleeding diathesis (essential thrombocythemia, idiopathic thrombocytopenic purpura, von Willebrand disease, and hemophilia A or B), neurological dysfunction (multiple sclerosis, subacute myelo-opticoneuropathy or preexisting lower limb neurological deficit), prior extensive spinal surgery or major spinal deformity, pre-operative use of anti-coagulant with planned use of therapeutic dose of anti-coagulant in post-operatively, documented pre-operative coagulopathy (INR greater than 1.3 not on Coumadin or PTT greater than 42), platelets less than 100,000/?L, or evidence of infection at potential epidural site"
6070,NCT02522715,",,61:70:allergy_name,72:86:allergy_name,141:153:allergy_name,165:173:allergy_name,175:199:allergy_name,205:229:allergy_name","History of severe hypersensitivity reaction (>= grade 3) to docetaxel, polysorbate 80 containing drugs, or any of the capsule components of enzalutamide, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene"
6071,NCT02522715,"1:13:treatment,20:33:treatment,23:33:treatment,54:82:cancer,119:125:cancer,","chemotherapy given neoadjuvantly, adjuvantly, or for hormone sensitive metastatic disease is permitted as long as the cancer did not progress on chemotherapy AND > 6 months have elapsed"
6072,NCT02522715,"21:30:treatment,67:76:treatment,78:91:treatment,93:105:treatment,134:143:treatment","may not be on other therapies that affect hormone levels, such as estrogens, testosterones, ketoconazole during this study; however, megestrol for hot flashes is permitted"
6073,NCT02521493,",43:53:treatment,63:72:treatment,76:79:chronic_disease",Patients =< 30 days from the last dose of cytarabine used for treatment of TMD
6074,NCT02520791,"16:48:cancer,43:47:cancer,73:109:cancer,114:136:chronic_disease,,215:228:treatment,235:245:treatment,247:260:treatment,262:280:treatment,282:292:treatment,300:348:cancer,353:376:chronic_disease","Advanced stage cutaneous T-cell lymphoma (CTCL), specifically CTCL NOS, small/medium T-cell lymphoma (SMTCL) and mycosis fungoides (MF) stage IB, IIA, IIB, III and IV that have relapsed after at least one specific prior therapy (e.g. interferon, photopheresis, denileukin difitox, bexarotene, etc); anaplastic cutaneous large cell lymphoma (ACLCL) and lymphomatoid papulopsis"
6075,NCT02520791,"24:57:cancer,61:102:cancer,,138:153:treatment",Confirmed diagnosis of peripheral T-cell lymphoma (PTCL) or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy
6076,NCT02520791,",88:124:treatment,126:163:treatment,203:207:cancer,209:213:cancer,218:237:cancer,326:335:cancer,337:341:cancer,346:348:cancer","Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC criteria])"
6077,NCT02520791,"77:93:chronic_disease,107:131:chronic_disease,142:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
6078,NCT02520778,"15:34:cancer,46:51:cancer,69:104:treatment,185:193:cancer,197:220:cancer",Patients with active malignancies other than NSCLC or patients with prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers
6079,NCT02520778,",95:102:treatment,104:115:treatment,119:137:treatment,171:186:treatment,188:196:treatment,198:209:treatment,211:233:treatment,288:296:treatment,298:309:treatment,311:333:treatment","currently receiving (or unable to stop use at least 1 week prior to receiving the 1st dose of AZD9291) medications or herbal supplements known to be potent inhibitors of cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) and potent inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)"
6080,NCT02520427,"5:21:treatment,27:42:treatment,,151:158:treatment","All herbal medicines (eg, St. John's wort), vitamins, and supplements consumed by the subject within the 30 days prior to receiving the first dose of AMG 330"
6081,NCT02520011,",42:44:treatment,61:78:treatment,90:93:treatment,100:135:treatment,141:154:treatment,155:165:treatment,168:177:treatment","Be in first relapse (within 24 months of CR) or have failed induction therapy* (no CR or CRi after treatment with an intensive regimen (eg, anthracycline/cytarabine ± etoposide, gemtuzumab ozogamicin, or cladribine)"
6082,NCT02520011,"10:30:treatment,23:30:treatment,,78:89:treatment",Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor
6083,NCT02519452,"17:25:cancer,30:63:cancer,68:99:cancer,104:114:cancer","(exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence)"
6084,NCT02519452,"4:32:treatment,43:54:treatment,56:68:treatment,70:82:treatment,118:127:treatment","an immunomodulatory drug (IMiD) (example, thalidomide, lenalidomide, pomalidomide) in any order during the course of treatment"
6085,NCT02519348,"58:67:treatment,73:82:treatment,103:106:treatment","Have either progressed on, are intolerant to, or refused treatment with sorafenib or another approved TKI"
6086,NCT02519322,"30:41:chronic_disease,45:46:chronic_disease,64:69:chronic_disease,73:90:chronic_disease",Any positive test result for hepatitis B or C virus indicating acute or chronic infection
6087,NCT02519322,"41:63:chronic_disease,71:85:chronic_disease,87:111:chronic_disease,,,185:197:chronic_disease,212:231:chronic_disease,271:293:chronic_disease","History of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, deep venous thrombosis, etc )"
6088,NCT02519322,",33:41:cancer,74:80:treatment,,117:128:treatment",Patients will have at least one melanoma deposit that can undergo serial biopsy (at least 2 time points) during the neoadjuvant phase of the protocol
6089,NCT02519322,"63:237:treatment,318:337:treatment,344:358:chronic_disease","Subjects with history of life-threatening toxicity related to prior immune therapy (e.g., anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures (e.g., hormone replacement after endocrinopathy)"
6090,NCT02519322,"1:8:treatment,12:28:treatment,34:61:treatment,,85:95:treatment,147:165:chronic_disease","inhaled or topical steroids, and adrenal replacement steroid doses of > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease"
6091,NCT02518594,"18:49:chronic_disease,51:57:chronic_disease,62:68:chronic_disease","Active, unhealed herpetic lesion on labia minora, vagina, or cervix due to the potential for significant patient discomfort or increasing genital tract viral spread. Once lesion(s) heal and the patient is asymptomatic, she may be randomized"
6092,NCT02518594,"1:14:chronic_disease,70:86:chronic_disease,175:188:chronic_disease,190:202:chronic_disease,212:236:chronic_disease,,","Fetal anomaly in either twin or imminent fetal demise. This includes lethal anomalies, or anomalies that may lead to early delivery or increased risk of neonatal death e.g., gastroschisis, spina bifida, serious karyotypic abnormalities). An ultrasound examination from 14 weeks 0 days to 23 weeks 6 days by project EDC (estimated date of conception) must be performed prior to randomization to evaluate the fetuses for anomalies"
6093,NCT02518594,"29:46:chronic_disease,48:51:chronic_disease,178:197:treatment,198:202:treatment,203:207:treatment","Specifically, patients with seizure disorders, HIV, and other medical conditions not specifically associated with an increased risk of indicated preterm birth are not excluded. Prior cervical cone/LOOP/LEEP"
6094,NCT02516969,"1:37:treatment,30:37:treatment,95:101:treatment,105:115:treatment",Macroscopic complete salvage surgery with curative intent (surgery was not performed only for biopsy or palliation)
6095,NCT02516813,"11:19:treatment,,,84:101:treatment,102:127:treatment,",Extensive prior RT on ?30% of bone marrow reserve as judged by the investigator or prior bone marrow/stem cell transplantation within 5 years before trial start
6096,NCT02516813,"16:25:treatment,46:51:cancer,69:87:treatment,102:116:treatment,161:166:cancer,232:241:treatment",Phase Ib part: treatment-naïve Stage III A/B NSCLC not eligible for surgical resection or concurrent chemoradiation (Arm A expansion cohort) or treatment-naïve SCCHN eligible for fractionated curatively intended RT with concurrent cisplatin (Arm B expansion cohort)
6097,NCT02516813,"104:115:treatment,119:137:treatment,171:186:treatment,187:194:treatment,198:205:treatment,,260:265:treatment,,344:381:treatment,","Subjects currently receiving (or unable to stop using prior to receiving the first dose of trial drug) medications or herbal supplements known to be potent inhibitors of cytochrome P450 (CYP)3A or CYP2C19 (must stop at least 1 week prior), potent inducers of CYP3A or CYP2C19 (must stop at least 3 weeks prior), or drugs mainly metabolized by CYP3A with a narrow therapeutic index (must stop at least one day prior)"
6098,NCT02516696,"13:25:chronic_disease,29:49:chronic_disease,136:145:treatment",Subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program
6099,NCT02516696,",,,,,,271:286:cancer,,347:358:treatment,362:365:treatment","Subject has measurable disease as defined by > 0.5 g/dL serum monoclonal protein, >10 mg/dL involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, >0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either CT scanning or MRI"
6100,NCT02516670,"24:47:treatment,49:56:treatment,61:106:treatment",Are being treated with anticoagulation therapy (aspirin and nonsteroidal anti-inflammatory drugs [NSAIDS] are allowed)
6101,NCT02516670,"10:30:treatment,34:59:treatment,,102:112:treatment",Have had palliative radiation or biological cancer therapy within 2 weeks prior to the first dose of study drug
6102,NCT02516332,"4:6:treatment,10:46:treatment,54:58:treatment,62:96:treatment,","An MI or coronary revascularization procedure (i.e., CABG or percutaneous coronary intervention) within the last 3 months"
6103,NCT02516241,"1:17:chronic_disease,28:40:chronic_disease,42:53:chronic_disease,55:66:chronic_disease,71:105:chronic_disease","Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)"
6104,NCT02516241,"25:53:treatment,,94:122:treatment,174:184:treatment,186:193:treatment,195:211:treatment,216:240:treatment,246:271:treatment,275:299:treatment,303:320:treatment,,348:358:treatment,379:387:treatment,441:462:treatment","Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion:  Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent  Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)"
6105,NCT02515773,"1:8:chronic_disease,1:10:chronic_disease,12:22:chronic_disease,56:65:chronic_disease,67:112:chronic_disease,114:134:chronic_disease,194:207:chronic_disease","bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified (if diagnosed in the past as per DSM-IV)"
6106,NCT02515110,"1:13:treatment,,55:67:treatment,72:85:cancer,106:127:treatment",Radiotherapy must begin within 10 weeks following the last surgery for breast cancer or the last dose of adjuvant chemotherapy
6107,NCT02514083,"1:37:treatment,39:51:treatment,53:65:treatment,69:89:treatment","Concomitant immunomodulatory therapy, chemotherapy, radiotherapy or experimental therapy"
6108,NCT02514083,"1:17:treatment,29:49:treatment,99:102:cancer",Immunophenotypic profile or immunohistochemistry read by an expert pathologist as consistent with CLL
6109,NCT02514083,"1:4:cancer,6:21:chronic_disease,52:55:cancer,","SLL: lymphadenopathy with the tissue morphology of CLL but that are not leukemic, < 5,000 cells/microL"
6110,NCT02514083,"1:10:treatment,17:20:cancer,34:56:treatment,58:74:treatment,84:98:treatment,100:121:treatment,127:199:treatment","Treatment-naive CLL indicates no prior anti-CLL therapy. Anti-CLL therapy includes chemotherapies, monoclonal antibodies, and targeted agents with known or reasonably expected anti-leukemic activity"
6111,NCT02514070,"23:30:treatment,40:53:treatment,57:79:treatment,81:87:treatment",Subjects taking daily aspirin or other anti-platelet or anti-coagulants agents (Plavix)
6112,NCT02514070,"36:51:chronic_disease,82:101:chronic_disease,103:112:chronic_disease,117:126:chronic_disease","Subjects with clinically diagnosed hepatic disease (including but not limited to auto immune disease, hepatitis and cirrhosis)"
6113,NCT02513797,"12:26:chronic_disease,28:53:chronic_disease,57:77:chronic_disease,","Documented embolic stroke, transient ischemic attach or suspected neurologic event within 3 months prior to the planned intervention"
6114,NCT02513797,"95:123:treatment,125:146:treatment,148:161:treatment","Prior procedure involving opening of the pericardium or entering the pericardial space (e.g., coronary artery bypass graft, heart transplantation, valve surgery) where adhesions are suspected"
6115,NCT02513485,"23:32:chronic_disease,34:42:chronic_disease,44:52:cancer,57:74:chronic_disease","Current or history of migraines, glaucoma, melanoma, or bleeding disorder of any kind"
6116,NCT02513485,"27:40:chronic_disease,42:66:chronic_disease,79:92:chronic_disease,94:103:chronic_disease,105:115:chronic_disease,150:168:chronic_disease,170:178:chronic_disease","History of the following: schizophrenia, schizoaffective disorder, other (non mood disorder) psychosis, depression secondary to a medical condition, mental retardation, dementia, or delirium"
6117,NCT02512926,"32:37:cancer,41:54:cancer,64:69:cancer,85:96:cancer","Patients may have asymptomatic CNS 1 or CNS 2 disease, but not CNS 3 or symptomatic CNS disease"
6118,NCT02512718,"132:156:treatment,170:173:chronic_disease,,,213:221:treatment,243:266:treatment","Planned myeloablative allogeneic bone marrow, cord, or peripheral blood stem cell (from any donor, including haploidentical donor) HCT conditioning regimen using either TBI (planned cumulative dose >1100 cGy) or busulfan in addition to other chemotherapeutic agents"
6119,NCT02512497,"1:31:chronic_disease,,,,,158:172:treatment,180:183:treatment",Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI
6120,NCT02512497,"1:26:chronic_disease,14:26:chronic_disease,,,127:137:treatment","Uncontrolled hypertension, i.e., blood pressure (BP) of >/= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose and meet all other inclusion criteria"
6121,NCT02510456,"20:34:treatment,36:46:treatment,50:60:treatment,61:80:treatment,106:125:treatment",Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy
6122,NCT02509546,"60:94:treatment,99:116:treatment,134:143:treatment","Current or planned use of other investigational agents, or concurrent biological chemotherapy, or radiation therapy during the study treatment period"
6123,NCT02509507,"5:8:cancer,20:50:chronic_disease,52:55:chronic_disease,63:66:chronic_disease,91:123:treatment,173:189:treatment,,234:255:treatment","For HCC with prior hepatitis B and/or C infection, HBV and/or HCV viral load by real time polymerase chain reaction (qPCR) must be undetectable, and they must not have had recent treatment within 12 weeks for HBV or HCV with certain antiviral medications"
6124,NCT02509507,"1:8:cancer,,48:99:treatment,118:126:cancer,130:148:cancer",Non-HCC subjects must have received at least 1 prior standard of care systemic anti-cancer therapy for their locally advanced or metastatic disease
6125,NCT02509507,"58:60:cancer,62:65:cancer,67:70:cancer,72:80:cancer,82:87:cancer,92:95:cancer,101:117:cancer,121:124:cancer","They must have histologically or cytologically confirmed BC, CRC, GEC, melanoma, NSCLC, or RCC with liver metastases or HCC"
6126,NCT02508038,"10:14:chronic_disease,26:30:chronic_disease,42:45:chronic_disease","MPX for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR)"
6127,NCT02508038,"15:24:cancer,28:43:cancer,74:81:treatment,89:101:treatment",Relapsed with pulmonary or bone metastases and did not achieve a CR with surgery and/or chemotherapy
6128,NCT02507687,"1:12:treatment,24:40:treatment,49:66:treatment,",Eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months
6129,NCT02507232,"1:22:cancer,24:37:cancer,39:67:cancer,72:111:cancer","Pilocytic astrocytoma, ganglioglioma, pleomorphic xanthastrocytoma, or dysembryoplastic neuroepithelial tumors"
6130,NCT02506192,"1:7:cancer,20:42:cancer,55:64:treatment,,,","Cancer (other than basal cell skin cancer), requiring treatment within the past 12 months, or life expectancy of less than 1 year"
6131,NCT02506192,"1:14:chronic_disease,27:39:chronic_disease,42:55:chronic_disease,59:81:chronic_disease,","Heart Disease (other than Hypertension), Heart Failure or Coronary Heart Disease requiring hospitalization within the past 12 months"
6132,NCT02505165,"35:43:cancer,47:55:cancer,57:78:cancer,83:104:cancer","The child has been diagnosed with leukemia or lymphoma, malignant solid tumor, or malignant brain tumor"
6133,NCT02504489,"1:9:treatment,13:37:treatment,45:60:treatment,101:123:treatment",Adjuvant or neoadjuvant chemotherapy and/or chemo-radiation for early stage disease do not count as prior systemic therapy
6134,NCT02503722,"31:53:treatment,57:69:treatment,71:93:treatment,129:143:treatment","Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation"
6135,NCT02503722,"1:20:chronic_disease,38:44:chronic_disease,55:62:treatment,67:91:treatment","Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures"
6136,NCT02503722,"1:21:treatment,,87:107:treatment,,,177:185:chronic_disease",Prior EGFR inhibitor: A minimum of 7 days must have elapsed from the last dose of the prior EGFR inhibitor and resolution of any drug-related toxicity to =< grade 1 except for alopecia
6137,NCT02503722,"4:13:treatment,39:47:treatment,49:56:treatment,61:82:treatment,88:103:treatment",be treatment naive for 3rd generation EGFR-TKI (CO-1686 and osimertinib [AZD9291]) and mTOR inhibitors
6138,NCT02503722,"15:24:treatment,28:34:treatment,64:89:treatment,",substrates of CYP 3A4/5 or CYP1A2 that are sensitive or have a narrow therapeutic window at least three weeks prior to study registration
6139,NCT02503709,"21:37:cancer,41:65:cancer,141:157:cancer,191:225:treatment,,244:253:treatment,263:271:treatment,275:301:treatment","Patients with known brain metastases or carcinomatous meningitis are excluded from this clinical trial, with the exception of patients with brain metastatic disease that has previously been treated and remained stable on MRI >= 2 months after treatment, without steroids or anti-epileptic medications; these patients may be enrolled at the discretion of the principal investigator"
6140,NCT02503358,"34:45:treatment,77:85:treatment,89:93:treatment","A history of hypersensitivity to selumetinib, or any excipient agents (e.g. Captisol or TPGS- a water soluble form of Vitamin E)"
6141,NCT02503358,"48:66:treatment,86:95:treatment,119:131:treatment,142:163:treatment,165:177:treatment,179:189:treatment,191:202:treatment,204:214:treatment,216:225:treatment,227:237:treatment,239:248:treatment,253:263:treatment,281:291:treatment,293:306:treatment,308:317:treatment,319:328:treatment,333:343:treatment,421:432:treatment","Caution should be exercised when administering paclitaxel (Taxol) concomitantly with medicines known to inhibit (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir and nelfinavir) OR induce (e.g. rifampicin, carbamazepine, phenytoin, efavirenz and nevirapine) either CYP2C8 or CYP3A4. Based on the in vitro data and SimCYP simulations, selumetinib is considered unlikely to perpetrate clinically significant drug-drug interaction via inhibition or induction of CYP enzymes"
6142,NCT02502708,"34:46:treatment,48:64:treatment,73:82:treatment","Patients previously treated with temozolomide, cyclophosphamide, and/or etoposide are eligible for enrollment"
6143,NCT02502006,"6:35:treatment,17:35:treatment,47:58:treatment,60:69:treatment,71:79:treatment,","Used dietary or herbal supplements containing salicylates, Vitamin E, fish oil, or any other herbal supplements, within 14 days of study drug administration"
6144,NCT02501954,"28:49:chronic_disease,51:66:chronic_disease,71:94:chronic_disease,","Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment"
6145,NCT02501473,"41:49:cancer,61:72:cancer,77:99:cancer","Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease"
6146,NCT02501473,"18:24:cancer,,48:83:cancer,88:114:cancer",History of other cancer within 2 years (except non-melanoma cutaneous malignancies and cervical carcinoma in situ)
6147,NCT02501473,",46:55:chronic_disease,57:76:chronic_disease,99:110:chronic_disease,112:123:chronic_disease,127:140:chronic_disease","Recent (< 1 week ago) clinically significant infection, active tuberculosis or evidence of active hepatitis B, hepatitis C or HIV infection"
6148,NCT02501096,"9:43:chronic_disease,48:56:cancer,112:146:treatment,148:158:treatment,163:178:treatment","For the non-small cell lung cancer (NSCLC) and melanoma cohorts, participants must have progressed on or after prior treatment with one anti-PD-1, anti-PD-L1, or anti-PDL2 agent"
6149,NCT02501096,"16:38:treatment,,57:74:treatment,91:103:treatment",Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted
6150,NCT02501096,",28:52:chronic_disease,,75:90:chronic_disease,92:113:chronic_disease,","New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months"
6151,NCT02501096,"24:40:cancer,85:106:treatment,116:140:treatment,142:167:treatment,180:198:treatment,269:277:treatment,,315:330:treatment","articipants with known brain metastases will be eligible if they have completed the primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection) and if they have remained clinically stable, asymptomatic and off of steroids for at least 28 days before starting study treatment"
6152,NCT02500602,"17:31:chronic_disease,107:110:treatment,150:167:treatment,169:184:treatment,218:226:treatment,228:251:treatment,253:264:treatment,266:281:treatment,341:357:treatment,359:378:treatment,380:385:treatment,390:402:treatment,404:422:treatment,431:441:treatment,448:453:treatment,458:473:treatment,475:493:treatment,495:520:treatment,522:537:treatment,542:554:treatment,556:569:treatment,571:595:treatment,597:608:treatment,609:612:treatment,613:619:treatment,620:625:treatment,640:654:treatment","MRI exclusions: Claustrophobia; tattoos above the shoulders after evaluation by MRI technician; permanent eyeliner or permanent artificial eyebrows; cardiac pacemaker; metal fragments in eye, skin, or body, including shrapnel; heart valve replacement; brain clips; venous umbrella; being a sheet-metal worker or welder; lifetime history of aneurysm surgery; intracranial bypass, renal, or aortic clips; prosthetic devices such as middle ear, eye, joint, or penile implants; joint replacements; non-removable hearing aid, neurostimulator, or insulin pump; shunts/stents; metal mesh/coil implants; metal plate/pin/screws/wires; or any other metal implants"
6153,NCT02500407,"1:19:chronic_disease,61:75:chronic_disease,93:124:chronic_disease,129:145:chronic_disease","Autoimmune disease with the exception of controlled/treated hypothyroidism, disease-related immune thrombocytopenic purpura, or hemolytic anemia"
6154,NCT02500407,"1:28:treatment,,63:72:treatment,74:87:treatment",Treatment with radiotherapy within 2 weeks prior to the first BTCT4465A (Mosunetuzumab) administration
6155,NCT02500147,"1:8:allergy_name,63:78:treatment,82:101:treatment","Insulin secretion and sensitivity, or the GH-IGF-I axis (e.g. steroid hormone or thyroid replacement)"
6156,NCT02498951,"47:52:cancer,56:91:cancer,95:126:cancer",Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix
6157,NCT02498613,",41:68:treatment,81:89:cancer,93:111:cancer,138:143:cancer,154:159:cancer,155:159:cancer,174:194:treatment,199:231:treatment,239:269:treatment,276:289:treatment,323:327:cancer,369:389:treatment,391:402:treatment,408:438:treatment,462:479:treatment","Must have received at least one line of standard systemic treatment for locally advanced or metastatic disease setting of the respective tumor type; for NSCLC, it is either PD-1/PD-L1 inhibitor, or platinum-containing chemotherapy, or an EGFR tyrosine kinase inhibitor or an ALK inhibitor if sensitizing mutation present; TNBC: platinum-containing chemotherapy; PDAC: fluorouracil (5-FU-), gemcitabine-, or taxane-containing chemotherapy either with or without radiation therapy; SCLC: platinum-containing chemotherapy for limited or extensive stage disease"
6158,NCT02498613,"73:83:cancer,112:146:cancer,152:187:cancer,,,,284:310:treatment,350:391:treatment,417:449:cancer,458:487:cancer","Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined by estrogen receptor [ER] < 1%, progesterone receptor [PR] < 1% and HER2 1+ or less by immunohistochemistry [IHC]; if HER-2 expression is 2+, a negative fluorescence in situ hybridization [FISH] testing is required) (c) pancreatic adenocarcinoma (PDAC), or (d) small cell lung cancer (SCLC)"
6159,NCT02498613,",,53:61:treatment,66:75:treatment,248:257:treatment","Pregnant women are excluded from this study because olaparib and cediranib have the potential for teratogenic or abortifacient effects; due to the fact that there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib and cediranib, breastfeeding should be discontinued if the mother is treated with cediranib and olaparib"
6160,NCT02498613,"58:81:treatment,72:81:treatment,90:104:chronic_disease","patients with long-standing stable grade 2 neuropathy or prior grade 2 treatment-related hypothyroidism requiring treatment, provided free T4 within normal range, may be considered eligible after discussion with the study principal investigator (PI)"
6161,NCT02498535,"19:38:treatment,46:55:treatment,57:66:treatment,69:86:treatment,88:100:treatment,102:106:treatment,109:116:treatment,","Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, TOBI®, Cayston®) within 4 weeks prior to screening"
6162,NCT02496663,"33:39:treatment,82:99:treatment,128:146:treatment",Adequate archival tissue from a biopsy performed after progression of disease on previous EGFR-TKI or willing to consent for a fresh tumor biopsy
6163,NCT02496663,"96:105:treatment,107:118:treatment,122:140:treatment,172:178:treatment,",Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior)
6164,NCT02496663,"38:46:treatment,48:59:treatment,61:93:treatment,111:137:treatment","be treatment naive to 3rd generation EGFR-TKI (rociletinib, EGFR inhibitor HM61713 [HM61713] and AZD9291) and EGFR monoclonal antibodies"
6165,NCT02496663,"6:12:treatment,16:21:cancer,49:58:treatment,60:69:treatment,73:81:treatment,,154:163:treatment,","have biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib which must be EGFR-T790M negative confirmed by central testing prior to treatment (if EGFR-T790M status is unknown, patients may consent for trial and for biopsy and testing for EGFR T790M will be performed as part of initial biopsy for trial)"
6166,NCT02496611,"23:38:chronic_disease,40:53:chronic_disease,55:71:chronic_disease","Clinical diagnosis of bipolar illness, schizophrenia, conduct disorder, and/or substance use/abuse"
6167,NCT02496585,"9:18:treatment,24:36:treatment,48:57:treatment,61:81:treatment,91:101:cancer","Ongoing treatment with radiotherapy to thorax, cytotoxic or biological therapies for this malignancy"
6168,NCT02496208,",91:106:treatment,118:128:cancer,144:162:treatment",For disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
6169,NCT02496208,"1:16:treatment,22:33:treatment,26:33:treatment,176:196:cancer",Prior treatment with any therapy on the programmed cell death 1 (PD-1)/PD-L1 axis or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors unless enrolling the urothelial carcinoma with previous checkpoint inhibition therapy expansion cohort
6170,NCT02496208,"97:109:treatment,,322:355:treatment,373:391:treatment,427:438:treatment,,,,,,,,946:963:treatment,","The effects of the drugs used in this trial on the developing human fetus are unknown; however, cabozantinib was embryolethal in rats at exposures below the 140mg dose in the label, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits; for this reason and because tyrosine kinase inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception, as defined below, prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 7 months after completion of all study medications; women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 5 months after completion of all study medications"
6171,NCT02496208,"26:63:treatment,32:41:treatment,,,219:281:treatment","The subject has received prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment; subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate"
6172,NCT02495935,"15:24:treatment,80:97:chronic_disease,108:127:chronic_disease,129:142:chronic_disease","Presence of a pacemaker, any metal artifacts in head and trunk, any history of epileptic seizure or severe psychiatric disease (schizophrenia, etc.)"
6173,NCT02495415,"18:23:cancer,87:105:treatment,113:119:treatment",Bone marrow with tumor cells seen on routine morphology (not by NSE staining only) of bilateral aspirate and/or biopsy on one bone marrow sample
6174,NCT02495415,"34:56:cancer,60:76:cancer,107:112:cancer,116:119:treatment,121:129:treatment","Patients with previously treated leptomeningeal disease or brain metastases without evidence of remaining tumor by PET, MRI scan, or spinal fluid"
6175,NCT02495168,"1:22:treatment,23:38:treatment,70:76:chronic_disease,86:97:treatment,99:109:treatment,111:123:treatment","Monoclonal antibodies/Biologic agents which may affect the course of asthma (such as mepolizumab, reslizumab, lebrikizumab, and others)"
6176,NCT02495168,"1:6:chronic_disease,10:19:chronic_disease,21:63:chronic_disease,67:72:chronic_disease,","Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection"
6177,NCT02495168,",,,,90:99:treatment,109:119:treatment,121:138:treatment",?15% and ? 0.20 L reversibility of FEV1 within 30 minutes following 360 mcg (4 puffs) of albuterol (400 mcg salbutamol) inhalation (pMDI)
6178,NCT02494258,"23:32:treatment,38:66:treatment,81:107:treatment",subject is tolerating treatment with oral azacitidine monotherapy and continued oral azacitidine treatment
6179,NCT02493530,"12:38:chronic_disease,40:55:chronic_disease,57:78:chronic_disease,83:105:chronic_disease,","History of cerebral vascular accident, unstable angina, myocardial infarction, or ventricular arrhythmia within the last 6 months"
6180,NCT02493426,"91:101:cancer,121:134:chronic_disease,136:145:chronic_disease,147:158:chronic_disease,160:167:chronic_disease,169:183:chronic_disease,187:211:chronic_disease","This includes, but is not limited to impairment of renal function, evidence or history of malignancy or any significant hematological, endocrine, respiratory, hepatic, cardiovascular or gastrointestinal disease"
6181,NCT02489045,"28:48:chronic_disease,52:56:allergy_name,60:72:allergy_name,247:272:chronic_disease","Patients with a history of anaphylactic allergy to eggs or egg products, manifested by one or more of the following symptoms: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock. (Subjects with nonanaphylactic allergies to eggs or egg products may be enrolled in the study, but must be watched carefully for 1 h following the administration of SONAZOID)"
6182,NCT02488967,"1:45:treatment,,74:92:treatment,115:131:treatment",Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)
6183,NCT02488967,",,107:131:treatment,133:165:treatment,167:204:treatment,209:217:treatment,,288:306:cancer","Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements above are met"
6184,NCT02487095,"1:4:chronic_disease,38:60:treatment,105:145:treatment,200:217:chronic_disease,236:262:treatment","HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with VX-970. In addition, these subjects are at increased risk of lethal infections when treated with marrow-suppressive therapy"
6185,NCT02487095,"37:66:chronic_disease,213:232:chronic_disease,234:245:chronic_disease,247:258:chronic_disease,260:281:chronic_disease,283:308:chronic_disease,310:346:chronic_disease,348:372:chronic_disease,374:395:chronic_disease,,422:453:chronic_disease,455:486:chronic_disease,516:553:chronic_disease","Subjects with evidence of severe or uncontrolled systemic disease, or any concurrent condition, which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, stroke/cerebrovascular accident within the past 6 months, or psychiatric illness/social situations which would jeopardize compliance with the protocol"
6186,NCT02487082,"60:77:treatment,79:95:treatment,97:121:treatment,123:136:treatment,138:151:treatment,153:166:treatment,194:205:chronic_disease","Use of any of the following drugs that might interact with study medications (anticholinergics, systemic corticosteroids, phenobarbital, peginterferon, beta-blockers or any drug that may cause arrhythmias)"
6187,NCT02485418,"8:28:treatment,,47:55:treatment,67:74:treatment,76:91:treatment,93:105:treatment","Use of sedative medications within 6 hours of infusion, including opioids, benzodiazepines, barbiturates"
6188,NCT02484404,"45:50:treatment,59:84:treatment,114:125:treatment,127:138:treatment,140:149:treatment,151:160:treatment,171:187:treatment","Patients are allowed to have received prior PARPi, and/or anti-angiogenesis therapy including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, or other anti-angiogenics"
6189,NCT02484404,"27:47:cancer,100:109:treatment,113:143:treatment","Patients who have a known KRAS wild type tumor must have progressed, been intolerant of or refused cetuximab or panitumumab-based chemotherapy"
6190,NCT02484404,"28:47:chronic_disease,58:65:treatment,93:117:chronic_disease","Patients with a history of auto-immune disease requiring steroid maintenance, or history of primary immunodeficiency are not eligible"
6191,NCT02484300,"11:18:chronic_disease,39:51:chronic_disease,87:96:chronic_disease,108:114:chronic_disease,117:122:chronic_disease,124:134:chronic_disease,146:154:chronic_disease,157:170:chronic_disease,172:187:chronic_disease,206:214:chronic_disease","Any known cardiac (apart from treated hypertension with acceptable drugs, see below), pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular, hepatic disease, or patients with diabetes"
6192,NCT02484248,"1:19:treatment,25:47:treatment,52:63:treatment",previous treatment with acid-reduction therapy and montelukast with a level 3 (as defined below)or lesser response
6193,NCT02483728,"18:47:treatment,,66:79:treatment,83:106:treatment,",Patients on oral immunosuppressant medications within 4 weeks of patch testing or topical corticosteroids to the back within 1 week of patch testing
6194,NCT02481765,"1:8:chronic_disease,10:21:chronic_disease,23:46:chronic_disease","Cardiac, hematologic, oncologic comorbidities that require intensive medical treatment"
6195,NCT02481245,"19:33:treatment,35:42:treatment,48:62:treatment","Current use of of MAO Inhibitors, statins, and anticoagulants"
6196,NCT02480036,"22:38:chronic_disease,49:68:treatment,72:89:chronic_disease,160:171:treatment","Patients with severe spinal deformity requiring open reconstruction or extreme adiposity, in which determining placement of metal sleeve would be difficult by fluoroscopy (limited bone margin)"
6197,NCT02479698,"5:25:chronic_disease,15:24:chronic_disease,54:72:treatment,","For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment"
6198,NCT02479620,"8:27:treatment,34:51:treatment,68:90:treatment,106:131:treatment,135:200:treatment,","Use of alternative therapy, e.g. radiation therapy, as part of the index lesion treatment, or use of any drug eluting stents (DES) or drug-eluting balloon/drug-coated balloons (DEB/DCB) for treatment of any infra-inguinal lesions during the study procedure or during the initial six-month follow up period"
6199,NCT02477839,"36:59:chronic_disease,61:89:chronic_disease,91:119:chronic_disease,121:136:chronic_disease,141:149:chronic_disease","Subject has a current diagnosis of Lennox-Gastaut syndrome, epilepsia partialis continua, primary generalized epilepsy, Dravet Syndorme, or seizures that are not of partial-onset origin"
6200,NCT02477839,"57:70:chronic_disease,72:87:chronic_disease,99:108:treatment","has experienced any serious toxicity issues (defined as liver failure, aplastic anemia) with this treatment"
6201,NCT02477124,"21:34:treatment,38:48:treatment,52:55:chronic_disease,79:83:treatment,92:101:treatment,105:120:cancer",Patients undergoing cervicography OR colposcopy OR VIA OR patients undergoing LEEP for the treatment of cervical cancer
6202,NCT02476409,"54:90:chronic_disease,203:216:chronic_disease,252:267:chronic_disease","Patients with the following predisposing factors for osmotic demyelinating syndrome (ODS), assessed by the study investigator judgment, will be excluded: chronic alcoholism at the time of study, severe liver disease, marked malnutrition, and risk for chronic hypoxia"
6203,NCT02474667,"8:25:cancer,40:45:cancer,47:57:cancer,61:83:cancer,106:111:cancer,115:158:cancer","Has an active malignancy or history of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma in situ of the skin that has been adequately treated"
6204,NCT02474667,"10:46:treatment,48:61:treatment,69:80:treatment","Requires treatment with the CYP1A2 inhibitors, ciprofloxacin and/or fluvoxamine"
6205,NCT02474199,"31:57:cancer,65:76:cancer,78:83:cancer,87:100:cancer",History of adequately treated in-situ cervical carcinoma and/or skin cancer (basal or squamous cell) will be permitted
6206,NCT02474199,"1:11:treatment,16:29:chronic_disease,43:61:chronic_disease",Transplant for liver disease secondary to autoimmune disease
6207,NCT02474173,"21:37:cancer,145:179:chronic_disease,378:386:treatment,398:415:treatment,,487:495:chronic_disease","Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; however, patients with previously treated and stable brain metastases are eligible as long as they are no longer requiring steroids, completed radiation therapy more than 2 weeks prior to the first dose of study regimen and have no seizures or worsening neurologic symptoms"
6208,NCT02473276,"84:122:treatment,143:163:treatment,167:184:treatment","who are known to have had accidental dural puncture with an epidural needle during placement of neuraxial labor analgesia, and have either an intrathecal catheter or epidural catheter in place"
6209,NCT02473250,"1:15:treatment,17:26:treatment,28:44:treatment,46:74:treatment,78:86:treatment","Metal implants, pacemaker, metal prostheses, metal orthodontic appliances or shrapnel in the body"
6210,NCT02471911,"29:48:treatment,41:48:treatment,60:69:treatment,73:90:treatment,","Patients who have had other anti-cancer therapy, including radiation or experimental drug or therapy, within 28 days of enrollment"
6211,NCT02471430,"65:83:allergy_name,84:102:allergy_name,106:118:allergy_name","History of anaphylaxis, allergy or serious adverse reactions to Interferon-alpha2a/Interferon-alpha2b or panobinostat"
6212,NCT02470897,",19:22:cancer,101:113:treatment,126:128:cancer,132:134:cancer",Clinical stage =< T2b (American Joint Committee on Cancer [AJCC] 7th Edition Staging Manual) and no radiographic evidence of T3 or T4 disease
6213,NCT02469857,"43:57:treatment,64:101:treatment,107:131:chronic_disease,168:178:treatment","Patients that are treated with continuous hemofiltration (e.g. Continuous Veno-Venous Hemofiltration) for acute kidney dysfunction, not due to NSTI, starting prior to study drug administration"
6214,NCT02469129,"39:65:chronic_disease,80:89:treatment,93:113:treatment",Healthy volunteers without history of cardiopulmonary conditions requiring any treatment or medical intervention and who are not current smokers (Dosimetry Studies Arm only)
6215,NCT02468778,"1:15:chronic_disease,,55:90:treatment,94:108:treatment",Cardiac arrest within 24 hours of procedure requiring cardiopulmonary resuscitation (CPR) or defibrillation
6216,NCT02468453,"16:31:chronic_disease,35:59:chronic_disease,70:97:treatment,,131:140:treatment","Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion)"
6217,NCT02468453,"26:71:chronic_disease,83:96:chronic_disease,100:104:chronic_disease,125:154:treatment",Subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications
6218,NCT02468453,"16:25:chronic_disease,126:154:chronic_disease,187:202:chronic_disease,204:215:chronic_disease,217:239:chronic_disease,241:250:chronic_disease,252:258:chronic_disease,260:264:chronic_disease,266:273:chronic_disease,314:329:chronic_disease,365:382:chronic_disease,386:398:chronic_disease,399:417:treatment","Subject has an infection or is suffering from current or has a history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: photodermatoses, active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course"
6219,NCT02468453,"27:35:treatment,37:56:treatment,60:73:treatment,81:90:treatment,","Subject has undergone any surgical, light-based therapy or RF procedures in the treatment area within 3 months of treatment or during the study"
6220,NCT02467478,"16:20:treatment,24:59:treatment,71:80:treatment,85:92:treatment",Current use of oral or injectable anti-diabetic medication other than Metformin and insulin
6221,NCT02466971,"90:114:chronic_disease,116:140:chronic_disease,142:163:chronic_disease,,206:224:chronic_disease,297:309:chronic_disease,334:351:chronic_disease,362:369:chronic_disease,449:460:chronic_disease,487:512:chronic_disease,,,555:574:chronic_disease","Patient has uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within six months of protocol initiation, cardiac arrhythmia within six months of protocol initiation; known inadequately controlled hypertension; clinically significant pulmonary disease including dyspnea at rest, or patients requiring supplemental oxygen, or poor pulmonary reserve; proteinuria or clinically significant renal function impairment (baseline serum creatinine > 2 mg/dL); or psychiatric illness/social situations that would limit compliance with study requirements"
6222,NCT02466750,"31:47:chronic_disease,60:106:treatment,142:157:treatment,163:173:treatment,,227:234:treatment","Have a personal history of an immunodeficiency or received treatment with an immunosuppressive medication, such as systemically administered glucocorticoids (eg, prednisone) within 1 month before planned administration of the vaccine"
6223,NCT02466685,"12:18:chronic_disease,20:32:cancer,33:71:chronic_disease,105:127:chronic_disease,","History of stroke, brain tumor, head trauma with loss of consciousness, or other clinically significant neurological condition within 12 months before screening"
6224,NCT02466126,"13:20:chronic_disease,22:31:chronic_disease,35:60:chronic_disease","presence of bipolar, psychotic or substance-abuse disorders"
6225,NCT02465541,"1:21:chronic_disease,29:42:chronic_disease,44:69:chronic_disease","Major mental illness (e.g., schizophrenia, major depressive disorder)"
6226,NCT02465268,"21:23:treatment,,,,93:96:treatment,,140:147:treatment,",Must have completed RT (targeted total dose of 59.4-60.0 Gy over ? 7 weeks) and concomitant TMZ (targeted dose of 75mg/m2/d for ? 49 days) therapy without significant toxicity that persisted over 4 weeks
6227,NCT02465060,"5:18:treatment,20:32:treatment,41:69:treatment,,99:112:treatment,,167:176:treatment","Any prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment"
6228,NCT02465060,"1:25:chronic_disease,29:49:treatment,54:62:treatment","Unstable angina pectoris or coronary angioplasty, or stenting"
6229,NCT02464904,"1:15:treatment,24:35:treatment,37:44:treatment,46:74:treatment,76:84:treatment,94:114:treatment","Anticoagulants such as clopidogrel, heparin, low-molecular weight heparin, warfarin or other novel anticoagulants have not been held for the standard time period published"
6230,NCT02464878,"1:21:chronic_disease,23:37:chronic_disease,43:70:chronic_disease","Invasive aspergillus, histoplasmosis, and coccidoidomycosis infection within the last year"
6231,NCT02464696,"8:27:chronic_disease,35:47:chronic_disease,51:70:chronic_disease",Active myocardial ischemia (acute ST elevation or non ST elevation MI
6232,NCT02464436,"1:24:chronic_disease,28:40:chronic_disease,60:84:chronic_disease,140:147:treatment","Active ocular infection or inflammation, or any history of intraocular inflammation, that would expose subject to risk during or following surgery"
6233,NCT02464436,"23:57:chronic_disease,59:76:chronic_disease,78:95:chronic_disease","Negative serology for human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV)"
6234,NCT02463305,"9:32:treatment,46:66:treatment,,,150:161:treatment,163:175:treatment,177:193:treatment,","Allowed concomitant medications will include mesalamine compounds if used for at least 8 weeks and at a stable dose for at least 4 weeks, as well as thiopurines (azathioprine, 6-mercaptopurine) if used at a stable dose for at least 3 months"
6235,NCT02462590,"41:71:chronic_disease,134:151:chronic_disease,165:168:chronic_disease,,212:241:treatment,249:261:treatment,263:275:treatment,277:293:treatment,295:305:treatment,307:319:treatment,321:333:treatment,335:343:treatment,346:370:treatment,382:391:treatment,406:416:cancer,427:439:treatment,,462:473:chronic_disease,,,538:553:treatment","Patients at potential increased risk of iatrogenic probiotic infection (see Section 2.6 for detailed explanation) including specific immunocompromised populations (HIV <200 CD4 cells/?L, those receiving chronic immunosuppressive medications (e.g., azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate, Anti-IL2), previous transplantation (including stem cell) at any time, malignancy requiring chemotherapy in the last 3 months, neutropenia [absolute neutrophil count < 500]). However, patients receiving corticosteroids previously or presently or projected to receive corticosteroids are not excluded"
6236,NCT02461927,"1:7:treatment,,54:75:treatment,90:96:treatment",Opioid use within 10 days prior to study medication (injectable naltrexone) or risks for opioid use during the study
6237,NCT02460783,"23:26:treatment,28:38:treatment,40:62:treatment","Contraindications for MRI (pacemakers, ferrous metal implants or shrapnel in or around the head, etc.)"
6238,NCT02460692,"30:44:chronic_disease,46:53:chronic_disease,57:70:chronic_disease,72:97:chronic_disease,103:128:chronic_disease,134:140:chronic_disease,142:146:chronic_disease","Individuals with significant cardiovascular, hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (eg, asthma, COPD)"
6239,NCT02459119,"15:25:cancer,49:59:cancer,115:142:cancer","Patients with metastatic (lymph node or distant metastasis, i.e. N+ or M1) or locally advanced unresectable (T4b) transitional cell carcinoma"
6240,NCT02459119,"15:25:chronic_disease,27:34:chronic_disease,36:42:chronic_disease,47:62:chronic_disease,72:96:chronic_disease,108:134:chronic_disease,136:156:chronic_disease,160:178:chronic_disease,,213:222:treatment","Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment within 6 months of informed consent"
6241,NCT02458482,"28:52:chronic_disease,61:67:treatment,69:73:treatment,77:90:treatment,110:128:treatment,206:221:chronic_disease,223:232:chronic_disease,241:251:chronic_disease","Patients with a history of spontaneous pneumothorax, recent facial, oral or skull surgery/trauma, history of esophageal surgery, known or suspected tympanic membrane rupture or other middle ear pathology, acute sinusitis, epistaxis, active hemoptysis or nausea will be excluded as these are contraindications for AccuPAP use"
6242,NCT02458014,"1:37:treatment,90:133:treatment,135:149:treatment,151:163:treatment,165:173:treatment,182:202:treatment,","Radiotherapy and cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within 2 weeks before study entry"
6243,NCT02457845,"48:59:cancer,54:59:cancer,71:94:cancer,96:119:cancer,121:143:cancer,145:176:cancer,178:188:cancer,190:222:cancer,224:239:cancer,344:351:treatment,353:365:treatment,374:386:treatment","Pathologically proven malignant supratentorial brain tumor (including glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid/rhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy"
6244,NCT02456857,"7:42:chronic_disease,55:65:chronic_disease,113:128:treatment",Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
6245,NCT02456857,"1:24:treatment,32:56:cancer,60:80:cancer",Prior radiation therapy of the primary breast carcinoma or axillary lymph nodes
6246,NCT02455193,"29:39:treatment,41:52:treatment,54:63:treatment,68:79:treatment,121:144:treatment","Currently prescribed either olanzapine, risperidone, clozapine, or haloperidol, OR not currently being treated with any neuroleptic medications"
6247,NCT02454517,"13:35:chronic_disease,,103:124:chronic_disease,128:134:chronic_disease,136:151:chronic_disease,153:164:chronic_disease,166:178:chronic_disease,180:195:chronic_disease,262:274:chronic_disease,,,,,365:375:chronic_disease,377:390:chronic_disease","Significant cardiovascular disease precluding an exercise program, including recent (within 6 months) myocardial infarction or stroke, pulmonary edema, myocarditis, pericarditis, unstable angina, pulmonary embolism/deep venous thrombosis (PE/DVT), uncontrolled hypertension (systolic blood pressure [SBP] > 200; diastolic blood pressure [DBP] > 110), uncontrolled arrhythmia, heart failure"
6248,NCT02454010,"14:48:chronic_disease,50:91:chronic_disease,95:118:chronic_disease","positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)"
6249,NCT02453373,"14:37:chronic_disease,41:53:treatment,83:95:treatment","Suspicion of subarachnoid hemorrhage on pretreatment evaluation, even with normal neuroimaging"
6250,NCT02452697,"15:35:chronic_disease,55:88:treatment,92:131:treatment","Patients with hematologic diseases who have undergone T-cell depleted reduced intensity or non-ablative allogeneic transplantation, using a 7-8/8 HLA-matched related or unrelated donor or 4-6/8 HLA-matched related donor"
6251,NCT02452268,"26:37:cancer,38:48:cancer,57:67:cancer,,124:131:treatment",Histologically confirmed solid tumor malignancy that is metastatic or unresectable and have progressed on at least 1 prior therapy and for whom standard curative or palliative measures do not exist or are associated with minimal subject survival benefit
6252,NCT02452203,"18:29:treatment,74:92:treatment,100:115:treatment,117:124:treatment,126:165:treatment,167:184:treatment,186:198:treatment,200:204:treatment,206:209:treatment,211:221:treatment,223:229:treatment,231:244:treatment,246:254:treatment","Certain drugs or medications consumed within the past week including any psychoactive drugs (e.g., benzodiazepines, opiates, selective serotonin reuptake inhibitors, dopamine agonists, barbiturates, MDMA, LSD, psilocybin, peyote, phencyclidine, ketamine)"
6253,NCT02452008,"5:14:treatment,16:26:treatment,37:67:treatment,,110:120:treatment","Had radiation, biological, or other investigational cancer therapy within 2 weeks prior to the first dose of study drug"
6254,NCT02452008,"31:36:cancer,37:43:treatment,87:96:treatment,118:126:treatment",Patients acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator)
6255,NCT02451982,"30:48:chronic_disease,30:40:chronic_disease,49:75:chronic_disease,88:106:chronic_disease,111:126:chronic_disease,129:149:chronic_disease,151:195:chronic_disease,197:231:chronic_disease,232:253:chronic_disease,261:285:chronic_disease,288:291:chronic_disease,295:311:chronic_disease,357:380:chronic_disease,382:399:chronic_disease,401:419:chronic_disease","Patients with history of any autoimmune disease:inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), CNS or motor neuropathy considered to be of autoimmune origin (e.g., Guillian-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis)"
6256,NCT02451553,",84:99:chronic_disease,101:122:chronic_disease,137:155:chronic_disease,157:181:chronic_disease,183:207:chronic_disease,211:236:chronic_disease","Diagnosis with any of the following in the 12 months prior to registration: severe/unstable angina, myocardial infarction, uncontrolled cardiac arrhythmia, congestive heart failure, cerebrovascular accident or transient ischemic attack"
6257,NCT02451553,"1:31:treatment,33:42:treatment,46:81:treatment,83:92:treatment,97:108:treatment","Prior treatment with erlotinib, gefitinib or EGFR-blocking monoclonal antibodies (cetuximab and panitumumab)"
6258,NCT02451553,"27:35:treatment,56:77:treatment,147:165:treatment,153:165:treatment","patients who already have OncoPlex or other equivalent gene sequencing assay (eg Foundation One, Perthera, Caris etc) test results available from prior tumor biopsy are eligible to participate, without the needed of a repeat tumor biopsy, but the test results need to be available to the study principal investigator"
6259,NCT02451488,"1:29:treatment,31:39:treatment,41:79:treatment,81:93:treatment,","Immunosuppressive mediations (steroids, tumor necrosis factor (TNF)-inhibitors, azathioprine, etc.) within the past 6 weeks"
6260,NCT02451423,"12:41:chronic_disease,43:63:chronic_disease,71:95:chronic_disease,111:122:chronic_disease,124:146:chronic_disease,195:208:treatment","History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan"
6261,NCT02451423,"1:13:cancer,25:27:chronic_disease,,115:125:treatment","Malignancies other than UC within 5 years prior to Cycle 1, Day 1, with the exception of those with a low risk of metastasis"
6262,NCT02451423,"1:76:treatment,88:99:treatment,101:147:treatment","Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti CTLA-4, anti-PD1 and anti-PD-L1 therapeutic antibodies"
6263,NCT02451423,"15:40:treatment,93:111:treatment,116:130:treatment",Subjects with malignant lymphadenectomy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadnectomy with the goal of complete resection of all malignant disease are allowed
6264,NCT02451423,"1:7:cancer,,50:57:treatment,104:127:treatment",cancer recurrence within 1 year of initiation of therapy for patients who have received induction plus maintenance BCG therapy
6265,NCT02451215,"17:36:cancer,27:36:cancer,157:192:treatment",Newly diagnosed low-grade CNS tumor located in a site that is difficult to access surgically or recurrent/persistent low-grade CNS tumor (any site) despite treatment with conventional therapy
6266,NCT02448381,"38:64:chronic_disease,96:99:chronic_disease,103:109:chronic_disease",Subjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1
6267,NCT02446886,"29:40:treatment,42:51:treatment,57:73:treatment","Patients being treated with Natalizumab, Rituximab, and Cyclophosphamide"
6268,NCT02446457,"17:42:chronic_disease,46:52:chronic_disease,54:80:chronic_disease,95:103:treatment,107:126:chronic_disease","Has evidence of interstitial lung disease or active, non-infectious pneumonitis that required steroids or current pneumonitis"
6269,NCT02446457,"39:52:treatment,90:111:treatment,125:135:treatment,148:168:treatment,,191:214:treatment",currently participating and receiving study therapy or has participated in a study of an investigational agent and received study drug or using an investigation device within 4 weeks of the first dose of treatment
6270,NCT02446457,"15:23:chronic_disease,36:52:chronic_disease,53:58:chronic_disease",subjects with vitiligo or resolved childhood asthma/atopy
6271,NCT02446236,"10:20:cancer,33:65:cancer,72:100:cancer,119:124:cancer,","A second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix (unless for other tumor type patient was treated with curative intent at least 2 years previously.)"
6272,NCT02446210,"106:121:chronic_disease,123:135:chronic_disease,139:162:chronic_disease","Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk"
6273,NCT02445768,"1:12:chronic_disease,16:32:chronic_disease,48:51:treatment",subcortical or cortical infarct confirmed with MRI
6274,NCT02442297,"25:81:cancer,71:74:cancer,85:115:cancer",Recurrent or refractory HER2 positive primary central nervous system (CNS) tumor or HER2 positive tumor metastatic to the CNS
6275,NCT02442102,"1:29:treatment,37:47:treatment,49:60:treatment","Prior major thoracic surgery (e.g., sternotomy, thoracotomy)"
6276,NCT02441101,"23:32:treatment,33:46:treatment,64:93:treatment",Prior implantation of pacemaker/defibrillator with at least an atrial and RV mid septal lead
6277,NCT02440815,"1:22:chronic_disease,30:49:chronic_disease,51:59:chronic_disease,61:76:chronic_disease,78:97:chronic_disease,99:121:chronic_disease,126:134:chronic_disease","Neurological diseases (e.g., Parkinson's disease, epilepsy, cortical stroke, Alzheimer's disease, traumatic brain injury) or dementia"
6278,NCT02440581,"1:19:chronic_disease,23:37:chronic_disease,67:101:chronic_disease",Systemic illnesses or organ diseases that may affect bone (except type 1 or type 2 diabetes mellitus)
6279,NCT02439450,"89:102:treatment,125:138:treatment,141:151:treatment","radiographically per RECIST 1.1 at first imaging assessment, and will begin maintenance immunotherapy with standard of care pembrolizumab ± pemetrexed"
6280,NCT02438995,",57:62:cancer,149:151:treatment,152:155:treatment,156:164:treatment",Patients must have at least one confirmed and evaluable tumor site.* The recurrence must have bidimensional measurements by clinical examination or CT/MRI/PET scan. A confirmed recurrence site may also be biopsy-proven
6281,NCT02437851,"7:16:treatment,24:33:chronic_disease,45:73:chronic_disease,78:109:chronic_disease,",Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 2 weeks before enrollment
6282,NCT02437851,"20:37:cancer,41:59:cancer,77:111:treatment,112:144:treatment,",No evidence of any lymph node spread or distant metastases as determined by positron emission tomography (PET) computed tomography (CT) imaging within 8 weeks of enrollment
6283,NCT02437851,"33:50:treatment,54:86:treatment,90:118:treatment,125:136:treatment,163:181:cancer","alternatively for those without PET CT capability, a magnetic resonance imaging (MRI) or CT of the abdomen and pelvis and a chest x-ray confirming no evidence of metastatic disease is acceptable"
6284,NCT02437370,"20:36:chronic_disease,53:77:treatment,99:124:treatment,,152:181:treatment",Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
6285,NCT02437370,"18:57:cancer,65:89:cancer,124:140:cancer,218:225:treatment,,277:292:treatment,422:430:treatment,","Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment"
6286,NCT02437110,"10:25:chronic_disease,35:50:chronic_disease,54:91:chronic_disease,97:122:chronic_disease,132:143:chronic_disease,147:159:chronic_disease,173:183:cancer","Unstable medical disease (such as unstable angina or chronic obstructive pulmonary disease), or active infectious disease (such as Hepatitis C or tuberculosis), or current malignancy"
6287,NCT02436070,"61:67:chronic_disease,110:130:chronic_disease,132:140:chronic_disease","Presentation to the ED with a chief complaint related to an asthma exacerbation such as shortness of breath, respiratory distress, wheezing, etc"
6288,NCT02435992,"14:16:chronic_disease,18:39:chronic_disease,60:67:chronic_disease,90:109:chronic_disease,111:128:chronic_disease,133:149:chronic_disease","Diagnosis of CD, indeterminate colitis, or the presence of fistula consistent with CD or microscopic colitis, radiation colitis, or ischemic colitis"
6289,NCT02433977,"88:101:chronic_disease,103:109:cancer,111:119:chronic_disease","Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes"
6290,NCT02433626,"1:14:treatment,26:101:treatment,,140:146:treatment","Major surgery, excluding skin biopsies and procedures for insertion of central venous access devices, within 28 days prior to the start of COTI-2"
6291,NCT02433210,"1:19:chronic_disease,56:63:chronic_disease,65:78:chronic_disease,80:89:chronic_disease","Medical conditions which may interfere with the study (cardiac, liver disease, Hepatitis)"
6292,NCT02431806,"46:61:allergy_name,50:61:allergy_name,76:86:allergy_name,111:146:allergy_name,150:201:allergy_name","Allergy, intolerance, or hypersensitivity to levomilnacipran, milnacipran, fluoxetine, or any other selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)"
6293,NCT02430077,"13:37:cancer,,,94:104:chronic_disease,136:148:cancer",Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml and/or liver mass on imaging study suggestive of liver cancer
6294,NCT02430077,"1:21:treatment,38:53:chronic_disease,61:76:treatment,88:97:treatment,99:111:treatment,113:123:treatment,125:134:treatment,136:149:treatment,151:164:treatment,169:178:treatment,","Treatment with drugs associated with steatohepatitis, e.g., corticosteroids, high dose estrogens, methotrexate, amiodarone, tamoxifen, valproic acid, sulfasalazine, or oxacillin for more than 2 weeks in the 6 months prior to the study"
6295,NCT02429934,"28:34:cancer,,74:104:cancer,114:129:treatment",Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection)
6296,NCT02429934,"1:25:treatment,,111:120:treatment,143:152:treatment,,179:195:treatment,","Treatment with rituximab within the past 6 months (B cells must be detectable in peripheral blood at onset of treatment with study biologic), belimumab within the past 5 months, cyclophosphamide within the past 3 months"
6297,NCT02429830,"16:34:treatment,38:46:treatment,48:66:treatment","Subject has an electrical implant or metallic, abdominal implants"
6298,NCT02429557,"6:40:chronic_disease,57:82:chronic_disease,84:101:chronic_disease,103:126:chronic_disease,131:153:chronic_disease","with neurogenic orthostatic hypotension associated with primary autonomic failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure)"
6299,NCT02427997,"14:35:chronic_disease,46:68:chronic_disease,70:78:chronic_disease,80:100:chronic_disease,144:165:chronic_disease,167:176:chronic_disease,187:207:chronic_disease,259:279:chronic_disease","have another neurological disorder, unstable cardiovascular disease, diabetes, lower limb arthritis, acute lower back or lower extremity pain, peripheral neuropathy, rheumatic or severe orthopaedic problems that may interfere with walking, or have diagnosed psychiatric problems"
6300,NCT02427841,"4:17:treatment,22:39:cancer,51:63:treatment,65:82:treatment,95:102:treatment,106:129:treatment","No prior therapy for pancreatic cancer, including chemotherapy, radiation therapy, definitive surgery or investigational therapy"
6301,NCT02427581,"27:45:chronic_disease,72:89:treatment,105:131:chronic_disease,133:151:chronic_disease,153:168:chronic_disease,170:189:chronic_disease,191:202:chronic_disease,204:213:chronic_disease,215:233:chronic_disease,235:251:chronic_disease,253:285:chronic_disease,287:307:chronic_disease,309:337:chronic_disease,339:357:chronic_disease,359:370:chronic_disease,381:402:chronic_disease,416:433:chronic_disease,444:454:treatment,462:477:treatment,469:477:treatment,556:566:treatment,604:612:treatment,614:620:chronic_disease,624:661:chronic_disease,690:714:treatment","Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjorgen's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable. Any patients receiving steroids should be discussed with the PI to determine if eligible"
6302,NCT02426476,"14:21:chronic_disease,23:32:chronic_disease,34:39:chronic_disease,43:72:chronic_disease,80:90:chronic_disease","a history of bipolar, psychotic, panic or obsessive-compulsive disorder (note: depression is an exclusion)"
6303,NCT02425904,"1:12:treatment,99:109:treatment,111:125:treatment,127:136:treatment,138:149:treatment,151:163:treatment,165:175:treatment,,239:260:treatment","Clofarabine is excreted primarily by the kidneys. Therefore, drugs with known renal toxicity (e.g.vancomycin, amphotericin B, acyclovir, cyclosporin, methotrexate, tacrolimus) should be avoided to the extent possible during the 5 days of clofarabine treatment in each cycle or, if required, administered cautiously and with close monitoring"
6304,NCT02425904,"27:39:treatment,43:55:treatment,,84:96:treatment,100:111:treatment,247:271:treatment",Participants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Corticosteroid treatment is allowed
6305,NCT02424968,"24:42:cancer,72:75:treatment,80:83:treatment,119:140:treatment,163:166:cancer,168:198:cancer,200:232:cancer,234:237:cancer,239:254:cancer,252:254:cancer","Must have a myeloid or lymphoid malignant disease that is treated with TLI and ATG reduced intensity conditioning for allogeneic transplant (any of the following AML, myelodysplastic syndrome [MDS], myeloproliferative disease [MPD], CLL, B or T-cell NHL, HL)"
6306,NCT02424968,"31:42:chronic_disease,80:111:treatment,138:159:chronic_disease",donors with prior evidence of hepatitis B core antibody positivity will have a polymerase chain reaction (PCR) test done to evaluate for hepatitis B infection
6307,NCT02423863,"1:38:cancer,87:103:cancer,122:129:treatment",Bulky intracranial metastatic disease with shift of midline structures or progressive brain metastasis such that ongoing therapy for these brain metastasis is required at the time of enrollment
6308,NCT02423772,"65:78:chronic_disease,80:99:chronic_disease,101:110:chronic_disease,114:136:chronic_disease","Meet diagnostic criteria for a current or past DSM diagnosis of schizophrenia, delusional disorder, psychotic or dissociative disorders"
6309,NCT02423525,"12:76:treatment,112:118:cancer,126:143:treatment,197:213:treatment","Has failed prior standard therapy including maximal safe surgical resection (when appropriate for the specific cancer type), radiation therapy (when appropriate for the specific cancer type), and systemic therapy (when appropriate for the specific cancer type)"
6310,NCT02423525,"21:46:cancer,48:79:cancer,81:105:cancer,129:139:cancer,157:166:treatment,","effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured"
6311,NCT02422641,"1:16:treatment,26:38:treatment,50:66:treatment,",Prior treatment with any methotrexate containing systemic regimen within 1 year
6312,NCT02421380,"48:60:chronic_disease,85:93:cancer,100:103:treatment",Patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features
6313,NCT02419495,"1:13:treatment,18:31:treatment,45:72:treatment,,93:103:treatment,144:163:treatment,154:163:treatment,226:235:treatment,290:311:treatment,335:359:treatment","Chemotherapy, or immunotherapy or any other systemic anticancer therapy =< 3 weeks prior to study drug administration date; patients receiving anti-PD-1 treatment, and continue to receiving this treatment in combination with selinexor (Arms L and M), can start receiving the selinexor and anti-PD-1 combination without washout of the prior anti-PD-1 antibody"
6314,NCT02419495,"1:30:chronic_disease,52:63:treatment,65:75:treatment,80:91:treatment,","Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to the first dose"
6315,NCT02419495,",,157:171:treatment,173:185:treatment,187:199:treatment,201:217:treatment,228:246:treatment,270:278:chronic_disease","recovered to grade =< 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 (NCI-CTCAE v4.03) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other targeted therapies, with the exception of alopecia"
6316,NCT02418195,"1:4:chronic_disease,26:41:chronic_disease,48:65:chronic_disease","MDD Participants without Suicide Attempt, with Suicidal Ideation"
6317,NCT02417701,"42:62:treatment,58:61:treatment,117:128:treatment,,209:220:treatment",Concomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for 7 days before their first dose of study drugs
6318,NCT02416206,"19:37:chronic_disease,46:62:chronic_disease,63:78:chronic_disease,89:123:chronic_disease","Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive"
6319,NCT02415660,"16:33:chronic_disease,43:70:treatment,75:78:treatment,110:122:chronic_disease,124:142:chronic_disease,146:170:treatment","History of any systemic disorder in which thoracic spine manipulation and TDN would be contraindicated (i.e. osteoporosis, bleeding disorders or anticoagulant medication use)"
6320,NCT02415556,"1:6:chronic_disease,10:23:chronic_disease,27:37:treatment",Liver or renal failure or transplant
6321,NCT02415387,"1:11:treatment,36:44:treatment,56:63:treatment,74:85:treatment,91:108:treatment",Medication exclusions will include steroids as well as statins and other medications with anti-inflammatory actions
6322,NCT02414269,"25:49:treatment,92:109:treatment,113:136:treatment",A requirement for daily systemic corticosteroids for any reason or a requirement for other immunosuppressive or immunomodulatory agents
6323,NCT02414269,"1:14:cancer,15:25:cancer,95:102:treatment",Breast cancer metastatic to the pleura that extends outside of the pleura requiring immediate therapy
6324,NCT02414269,"21:35:cancer,62:77:treatment,81:96:treatment",Untreated or active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
6325,NCT02413970,"8:27:chronic_disease,29:46:chronic_disease,48:64:chronic_disease,69:90:chronic_disease","Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject compliance with the requirements of the investigational study testing"
6326,NCT02413047,"15:41:chronic_disease,69:79:treatment,83:93:treatment,,167:177:treatment",Patients with inflammatory bowel disease who on are stable doses of infliximab or adalimumab for at least 3 months who experience a secondary loss of response to the medication based on clinical symptoms
6327,NCT02412540,"8:19:treatment,35:46:chronic_disease,,92:116:treatment,118:130:treatment,132:149:treatment,151:164:treatment","use of medications known to cause fatty liver for > 2 consecutive weeks in past year (i.e. systemic glucocorticoids, tetracycline, anabolic steroids, valproic acid)"
6328,NCT02411656,"34:62:cancer,92:95:cancer,180:188:chronic_disease,193:198:chronic_disease,200:213:chronic_disease,335:360:cancer,414:440:cancer,546:578:cancer,,","Has histological confirmation of HER2 normal breast carcinoma with a clinical diagnosis of IBC based on presence of inflammatory changes in the involved breast, including diffuse erythema and edema (peau d'orange), with or without an underlying palpable mass involving the majority of the skin of the breast; pathological evidence of dermal lymphatic invasion should be noted but is not required for diagnosis of inflammatory breast cancer regardless estrogen receptor (ER)/progesterone receptor (PR) status; OR has histological confirmation of triple negative breast carcinoma (HER2 normal, ER/PR < 10%) without clinical diagnosis of IBC"
6329,NCT02411656,"44:70:treatment,66:69:treatment,87:128:treatment,123:127:treatment,189:202:cancer","Is HER2 normal, defined as HER2 0 or 1+ by immunohistochemistry (IHC) and negative by fluorescence in situ hybridization (FISH) if performed; or HER2 is 2+ by IHC and negative by FISH; or HER2 negative by FISH if IHC is not performed"
6330,NCT02409316,",90:92:treatment,94:103:treatment,105:108:treatment,110:120:treatment","At least one site of disease outside of the liver that is seen on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT)"
6331,NCT02408861,"40:51:cancer,120:129:treatment,139:147:cancer,149:157:cancer,163:208:cancer","For participants in the 24 participant solid tumor cohort, only those histologies not known to respond to single agent nivolumab (such as pancreas, prostate, and microsatellite stable [MSS] colorectal cancer)"
6332,NCT02408861,"16:25:treatment,30:40:treatment,118:136:treatment,172:183:treatment,,,,,,,,489:509:treatment","The effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug"
6333,NCT02408861,"19:50:treatment,67:78:allergy_name,87:96:treatment,","a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen)"
6334,NCT02408406,"1:10:cancer,24:30:cancer,32:49:cancer,51:76:cancer","Malignant diagnosis in breast, gynecologic (GYN), genitourinary (GU) cancer at any stage"
6335,NCT02407171,"14:30:chronic_disease,47:71:treatment,93:118:treatment,,147:165:treatment",diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks of the first protocol treatment
6336,NCT02407028,"25:58:treatment,,112:122:treatment,123:134:treatment,138:162:treatment",Ability to initiate the first hyperbaric oxygen treatment within 14 hours of admission in patients requiring a craniotomy/craniectomy or major surgical procedure
6337,NCT02406885,"46:61:treatment,65:91:treatment,103:110:treatment,112:141:treatment,143:149:treatment,151:158:treatment,160:166:treatment","Participants currently receiving any type of anticoagulation or blood thinning medications, including heparin, low molecular weight heparins, Plavix, aspirin, NSAIDS"
6338,NCT02405078,"24:31:treatment,46:66:treatment,71:109:treatment",Suitable candidate for therapy with standard salvage chemotherapy and autologous stem cell transplant (ASCT) as determined by the treating physician
6339,NCT02404194,"21:44:chronic_disease,59:72:chronic_disease,82:88:chronic_disease,92:108:chronic_disease",clear evidence that psychosis-risk syndrome is due to non-schizophrenia-spectrum Axis I or Axis II disorder
6340,NCT02403193,"1:20:treatment,33:70:treatment,72:83:treatment,85:94:treatment,96:106:treatment","Prior immunotherapy is allowed (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations)"
6341,NCT02403128,"1:21:chronic_disease,23:41:chronic_disease,43:66:chronic_disease","pre-retinal fibrosis, retinal detachment, vitreo-macular traction"
6342,NCT02402088,"5:23:chronic_disease,105:128:treatment,141:157:chronic_disease,162:179:chronic_disease","Any psychotic disorder or current psychiatric symptoms requiring specific attention, including need for psychiatric medications for current major depression and anxiety disorders"
6343,NCT02401347,"54:68:cancer,,102:120:treatment,155:171:cancer",A repeated CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases
6344,NCT02401347,"50:79:cancer,,102:215:treatment,,144:148:cancer,162:188:treatment","Histologically-confirmed metastatic or recurrent triple-negative breast cancer (defined as estrogen receptor ? 5%, progesterone receptor ? 5%, HER2-negative via immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH])"
6345,NCT02401074,"45:57:treatment,97:104:treatment,106:117:treatment,128:142:treatment,152:160:treatment,162:169:treatment,171:179:treatment,","It is required that the subjects undergoing bronchoscopy are not on any anti-platelets (such as aspirin, clopidogrel, etc.) or anticoagulants (such as coumadin, heparin, Xarelto®, etc.) at least 5 days prior to the bronchoscopy"
6346,NCT02401035,",,,88:120:treatment,164:168:chronic_disease,314:328:treatment,","Subjects aged 1 to 16 years who in the judgment of the investigator are candidates for gastric acid suppression therapy (ie, those with a presumptive diagnosis of GERD, a clinical diagnosis of suspected GERD, symptomatic GERD, or endoscopically proven GERD) and whom the investigator judges would need to receive IV PPI therapy for at least 4 days"
6347,NCT02400463,"11:21:cancer,56:80:cancer,84:101:cancer","No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ"
6348,NCT02400255,"1:24:treatment,29:36:treatment,40:43:cancer",Chemotherapeutic agents for therapy of AML
6349,NCT02400255,"1:16:treatment,,,76:94:treatment,105:120:treatment,",Post-transplant bone marrow blast count ? 5% confirmed by standard of care bone marrow biopsy performed post-transplant (at least 30 days post-transplant)
6350,NCT02398773,"41:67:treatment,77:87:treatment,91:102:treatment,108:129:treatment,145:162:treatment",Patient must NOT be planning to receive molecular targeted therapy (such as everolimus or palbociclib) nor HER2 directed therapy in addition to endocrine therapy
6351,NCT02398773,"24:42:chronic_disease,65:91:treatment,134:149:treatment,159:198:treatment",patients who developed metastatic disease while still receiving adjuvant endocrine therapy must have a planned change in the type of endocrine agent used for subsequent metastatic disease treatment
6352,NCT02397889,"46:60:treatment,65:82:treatment,89:104:treatment,114:127:treatment,131:138:treatment,","Patients who report current treatment with a benzodiazepine, an opioid medication, or a mood stabilizer (such as valproic acid or lithium) within 2 weeks prior to randomization"
6353,NCT02397083,"42:62:cancer,67:87:cancer,91:119:cancer,137:174:cancer,178:196:treatment,200:230:treatment,","All patients with a diagnosis of complex atypical hyperplasia OR, grade 1 endometrioid OR focal grade 2 adenocarcinoma in predominately grade 1 disease endometrial carcinoma on endometrial biopsy or dilation and curettage (D & C) within three months of study enrollment"
6354,NCT02397083,"30:50:treatment,62:74:treatment,76:93:treatment,95:103:treatment,108:130:treatment","Patients currently receiving anticancer therapies (including chemotherapy, radiation therapy, hormonal, or antibody-based therapy)"
6355,NCT02397083,"14:31:chronic_disease,,,91:98:treatment,133:183:chronic_disease,227:249:treatment","Uncontrolled diabetes mellitus as defined by hemoglobin A1c (HbA1c) > 8% despite adequate therapy; patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary"
6356,NCT02394704,"1:23:chronic_disease,25:31:chronic_disease,33:44:chronic_disease,46:57:chronic_disease,59:67:chronic_disease","Neurological disorders (stroke, Alzheimer's, Parkinson's, epilepsy, etc.)"
6357,NCT02394535,"33:45:chronic_disease,47:54:chronic_disease,56:65:chronic_disease,73:84:chronic_disease,91:105:treatment","Prior severe infusion reaction (bronchospasm, stridor, urticaria and/or hypotension) to a taxane therapy"
6358,NCT02394028,"1:49:treatment,54:56:chronic_disease,86:95:chronic_disease",Treatment with antibiotics as adjunctive therapy for CD in the absence of documented infection
6359,NCT02393885,"23:66:treatment,79:91:chronic_disease,93:113:chronic_disease,118:127:chronic_disease","Documented history of previous catheter ablation with perforation, history of pericarditis, pericardial effusion, or tamponade"
6360,NCT02393885,"1:43:chronic_disease,47:101:chronic_disease,143:147:treatment",Symptomatic Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation refractory to a minimum of one Class I or Class III AADs
6361,NCT02393794,"1:14:cancer,30:47:chronic_disease,64:80:treatment",Breast cancer that is either stage III disease not amenable to curative therapy or stage IV
6362,NCT02393794,"19:36:chronic_disease,47:94:chronic_disease,96:115:chronic_disease,120:131:chronic_disease","Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia"
6363,NCT02393794,"44:81:treatment,83:97:treatment,99:114:treatment,116:131:treatment,133:149:treatment","Subject has previously been treated with a Histone deacetylases (HDAC) inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor"
6364,NCT02393794,"1:20:treatment,22:57:treatment,59:68:treatment,72:84:treatment","herapy with heparin, low molecular weight heparin (LMWH), Factor Xa or fondaparinux is allowed"
6365,NCT02393690,"19:22:treatment,31:57:treatment,73:85:treatment,",It is noted to be RAI-avid on radioactive iodine imaging (diagnostic or post-therapy whole body scans acceptable) and it measures >= 1 cm in the long axis
6366,NCT02393690,"77:93:chronic_disease,95:116:chronic_disease,118:139:chronic_disease,153:177:chronic_disease,179:203:chronic_disease,205:223:chronic_disease,228:265:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hepatitis B infection, hepatitis C infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
6367,NCT02392897,"84:106:chronic_disease,110:127:chronic_disease,188:234:treatment","Presence of diseases requiring dietary modification, including physician diagnosed cardiovascular disease or diabetes mellitus, use of medications that may impact study results including non-steroidal anti-inflammatory drugs (NSAIDS)"
6368,NCT02392572,"4:13:treatment,29:37:treatment,42:46:chronic_disease,,64:76:treatment",No treatment with high dose steroids for GVHD (up to >/= 20 mg Prednisolone or equivalent per day)
6369,NCT02392572,"19:34:treatment,,103:119:treatment,,149:168:treatment",The interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents
6370,NCT02392286,"1:18:chronic_disease,27:33:cancer,37:49:treatment,53:72:treatment",immunocompromised (active cancer on chemotherapy or radiation treatment)
6371,NCT02391987,"1:20:chronic_disease,22:31:chronic_disease,35:40:chronic_disease","shortness of breath, orthopnea or edema"
6372,NCT02390752,"5:9:cancer,18:21:treatment,84:103:treatment,121:126:treatment,130:149:treatment","For DIPG typical MRI findings must be present which include hypo- or isointense on T1-weighted imaging, hyperintense on FLAIR or T2-weighted imaging, epicenter in the pons in the face of a typical clinical presentation"
6373,NCT02390752,"9:18:treatment,34:48:treatment,52:73:treatment,100:112:treatment,117:125:cancer","Ongoing treatment with any other cancer therapy or investigational agent, with the exception of IT chemotherapy for leukemia, when indicated"
6374,NCT02390752,"22:24:chronic_disease,73:77:cancer,82:94:cancer,146:154:cancer,158:179:cancer,289:304:cancer,321:338:chronic_disease,376:392:chronic_disease,451:454:chronic_disease","Phase II: inoperable PN causing morbidity, such as (but not limited to) head and neck lesions that could compromise the airway or great vessels, brachial or lumbar plexus lesions that could cause nerve compression and loss of function, lesions that could result in major deformity (e.g., orbital lesions) or significant cosmetic problems, lesions of the extremity that cause limb hypertrophy or loss of function, and painful lesions in patients with NF1"
6375,NCT02389517,"34:59:treatment,84:102:treatment,111:123:treatment,128:147:chronic_disease,,,,196:220:chronic_disease,225:240:chronic_disease,244:265:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including uncontrolled cardiac conditions such as hypertension, or cardiac arrhythmias, or New York Heart Association stage III and IV congestive heart failure, or unstable angina or myocardial infarction within the past 6 months"
6376,NCT02389517,"15:38:cancer,42:59:cancer,121:130:treatment",patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
6377,NCT02389465,"12:25:chronic_disease,27:42:chronic_disease,44:55:chronic_disease,59:65:chronic_disease","History of ulcer disease, Chron's disease, GI bleeding or anemia"
6378,NCT02389465,"1:4:allergy_name,30:55:allergy_name,57:66:allergy_name","MRI contraindications (e.g., foreign metallic implants, pacemaker)"
6379,NCT02389309,"1:15:treatment,16:30:treatment,44:90:treatment,97:105:treatment,107:135:treatment","Anticoagulants/anti-platelets: patients on therapeutic (treatment) dose of anticoagulants (e.g. warfarin, low molecular-weight heparin)"
6380,NCT02389309,",28:40:treatment,42:56:treatment,58:69:treatment,71:82:treatment,84:95:treatment,101:110:treatment","Drugs prolong QT interval; erythromycin, clarithromycin, pentamidine, ondansetron, granisetron, and methadone"
6381,NCT02389309,"38:60:chronic_disease,73:81:chronic_disease,85:103:chronic_disease,,126:151:chronic_disease,,,230:251:chronic_disease,255:270:chronic_disease,,,341:365:chronic_disease,375:393:chronic_disease,404:414:treatment,416:440:chronic_disease,486:513:chronic_disease,536:554:chronic_disease,556:582:chronic_disease,593:613:chronic_disease,646:673:chronic_disease,713:736:chronic_disease,746:769:chronic_disease,771:795:chronic_disease,800:819:chronic_disease,,848:875:treatment,","Patients with clinically significant cardiovascular disease: history of ischemic or hemorrhagic stroke within past 6 months; uncontrolled hypertension, on at least 2 repeated determinations on separate days within past 3 months; myocardial infarction or unstable angina within past 6 months; New York Heart Association grade III or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris within past 6 months; clinically significant peripheral vascular disease within past 6 months; pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within past 6 months; diagnosed congenital long QT syndrome; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)"
6382,NCT02389309,"1:27:treatment,,56:70:treatment,,88:102:treatment",Stem cell transplant (SCT): at least 8 weeks following autologous SCT and 12 weeks for allogeneic SCT
6383,NCT02389309,"36:51:treatment,55:75:treatment,127:139:chronic_disease",patients must not be receiving any anti-thrombotic or anti-platelet agents; patient cannot be on drugs that cause significant prolonged QT (category I drug)
6384,NCT02389023,"1:23:treatment,40:57:treatment,79:93:treatment,101:109:treatment,117:144:treatment,484:502:treatment,504:544:treatment,546:580:treatment","femoral endarterectomy with or without patch angioplasty involving the common femoral artery and/or profunda and/or proximal superficial artery. The index groin may have undergone prior procedures (may be inflow or outflow for existing grafts), but the patient must have fully healed from the prior operation. May include patients with concomitant proximal and/or distal peripheral vascular intervention. The patch may be autogenous venous or arterial or prosthetic material such as bovine pericardium, dacron or polytetrafluoroethylene (PTFE). Bilateral femoral endarterectomies are eligible for enrollment. The right and left groin incision would be randomized to the same dressing which is consistent with routine clinical practice"
6385,NCT02387905,"30:38:cancer,40:47:cancer,52:74:cancer","Patients with a histology of lymphoma, myeloma and small cell lung cancer histologies"
6386,NCT02384954,"1:33:chronic_disease,99:124:treatment,,260:267:treatment",Anti-CD20 mAb-refractory disease is defined as progressive disease while on rituximab (or another treatment of an anti-CD20 monoclonal antibody) or progression within 6 months of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy
6387,NCT02383979,"34:48:treatment,41:48:treatment,61:70:chronic_disease",possessing a contraindication to mirror therapy for example blindness or inability to position properly for the therapy
6388,NCT02382549,"6:22:cancer,60:67:treatment,132:157:treatment",Each brain metastasis must have been completely removed by surgery or each unresected brain metastasis must have been treated with stereotactic radiosurgery
6389,NCT02382549,"17:36:treatment,40:59:treatment,64:82:cancer,,",The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed ? 1 week and ? 6 months prior to registration
6390,NCT02382419,"12:56:chronic_disease,58:71:chronic_disease,73:82:chronic_disease,87:114:chronic_disease,143:152:treatment","Documented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatment"
6391,NCT02382419,",14:21:treatment,,111:126:treatment,111:114:chronic_disease,115:126:treatment,,342:352:treatment,,,478:486:treatment,,","Women in the vaccine-eligible age range cannot have received vaccine prior to enrollment, but will be offered HPV vaccination at the end of the study; in brief, we are interested in the efficacy of intervention in preventing HPV in the absence of HPV vaccination, since most women worldwide who might utilize intervention will not have been vaccinated; this includes United States (US) women in the vaccine catch-up 19-26 year old age group (beyond the age groups eligible for Vaccines for Children- funded vaccination) who have so far had very low (< 10%) vaccine uptake; it also includes the entire group of US women > 26 years of age; moreover, it includes women of all ages in developing countries, who most need an HPV prevention strategy, but may never be vaccinated; it should be noted that delaying vaccination in women 19-26 years of age by one year is safe and reasonable, since there is insufficient data to establish a recommendation for or against universal vaccination in this age group as concluded by an American Cancer Society expert panel, which includes the Principal Investigator (PI) of this protocol, Dr. Mark Einstein; it is anticipated that if the intervention gel is efficacious, HPV vaccinated women would need to be studied in a similar future trial with power analysis taking into account vaccine effectiveness as well"
6392,NCT02378714,"19:57:chronic_disease,85:108:chronic_disease,119:131:treatment,135:154:treatment,158:180:treatment",history of severe (stage IV or V) chronic kidney disease including current or prior end stage renal disease on either hemodialysis or peritoneal dialysis or prior renal transplant
6393,NCT02377089,"23:37:treatment,39:50:treatment,52:65:treatment,70:96:treatment,","evidence of receiving antidepressant, antianxiety, antipsychotic, or mood-stabilizer medication where the dose has not been stable for a minimum of six weeks prior to entering the randomization"
6394,NCT02374333,"1:4:cancer,34:41:treatment,76:90:treatment","ALL without curative options for therapy, including those not eligible for allogeneic SCT"
6395,NCT02374333,"26:51:cancer,69:87:treatment,105:115:treatment,119:133:treatment,,224:233:treatment",subjects with documented CD19+ B cell malignancies and no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to <2 year survival) with currently available therapies will be enrolled
6396,NCT02374021,"4:22:treatment,,60:63:treatment,68:71:treatment",No non-biologic DMARDs in preceding two months (other than MTX and HCQ)
6397,NCT02372006,"14:17:cancer,19:23:cancer,25:46:cancer,48:63:cancer,64:68:cancer,70:80:cancer,82:95:cancer,97:100:cancer,105:112:cancer","diagnosis of HGG, DIPG, low grade astrocytoma, medulloblastoma/PNET, ependymoma, neuroblastoma, RMS and tumours with ErbB deregulation"
6398,NCT02370095,"32:52:treatment,54:66:treatment,68:74:treatment,78:84:treatment,87:106:treatment,108:120:treatment,122:131:treatment,140:159:treatment","Patient is currently receiving prostacyclin therapy [Epoprostenol (Flolan or Veltri), Iloprost (Ventavis), Treprostinil (Orenitram, oral) (Remodulin, IV or SC)]"
6399,NCT02369653,"1:14:treatment,26:73:treatment,78:100:treatment,105:120:treatment,",Major surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy] within the last 7 days prior to enrollment that may be associated with a risk of bleeding
6400,NCT02369458,"7:10:chronic_disease,25:59:treatment,127:138:treatment,229:255:treatment","Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study drugs. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated"
6401,NCT02367196,"1:21:cancer,23:31:cancer,35:48:cancer,51:71:cancer","High grade lymphomas (Burkitts or lymphoblastic), plasma cell leukemia"
6402,NCT02367040,"1:18:chronic_disease,14:17:chronic_disease,22:39:chronic_disease,35:38:chronic_disease,159:189:treatment","Hepatitis B (HBV) or hepatitis C (HCV). Patients positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA, these patients should receive prophylactic antiviral therapy. Patients positive for anti- HCV antibody will be eligible if they are negative for HCV-RNA"
6403,NCT02367040,"32:44:treatment,,118:137:treatment,127:136:treatment,,312:342:treatment","be considered unfit to receive chemotherapy on reason of age, concomitant morbidities, and/or residual toxicity from previous treatments, or unwillingness to receive chemotherapy. These patients must also have had a progression-free and treatment-free interval of at least 6 months after completion of the last rituximab-containing treatment. Patients in whom chemotherapy is contraindicated are defined by one of the following features"
6404,NCT02366871,"1:6:treatment,11:16:treatment,25:50:treatment",SSRIs and SNRIs (common anti-depressant therapies)
6405,NCT02366819,"43:70:treatment,79:92:cancer,146:164:cancer","Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)"
6406,NCT02366754,"6:9:treatment,13:16:treatment,54:68:chronic_disease","Have MRI or TMS contraindications such as pre-injury claustrophobia, metal in eyes/face or brain"
6407,NCT02366611,"41:45:treatment,56:73:chronic_disease,75:90:treatment,92:119:treatment,121:137:chronic_disease,139:159:chronic_disease","Any condition that would prevent use of tDCS including skull abnormality, implanted metal, implanted electronic device, seizure disorder, neurologic condition"
6408,NCT02365766,"14:81:treatment,86:134:treatment,136:152:treatment,144:152:treatment,164:174:treatment","Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)"
6409,NCT02365766,"23:37:treatment,69:77:treatment,81:116:treatment,",Subjects on full dose anticoagulants must be on a stable regimen of warfarin or low molecular weight heparin (LMWH) for at least two weeks
6410,NCT02365467,"16:26:chronic_disease,28:36:chronic_disease,41:56:chronic_disease","Subject has an aneurysmal, tortuous, or atherosclerotic LSA"
6411,NCT02365467,"18:27:treatment,45:53:chronic_disease,73:85:treatment",Subject requires treatment of an infrarenal aneurysm at the time of the implantation
6412,NCT02362997,",24:61:treatment,54:61:treatment,62:75:treatment,","No more than 1 line of anthracycline-containing chemotherapy prior to ASCT, and no more than 3 lines of therapy total prior to ASCT for arms A and B; no more than 1 line of therapy prior to ASCT for arm C"
6413,NCT02362997,"19:41:chronic_disease,52:56:chronic_disease,127:131:chronic_disease","Participants with active viral hepatitis (positive HepB sAg, positive HepB core Ab with positive HepB viral load, or positive HepC antibody with positive HepC viral load)"
6414,NCT02362308,"20:38:chronic_disease,47:66:chronic_disease,68:74:chronic_disease,76:83:chronic_disease,88:113:chronic_disease","History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack"
6415,NCT02361944,"1:8:treatment,45:55:treatment,59:70:treatment",surgery on the heart or aorta that requires sternotomy or thoracotomy
6416,NCT02361554,"12:34:chronic_disease,,,92:104:chronic_disease,105:113:chronic_disease,114:131:chronic_disease",history of traumatic brain injury associated with loss of consciousness of > 1 hour and/or intracranial/epidural/subdural bleeding
6417,NCT02360579,"1:31:treatment,33:49:treatment,51:56:treatment,62:73:treatment","NMA-LD preconditioning regimen (cyclophosphamide, mesna, and fludarabine)"
6418,NCT02360579,"113:139:chronic_disease,150:162:treatment,164:185:chronic_disease","Patients who have active medical illness(es) that would pose increased risk for study participation, including: active systemic infections requiring systemic ABX, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune system"
6419,NCT02360579,",,54:76:chronic_disease,78:88:chronic_disease,130:153:chronic_disease","Patients ? 60 years of age and who have a history of ischemic heart disease, chest pain, or clinically significant atrial and/or ventricular arrhythmias must have a cardiac stress test. Patients with any irreversible wall movement abnormalities"
6420,NCT02359825,"6:31:chronic_disease,68:76:chronic_disease,80:97:chronic_disease",have peripheral nerve injuries that are complicated by significant vascular or orthopedic damage
6421,NCT02358850,"35:46:treatment,48:55:treatment,57:62:treatment,64:72:treatment,74:82:treatment","Contraindications to pain regimen medications (Tylenol, Norco, Percocet, Dilaudid)"
6422,NCT02358187,"4:17:chronic_disease,19:35:chronic_disease,37:46:chronic_disease,50:69:chronic_disease","No overt cardiac, gastrointestinal, pulmonary or psychiatric disease"
6423,NCT02357849,"26:51:chronic_disease,64:89:chronic_disease,91:104:chronic_disease,106:130:chronic_disease,132:148:chronic_disease,153:169:chronic_disease","lifetime diagnosis of an Axis I psychotic disorder, including: schizophreniform disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features"
6424,NCT02355535,"18:49:treatment,119:133:chronic_disease,135:159:chronic_disease,161:184:chronic_disease,,,","Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be clinically significant (such as acute ischemia, left bundle branch block, ventricular arrhythmias) or baseline prolongation of the rate-corrected QT interval (e.g., repeated demonstration of QTc interval > 480 milliseconds)"
6425,NCT02355535,"18:29:chronic_disease,31:49:chronic_disease,54:57:chronic_disease,79:102:treatment","Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment"
6426,NCT02355002,"23:33:chronic_disease,37:56:chronic_disease,64:82:chronic_disease,84:92:chronic_disease,94:106:chronic_disease,117:137:chronic_disease,186:189:treatment","Current or history of neurologic or psychiatric disease (e.g., mental retardation, dementia, brain damage, or other cognitive impairment) that would interfere with ability to engage in TMS"
6427,NCT02355002,"8:23:treatment,27:42:treatment,,95:112:treatment",Use of benzodiazepines or anticonvulsants within 2 weeks prior to study (to be ruled out by a urine drug screen)
6428,NCT02354703,",60:89:treatment,97:107:treatment,132:143:treatment","Current or recent (within 4 weeks prior to Baseline Visit) treatment with antipsychotics or any medication likely to interact with ondansetron to produce an adverse effect, as judged by a study physician"
6429,NCT02353819,"25:48:treatment,55:63:treatment,65:73:treatment","Clinically eligible for rectal spacer insertion (e.g. Duraseal, SpaceOAR, or equivalent product) per physician evaluation"
6430,NCT02353819,"10:17:treatment,21:33:treatment,38:53:cancer",Previous surgery or chemotherapy for prostate cancer
6431,NCT02353728,"1:19:treatment,35:60:treatment,,89:98:treatment",Previous treatment with any other tyrosine kinase inhibitor except for up to 2 weeks of nilotinib
6432,NCT02352454,"1:6:chronic_disease,46:54:chronic_disease,56:66:chronic_disease,79:89:chronic_disease,91:116:chronic_disease","Ulcer not of VLU pathophysiology (e.g., pure diabetic, vasculitic, radiation, rheumatoid, collagen vascular disease, pressure, or arterial etiology)"
6433,NCT02351544,"70:77:treatment,79:102:chronic_disease,117:134:chronic_disease","Patients with systemic conditions that make them poor candidates for surgery (coronary artery disease, uncontrolled diabetes mellitus, etc)"
6434,NCT02350764,"1:8:treatment,10:16:treatment,18:33:treatment,35:45:treatment,51:74:treatment,59:74:treatment,110:128:chronic_disease","Inhaled, ocular, intra-articular, intranasal, and topical corticosteroids are permitted in absence of active autoimmune disease"
6435,NCT02350764,"15:38:chronic_disease,40:54:chronic_disease,70:89:treatment,110:116:chronic_disease,117:122:chronic_disease,155:190:treatment,192:206:chronic_disease,216:224:chronic_disease,226:235:chronic_disease,240:248:chronic_disease,264:282:treatment","Subjects with type I diabetes melitis, hypothyroidism only requiring hormone replacement, resolved childhood asthma/atopy, patients with asthma requiring intermittent bronchodilator therapy, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger"
6436,NCT02349958,"1:29:cancer,74:105:cancer,106:120:cancer,141:172:treatment",Primary ovarian cancer (POC) with Stage IC or greater stage Recurrent or persistent ovarian cancer (ROC) Ovarian cancer patients who desire Consolidation Chemotherapy (CC)
6437,NCT02349867,"24:39:chronic_disease,57:76:chronic_disease,86:105:chronic_disease,116:140:chronic_disease,,,,197:220:chronic_disease,231:254:treatment,,281:302:chronic_disease,315:338:chronic_disease","Clinically significant cardiac disease, including major cardiac dysfunction, such as uncontrolled angina, clinical congestive heart failure with New York Heart Association (NYHA) class III or IV, ventricular arrhythmias requiring anti-arrhythmic therapy, recent (within 6 months) myocardial infarction or unstable coronary artery disease"
6438,NCT02349867,"34:45:treatment,47:57:treatment,61:70:treatment","Known or presumed intolerance of gemcitabine, vorinostat or sorafenib"
6439,NCT02349867,",39:60:treatment,107:113:chronic_disease,118:129:chronic_disease","Recovery from ? grade 2 toxicities of prior therapy regimen to grade 1 or baseline, with the exception of anemia and lymphopenia and chronic residual toxicities"
6440,NCT02347891,"12:30:cancer,,86:105:cancer,107:112:cancer,116:129:cancer","History of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell)"
6441,NCT02347202,"17:23:chronic_disease,27:43:chronic_disease,66:85:chronic_disease","apparent severe mental or physical illness (e.g., self report of clinical depression)"
6442,NCT02346526,"1:20:cancer,36:45:treatment,49:80:treatment",Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) or other imaging modality
6443,NCT02346201,"22:41:treatment,46:59:treatment,61:70:treatment,79:89:treatment,137:152:treatment,183:211:treatment,216:241:treatment,,","Currently taking any amphetamine product, an antipsychotic, bupropion, or any medication that would prohibit the safe concurrent use of methylphenidate, including but not limited to monoamine oxidase inhibitors and tricyclic antidepressants within the 30 days preceding randomization or a period of time equal to 5 half-lives of drug, whichever period of time is longer"
6444,NCT02344355,"28:46:treatment,58:72:treatment,90:96:cancer",Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma
6445,NCT02343549,"18:39:treatment,41:86:treatment,91:122:treatment","Currently taking cytotoxic medications, non-steroidal ant-inflammatory drugs (NSAIDS), or enzyme inducing anticonvulsants"
6446,NCT02343042,",46:67:chronic_disease,140:150:treatment,154:179:treatment,",Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #24) that patients experienced from treatments in previous clinical studies must have resolved to ? Grade 2 by Cycle 1 Day 1
6447,NCT02343042,"20:39:cancer,89:96:cancer,122:138:treatment",Patients must have symptomatic myeloma per IMWG guidelines with either CRAB criteria or Myeloma Defining Events and need systemic therapy
6448,NCT02343042,"1:10:treatment,12:24:treatment,29:42:treatment,56:74:treatment,,94:98:treatment,104:123:treatment,","Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ? 2 weeks prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1"
6449,NCT02342808,"8:30:chronic_disease,32:55:chronic_disease,71:79:chronic_disease,",Severe ischemic heart disease (CCS Class 3 or 4 angina or evidence of ischemia at <85% heart rate reserve on treadmill testing)
6450,NCT02342782,"13:56:treatment,100:125:treatment,192:215:treatment,,,",Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the Radiation Oncology PI; patients who have had prior external beam radiation > 2000 cGy (at 180 to 200 cGy per day) to the lung will be ineligible
6451,NCT02342782,"55:88:cancer,181:190:cancer,225:242:treatment,247:251:treatment","pathologically confirmed diagnosis of systemic mature T-cell non-Hodgkin lymphoma (NHL) with City of Hope pathology review as per World Health Organization (WHO) classification of lymphomas 2008, who are deemed eligible for high dose therapy and AHCT"
6452,NCT02341209,",88:189:treatment,193:226:treatment,271:279:cancer","Measurable disease in at least one target lesion in the skin or able to be assessed by radiographic examination with FDG-PET fluorodeoxyglucose possitron emission tomography (FDG-PET) scan or computarized tomography (CT) scan, or peripheral blood showing involvement of lymphoma"
6453,NCT02340156,"1:18:treatment,9:18:treatment,42:62:treatment,","Planned treatment, or treatment with any investigational drug within 4 weeks prior to screening"
6454,NCT02339922,"34:59:chronic_disease,84:96:chronic_disease,98:117:chronic_disease,122:146:chronic_disease,152:167:chronic_disease,171:192:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, cardiac arrhythmias, or congestive heart failure, and unstable angina or myocardial infarction within the past 6 months"
6455,NCT02339922,"1:19:treatment,,61:69:treatment,76:112:treatment,137:159:treatment,161:172:treatment,174:182:treatment,184:197:treatment,261:266:treatment,269:283:treatment,285:298:treatment,300:312:treatment,314:326:treatment,328:340:treatment,342:352:treatment,354:366:treatment,371:392:treatment,394:402:treatment,404:415:treatment,417:426:treatment,428:441:treatment,443:452:treatment,454:467:treatment,480:493:treatment,497:512:treatment","Systemic treatment, within 14 days before the first dose of ixazomib, with strong inhibitors of cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P450, family 3, subfamily A (CYP3A) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of ginkgo biloba or St. John's wort"
6456,NCT02339233,"1:4:chronic_disease,8:12:chronic_disease,21:28:chronic_disease",HIV or AIDS related illness
6457,NCT02338999,"22:37:chronic_disease,48:51:chronic_disease,48:57:chronic_disease,,,137:150:chronic_disease,164:192:treatment,201:212:chronic_disease,366:381:treatment","Patients with active lupus nephritis or active CNS lupus at baseline even if SLEDAI-2K <20. Active disease will be considered as CNS or renal disease that require aggressive immunosuppression. Active CNS disease will be diagnosed based on clinical presentation and physical exam, exclusion of other conditions that could explain symptomatology and, when warranted, ancillary tests (imaging) that support the diagnosis"
6458,NCT02338999,"18:38:chronic_disease,42:51:chronic_disease,68:84:treatment",Prior history of hemorrhagic cystitis or hematuria while receiving cyclophosphamide that could not be explained by other causes
6459,NCT02338232,"17:31:treatment,33:54:treatment,59:73:treatment,88:115:treatment,200:219:treatment","Subjects taking ACE inhibitors, potassium supplements, or spironolactone (or any other potassium-sparing diuretics) who cannot discontinue use prior to initiation of study treatment OR who require a high-potassium diet"
6460,NCT02337465,"1:16:cancer,20:26:treatment,74:91:treatment","prostate cancer by biopsy, with the intent of undergoing definitive dose radiation therapy to targets within the liver, or prostate"
6461,NCT02336451,"28:46:treatment,48:58:treatment,66:80:treatment,99:115:treatment,125:147:treatment","Patients may have received prior chemotherapy, crizotinib (other ALK inhibitors are not allowed), biologic therapy or other investigational agents"
6462,NCT02336217,"1:7:chronic_disease,11:26:chronic_disease,30:51:treatment",Type 1 or type 2 diabetes on therapeutic treatment other than just lifestyle changes
6463,NCT02335242,"19:32:treatment,36:49:treatment,59:61:chronic_disease,115:124:treatment,135:145:treatment",Has had extensive prior surgery or sclerotherapy to treat LM such that scarring may interfere with evaluation and treatment effect of sildenafil
6464,NCT02335242,"29:66:treatment,76:88:treatment,90:102:treatment,104:116:treatment,118:128:treatment,153:162:treatment","Requires concomitant use of potent cytochrome P450 3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin, saquinavir), or concomitant use of ritonavir"
6465,NCT02334865,"23:35:cancer,,86:106:cancer,108:143:cancer,148:189:cancer","Disease free of prior malignancies for > 2 years with exception of currently treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast"
6466,NCT02334579,"1:16:treatment,27:40:treatment,47:57:treatment,59:68:treatment,70:81:treatment,84:95:treatment,102:111:treatment,114:133:treatment,140:149:treatment,151:163:treatment,165:175:treatment,178:187:treatment,194:197:treatment,203:224:treatment","Hormone therapy: includes LHRH agonists (e.g. leuprolide, goserelin, triptorelin), antagonists (e.g. degarelix), peripheral blockers (e.g. flutamide, bicalutamide, nilutamide), estrogens (e.g. DES) and bilateral orchiectomy"
6467,NCT02332850,"1:7:treatment,15:27:cancer,,80:101:treatment",Biopsy proven plasmacytoma (should be measured within 28 days prior to initial investigational agent dosing)
6468,NCT02332850,"1:19:treatment,23:43:cancer,47:82:cancer,87:105:cancer,95:105:cancer,116:131:cancer,138:154:treatment","complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, low-risk prostate cancer after curative therapy or complete resection of other advanced malignancy with the expectation that the patient has received curative therapy"
6469,NCT02332668,"18:37:chronic_disease,39:41:chronic_disease,43:64:chronic_disease",Known history of active tuberculosis (TB; Bacillus tuberculosis)
6470,NCT02332291,"8:22:treatment,44:68:treatment,,,114:124:treatment",Use of antidepressant medications or other psychotropic medications in the last 4 weeks (or the last 6 weeks for fluoxetine)
6471,NCT02329327,"27:30:treatment,32:57:treatment,61:67:treatment,,126:144:treatment","Planned administration of PCC, fresh frozen plasma (FFP) or rfVIIa from Screening until within 12 hours after the end of the andexanet infusion"
6472,NCT02327403,"17:20:chronic_disease,22:34:treatment,38:48:treatment,54:62:treatment",patient only on CNI (cyclosporine or tacrolimus) and steroids
6473,NCT02324582,"10:23:treatment,32:41:treatment,43:53:treatment,55:65:treatment,67:77:treatment,82:148:treatment,160:170:treatment,280:289:treatment,294:314:treatment","received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) including anti-CD40 and anti-OX40 antibodies"
6474,NCT02324439,"30:32:cancer,43:71:cancer,73:98:cancer,102:123:cancer,145:163:treatment,,237:253:treatment","Patients with a diagnosis of OC including epithelial ovarian carcinoma, primary peritoneal cancer or fallopian tube cancer who are currently in clinical remission as determined by the PI or co-I and are within 4 months of completion of cancer treatment"
6475,NCT02323945,"42:51:chronic_disease,53:75:chronic_disease,101:122:chronic_disease,133:141:chronic_disease,158:181:chronic_disease","Concurrent severe medical illness (i.e., infection, cardiovascular disease, ossification, recurrent autonomic dysreflexia, unhealed decubiti, and history of pulmonary complications)"
6476,NCT02323880,"58:64:cancer,98:116:treatment,128:132:cancer,137:156:cancer,,,,,271:280:treatment,300:307:treatment","Part C: Patients with recurrent or refractory high grade glioma (WHO grade III/IV) and requiring surgical resection (excluding DIPG and disseminated tumors), who in the opinion of treating physicians, are medically stable to receive 3-4 doses of selinexor (8-10 days of treatment) before undergoing surgery without compromising the success of the procedure"
6477,NCT02323880,",40:74:treatment,59:68:treatment,76:92:treatment,","at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if >= 50% radiation of pelvis"
6478,NCT02323581,",120:136:treatment,,,,,346:365:treatment,,,,,,,745:760:treatment","Iliac artery access: i) ? 6mm diameter, and absence of severe calcification and tortuosity ii) Or, planned creation of surgical conduit for TAAA device delivery f. For patients with associated common iliac artery aneurysms (>20mm diameter), adequate internal and external iliac artery landing zones and common iliac artery luminal diameter (for iliac branch device use): i. ? 10mm long segment of healthy internal iliac artery for branch attachment ii. Internal iliac diameter ? 5mm and ? 12mm iii. External iliac diameter ? 6mm diameter, and absence of severe calcification and tortuosity iv. Minimum common iliac artery luminal diameter ? 14mm v. Or, in patients with bilateral common iliac artery aneurysms without suitable anatomy, planned surgical bypass to maintain patency of at least one internal iliac artery"
6479,NCT02323191,"14:33:treatment,45:57:treatment,61:77:treatment,","Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the exceptions provided in the protocol"
6480,NCT02323191,"1:22:treatment,26:45:treatment,,94:104:treatment",Prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first receipt of study drug
6481,NCT02323126,"19:36:chronic_disease,40:57:chronic_disease,78:95:chronic_disease",positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
6482,NCT02323100,"24:31:chronic_disease,33:38:chronic_disease,42:56:chronic_disease","Clinically significant cardiac, liver or kidney disease"
6483,NCT02322047,"25:45:chronic_disease,82:98:treatment,117:127:treatment,129:140:treatment,145:155:treatment,","Psychiatric/behavioral: psychiatric disorder requiring any medication other than anti-depressants; currently taking disulfiram, acamprosate, or naltrexone or planning to take any of these medications during the 8-week medication phase of the study"
6484,NCT02321501,"1:19:chronic_disease,58:73:cancer,127:145:cancer","Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)"
6485,NCT02321501,"21:26:cancer,45:67:treatment,71:82:treatment,,116:120:treatment",Patient will have a tumor suitable for fine needle aspirates (FNA) or core biopsy for research purposes (2 or more FNAs if core is not feasible)
6486,NCT02321501,"22:30:treatment,22:48:treatment,79:93:treatment,95:109:treatment,153:163:treatment,165:176:treatment,178:186:treatment","Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived anti-coagulant. Anticoagulants not derived from warfarin are allowed (eg, dabigatran, rivaroxaban, apixaban)"
6487,NCT02321501,"1:24:chronic_disease,13:24:chronic_disease,26:42:chronic_disease,85:95:treatment",ventricular arrhythmias; supraventricular and nodal arrhythmias not controlled with medication
6488,NCT02320292,"21:42:treatment,73:82:treatment,91:99:cancer",Receiving any other investigational agent that would be considered as a treatment for the lymphoma
6489,NCT02319369,"8:30:chronic_disease,41:55:treatment,57:67:treatment,72:83:treatment,91:129:chronic_disease,141:167:chronic_disease","Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or active hepatitis B or C infection"
6490,NCT02319369,"19:45:treatment,160:174:treatment,230:268:treatment","Participated in a therapeutic clinical study within a washout time of 2 weeks or 5 half-lives of the drug/biologic (whichever is longer) before starting study drug treatment under this protocol, or current participation in other therapeutic investigational procedures"
6491,NCT02317991,"38:60:treatment,62:74:treatment,76:92:treatment,97:114:treatment,","Patients who have received any other investigational agents, chemotherapy, biologic therapy, or radiation therapy within the 28 days prior to Day 1 of the study"
6492,NCT02315612,"47:51:treatment,86:93:chronic_disease,150:177:treatment","(For children who are unable to cooperate for PFTs, the criterion is: No evidence of dyspnea at rest, no exercise intolerance and no requirement for supplemental oxygen therapy. )"
6493,NCT02315612,"131:155:cancer,168:182:treatment,184:196:treatment,201:232:treatment","Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis"
6494,NCT02315612,"1:18:cancer,33:61:cancer,74:79:cancer,","Second malignancy other than in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least two years previously and subject is in remission"
6495,NCT02315612,"1:21:treatment,39:58:treatment,60:74:treatment","immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples and CSF when feasible"
6496,NCT02315196,"1:19:chronic_disease,23:38:chronic_disease,32:38:chronic_disease,,,,128:141:chronic_disease,184:207:chronic_disease,232:251:chronic_disease,253:269:chronic_disease,321:341:treatment,354:368:chronic_disease,372:410:chronic_disease","Myocardial infarct or unstable angina within 6 months before enrollment, New York Heart Association (NYHA) class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, valvular disease with documented compromise in cardiac function, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities"
6497,NCT02315196,"7:20:treatment,40:46:treatment,55:65:cancer","Prior anthracycline, platinum salt, or taxane for any malignancy"
6498,NCT02315196,",,,58:71:cancer,,,,,,,129:155:treatment,159:200:treatment,,246:251:cancer,,318:328:treatment","Women with previously untreated, unilateral stage II-III breast cancer, ER/PgR/HER2 negative (ER =< 5%, PgR =< 5%, HER2 0-1+ by immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH] =< 2.0); if clinically negative lymph nodes, tumor size should be minimum 1.0 cm and identifiable under office-based ultrasound guidance"
6499,NCT02314377,"25:29:chronic_disease,26:29:chronic_disease,77:110:chronic_disease,137:145:chronic_disease,151:154:chronic_disease,310:319:chronic_disease,321:332:chronic_disease","In the case of sporadic bAVM, these would be referable to the lesion, e.g., progressive neurological deficits, refractory headaches and seizures; for HHT patients, bAVM may be asymptomatic, but patient must have one progressively symptomatic manifestation of HHT that is referable to a vascular lesion, e.g., epistaxis, GI bleeding; or another solid organ AVM"
6500,NCT02314221,"1:16:chronic_disease,18:42:chronic_disease,58:79:chronic_disease","Atherosclerosis, congestive heart failure, or history of myocardial infarction"
6501,NCT02313428,"11:20:chronic_disease,32:37:chronic_disease,44:54:chronic_disease,58:71:chronic_disease",Untreated infection at site of ulcer (i.e. cellulitis or osteomyelitis)
6502,NCT02312596,"8:21:chronic_disease,61:70:chronic_disease,74:83:chronic_disease,,,,,,","Severe liver disease is defined as known history of chronic hepatitis or cirrhosis &/or the following abnormal Liver Function Tests: ALT & AST >35, ALP >120, PT >12 seconds"
6503,NCT02312570,"1:21:chronic_disease,33:58:chronic_disease,61:71:chronic_disease,73:92:chronic_disease,94:97:chronic_disease,105:118:chronic_disease","Rheumatoid arthritis (and other collagen vascular disease), vasculitis, sickle cell disease, HIV Severe liver disease"
6504,NCT02312518,"18:48:treatment,,87:96:treatment,98:107:treatment,111:120:treatment","Received another investigational device or drug within 30 days of enrollment Received allograft, autograft or xenograft within 30 days of enrollment"
6505,NCT02312245,"14:24:cancer,,71:96:cancer,100:131:cancer",Other active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix
6506,NCT02311621,",16:37:treatment,42:73:treatment,86:104:treatment",? 6 weeks from myeloablative therapy and autologous stem cell transplant (timed from stem cell infusion)
6507,NCT02311361,"1:4:chronic_disease,33:56:treatment,149:175:treatment,180:204:treatment",HIV-positive patients receiving anti-retroviral therapy are excluded from this study due to the possibility of pharmacokinetic interactions between antiretroviral medications and Tremelimumab or MEDI4736
6508,NCT02310633,"41:69:chronic_disease,82:86:chronic_disease,91:101:chronic_disease",no current or past history of disabling Axis I psychiatric disorders (except for PTSD and depression)
6509,NCT02310464,"1:14:treatment,16:20:treatment,22:33:treatment,35:44:treatment,53:57:treatment","Immunotherapy [mAbs, Interferons, Cytokines (except GCSF)]"
6510,NCT02310464,"38:59:chronic_disease,81:98:chronic_disease,112:136:chronic_disease,,,147:171:chronic_disease,173:191:chronic_disease,196:215:chronic_disease,216:233:chronic_disease","Subjects with any known uncontrolled inter-current illness including ongoing or active infections, symptomatic congestive heart failure (NYHA>2), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
6511,NCT02310464,"23:40:chronic_disease,64:84:chronic_disease,86:101:chronic_disease,103:126:chronic_disease,128:133:chronic_disease,135:146:chronic_disease,157:167:chronic_disease,169:185:chronic_disease,187:219:chronic_disease","Type 1 juvenile onset diabetes mellitus, antibody positive for rheumatoid arthritis, Grave's disease, Hashimoto's thyroiditis, lupus, scleroderma, systemic vasculitis, hemolytic anemia, immune mediated thrombocytopenia, etc"
6512,NCT02309580,"12:46:treatment,52:66:treatment,68:78:treatment,,122:132:treatment","Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc.) within 28 days of the first dose of study drug"
6513,NCT02309580,"1:19:treatment,21:37:treatment,43:50:treatment,,105:114:treatment","Previous radiation, hormonal therapy, and surgery must have been discontinued at least 2 weeks prior to treatment in this study and adverse effects must have resolved"
6514,NCT02309580,"12:33:chronic_disease,35:50:chronic_disease,55:78:chronic_disease,","history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to enrollment"
6515,NCT02308709,"1:19:treatment,7:19:treatment,24:39:cancer,49:59:cancer",Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of planned radiotherapy fields
6516,NCT02307565,"16:36:chronic_disease,45:75:chronic_disease,77:90:chronic_disease,94:110:chronic_disease","Diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder"
6517,NCT02306954,"13:21:chronic_disease,25:43:treatment,50:71:treatment,76:88:treatment","Evidence of ischemia on exercise tolerance test, stress thallium study, or baseline EKG"
6518,NCT02304458,"1:38:treatment,34:37:treatment,39:64:treatment,,,130:158:treatment,160:176:treatment,","External beam radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after total body irradiation (TBI), craniospinal XRT or if radiation to >= 50% of the pelvis"
6519,NCT02304458,"51:60:treatment,137:152:treatment,156:166:treatment","Patients must not have received prior exposure to nivolumab; for patients enrolled in parts C, D and E, patients must not have received prior nivolumab or ipilimumab"
6520,NCT02303977,"1:21:treatment,38:67:treatment,77:88:treatment,92:101:treatment,173:183:treatment,185:194:treatment,196:207:treatment,209:220:treatment,222:232:treatment,237:246:treatment","First-line treatment with a standard platinum doublet chemotherapy regimen (carboplatin or cisplatin at standard dosing plus one of the following drugs at standard dosing: paclitaxel, docetaxel, vinblastine, vinorelbine, pemetrexed, or etoposide)"
6521,NCT02302976,"35:49:chronic_disease,54:74:chronic_disease,79:106:chronic_disease,135:157:chronic_disease,160:166:chronic_disease,180:219:chronic_disease,221:238:chronic_disease,251:279:treatment,281:301:chronic_disease,310:336:chronic_disease,338:344:chronic_disease,353:361:chronic_disease","a history of significant medical (cardiovascular) or neurological illness, ie prior myocardial infarction, current active symptoms of cardiovascular disease / angina, evidence of cocaine-related cardiovascular symptoms, prior arrhythmias or need for cardiovascular resuscitation, neurovascular events such as transient ischemic attacks, stroke, and/or seizures Parameters re: elevations in vital signs are now explicitly specified under Safety features built into our one-day self-administration paradigm)"
6522,NCT02301611,"12:32:treatment,64:76:treatment,78:95:treatment","Completing SoC adjuvant therapy per NCCN guidelines to include chemotherapy, radiation therapy"
6523,NCT02301546,"17:42:chronic_disease,50:63:chronic_disease,65:91:chronic_disease","Current or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder)"
6524,NCT02299414,"1:18:chronic_disease,20:34:chronic_disease,36:42:chronic_disease,44:47:chronic_disease","Cardiac disorders: cardiomyopathy, angina, CAD"
6525,NCT02296684,"31:52:treatment,31:53:treatment,125:147:treatment,,184:191:treatment",Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of MK-3475
6526,NCT02296684,"18:29:chronic_disease,42:77:treatment,104:115:chronic_disease,128:135:treatment,163:172:chronic_disease",Known history of hepatitis B (defined as hepatitis B survace antigen [HBsAg] reactive) or known active hepatitis C (defined as HCV RNA [qualitative] is detected) infection
6527,NCT02296684,"1:30:treatment,37:44:treatment,50:73:treatment",intranasal influenza vaccines (e.g. FluMist) are live attenuated viruses
6528,NCT02293109,"1:16:chronic_disease,20:41:chronic_disease,,,,,100:113:chronic_disease,115:134:chronic_disease,154:177:chronic_disease,199:222:chronic_disease,224:243:chronic_disease,287:295:chronic_disease,299:338:chronic_disease","Unstable angina or myocardial infarction within 6 months prior to enrollment, NYHA class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or grade 3 conduction system abnormalities unless subject has a pacemaker"
6529,NCT02291978,"36:46:treatment,95:98:treatment,123:137:chronic_disease","Patients with contraindication for MR imaging such as implanted metallic devices that are not MRI-safe, size limitations, claustrophobia. etc"
6530,NCT02291978,"8:31:chronic_disease,33:46:chronic_disease,42:45:chronic_disease,",Severe cerebrovascular disease (multiple CVAs or CVA within 6 months)
6531,NCT02291523,"37:46:treatment,,65:70:treatment,72:80:treatment,84:100:treatment","Children with recent dose change of biologics (within 4 weeks), 5-ASA, steroids or immunomodulators (within 4 weeks)"
6532,NCT02290951,"16:50:chronic_disease,54:71:chronic_disease,77:100:chronic_disease,104:127:chronic_disease",Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
6533,NCT02287558,"9:16:treatment,18:31:treatment,33:56:treatment,60:79:treatment","Chronic aspirin, NSAID therapy, anticoagulation therapy or antiplatelet agents"
6534,NCT02286687,"1:17:chronic_disease,28:56:treatment,79:99:chronic_disease,110:125:treatment",Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization
6535,NCT02286687,"18:57:cancer,65:89:cancer,124:140:cancer,,263:292:treatment,277:292:treatment,422:430:treatment,","Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless or clinical stability"
6536,NCT02286687,",36:45:treatment,36:152:treatment,112:120:treatment,122:132:treatment,137:152:treatment,","Patients must be >= 4 weeks beyond treatment with any chemotherapy or other investigational therapy to include hormonal, biological, or targeted agents; or at least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of treatment initiation"
6537,NCT02285114,"1:27:chronic_disease,40:55:chronic_disease,67:88:treatment,92:110:treatment,","Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline/Day 1"
6538,NCT02285101,"13:20:chronic_disease,24:41:chronic_disease,,,,,208:212:treatment,216:220:treatment,233:254:chronic_disease,,302:312:chronic_disease,328:336:chronic_disease,340:343:treatment","Significant cardiac or pulmonary disease defined by New York Heart Association (NYHA) Class III or IV (see Appendix 13.5), left ventricular ejection fraction (LVEF) lower than institutional normal limits by echo or MUGA, history of myocardial infarction within the past 6 months, significant unstable arrhythmia or evidence of ischemia on ECG"
6539,NCT02282462,"12:35:treatment,40:55:chronic_disease,57:69:chronic_disease,73:87:chronic_disease","undergoing anatomic lung resection for bullous disease, lung abscess or bronchiectasis"
6540,NCT02278315,"1:16:treatment,40:60:treatment,65:80:treatment",Prior treatment with or intolerance to proteasome inhibitor and immunomodulator
6541,NCT02278250,"59:69:cancer,113:145:cancer,208:227:cancer,264:280:treatment,285:303:cancer,",Participants with advanced (locally advanced incurable or metastatic) histologically or cytologically confirmed high-grade serous ovarian cancer (high nuclear Grades 2 or 3). Participants should have either platinum-refractory (disease progression during initial platinum therapy) or platinum-resistant (disease progression <6 months after completion of platinum therapy) disease
6542,NCT02278198,"18:37:treatment,57:71:cancer,86:104:cancer,145:187:treatment",status post near total thyroidectomy for differentiated thyroid cancer without known distant metastases and who are planning to undergo routine remnant thyroid tissue ablation with I-131
6543,NCT02277548,"1:10:treatment,40:61:chronic_disease,80:96:treatment","Treatment entails significant risk for symptomatic mucositis likely to require opioid analgesia, as per the discretion of treating physician/NP"
6544,NCT02276443,",,71:106:treatment,110:131:treatment,,166:176:treatment",Patients must have left ventricular ejection fraction (LVEF) > 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 12 weeks prior to starting adriamycin
6545,NCT02276443,"18:33:cancer,,78:95:cancer,151:156:cancer,161:196:cancer","Prior history of invasive cancer within 5 years of study entry or history of metastatic cancer; exceptions include non-metastatic, curatively treated basal and squamous cell carcinoma of the skin"
6546,NCT02273375,"18:28:cancer,33:59:cancer,61:87:cancer,91:134:cancer","A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour or large-cell neuroendocrine carcinoma (LCNEC)"
6547,NCT02273375,"10:28:treatment,33:42:treatment,46:51:cancer,96:108:treatment",No prior anticancer therapy for treatment of NSCLC other than standard post-operative adjuvant chemotherapy is permissible
6548,NCT02273375,"82:86:cancer,88:94:cancer,96:102:cancer,107:112:cancer","according to WHO Classification of Tumours (WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. WHO/IARC Classification of Tumours, 4th Edition, Volume 7)"
6549,NCT02273362,"1:13:treatment,17:36:treatment,40:55:chronic_disease,,81:96:treatment,98:113:treatment",Percutaneous or transjugular biopsy of cirrhotic liver at least 7 days prior to liver resection (surgical cohort)
6550,NCT02273362,"34:38:treatment,181:195:treatment,207:245:chronic_disease,246:272:chronic_disease",individuals who use prescription PPIs and have approval from their primary health care provider to discontinue for the duration of clinical trial participation may be enrolled; an alternate drug to control gastroesophageal reflux disease (GERD)/peptic ulcer disease (PUD) symptoms will be suggested
6551,NCT02272998,"20:25:cancer,39:45:treatment,152:170:treatment",Patients must have tumor suitable for biopsy (as assessed by trained specialists in interventional radiology) and medically fit to undergo a biopsy or surgical procedure
6552,NCT02272998,"15:28:chronic_disease,30:52:chronic_disease,56:74:chronic_disease","Patients with macular edema, retinal vein occlusion or retinal hemorrhage are excluded"
6553,NCT02272218,"72:96:chronic_disease,105:116:chronic_disease,118:125:chronic_disease,129:144:chronic_disease,146:156:cancer,160:175:chronic_disease,177:203:chronic_disease,211:220:chronic_disease,222:242:chronic_disease,282:299:treatment,304:321:chronic_disease","comorbidities that would make lap band surgery contraindicated (severe cardiopulmonary diseases, severe esophagitis, stomach or duodenal ulcers, esophageal or gastric varices, inflammatory bowel disease, liver cirrhosis, chronic pancreatitis, alcohol or drug addiction, on chronic steroid treatment, or active infections)"
6554,NCT02271919,"5:12:chronic_disease,16:37:chronic_disease,39:46:chronic_disease,48:56:chronic_disease,61:83:treatment,128:137:treatment","Any medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the principal investigator and/or study physician"
6555,NCT02271919,"19:39:treatment,47:69:treatment,73:96:treatment,141:151:treatment,","Plan to use other nicotine substitutes (i.e., over-the-counter [OTC] or prescription medication for smoking cessation) or smoking cessation treatments in the next 12 months"
6556,NCT02270970,"1:7:cancer,,54:80:cancer,92:116:cancer",Cancer within 5 years (except for completely excised cervical carcinoma in situ or excised non-melanoma skin cancer)
6557,NCT02270450,"20:47:chronic_disease,58:88:cancer,95:102:cancer,104:115:cancer,138:146:cancer,148:153:cancer,155:161:cancer,163:174:cancer,176:183:cancer,185:192:cancer,194:202:cancer,204:210:cancer,212:219:cancer,221:229:cancer,231:268:cancer,286:293:cancer","Patients must have malignant bowel obstruction due to an intra-abdominal primary cancer (i.e. stomach, small bowel [including duodenum], pancreas, colon, rectum, appendiceal, ovarian, uterine, cervical, kidney, bladder, prostate, gastrointestinal stromal tumor [GIST] [all sites], and sarcoma)"
6558,NCT02269293,"11:24:treatment,41:56:cancer,68:80:treatment,82:107:treatment,112:131:treatment,,186:195:treatment","Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted therapy and immunologic therapy, must be discontinued at least 3 weeks prior to study treatment initiation"
6559,NCT02269293,"15:33:cancer,37:63:cancer,78:90:treatment,78:96:treatment,113:139:treatment,257:281:treatment,369:389:treatment,448:457:cancer",Patients with endometrial cancer or endometrial carcinosarcoma may either be chemotherapy naive OR have had one prior line of chemotherapy that must have been a platinum-based chemotherapy regimen in the adjuvant or advanced/recurrent setting. The initial platinum-based treatment may have included consolidation/maintenance and/or biologic/targeted agents as part of first-line treatment. Patients entering the trial chemotherapy naive MUST have Stage IVB or recurrent disease AND have disease that is not amenable to curative intent
6560,NCT02269280,"1:14:treatment,20:30:treatment,34:45:treatment",Prior therapy with decitabine or azacitidine
6561,NCT02268253,"15:25:cancer,33:39:cancer,59:87:chronic_disease,104:124:cancer",has an active malignancy and/or cancer history (excluding myeloproliferative disorders and concomitant myeloid malignancies as specified in the inclusion criteria) that can confound the assessment of the study endpoints
6562,NCT02268253,"42:59:chronic_disease,67:104:chronic_disease,106:128:chronic_disease","has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the patient at significant risk for pulmonary complications during the study"
6563,NCT02267863,"14:36:chronic_disease,38:66:chronic_disease,125:143:chronic_disease","Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder"
6564,NCT02266745,"1:17:chronic_disease,19:24:chronic_disease,29:45:chronic_disease,56:72:treatment","Active bacterial, viral, or fungal infection requiring systemic therapy"
6565,NCT02266719,"12:38:chronic_disease,45:67:chronic_disease,69:86:chronic_disease,134:172:treatment,176:195:treatment,205:219:treatment,226:235:treatment,272:297:treatment","History of connective tissue disorder (e.g. vascular Ehlers Danlos, Marfan's syndrome), with the exception of those patients who had prior open surgical aortic replacement or endovascular repair, where a surgical graft or an endograft would serve as landing zone for the investigational endograft"
6566,NCT02266719,",218:285:treatment,276:285:chronic_disease,379:428:treatment,525:535:chronic_disease,539:556:chronic_disease","Prior surgical or interventional procedure within 30 days of the anticipated date of the fenestrated procedure, with the exception of planned staged procedures to provide access for repair (e.g. staged iliac conduit, thoracic endovascular aortic aneurysm repair for proximal aneurysms), to facilitate the procedure by allowing open reparation of a target artery not amenable to revascularization with the investigational device, such us an internal iliac artery, subclavian artery or visceral artery with early bifurcation, tortuosity or occlusive disease preventing successful placement and alignment side stents, or to treat proximal aortic aneurysms"
6567,NCT02266329,"52:62:treatment,52:63:treatment,64:74:treatment,,213:231:treatment,245:260:treatment,262:277:treatment,279:294:treatment,296:304:treatment,305:314:treatment,316:332:treatment,356:369:treatment,371:395:treatment,397:437:treatment,443:472:treatment","Subjects must be on a stable dose of the following medications/treatments for at least 4 weeks prior to the preliminary screening period, and must intend to continue the medication for the duration of the trial: psychoactive drugs, for example anticonvulsants, benzodiazepines, antidepressants, sedative/hypnotics; antihypertensive medications, including beta blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers; magnesium prescribed specifically for headache"
6568,NCT02265874,",60:70:treatment,125:143:treatment,145:157:treatment,159:171:treatment,173:184:treatment,","Patients must have been treated with at least 10 mg/day of prednisone or equivalent or one or more immunomodulating agents (hydroxychloroquine, methotrexate, azathioprine, leflunomide) for >3 months before screening"
6569,NCT02264678,"22:28:cancer,,80:82:treatment,86:94:treatment",patients must have a tumour at least 1 cm in size that can be measured using a CT or MRI scan
6570,NCT02263729,"27:35:allergy_name,27:43:treatment,75:94:allergy_name","Has contraindications for Losartan therapy (hypersensitivity to Losartan, hepatic involvement)"
6571,NCT02263274,"17:39:chronic_disease,50:61:cancer,63:88:chronic_disease,90:112:chronic_disease,114:138:treatment,154:169:chronic_disease","Space occupying intracranial pathology including brain tumor, ateriovenous malformation, cavernous malformation, prior surgical resection or significant encephalomalcia that would create unknown tissue inhomogeneity that cannot be accurately modeled"
6572,NCT02261519,"12:18:cancer,,68:88:cancer,93:116:cancer",History of cancer not in remission for the last 3 years except for basal cell carcinoma and squamous cell carcinoma
6573,NCT02261519,"49:72:chronic_disease,74:95:chronic_disease,97:113:chronic_disease,115:140:chronic_disease,142:166:chronic_disease,168:193:chronic_disease,195:212:chronic_disease,214:258:chronic_disease,260:268:chronic_disease,292:308:chronic_disease","Meets the DSM-IV or V criteria at screening for intellectual disability, dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, primary substance-induced psychotic disorder, dementia, or any other comorbid mental disorders that in the opinion of the Investigator may interfere with study conduct and results interpretation"
6574,NCT02259621,"49:58:treatment,72:95:treatment,194:222:treatment","As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen"
6575,NCT02259621,"1:26:cancer,28:43:cancer,45:52:cancer,54:60:cancer,62:67:cancer,71:97:cancer","non melanoma skin cancers, in situ bladder, gastric, breast, colon or cervical cancers/dysplasia"
6576,NCT02257424,"5:32:treatment,23:32:treatment,60:68:chronic_disease","All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed in Eligibility Criteria #4) must be Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03, 2009) at the time of starting treatment"
6577,NCT02257424,"20:38:treatment,49:54:cancer,61:78:treatment,82:104:treatment",Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
6578,NCT02257424,"15:31:cancer,45:56:treatment,60:67:treatment,,250:261:treatment",patients with brain metastases treated with gamma knife or surgery are allowed to participate after 3 weeks have elapsed since their procedure . Demonstration of brain stability by an imaging study after the procedure is required for gamma knife or CNS surgery patients
6579,NCT02257138,"26:38:chronic_disease,40:74:chronic_disease,78:95:chronic_disease","patients with history of tuberculosis, human immunodeficiency virus (HIV) or hepatitis B and C"
6580,NCT02256631,"52:66:treatment,71:96:treatment,132:165:treatment,220:239:treatment","Receipt of or anticipated need for blood products, immunoglobulin, or immunosuppressive therapy. This includes infants who require hepatitis B immunoglobulin (HBIG) but does not require exclusion of infants who receive hepatitis B vaccine in the newborn period"
6581,NCT02254863,"14:23:chronic_disease,25:30:chronic_disease,35:51:chronic_disease,67:89:treatment","Uncontrolled bacterial, viral, or fungal infection at the time of pre-UCBT cytoreduction"
6582,NCT02253316,"12:23:cancer,27:53:cancer,64:73:treatment",Concurrent hematologic or non-hematologic malignancy requiring treatment
6583,NCT02253316,"20:35:treatment,85:101:cancer,109:130:chronic_disease,132:152:chronic_disease","Patients may be on corticosteroids if they are being given for disorders other than multiple myeloma (e.g., adrenal insufficiency, rheumatoid arthritis, etc.)"
6584,NCT02252588,"23:29:chronic_disease,31:45:chronic_disease,47:62:chronic_disease,67:104:chronic_disease","Clinical diagnosis of asthma, bronchiectasis, cystic fibrosis, or severe alpha-1 antitrypsin deficiency"
6585,NCT02252432,"30:53:chronic_disease,65:78:chronic_disease,80:85:chronic_disease,87:103:chronic_disease,107:116:chronic_disease","Individuals with significant psychological disorders including: schizophrenia, mania, bipolar disorder or psychosis"
6586,NCT02252081,"16:26:cancer,30:36:cancer,,77:118:cancer",Current active malignancy or cancer history in the prior 5 years (excluding squamous cell and basal cell skin cancers)
6587,NCT02251431,"1:28:treatment,30:43:treatment,45:58:treatment,69:94:treatment","Implanted cardiac pacemaker, defibrillator, loop recorder, or other implanted metallic device"
6588,NCT02250664,"36:51:chronic_disease,101:110:treatment,114:127:treatment,",Be in good physical health without serious illness or change in health or medication (not including methadone or buprenorphine dose) in the past three months as determined by the license medical professional at each site
6589,NCT02250534,"6:26:treatment,28:37:treatment,41:64:treatment","used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month"
6590,NCT02250157,"10:20:treatment,58:95:treatment,101:113:treatment,,154:162:treatment,167:182:treatment,211:234:treatment","Taking a medication known to be a clinically significant cytochrome (CYP) 3A4 strong inhibitor (eg, ketoconazole within 14 days) or strong inducers (eg, rifampin and St. John's Wort within 14 days) of starting treatment with Oratecan"
6591,NCT02245841,"8:27:treatment,32:41:treatment,123:140:chronic_disease",Use of topical medications and sunscreen currently and in past will be noted but not weighed for assessment of refractory cutaneous disease
6592,NCT02243813,"55:66:treatment,127:136:treatment,169:204:treatment","Currently taking on a regular (e.g., daily) basis any medications having a primary centrally-acting pharmacological effect on serotonin neurons or medications that are Mono amine Oxidase (MAO) inhibitors"
6593,NCT02242526,"12:38:chronic_disease,92:104:chronic_disease,106:109:chronic_disease,111:126:chronic_disease","Absence of chronic medical conditions that will affect the quality of life survey, such as fibromyalgia, SLE, Crohn's disease, etc"
6594,NCT02239913,"64:87:chronic_disease,101:138:chronic_disease,151:158:chronic_disease,199:219:chronic_disease","History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study"
6595,NCT02237183,"29:43:treatment,67:74:treatment,84:127:treatment","patients must not be taking anticoagulants, with the exception of aspirin or other non-steroidal anti-inflammatory medications"
6596,NCT02236000,"1:17:chronic_disease,21:38:chronic_disease,57:80:treatment",Active infection or chronic infection requiring chronic suppressive antibiotics
6597,NCT02235857,"10:25:treatment,52:69:chronic_disease,78:98:chronic_disease,107:130:chronic_disease,153:185:treatment","Adequate anticoagulation cannot be achieved due to severe hemophilia, severe hemorrhage diathesis, severe gastrointestinal ulcers, or are recipients of vitamin K antagonist medications"
6598,NCT02235857,"1:65:treatment,100:121:chronic_disease,123:150:chronic_disease,159:177:chronic_disease,185:193:chronic_disease,202:229:chronic_disease,241:267:chronic_disease","Extracorporeal circulation therapy with Liposorber® LA-15 System cannot be tolerated due to severe cardiac insufficiency, acute myocardial infarction, severe cardiac arrhythmia, acute apoplexy, severe uncontrollable hypertension, or severe uncontrollable hypotension"
6599,NCT02235857,"1:30:chronic_disease,40:58:treatment,118:141:treatment,149:178:treatment,,232:240:treatment,244:261:treatment","Refractory nephrotic syndrome in which standard treatment options are unsuccessful (i.e., patient is unresponsive to standard corticosteroid and/or calcineurin inhibitor therapy for at least 8 weeks resulting in failure to achieve complete or partial remission)"
6600,NCT02234934,"20:40:chronic_disease,42:53:chronic_disease,55:66:chronic_disease,68:71:chronic_disease,73:83:chronic_disease,85:99:chronic_disease,103:116:chronic_disease,,,165:173:treatment","Evidence of active infection with HIV-1, hepatitis B, Hepatitis C, CMV, adenovirus, parvovirus B19 or toxoplasmosis by DNA PCR within 8 weeks prior to mobilization/pheresis or bone marrow harvest"
6601,NCT02234557,"14:37:chronic_disease,39:70:chronic_disease,72:90:chronic_disease,95:101:chronic_disease","diagnosis of Intellectual Disability, Developmental Language Disorder, Reading Disability, or Autism (screened for using the Social Competence Questionnaire (SCQ)"
6602,NCT02234193,"24:32:treatment,76:90:treatment,110:116:treatment","Willingness to undergo biopsies of full-thickness skin tissue from the pre-abdominoplasty skin, and have the biopsy sites marked by tattoos"
6603,NCT02233868,"1:11:treatment,24:33:treatment,37:40:chronic_disease,61:64:treatment,80:89:treatment,91:102:treatment,104:115:treatment,117:129:treatment,132:143:treatment,170:186:treatment,201:216:treatment,241:268:treatment,270:289:treatment,295:323:treatment,326:333:treatment,335:342:treatment,344:360:treatment,362:380:treatment,493:502:treatment,504:517:treatment","antivirals (except for treatment of HSV with agents without CNS activity, e.g. acyclovir, ganciclovir, famciclovir, valacyclovir); anxiolytics; cough/cold preparations (dextromethorphan preparations, pseudoephedrine); hormones (exceptions: thyroid hormone replacement, oral contraceptives, and estrogen replacement therapy); insulin; lithium; muscle relaxants; psychotropic drugs not otherwise specified (nos) including herbal products (no drugs with psychomotor effects or with anxiolytics, stimulant, antipsychotic, or sedative properties); sedatives/hypnotics"
6604,NCT02233322,"1:25:chronic_disease,32:46:chronic_disease,48:57:chronic_disease","severe end-organ disease, e.g. cardiovascular, pulmonary, etc, which may limit ability to complete study"
6605,NCT02232516,"1:18:chronic_disease,62:80:cancer,112:116:cancer",topical treatment may have been given for prior existence of cutaneous lymphoma that has since become systemic PTCL
6606,NCT02231073,"1:13:chronic_disease,24:56:chronic_disease,65:95:chronic_disease,97:120:chronic_disease,122:143:chronic_disease,148:165:chronic_disease","Parkinsonism subjects: iPD and Parkinson plus syndromes such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Syndrome, or Cerebellar Ataxia"
6607,NCT02229565,"15:37:treatment,79:88:treatment,92:97:treatment,101:114:treatment","Patients with prior systemic therapy will not be eligible for the study, i.e. radiation or chemo or immunotherapy"
6608,NCT02226341,"38:43:chronic_disease,45:52:chronic_disease,54:67:chronic_disease,69:85:chronic_disease,87:96:chronic_disease,98:105:chronic_disease,110:130:chronic_disease,338:341:chronic_disease","Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease (or, in the investigator's opinion, any other concomitant medical condition that places the participant at risk by participating in this study) with the exception of diseases or conditions related to active SLE"
6609,NCT02225548,"27:37:cancer,,74:82:cancer,86:108:cancer",Subject with a history of malignancy within the past 5 years (other than squamous or basal cell skin cancer)
6610,NCT02225548,"23:53:chronic_disease,76:88:chronic_disease,102:114:chronic_disease,116:134:chronic_disease","Subject with a severe chronic or acute liver disease, history of moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment"
6611,NCT02225548,"31:40:treatment,45:65:chronic_disease,94:109:treatment,111:125:treatment,127:147:treatment,149:159:treatment,161:183:treatment,185:189:treatment,195:242:treatment","unwilling to cease use of any treatment for erectile dysfunction during the study, including oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or nonprescription medications, and products purchased via the internet"
6612,NCT02219555,"1:21:chronic_disease,31:53:chronic_disease,65:69:chronic_disease","rheumatoid arthritis or other inflammatory arthritis, including gout"
6613,NCT02217345,"1:5:chronic_disease,34:51:chronic_disease,55:62:treatment,66:72:treatment",AFLD defined as demonstration of hepatic steatosis by imaging or biopsy in absence of significant alcohol consumption and other causes of hepatic steatosis
6614,NCT02215096,"74:87:treatment,93:116:treatment,124:143:treatment,145:157:treatment,159:176:treatment,178:191:treatment,193:209:treatment,214:229:treatment,259:273:treatment,281:293:treatment,295:304:treatment,306:316:treatment,319:347:treatment,355:366:treatment,368:379:treatment,382:391:treatment,399:411:treatment,413:435:treatment,438:458:treatment,493:505:treatment,514:532:treatment,564:579:treatment,581:605:treatment,607:620:treatment,622:629:treatment,634:641:treatment","Current use of or anticipated requirement during the study of prohibited medication(s) (any investigational drug(s), Other anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, or hormone therapy other than for replacement), AR antagonists (e.g., bicalutamide, flutamide, nilutamide), 5-alpha reductase inhibitors (e.g., finasteride, dutasteride), Androgens (e.g., testosterone, dihydroepiandrosterone), Herbal medication(s) that may affect PSA levels (e.g., saw palmetto), Other herbal medications including, but not limited to: St. John's wort, kava, ephedra (ma huang), gingko biloba, yohimbe and ginseng)"
6615,NCT02215096,"7:23:chronic_disease,34:50:treatment,54:83:treatment",Known active infection requiring intravenous (IV) or oral anti-infective treatment
6616,NCT02215096,"20:48:treatment,54:58:treatment,60:63:treatment,67:114:treatment","Subjects must have prior enzalutamide treatment; Any PI3K, AKT or mammalian target of rapamycin (mTOR) inhibitors"
6617,NCT02213913,"34:52:chronic_disease,54:77:chronic_disease,79:105:chronic_disease,124:137:chronic_disease","(with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement with NHL or stable chronic liver disease per investigator assessment)"
6618,NCT02213913,"12:22:cancer,,129:153:cancer,179:196:cancer","No current malignancy. Subjects who have been free of malignancy for at least 2 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma (any site) are eligible"
6619,NCT02213575,"12:30:treatment,32:58:chronic_disease,60:74:chronic_disease,76:95:chronic_disease,97:117:chronic_disease,127:149:chronic_disease","history of intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance, chronic pancreatitis or other malabsorption disorder"
6620,NCT02213289,",31:47:treatment,59:71:treatment,79:91:treatment",>6 months after completion of adjuvant therapy (including chemotherapy and/or radiotherapy)
6621,NCT02213289,"21:31:treatment,35:51:treatment,59:76:cancer",Must be amenable to ultrasound or CT-guided biopsy of one metastatic lesion
6622,NCT02209636,"8:17:treatment,37:47:treatment,49:61:treatment,63:78:treatment","Active vitamin D analogue use (i.e. calcitriol, paricalcitol, doxercalciferol)"
6623,NCT02208362,"65:87:cancer,144:159:cancer,215:252:cancer,270:286:treatment","Participant has a prior histologically-confirmed diagnosis of a grade III or IV glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now has radiographic progression consistent with a grade III or IV malignant glioma (MG) after completing standard therapy"
6624,NCT02207465,"15:31:chronic_disease,54:68:cancer,128:142:treatment,143:151:treatment",Short-segment venous occlusion resulting from either tumor thrombus or encasement with suitable proximal and distal vessel for reconstruction/grafting
6625,NCT02207439,"10:17:treatment,25:59:chronic_disease,60:78:treatment",Previous therapy with a human immunodeficiency virus (HIV) protease inhibitor
6626,NCT02204098,",,,125:138:cancer,197:204:treatment,230:235:cancer","Clinical T2-T4c, any N, M0 invasive ER+ (Allred Score of 6-8) and HER2- (0 or 1+ by IHC or FISH negative for amplification) breast cancer by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node"
6627,NCT02203903,"13:15:chronic_disease,31:37:treatment,154:157:cancer,162:165:cancer,187:194:treatment","Evidence of HD by morphology, PET/CT uptake in a site of previous disease in the absence of other etiologies ARM C only includes patients with high risk AML and MDS who have received an alloBMT and have not had hematologic relapse of disease"
6628,NCT02203903,"23:50:chronic_disease,,,,128:137:treatment,138:159:treatment",patients (Arm B) with relapsed/refractory disease (> 2 regimens with greater than M1 marrow or persistent HD) with anticipated allo-HSCT pre- and/or post-HSCT
6629,NCT02203695,"20:37:chronic_disease,68:75:chronic_disease,77:86:chronic_disease,88:106:chronic_disease,110:130:chronic_disease,148:158:chronic_disease,170:173:chronic_disease,175:188:chronic_disease","Serious concurrent medical illnesses (including uncontrolled major cardiac, pulmonary, Child-Pugh C liver or psychiatric diseases) or active major infections (including HIV, Hepatitis A-C)"
6630,NCT02203552,"12:29:chronic_disease,31:44:chronic_disease,48:54:chronic_disease","History of diabetes mellitus, heart disease or stroke"
6631,NCT02203513,"38:48:cancer,,115:142:cancer,156:183:cancer,189:225:cancer","Another previous or current invasive malignancy within the last 2 years, with the exception of curatively treated stage Ia cervical carcinoma, or resected stage Ia endometrial cancer, and noninvasive nonmelanoma skin cancers"
6632,NCT02203513,"27:56:cancer,,,,129:133:cancer,156:165:treatment","Patients enrolling in the triple negative breast cancer (ER-/PR-/Her2-) group, Cohort 3, must have a negative family history of HBOC syndrome, or negative gBRCA1/2m test"
6633,NCT02203513,"12:22:treatment,24:33:treatment,38:53:treatment","The use of raloxifene, denosumab, or bisphosphonates for bone health"
6634,NCT02201992,"10:19:treatment,25:35:treatment,47:60:treatment",No prior treatment with crizotinib or another ALK inhibitor
6635,NCT02201589,"21:54:treatment,56:100:treatment,102:121:treatment,123:140:chronic_disease,144:158:chronic_disease","Patient must have a Type A thoracic aortic dissection, retrograde Type A thoracic aortic dissection, intramural hematoma, penetrating ulcer or pseudoaneurysm of the ascending thoracic aorta affecting the area between the Sinus of Valsalva and the innominate artery orifice (with no involvement of the aortic valve) and be considered candidates for endovascular repair;"
6636,NCT02200445,"10:18:treatment,23:26:chronic_disease,28:51:chronic_disease,55:58:chronic_disease","Positive serology for HIV, hepatitis B virus (HBV) or HCV"
6637,NCT02195232,"22:29:treatment,,45:65:treatment,67:86:treatment,88:119:treatment,,189:227:treatment,273:282:treatment,","Current daily use of aspirin (>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen > 800 mg daily or equivalent)"
6638,NCT02194738,"4:20:cancer,24:41:cancer,52:68:treatment,",No locally advanced or metastatic cancer requiring systemic therapy within 5 years prior to registration
6639,NCT02193841,"15:27:chronic_disease,33:56:chronic_disease,58:64:cancer,66:78:chronic_disease,80:95:chronic_disease","Patients with bone disease (ie. osteogenesis imperfecta, cancer, osteoporosis, Paget's disease)"
6640,NCT02193191,"1:8:chronic_disease,9:28:chronic_disease,29:46:chronic_disease",Medical/psychiatric illness/social situations that would limit compliance with study requirements as determined by the treating physician
6641,NCT02192398,"16:33:treatment,16:25:treatment,77:86:treatment,90:103:treatment,110:118:treatment,120:127:treatment,170:191:treatment,209:213:chronic_disease","Currently in a treatment program for alcohol or drug abuse, or currently on methadone or buprenorphine (i.e. suboxone, subutex) for treatment of addiction, or currently prescribed stimulants for treatment of ADHD"
6642,NCT02192398,"7:28:chronic_disease,,89:105:chronic_disease,107:123:chronic_disease,125:138:chronic_disease,140:156:chronic_disease,161:180:chronic_disease","Major psychiatric disorders that required hospitalization in the past 6 months such as: major depression, bipolar disorder, schizophrenia, anxiety disorder, or psychotic disorders"
6643,NCT02192359,"1:18:chronic_disease,52:67:treatment,73:88:treatment,93:105:treatment",High-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide
6644,NCT02192359,"8:23:treatment,25:33:treatment,35:46:treatment,48:79:treatment,90:129:treatment,131:140:treatment,142:154:treatment,156:169:treatment,171:184:treatment,186:195:treatment,197:210:treatment,,251:260:treatment","Use of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers including hepatic enzyme-inducing anticonvulsants (phenytoin, fosphenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) within 2 weeks prior to start of study treatment"
6645,NCT02191488,"22:38:chronic_disease,40:49:chronic_disease,71:81:allergy_name,83:98:allergy_name,100:122:allergy_name","History of cutaneous photosensitivity, porphyria, hypersensitivity to porphyrins, photodermatosis, exfoliative dermatitis"
6646,NCT02191098,"21:63:chronic_disease,74:83:treatment,88:107:treatment",Active or recurrent herpes or varicella-zoster virus infection requiring treatment (or chronic suppression)
6647,NCT02189889,"1:7:chronic_disease,11:21:chronic_disease,42:55:treatment",sepsis or bacteremia defined by positive blood culture
6648,NCT02189798,"29:39:treatment,50:66:treatment,72:80:treatment,81:87:treatment,92:113:treatment",Unilaterally implanted with HiRes 90K Advantage cochlear implant with HiFocus Helix® and HiFocus 1j electrode
6649,NCT02188745,"62:68:treatment,73:81:treatment,86:95:treatment","Baseline radiographic staging, including specifically either PET/CT, or CT (CAP) and bone scan"
6650,NCT02188745,"13:31:treatment,36:44:cancer,45:63:cancer",One line of prior chemotherapy for advanced/metastatic disease is permissible
6651,NCT02188745,"1:16:treatment,,34:44:cancer,48:72:cancer,",surgical biopsy of ?1 site(s) of metastatic or locally advanced disease performed as standard of care within the past 4 months for assessment of eligibility for study participation (except as noted below in c/d/e)
6652,NCT02188121,"1:14:chronic_disease,16:29:chronic_disease,39:45:treatment,50:67:treatment","renal failure, liver failure, or both statin and angiotension drug contraindications"
6653,NCT02187848,"1:19:chronic_disease,60:71:treatment,77:102:treatment,","Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by cytochrome P450 (CYPs) enzymes and for which a dose reduction cannot be considered"
6654,NCT02187198,"1:28:chronic_disease,39:48:chronic_disease,50:81:chronic_disease","serious psychiatric illness including psychosis, bipolar disorder with psychosis"
6655,NCT02186418,"49:69:chronic_disease,55:69:chronic_disease,80:98:treatment,285:294:treatment,300:327:treatment","Minimum of two episodes of clinically diagnosed acute chest syndrome requiring hospital admission, or one life threatening episode of acute chest syndrome requiring ICU admission for exchange transfusion and or intubation, or frequent acute chest syndrome episodes, which necessitate treatment with chronic transfusion therapy"
6656,NCT02186418,"20:23:treatment,43:63:treatment,67:78:treatment,134:146:treatment,213:219:chronic_disease","Patients with high TCD do equally well on chronic transfusions or hydroxyurea, as per a subsequent TWITCH study, where patients with elevated TCD were randomized to hydroxyurea or chronic transfusions to prevent stroke"
6657,NCT02184520,"1:24:chronic_disease,33:51:chronic_disease,53:76:chronic_disease,78:107:chronic_disease","Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, etc"
6658,NCT02181478,"1:19:treatment,24:47:cancer,51:88:cancer",Concurrent therapy for extramedullary leukemia or central nervous system (CNS) lymphoma
6659,NCT02181257,"34:37:chronic_disease,114:129:treatment,131:158:chronic_disease,164:196:chronic_disease","Inherent to the diagnosis of new BOS is the exclusion of other potential causes of allograft dysfunction such as acute rejection, respiratory tract infection, and airway anastomotic complications"
6660,NCT02181257,"15:34:chronic_disease,36:59:chronic_disease,61:90:chronic_disease,92:111:chronic_disease,113:134:chronic_disease,136:144:chronic_disease,155:167:chronic_disease,171:187:chronic_disease,220:231:treatment","patients with lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, albinism, or other dermatologic or ocular condition that contraindicates the use of methoxsalen or markedly enhances photosensitivity in the investigator's judgment"
6661,NCT02179359,"14:33:chronic_disease,35:46:chronic_disease,48:71:chronic_disease,95:116:chronic_disease,129:149:treatment","Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other non-malignant hematologic disorders for which a stem cell transplant is indicated"
6662,NCT02178709,"43:55:treatment,59:73:treatment,82:91:treatment,93:106:treatment,108:121:treatment,123:131:treatment,136:145:treatment","Unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated"
6663,NCT02177838,"23:64:cancer,66:77:cancer,81:87:cancer","Histologically proven squamous cell carcinoma of the oropharynx, hypopharynx or larynx"
6664,NCT02177695,"37:39:treatment,43:51:treatment,56:63:treatment,67:72:treatment,",Staging scans with abdominal/pelvic CT or MRI scan and CT scan or x-ray of the chest within 56 days prior to registration
6665,NCT02176967,"4:22:treatment,26:38:treatment,62:75:treatment","No prior radiotherapy or chemotherapy, with the exception of dexamethasone, which is allowed"
6666,NCT02176161,"28:51:treatment,53:71:treatment,73:82:treatment,84:116:treatment","Current or previous use of 5?-reductase inhibitors, antiandrogen drugs, metformin, oral or injectable diabetes drug"
6667,NCT02174549,"48:51:cancer,88:106:treatment,110:113:treatment,127:132:cancer,,,262:302:cancer,314:334:cancer","Patients with single or multiple (2-4 nodules) HCC who are unsuitable or unwilling for surgical resection or RFA. The largest tumor nodule should be less than 10 cm in the largest diameter. The total volume of tumor cannot exceed 50% of liver; or patients with liver metastatic gastrointestinal cancer, including neuroendocrine tumor"
6668,NCT02172651,"18:38:chronic_disease,81:97:chronic_disease,111:135:chronic_disease,137:161:chronic_disease,163:181:chronic_disease,186:205:chronic_disease,206:223:chronic_disease,334:343:treatment","Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, may increase the risks associated with study participation or study treatment, limit compliance with study requirements, or interfere with the interpretation of study results"
6669,NCT02172651,"25:59:chronic_disease,61:78:chronic_disease,92:121:chronic_disease","Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection"
6670,NCT02172651,"27:39:treatment,43:55:treatment,,,84:95:treatment,100:115:treatment",Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for bevacizumab) of liver resection
6671,NCT02172651,"16:25:treatment,29:46:treatment,87:103:cancer",Prior systemic treatment or radiation therapy is allowed for patients with resectable liver metastases
6672,NCT02171429,"88:109:chronic_disease,124:132:chronic_disease,134:143:chronic_disease,147:166:chronic_disease,185:193:chronic_disease,197:216:chronic_disease,218:243:chronic_disease,245:278:chronic_disease,280:295:chronic_disease,310:336:chronic_disease","A history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, stricture (stenosis) of the colon, toxic megacolon, or unremoved adenomatous colonic polyps"
6673,NCT02171429,"22:46:chronic_disease,72:82:chronic_disease,104:120:chronic_disease,125:141:treatment","History of active or latent tuberculosis (TB), recurrent opportunistic infections, severe disseminated viral infections and organ transplant"
6674,NCT02169830,"1:14:treatment,16:50:treatment,59:69:treatment",Nortriptyline: monoamine oxidase inhibitors (MAO) such as phenelzine
6675,NCT02169739,"23:39:chronic_disease,46:69:treatment,79:101:chronic_disease","Known history of limb vascular disease, limb vascular bypass surgery, or limb deep venous thrombosis"
6676,NCT02169739,"7:15:chronic_disease,19:33:chronic_disease,69:81:treatment",Prior cortical or retinal stroke (diagnosed either clinically or by neuroimaging)
6677,NCT02169089,"18:28:cancer,39:47:cancer,52:60:cancer",History of prior malignancy including leukemia and lymphoma
6678,NCT02169037,"1:19:treatment,21:39:treatment,41:77:treatment","ASD closure device, LAA closure device, prosthetic mitral or tricuspid valve"
6679,NCT02169037,"19:42:chronic_disease,44:50:chronic_disease,54:57:chronic_disease,,",history of recent cerebrovascular disease (stroke or TIA) or systemic thromboembolism within < 6 months
6680,NCT02169037,",71:106:chronic_disease,,,187:198:treatment,202:218:treatment",reported incidence of at least two documented episodes of symptomatic paroxysmal atrial fibrillation (AF) during the three months preceding trial entry (at least 1 episode documented by 12-lead ECG or ECG rhythm strip)
6681,NCT02167022,"1:19:chronic_disease,59:83:treatment,177:186:chronic_disease,255:261:cancer,263:278:chronic_disease","Medical conditions that may prevent the administration of rehabilitation therapies at the intensity required by the study, or that may compromise the study ability to maintain blindness, or that have a co-morbidity not typically associated with CP (i.e. cancer, cystic fibrosis)"
6682,NCT02166905,"1:13:treatment,15:32:treatment,37:50:treatment,,91:101:treatment,,115:127:treatment","Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study drug (6 weeks for nitrosoureas)"
6683,NCT02166905,"7:24:chronic_disease,32:50:chronic_disease,61:72:treatment,74:92:chronic_disease","Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)"
6684,NCT02166905,"8:35:treatment,46:79:treatment,91:101:treatment,103:113:treatment,119:131:treatment","Use of UDP glucuronosyltransferase 1 family, polypeptide A9 (UGT1A9) inhibitor including: diclofenac, imipramine, and ketoconazole"
6685,NCT02165007,"10:18:chronic_disease,22:31:chronic_disease,35:47:treatment,41:47:treatment,81:108:treatment,,,",bridging fibrosis or cirrhosis on liver biopsy (biopsy required for patients on chronic transfusion therapy for > 1 year and evidence of iron overload with ferritin >1000 ng/mL)
6686,NCT02163434,"35:57:treatment,69:83:treatment,85:91:treatment,,104:114:treatment,116:125:treatment,129:149:treatment,151:167:treatment,169:180:treatment,182:190:treatment,195:206:treatment,","Agrees to discontinue any current anti-emetic treatments (including antihistamines, ginger, > 10mg/day vitamin B6, serotonin or dopamine antagonists, anticholinergics, acupuncture, hypnosis, or wrist bands) for the next 4 weeks"
6687,NCT02163317,"1:25:treatment,27:40:treatment,43:54:treatment,59:99:treatment,104:119:cancer","Previous radical surgery (prostatectomy), cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer"
6688,NCT02162511,"49:75:treatment,163:179:treatment,184:209:treatment",Participant's medical screening clears s/he for allogeneic transplantation as per current institutional SOP based on standards of foundation for accreditation of cellular therapy and stem cell transplantation (FACT)
6689,NCT02159703,"39:62:cancer,70:80:cancer,93:105:cancer,","Histologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, stage IVa, p16-positive on immunohistochemistry"
6690,NCT02159495,"22:40:treatment,42:55:treatment,59:68:treatment,","His/her last dose of prior chemotherapy, immunotherapy or radiation is at least 2 weeks out from PBMC collection"
6691,NCT02159495,"19:22:cancer,37:61:cancer,,112:134:treatment","for patients with AML evolving from myelodysplastic syndrome, they should have completed at least one cycle of induction chemotherapy"
6692,NCT02159027,"1:18:chronic_disease,29:40:chronic_disease,42:51:chronic_disease,57:76:chronic_disease,81:97:chronic_disease,128:136:chronic_disease,140:162:chronic_disease,206:218:treatment,222:240:treatment","Chronic illnesses including hematologic, pulmonary, and autoimmune diseases and endocrinopathies, except for stable controlled diabetes or cardiovascular disease in the view of the investigator and stable testosterone or thyroid medication use"
6693,NCT02158793,"19:37:chronic_disease,51:79:chronic_disease,91:121:chronic_disease",Subjects with any cognitive deficits related to a TBI (traumatic brain injury) and or any organic neurological disorders will not be considered for this protocol
6694,NCT02153229,"22:38:cancer,51:54:cancer,80:89:treatment,98:126:cancer,128:147:cancer,151:166:cancer,184:199:cancer","Patients with active invasive cancers, other than MPM, that require additional treatment, except non-melanomatous skin cancer, superficial bladder or cervical cancer, and early-stage prostate cancer"
6695,NCT02152995,"26:31:cancer,48:62:cancer,74:84:cancer",Availability of archival tumor tissue from the thyroid cancer primary or metastasis (a tissue block or a minimum of 30 unstained slides would be required; patients with less archival tissue available may still be eligible for the study after discussion with the MSK principal investigator)
6696,NCT02152995,"4:16:treatment,9:16:treatment,20:36:treatment,44:69:treatment,","No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed < 4 weeks prior to the initiation of therapy on this protocol"
6697,NCT02152995,"20:23:chronic_disease,28:31:chronic_disease,32:41:chronic_disease",chronic or cleared HBV and HCV infection
6698,NCT02152254,"26:38:treatment,40:47:treatment,52:64:treatment,,127:136:treatment,150:161:treatment,165:186:treatment","The patient has received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within 3 weeks of initiating study treatment (4 weeks for bevacizumab or investigational drugs)"
6699,NCT02151175,"34:86:treatment,90:99:treatment,104:114:treatment,115:134:chronic_disease",Subjects who have been offered a non-dominant anterior-mesial temporal lobe resection as treatment for medication refractory epilepsy
6700,NCT02150967,",67:78:treatment,95:104:treatment,119:129:cancer",Patients must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/ metastatic disease
6701,NCT02148003,"27:37:chronic_disease,39:51:chronic_disease,55:73:chronic_disease","Psychopathology including depression, somatization or poor coping skills"
6702,NCT02146924,"39:52:treatment,146:177:treatment,189:229:treatment","If research participant is undergoing leukapheresis and the research participant has undergone prior alloSCT, two months must have elapsed since allogeneic stem cell transplant to undergo PBMC collection for T cell manufacturing"
6703,NCT02146924,"43:65:treatment,70:91:treatment,93:105:treatment,110:127:treatment","Research participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy"
6704,NCT02145351,"1:16:treatment,21:23:chronic_disease,29:54:treatment,58:72:treatment",Acute treatment for HF with intravenous loop diuretic or hemofiltration
6705,NCT02143726,"17:26:treatment,33:69:treatment,81:113:treatment,117:150:treatment,159:168:treatment,172:186:cancer",No prior use of sorafenib or an mammalian target of rapamycin (mTOR) (including phosphoinositide 3-kinase [PI3k] or protein kinase B [AKT]) inhibitor for the treatment of thyroid cancer
6706,NCT02143050,"10:22:treatment,27:42:chronic_disease,,88:97:treatment",Received radiotherapy for non CNS disease within the 2 weeks prior to commencing study treatment
6707,NCT02140554,"26:66:chronic_disease,68:73:chronic_disease,78:83:chronic_disease,86:109:chronic_disease,114:131:chronic_disease","Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV)"
6708,NCT02139280,"1:16:treatment,21:52:treatment,45:52:treatment,",Prior Treatment: No previous cytotoxic chemotherapy within 4 weeks prior to initiation of therapy
6709,NCT02138617,"1:25:treatment,27:38:treatment,55:71:chronic_disease,,105:137:treatment,166:190:treatment","Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of FOLFIRI + bevacizumab initiation or anticipation of need for major surgical procedure during the course of the study"
6710,NCT02138617,"16:38:treatment,,72:79:treatment,82:93:treatment","placement of a vascular access device, within 7 days prior to Day 1 of FOLFIRI + bevacizumab initiation"
6711,NCT02135588,"1:17:chronic_disease,32:38:chronic_disease,43:55:chronic_disease","Major hemorrhage, coincidental stroke, or major trauma"
6712,NCT02134392,"15:51:treatment,53:75:treatment,77:102:treatment,104:121:treatment","Recent use of potent immunosuppressive medications (calcineurin inhibitors, exogenous glucocorticoids, biological agents, etc..)"
6713,NCT02133573,"30:41:treatment,65:77:treatment,84:97:treatment,99:108:treatment,110:122:treatment,126:137:treatment","Prescription or ingestion of medications known to interact with progesterone (e.g. Bromocriptine, Rifamycin, Ketoconazole or Cyclosporin)"
6714,NCT02132598,"1:27:chronic_disease,78:89:chronic_disease,93:110:chronic_disease",Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation
6715,NCT02132598,"54:70:chronic_disease,84:93:treatment,97:135:treatment",Patients must have received at least one regimen for systemic disease which may be cytotoxic or oral tyrosine kinase inhibitor therapy
6716,NCT02132598,"1:26:chronic_disease,27:32:chronic_disease,,93:102:treatment",Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
6717,NCT02132598,",67:76:treatment,88:98:cancer,114:132:treatment",The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
6718,NCT02132598,"38:61:treatment,63:86:treatment,91:126:treatment,121:125:treatment,176:193:treatment,","The subject is receiving concomitant treatment with warfarin, warfarin-related agents, or low molecular weight heparin (LMWH) at the time of study entry at therapeutic doses. Low-dose warfarin (? 1 mg/day) or LMWH at prophylactic doses"
6719,NCT02132130,"33:47:chronic_disease,49:62:chronic_disease,64:93:chronic_disease,128:144:treatment,148:165:treatment","Any otological history, such as chronic otitis, cholesteatoma, tympanic membrane perforation, that suggests poor candidacy for cochlear implant or inner ear surgery or suggests potential interference with study auditory or vestibular function tests"
6720,NCT02131805,"55:64:treatment,66:81:treatment,85:99:treatment",Receipt of drug that will affect biologic response to radiation (radiosensitizer or radioprotector)
6721,NCT02131597,"16:31:cancer,169:185:treatment,210:231:treatment",organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed
6722,NCT02131467,"27:50:treatment,,86:102:treatment,104:112:treatment,118:129:treatment,140:155:treatment","Subjects may be on stable anti-dystonia treatment (for at least one month) including anticholinergics, baclofen, and anxiolytics including benzodiazepines"
6723,NCT02131389,"15:38:treatment,51:55:treatment,57:89:treatment",Has undergone partial hip replacement or previous ORIF (open reduction internal fixation of femur or acetabulum)
6724,NCT02129348,"22:29:treatment,76:97:chronic_disease,145:160:chronic_disease","Contraindications to lithium in this study include: resting tremor causing functional impairment, history of falls in the last month, untreated thyroid disease or any abnormal thyroid function test (T3, T4, or TSH)"
6725,NCT02129348,"1:20:chronic_disease,22:39:chronic_disease,41:59:chronic_disease,61:74:chronic_disease,76:96:chronic_disease,98:127:chronic_disease,141:162:chronic_disease","Parkinson's disease, Lewy body disease, multiple sclerosis, CNS infection, Huntington's disease, amyotrophic lateral sclerosis, other major neurological disorder"
6726,NCT02128906,"48:64:chronic_disease,66:87:chronic_disease,89:114:chronic_disease","No uncontrolled intercurrent illness including active infection, uncontrolled diabetes, uncontrolled hypertension"
6727,NCT02128906,"15:19:cancer,21:23:cancer,25:27:cancer,52:69:cancer","patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible"
6728,NCT02124902,",,42:55:cancer,70:87:treatment,115:139:treatment,147:156:treatment",Newly diagnosed clinical stage II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal
6729,NCT02124772,"19:31:cancer,53:88:cancer,108:131:cancer,171:185:cancer,189:205:cancer,209:232:chronic_disease",For subjects with solid tumors that are not primary central nervous system (CNS) tumors or NF-1 associated plexiform neurofibromas subjects with symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
6730,NCT02124772,"33:67:treatment,75:89:treatment,91:101:treatment,113:126:treatment,135:182:treatment","Part B, Part C and Part D only: Previous treatment with dabrafenib or any BRAF inhibitor, trametinib or another MEK inhibitor, or and Extracellular signal-regulated kinase inhibitor"
6731,NCT02124772,"15:28:cancer,54:75:treatment,75:81:treatment,94:111:treatment,114:135:treatment",Subjects with neuroblastoma that is only detected by bone marrow aspirate/biopsy or elevated homovanillic acid / vanillylmandelic acid (HVA/VMA)
6732,NCT02122185,"26:35:cancer,52:59:cancer,61:75:cancer,80:108:cancer","Histologically confirmed carcinoma consistent with ovarian, fallopian tube, or primary peritoneal carcinoma"
6733,NCT02122185,"14:38:cancer,40:54:cancer,56:73:chronic_disease","evidenced by abdominal carcinomatosis, omental caking, pleural effusions"
6734,NCT02122185,"71:95:cancer,113:130:chronic_disease,134:141:chronic_disease","they should have presumed stage III or IV disease, generally based on abdominal carcinomatosis, omental caking, pleural effusions or ascites"
6735,NCT02122172,"14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,142:157:treatment,162:181:treatment","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements"
6736,NCT02121184,"17:33:chronic_disease,39:56:chronic_disease,58:70:chronic_disease,72:84:chronic_disease","Presence of any systemic disease (ex: diabetes mellitus, hypertension, preeclampsia"
6737,NCT02120222,"69:92:chronic_disease,96:111:treatment,129:167:chronic_disease,184:221:chronic_disease,222:254:chronic_disease",Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch block [RBBB]
6738,NCT02115295,"26:60:treatment,65:73:treatment,75:88:treatment,94:105:treatment,107:135:treatment,137:148:treatment,150:160:treatment,162:166:treatment,,,271:284:cancer,316:343:cancer,379:392:cancer","For Frontline cohort: No prior potentially-curative therapy for leukemia. Prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, decitabine, ATRA, or a total dose of cytarabine up to 2g (for emergency use for stabilization) is allowed. Patients with secondary AMLwho have been treated for their antecedent myeloid neoplasm will be enrolled into the separate Secondary AML cohort"
6739,NCT02114229,"73:75:cancer,76:78:cancer,82:85:cancer","For Stratum A participants, histologic confirmation of the diagnosis of AT/RT or MRT may be from the original diagnosis or at the time of recurrence/progression"
6740,NCT02114229,"1:22:chronic_disease,,,,,105:118:chronic_disease,120:139:chronic_disease,161:184:chronic_disease,189:209:treatment,228:236:chronic_disease","Myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities"
6741,NCT02114229,"21:30:treatment,,49:67:treatment,60:67:treatment,129:138:treatment,149:163:cancer",Patients must begin treatment within 42 days of definitive surgery (day of surgery is day 0; definitive surgery includes repeat surgeries to resect residual tumor)
6742,NCT02112617,"20:23:treatment,31:33:treatment,,82:91:treatment,102:120:treatment,125:134:treatment,141:160:treatment,164:173:treatment,175:184:treatment,188:197:treatment",Diagnostic Imaging MRI and/or CT of the area to be treated within 8 weeks of any treatment. Baseline bone marrow biopsy and bone scan (with 99mTc-diphosphonate or MIBG scan (131I-MIBG or 123I-MIBG) from time of original diagnosis is required
6743,NCT02111850,"8:27:chronic_disease,46:70:treatment,73:94:chronic_disease","Active systemic infections, (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnesses"
6744,NCT02111850,",50:72:treatment,110:129:treatment,,228:236:chronic_disease,240:248:chronic_disease","More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)"
6745,NCT02110069,"22:33:treatment,70:83:treatment,104:119:treatment","Patients who require medications that are strong inhibitors/inducers CYP3A4 enzyme activity, including anticonvulsants, (Appendix II) to control concurrent medical conditions"
6746,NCT02109627,",,28:56:treatment,60:87:treatment,94:103:treatment","Ejection fraction >=40% by transthoracic echocardiogram or radionuclide ventriculogram, i.e. MUGA scan"
6747,NCT02109627,",,67:79:treatment,129:139:treatment,,187:198:treatment",Pregnant women are excluded from this study because the effect of ficlatuzumab on the developing fetus remains unknown and that cytarabine is a pregnancy risk category D drug with known teratogenic or abortifacient effects
6748,NCT02108860,"12:22:cancer,,113:123:cancer,127:163:cancer,168:194:cancer,234:252:treatment","History of malignancy within the past five years or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ which has been treated or excised in a curative procedure"
6749,NCT02108860,"10:53:treatment,72:84:treatment,88:103:treatment,116:141:treatment",Positive anti-neutrophil cytoplasmic antibody (ANCA) test specific for proteinase-3 or myeloperoxidase measured by enzyme-linked immunoassay
6750,NCT02107703,",98:121:chronic_disease,123:146:chronic_disease,148:172:chronic_disease","Have a personal history within the last 12 months of any of the following conditions: syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest"
6751,NCT02107703,"14:30:cancer,47:65:treatment,69:76:treatment,80:98:cancer",Have locally advanced disease not amenable to curative treatment by surgery or metastatic disease
6752,NCT02107703,",56:73:treatment,81:99:treatment,104:122:cancer",Participants may not have received more than 1 line of endocrine therapy or any prior chemotherapy for metastatic disease
6753,NCT02106988,"1:16:treatment,7:16:treatment,60:72:treatment","Prior radiation to the site of current primary disease, if re-treatment would lead to violation of known radiation dose tolerance limits for that site"
6754,NCT02106650,"1:30:chronic_disease,43:60:chronic_disease,71:86:chronic_disease,152:161:treatment","active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment"
6755,NCT02106598,"1:24:treatment,26:38:treatment,43:50:treatment","Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region"
6756,NCT02106312,"1:7:treatment,15:18:chronic_disease,34:70:treatment,96:111:cancer,123:145:cancer,233:248:cancer,310:315:treatment,363:384:treatment","Biopsy proven MLS (including the reciprocal chromosomal translocation t(12;16)(q13;p11); A the primary sarcoma in case of non-metastatic disease for management is with curative intent (regimen to be chosen = 18 x 2 GY) B in case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 GY in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes (see paragraph 10 for radiobiological considerations)"
6757,NCT02105766,"1:21:chronic_disease,31:34:chronic_disease,53:64:treatment,",Acute chest syndrome/ 2 prior ACS/ any ACS while on hydroxyurea (at MTD for at least 6 months)
6758,NCT02105766,"1:7:chronic_disease,114:135:chronic_disease,146:173:treatment",Stroke defined as a clinically significant neurologic event that is accompanied by an infarct on cerebral MRI or cerebral arteriopathy requiring chronic transfusion therapy
6759,NCT02101944,"52:80:treatment,85:105:treatment,129:140:treatment,,191:221:treatment","Patients must have been previously treated with an immunomodulatory drug (IMiD) and proteasome inhibitor, must be refractory to carfilzomib defined as progression on or within 2 months of a carfilzomib-containing therapy, and must be progressing"
6760,NCT02101853,"1:18:treatment,11:18:treatment,,61:78:treatment,101:112:chronic_disease,,191:215:treatment,220:244:treatment,246:258:treatment","Cytotoxic therapy: at least 14 days since the completion of cytotoxic therapy with the exception of hydroxyurea, which is permitted up to 24 hours prior to the start of protocol therapy, or maintenance chemotherapy, or intrathecal chemotherapy (methotrexate strongly preferred) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status"
6761,NCT02101853,"15:47:cancer,48:87:cancer,88:143:cancer",Patients with Philadelphia chromosome positive/breakpoint cluster region protein (BCR)-Abelson murine leukemia viral oncogene homolog 1 (ABL1)+ ALL
6762,NCT02101736,"1:17:chronic_disease,39:48:treatment,,89:104:treatment",Active infection requiring systematic treatment within 28 days before the first dose of study treatment
6763,NCT02101736,"1:39:treatment,94:113:chronic_disease,203:217:treatment","Concomitant treatment with medications that prolong the QT interval and have a known risk of Torsades de Pointes is not contraindicated, but should be avoided if possible and will require more frequent EKG monitoring"
6764,NCT02101736,"10:17:treatment,28:36:treatment,42:83:treatment","Low dose aspirin, low-dose warfarin, and prophylactic low molecular weight heparin"
6765,NCT02101034,",,71:81:cancer,85:120:cancer,145:160:treatment,167:198:cancer","A history of other malignancy ? 1 year previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only, carcinoma in situ of the cervix, or synchronous H&N primaries"
6766,NCT02101034,"38:41:chronic_disease,72:94:treatment,124:168:treatment",Phase I and Arm 1 of Phase II: Known HIV-positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with PD 0332991
6767,NCT02101034,"45:59:cancer,111:119:treatment,123:147:treatment,171:177:treatment,,214:224:treatment","individuals who have had previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of PD 0332991"
6768,NCT02100891,"11:29:cancer,82:99:treatment,110:124:treatment","High Risk Neuroblastoma (NB): Must have progressed on or recurred after standard frontline therapy including autologous HCT, or be ineligible for autologous HCT"
6769,NCT02100722,",,206:223:treatment,232:235:treatment,240:244:treatment","Three vessel CAD, defined as ? 50% diameter stenosis by visual estimation in each of the three major epicardial vessels or major side branches, but not involving left main coronary artery, and amenable to revascularization by both PCI and CABG as determined by the Heart Team"
6770,NCT02099058,"24:55:chronic_disease,51:54:chronic_disease,59:70:chronic_disease,85:117:treatment","Subject has history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis"
6771,NCT02099058,"19:35:cancer,129:140:allergy_name,152:157:allergy_name,159:164:allergy_name,166:171:allergy_name,175:180:allergy_name","Subject must have metastatic NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) known to be sensitive to osimertinib, including del19, L858R, G719X or L861Q"
6772,NCT02098876,"13:32:chronic_disease,50:65:chronic_disease,59:65:chronic_disease,90:105:chronic_disease","Evidence of myocardial ischemia (e.g., stable or unstable angina, post-infarct angina or silent ischemia) suitable for PCI"
6773,NCT02098161,",58:88:treatment,,111:121:treatment,130:144:treatment,179:214:treatment,261:271:treatment","Patients who are currently receiving chronic (> 14 days) treatment with corticosteroids at a dose >= 10 mg of prednisone (or its glucocorticoid equivalent) per day, or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug"
6774,NCT02095184,"37:55:treatment,57:74:treatment,79:96:treatment,115:128:cancer","Patients must not have received any prior chemotherapy, radiation therapy, or endocrine therapy for their current breast cancer"
6775,NCT02094794,"57:79:treatment,107:119:treatment,124:141:treatment","Plans during the trial to receive any other (non-trial) investigational agents, or concurrent biological, chemotherapy, or radiation therapy"
6776,NCT02094625,"1:37:chronic_disease,154:173:chronic_disease,195:205:treatment,223:238:treatment,",Moderate or Severe Persistent Asthma as defined by the latest recommendations from the National Heart Lung and Blood Institute definition includes daily asthma exacerbation with need for rescue medication) or an overnight hospitalization for asthma exacerbation within the previous 28 days
6777,NCT02092324,"24:34:cancer,,88:110:cancer,148:171:cancer,197:214:cancer,219:245:cancer","Subjects with invasive malignancy over the previous 2 years except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers"
6778,NCT02091999,"1:17:chronic_disease,21:34:chronic_disease,41:50:chronic_disease",Active infection or corneal ulcer (e.g. keratitis)
6779,NCT02091999,"18:37:chronic_disease,39:44:cancer,49:52:treatment","Dose Escalation, Renal insufficiency, NSCLC and CPI-Treated Expansion Cohorts"
6780,NCT02091999,"15:38:cancer,40:65:cancer,186:205:treatment,251:268:cancer","Subjects with nonmelanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low risk localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any time"
6781,NCT02091999,"26:37:chronic_disease,39:63:chronic_disease,65:72:chronic_disease,74:85:chronic_disease,90:109:chronic_disease","Uncontrolled or evolving retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disorder"
6782,NCT02091141,"33:68:treatment,,123:138:treatment,152:176:treatment",Administration of strong/potent cytochrome P3A4 (CYP3A4) inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib
6783,NCT02091141,"40:59:treatment,,91:106:cancer,117:134:treatment,137:152:treatment,157:166:treatment,,277:285:chronic_disease,287:304:treatment,","Concurrent administration of any other anti-cancer therapy (except male participants with prostate cancer receiving androgen blockade): Bisphosphonates and denosumab are allowed; Most recent anti-cancer therapy ?28 days and have not recovered from the side effects, excluding alopecia; Radiation therapy within ?14 days"
6784,NCT02091141,"18:28:cancer,,118:128:cancer,166:197:cancer,199:226:cancer,228:253:cancer,255:279:cancer,284:306:cancer","History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer"
6785,NCT02091141,"32:59:treatment,41:59:treatment,52:59:treatment,75:81:cancer,98:104:cancer,218:227:treatment,284:293:treatment",Participants who have received standard first-line therapy for metastatic cancer (except for the tumors for which no first-line therapy exists) and in whom a trial of targeted therapy is considered the best available treatment option. Eligible participants should not have available therapies that will convey clinical benefit and/or are not suitable options per the treating physician's judgment
6786,NCT02091141,"1:19:treatment,25:36:treatment,50:64:treatment,66:81:treatment",Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is allowed)
6787,NCT02091141,"33:46:chronic_disease,75:102:treatment,137:148:treatment","Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vemurafenib"
6788,NCT02091141,"1:10:treatment,25:53:treatment,,98:107:treatment","Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study"
6789,NCT02089607,"37:52:allergy_name,54:61:allergy_name,56:59:allergy_name,63:72:allergy_name,74:80:allergy_name,87:93:allergy_name,96:109:allergy_name,111:115:allergy_name,117:125:allergy_name,129:133:allergy_name","Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, PTFE, urethane or gold"
6790,NCT02088554,"15:44:treatment,48:67:treatment,129:165:treatment","Patient has a pre-existing prosthetic valve or annuloplasty device in another position or requires replacement or repair of the mitral, pulmonary or tricuspid valve"
6791,NCT02088554,"30:42:chronic_disease,44:62:chronic_disease,72:90:chronic_disease","Patient presents with active endocarditis, active myocarditis or other systemic infection"
6792,NCT02085941,"1:7:cancer,37:40:treatment,56:59:treatment,60:62:treatment",Tumors that are not clearly seen by MRI but showing on PET/CT will be ablated with PET/CT guidance
6793,NCT02080221,"13:24:treatment,66:70:chronic_disease,74:88:chronic_disease",patients on antibiotics for infection or patients getting over a cold or seasonal virus
6794,NCT02078102,",45:67:treatment,79:89:treatment,91:105:treatment,107:125:treatment,131:145:treatment,151:173:treatment,185:197:treatment,201:213:treatment,250:259:treatment","Patients must be at least 4 weeks from last cytotoxic chemotherapy (including alkylating, anthracyclines, epipodophylatoxins, and platinum drugs), or immunomodulatory drugs (including lenalidomide or pomalidomide, or related derivatives) at time of treatment on this protocol"
6795,NCT02076906,"1:8:treatment,12:22:treatment,61:70:treatment",Implant or prosthesis or scar tissue within the path of the HIFU beam
6796,NCT02076906,"18:31:treatment,33:52:treatment,56:63:treatment",The last dose of immunotherapy (monoclonal antibody or vaccine)
6797,NCT02075671,",33:55:treatment,46:55:treatment,60:67:chronic_disease,69:82:treatment,84:104:treatment,106:118:treatment,120:132:treatment","History of failing at least one conventional treatment for rosacea (metronidazole, sodium sulfacetamide, tetracycline, azelaic acid) or not interested in continuous treatment with these agents"
6798,NCT02074631,"1:23:chronic_disease,34:73:chronic_disease,84:113:chronic_disease,115:133:chronic_disease,135:155:chronic_disease,157:176:chronic_disease,177:200:chronic_disease,223:236:treatment","Non-malignant diseases including idiopathic severe aplastic anemia (SAA) and other bone marrow failure disorders, hemoglobinopathies, adrenoleukodystrophy, immune deficiencies/dysregulation disorders who will be receiving myeloablative or reduced toxicity preparative regimens that meet the following criteria"
6799,NCT02074436,"10:34:chronic_disease,52:66:cancer,68:80:cancer,84:97:cancer,109:147:treatment,",Acute or chronic thrombocytopenia in patients with acute leukemia (myeloblastic or lymphoblastic) receiving induction or re-induction chemotherapy that is expected to induce marrow aplasia for at least 2 weeks
6800,NCT02074436,"1:35:treatment,60:76:chronic_disease,119:123:chronic_disease",Hematopoietic stem cell transplant recipients with chronic thrombocytopenia due to chronic graft-versus-host disease (GVHD) or other causes
6801,NCT02073097,"8:32:chronic_disease,,,,91:99:chronic_disease,174:195:chronic_disease,","Active congestive heart failure (New York heart Association Class III or IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within four months prior to enrollment"
6802,NCT02073097,"16:27:treatment,99:122:treatment,,,,,,,339:348:treatment,,,,,,,699:710:treatment","The effects of Carfilzomib on the developing human fetus are unknown. For this reason and because chemotherapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 2 weeks prior to initiation of treatment, for the duration of study participation and for 3 months after completing treatment. Should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately. Men must agree to refrain from sperm donation for at least 90 days after the last dose of carfilzomib"
6803,NCT02072148,"1:4:chronic_disease,14:19:cancer,51:54:treatment",HPV negative OPSCC as determined by determined by PCR
6804,NCT02072148,"21:33:cancer,91:122:cancer,124:129:cancer,133:168:cancer,170:184:cancer,178:184:cancer,224:231:treatment,","Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix, basal or squamous cell carcinoma of the skin, thyroid cancer, or other cancer curatively treated by surgery and with no current evidence of disease for at least 5 years"
6805,NCT02070549,"5:18:treatment,30:42:treatment,44:56:treatment,44:78:treatment,80:96:treatment,101:114:treatment,,","Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrollment"
6806,NCT02070549,"1:31:cancer,108:118:cancer,162:167:cancer","Hepatocellular carcinoma (HCC) patients are not required to have histologically or cytologically confirmed malignancy, patients are considered eligible based on tumor markers and/or imaging assessment"
6807,NCT02070549,"1:11:treatment,,,,,155:163:chronic_disease,,,,,,,487:496:treatment,,","Trametinib can cause fetal harm when administered to a pregnant woman; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for four months after the last dose of the drug; women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to registration and agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately"
6808,NCT02068612,"39:59:chronic_disease,71:90:chronic_disease,92:103:chronic_disease,108:116:chronic_disease","Are currently under treatment for any psychiatric disorder, including clinical depression, Alzheimer's, or dementia"
6809,NCT02068092,"29:49:treatment,58:67:treatment,85:91:cancer",Must not participate in any other clinical trial for the treatment or prevention of cancer unless they are no longer receiving the intervention and are in the follow-up phase only. Participants must also agree not to join such a trial while participating in this study
6810,NCT02067975,"38:51:chronic_disease,53:77:chronic_disease,81:106:chronic_disease","Has met DSM-IV-TR/DSM-5 Criteria for schizophrenia, schizoaffective disorder or schizophreniform disorder"
6811,NCT02067819,"7:27:chronic_disease,110:119:chronic_disease,121:126:chronic_disease,128:138:chronic_disease,164:168:chronic_disease,170:176:chronic_disease,181:214:chronic_disease","Major psychiatric disorder at screening that would preclude full participation in study procedures including psychosis, mania, depression, untreated combined type ADHD, autism and pervasive developmental disorders"
6812,NCT02064673,"1:18:treatment,30:39:treatment,46:53:treatment",radiation therapy as primary treatment after surgery
6813,NCT02064296,"21:44:chronic_disease,46:62:chronic_disease,67:85:chronic_disease","Presence of a known coagulation abnormality, thrombocytopenia, or bleeding diathesis that may preclude the safe use of acupuncture"
6814,NCT02064296,"8:41:treatment,43:49:treatment,71:79:treatment","Use of over the counter pain medications (NSAIDs, etc.) on the day of MRI scan"
6815,NCT02064036,"10:28:treatment,30:52:treatment,57:78:treatment","Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy"
6816,NCT02064036,"39:51:chronic_disease,53:62:chronic_disease,67:81:chronic_disease","Severe, active co-morbidity including heart issues, infection and liver problems"
6817,NCT02061761,"20:31:treatment,33:36:cancer,38:40:cancer,42:45:cancer","For dose expansion monotherapy: CLL, HL, NHL"
6818,NCT02061293,"21:34:chronic_disease,38:62:chronic_disease,102:125:chronic_disease","A family history of schizophrenia or schizoaffective disorder (first or second degree relatives), or bipolar disorder type 1 (first degree relatives)"
6819,NCT02061293,"79:95:chronic_disease,111:134:chronic_disease,136:159:chronic_disease,161:174:chronic_disease,176:201:chronic_disease,,247:271:chronic_disease,273:279:chronic_disease,281:296:chronic_disease,298:319:chronic_disease,321:343:chronic_disease,345:371:chronic_disease,373:406:chronic_disease,411:435:chronic_disease","Medical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, uncontrolled hypertension (above 165/95 mmHg at screening), history of cerebrovascular accident, asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction)"
6820,NCT02059239,"84:92:cancer,104:122:cancer,136:175:treatment",must have histologically or cytologically confirmed relapsed or primary refractory lymphoma (including Hodgkin's Lymphoma) staged with Positron Emission Tomography (PET) scan to have
6821,NCT02058095,"1:11:treatment,15:27:treatment,19:27:treatment,,76:91:treatment",Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period
6822,NCT02057133,"13:35:treatment,73:105:treatment,,124:156:treatment,158:169:treatment,171:180:treatment,186:204:cancer,234:257:treatment","For Part D (LY2835219 + exemestane): The participant must have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy with exemestane"
6823,NCT02057133,"29:46:treatment,126:148:chronic_disease,168:187:chronic_disease,189:200:chronic_disease,,","For Part G: Have a baseline electrocardiogram (obtained from Day -14 to Day -1) with any of the following abnormal findings: ventricular arrhythmia, evidence of acute myocardial ischemia, heart block (of any degree), or QTc prolongation (defined as QTcB ?450 milliseconds)"
6824,NCT02057133,"21:52:cancer,54:101:cancer,111:135:cancer","Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer for Parts A to E, G, and I"
6825,NCT02056873,"10:53:treatment,65:79:chronic_disease,81:94:chronic_disease,96:102:chronic_disease,104:122:chronic_disease,124:145:chronic_disease,150:168:chronic_disease,230:237:treatment","Abnormal brain magnetic resonance imaging (MRI) scan, including severe atrophy, hydrocephalus, stroke, structural lesions, demyelinating lesions, or infectious lesions that would potentially confound the outcome or safety of the surgery as judged by the study neurosurgeon"
6826,NCT02056873,"24:46:treatment,47:88:treatment,90:93:treatment",Must have been offered habit reversal therapy/cognitive behavioral intervention therapy (HRT) if subject did not have it prior to enrollment
6827,NCT02056873,"23:30:chronic_disease,32:42:chronic_disease,44:60:chronic_disease,71:98:chronic_disease","Untreated or unstable anxiety, depression, bipolar disorder, or other Axis I psychiatric disorder"
6828,NCT02053766,"32:55:treatment,59:80:treatment,116:134:treatment,",Subject is scheduled to have a non-emergent diagnostic or therapeutic procedure for routine medical care requiring general anesthesia estimated to last at least one hour
6829,NCT02050347,"5:13:cancer,102:116:treatment,122:148:treatment",Any leukemia specific marker (such as t(9:22) or t(4:11)) documented in the patient's leukemia cells pre transplant on a post transplant evaluation
6830,NCT02050113,"27:42:allergy_name,44:53:allergy_name,55:68:allergy_name,70:76:allergy_name,92:96:allergy_name,101:108:allergy_name","Allergy or sensitivity to stainless steel, polyester, polypropylene, solder (tin, silver), gold, or nitinol"
6831,NCT02050113,"1:32:treatment,50:61:treatment,76:108:treatment",Previous left-sided thoracotomy (if the proposed open repair would require dissection of the thoracic aorta)
6832,NCT02048852,"54:66:treatment,68:76:treatment,78:92:treatment,97:112:treatment,121:128:treatment,132:141:treatment","not using an acceptable form of birthcontrol such as Depo-provera, Norplant, tubal ligation and barrier methods such as condoms or diaphragm"
6833,NCT02048722,"25:55:chronic_disease,66:82:chronic_disease,105:133:cancer,137:153:cancer","Evidence of significant central nervous system disease including seizure disorder requiring medication, symptomatic metastatic brain or meningeal tumors"
6834,NCT02048722,"15:32:chronic_disease,34:51:chronic_disease,56:69:chronic_disease","Presence of a non-healing wound, non-healing ulcer, or bone fracture"
6835,NCT02048722,"1:25:chronic_disease,37:63:chronic_disease,66:86:chronic_disease,90:108:chronic_disease,","cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent"
6836,NCT02048371,",,19:30:cancer,32:44:cancer,50:63:cancer","Age ? 10 year for Liposarcoma, Osteosarcoma, and Ewing sarcoma"
6837,NCT02048371,"82:93:cancer,95:113:chronic_disease,115:120:cancer,121:139:cancer,180:205:cancer,209:235:cancer","Patients must have histologically or cytologically confirmed advanced/metastatic liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcoma of soft tissue or bone, fusion-positive alveolar rhabdomyosarcoma or embryonal rhabdomyosarcoma/fusion-negative alveolar rhabdomyosarcoma"
6838,NCT02048371,"1:23:treatment,46:67:treatment,99:108:treatment,110:119:treatment,121:130:treatment,132:142:treatment,144:153:treatment,155:166:treatment,168:177:treatment,182:192:treatment","Prior systemic therapy with a small molecule oral kinase inhibitor, including but not limited to: pazopanib, sunitinib, sorafenib, everolimus, sirolimus, vemurafenib, dasatinib and trametinib"
6839,NCT02047474,"16:39:chronic_disease,43:66:treatment,68:76:treatment,81:92:treatment,171:181:cancer","No evidence of extrapancreatic disease by cross sectional imaging, PET scan, or laparoscopy, including nodal involvement beyond the peripancreatic tissues and/or distant metastases"
6840,NCT02047474,"17:33:chronic_disease,42:62:chronic_disease,73:109:chronic_disease","No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease"
6841,NCT02046330,"31:49:chronic_disease,51:67:chronic_disease,69:82:chronic_disease,87:111:chronic_disease","Current or past non-affective psychotic disorder, Bipolar Disorder, Schizophrenia, or Schizoaffective disorder"
6842,NCT02044120,"30:47:cancer,,97:132:cancer,136:160:cancer","Other clinically significant malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer"
6843,NCT02044120,"28:35:treatment,,58:74:treatment,,90:107:treatment,111:124:treatment","Time elapsed from previous therapy must be ? 3 weeks for systemic therapy, ? 2 weeks for radiation therapy or major surgery"
6844,NCT02043548,"1:27:treatment,46:58:treatment,60:72:treatment,74:86:treatment,88:109:treatment,115:125:treatment","Concomitant IS medications permitted include methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, and tacrolimus"
6845,NCT02043548,"36:55:chronic_disease,57:62:chronic_disease,64:70:chronic_disease,72:85:chronic_disease,95:105:chronic_disease,136:148:chronic_disease,153:183:chronic_disease,185:202:chronic_disease,208:221:chronic_disease","Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster"
6846,NCT02043548,"12:20:chronic_disease,131:146:treatment,,203:225:treatment,229:251:treatment,258:270:treatment,272:284:treatment,286:298:treatment,300:310:treatment,312:333:treatment,335:351:treatment,353:357:treatment,359:374:treatment,380:389:treatment","Refractory myositis patients are defined (see Section 3.1.1) as having failed (or considered intolerant to) an adequate course of glucocorticoids or having failed glucocorticoids and at least one other immunosuppressive (IS) or immunomodulatory agent (e.g. methotrexate, azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, cyclophosphamide, IVIg, anti-TNF agents, and rituximab)"
6847,NCT02041936,"19:27:chronic_disease,31:49:chronic_disease,51:57:chronic_disease,61:85:chronic_disease",Have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation)
6848,NCT02040610,"1:30:treatment,40:53:treatment,55:66:treatment,71:83:chronic_disease","Prior prostate cancer therapy such as: prostatectomy, cryotherapy, or hyperthermia"
6849,NCT02037048,"34:43:chronic_disease,49:60:chronic_disease,64:81:chronic_disease,170:184:chronic_disease,224:245:treatment","Patients with a known history of infection with hepatitis B or hepatitis C virus (active, previously treated, or both) will not be eligible due to the increased risk of hepatotoxicity and viral reactivation associated with systemic chemotherapy"
6850,NCT02037048,"24:66:treatment,73:129:treatment,130:159:treatment,177:187:treatment,188:194:treatment",staging should include upper endoscopy with endoscopic ultrasound and a fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scan (with diagnostic CT abdomen/pelvis preferred)
6851,NCT02035085,"1:11:treatment,16:33:treatment,38:54:cancer",Lumpectomy and radiation therapy for breast carcinoma
6852,NCT02033616,"18:33:chronic_disease,50:72:chronic_disease,87:111:treatment",Known underlying cardiac disease associated with myocardial dysfunction that requires active medical treatment
6853,NCT02031250,"1:4:chronic_disease,9:29:chronic_disease,69:104:cancer",HPV(?) (Human Papillomavirus) or p16(-) locally/regionally advanced (T3?4 or N2?3) oropharyngeal cancer
6854,NCT02030990,"13:24:chronic_disease,26:46:chronic_disease,60:77:treatment","Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye"
6855,NCT02025465,"1:14:chronic_disease,32:45:chronic_disease,,,,,143:197:chronic_disease,201:222:chronic_disease",Heart failure and a history of heart failure with an ejection fraction of 40-50% may occur with a normal ejection fraction now referred to as Heart Failure With Preserved Ejection Fraction (HFpEF) or diastolic dysfunction
6856,NCT02021279,"86:104:chronic_disease,106:124:chronic_disease,129:135:chronic_disease","Subject has a known neurologic or medical condition affecting bladder function (e.g. multiple sclerosis, spinal cord injury, or stroke with residual neurologic deficit)"
6857,NCT02021279,"50:59:treatment,61:74:treatment,79:91:treatment","Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area"
6858,NCT02020707,"1:25:chronic_disease,51:70:treatment,92:115:chronic_disease",Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
6859,NCT02020707,"12:48:chronic_disease,56:75:cancer,77:99:chronic_disease","History of central nervous system (CNS) disease (e.g., primary brain tumor, vascular abnormalities, etc.)"
6860,NCT02020707,"27:42:cancer,51:74:cancer,76:90:cancer,102:125:cancer","allowable histologies for cervical cancer include squamous cell carcinoma, adenocarcinoma, and mixed/adenosquamous carcinoma"
6861,NCT02020707,"85:97:treatment,116:127:treatment,131:140:treatment,169:175:cancer,,,,","platinum-resistant, defined as =< 183 days from the date of the most recent dose of chemotherapy containing either carboplatin or cisplatin until the first evidence of cancer recurrence or progression either symptoms directly attributable to cancer, radiographic recurrence of cancer, or cancer antigen 125 (CA-125) > 70, confirmed >= 7 days later (confirmation of elevated CA-125 may be beyond 183 days and still count as platinum-resistant)"
6862,NCT02019641,"16:41:chronic_disease,53:88:chronic_disease,90:134:chronic_disease,136:147:chronic_disease,166:187:chronic_disease","A diagnosis of interstitial lung disease, including idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonitis (NSIP), sarcoidosis, or other form of chronic lung fibrosis based on clinical context via clinic note from a pulmonologist"
6863,NCT02016924,"8:17:treatment,26:36:treatment,58:67:treatment,",either ritonavir-boosted atazanavir or ritonavir-boosted darunavir once or twice daily as per product label for a minimum of 3 months prior to the screening visit
6864,NCT02016781,"1:20:treatment,17:20:cancer,89:101:treatment,109:118:treatment,123:133:cancer",Therapy-related MDS (defined as the occurrence of MDS due to prior exposure to systemic chemotherapy and/or radiation for malignancy)
6865,NCT02016235,"55:95:chronic_disease,97:112:chronic_disease,,,146:162:chronic_disease,181:199:treatment,201:216:treatment,221:230:treatment,","Exclusion criteria for calcium stone formers include: primary or secondary hyperparathyroidism, hyperthyroidism, estimated GFR <40 ml/mn/1.73m2, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study"
6866,NCT02013778,"24:48:cancer,134:137:cancer,141:147:treatment,,300:303:treatment,307:309:treatment,,400:409:chronic_disease,417:436:chronic_disease,,",Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL
6867,NCT02013492,"43:68:cancer,70:83:cancer,89:107:cancer,118:130:cancer","preference will be given to patients with metastatic ovarian cancer, breast cancer, and malignant melanoma, as these malignancies have been shown to be sensitive to manipulation of the beta-adrenergic receptor"
6868,NCT02013154,"50:62:cancer,,132:142:cancer,144:167:cancer,184:201:cancer","Disease-free of active second/secondary or prior malignancies for equal to or over 2 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast"
6869,NCT02013154,"57:78:cancer,82:108:cancer,109:122:cancer,126:140:cancer,144:166:cancer",Participants with histologically confirmed recurrent or metastatic esophageal or gastro-esophageal junction squamous cell or adenocarcinoma or gastric adenocarcinoma with Wnt Signaling Alterations
6870,NCT02013154,"1:10:treatment,16:31:treatment,,84:108:treatment,",Treatment with corticosteroids (? 10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to study entry
6871,NCT02012296,"5:18:treatment,61:121:treatment,128:147:treatment,149:158:treatment,163:201:treatment,208:220:treatment,224:230:treatment","Any prior therapy for castrate disease is acceptable except prior specific cytochrome P450 family 17 (CYP17) antagonists (e.g. abiraterone acetate, orteronel) or prior second generation AR antagonists (e.g. enzalutamide or ARN509) which are excluded other than enzalutamide as specified for phase II portion"
6872,NCT02011971,"1:22:chronic_disease,30:38:chronic_disease,40:53:chronic_disease,62:68:cancer,70:80:chronic_disease","Major medical disease (e.g., diabetes, heart disease, active cancer, depression)"
6873,NCT02008656,"4:21:chronic_disease,32:61:treatment,63:79:treatment",No active infections requiring systemic antibiotic treatment (oral antibiotics are acceptable at the discretion of the treating physician)
6874,NCT02008656,"31:41:cancer,45:70:cancer,82:97:cancer",except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
6875,NCT02007239,"1:26:chronic_disease,,83:96:treatment,,250:269:chronic_disease","Respiratory insufficiency requiring oxygen supplementation of at least 2 Liter by nasal cannula for at least 12 hours (also including invasive, noninvasive, continuous positive airway pressure or biphasic airway pressure for the purpose of treating respiratory failure)"
6876,NCT02004275,",17:33:treatment,26:33:treatment,38:54:cancer,47:54:cancer,134:146:treatment,150:169:treatment,202:220:treatment,263:275:treatment,277:287:treatment,292:323:treatment,349:385:treatment,395:427:treatment,458:471:treatment","1 prior line of systemic therapy for multiple myeloma, where a line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy, as well as a planned series of treatment regimens administered in a sequential manner (e.g. lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy)"
6877,NCT02004275,"1:9:treatment,15:34:treatment,39:45:treatment",Ixazomib is a substrate of CYP3A4 and CYP1A2
6878,NCT02004275,"23:48:treatment,52:58:treatment,83:89:treatment",No strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2
6879,NCT02004275,"56:68:treatment,69:82:treatment,87:97:treatment,101:112:treatment",initial response followed by progression on continuous lenalidomide-dexamethasone +/- elotuzumab or daratumumab
6880,NCT02004028,"24:34:cancer,106:130:treatment,134:165:treatment",Localized disease. The malignancy is confined to one affected hemithorax. Mediastinal N2 lymph nodes via cervical mediastinoscopy or EBUS (endobronchial ultrasound) must be negative in order to be eligible
6881,NCT02004028,"57:81:chronic_disease,83:101:chronic_disease,106:143:chronic_disease","Uncontrolled intercurrent illness including symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations which in the opinion of the study investigators would be associated with undue risk of participation in the study"
6882,NCT02003222,"47:66:treatment,68:80:treatment,103:122:treatment,123:136:treatment,167:188:treatment","It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine"
6883,NCT02003222,"31:50:treatment,89:99:treatment,101:110:treatment,118:126:treatment","Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine"
6884,NCT02002260,"12:20:treatment,24:36:treatment,70:74:treatment,78:85:treatment",History of ablation or hysterectomy or have any contraindications to COCs or LNG-IUS
6885,NCT02000115,"1:17:chronic_disease,30:40:cancer,,,63:69:chronic_disease,,,86:102:chronic_disease,,","Blood dyscrasias as defined: leukopenia (WBC<3000 mm3), acute anemia (Hb < 9 mg/dL), thrombocytopenia (platelet count <50,000 cells/mm³)"
6886,NCT02000115,"14:36:treatment,77:92:treatment,117:151:treatment,223:243:chronic_disease,255:270:chronic_disease","Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic ring, severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the LVOT, severe (greater than 3+) mitral insufficiency, or severe mitral stenosis with pulmonary compromise"
6887,NCT01999179,"17:34:chronic_disease,88:98:treatment,100:102:treatment,106:116:treatment","Upper extremity venous thrombosis associated with an indwelling catheter documented by ultrasound, CT or venography"
6888,NCT01996865,"27:49:chronic_disease,55:78:chronic_disease,80:103:chronic_disease,105:139:chronic_disease","Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)"
6889,NCT01994538,"7:28:treatment,67:70:chronic_disease,88:98:chronic_disease,100:109:chronic_disease","Other antimicrobial therapy (new or ongoing) prescribed for a non-UTI diagnosis (e.g., cellulitis, pneumonia, etc.)"
6890,NCT01994382,"24:42:cancer,38:42:cancer,39:42:cancer,95:98:cancer,99:101:cancer,103:106:cancer,109:113:cancer,126:131:cancer,133:144:cancer,146:149:cancer,194:197:cancer,198:201:cancer,203:207:cancer,212:216:cancer,223:225:cancer,226:228:cancer","Histological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or refractory"
6891,NCT01994382,"13:23:chronic_disease,34:61:treatment,63:84:chronic_disease,88:110:chronic_disease","Significant GI disease, previous major gastric/bowel surgery, difficulty swallowing or malabsorption syndrome"
6892,NCT01993810,"1:38:chronic_disease,61:80:chronic_disease,106:117:cancer,158:171:treatment,",Chronic obstructive pulmonary disease exacerbation or other respiratory illness other than the diagnosed lung cancer requiring hospitalization or precluding study therapy within 30 days before registration
6893,NCT01993810,"39:61:cancer,65:70:cancer,89:98:treatment",Patients with prior history of either small cell lung cancer or NSCLC regardless of the treatment received
6894,NCT01993719,",50:72:treatment,110:129:treatment,,227:235:chronic_disease,239:247:chronic_disease,295:310:treatment","More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). Patients must have progressive disease after prior treatment"
6895,NCT01992861,"32:62:treatment,38:54:treatment,82:87:cancer",Patients who have received any prior pelvic radiation therapy in the area of the tumor that precludes the delivery of a curative dose of pelvic radiation
6896,NCT01990209,"1:22:cancer,30:44:treatment,48:58:cancer",Archived tumor tissue from a primary biopsy or metastatic lesion for centralized determination of AR expression is mandatory
6897,NCT01990209,"36:55:treatment,87:96:treatment,100:103:treatment",LHRH agonists maybe used to render ovarian suppression with post-menopausal ranges of estradiol or FSH per institutional guidelines
6898,NCT01990209,"20:49:chronic_disease,166:178:treatment,184:202:chronic_disease,,,259:281:chronic_disease","Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea ? Grade 2, and malabsorption syndrome)"
6899,NCT01989585,"28:43:treatment,89:119:chronic_disease,154:176:chronic_disease,180:195:treatment",Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
6900,NCT01989585,"1:15:treatment,19:38:treatment,66:73:treatment","Anticoagulants or antiplatelet agents except for low-dose, 81 mg aspirin"
6901,NCT01989585,"12:21:treatment,12:42:treatment,27:42:treatment,127:134:treatment,136:148:treatment,238:263:treatment","Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis"
6902,NCT01989585,"12:36:chronic_disease,48:69:chronic_disease,74:89:chronic_disease,92:112:treatment,117:125:treatment,,151:164:treatment","History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization"
6903,NCT01989585,"18:41:chronic_disease,37:40:chronic_disease,46:69:chronic_disease,65:68:chronic_disease","Known history of hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); it is not necessary to conduct HBV and HCV testing at screening"
6904,NCT01989585,"38:60:treatment,85:106:treatment,,,245:254:treatment","Patients who are receiving any other investigational agents have received any other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study treatment and during the study"
6905,NCT01989585,"1:17:treatment,19:33:treatment,39:52:treatment","Prior navitoclax, BRAF inhibitor, and MEK inhibitor is prohibited; (exceptions for Phase I are described above)"
6906,NCT01989585,"14:34:chronic_disease,77:101:chronic_disease,115:139:chronic_disease,141:165:chronic_disease,167:185:chronic_disease,187:208:chronic_disease,213:232:chronic_disease,233:250:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirements"
6907,NCT01989507,"105:119:treatment,121:129:treatment,131:143:treatment,148:155:treatment","medication contraindications for smoking cessation (smoking cessation may change the bioavailability of antipsychotics, warfarin, theophylline and insulin)"
6908,NCT01988246,"43:49:allergy_name,53:61:allergy_name,92:102:treatment",Patients with a known hypersensitivity to NSAIDs or steroids or any component of the study medication
6909,NCT01988246,"8:19:treatment,58:90:treatment,95:109:treatment,117:140:treatment,142:169:treatment,187:193:treatment,","Use of medications known to affect the macula, including hydroxychloroquinine (Plaquenil) and phenothiozines (e.g., thioridazine [Mellaril], chloropromazine [Thorazine]) or supplemental niacin ?3 grams/day"
6910,NCT01986205,"8:18:cancer,48:68:cancer,,104:140:treatment,142:187:treatment,220:236:treatment","Active malignancy, previous malignancy (except basal cell carcinoma) in the last 5 years, or any prior treatment with bleomycin (Blenoxane). Prior treatment with doxorubicin (Adriamycin) is acceptable as long follow-up echocardiography is normal"
6911,NCT01986205,"1:13:chronic_disease,23:32:chronic_disease,34:52:chronic_disease,54:60:chronic_disease,93:113:chronic_disease,139:159:chronic_disease","Lung disease, such as emphysema, chronic bronchitis, asthma that is not well-controlled, or bullous lung disease that raises the risk for pulmonary barotrauma due to air trapping"
6912,NCT01986075,"19:22:chronic_disease,,105:132:chronic_disease,302:317:treatment,321:334:treatment","Participants with MDD, with symptom severity that exceeds a HAM-D score of 20, and/or any other current Axis I psychiatric disorder as defined by DSM-V supported by the MINI that in the investigator's judgment are unstable, would be disrupted by study medication, or are likely to require specialized pharmacotherapy or psychotherapy during the study period"
6913,NCT01985087,"36:49:treatment,54:77:cancer,88:97:treatment,101:113:treatment",Participants must not have had any prior therapy for glioblastoma multiforme including radiation or chemotherapy
6914,NCT01983462,"12:34:chronic_disease,43:60:treatment,61:84:treatment,86:107:chronic_disease,109:115:chronic_disease,117:130:chronic_disease,,,188:202:chronic_disease,204:226:chronic_disease,244:265:treatment,267:293:chronic_disease","History of cardiovascular disease such as heart angioplasty/stent or bypass surgery, myocardial infarction, stroke, heart failure with or without left ventricular ejection fraction <40%, cardiomyopathy, valvular heart disease, cardiomyopathy, heart transplantation, Type 2 and Type 1 diabetes"
6915,NCT01983462,"12:32:chronic_disease,34:49:chronic_disease,51:79:chronic_disease,85:109:chronic_disease","History of rheumatoid arthritis, Grave's disease, systemic lupus erythematosis, and Wegener's granulomatosis"
6916,NCT01983462,"4:21:treatment,29:36:treatment,38:46:treatment,49:56:treatment,58:69:treatment,72:79:treatment,81:101:treatment,115:143:treatment,","On weight loss drugs (e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications) within 3 months of screening"
6917,NCT01983462,"8:24:treatment,26:34:treatment,36:41:treatment,51:62:treatment,64:72:treatment,74:81:treatment,83:92:treatment","Taking cox-2 inhibitors (Celebrex, Vioxx, etc) or allopurinol (Zyloprim, Lopurin, Allopurin)"
6918,NCT01983462,"8:27:treatment,36:49:treatment,51:58:treatment,60:69:treatment,80:89:treatment,92:100:treatment","Taking thyroid medications such as levothyroxine (Levoxyl, Synthroid, Levoxyl, Unithroid); Levodopa"
6919,NCT01980823,"10:22:treatment,24:41:treatment,46:62:treatment,","No prior chemotherapy, radiation therapy, or breast resection within 6 months of study entry"
6920,NCT01976585,"13:35:chronic_disease,,55:79:chronic_disease,81:102:chronic_disease,,127:142:chronic_disease,144:164:treatment,189:208:chronic_disease,212:243:chronic_disease",Significant cardiovascular disease (i.e. NYHA class 3 congestive heart failure; myocardial infarction with the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias)
6921,NCT01976169,"13:37:chronic_disease,39:63:chronic_disease,65:96:chronic_disease,","Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months"
6922,NCT01974609,"41:52:allergy_name,54:67:allergy_name,72:81:allergy_name","reported allergy or adverse reaction to hydrocodone, acetaminophen, or ibuprofen"
6923,NCT01973283,"86:100:treatment,122:131:treatment,178:196:treatment,202:205:treatment","Subject is considered based on history to be unlikely to respond to the single agent antidepressant (i.e., subjects with treatment resistant depression, including subjects with previous treatment with ECT)"
6924,NCT01972919,"1:27:cancer,29:46:cancer,50:68:chronic_disease","Distant metastatic disease, second malignancy or peritoneal seeding"
6925,NCT01970176,"1:13:chronic_disease,17:48:chronic_disease,50:57:chronic_disease,59:66:chronic_disease","Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)"
6926,NCT01969643,"1:24:cancer,,71:95:treatment,330:346:treatment","Triple-negative disease (ER/PR/HER2-negative) and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting; or ER-positive and/or PR-positive/HER2-negative disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting and are no longer a candidate for hormonal therapy (not enrolling new patients)"
6927,NCT01968109,"36:44:cancer,46:53:cancer,55:62:cancer,67:90:cancer,92:105:cancer,107:114:cancer,119:140:cancer,150:172:treatment,174:191:cancer,183:191:cancer,214:219:cancer,221:241:cancer,251:253:treatment,285:323:treatment,369:439:treatment","For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4"
6928,NCT01967823,"113:123:cancer,158:175:treatment,184:190:treatment,207:216:treatment","Confirmation of ESO expression and pathology is not required in patients with definitive radiologic evidence of meningioma who are unresectable, and in whom radiation therapy without biopsy is the standard treatment"
6929,NCT01967823,"51:67:treatment,82:111:treatment,117:135:cancer","Patients must have previously received first-line standard therapy (or effective salvage chemotherapy regimens) for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease) or have recurred"
6930,NCT01967238,"13:28:chronic_disease,30:42:treatment,46:67:treatment","(either the influenza virus, pneumococcal or meningococcal vaccine)"
6931,NCT01967238,"36:42:chronic_disease,44:48:chronic_disease,52:69:chronic_disease,103:124:chronic_disease","Documented previous infection with dengue, zika or chikungunya virus or no history of dengue, zika or chikungunya infection"
6932,NCT01964859,"130:151:chronic_disease,153:170:cancer,172:191:chronic_disease,200:203:chronic_disease,205:214:chronic_disease,216:227:chronic_disease,229:240:chronic_disease","Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I/II, Hepatitis B, Hepatitis C)"
6933,NCT01964261,"11:32:treatment,34:43:treatment,45:67:treatment,72:94:treatment","Implanted Cardiac Defibrillator, Pacemaker, vagal nerve stimulator, or spinal cord stimulator"
6934,NCT01959698,"8:44:chronic_disease,68:86:chronic_disease,100:120:chronic_disease,154:159:cancer",Active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma; a lumbar puncture demonstrating DLBCL at the time of registration to this study is not exclusion for study enrollment
6935,NCT01959698,",,142:171:treatment,179:197:treatment,206:219:treatment","Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam"
6936,NCT01959698,"65:78:treatment,80:97:treatment,99:111:treatment,116:129:treatment","Patients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretion"
6937,NCT01959425,"1:14:chronic_disease,25:43:chronic_disease,47:53:chronic_disease",Acute illness or active systemic infection or sepsis
6938,NCT01959425,"1:4:treatment,51:67:treatment,69:80:chronic_disease,91:109:chronic_disease,123:154:chronic_disease,","OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up)"
6939,NCT01959204,"11:20:treatment,24:35:treatment,,87:97:treatment",Has taken oxycodone or oxymorphone within the 48 hours before anticipated dosing with study drug
6940,NCT01959204,"10:20:treatment,60:66:treatment,,110:133:treatment,134:146:treatment,151:163:treatment,165:186:treatment,195:207:treatment,213:232:treatment,241:250:treatment,285:293:treatment,295:308:treatment,314:323:treatment","Uses any medication known to be an inhibitor or inducer of CYP3A4 within 14 days (for inhibitors such as the azole-antifungal agents voriconazole and ketoconazole, macrolide antibiotics such as erythromycin, and protease inhibitors such as ritonavir) or 28 days (for inducers such as rifampin, carbamazepine, and phenytoin) of dosing with study drug"
6941,NCT01954966,"16:39:treatment,41:56:treatment,58:72:treatment,77:88:treatment,124:135:chronic_disease,150:159:treatment,164:180:chronic_disease,191:207:chronic_disease,209:235:chronic_disease,237:265:chronic_disease,267:297:chronic_disease,302:316:chronic_disease","Regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent (within previous year) psychiatric diagnosis and treatment for Axis I disorders including major depression, bipolar affective disorder, generalized anxiety disorder, post-traumatic stress disorder and panic disorder"
6942,NCT01954576,"31:53:treatment,75:85:treatment,99:102:cancer",Currently receiving any other investigational agents that are intended as treatments of recurrent GBM
6943,NCT01954576,"9:15:treatment,19:28:treatment,42:47:cancer,175:192:treatment","Planned biopsy or resection of recurrent tumor for therapeutic and/or diagnostic purpose, and with adequate bone marrow, hepatic, cardiac, and renal function to undergo this planned procedure"
6944,NCT01954576,"50:53:cancer,70:91:treatment,182:188:treatment,192:201:treatment",Unequivocal evidence of recurrent or progressive GBM before or after bevacizumab treatment first based on radiographic appearances then confirmed by histologic confirmation through biopsy or resection
6945,NCT01954173,"30:40:treatment,42:58:treatment,60:78:treatment,83:111:treatment","Patients must have undergone cystectomy (total cystectomy, radical cystectomy +/- pelvic lymph node dissection) with no evidence of macroscopic residual disease"
6946,NCT01953588,"1:6:cancer,,,,58:62:cancer,75:78:treatment,,",Tumor estrogen receptor (ER) Allred score between 0-5 or HER2 positive by IHC (3+) or amplified by FISH > 2.0
6947,NCT01953263,"78:81:chronic_disease,83:91:chronic_disease,96:117:chronic_disease,129:145:chronic_disease","Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study"
6948,NCT01952730,",37:49:treatment,51:63:treatment,65:78:treatment,89:111:treatment","At least 4 weeks since last dose of chemotherapy, radiotherapy, immunotherapy, systemic glucocorticoid therapy or operation in order to receive vaccine"
6949,NCT01950351,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
6950,NCT01950234,"1:5:chronic_disease,7:11:chronic_disease,16:20:chronic_disease","SPMS, PPMS, or PRMS phenotype, according to Lublin and Reingold criteria"
6951,NCT01950234,"1:10:treatment,16:29:treatment,44:66:treatment,96:105:treatment,",Treatment with dalfampridine or compounded 4-aminopyridine (4-AP) will be permitted as long as treatment has been ongoing and stable for at least 3 months prior to randomization
6952,NCT01947140,"8:19:chronic_disease,21:32:chronic_disease,37:48:chronic_disease","Active Hepatitis A, Hepatitis B, or Hepatitis C infection"
6953,NCT01946074,"17:36:treatment,111:121:treatment,125:132:treatment","Subjects in the combination therapy cohorts must meet the above inclusion criteria and be eligible to receive paclitaxel or FOLFIRI per most current prescribing information, or at the discretion of the Investigator"
6954,NCT01945814,"1:39:treatment,44:47:chronic_disease,49:52:chronic_disease,57:67:chronic_disease","Treatment of reactivation or infection for EBV, CMV, or Adenovirus"
6955,NCT01943851,"21:35:treatment,37:49:treatment,51:68:treatment,70:85:treatment,87:103:treatment,105:121:treatment,123:130:treatment,139:158:treatment","Currently receiving cancer therapy (chemotherapy, radiation therapy, immuno- therapy, biologic therapy, hormonal therapy, surgery, and/or tumour embolization)"
6956,NCT01943851,"1:12:treatment,17:38:cancer,40:55:treatment","Hydroxyurea for proliferative disease, Corticosteroids, Use of hematopoetic growth factors is permitted at the discretion of the investigator according to published guidelines (e.g., National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), etc.)"
6957,NCT01943851,"34:54:treatment,56:66:treatment,74:84:treatment",Subjects with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed
6958,NCT01941316,"86:96:treatment,132:147:allergy_name,152:172:allergy_name,174:189:allergy_name,238:247:chronic_disease,251:269:chronic_disease","Must have no contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment"
6959,NCT01941316,"40:62:treatment,117:122:cancer,163:181:cancer","Patients who received primary curative chemoradiation therapy for limited disease, but who recur within the primary tumor site, previously radiated field or with distant metastases"
6960,NCT01940094,"39:51:treatment,53:64:treatment,66:82:treatment,84:96:treatment,98:119:treatment,121:141:treatment,146:155:treatment,176:215:treatment,207:214:treatment,261:272:treatment","Acceptable maintenance agents include azathioprine, leflunomide, 6-mercaptopurine, methotrexate, mycophenolate mofetil, mycophenolate sodium, or rituximab. Patients may be on trimethoprim/sulfamethoxazole (TMP/SMX) for use as either a maintenance agent or for prophylaxis for infection. TMP/SMX may be used in combination with other drugs"
6961,NCT01931202,"23:42:chronic_disease,44:61:chronic_disease,66:85:chronic_disease","Diagnosis of probable Alzheimer's Disease, Vascular Dementia, or Parkinson's Disease"
6962,NCT01928589,"28:52:treatment,56:84:treatment,101:107:cancer",Patients who have received neoadjuvant chemotherapy or neoadjuvant hormonal therapy for the current cancer
6963,NCT01928576,"1:8:treatment,12:28:treatment,41:60:treatment,,81:91:treatment,143:161:chronic_disease","Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease"
6964,NCT01928576,",57:69:treatment,,102:111:treatment,116:137:cancer","Patients must have received at least one platinum based chemotherapy, and not more than three, prior therapies for stage IIIB/IV disease"
6965,NCT01928576,",,53:63:treatment,65:76:treatment,82:91:treatment,126:137:treatment,141:154:treatment","Pregnant women are excluded from this study because entinostat, azacitidine, and Nivolumab are agents with the potential for teratogenic or abortifacient effects"
6966,NCT01928576,"15:23:chronic_disease,25:49:chronic_disease,60:74:chronic_disease,85:104:treatment","Subjects with vitiligo, type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger are permitted to enroll"
6967,NCT01925573,"57:75:chronic_disease,82:114:chronic_disease,116:137:chronic_disease,,","Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol 12 Pregnant or breast-feeding women. 13 Patients unwilling or unable to comply with the protocol"
6968,NCT01925573,"40:52:cancer,62:87:cancer,108:119:cancer,121:144:cancer","Patients with recurrent or progressive glioblastoma or other grade IV malignant glioma (i.e. glioblastoma, gliosarcoma, giant cell glioblastoma, etc.)"
6969,NCT01925378,"28:39:chronic_disease,44:60:chronic_disease,76:93:chronic_disease","Patients with a chronic or acute renal, or hepatic disorder, a significant bleeding disorder, or any other condition which in the Investigator's opinion might preclude study participation for the duration of the trial"
6970,NCT01925131,"4:14:treatment,18:27:treatment,61:64:chronic_disease",No zidovudine or stavudine as part of cART Patients who are HIV+ and do not meet all of these criteria are not eligible for this study
6971,NCT01925131,"26:44:chronic_disease,46:52:chronic_disease,57:72:chronic_disease,63:72:chronic_disease,211:222:treatment,232:241:treatment","Patients must not have a systemic bacterial, fungal, or viral infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)"
6972,NCT01925131,"3:29:treatment,59:68:treatment,83:94:treatment,99:109:treatment,113:126:treatment,128:138:treatment,139:152:treatment,157:177:treatment","a standard induction regimen is defined as any program of treatment that includes vincristine and prednisone or dexamethasone, cytarabine/anthracycline, or high dose cytarabine"
6973,NCT01923662,"1:10:chronic_disease,26:47:chronic_disease,60:68:chronic_disease,69:98:chronic_disease",Paralysis resulting from neurological disorder such as low cervical/thoracic spinal cord injuries (C6-T12
6974,NCT01920737,"15:54:cancer,81:91:treatment,96:114:treatment",Patients with T-cell or B cell lymphoblastic lymphoma confirmed by conventional immature T- or pre B cell markers even if the bone marrow is not involved are also eligible
6975,NCT01920061,"15:19:cancer,,,41:60:treatment,68:78:cancer",Patients with TNBC and one or two prior cytotoxic therapies in the metastatic setting
6976,NCT01920061,"1:35:cancer,37:59:cancer,64:91:cancer,116:160:treatment","castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination"
6977,NCT01918683,"45:49:treatment,64:70:cancer,75:99:treatment",Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
6978,NCT01918644,"64:66:allergy_name,68:71:allergy_name,121:147:treatment,199:225:treatment",History of prior allergic reactions attributed to compounds of CT/ MRI contrast that cannot be managed with appropriate pre-medication prophylaxis and thereby preclude use of baseline/ follow-up or radiation planning imaging
6979,NCT01915095,"20:36:chronic_disease,40:49:chronic_disease,51:75:chronic_disease","Premorbid, ongoing major depression or psychosis, altered cognitive status"
6980,NCT01912651,",39:46:treatment,48:67:treatment,93:104:treatment,109:119:treatment,147:167:cancer,208:232:treatment","current or recent (within one week of surgery) systemic antibiotic use, intolerance to both clindamycin and cephalexin, discovery of a persistent cutaneous malignancy at the site of the defect following the reconstructive procedure and previous reconstruction at the site of the skin/soft-tissue defect"
6981,NCT01912612,"26:65:treatment,70:95:treatment,105:114:treatment",Willing to withdraw from selective serotonin reuptake inhibitors and tricyclic antidepressants prior to treatment initiation
6982,NCT01910818,"41:62:chronic_disease,,,192:202:treatment,204:213:treatment,236:256:chronic_disease","Significant concurrent illness, such as uncontrolled diabetes (with a hemoglobin A1C of more than 8) (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process); Mentally incompetent, prisoner or evidence of active substance or alcohol abuse"
6983,NCT01908777,"1:31:chronic_disease,,,,,,154:163:treatment,,175:189:treatment,197:200:treatment",Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix 2) and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI
6984,NCT01906385,"1:22:chronic_disease,24:30:chronic_disease,32:57:chronic_disease,","Myocardial infarction, stroke, transient ischemic attack within 6 months"
6985,NCT01905709,",,,,86:96:treatment,128:138:treatment,146:155:treatment,157:169:treatment,171:182:treatment","At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g., rifaximin, nitazoxanide, fidaxomicin)"
6986,NCT01905046,",18:29:treatment,33:50:treatment,62:77:cancer",Women who have a core biopsy or excisional biopsy containing invasive cancer
6987,NCT01904136,"1:29:cancer,25:28:cancer,,123:140:treatment,133:140:treatment,187:217:cancer,237:251:cancer,,,,,,589:610:cancer,825:847:treatment","acute myeloid leukemia (AML): a. first complete remission with high-risk features defined as: (i) greater than 1 cycle of induction therapy required to achieve remission; (ii) preceding myelodysplastic syndrome (MDS); (iii) presence of FLT3 mutations or internal tandem duplication or other mutations associated with poor-risk AML (e.g. DNMT3A, TET2); (iv) French-American-British Classification (FAB) M6 or M7 classification; (v) adverse cytogenetics: -5, deletion (del) 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype (> 3 abnormalities); (vi) treatment-related AML, or b. second or greater remission; patients beyond second remission have to be in complete remission (CR) at transplant to be eligible, or c. primary induction failure with partial response to therapy who achieve adequate cytoreduction"
6988,NCT01903330,",86:101:treatment,,131:148:treatment,131:140:treatment,215:244:treatment","MRI record must be obtained showing the MRI was conducted at least 4 weeks after any salvage surgery, and at least 12 weeks after radiation therapy, or at least 4 weeks after radiation for a new lesion outside the prior primary radiation field"
6989,NCT01903330,"18:29:treatment,39:43:treatment,48:77:treatment",Prior receipt of bevacizumab or other VEGF- or VEGF receptor-targeted agents
6990,NCT01902810,"23:67:chronic_disease,69:75:chronic_disease,85:113:chronic_disease","Currently treated for Chronic Obstructive Pulmonary Disease (COPD), asthma or other chronic pulmonary conditions"
6991,NCT01901055,"7:14:chronic_disease,18:37:chronic_disease,41:56:treatment,",Acute medical or surgical conditions or hospitalization ? 3 months
6992,NCT01900093,"14:25:chronic_disease,27:53:chronic_disease,55:76:chronic_disease,78:102:chronic_disease,124:136:chronic_disease","Diagnosis of scleroderma, systemic fungal infections, ocular herpes simplex, congestive heart failure, and/or uncontrolled hypertension, and/or any clinically relevant medical disease that would put the patient at risk by participating in the study"
6993,NCT01898793,"27:36:chronic_disease,,91:98:treatment,131:148:chronic_disease",Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections)
6994,NCT01898793,"102:141:treatment,339:363:cancer,377:389:treatment,391:408:treatment,417:431:treatment","OR High-risk AML (by ELN criteria; See Appendix C) in complete remission (CR) and has either refused hematopoietic stem cell transplantation OR is currently not eligible for hematopoietic stem cell transplantation OR for whom hematopoietic stem cell transplantation is being reserved for later relapse. This is inclusive of patients with minimal residual disease evidenced by cytogenetics, molecular testing, and/or flow cytometry"
6995,NCT01898793,"1:24:treatment,35:48:treatment,52:63:treatment",cytoreductive therapies including leukapheresis or hydroxyurea
6996,NCT01896999,"15:42:chronic_disease,44:86:chronic_disease,91:107:chronic_disease","No history of Steven's Johnson's syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathy"
6997,NCT01896999,"19:41:treatment,45:54:treatment,59:81:treatment",continuous use of topical steroid creams or ointments or ophthalmologic steroids
6998,NCT01896921,"1:15:treatment,25:33:treatment,35:48:treatment,50:63:treatment,68:77:treatment","CYP3A inducers (such as rifampin, carbamazepine, phenobarbital and phenytoin)"
6999,NCT01896921,"29:37:treatment,39:48:treatment,50:73:treatment,75:90:treatment","Inducers of UGT1A1 (such as rifampin, phenytoin, phenobarbital rifabutin, St. John's wort)"
7000,NCT01895777,"43:46:chronic_disease,53:56:chronic_disease,58:60:chronic_disease,62:85:chronic_disease,87:108:chronic_disease","Documented diagnosis of clinically stable VTE (e.g. DVT, PE, central line thrombosis, sinus vein thrombosis) per investigator judgment"
7001,NCT01894061,"20:54:chronic_disease,50:53:chronic_disease,55:64:chronic_disease",Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)
7002,NCT01893554,"14:25:treatment,41:62:treatment,67:80:chronic_disease,,117:128:treatment,165:184:treatment",Has received antibiotics or systemic or nasal steroid therapy for acute illness within the previous 3 days prior to vaccination (steroid skin creams or lotions and topical antibiotics or antifungal preparations are permitted)
7003,NCT01893554,"20:57:chronic_disease,98:101:chronic_disease,118:178:treatment,183:217:treatment,230:246:treatment,248:267:treatment,273:303:treatment","Known or suspected impairment of immunological functions, including maternal history of positive HIV test, receiving immunosuppressive therapy including systemic corticosteroids, or bone marrow/solid organ transplant recipients (topical steroids, topical antibiotics, and topical antifungal medications are acceptable)"
7004,NCT01893554,"23:34:treatment,43:66:treatment,84:107:chronic_disease,109:118:treatment,124:143:treatment,155:171:treatment,173:192:treatment,198:223:treatment","Permitted concomitant medications include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including topical steroids, topical antibiotics, and topical antifungal agents"
7005,NCT01893307,"1:6:cancer,26:45:cancer,61:88:chronic_disease",Tumor tissue (primary or cervical metastasis) available for human papilloma virus (HPV)
7006,NCT01890590,"67:104:cancer,,,171:174:treatment,178:185:treatment",Participants must have histologically or radiological evidence of Stage I (T1N0M0) renal cell carcinoma with a size no larger than 8 cm in greatest dimension measured by MRI or CT Scan
7007,NCT01884740,"49:71:treatment,162:171:treatment,175:189:treatment",Patients with significant concurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring
7008,NCT01884740,"1:11:treatment,42:51:treatment,,114:124:treatment",craniotomy patients are eligible for the treatment if they have had a craniotomy greater than two weeks prior to IA therapy
7009,NCT01880567,"17:20:cancer,44:56:cancer,,130:140:cancer,142:177:cancer,179:210:cancer,214:220:cancer,268:283:cancer,311:328:treatment,330:337:treatment,341:354:treatment,,","Newly diagnosed MCL: Disease free of prior malignancies of equal to or greater than 6 months with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy > 3 years"
7010,NCT01880567,"17:20:cancer,36:44:cancer,49:69:cancer",Newly diagnosed MCL: Patients with blastoid and pleomorphic variants
7011,NCT01880567,"21:24:cancer,49:69:cancer,162:168:treatment",Relapsed/refractory MCL: Confirmed diagnosis of mantle cell lymphoma with cluster of differentiation (CD)20 and cyclin D1 through cyclin D3 positivity in tissue biopsy
7012,NCT01880567,"10:24:chronic_disease,35:64:treatment,79:99:treatment",Relapsed/refractory MCL: Requires anticoagulation with warfarin or equivalent vitamin K antagonist
7013,NCT01880567,"14:26:chronic_disease,41:58:chronic_disease,67:102:chronic_disease,104:120:chronic_disease,131:140:treatment,146:166:treatment,168:177:treatment,181:198:treatment,200:217:chronic_disease,222:241:chronic_disease","uncontrolled hypertension, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, active infection requiring treatment with systemic antibiotics, antiviral or antifungal agents, active hemorrhage, or psychiatric illness"
7014,NCT01878617,"10:37:chronic_disease,100:124:chronic_disease,126:135:chronic_disease,155:163:chronic_disease,164:187:chronic_disease,189:198:chronic_disease,211:234:chronic_disease,322:346:chronic_disease,355:362:chronic_disease,366:385:chronic_disease","No major sensory or motor impairment that would preclude valid cognitive testing (e.g., unresolved posterior fossa syndrome, blindness, poorly controlled seizures/photosensitive epilepsy, psychosis) or a major psychological condition that would preclude completion of the intervention (e.g., significant oppositionality, autism spectrum disorder, severe anxiety or depressive symptoms)"
7015,NCT01877382,"5:34:treatment,38:51:treatment,,74:94:treatment",Had therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment
7016,NCT01877382,"1:28:treatment,32:43:treatment,,72:86:treatment",treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment
7017,NCT01876511,"12:24:treatment,,70:77:treatment,90:114:treatment",received a live vaccine within 4 weeks prior to or after any dose of MK-3475 (exception: inactivated flu vaccines)
7018,NCT01873131,"15:21:chronic_disease,46:83:chronic_disease,87:109:chronic_disease,121:138:chronic_disease,140:185:chronic_disease,187:208:chronic_disease,214:231:chronic_disease,270:277:allergy_name,338:351:allergy_name,355:369:allergy_name","Patients with asthma or a history of asthma, chronic obstructive pulmonary disease or cardiovascular disease, including sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock; hypersensitivity to any component of timolol; and in those patients receiving systemic administration of beta-blockers or ace inhibitors"
7019,NCT01872975,"26:36:treatment,121:135:cancer,140:144:cancer","For patients who undergo lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS as determined by the local pathologist"
7020,NCT01872975,"101:120:treatment,149:175:treatment,211:238:treatment,263:277:cancer",Patient must have had pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy) based on either a positive fine needle aspirate (FNA) (demonstrating malignant cells) or positive core needle biopsy (demonstrating invasive adenocarcinoma)
7021,NCT01872975,"21:34:cancer,50:63:cancer,67:80:cancer",patients who have a primary tumor that is either HER2-positive or HER2-negative
7022,NCT01871766,"29:47:treatment,51:84:treatment,96:104:treatment,151:156:cancer,157:166:treatment",Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma (excluding steroids) unless an emergency situation requires local tumor treatment
7023,NCT01871727,"12:27:treatment,32:36:cancer,63:76:treatment","History of prior therapies for CTCL as follows: must have had prior therapy, any number of prior therapies allowed"
7024,NCT01871727,"1:19:treatment,28:48:treatment,54:62:treatment,85:100:treatment",Topical treatments (except topical chemotherapy) and steroids are not considered as prior therapies
7025,NCT01869114,"1:4:cancer,8:11:cancer,30:60:treatment,49:60:treatment",MDS or AML as above BUT with prior therapy with Azacitibine (Arm C): Patients who meet criteria for either Arm A or Arm B but have been treated or are currently treated with Azacitibine
7026,NCT01869114,"15:47:chronic_disease,49:64:chronic_disease,78:102:chronic_disease,104:125:chronic_disease,,175:193:chronic_disease","Patients with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia"
7027,NCT01865162,"96:103:chronic_disease,127:149:chronic_disease,151:156:chronic_disease,160:173:chronic_disease,191:204:chronic_disease,206:219:chronic_disease,221:234:chronic_disease,236:257:chronic_disease,265:298:chronic_disease,300:309:chronic_disease,311:331:chronic_disease,336:348:chronic_disease","Any systemic illness or unstable medical condition that might pose additional risk, including: cardiac, unstable metabolic or endocrine disturbances, renal or liver disease, past history of renal calculi, hyperuricemia, hypercalcemia, mitochondrial disease, known disorder of fatty acid metabolism, porphyria, carnitine deficiency and pancreatitis"
7028,NCT01864265,"18:32:chronic_disease,60:83:treatment,85:92:treatment,","Individuals with claustrophobia, tattoos containing metal, magnetic endoprostheses, surgery on bone in between a time interval < 3 months"
7029,NCT01861106,"18:28:cancer,39:45:cancer,96:103:treatment","History of prior malignancy. However, cancer survivors who have undergone potentially curative therapy may be considered for stem cell donation on a case-by-case basis"
7030,NCT01859819,"49:74:chronic_disease,94:118:chronic_disease,206:213:treatment","These patients are excluded due to the expected intense immunosuppression, increased risk of opportunistic infections, and higher expected septic death rate in this subgroup of patients with this proposed therapy"
7031,NCT01858168,"36:60:cancer,115:118:cancer,123:145:cancer",Previously documented diagnosis of myelodysplastic syndrome (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia
7032,NCT01851369,"1:4:chronic_disease,26:60:treatment,117:123:treatment",HIV-positive patients on combination antiretroviral therapy are ineligible because of possible PK interactions with TRC102
7033,NCT01851369,"30:47:cancer,59:75:chronic_disease,118:131:treatment,152:180:treatment",Phase II only: patients with colorectal cancer with known MSI-high disease who have not previously been treated with immunotherapy or who have refused treatment with immunotherapy
7034,NCT01850758,"35:49:chronic_disease,92:112:chronic_disease,114:142:chronic_disease,144:163:chronic_disease,165:176:chronic_disease,178:190:chronic_disease,192:207:chronic_disease","Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)"
7035,NCT01850758,"43:53:cancer,132:141:treatment,145:167:treatment","Tested positive or has been treated for a malignancy in the past or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site"
7036,NCT01849146,",34:47:treatment,49:67:treatment,75:82:treatment,84:102:treatment,104:115:treatment","2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., Tarceva, hydroxychloroquine, bevacizumab, etc.)"
7037,NCT01849146,"20:30:cancer,57:62:cancer,66:101:cancer,105:136:cancer,138:144:cancer,149:156:cancer","have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder"
7038,NCT01849146,"56:68:cancer,72:75:treatment,,103:112:treatment",measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within 21 days of starting treatment
7039,NCT01842399,"8:17:treatment,65:84:treatment,86:106:treatment,108:129:treatment,131:150:treatment,152:170:treatment,174:210:treatment,251:262:treatment,308:321:treatment","Taking medicines that may increase the risk of bleeding such as Coumadin (warfarin), Plavix (clopidogrel), Xarelto (rivaroxaban), Pradaxa (dabgatran), Eliquis (apixaban) or Heparin (blood thinning medications) due to their potential interaction with resveratrol and the increased risk for bleeding with the muscle biopsy"
7040,NCT01841333,"21:33:chronic_disease,35:44:chronic_disease,55:64:chronic_disease,89:96:treatment","Active uncontrolled acute fungal, bacterial, or other infection that is unresponsive to therapy at time of study drug dosing"
7041,NCT01835626,"19:42:cancer,38:42:cancer,118:127:treatment,158:165:treatment,227:258:treatment","For patients with multiple cutaneous BCCs at baseline that are not designated by the investigator as target lesions, treatment of these non-target BCCs with surgery may be permitted but must be discussed with Data Coordinator prior to any surgical procedure"
7042,NCT01835626,",,59:68:treatment,,,171:180:treatment,186:196:treatment","Male patients must use condoms at all times, even after a vasectomy, during sexual intercourse with pregnant partners or female partners of reproductive potential during treatment with vismodegib"
7043,NCT01829958,"20:31:chronic_disease,20:41:chronic_disease,118:130:treatment",Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B surface antigen or viral DNA by PCR analysis)
7044,NCT01829958,"1:16:chronic_disease,18:33:chronic_disease,37:55:chronic_disease",Serous effusion (plural effusion or peritoneal ascites)
7045,NCT01827384,"29:38:treatment,48:62:treatment,83:95:treatment",Patients who have had prior treatment with any PARP inhibitor in combination with temozolomide
7046,NCT01827384,"15:42:chronic_disease,138:153:treatment,192:217:treatment,240:262:chronic_disease,268:295:chronic_disease","Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease)"
7047,NCT01827384,"15:24:treatment,33:69:cancer,57:60:cancer,70:100:cancer,96:99:cancer,158:197:treatment,201:244:treatment","Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS), or with features suggestive of AML/MDS, or who have had prior allogeneic bone marrow transplant or double umbilical cord blood transplantation"
7048,NCT01827384,"15:30:cancer,44:57:treatment,61:72:treatment",patients with prostate cancer may continue LHRH agonists or antagonists
7049,NCT01823198,"1:23:chronic_disease,55:75:treatment,,96:103:treatment","Uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy; the protocol principal investigator (PI) is the final arbiter of eligibility"
7050,NCT01822522,"28:41:chronic_disease,28:31:chronic_disease,101:142:treatment,144:165:treatment,359:387:treatment","Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and western blot, or other approved diagnostic tests"
7051,NCT01822522,",,,,,118:135:chronic_disease,139:170:chronic_disease,214:224:treatment,228:245:treatment,","Total bilirubin=< 1.5 x upper limit of normal (ULN) (within 1 week of study entry) (if, however, the participant has Gilbert's disease or unconjugated hyperbilirubinemia that is considered to be secondary to with atazanavir or indinavir therapy, then the total bilirubin must be =< 3 x ULN)"
7052,NCT01822522,"1:13:treatment,43:47:cancer,51:67:cancer,",radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registration
7053,NCT01817751,"1:24:chronic_disease,51:72:chronic_disease,74:98:chronic_disease,110:136:chronic_disease,,161:176:treatment","Arterial thromboembolic or embolic events such as myocardial infarction, cerebrovascular accident, including transient ischemic attacks 6 months prior to first study treatment"
7054,NCT01817751,"37:43:cancer,,,80:104:treatment,108:140:treatment","Pathologically confirmed high-grade glioma (WHO grade 3 or 4), with documented computed tomography (CT) or magnetic resonance imaging (MRI) progression or recurrence"
7055,NCT01815359,"13:25:cancer,44:68:cancer,92:120:cancer,,","Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option"
7056,NCT01811368,"1:10:chronic_disease,28:47:chronic_disease,51:68:chronic_disease",Cirrhosis with evidence of portal hypertension or bridging fibrosis
7057,NCT01809002,"13:28:allergy_name,37:52:allergy_name,53:63:allergy_name",Allergic to Bovine products such as Bovine Collagen Nerve Cuff
7058,NCT01807091,"51:63:chronic_disease,65:74:chronic_disease,76:92:chronic_disease","Afebrile with clear chest imaging and no signs of active viral, bacterial, fungal infection unless determined to be, at the discretion of the investigator, not clinically significant in the context of this study"
7059,NCT01804634,",,51:60:treatment,62:74:treatment,78:99:treatment,101:110:treatment",Patients with >5 identified lesions on the end of induction (COG ANBL0532 or standard chemotherapy) MIBG scan
7060,NCT01804465,"27:61:cancer,63:81:treatment,111:118:treatment,126:155:treatment","Histologically confirmed, metastatic prostate adenocarcinoma (positive bone scan and/or measurable disease on CT scan and/or MRI of the abdomen and pelvis)"
7061,NCT01802346,"1:14:cancer,52:64:treatment,88:116:treatment,","Breast cancer subjects may not have received prior chemotherapy, with the exception of curative-intent chemotherapy for a separate malignancy more than 3 years ago"
7062,NCT01802346,"44:61:cancer,63:75:treatment,103:114:treatment,106:114:treatment,129:147:treatment","Subjects do not need to have measurable or evaluable disease; chemotherapy may be administered in the neoadjuvant, adjuvant, or metastatic setting"
7063,NCT01799538,"1:42:treatment,44:69:treatment,73:109:treatment,113:156:treatment,","Treatment with monoaminoxidase inhibitors, tricyclic antidepressants or Beta-adrenergic receptor antagonists or long acting anticholinergic bronchodilators who are unable to be discontinued for at least seven days before enrollment"
7064,NCT01795573,"1:4:cancer,,,,100:119:treatment,,,,,298:315:treatment,349:359:cancer,364:378:treatment,386:406:treatment","CLL: Absence of constitutional symptoms attributable to CLL; No lymph nodes >1.5 cm in diameter on computed tomography; No hepatomegaly or splenomegaly by computed tomography; Absolute neutrophil count >1500/microL; Platelet count >100,000/microL; No clonal lymphocytes in the peripheral blood by immunophenotyping; Bone marrow with no evidence of clonal CLL (by flow cytometry and/or immunohistochemistry"
7065,NCT01795573,"1:18:chronic_disease,31:39:treatment,43:49:treatment",Hepatitis B and C negative by serology or RT-PCR
7066,NCT01795573,"77:80:treatment,77:94:cancer,77:95:cancer,104:113:treatment,263:265:treatment,321:352:treatment,334:352:treatment,445:465:treatment","NHL: No clinical evidence of disease or disease-related symptoms; Typically FDG-avid lymphomas: a post-treatment residual mass of any size is permitted as long as it is PET negative; Variably FDG-avid lymphoma/FDG avidity unknown: all lymph nodes normal size by CT; Spleen and liver non-palpable and without nodules; If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative"
7067,NCT01794793,",8:21:treatment,32:92:treatment,97:111:treatment,,145:160:treatment",Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment
7068,NCT01794559,"12:22:treatment,24:43:cancer,45:69:chronic_disease,92:108:chronic_disease,110:126:chronic_disease,128:141:chronic_disease,143:168:chronic_disease,170:178:chronic_disease,180:198:chronic_disease,203:243:chronic_disease,255:273:treatment,","History of craniotomy, cerebral metastases, cerebrovascular accident, current diagnosis of seizure disorder, bipolar disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features, or use of depot neuroleptics in the last 12 months"
7069,NCT01793519,",,,71:80:treatment,93:103:treatment,105:115:treatment,120:130:treatment,,170:182:treatment,184:202:treatment,204:217:treatment,219:230:treatment,232:243:treatment,245:257:treatment,259:271:treatment,279:292:treatment,,,,,,,","In sustained clinical remission for the last 6 months while receiving treatment with either etanercept, infliximab, or adalimumab, and greater than or equal to 1 DMARD (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine). DAS28 should be less than 2.6 on each visit over the preceding 6 months, with at least one visit 2-4 months before enrollment. If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6"
7070,NCT01791543,"10:46:chronic_disease,50:79:treatment,85:96:treatment",Definite protruding left ventricular thrombus on pre-ablation echocardiography when LV ablation is required
7071,NCT01791543,"7:34:treatment,63:84:chronic_disease,86:94:chronic_disease","prior antiarrhythmic drug therapy has failed due to recurrent ventricular arrythmia, toxicity, or intolerance"
7072,NCT01787487,"30:56:chronic_disease,58:103:chronic_disease,108:161:chronic_disease,172:179:treatment","Patients with a diagnosis of primary myelofibrosis (PM), post polycythemia vera myelofibrosis (PPV MF), or post essential thrombocythemia myelofibrosis (PET MF) requiring therapy, including those previously treated and relapsed or refractory, or if newly diagnosed, with intermediate or high risk according to International Working Group (IWG-MRT) criteria"
7073,NCT01787409,"25:30:cancer,34:69:cancer,99:131:treatment,133:142:treatment,143:159:treatment,161:186:treatment,188:207:treatment","Newly diagnosed de-novo DLBCL or primary mediastinal B-cell lymphoma that will be treated with an anthracycline-containing regimen (rituximab-cyclophosphamide, doxorubicin hydrochloride, prednisone [R-CHOP] or equivalent)"
7074,NCT01782599,"30:53:chronic_disease,55:68:chronic_disease,70:94:chronic_disease,96:112:chronic_disease,114:133:chronic_disease","lifetime DSM-IV diagnosis of organic mental disorder, schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder"
7075,NCT01774019,"30:42:cancer,54:71:cancer,73:102:cancer,113:134:cancer","Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers"
7076,NCT01773707,"28:43:chronic_disease,45:49:chronic_disease,51:63:chronic_disease,68:93:chronic_disease,103:114:cancer,116:126:cancer,131:147:chronic_disease","These include pre-existing cardiac disease, COPD, neurological, or blood count abnormalities (such as lymphopenia, leukopenia, or thrombocytopenia)"
7077,NCT01772329,"21:32:treatment,34:37:treatment,41:57:treatment",undergoing standard primary TKR; THR or Shoulder Surgery
7078,NCT01760863,"27:75:treatment,187:210:treatment,246:262:treatment",Adult patients undergoing 2-stage revision arthroplasty of the knee or hip with the causative organism(s) identified using tissue culture and/or joint fluid analysis that is amenable to oral antibiotic therapy. Patients must be able to tolerate oral antibiotics and agree to participate in the study
7079,NCT01760655,"28:69:treatment,81:84:chronic_disease,107:128:treatment,147:168:treatment","Examples are patients with previous treatment with radiation therapy precluding TBI, or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen"
7080,NCT01760655,"35:45:cancer,62:73:cancer,93:108:treatment","Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol"
7081,NCT01760005,"13:23:treatment,25:39:treatment,41:64:treatment","Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan"
7082,NCT01757418,"25:44:chronic_disease,46:48:chronic_disease,52:76:chronic_disease",Documented diagnosis of sickle cell disease (SS or S-? thalassemia genotype)
7083,NCT01754857,"7:14:treatment,20:29:treatment,67:95:chronic_disease","Prior therapy with rituximab is permitted, even in the setting of rituximab-refractory disease"
7084,NCT01750567,"12:28:chronic_disease,44:50:chronic_disease,54:58:chronic_disease",Ongoing or active infection concerning for sepsis or SIRS
7085,NCT01743950,"1:25:cancer,33:57:cancer,61:84:cancer",active second malignancy unless non-melanoma skin cancer or cervical cancer in situ
7086,NCT01742299,",32:63:treatment,80:92:treatment,,151:160:treatment",Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment
7087,NCT01737502,"41:52:cancer,54:62:cancer,64:90:cancer,94:116:cancer","Histologic or cytologic confirmation of lung cancer (squamous, ras-mutated adenocarcinoma or small cell lung cancer)"
7088,NCT01734512,",,12:27:treatment,79:87:treatment,111:122:treatment,",INR ?1.5. (Anticoagulation is allowed if target INR ? 1.5 on a stable dose of warfarin or on a stable dose of LMW heparin for >2 weeks at time of randomization)
7089,NCT01734512,"43:53:allergy_name,63:73:allergy_name,80:89:allergy_name,91:103:allergy_name","Patients with a known hypersensitivity to everolimus or other rapamycins (e.g. sirolimus, temsirolimus)"
7090,NCT01730937,"64:83:chronic_disease,210:212:treatment,216:219:treatment,244:247:cancer,","For patients whose CURRENT disease is vascular only: enhancing vascular thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early arterial enhancement and delayed washout on multi-phasic CT or MRI in a patient with known HCC (diagnosed previously <720 days) using the above criteria"
7091,NCT01730937,"18:21:chronic_disease,69:78:treatment,84:128:treatment,,","patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ? (350) cells/microliter, and no known detectable viral load, at the time of study entry"
7092,NCT01730118,"8:22:chronic_disease,24:33:chronic_disease,37:53:chronic_disease,64:73:treatment","Active systemic viral, bacterial or fungal infection requiring treatment"
7093,NCT01730118,"10:36:treatment,39:62:treatment,68:89:treatment,92:130:treatment,141:164:treatment","Naive to trastuzumab (Herceptin(TM)), pertuzumab (Perjeta(TM)) and lapatinib (Tykerb(TM)), ado-trastuzumab emtansine (Kadcyla(TM)) or other HER2-directed therapies"
7094,NCT01730118,"26:53:chronic_disease,105:114:treatment,142:170:treatment",Patients with inadequate bilateral peripheral venous or central venous catheter access for the required apheresis to allow generation of the autologous AdHER2 DC vaccine product
7095,NCT01730118,"27:36:treatment,40:60:treatment,91:104:cancer","Stable, concurrent use of tamoxifen or aromatase inhibitors for hormone receptor positive breast cancer are allowed"
7096,NCT01722240,"1:16:chronic_disease,44:60:treatment,82:94:treatment",Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII; also known as insulin pump)
7097,NCT01720147,"14:16:chronic_disease,27:35:treatment,39:56:treatment",Diagnosis of FA proven by DEB test or molecular testing
7098,NCT01715220,"15:54:chronic_disease,67:78:chronic_disease,,136:141:chronic_disease,162:172:chronic_disease,174:204:chronic_disease,248:269:chronic_disease,271:288:chronic_disease,349:377:treatment,,417:430:allergy_name","Patients with obstructive hypertrophic cardiomyopathy, pronounced hypovolemia, alcohol use in the last 8 hours, clinical intoxication, STEMI or presumed cardiac chest pain, inferior myocardial infarction with right ventricular involvement, raised intracranial pressure, cardiac tamponade and patients taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), pregnancy or with a known allergy to nitroglycerin will be excluded from the study"
7099,NCT01712308,"20:58:chronic_disease,63:79:chronic_disease,85:102:chronic_disease","Known positive for human immunodeficiency virus-1 (HIV-1), or active infection with hepatitis-B or -C"
7100,NCT01703949,"7:41:chronic_disease,45:56:chronic_disease,77:125:chronic_disease",Known human immunodeficiency virus (HIV) or hepatitis B positivity or prior progressive multifocal leukoencephalopathy (PML)
7101,NCT01703117,"18:29:treatment,89:101:treatment,184:193:treatment,195:206:treatment,208:215:treatment,217:224:treatment,226:235:treatment,237:253:treatment,262:274:treatment,279:294:treatment,296:321:treatment,323:338:treatment","Currently taking medications that either have evidence of glutamatergic activity or has previous MRS evidence of effects on brain glutamate levels at the discretion of the PI such as memantine, lamotrigine, lithium, opiates, bupropion, psychostimulants such as amphetamines and methylphenidate, tricyclic antidepressants, benzodiazepines and any other drug that the investigators judge might interfere with the study"
7102,NCT01703117,"13:39:chronic_disease,48:64:chronic_disease,66:79:chronic_disease,81:104:chronic_disease,106:123:chronic_disease,115:123:chronic_disease,125:151:chronic_disease,153:165:chronic_disease","Significant neuropsychiatric illnesses such as bipolar disorder, schizophrenia, moderate-severe anxiety, vascular dementia, Creutzfeldt-Jakob dementia, HIV dementia, and dementia in other specified diseases"
7103,NCT01698658,"15:24:treatment,26:43:treatment,51:61:treatment","Scheduled for mammogram, breast ultrasound and/or breast MRI"
7104,NCT01697371,"1:13:treatment,30:43:treatment,,88:97:treatment,,,,",Chemotherapy and/or targeted agent therapy must be completed at least 2 weeks prior to radiation and started at least 14 days after completion of SBPT Women of childbearing potential and male participants must practice adequate contraception
7105,NCT01697293,"102:109:allergy_name,151:161:allergy_name,163:173:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX-200 or other agents used in the study (e.g., imidazoles, quinolones)"
7106,NCT01697293,",39:55:treatment,61:72:treatment,77:94:treatment,,111:123:treatment,134:144:treatment","at least 3 weeks for the last dose of biologic therapy (eg, bevacizumab) or cytotoxic therapy (or 2 weeks for capecitabine or weekly paclitaxel"
7107,NCT01697293,"18:43:cancer,96:105:treatment,109:122:cancer,130:141:treatment","patients who are hormone-receptor positive and who have received other hormonal agents for the treatment of breast cancer (e.g., Fulvestrant) are also eligible"
7108,NCT01696734,"12:50:chronic_disease,72:83:chronic_disease,85:105:chronic_disease,107:132:chronic_disease","refractory gastroesophageal reflux disease (GERD) including persistent esophagitis, refractory heartburn, reflux-related laryngitis, and respiratory symptoms"
7109,NCT01690468,"1:27:chronic_disease,,98:137:treatment,176:198:treatment","platinum-resistant disease is defined by a disease-free interval of less than 6 months following treatment with a platinum-based regimen, or the progression of disease during platinum-based therapy"
7110,NCT01684904,"16:26:cancer,35:63:cancer,,118:145:cancer,147:158:cancer,163:169:cancer","Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 2 years ( e.g. carcinoma in situ of breast, oral cavity, or cervix are permissible)"
7111,NCT01684397,"1:30:treatment,35:61:cancer,72:80:treatment,84:106:treatment",Prior VEGF targeted therapies for renal cell carcinoma (RCC) including adjuvant or neoadjuvant treatments
7112,NCT01681589,"39:64:chronic_disease,66:99:chronic_disease,114:134:chronic_disease,143:154:chronic_disease,162:168:chronic_disease,170:178:chronic_disease,182:203:chronic_disease","Complicating medical problems such as uncontrolled hypertension, diabetes with signs of neuropathy, and previous neurological illness such as head trauma, prior stroke, epilepsy or demyelinating disease, implanted neuromodulatory or electronic device, metal in head"
7113,NCT01681264,"16:25:treatment,16:33:treatment,77:86:treatment,90:103:treatment,110:118:treatment,120:127:treatment,188:192:chronic_disease","Currently in a treatment program for alcohol or drug abuse, or currently on methadone or buprenorphine (i.e. suboxone, subutex) for treatment of addiction, or stimulants for treatment of ADHD"
7114,NCT01681264,"17:28:treatment,43:62:treatment,66:81:treatment,117:130:treatment,132:153:treatment,155:171:treatment,173:186:treatment,188:202:treatment,204:214:treatment,216:230:treatment,233:257:treatment,259:282:treatment,284:306:treatment,312:331:treatment","Subjects are on medications that serve as CYP3A4/5 inhibitors or CYP3A4 inducers including, but are not limited to, valproic acid, macrolide antibiotics, antifungal drugs, St. John wort, ACE inhibitors, nefazodone (antidepressant), calcium channel blockers, H2-receptor antagonists, anti-HIV or AIDS drugs, and antiepileptic drugs"
7115,NCT01676753,"28:44:chronic_disease,69:94:treatment,106:141:treatment,153:189:treatment,218:233:treatment,238:244:chronic_disease,246:283:chronic_disease,285:302:chronic_disease,325:341:treatment,,426:441:treatment","Patient has a diagnosis of immunodeficiency or is receiving ongoing immunosuppressive therapy, including systemic or enteric corticosteroids except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, chronic obstructive pulmonary disease, allergic rhinitis). Patient must be off systemic steroid or any other form of immunosuppressive therapy within 7 days prior to first dose of trial treatment"
7116,NCT01676753,",28:57:treatment,33:57:treatment,214:232:treatment","Patients less than 2 weeks post major surgical procedure (all surgical wounds must be fully healed). For the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia"
7117,NCT01676259,"15:20:cancer,75:102:treatment,179:192:treatment",Have a target tumor that is accessible for intratumoral administration by EUS (Endoscopic Ultrasound) guidance as determined by the radiologist/gastroenterologist performing the EUS insertion
7118,NCT01672138,"22:39:chronic_disease,48:63:chronic_disease,65:76:chronic_disease,78:96:chronic_disease","Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis, pulmonary embolism etc"
7119,NCT01670877,"33:50:treatment,,88:109:treatment,201:210:treatment","The patient must have completed radiation therapy and be at least 1 week from the last systemic chemotherapy administration, with adequate recovery of bone marrow and organ functions, before starting neratinib"
7120,NCT01668563,"17:25:chronic_disease,64:72:treatment,76:98:treatment",The patient and aneurysm are considered appropriate for either surgical or endovascular treatment by the treating team
7121,NCT01662466,"7:11:treatment,16:25:treatment,29:32:chronic_disease,33:36:chronic_disease",Using DHEA for treatment of DOR/POA
7122,NCT01660607,"14:19:chronic_disease,24:35:chronic_disease,,84:93:treatment",negative for HIV 1 and hepatitis C by nucleic acid testing (NAT) within 30 days of apheresis collection
7123,NCT01653093,"27:92:treatment,100:117:treatment,119:129:treatment,131:147:treatment,149:163:treatment,165:190:treatment","Patients with any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.)"
7124,NCT01652092,"1:16:chronic_disease,44:66:chronic_disease,70:79:chronic_disease,83:89:treatment",acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
7125,NCT01648751,"31:39:chronic_disease,46:53:treatment,55:59:treatment","Other prior interventions for prolapse (e.g. pessary, PFPT)"
7126,NCT01648023,"28:50:treatment,63:73:treatment,75:86:treatment,91:100:treatment","Patients who have received prior systemic therapy with either irinotecan, gemcitabine, or cisplatin"
7127,NCT01643473,"6:31:chronic_disease,,,,,144:152:chronic_disease,156:170:chronic_disease,,,,227:230:chronic_disease,253:267:chronic_disease",Have uncontrolled hypertension defined as BP>140/90 mmHg on at least two consecutive visits in the past year (or BP>130/80 mmHg for those with diabetes or kidney disease) and Framingham Risk Scores (FRS) >20% (or at least one CVD risk factor including hyperlipidemia or diabetes)
7128,NCT01639508,"1:18:treatment,23:27:cancer,31:47:cancer,,74:100:treatment,,145:182:treatment,,259:282:treatment","Radiation therapy for bone or brain metastasis within 2 weeks, any other external radiation therapy within 4 weeks of first dose of study drug. Systemic treatment with radionuclides within 4weeks. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible"
7129,NCT01639508,"1:17:chronic_disease,28:46:treatment,,87:102:treatment",active infection requiring systemic treatment within 28 days before the first dose of study treatment
7130,NCT01631617,"28:33:allergy_name,35:46:allergy_name,51:75:allergy_name,80:89:allergy_name,93:104:allergy_name","Known allergic reaction to sulfa, beta-lactam, or tetracycline class drugs; or lidocaine or epinephrine"
7131,NCT01631617,"40:58:chronic_disease,78:93:treatment,166:175:treatment,",Subjects with unstable or uncontrolled medical conditions that could require hospitalization during the initial month of the study or who have been hospitalized for treatment of these conditions in the one month prior to baseline sampling
7132,NCT01627821,"88:126:treatment,,,194:224:treatment,255:267:treatment","Patients on Optimal Medical Management (OMM) as defined in Section 9.2 OR dependent on intra-aortic balloon counter-pulsation for 7 days OR other temporary (indicated for 30 days use, or less) mechanical circulatory support for 7 days, OR supported with IV inotropes for 7 days and failing to respond"
7133,NCT01626079,"1:4:treatment,8:17:treatment,76:80:treatment,",BNP or NT-proBNP must be obtained after the subject has been stabilized on GDMT and at least 30 days after
7134,NCT01626079,"1:24:chronic_disease,35:44:treatment,56:83:treatment",Hemodynamic instability requiring inotropic support or mechanical heart assistance
7135,NCT01626079,"1:30:chronic_disease,38:49:chronic_disease,51:66:chronic_disease,68:79:chronic_disease","Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)"
7136,NCT01626079,"155:170:treatment,207:214:treatment,231:240:treatment","The subject or the subject's legal representative understands and agrees that should he/she be assigned to the Control group, he/she will be treated with medical therapy and conservative management without surgery and without the MitraClip, either domestically or abroad"
7137,NCT01626079,"37:92:treatment,79:82:treatment,86:91:treatment,",revascularization and/or implant of Cardiac Resynchronization Therapy device (CRT or CRT-D) or reprogramming of an implanted CRT or CRT-D that results in increased biventricular pacing (from <92% to ?92%)
7138,NCT01625923,"25:36:treatment,42:74:treatment,94:125:treatment,","Subject has never had a gastrectomy, nor major gastric surgical procedure or any evidence of bowel obstruction or strictures within the previous 12 months"
7139,NCT01625234,"5:18:treatment,20:32:treatment,37:50:treatment,,76:91:treatment,,140:144:treatment","Any major surgery, radiotherapy, or immunotherapy within the last 21 days (focal radiation does not require a washout period; ?4 weeks for WBRT)"
7140,NCT01625234,"71:104:allergy_name,112:122:allergy_name,134:160:allergy_name","Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to X-396 (e.g., crizotinib) or to the active ingredient of X-396"
7141,NCT01624090,"21:44:treatment,63:92:treatment,101:113:treatment,115:127:treatment,129:140:treatment,145:157:treatment","Disease amenable to biopsy via percutaneous approach or other minimally invasive procedures such as thoracoscopy, bronchoscopy, laparoscopy, or GI endoscopy"
7142,NCT01624090,"27:42:chronic_disease,44:67:chronic_disease,82:100:chronic_disease","Patients with evidence of active bleeding, intratumoral hemorrhage or history of bleeding diatheses"
7143,NCT01623167,"1:32:treatment,42:45:treatment,47:58:treatment,73:89:treatment","Prior immunosuppressive therapy with any ATG, alemtuzumab, or high dose cyclophosphamide"
7144,NCT01622868,"7:26:cancer,35:63:cancer,85:112:cancer,144:151:cancer,167:180:cancer,","Prior invasive malignancy (except non-melanomatous skin cancer, curatively resected thyroid papillary carcinoma, and invasive and non-invasive cancers related to the breast cancer) unless disease free for a minimum of 3 years"
7145,NCT01620216,"1:11:chronic_disease,15:29:chronic_disease,104:120:chronic_disease,122:141:chronic_disease,143:163:chronic_disease,168:186:chronic_disease","Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism"
7146,NCT01620216,"26:34:cancer,65:97:cancer,101:135:cancer",with relapsed/refractory leukemia with a confirmed diagnosis of acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL)
7147,NCT01619761,"1:29:cancer,58:67:treatment,69:83:cancer,88:100:cancer,120:170:treatment,173:193:cancer,221:237:cancer","Non-Hodgkin's lymphoma (NHL) in second or third complete remission, refractory NHL, or relapsed NHL (including relapse post autologous hematopoietic stem cell transplant); double hit lymphomas in first remission or more advanced disease"
7148,NCT01618357,"1:19:treatment,21:39:treatment,,91:95:treatment",Anti-cancer Agents: Anti-cancer agents are not permitted within 21 days prior to start of POPI
7149,NCT01618357,"14:26:treatment,19:26:treatment,28:41:treatment,43:59:treatment,64:87:treatment,,138:147:treatment,152:161:treatment","Last dose of chemotherapy, immunotherapy, biologic therapy, or investigational therapy, was less than 14 days prior to protocol therapy (radiation and veliparib)"
7150,NCT01618357,"1:8:treatment,19:34:treatment,59:63:treatment,98:101:treatment",Surgery: Incident breast biopsies only permitted prior to POPI to confirm residual disease after NAC
7151,NCT01617161,"1:15:treatment,17:43:chronic_disease,47:73:chronic_disease,89:100:chronic_disease,104:109:chronic_disease","Hip prosthesis, inflammatory bowel disease or connective tissue disorder such as active scleroderma or lupus"
7152,NCT01614990,",,14:17:chronic_disease,19:23:chronic_disease,32:36:chronic_disease,54:61:treatment","class III-IV CHF, AIDS, severe COPD requiring use of home O2"
7153,NCT01614197,"1:10:chronic_disease,32:63:treatment,92:104:treatment,106:116:treatment,151:176:chronic_disease,177:204:treatment,208:239:treatment","Anti-GVHD or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post transplant are not eligible for this trial"
7154,NCT01614197,"1:33:treatment,72:103:treatment,108:117:treatment,119:132:treatment,137:150:treatment","Enzyme inducing Anti-convulsants: Patients who are currently receiving enzyme inducing anticonvulsants (ie phenytoin, phenobarbitol, or carbamazepine) are not eligible"
7155,NCT01614197,"15:23:cancer,27:35:cancer,76:88:treatment",Patients with leukemia or lymphoma who relapse while receiving maintenance chemotherapy will not be required to have a waiting period before enrollment onto this study
7156,NCT01608438,"1:16:chronic_disease,18:32:chronic_disease,36:46:chronic_disease,","Skull fractures, skull deficits or concussion within the last 6 months"
7157,NCT01604512,"28:43:chronic_disease,89:112:treatment,152:169:cancer,174:190:chronic_disease","New or increased enhancing brain lesion(s) OR nonenhancing brain lesion(s) if receiving anti-angiogenic therapy, which is considered indeterminate for tumor progression vs. radiation injury by the neuroradiologist or clinician"
7158,NCT01599559,"13:22:treatment,24:32:treatment,34:43:treatment,,59:66:treatment,70:77:treatment","6 cycles of CHOP14-21, DA-EPOCH, Mega-CHOP or 12 weeks of VACOP-B or MACOP-B"
7159,NCT01597518,"1:18:cancer,33:52:cancer,,103:135:cancer,139:174:cancer","Active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated"
7160,NCT01595529,"24:33:chronic_disease,,,90:111:treatment,115:123:treatment,","A urine culture proven infection with a second uropathogen > 10,000 CFU/mL collected via suprapubic aspiration or catheter or > 50,000 CFU/mL collected via clean void"
7161,NCT01595061,"34:44:chronic_disease,53:62:chronic_disease,64:89:chronic_disease,100:125:chronic_disease,136:163:treatment","Patients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy"
7162,NCT01591356,"34:55:chronic_disease,106:123:chronic_disease,125:137:chronic_disease,142:147:cancer","Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as a known bleeding disorder, coagulopathy, or tumor involving major vessels"
7163,NCT01591356,"20:36:treatment,46:61:cancer,68:78:treatment,82:127:treatment","stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a gonadotropin-releasing hormone [GnRH] agonist)"
7164,NCT01589263,"22:50:chronic_disease,68:72:chronic_disease,84:87:chronic_disease",Current diagnosis of acute or chronic prostatitis (which may cause LUTS that mimic BPH)
7165,NCT01589263,"11:24:treatment,26:41:treatment,43:53:treatment,58:73:treatment,78:100:treatment,","Has taken phenylephrine, pseudoephedrine, imipramine, an anticholinergic, or cholinergic medication within the past 2 weeks"
7166,NCT01584076,"1:10:chronic_disease,27:37:chronic_disease,45:58:chronic_disease",Amblyopia associated with strabismus and/or anisometropia
7167,NCT01582191,"32:42:allergy_name,44:51:allergy_name,53:68:allergy_name,77:105:allergy_name","History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation"
7168,NCT01581749,"15:34:cancer,52:67:cancer,71:101:cancer,","history of an invasive malignancy (other than this prostate cancer,or basal or squamous skin cancers) within prior 5 years"
7169,NCT01581580,"42:61:chronic_disease,71:90:chronic_disease,94:98:chronic_disease","current or pre-existing life-threatening respiratory disease, such as respiratory failure or ARDS"
7170,NCT01572480,"37:47:treatment,59:69:treatment,71:98:treatment,100:123:treatment,128:137:treatment,153:160:treatment","Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy"
7171,NCT01572480,"14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations"
7172,NCT01568255,"23:49:chronic_disease,51:63:chronic_disease,65:72:chronic_disease,74:86:chronic_disease,88:104:chronic_disease","Clinical diagnosis of overt vitamin D deficiency: osteomalacia, rickets, hypocalcemia, hypophosphatemia"
7173,NCT01562626,"51:60:treatment,96:107:treatment,109:119:treatment,121:132:treatment,137:149:treatment,150:164:treatment","Patient's medical history does not contraindicate treatment with at least one of the following antibiotics: ampicillin, clindamycin and erythromycin/clarithromycin"
7174,NCT01562626,"13:31:chronic_disease,46:61:treatment,69:93:treatment",Presence of autoimmune disease that requires corticosteroids and/or immunosuppressive agents
7175,NCT01558544,"1:8:treatment,81:106:treatment,110:114:cancer","Surgery that requires removal of ovaries for medical condition or disease, e.g. Prophylactic oophorectomy in BRCA patients"
7176,NCT01554410,",,15:30:cancer,47:53:treatment,61:83:cancer","Stage IB2-IVA cervical cancer or stage I with biopsy-proven pelvic node metastases, positive surgical margins, or parametrial extension based upon standard diagnostic workup"
7177,NCT01554371,"37:57:cancer,70:87:cancer,105:129:cancer","Patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer"
7178,NCT01553071,"1:14:treatment,,65:76:treatment,81:89:treatment",Major surgery in the last three weeks due to unknown effects of fenretinide and safingol on wound healing
7179,NCT01553071,"36:52:cancer,64:75:chronic_disease,77:86:chronic_disease,90:113:chronic_disease","Patients with previously untreated brain metastases (including parenchymal, meningeal or dural-based CNS lesions)"
7180,NCT01553071,"7:30:chronic_disease,79:98:chronic_disease,99:116:chronic_disease",other major medical illnesses of the cardiovascular or respiratory systems or psychiatric illness/social situations that would limit compliance with study requirements
7181,NCT01547429,"1:16:chronic_disease,72:98:chronic_disease,102:145:chronic_disease",Retinal disease that may limit the visual potential of the eye such as retinopathy of prematurity or Stargardt's retinopathy Optic nerve disease that may limit the visual potential of the eye
7182,NCT01542879,"1:14:chronic_disease,15:30:chronic_disease,85:96:treatment",Hemosiderosis/hemochromatosis (patients can still be included in 2nd branch without ferumoxytol)
7183,NCT01538966,"1:11:chronic_disease,39:42:treatment,47:71:treatment,","Acromegaly patients who have received SRL and dopamine agonist therapy, after a 6 week washout period of the dopamine agonist"
7184,NCT01532687,"5:35:treatment,,84:152:treatment,158:167:treatment,169:178:treatment,184:195:treatment","Any prior treatment with pazopanib or vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)-targeting agents (eg. sorafenib, sunitinib, and bevacizumab)"
7185,NCT01532687,"33:72:cancer,76:105:cancer,158:172:cancer","History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic"
7186,NCT01532687,"1:18:treatment,20:27:treatment,31:49:treatment","Radiation therapy, surgery or tumor embolization"
7187,NCT01522768,"25:46:treatment,37:46:treatment,71:84:treatment,86:103:treatment,127:144:treatment,150:173:treatment,289:305:treatment,,363:371:treatment,,548:563:treatment","Additional experimental anti-cancer treatment and/or standard chemo-, immunotherapy, hormone treatment (with the exception of megestrol acetate), or concurrent radiotherapy is not allowed concomitantly with the administration of study treatment (with the exception listed in section 9.0) 89Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permitted. Afatinib is a substrate of P-gp and its plasma concentrations can be affected by the use of P-gp inhibitors (data on file) and it is also likely that P-gp inducers could also influence afatinib plasma concentrations"
7188,NCT01522768,"12:30:chronic_disease,93:109:chronic_disease,134:151:chronic_disease,165:171:cancer,173:202:chronic_disease,184:202:chronic_disease,,250:253:chronic_disease","Concurrent medical conditions which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), HIV-positive"
7189,NCT01522768,"65:76:treatment,108:114:treatment,131:138:treatment",Patients who have previously provided samples at any time after trastuzumab resistance will be exempt from biopsy at the start of therapy
7190,NCT01522768,"19:34:treatment,46:58:treatment,60:72:treatment,74:86:treatment,88:100:treatment,102:111:treatment,113:146:treatment,148:157:treatment,159:168:treatment,170:179:treatment,192:205:treatment,217:231:treatment,233:243:treatment,270:293:treatment","The use of potent P-gp inhibitors (including cyclosporine, erythromycin, ketoconazole, itraconazole, quinidine, Phenobarbital salt with quinidine, ritonavir, valspodar, verapamil) and potent P-gp inducers (including St John's wort, rifampicin) has to be avoided during treatment with afatinib"
7191,NCT01512888,",,36:45:treatment,71:91:treatment,108:138:treatment",Less than 300 CD3+ T-cells by flow cytometry or higher if evidence of maternal engraftment as supported by peripheral blood FISH analysis for XY and XX
7192,NCT01505569,"1:41:cancer,,,74:83:cancer,101:119:cancer",Atypical Teratoid/Rhabdoid Tumor (AT/RT): less than 70 years of age with CNS AT/RT (with or without metastatic disease)
7193,NCT01505569,"8:23:cancer,,,75:93:treatment,188:197:treatment","Infant Medulloblastoma: Children less than 8 months of age at the time of definitive surgery (for histopathologic diagnosis), any histology, any metastatic state, with total or sub-total resection"
7194,NCT01505569,"1:13:cancer,42:54:cancer,73:91:cancer,96:110:cancer",Renal Tumors - relapsed (all histology - Wilm's tumor) or at diagnosis (clear cell sarcoma and Rhabdoid tumor)
7195,NCT01505062,"13:30:chronic_disease,141:153:cancer,155:163:chronic_disease,165:194:chronic_disease,198:217:chronic_disease","Concomitant systemic diseases including those in which the disease itself, or the treatment for the disease, can alter ocular function (eg, malignancies, diabetes, juvenile rheumatoid arthritis or sickle cell disease)"
7196,NCT01505062,"1:18:treatment,46:57:treatment,59:73:treatment,175:199:treatment","diagnostic agents used during the study (eg, fluorescein, dilation drops), or medications planned for use during the peri-operative period, particularly topical, injected or systemic corticosteroids"
7197,NCT01495819,"36:59:treatment,61:76:treatment,78:92:treatment,97:108:treatment,139:148:treatment,153:174:chronic_disease,185:201:chronic_disease,203:219:chronic_disease,221:234:chronic_disease","requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) or psychiatric diagnosis and treatment for psychiatric disorders including major depression, bipolar disorder, schizophrenia in the past 6 months"
7198,NCT01494662,"1:21:chronic_disease,27:47:chronic_disease,51:73:chronic_disease",Active liver disease from autoimmune disorders or sclerosing cholangitis
7199,NCT01494662,"1:8:treatment,46:49:treatment,133:144:chronic_disease,175:182:treatment",Head CT with contrast is allowed in place of MRI at baseline and throughout the study if MRI is contraindicated and a participant's CNS lesions are clearly measurable on the head CT
7200,NCT01494662,"1:13:chronic_disease,39:63:cancer,77:84:chronic_disease",Lung disease from etiology other than metastatic breast cancer resulting in dyspnea at rest (4A-4C)
7201,NCT01494662,"23:33:treatment,41:44:treatment,74:81:cancer",Patients who have had prior WBRT and/or SRS and then whose prior treated lesions have progressed thereafter
7202,NCT01494324,"19:26:treatment,42:63:treatment,82:91:treatment",refuse to undergo surgery and choose any percutaneous ablation as an alternative treatment option
7203,NCT01481974,"36:50:allergy_name,52:64:allergy_name,68:80:allergy_name","Have any known hypersensitivity to prostaglandins, prostacyclin or treprostinil"
7204,NCT01465100,"13:19:chronic_disease,21:30:chronic_disease,38:54:chronic_disease","Subject has sepsis, pneumonia, other active infection"
7205,NCT01464034,"17:35:treatment,37:44:treatment,59:76:treatment,,140:148:treatment,213:236:chronic_disease","Exposure to any prior chemotherapy, steroid use, or other myeloma treatment within 14 days prior to first dose. Pts currently on long term steroids do not require any washout period. in addition, steroid use for spinal cord compression is permitted and does not require a washout period"
7206,NCT01464034,"13:23:chronic_disease,25:32:chronic_disease,34:41:chronic_disease,46:53:chronic_disease,","Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment"
7207,NCT01459107,"7:33:chronic_disease,38:55:chronic_disease,95:102:treatment",Mixed connective tissue diseases and collagen diseases can result in poor wound healing after surgery
7208,NCT01445821,"10:13:treatment,69:86:treatment,259:279:chronic_disease,283:313:treatment","Abnormal EKG [non-specific ST-segment and T-wave (ST-T) (pattern in electrocardiogram) wave abnormalities, low QRS (a pattern seen in an electrocardiogram that indicates the pulses in a heart beat and their duration) voltage, or ventricular hypertrophy], or pericardial effusion or pericardial enhancement on MRI"
7209,NCT01445821,"1:19:chronic_disease,23:33:chronic_disease,37:44:treatment,48:65:treatment",Pulmonary fibrosis or alveolitis on CT scan or chest X-ray (CXR) (ground glass appearance of alveolitis)
7210,NCT01436968,"1:14:chronic_disease,32:41:chronic_disease,52:61:chronic_disease","Liver disease, including known cirrhosis or active hepatitis"
7211,NCT01434472,"1:18:chronic_disease,45:71:treatment,115:148:chronic_disease,150:159:chronic_disease","Medical condition that would contraindicate allogeneic transplantation as per standard practice guidelines (e.g., impaired cardiopulmonary function, hepatitis, etc)"
7212,NCT01434316,"76:84:treatment,130:144:treatment,130:135:cancer,160:166:treatment,288:297:allergy_name,392:407:treatment,429:437:treatment,441:469:treatment,510:533:treatment,,,,,653:675:treatment","Eligible patients in the dose escalation phases of the trial must agree to biopsies of normal skin, unless they undergo optional tumor biopsies; the mandatory biopsy requirement can be waived at the discretion of principal investigator in the event of any medical contraindication (e.g. lidocaine allergy); patients enrolled to the expanded cohorts must agree to tumor sampling; patients on anticoagulation must be able to hold warfarin or low molecular weight heparin for a sufficient amount of time to make skin and tumor biopsies safe to perform; PT/INR and PTT should be =< 1.5 times the institutional upper limit of normal prior to performance of skin or tumor biopsies, with values re-checked after the eligibility screen as medically indicated"
7213,NCT01434316,"22:38:treatment,42:56:treatment,90:100:treatment",Subjects on a potent CYP3A4 inhibitor or CPY3A4 inducer who cannot be changed to another medication
7214,NCT01434316,"33:45:treatment,,91:100:treatment,159:177:treatment",patients must not have received chemotherapy for 3 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of any prior chemotherapy
7215,NCT01433965,"32:47:chronic_disease,57:80:chronic_disease,84:107:chronic_disease","Known sero-positive for active viral infection with HI, hepatitis B virus (HBV) or hepatitis C virus (HCV)"
7216,NCT01430390,"35:57:chronic_disease,61:80:chronic_disease,101:110:chronic_disease,131:142:chronic_disease","History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration"
7217,NCT01430390,"26:43:chronic_disease,95:117:chronic_disease,190:215:chronic_disease",Preceding and/or ongoing organ dysfunction or other co-morbidity including but not limited to uncontrolled infection that would impair the patient's ability to endure known side effects of cytokine release syndrome or neurological toxicity
7218,NCT01430390,"20:35:treatment,39:64:treatment,,179:188:treatment,192:201:treatment",Subjects receiving steroid therapy at physiological replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to subject starting apheresis or treatment
7219,NCT01422746,"9:17:treatment,,42:58:chronic_disease,62:83:chronic_disease",Morning cortisol < 3 µg/dL or history of Cushing syndrome or adrenal insufficiency
7220,NCT01422005,"10:30:chronic_disease,39:50:chronic_disease,58:64:chronic_disease,66:74:chronic_disease,79:100:chronic_disease","Previous neurological illness such as head trauma, prior stroke, epilepsy, or demyelinating disease"
7221,NCT01420887,"28:31:treatment,35:65:treatment,75:93:chronic_disease,102:116:treatment","Contraindication to use of CPM or regional brachial plexus block, such as bleeding diathesis, use of anticoagulants or severe restriction in shoulder range of movement"
7222,NCT01419561,"37:62:cancer,67:84:chronic_disease,105:127:chronic_disease",Body cavity effusions not caused by primary effusion lymphoma nor chylous effusions directly related to lymphatic infiltration by KS
7223,NCT01415882,"1:11:treatment,18:27:treatment,29:45:treatment,","Alkylators (e.g. melphalan, cyclophosphamide) =< 14 days prior to registration"
7224,NCT01415882,"20:40:treatment,58:68:treatment,73:84:treatment,,125:132:treatment,,",Patients should be proteasome inhibitor naïve (including bortezomib and carfilzomib) OR have received less than 6 cycles of therapy with a bortezomib or carfilzomib containing regimen and were not refractory to the bortezomib or carfilzomib based regimen (less than a PR or progression on or within 60 days of discontinuation)
7225,NCT01415752,"36:62:cancer,93:119:treatment,155:196:treatment","Histologically confirmed untreated mantle cell lymphoma (MCL), with documented cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH)"
7226,NCT01415752,",,,45:58:chronic_disease,60:79:chronic_disease,101:124:chronic_disease,129:149:treatment,168:176:chronic_disease","Patients must not have NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia"
7227,NCT01409161,"16:19:cancer,49:90:treatment,92:123:treatment,128:136:treatment","A diagnosis of APL based on the presence of the PML-RAR-alpha fusion gene by cytogenetics, polymerase chain reaction (PCR), or POD test"
7228,NCT01407809,"1:36:treatment,40:76:treatment,91:126:chronic_disease,130:166:chronic_disease,172:213:chronic_disease,217:224:chronic_disease",Magnetic Resonance Venography (MRV) or Computed Tomography Venography (CTV) demonstrating bilateral transverse sinus stenosis or unilateral transverse sinus stenosis with contralateral transverse sinus hypoplasia or atresia
7229,NCT01389024,",24:27:treatment,24:35:treatment,,,72:93:treatment,","History of two or more TCD studies with a velocity ? 200 cm/sec by the non-imaging technique, or ?185 cm/sec for the imaging technique or a indeterminate TCD"
7230,NCT01389024,"23:41:chronic_disease,43:56:chronic_disease,61:96:chronic_disease,98:113:chronic_disease,,",Participant must have sickle cell anemia (hemoglobin SS) or sickle Beta-zero (null) thalassemia (hemoglobin S-B0) as confirmed at the local institution by hemoglobin analysis after six months of age
7231,NCT01384513,"1:8:cancer,12:43:cancer,49:71:cancer",Hodgkin or Indolent Non-Hodgkin's lymphoma with chemosensitive disease
7232,NCT01379573,"22:37:treatment,88:96:treatment,242:245:treatment,,278:281:chronic_disease","Mother is taking any glucocorticoids. Although unlikely to be preventative, the use of steroids may confound the interpretation of results. The final point of intense discussion centered around whether another exclusion should be the use of HCQ in the first pregnancy in which CHB occurred. While one could argue that in these mothers HCQ was not effective and perhaps will not be again, this assumption remains speculative and thus prior absence of efficacy of HCQ will not constitute an exclusion criteria"
7233,NCT01372631,"23:33:treatment,34:44:treatment,53:62:treatment,69:77:cancer,81:111:cancer",Patients undergoing a lumpectomy mastectomy for the treatment of an invasive or non-invasive breast malignancy
7234,NCT01367444,"34:54:chronic_disease,56:66:chronic_disease,68:81:chronic_disease,86:106:treatment","History or signs consistent with unilateral amblyopia (strabismic, anisometropic, or stimulus deprivation)"
7235,NCT01366612,"32:43:allergy_name,47:56:allergy_name,63:73:allergy_name,75:80:allergy_name,84:92:allergy_name","Documented hypersensitivity to fludarabine or melphalan or to bortezomib, boron or mannitol or any components of the formulation"
7236,NCT01365169,"21:30:treatment,37:43:cancer,176:200:cancer",Currently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3)
7237,NCT01365169,"27:50:treatment,55:80:cancer,82:114:cancer,119:135:chronic_disease","Patients who will undergo curative pancreatectomy for pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, or pancreatic cysts (malignant or benign) (PCS study)"
7238,NCT01360606,"1:31:treatment,35:62:treatment,72:79:treatment,81:105:treatment,107:124:treatment,126:149:treatment,151:181:treatment,185:197:treatment,287:300:treatment,,390:399:treatment,461:465:treatment,521:537:treatment,","Previous systemic chemotherapy or non-radiation local therapy (such as surgery, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) is allowed. The lesion must however have shown criteria of progression based on RECIST. Local therapy must be completed at least 4 weeks prior to the baseline scan. This is to create a safer treatment environment and to help determine the effect of treatment by SBRT alone. Patients will be allowed to go onto appropriate systemic therapy, as determined by their medical oncologist, 2 weeks following delivery of SBRT"
7239,NCT01356290,",,,,,,,,,,304:313:treatment,319:328:treatment,333:349:treatment","Participants must have normal organ and bone marrow function (ALT <5x institutional upper limit of normal, creatinine <1.5x institutional upper limit of normal for age, WBC >1000/mm3, platelets > 20,000/mm3. Patients with values less than WBC 2000/mm3 or platelets 50,000/mm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol"
7240,NCT01349101,"19:23:cancer,27:33:chronic_disease,56:76:treatment",For patients with CMML or RAEB-2 they must demonstrate chemo-responsiveness
7241,NCT01345344,"16:33:treatment,37:58:treatment,90:101:chronic_disease,123:132:treatment","current use of opioid analgesics or stimulant medications or the fatigue associated with sleep apnea or shift work (e.g., modafinil)"
7242,NCT01341080,"1:16:chronic_disease,28:46:treatment,102:109:treatment,","Serious illness (requiring systemic treatment/or hospitalization) until the subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 60 days prior to study entry"
7243,NCT01333046,",54:64:treatment,68:81:treatment,86:102:treatment",Patients greater than or equal to 18 years old after autologous or syngeneic SCT (as adjuvant therapy)
7244,NCT01326715,"44:61:chronic_disease,71:76:chronic_disease,80:94:chronic_disease","Reported history of clinically significant medical disorders, such as liver or kidney disease, that could potentially increase the risk of CNS damage due to manganese exposure"
7245,NCT01313533,"1:22:chronic_disease,57:89:treatment,91:157:treatment,161:177:treatment","cute traumatic injury, vasculitis or planned concurrent ventricular surgical restoration, automatic implantable cardioverter defibrillators (AICD) placement or valvular surgery"
7246,NCT01312857,"23:38:treatment,39:55:treatment,102:111:treatment",Patients who have had prior anti EGFR antibody therapy inhibitors and who have not responded to this treatment will be excluded
7247,NCT01306045,"5:33:chronic_disease,79:109:treatment,129:186:treatment",Any uncontrolled medical illness that precludes the patient from undergoing a biopsy for molecular profiling and / or receiving treatment under one of the experimental arms of the study
7248,NCT01306045,"15:43:cancer,27:43:cancer,110:119:chronic_disease,163:173:chronic_disease,163:185:chronic_disease,292:301:treatment,339:363:cancer,,428:443:treatment,","Patients with symptomatic brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. However, patients who have had treatment for their brain metastases and whose brain metastatic disease status has remained stable for at least 1 week after the end of brain radiation may be enrolled to undergo molecular profiling at the discretion of the principal investigator. In addition, brain metastatic disease should be stable for at least 4 weeks, before the patients can be enrolled in any of the experimental treatment arms"
7249,NCT01306019,"48:54:treatment,56:67:chronic_disease,76:89:treatment,91:103:treatment,169:178:chronic_disease","Isolation of a bacteria, fungus, or virus from biopsy, skin lesion, blood, nasal washing, bronchoscopy, cerebrospinal fluid or stool likely to be an etiologic agent of infection"
7250,NCT01293214,"29:41:treatment,55:65:treatment,75:84:chronic_disease,89:100:chronic_disease","Willing to receive standard vaccinations prior to the transplant, such as influenza and hepatitis B"
7251,NCT01280669,"15:32:chronic_disease,25:32:chronic_disease,51:85:treatment,93:105:treatment,107:119:treatment,121:137:treatment,139:151:treatment,153:166:treatment,167:174:treatment,176:186:treatment,191:203:treatment,216:226:treatment,236:251:treatment,260:269:treatment,378:402:treatment","Patients with bilateral uveitis who are receiving systemic immunosuppressive therapy (e.g., methotrexate, cyclosporine, cyclophosphamide, chlorambucil, mycophenolate mofetil, tacrolimus, or azathioprine) other than prednisone or other corticosteroids for the treatment of uveitis and the uveitis in the fellow eye, in the opinion of the Investigator, cannot be controlled with standard local therapies alone"
7252,NCT01270724,"28:39:treatment,41:52:treatment,60:70:treatment","Patients who have received gemcitabine, oxaliplatin and/or paclitaxel"
7253,NCT01261728,"43:76:cancer,142:147:cancer,201:217:treatment",Histologically confirmed high-grade upper tract transitional cell carcinoma at MSKCC or a participating site and/or radiographically visible tumor stage T2-T4a N0/X M0 disease with positive selective urinary cytology or high-grade concomitant bladder tumor
7254,NCT01261728,"22:29:chronic_disease,33:52:chronic_disease,72:88:chronic_disease","Serious intercurrent medical or psychiatric illness, including serious active infection"
7255,NCT01245712,"1:35:cancer,44:51:cancer,55:63:cancer",Non-epithelial breast malignancies such as sarcoma or lymphoma
7256,NCT01245712,"8:30:cancer,32:47:cancer,51:55:cancer,,",Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters
7257,NCT01243931,"1:10:chronic_disease,12:27:chronic_disease,29:37:chronic_disease,103:110:treatment","Cataracts, retinal disease, glaucoma, or other eye conditions that may limit the visual outcome after surgery"
7258,NCT01228448,"28:32:cancer,37:41:cancer,47:64:cancer,96:108:treatment","Adult subjects with brain, head and neck, and skull base tumors receiving external beam proton radiotherapy at the Francis H. Burr Proton Therapy Center at MGH"
7259,NCT01220583,"4:31:treatment,35:52:treatment,57:82:cancer",No prior systemic chemotherapy or radiation therapy for salivary gland malignancy
7260,NCT01200940,"61:71:allergy_name,75:79:allergy_name,87:94:allergy_name","Known allergy, sensitivity or other contraindication to any study food or drug or its vehicle"
7261,NCT01185210,"17:24:treatment,26:35:treatment,37:46:treatment,48:54:treatment","Medication use: opioids, Tegaserod, laxatives, enemas"
7262,NCT01184547,"1:19:chronic_disease,23:29:chronic_disease,43:58:chronic_disease","Mental retardation or autism or any other mental disorder, which makes it impossible to participate in an exercise program"
7263,NCT01174121,"40:57:cancer,89:94:cancer,98:120:cancer,122:135:cancer,137:150:cancer,152:158:cancer,160:179:cancer,184:196:cancer","Measurable (per RECIST v1.0 criteria), metastatic cancer of one of the following types: upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian/endometrial, or glioblastoma"
7264,NCT01174108,"1:4:chronic_disease,43:46:chronic_disease,48:51:chronic_disease,55:64:chronic_disease,66:82:chronic_disease","HIV positive (donors who are positive for HBV, HCV or HTLV-I/II, T.cruzi [Chagas] may be used at the discretion of the investigator following counseling and approval from the recipient)"
7265,NCT01174108,"1:23:chronic_disease,27:35:chronic_disease,65:76:treatment,95:106:chronic_disease",Refractory anemia (RA) or RARS MDS patients who have associated transfusion dependence and/or neutropenia
7266,NCT01174108,"18:36:treatment,48:57:treatment,70:76:chronic_disease,78:80:chronic_disease,82:97:chronic_disease,99:124:chronic_disease,133:146:chronic_disease,150:165:chronic_disease","Unfit to receive filgrastim (G-CSF) or undergo apheresis (history of stroke, MI, unstable angina, uncontrolled hypertension, severe heart disease or palpable spleen)"
7267,NCT01130077,"28:35:cancer,41:59:cancer,85:115:treatment,98:107:treatment,108:115:treatment,155:167:treatment","Newly diagnosed high-grade gliomas with metastatic disease within the CNS requiring craniospinal radiation therapy. Patients may or may not have received chemotherapy during radiation, but cannot have received chemotherapy after radiation therapy was completed"
7268,NCT01130077,",64:82:treatment,70:82:treatment,86:111:treatment,,,272:289:treatment","Patients enrolled on stratum C must have received at least two prior chemotherapy or biologic therapy regimens and may not have received radiation to the index lesion within 1 year of enrollment. Patients on Strata A, B, E, and F can not have received chemotherapy after radiation therapy was completed"
7269,NCT01128816,"1:51:chronic_disease,59:67:chronic_disease,69:79:chronic_disease,83:95:chronic_disease,","American Heart Association Stage B-D Heart failure due to ischemic, idiopathic or hypertensive causes, present for at least 3 months"
7270,NCT01101451,"31:46:cancer,,,58:81:cancer,83:106:cancer,110:124:cancer,167:179:treatment,185:207:treatment","Pathologically proven primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy"
7271,NCT01099644,"5:11:cancer,23:28:cancer,30:38:treatment","For tumors other than DSRCT, Burtomab reactivity must be confirmed by immunohistochemistry"
7272,NCT01099644,"7:15:treatment,25:37:cancer,69:92:cancer,95:107:cancer","other Burtomab-positive solid tumors involving the peritoneum (e.g. adrenocortical carcinoma, Wilm's tumor)"
7273,NCT01096368,"54:64:cancer,76:95:chronic_disease,117:122:cancer,313:320:treatment","There is no minimum performance level; children with ependymoma may suffer neurologic sequelae as a result of their tumor or surgical measures taken to establish a diagnosis and resect the tumor; in the majority of cases, there is neurologic recovery; neurologic recovery is not likely to be impeded by protocol therapy"
7274,NCT01087294,"12:24:chronic_disease,51:61:treatment,63:69:chronic_disease,81:94:chronic_disease,120:126:chronic_disease","History of hypertension that is not controlled by medication, stroke, or severe heart disease (donors with symptomatic angina will be excluded)"
7275,NCT01087294,"27:44:cancer,68:81:treatment,85:151:treatment,,155:194:treatment,,261:269:treatment,278:301:cancer","Recipients (patients with B-cell malignancy) must have received an HLA-identical or 9/10 matched sibling allogeneic hematopoietic stem cell transplant, a 1-antigen mismatched related transplant, or a greater than or equal to 9/10-matched unrelated donor (URD) alloHSCT for any CD19+ B-cell malignancy"
7276,NCT01061515,"30:47:treatment,53:66:treatment,,136:148:treatment",Patients must have undergone debulking surgery with peritonectomy and have been allowed at least 4 weeks to recover prior to receiving chemotherapy
7277,NCT01059786,"10:17:treatment,24:36:treatment,38:48:treatment,","No other therapy (i.e. chemotherapy, interferon) for 4 weeks prior to study entry"
7278,NCT01059786,"35:46:treatment,47:54:treatment,,112:127:treatment",The patient may have any required vaccination/booster administered at least 4 weeks prior to the initiation of study treatment
7279,NCT01054196,"62:70:cancer,72:90:cancer,95:135:cancer","Patients must have histologically or cytologically confirmed relapsed, primary refractory, or relapsed and refractory multiple myeloma"
7280,NCT01045148,"24:31:cancer,43:48:cancer,50:57:cancer,62:88:cancer,","Previous or concurrent cancers other than basal, in situ, or squamous cell skin cancers unless disease-free for ? 5 years"
7281,NCT01042522,"58:76:allergy_name,103:109:cancer,212:223:chronic_disease,240:255:treatment","Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization"
7282,NCT01037790,"1:25:cancer,,,,155:166:treatment,171:188:treatment,","Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B"
7283,NCT01037790,"13:37:chronic_disease,39:63:chronic_disease,65:71:chronic_disease,75:96:chronic_disease,","symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months"
7284,NCT01011777,"74:78:treatment,82:105:treatment,138:165:chronic_disease",Any degree of renal scarring at the time of screening as demonstrated by DMSA or MAG3 renal scintigraphy in the presence of any grade of vesicoureteral reflux (VUR)
7285,NCT00980538,"50:62:chronic_disease,64:83:chronic_disease,238:247:treatment,253:256:treatment","Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction) or findings of medical history, laboratory or physical examination that, in the investigator's opinion, would compromise the participant's safety during treatment with ETR"
7286,NCT00977977,"1:30:treatment,34:58:treatment,,121:130:treatment,135:147:treatment",Immunosuppressive medications or experimental medications of any type during the three month period prior to initiating Rituximab and cyclosporine
7287,NCT00977977,"53:75:treatment,115:123:chronic_disease,125:142:chronic_disease,146:158:chronic_disease","evidence of intolerance or toxicity associated with cyclosporine treatment of any duration including irreversible azotemia, liver dysfunction or hypertension"
7288,NCT00975520,"21:28:cancer,,,184:211:cancer,,230:254:cancer,259:268:cancer","Patients with prior cancers, except: those diagnosed ? 5 years ago with no evidence of disease relapse and clinical expectation of relapse of less than 5%; prior successfully treated Level 1 cutaneous melanomas ? 2 years ago; or non-melanoma skin cancer; or carcinoma in situ of the cervix"
7289,NCT00969111,"1:16:cancer,40:44:treatment,46:58:treatment,62:96:treatment","Prostate cancer treated primarily with open, laparoscopic or robotically assisted prostatectomy"
7290,NCT00967577,"7:29:treatment,37:54:treatment,,73:82:treatment",Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment
7291,NCT00967577,"13:35:treatment,28:35:treatment,39:48:treatment,,123:139:treatment",Subjects on bisphosphonate therapy or denosumab must be on a stable dose and must have started therapy > 4 weeks prior to protocol therapy
7292,NCT00959140,"1:4:cancer,20:29:treatment,34:49:treatment",ALL: Refractory to Induction and salvage therapy
7293,NCT00948285,"15:34:chronic_disease,,,73:103:chronic_disease,131:141:treatment",Patients with renal insufficiency (serum Cr > 1.5) due to the danger of nephrogenic systemic sclerosis with the administration of Gadolinium
7294,NCT00930228,"15:19:chronic_disease,30:46:chronic_disease,78:87:chronic_disease","subjects with PCOS will have hyperandrogenism, whether it is clinical (e.g., hirsutism) or biochemical (i.e., elevated plasma T)"
7295,NCT00929006,"53:71:chronic_disease,73:94:chronic_disease,99:109:chronic_disease","History and/or physical exam findings suggestive of Cushing's syndrome, adrenal insufficiency, or acromegaly"
7296,NCT00929006,"1:8:chronic_disease,39:53:chronic_disease,57:73:chronic_disease",Obesity resulting from a well-defined endocrinopathy or genetic syndrome
7297,NCT00926237,"17:23:treatment,36:63:treatment,52:62:treatment,68:83:treatment,96:120:treatment,126:136:chronic_disease,159:167:chronic_disease,",Subjects taking SSRI's (a class of anti-depressant medications)and benzodiazepines (a class of anti-anxiety medications) for depression or anxiety related to tinnitus must be stable on their current dose for at least 3 months and must not alter their dose or medication during their involvement with this study
7298,NCT00924027,"36:43:treatment,58:67:treatment,86:109:cancer",Patients who are unable to undergo surgery and must have treatment for an inoperable primary cervical cancer
7299,NCT00924027,"1:21:chronic_disease,33:36:chronic_disease,38:49:chronic_disease","autoimmune disorders, including SLE, Scleroderma, etc"
7300,NCT00914628,"1:4:cancer,9:12:cancer,34:36:treatment",AML and ALL in 2nd or subsequent CR
7301,NCT00911560,",33:45:treatment,49:62:treatment,67:82:treatment",? 3 weeks between completion of chemotherapy or immunotherapy and 1st vaccination
7302,NCT00909909,"15:25:treatment,29:39:treatment,51:71:treatment,75:94:treatment,99:117:cancer",Has undergone lumpectomy or mastectomy and either sentinel node biopsy or axillary dissection (if invasive carcinoma is present)
7303,NCT00909909,"24:33:cancer,35:41:cancer,35:40:cancer,,175:193:cancer,230:240:cancer,244:250:treatment",No proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by ? 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy
7304,NCT00902720,"1:10:treatment,19:28:treatment,69:79:cancer",radiation for the treatment or prevention of a medical condition or malignancy expected to result in permanent and complete loss of subsequent ovarian function or have a medical condition or malignancy that requires removal of all or part of one or both ovaries
7305,NCT00887146,"22:65:chronic_disease,22:56:chronic_disease,90:108:treatment",Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy
7306,NCT00887146,"38:47:treatment,71:87:treatment,91:107:treatment,119:125:cancer,151:179:treatment",if they are receiving other specific treatment (with the exclusion of hormonal therapy or Her-2 inhibitors) for their cancer or if they have received prior total body irradiation which included the brain
7307,NCT00887146,"21:28:treatment,50:65:treatment,67:79:treatment,72:79:treatment","patients with prior surgery cannot have received prior radiation, chemotherapy or targeted therapy"
7308,NCT00875342,"8:26:treatment,39:64:treatment,66:81:treatment,86:112:treatment","Taking oral anticoagulant medication, ethionamide (Trecator-SC), isoniazid (INH), or anti-depressant medication"
7309,NCT00862433,"18:21:allergy_name,25:28:allergy_name,30:51:allergy_name,56:61:allergy_name,62:68:allergy_name","Food allergy, to soy or egg, milk protein (casein), or wheat/gluten"
7310,NCT00862433,"8:19:treatment,32:56:treatment,58:81:treatment","Use of medications (other than oral hypoglycemic agents, hormonal contraceptives and medications taken only on an as-needed basis)"
7311,NCT00840047,"101:104:treatment,105:108:treatment,109:111:treatment,123:126:treatment,","Participants will have had, or are scheduled to have clinical imaging evaluations which may include FDG PET CT, or CT, or MRI within 4 weeks of entry"
7312,NCT00819208,"15:24:treatment,41:53:treatment,57:66:treatment",No concurrent treatment with additional chemotherapy or radiation
7313,NCT00801489,"30:33:cancer,38:79:cancer,81:98:chronic_disease,120:124:chronic_disease","Patients must have untreated AML, or high-risk myelodysplastic syndromes (MDS) (refractory anemia with excess blasts, [RAEB], or RAEB in transformation [RAEB-t]) characterized by t(8;21), inv(16), or t(16;16); the presence of additional abnormalities is irrelevant"
7314,NCT00788164,"1:16:treatment,21:27:treatment,38:80:chronic_disease",Colposcopically and biopsy confirmed grade 3 cervical intraepithelial neoplasia
7315,NCT00739362,"1:31:chronic_disease,33:58:chronic_disease,60:68:chronic_disease,70:97:chronic_disease,99:107:chronic_disease,122:133:chronic_disease","Central nervous system disease (cerebrovascular accidents, dementia, neurodegenerative disorders, epilepsy or history of head injury)"
7316,NCT00739362,"12:25:chronic_disease,37:54:chronic_disease,64:76:chronic_disease",History of HIV infection or ongoing chronic infection (such as tuberculosis)
7317,NCT00737893,"31:44:treatment,54:87:treatment,94:131:treatment","Scheduled to undergo curative prostatectomy applying bilateral nerve-sparing procedure, with intact pre-surgical erectile function"
7318,NCT00734877,"24:34:cancer,38:63:cancer,57:63:cancer,68:88:cancer,","for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years"
7319,NCT00720785,",43:65:treatment,96:109:cancer,118:125:treatment",Disease involving greater than 25% of the liver radiographically (estimated based on review of liver lesions seen on CT scan)
7320,NCT00720785,"1:19:cancer,21:31:cancer,35:49:cancer",cancer of the lung (small cell or non small cell)
7321,NCT00719888,"1:13:treatment,14:35:cancer,40:54:cancer,,92:108:treatment","Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after > 2 salvage regimens)"
7322,NCT00719888,"28:54:treatment,58:83:treatment,102:117:treatment","Patients who have received Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar), as part of their salvage therapy are not eligible for Regimen A"
7323,NCT00716066,"8:18:cancer,40:53:cancer,57:89:cancer",Active malignancy (excluding localized squamous cell or basal cell carcinoma of the skin)
7324,NCT00715611,"28:45:cancer,54:62:cancer,66:98:cancer",Patients with a concurrent active malignancy (except squamous or basal cell carcinoma of the skin)
7325,NCT00713492,"37:52:chronic_disease,64:67:chronic_disease,69:83:chronic_disease,85:96:chronic_disease,98:114:chronic_disease,116:123:chronic_disease,125:130:chronic_disease,132:141:chronic_disease,146:168:chronic_disease","Current or prior history of serious medical illness, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders"
7326,NCT00703105,"37:64:treatment,68:81:treatment,,111:116:cancer",Patients must not have received any antineoplastic chemotherapy or immunotherapy for the four weeks preceding tumor excision
7327,NCT00695214,"12:20:allergy_name,22:33:allergy_name,35:47:allergy_name,51:59:allergy_name","Allergy to propofol, soybean oil, egg lecithin or glycerol"
7328,NCT00673842,"1:27:treatment,35:59:chronic_disease,68:74:chronic_disease","mechanical tricuspid valve, known vascular access problems, active sepsis, etc"
7329,NCT00670358,"15:43:treatment,51:58:treatment,60:67:treatment","No concurrent erythroid-stimulating agents (e.g., Procrit, Aranesp)"
7330,NCT00670358,"10:27:cancer,46:70:cancer,64:70:cancer","No other active malignancy, except localized nonmelanotic skin cancer or any cancer that, in the judgment of the investigator, has been treated with curative intent and will not interfere with the study treatment plan and response assessment"
7331,NCT00630565,"29:57:treatment,82:105:treatment,129:147:treatment",Patients who cannot receive total body irradiation (TBI) (for example those with prior radiation therapy) will also receive the Bu/CY conditioning
7332,NCT00630253,"1:22:cancer,29:76:cancer,,96:99:treatment",Malignant solid tumor (e.g. squamous cell carcinoma of the head/neck/cervix) within 2 years of HCT
7333,NCT00594217,",37:44:chronic_disease,48:69:chronic_disease,96:120:chronic_disease,141:165:chronic_disease,167:173:chronic_disease,184:205:treatment","Women with a significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; known or suspected coronary atherosclerosis; asthma requiring systemic intermittent corticosteroids; etc.)"
7334,NCT00584649,"26:43:chronic_disease,61:76:chronic_disease,80:96:chronic_disease",An alternative cause for sinus tachycardia identified (e.g. hyperthyroidism or pheochromocytoma)
7335,NCT00573027,"1:11:chronic_disease,19:40:chronic_disease,47:59:chronic_disease,61:70:chronic_disease,72:88:chronic_disease","Chest pain with a non-ischemic etiology (e.g.,pericarditis, pneumonia, esophageal spasm)"
7336,NCT00542373,"43:56:chronic_disease,58:72:chronic_disease,129:140:cancer","Persons with any other condition (such as lichen planus, Fanconi anemia, heavy tobacco use, etc) making them at higher risk for oral cancer development"
7337,NCT00492778,"34:55:treatment,60:91:treatment,116:123:treatment,134:151:cancer",All patients must have undergone complete hysterectomy and bilateral salpingo-oophorectomy at the time of original therapy for their uterine carcinoma
7338,NCT00492778,"28:44:treatment,46:52:treatment,57:78:treatment","Patients who have received previous vaginal, pelvic, or abdominal irradiation"
7339,NCT00488696,"1:11:chronic_disease,22:64:chronic_disease,68:86:chronic_disease,96:115:chronic_disease,120:143:chronic_disease,178:187:treatment,201:224:treatment","Arrhythmia define as 2nd- and 3rd-degree atrioventricular block or sinus node disease, such as sick sinus syndrome and symptomatic bradycardia, unless the patient already has a pacemaker in place and cardiology consultation confirms that it is safe to proceed"
7340,NCT00467987,"13:31:treatment,33:40:treatment,42:56:treatment,58:87:treatment,91:103:treatment","Subjects on thiazolidinediones, statins, ACE inhibitors, angiotensin receptor blockers or antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the study"
7341,NCT00383656,",23:38:chronic_disease,42:88:chronic_disease,112:130:chronic_disease",Women and minors with GnRH deficiency or idiopathic hypogonadotropic hypogonadism (IHH) will have a history of primary amenorrhea
7342,NCT00368355,"17:33:chronic_disease,93:114:treatment,129:144:treatment",Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation
7343,NCT00358657,"4:42:treatment,46:75:treatment,89:112:chronic_disease,123:138:chronic_disease,149:156:treatment,197:212:chronic_disease","on multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (echo), symptomatic coronary artery disease, or other cardiac failure requiring therapy; patients with a history of, or current cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consult"
7344,NCT00357565,"27:51:cancer,73:80:treatment,103:106:cancer,155:169:treatment",Patients with evidence of minimal residual disease at the completion of therapy or evidence of rising MRD while on therapy. MRD will be defined by either flow cytometry
7345,NCT00338377,"9:20:treatment,24:44:treatment,,85:108:treatment",Has had prior B-RAF or MEK targeted therapy within 7 days prior to the start of the lymphodepletion regimen (Cohort A and Cohort B)
7346,NCT00338377,"31:50:cancer,68:80:treatment,81:94:treatment",Patients must have measurable metastatic melanoma. (Turnstile II - Chemotherapy/Cell Infusion -Inclusion Criteria)
7347,NCT00338377,"15:18:treatment,31:34:cancer,64:86:cancer","Patients with MRI evidence of LMD, with or without evidence of malignant cells in CSF (positive cytology)"
7348,NCT00338377,"9:16:treatment,9:56:treatment,71:88:treatment,,123:155:treatment,,176:200:treatment,269:281:treatment,282:295:treatment","Require steroid therapy or steroid-containing compounds, or have used systemic steroids in the past 30 days, or have used topical or inhalational steroids in the past 2 weeks prior to lymphodepletion. Exception: Patients on physiologic dose of steroid (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)"
7349,NCT00285935,"28:53:chronic_disease,55:63:chronic_disease,70:83:chronic_disease","Current DSM-5 diagnosis of Major Depressive Disorder, unipolar, with non-psychotic features"
7350,NCT00186927,"12:24:chronic_disease,26:32:chronic_disease,58:77:chronic_disease,79:95:chronic_disease,97:116:chronic_disease","History of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition"
7351,NCT00147056,"46:63:cancer,73:80:treatment,82:91:treatment,96:108:treatment","Subjects with (newly diagnosed or recurrent) metastatic cancer for whom surgery, radiation, or radiosurgery has not been advised by the treating physician"
7352,NCT00107289,"1:5:treatment,11:13:cancer,39:48:treatment",MIBG-avid NB and evaluable disease on MIBG scan at time of enrollment on protocol
7353,NCT00107289,"27:29:cancer,157:171:cancer,186:208:chronic_disease","ust have the diagnosis of NB in accordance with the International Criteria, i.e., either histopathology (confirmed by the MSKCC Department of Pathology) or BM involvement plus elevated urinary catecholamines"
7354,NCT00075387,"40:51:treatment,53:69:treatment,71:90:treatment,95:113:treatment","Subjects who have contraindications to carboplatin, cyclophosphamide, etoposide phosphate, or sodium thiosulfate"
7355,NCT00001337,"23:45:chronic_disease,47:68:chronic_disease,72:96:chronic_disease","No active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year"
